
<html lang="en"     class="pb-page"  data-request-id="639ada91-852f-47e3-bb9e-d89816ef7125"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b00640;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2020.63.issue-2;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="The Exploration of Chirality for Improved Druggability within the Human Kinome" /></meta><meta name="dc.Creator" content="Debasmita  Saha" /></meta><meta name="dc.Creator" content="Anupreet  Kharbanda" /></meta><meta name="dc.Creator" content="Wei  Yan" /></meta><meta name="dc.Creator" content="Naga Rajiv  Lakkaniga" /></meta><meta name="dc.Creator" content="Brendan  Frett" /></meta><meta name="dc.Creator" content="Hong-Yu  Li" /></meta><meta name="dc.Description" content="Chirality is important in drug discovery because stereoselective drugs can ameliorate therapeutic difficulties including adverse toxicity and poor pharmacokinetic profiles. The human kinome, a majo..." /></meta><meta name="Description" content="Chirality is important in drug discovery because stereoselective drugs can ameliorate therapeutic difficulties including adverse toxicity and poor pharmacokinetic profiles. The human kinome, a majo..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 24, 2019" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00640" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00640" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00640" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00640" /></link>
        
    
    

<title>The Exploration of Chirality for Improved Druggability within the Human Kinome | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00640" /></meta><meta property="og:title" content="The Exploration of Chirality for Improved Druggability within the Human Kinome" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0046.jpeg" /></meta><meta property="og:description" content="Chirality is important in drug discovery because stereoselective drugs can ameliorate therapeutic difficulties including adverse toxicity and poor pharmacokinetic profiles. The human kinome, a major druggable enzyme class has been exploited to treat a wide range of diseases. However, many kinase inhibitors are planar and overlap in chemical space, which leads to selectivity and toxicity issues. By exploring chirality within the kinome, a new iteration of kinase inhibitors is being developed to better utilize the three-dimensional nature of the kinase active site. Exploration into novel chemical space, in turn, will also improve drug solubility and pharmacokinetic profiles. This perspective explores the role of chirality to improve kinome druggability and will serve as a resource for pioneering kinase inhibitor development to address current therapeutic needs." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Chirality is important in drug discovery because stereoselective drugs can ameliorate therapeutic difficulties including adverse toxicity and poor pharmacokinetic profiles. The human kinome, a major druggable enzyme class has been exploited to treat a wide range of diseases. However, many kinase inhibitors are planar and overlap in chemical space, which leads to selectivity and toxicity issues. By exploring chirality within the kinome, a new iteration of kinase inhibitors is being developed to better utilize the three-dimensional nature of the kinase active site. Exploration into novel chemical space, in turn, will also improve drug solubility and pharmacokinetic profiles. This perspective explores the role of chirality to improve kinome druggability and will serve as a resource for pioneering kinase inhibitor development to address current therapeutic needs." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0046.jpeg" /></meta><meta name="twitter:title" content="The Exploration of Chirality for Improved Druggability within the Human Kinome" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00640"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00640">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00640&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00640&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00640&amp;href=/doi/10.1021/acs.jmedchem.9b00640" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 441-469</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b00775" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">The Exploration of Chirality for Improved Druggability within the Human Kinome</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Debasmita Saha</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Debasmita Saha</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Debasmita++Saha">Debasmita Saha</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anupreet Kharbanda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anupreet Kharbanda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anupreet++Kharbanda">Anupreet Kharbanda</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wei Yan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Yan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Yan">Wei Yan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Naga Rajiv Lakkaniga</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Naga Rajiv Lakkaniga</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Naga+Rajiv++Lakkaniga">Naga Rajiv Lakkaniga</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brendan Frett</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brendan Frett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</div></div><span class="conrtib-corresp"><strong>*</strong>For B.F.: E-mail, <a href="/cdn-cgi/l/email-protection#76343730041302023603171b0558131203"><span class="__cf_email__" data-cfemail="753734330710010135001418065b101100">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brendan++Frett">Brendan Frett</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Hong-Yu Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong-Yu Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</div></div><span class="conrtib-corresp"><strong>*</strong>For H.L.: E-mail, <a href="/cdn-cgi/l/email-protection#145c587d2654617579673a717061"><span class="__cf_email__" data-cfemail="3f7773560d7f4a5e524c115a5b4a">[email protected]</span></a>; 501-296-1154.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong-Yu++Li">Hong-Yu Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9212-2010" title="Orcid link">http://orcid.org/0000-0001-9212-2010</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00640&amp;href=/doi/10.1021%2Facs.jmedchem.9b00640" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 441–469</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 24, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 April 2019</li><li><span class="item_label"><b>Published</b> online</span>24 September 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 January 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00640" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00640</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D441%26pageCount%3D29%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDebasmita%2BSaha%252C%2BAnupreet%2BKharbanda%252C%2BWei%2BYan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D2%26contentID%3Dacs.jmedchem.9b00640%26title%3DThe%2BExploration%2Bof%2BChirality%2Bfor%2BImproved%2BDruggability%2Bwithin%2Bthe%2BHuman%2BKinome%26numPages%3D29%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D469%26publicationDate%3DJanuary%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00640"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4282</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00640" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;The Exploration of Chirality for Improved Druggability within the Human Kinome&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Debasmita&quot;,&quot;last_name&quot;:&quot;Saha&quot;},{&quot;first_name&quot;:&quot;Anupreet&quot;,&quot;last_name&quot;:&quot;Kharbanda&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Yan&quot;},{&quot;first_name&quot;:&quot;Naga&quot;,&quot;last_name&quot;:&quot;Rajiv Lakkaniga&quot;},{&quot;first_name&quot;:&quot;Brendan&quot;,&quot;last_name&quot;:&quot;Frett&quot;},{&quot;first_name&quot;:&quot;Hong-Yu&quot;,&quot;last_name&quot;:&quot;Li&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;441-469&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00640&quot;},&quot;abstract&quot;:&quot;Chirality is important in drug discovery because stereoselective drugs can ameliorate therapeutic difficulties including adverse toxicity and poor pharmacokinetic profiles. The human kinome, a major druggable enzyme class has been exploited to treat a wide range of diseases. However, many kinase inhibitors are planar and overlap in chemical space, which leads to selectivity and toxicity issues. By exploring chirality within the kinome, a new iteration of kinase inhibitors is being developed to better utilize the three-dimensional nature of the kinase active site. Exploration into novel chemical space, in turn, will also improve drug solubility and pharmacokinetic profiles. This perspective explores the role of chirality to improve kinome druggability and will serve as a resource for pioneering kinase inhibitor development to address current therapeutic needs.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00640&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00640" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00640&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00640" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00640&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00640" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00640&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00640&amp;href=/doi/10.1021/acs.jmedchem.9b00640" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00640" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00640" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00640%26sid%3Dliteratum%253Aachs%26pmid%3D31550151%26genre%3Darticle%26aulast%3DSaha%26date%3D2020%26atitle%3DThe%2BExploration%2Bof%2BChirality%2Bfor%2BImproved%2BDruggability%2Bwithin%2Bthe%2BHuman%2BKinome%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D2%26spage%3D441%26epage%3D469%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292325" title="Chirality">Chirality</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291763" title="Noncovalent interactions">Noncovalent interactions</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/2" title="Go to Volume 63, Issue 2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/jmcmar.2020.63.issue-2/20200123/jmcmar.2020.63.issue-2.largecover.jpg" alt="Go to Volume 63, Issue 2"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0046.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Chirality is important in drug discovery because stereoselective drugs can ameliorate therapeutic difficulties including adverse toxicity and poor pharmacokinetic profiles. The human kinome, a major druggable enzyme class has been exploited to treat a wide range of diseases. However, many kinase inhibitors are planar and overlap in chemical space, which leads to selectivity and toxicity issues. By exploring chirality within the kinome, a new iteration of kinase inhibitors is being developed to better utilize the three-dimensional nature of the kinase active site. Exploration into novel chemical space, in turn, will also improve drug solubility and pharmacokinetic profiles. This perspective explores the role of chirality to improve kinome druggability and will serve as a resource for pioneering kinase inhibitor development to address current therapeutic needs.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61757" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61757" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Stereochemistry has a vital role in pharmacology by dictating pharmacokinetic and pharmacodynamic properties of a drug molecule.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> The enantiomers of a chiral drug may have identical physical and chemical properties but, in a chiral environment, enantiomeric effects can be significantly different.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Hypothetically, an active enantiomer will perfectly fit into the receptor binding site to produce a pharmacological effect whereas the inactive enantiomer (distomer) does not and will not generate any active response.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> Moreover, the distomer may interact at a site elsewhere and cause an unwanted or adverse effect as a consequence of its pharmacodynamics, e.g., thalidomide, a drug used for morning sickness in the late 1950s, caused teratogenic effects in offspring (phocomelia).<a onclick="showRef(event, 'ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9">(6−9)</a> Later, it was discovered that only the <i>S</i>-isomer could cross the blood–placental barrier and was responsible for teratogenicity.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Considering the possible detrimental effects of the distomer, the FDA provided guidelines to ensure stereoisomeric composition of a drug and pharmacokinetics of specific enantiomers.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a></div><div class="NLM_p">In certain drugs, such as atropisomers,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> a chiral center does not exist but hindrance around a rotatable bond generates axial chirality. Compounds with axial chirality exhibit similar properties to that of traditional enantiomers, which can significantly impact drug properties. Recently, drug design and synthetic campaigns have been carried out to address the issue of atropisomers in pharmaceutical development. Because axial chirality can give rise to a single, stereochemically stable drug with improved efficacy and safety, atropisomers are being developed in a similar fashion to that of enantiomers to enhance drug properties.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a></div><div class="NLM_p">Chiral drug discovery has gained much attention in the human kinome as a method to improve drug properties of kinase inhibitors. As is known, the kinome represents promising drug targets because of their pivotal roles in cellular signaling.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Kinase inhibitors are divided between type I (ATP competitive), II (ATP noncompetitive), and III (allosteric) and are typically planar, nonchiral structures.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> An emerging paradigm to improve kinome selectivity is to explore the three-dimensional nature of the kinase active site by generating chiral inhibitors. Researchers have investigated this strategy to successfully address potency and selectivity issues.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> For example, FDA approved drugs crizotinib and lorlatinib were developed by exploiting chirality to improve potency, selectivity, and pharmacokinetics.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> Additionally, the FDA approved drug tofacitinib was selectively developed for JAK3 by evaluating selectivity of diastereomers.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In general, chirality can be engineered into kinase inhibitors to improve drug properties. Various approved enantiospecific kinase inhibitors are listed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Various Approved Chiral Kinase Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug name</th><th class="colsep0 rowsep0" align="center">trade name</th><th class="colsep0 rowsep0" align="center">approval</th><th class="colsep0 rowsep0" align="center">developer</th><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">indication</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sirolimus<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">Rapamune</td><td class="colsep0 rowsep0" align="center">1999<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></td><td class="colsep0 rowsep0" align="center">Wyeth-Ayerst Research</td><td class="colsep0 rowsep0" align="center">FKBP12/mTOR</td><td class="colsep0 rowsep0" align="center">immunosuppressant</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">temsirolimus<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">Torisel</td><td class="colsep0 rowsep0" align="center">2007<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></td><td class="colsep0 rowsep0" align="center">Wyeth Pharmaceuticals</td><td class="colsep0 rowsep0" align="center">FKBP12/mTOR</td><td class="colsep0 rowsep0" align="center">advanced RCC<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">everolimus<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">Afinitor</td><td class="colsep0 rowsep0" align="center">2009</td><td class="colsep0 rowsep0" align="center">Novartis</td><td class="colsep0 rowsep0" align="center">FKBP12/mTOR</td><td class="colsep0 rowsep0" align="center">immunosuppressant</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">crizotinib</td><td class="colsep0 rowsep0" align="center">Xalkori</td><td class="colsep0 rowsep0" align="center">2011</td><td class="colsep0 rowsep0" align="center">Pfizer</td><td class="colsep0 rowsep0" align="center">ALK, <i>c</i>-MET, HGFR</td><td class="colsep0 rowsep0" align="center">NSCLC</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ruxolitinib</td><td class="colsep0 rowsep0" align="center">Jakafi</td><td class="colsep0 rowsep0" align="center">2011</td><td class="colsep0 rowsep0" align="center">Incyte</td><td class="colsep0 rowsep0" align="center">JAK1, JAK2</td><td class="colsep0 rowsep0" align="center">myelofibrosis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tofacitinib</td><td class="colsep0 rowsep0" align="center">Xeljanz</td><td class="colsep0 rowsep0" align="center">2012</td><td class="colsep0 rowsep0" align="center">Pfizer</td><td class="colsep0 rowsep0" align="center">JAK2, JAK3</td><td class="colsep0 rowsep0" align="center">RA<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">afatinib</td><td class="colsep0 rowsep0" align="center">Gilotrif</td><td class="colsep0 rowsep0" align="center">2013</td><td class="colsep0 rowsep0" align="center">Boehringer Ingelheim</td><td class="colsep0 rowsep0" align="center">EGFR, HER2</td><td class="colsep0 rowsep0" align="center">NSCLC<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">inbrutinib</td><td class="colsep0 rowsep0" align="center">Imbruvica</td><td class="colsep0 rowsep0" align="center">2013</td><td class="colsep0 rowsep0" align="center">Pharmacyclics</td><td class="colsep0 rowsep0" align="center">BTK</td><td class="colsep0 rowsep0" align="center">CLL,<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a> MCL<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">idelalisib</td><td class="colsep0 rowsep0" align="center">Zydelig</td><td class="colsep0 rowsep0" align="center">2014</td><td class="colsep0 rowsep0" align="center">Gilead</td><td class="colsep0 rowsep0" align="center">PI3Kδ</td><td class="colsep0 rowsep0" align="center">haematological cancers</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cobimetinib</td><td class="colsep0 rowsep0" align="center">Cotellic</td><td class="colsep0 rowsep0" align="center">2015<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></td><td class="colsep0 rowsep0" align="center">Exelixis and Genentech</td><td class="colsep0 rowsep0" align="center">MEK1/2</td><td class="colsep0 rowsep0" align="center">melanoma</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">midostaurin<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">Rydapt</td><td class="colsep0 rowsep0" align="center">2017<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></td><td class="colsep0 rowsep0" align="center">Novartis</td><td class="colsep0 rowsep0" align="center">FLT3</td><td class="colsep0 rowsep0" align="center">AML<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">netarsudil</td><td class="colsep0 rowsep0" align="center">Rhopressa</td><td class="colsep0 rowsep0" align="center">2018<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></td><td class="colsep0 rowsep0" align="center">Aerie Pharm</td><td class="colsep0 rowsep0" align="center">Rho Kinase</td><td class="colsep0 rowsep0" align="center">glaucoma</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">acalabrutinib</td><td class="colsep0 rowsep0" align="center">Calquence</td><td class="colsep0 rowsep0" align="center">2017<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></td><td class="colsep0 rowsep0" align="center">Acerta Pharm</td><td class="colsep0 rowsep0" align="center">BTK</td><td class="colsep0 rowsep0" align="center">MCL<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">encorafenib</td><td class="colsep0 rowsep0" align="center">Braftovi</td><td class="colsep0 rowsep0" align="center">2018<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></td><td class="colsep0 rowsep0" align="center">Array BioPharma</td><td class="colsep0 rowsep0" align="center">B-Raf<sup>V600E/K</sup></td><td class="colsep0 rowsep0" align="center">melanoma</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">larotrectinib</td><td class="colsep0 rowsep0" align="center">Vitrakvi</td><td class="colsep0 rowsep0" align="center">2018<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></td><td class="colsep0 rowsep0" align="center">Bayer</td><td class="colsep0 rowsep0" align="center">NTRK</td><td class="colsep0 rowsep0" align="center">NTRK positive solid tumors</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Natural-product derived.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">RCC, renal cell carcinoma.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">RA, rheumatoid arthritis.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">NSCLC, nonsmall cell lung cancer.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">CLL, chronic lymphocytic leukemia.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">MCL, mantle cell lymphoma.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">AML, acute myeloid leukemia.</p></div></div></div><div class="NLM_p last">In this perspective, we consider the role of chirality in the discovery of safer, more efficacious kinase inhibitors to treat chronic diseases with an emphasis on malignancies. A comprehensive overview is provided outlining the discovery of clinically approved chiral kinase inhibitors or inhibitors under clinical development. This perspective serves as a resource for pioneering kinase inhibitor discovery to address new therapeutic needs through enantio-specific approaches.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">2.  Chiral Kinase Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20306" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20306" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.1.  ALK and c-MET Receptor Tyrosine Kinases</h3><div class="NLM_p">Receptor tyrosine kinases (RTKs) are transmembrane receptors activated by growth factors, cytokines, or hormones. They transfer the γ-phosphate of ATP to a tyrosine residue of a downstream signaling partner. RTKs play fundamental roles in cellular processes such as proliferation, migration, metabolism, differentiation, and survival.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Uncontrolled RTK activities are associated with various types of cancers and numerous small molecules targeting RTKs have been approved for the treatment of cancers.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In particular, hepatocyte growth factor receptor (HGFR) and anaplastic lymphoma kinase (ALK) have been targeted for their roles in nonsmall cell lung cancer.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a></div><div class="NLM_p">HGFR, also known as <i>c</i>-MET, has participating roles in normal cellular processes with subsequent signaling from RTKs. Consequently, aberrant <i>c</i>-MET signaling is correlated with poor prognosis and metastatic progression in a number of major cancers.<a onclick="showRef(event, 'ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37">(35−37)</a> ALK, belonging to the insulin receptor superfamily, was first discovered as a NPM-ALK fusion protein in anaplastic lymphoma.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> ALK chromosomal alterations have been observed in anaplastic large cell lymphoma (50%–60%), inflammatory myofibroblastic tumors (27%), and nonsmall cell lung cancer (NSCLC) (4%–7%). Hence, both <i>c</i>-MET and ALK underwent extensive targeting strategies for the treatment of cancer.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div id="sec2_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i6" class="anchor-spacer"></div><h4 class="article-section__title" id="_i6">2.1.1.  FDA-Approved RTK Drugs</h4><div id="sec2_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i7" class="anchor-spacer"></div><h5 class="article-section__title" id="_i7">2.1.1.1.  <b>Crizotinib</b> (Aug 2011, Pfizer)</h5><div class="NLM_p">In 2011, <b>crizotinib</b> (<b>7</b>, PF-02341066) became the first FDA approved chiral ALK kinase inhibitor for the treatment of NSCLC.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Crizotinib demonstrates concentration-dependent inhibition of ALK and <i>c</i>-MET and has antitumor activity in mice bearing tumor xenografts with <i>c</i>-MET and EML4- or NPM-ALK fusion proteins.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Although originally approved for ALK fusion oncogenes, crizotinib is also a potent inhibitor of <i>c</i>-MET and ROS1. Crizotinib was discovered through lead-based optimization, which focused on improving selectivity and pharmacokinetic properties of lead candidates by exploiting chirality.</div><div class="NLM_p">The discovery of crizotinib initiated with the identification of compound <b>1</b> (PHA-665752) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), which is a <i>c</i>-MET inhibitor with cellular potency (IC<sub>50</sub> = 0.009 μM in GTL-16 cell line) and moderate selectivity (>50-fold for <i>c</i>-MET compared to other kinases).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> However, poor pharmacokinetic properties of <b>1</b> led to an optimization campaign to improve drug properties as well as kinase selectivity. The cocrystal structure<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> of compound <b>1</b> with <i>c</i>-MET revealed inefficient interaction within the ATP pocket, so the warhead was re-engineered to 4-(6-amino-5-((2,6-dichlorobenzyl)oxy)pyridin-3-yl)phenol (<b>2</b>), which led to an increase in receptor affinity (<i>K</i><sub><i>i</i></sub> = 3.83 μM). Scaffold <b>2</b> was further optimized to improve solubility to afford <b>3</b> (<i>K</i><sub><i>i</i></sub> = 0.46 μM).</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Drug Design of Compound <b>7</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further modification of the linkage between the 2-aminopyridine core and the phenyl ring was investigated due to a small lipophilic pocket adjacent to the binding location of the 3-benzyloxy linker. Addition of a small α-methyl group enhanced the binding efficiency of <b>4</b> (<i>K</i><sub><i>i</i></sub> = 0.068 μM, IC<sub>50</sub>= 0.14 μM) along with lipophilicity (LipE <i>K</i><sub><i>i</i></sub> = 4.20; LipE IC<sub>50</sub> = 3.86). Also, the α-methyl group improved pharmacokinetics by impairing benzylic oxidation and created a chiral center. Finally, the combination of 2,6-dichloro, 3-fluoro, and α-methyl into compound <b>5</b> provided the greatest inhibition against <i>c</i>-MET and the highest LipE values (enzymatic LipE = 4.82, cell LipE = 4.60; <i>K</i><sub><i>i</i></sub> = 0.012 μM, cell IC<sub>50</sub> = 0.020 μM).</div><div class="NLM_p">Aforementioned, the addition of the α-methyl introduced a chiral center (<b>5</b>), and the two enantiomers of compound <b>5</b> were synthesized and assessed. The <i>R</i>-enantiomer (<b>7</b>) exhibited better potency than the racemate (<b>5</b>) and <i>S</i>-isomer (<b>6</b>), which can be attributed to improved solubility, binding affinity, and assay variation. Hence, compound <b>7</b> efficiently binds <i>c</i>-MET, resulting in improved cell-based ligand efficacy (LE) and LipE values with blocked benzylic oxidation.</div><div class="NLM_p">The cocrystal structure of compound <b>7</b><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> bound to nonphosphorylated <i>c</i>-MET was solved (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, left). 2-Aminopyridine is involved in two hydrogen bonds with the hinge region (Pro1158 and Met1160). The chiral methyl group interacts with the <i>c</i>-MET A-loop, which rigidifies the benzyl group and occupies a small lipophilic pocket between Val1092 and Leu1157 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, right). Moreover, the chiral benzyl group orients in a π–π interaction with Tyr1230. It can be concluded from structural analysis that the <i>R</i>-enantiomer preferentially interacts with Val1092, Leu1157, and Try1230; the <i>S</i>-enantiomer, however, would sterically clash with the <i>c</i>-MET back pocket and justifies the 100-fold loss in activity. Therefore, by exploiting chirality, <i>R</i>-enantiomer <b>7</b> was developed with enhanced enzymatic activity and improved pharmacokinetic profiles over the <i>S</i>-enantiomer <b>6</b>.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Cocrystal structure of compound <b>7</b> bound to <i>c</i>-MET (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WGJ">2WGJ</a>, 2.0 Å). (left) Interaction of compound <b>7</b> with the protein. The protein is depicted as yellow ribbons, and hydrogen bonds are illustrated with blue dashed lines. (right) The compound <b>7</b> binding site in <i>c</i>-MET. The surface of the protein is depicted in blue. Compound <b>7</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i9" class="anchor-spacer"></div><h5 class="article-section__title" id="_i9">2.1.1.2.  <b>Lorlatinib</b> (Nov 2018, Pfizer)</h5><div class="NLM_p">Because of poor blood–brain barrier permeability of crizotinib, modifications were made to the molecule to better target ALK-positive NSCLC brain metastasis (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> It was hypothesized that simultaneous improvement in cellular potency and multidrug resistance (MDR) BA/AB ratios (<2.5) could be achieved if crizotinib was redesigned with a restricted conformation and removal of the highly basic amine.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The cocrystal structure of compound <b>8</b> bound to ALK highlighted an acyclic U-shaped pose with the fluorobenzene and heteroaromatic tail in proximity to the binding site. This suggested that novel macrocyclic design templates, with restricted conformations, could retain potency while achieving desirable central nervous system (CNS) ADME properties.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Drug Design of Compound <b>9</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A series of 12–14-membered macrocycles were tested and <b>8a</b> (<i>R</i>-enantiomer) exhibited an improvement in potency (ALK <i>K</i><sub><i>i</i></sub> = 0.0002 μM, ALK-L1196 M <i>K</i><sub><i>i</i></sub> = 0.00029 μM) against both wild-type and mutant ALK compared with the <i>S</i>-enantiomer (<b>8b</b>) (ALK K<sub><i>i</i></sub> = 0.0017 μM, ALK-L1196M <i>K</i><sub><i>i</i></sub> = 0.00061 μM). This stereochemical preference of the <i>R</i>-isomer accounts for a 10-fold improvement compared to the <i>S</i>-enantiomer. Additional modifications were performed to obtain the required combination of potency, ADME, and CNS availability, which provided compound <b>9</b> (lorlatinib). Interestingly, <b>9</b> was found to exhibit atropisomerism via a “ring-flip”, but because of a high energy barrier, only a single diastereomer is physiologically relevant.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_p">Selectivity of the macrocycles for ALK over the highly conserved TrkB kinase was investigated because of the importance of TrkB in CNS homeostasis.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> It was found that the cyano group of compound <b>9</b> (<b>lortatinib</b>) was highly selective for the ALK mutation L1196M.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> The chiral α-methyl on compound <b>9</b> orients the fluorobenzene into a lipophilic pocket formed by Leu1256, Cys1255, and Gly1269 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, right). Consequently, in TrkB, the cyano moiety of <b>9</b> is oriented to Tyr635. This interaction causes unfavorable desolvation energies between the nitrile and Tyr635 resulting in 40-fold selectivity for ALK over TrkB. The cocrystal structure of <b>9</b> bound to ALK depicts key hydrogen bonding of the NH<sub>2</sub> and ring nitrogen of the 2-aminopyrazine core with hinge residues Glu1197 and Met1199 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, left).</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structure of compound <b>9</b> bound to ALK (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CMU">4CMU</a>, 1.8 Å). (left) Interaction of compound <b>9</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) Compound <b>9</b> binding site in ALK, protein is shown as surface. Compound <b>9</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The macrocycles were examined for CNS availability by analyzing MDR BA/AB efflux. Compound <b>9</b> exhibited low efflux potential, low clearance, and improved potency against wild-type and ALK mutants compared to crizotinib. On November 2, 2018, the FDA granted accelerated approval of compound <b>9</b> for ALK-positive NSCLC with metastatic disease.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> By exploiting chirality and macrocyclic atropisomerism, compound <b>9</b> achieved enhanced CNS penetration and improved kinome selectivity.</div></div></div><div id="sec2_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11">2.1.2.  RTK Inhibitors Under Clinical Development</h4><div class="NLM_p">Although crizotinib provides upfront efficacy, patients frequently develop resistance to treatment because of ALK mutations (L1196M, G1269A, S1206Y, C1156Y, F1174L, L1152R, and 1151Tins). Therefore, crizotinib was reengineered and optimized for ALK mutations by using a combination of LipE analysis and structure-based drug design.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Comparing the crizotinib–ALK cocrystal structure to its apo form suggested a smaller C2 group would relax the Gly1269 carbonyl and enhance ALK mutant potency. Hence, strategies focused on optimizing the 2,6-dichloro-3-fluorophenyl group as well as limiting structural bulk at the pyrazolopiperidine tail (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Drug Design of Compound <b>12</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Optimization efforts uncovered that a triazole on C6 and a thiazole with a tertiary alcohol (<b>10b</b>) afforded the best potency and lipophilic values (L1196M cell IC<sub>50</sub> = 0.027 μM, log <i>D</i> = 3.6). The alcohol formed a hydrogen bond with the carbonyl group of Asp1203 and structural analysis suggested another alcohol in proximity to Asp1203 could improve binding site interactions. The resulting <i>R</i> and <i>S</i> enantiomers with a primary alcohol were synthesized, among which the <i>S</i> enantiomer <b>12</b> (PF-06439015) exhibited an improved LipE value and an increase in cellular potency compared to crizotinib. Importantly, compound <b>12</b> also exhibited activity against ALK mutations L1196M and G1269A of which crizotinib is not active.</div><div class="NLM_p">The cocrystal structure of compound <b>12</b> with wild-type ALK illustrates that the hydroxy group formed two hydrogen bonds with Asp1203 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Moreover, introduction of the additional hydroxy group reduces lipophilicity but maintains membrane permeability because of intramolecular hydrogen bonding. Interestingly, the <i>R</i>-enantiomer of the chiral alcohol (<b>11</b>) demonstrated a reduced LipE value suggesting that an optimal chiral alignment is essential for improved drug properties.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cocrystal structure of compound <b>12</b> bound to ALK L1196M protein (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CD0">4CD0</a>, 2.23 Å). Interaction of compound <b>12</b> into the binding site of the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound <b>12</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Harmange et al. discovered a series of triazolo-pyridines/pyridazines<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> exhibiting cellular and enzymatic potency against <i>c</i>-MET.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> The U-shaped inhibitors adopt a unique <i>c</i>-MET binding mode and presented with exciting selectivity properties over other kinases. The first series was based on <i>O</i>-linked (<b>13</b>) and <i>N</i>-linked triazolopyridazine (<b>14</b>) but both suffered from poor solubility and rapid clearance in a patient-derived xenograft (PDX) model.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> These limitations were addressed with the generation of compound <b>15</b>. The combination of a PEG-like ethoxy solubilizing group, a fluorine to block aromatic oxidation, and an <i>R</i> α-methyl to block benzylic oxidation furnished the best combination of potency and pharmacokinetic properties. However, efficacy was not optimal in PDX models (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Further improvements were investigated to improve drug properties, which resulted in compound <b>16</b> (<b>AMG 337</b>). Compound <b>16</b> was predicted to form intramolecular hydrogen bonds to reinforce the rigidity of the U-shaped binding mode.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Compound <b>16</b> exhibited an improved half-life, high oral bioavailability (∼65%), and strong inhibition of <i>c</i>-MET over a 12 h period. Compound <b>16</b> was also evaluated in a <i>c</i>-MET dependent xenograft model and exhibited an ED<sub>50</sub> of 0.3 mg/kg.</div><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Drug Design of Compound <b>16</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Boezio et al. produced a cocrystal structure of compound <b>16</b> with unphosphorylated <i>c</i>-MET<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> and confirmed that the inhibitor adopts the predicted U-shaped binding mode. The chiral benzylic methyl forces the compound in a stable U-shaped binding mode around Met1211 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, left), which would cause a steric clash with the <i>S</i>-enantiomer. The naphthyridinone nitrogen hydrogen bonds with the hinge at Met1160, whereas the nitrogen of the fluorotriazolopyridine engages the amide backbone of Asp1222. Furthermore, Tyr1230 and the fluorotriazolopyridine ring system exhibit face-to-face π–π stacking. The bulky fluorotriazolopyridine orients toward the solvent front, which is unlikely for the <i>S</i>-analogue because of geometric constraints in the <i>c</i>-MET back pocket. Interestingly, the <i>R</i>-configuration is encapsulated in a small, lipophilic pocket generated by Val1092, Leu1157, and Lys1110 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, right), but the <i>S</i>-enantiomer is unable to interact in the same pocket. Also, the fluorine atom on fluorotriazolopyridine is confined to a small cleft perpendicular to the amide backbone of Asn1209. Compound <b>16</b> was selected as a clinical candidate and is currently in phase II clinical trials for <i>c</i>-MET amplified gastric/esophageal adenocarcinoma and other solid tumors (NCT02016534).</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cocrystal structure of compound <b>16</b> bound to <i>c</i>-MET (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EYD">5EYD</a>, 1.85 Å). (left) Interaction of compound <b>16</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) Compound <b>16</b> binding site in <i>c</i>-MET, protein is shown as surface. Compound <b>16</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Katz et al.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> uncovered inhibitor <b>17</b> while screening a Merck library. Follow on studies identified <b>17</b> as a potent ATP competitive inhibitor of <i>c</i>-MET (IC<sub>50</sub> = 0.031 μM). The tricyclic heptanone core is a unique kinase warhead; therefore, optimization efforts focused on the phenyl and sulfonamide regions while keeping the warhead fixed. Aryl and heteroaryl derivatives were tested at the 3-position, among which the <i>N</i>-methyl pyrazolyl analogue <b>18</b> displayed a 27-fold increase in potency (IC<sub>50</sub> = 0.004 μM) (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). To improve solubility, alterations were examined on the 7-position sulfonamide with analogues such as vinyl, phenyl, imidazolyl, trifluoromethyl, and <i>tert</i>-butyl. Further modifying the pyrazole substituent and diversifying the sulfonamide moiety led to free amine <b>18a</b> (<i>c</i>-MET IC<sub>50</sub> = 0.003 μM) and monomethyl amine <b>18b</b> (<i>c</i>-MET IC<sub>50</sub> = 0.002 μM), which were subjected to metabolic profiling. Metabolic studies revealed that rapid dealkylation of the sulfonamide was the main metabolic path. To block dealkylation, cyclic analogues were generated, which exhibited optimal cell-based activities and pharmacokinetics. The <i>R</i>-dioxanyl cyclic analogue <b>20</b> (<b>MK-2461</b>), displayed the best cell potency (GTL-16 IC<sub>50</sub> = 0.056 μM) and excellent rat pharmacokinetics (Clp = 10 mL/min/kg, <i>t</i><sub>1/2</sub> = 1.3 h).</div><figure id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Drug Design of Compound <b>18</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A piperidine analogue of compound <b>20</b>, <b>18c</b> (<i>c</i>-MET IC<sub>50</sub> = 0.0026 μM), was cocrystallized with <i>c</i>-MET and adopts a similar pose as compound <b>20</b>. The analogue forms a hydrogen bond with Met1160 at the hinge region, and the substituent on the pyrazole moiety extends into the solvent (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Other key interactions include a hydrogen bond with Asp1222 and a hydrogen bond between the (<i>R</i>)-1,4-dioxane moiety and Arg1086. The sulfonamide moiety is buried near the catalytic lysine and the glycine rich loop. The stereospecific alignment of (<i>R</i>)-1,4-dioxane allows a water mediated hydrogen bond between the most proximal dioxanyl oxygen and the carbonyl oxygen of the central core. As a result, the tricyclic core adopts a conformation slightly out of plane. Hence, inclusion of the chiral (<i>R</i>)-analogue generates a unique binding mode for compound <b>20</b> in <i>c</i>-Met and effectively interacts with the solvent improving pharmacokinetic properties. Compound <b>20</b> has progressed into clinical studies and is the first candidate to enter phase II clinical trials from the tricyclic series (NCT00518739).</div><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Cocrystal structure of analogue <b>18c</b> bound to <i>c</i>-MET (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7O">3R7O</a>, 2.3 Å). Interaction of analogue <b>18c</b> at the binding site of the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound <b>18c</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Insulin-like growth factor (IGF) receptor is another RTK that has been targeted with chiral molecules.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The IGF system is comprised of three receptors (IR, IGF-1R, IGF-2R), three ligands (insulin, IGF-1, IGF-2), and six 3-indole-<span class="smallcaps smallerCapital">d</span>-glycerol-3′-phosphate (IGP) binding proteins (IGFBP1–6). The IGF-1R downstream signaling pathway is activated by insulin receptor (IR) substrates-1–4 and Src-homology collagen proteins as adapter molecules. Activation of the receptor triggers both PI3K/Akt and Ras/Raf pathways, thereby controlling apoptosis. Several studies have highlighted the key roles IGF-1R plays in cancer cell proliferation and metastasis. Overexpression of IGF-1R has been associated with colorectal and breast cancer.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> In addition, increased levels of IGF-1 have been associated with prostate cancer and premenopausal breast cancer.<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60,61)</a> The two main approaches to control IGF-1R signaling include monoclonal antibody therapy and small molecule inhibition.<a onclick="showRef(event, 'ref62 ref63 ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref62 ref63 ref64 ref65">(62−65)</a></div><div class="NLM_p"><b>BMS-754807</b> (<b>23</b>) is a pyrrolo-triazine based IGF-1R inhibitor exhibiting good clinical results.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> For development, structural modifications were performed on compound <b>21</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>). The core of the inhibitor was developed into pyrrolotriazine with cyclopropyl substitution on pyrazole <b>22</b>, providing further scope of structure–activity relationship (SAR) studies on the C2 amine.</div><figure id="sch6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0025.jpeg" id="GRAPHIC-d7e1401-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Drug Design of Compound <b>23</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The primary amide (<b>22a</b>) was found to be potent against IGF-1R but also exhibited CDK2E inhibition. The <i>S</i>-amide (<b>22a</b>) was found to be 5-fold more potent than the <i>R</i>-amide (<b>22b</b>). Other substituents, such as phenyl, thiazole, and pyridine, showed improved potency, but the (<i>S</i>)-2-methyl analogues, with heterocyclic amides (<b>22c</b>), maintained potency with better selectivity. By optimizing the pyridyl substitution, analogue <b>23</b> was discovered and had an optimal combination of both potency (IC<sub>50</sub> = 0.002 μM). It exhibited lower toxicity and good pharmacokinetic properties.</div><div class="NLM_p">The cocrystal structure of compound <b>23</b> with IGF-1R demonstrates a donor/acceptor/donor hydrogen bonding motif with Met1052, Leu1051, and Glu1050 at the hinge. Moreover, the pyridyl ring nitrogen is involved in a hydrogen bond with the backbone of Asp1123. In the <i>S</i>-enantiomer, the cyclopropyl substituent on pyrazole could accommodate the gatekeeper (Met1049) and the fluoropyridyl amide engages the back pocket. The less active <i>R</i>-enantiomer would have a steric clash between the fluoropryidyl ring and the Gly-rich loop of the kinase. Because of the favorable interactions, the <i>S</i>-isomer (<b>23</b>) exhibits better potency compared to the <i>R</i>-isomer (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><figure id="fig6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cocrystal structure of compound <b>23</b> bound to IGF-1R (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3I81">3I81</a>, 2.08 Å). (left) Interaction of compound <b>23</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>23</b> in IGFR-1R. The surface of the protein is depicted in blue. Compound <b>23</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Additional chiral RTK inhibitors (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>) are being evaluated in clinical studies including LY2874455, AZD4547, and BMS-582664. Compound <b>24</b> (<b>LY2874455</b>) is a novel pan-FGFR inhibitor and is in phase I clinical trials for solid tumors (NCT01212107).<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67,68)</a> Compound <b>25</b> (<b>BMS-582664</b>) is a prodrug for dual inhibition of VEGFR-2/FGFR-1 and is in phase II clinical trials for hepatocellular carcinoma.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Clearly, chirality is an important chemical addition to target RTKs, which can improve potency, selectivity, and pharmacokinetic profiles and can result in improved target inhibition.</div><figure id="sch7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0026.jpeg" id="GRAPHIC-d7e1518-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Chemical Structures of Chiral RTK Inhibitors <b>24</b> and <b>25</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">2.2.  Nonreceptor Tyrosine Kinase Inhibitors</h3><div class="NLM_p">Nonreceptor tyrosine kinases (nRTKs) are a subgroup of tyrosine kinases with the same primary function as RTKs except that they are solubilized, cytoplasmic enzymes. NRTK phosphorylation is associated with activation of T-cell receptors (TCR), B-cell receptors (BCR), IL-2 receptors (IL-2R), Ig, and prolactin receptors, thereby contributing to the immune system and immune response.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Also, oncogenic nRTK mutations (e.g. BCR-ABL) are prevalent in a variety of hematological malignancies. Several small molecule nRTK inhibitors have been investigated for both cancer and immune disorders.<a onclick="showRef(event, 'ref71 ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref71 ref72 ref73">(71−73)</a></div><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">2.2.1.  FDA-Approved Non-RTK Drugs</h4><div id="sec2_2_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i19" class="anchor-spacer"></div><h5 class="article-section__title" id="_i19">2.2.1.1.  <b>Ruxolitinib</b> (Nov 2011, Incyte) and <b>tofacitinib</b> (Nov 2012, Pfizer)</h5><div class="NLM_p">Ruxolitinib and tofacitinib are the first-generation Janus kinase (JAK) inhibitors approved for primary myelofibrosis and immunological diseases (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>).<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74,75)</a> The JAK family is comprised of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). The JAK pathway is activated upon binding of a cytokine to a cytokine receptor leading to the phosphorylation of JAK. In its active, phosphorylated form, JAK signals through STAT, which translocates to the nucleus and regulates gene transcription and cellular function.<a onclick="showRef(event, 'ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref76 ref77">(76,77)</a></div><figure id="sch8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0027.jpeg" id="GRAPHIC-d7e1569-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. FDA Approved Chiral JAK Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ruxolitinib (<b>26</b>, INCB018424)<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> was the first FDA approved JAK inhibitor for the treatment of myelofibrosis and is selective for JAK1/JAK2 over JAK3/TYK2 (NCT01164163). To date, the preclinical drug discovery and development campaign of ruxolitinib has not been disclosed. There are reports of resistance to ruxolitinib, but the exact mechanism is still unknown and is likely patient dependent.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Resistance could be due to on-target, JAK2 mutations or from mutations in the heterodimerization domain between JAK2 and JAK1.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div><div class="NLM_p">Tofacitinib (<b>27</b>, CP-690550) received regulatory approval in 2012 for the treatment of severe rheumatoid arthritis. It has also been developed for other disorders such as psoriasis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and Crohn’s disease.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Because tofacitinib is approved to treat chronic, nonlethal disease, the side effect profile should be minimal. In the discovery of tofacitinib, chirality was exploited for JAK3 selectivity, which resulted in low off-target liabilities and a well-tolerated side effect profile.</div><div class="NLM_p">Tofacitinib was discovered through high-throughput screening, which uncovered a series of pyrrolo[2,3-<i>d</i>]pyrimidines (<b>28</b>) (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The pyrrolopyrimidine warhead was hypothesized to bind the hinge of JAK3, and different heterocyclic substitutions were examined, but all reduced potency. To reduce bulk at the binding site, the tricyclic ring system was truncated to <i>N</i>-methylcycloalkyl, which increased potency (<b>29</b>). Substitutions were further explored on the cyclohexane ring, and it was found that the introduction of 2′,5′-dimethyl groups increased activity (<b>30</b>). Compound <b>30</b> is a complex mixture of eight isomers so stereospecific isomers were synthesized and tested. It was found that a natural product-like terpenoid derivative (<b>31</b>) provided optimal activity but required further optimization because of the exposed alkene and stereochemical complexity. To improve drug-like properties, piperidine-based analogues were explored, which was hypothesized to provide access the JAK3 activation loop. Through the analysis of piperidine analogues, a cyanoacetamide substituent was found to provide the best combination of potency and selectivity resulting in tofacitinib (<b>27</b>).<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81,82)</a></div><figure id="sch9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0028.jpeg" id="GRAPHIC-d7e1632-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Drug Development of Compound <b>27</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>27</b> was docked into the JAK3 binding pocket and demonstrated that the 7-deazapurine warhead hydrogen bonds to the JAK3 hinge (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). In addition, the nitrile group hydrogen bonds with Arg953 at the opening of the JAK3 cleft. This docking pose in JAK3 illustrates that the 4<i>R</i>-methyl group is axial (as per image <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>a) while the 3<i>R</i>-group is equatorial, suggesting stereospecific JAK3 binding.</div><figure id="fig7" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Binding of compound <b>27</b> into JAK3 active site (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YVJ">1YVJ</a>, 2.55 Å). Interaction of compound <b>27</b> at the binding site of protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound <b>27</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To investigate the stereospecificity of compound <b>27</b> for JAK3, its three stereoisomers were synthesized and subjected to cell-based assays, molecular modeling studies, and target profiling. JAK3 and JAK2/TYK2 serve as a shared receptor for selected cytokines and is downregulated by STAT5 and STAT4 phosphorylation, respectively. Hence, the degree of STAT5 and STAT4 phosphorylation was evaluated via immunoblotting with each stereoisomer and only compound <b>27</b> (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>) could affect STAT5 phosphorylation at the concentration of 0.5 μM and no clear inhibition of STAT4 phosphorylation was observed.</div><figure id="sch10" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0029.jpeg" id="GRAPHIC-d7e1690-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Four Stereoisomers of Tofacitinib</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, the selectivity profile over other kinases was determined and all four isomers were JAK selective, but compound <b>27</b> was more selective for JAK3 (<i>K</i><sub>d</sub> = 0.0075 μM for JAK3).<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Further, the stereoisomers were docked into the JAK3 catalytic cleft.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> The lowest energy conformations of the unbound compounds <b>27</b> and <b>27a</b>–<b>c</b> were superimposed with their respective best docked poses (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). It was found that only compound <b>27</b> (3<i>R</i>,4<i>R</i>) binds to JAK3 in a conformation that best resembles its minimum energy conformation, whereas the other isomers, <b>27a</b> (3<i>R</i>,4<i>S</i>) and <b>27b</b> (3<i>S</i>,4<i>R</i>), resemble an unstable half chair and a twisted boat conformation. The (3<i>S</i>,4<i>S</i>) isomer <b>27c</b> assumes a chair conformation in JAK3, but the axial and equatorial substitutions on the cyclohexane are high energy, respectively. Therefore, by exploiting chirality, tofacitinib was developed as a selective JAK3 inhibitor that is well tolerated for nonlethal indications of inflammation.</div><figure id="fig8" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Superimposition of the six-membered ring of the lowest energy conformation (MM2 energy minimization) of compounds (A) [<b>27</b> (<i>R</i>,<i>R</i>)], (B) [<b>27a</b> (<i>R</i>,<i>S</i>)], (C) [<b>27b</b> (<i>S</i>,<i>R</i>)], and (D) [<b>27c</b> (<i>S</i>,<i>S</i>)] (colored by atom type) and their respective best docked poses (colored in pink).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23">2.2.2.  Non-RTK Inhibitors in Clinical Development</h4><div class="NLM_p">Proliferation and differentiation of T-cells or B-cells is induced by cytokines or chemokines via the JAK/STAT pathway.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Among the four members of the JAK family, JAK1 is activated by γ-common chain cytokines, IFNγ, IL-6, and other gp130 cytokines,<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> whereas TYK2 plays a significant role in cytokine signaling from IL-dependent type I interferons and IL-12 and IL-23. Thus, the idea of dual inhibition of JAK1 and TYK2 with selectivity over JAK2/JAK3 (minimizing erythropoietin signaling pathway) was envisioned.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></div><div class="NLM_p">To identify JAK1/TYK2 dual inhibitors, a series of constrained 2,4-diamino pyrimidines were investigated (compounds <b>33a</b>–<b>d</b>) (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>).<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> A piperazine ring was found optimal at the 4-position of 2,4-diamino pyrimidine, and the ring could tolerate a methylene bridge, which generated two enantiomers. The preferential <i>S</i>,<i>S</i>-enantiomer <b>33a</b> exhibited better activity (TYK2 IC<sub>50</sub> = 0.023 μM) compared to <i>R</i>,<i>R</i>-enantiomer <b>33b</b> (TYK2 IC<sub>50</sub> = 2.690 μM). The SAR was expanded to include more bridged diamines, which provided compound <b>34</b> with a 3,8-diazabicyclo[3.2.1]octane ring, <i>N</i>-methyl pyrazole, enhanced potency, and high LipE. Next, keeping the <i>N</i>-methyl pyrazole constant, a series of acylated derivatives, amides, and ureas were screened and uncovered that 1,1-difluoro-cyclopropane was very effective at this position (compounds <b>35a</b>–<b>c</b>). The eutomer <i>S</i>-1,1-difluoro cyclopropane <b>36a</b> (<b>PF-06700841</b>) provided a more balanced, potent JAK1/TYK2 profile (TYK2 and JAK1 IC<sub>50</sub> = 0.023 and 0.017 μM) compared to the <i>R</i>-enantiomer <b>36b</b> (TYK2 and JAK1 IC<sub>50</sub> = 0.702 and 0.842 μM).</div><figure id="sch11" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0030.jpeg" id="GRAPHIC-d7e1900-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Discovery of Compound <b>36a</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The cocrystal structure of compound <b>36a</b> with TYK2 shows the formation of two hydrogen bonds at the hinge region, whereas the ethylene bridge of the [3.2.1]-diazabicycle protrudes into a hydrophobic pocket between Gly1040 and Leu1030. The difluoromethylene of the cyclopropyl amide orients toward the P-loop of the ATP binding site composed of Gly909 and Lys910 (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). With the (<i>R</i>)-distomer (<b>36b</b>), the difluoromethylene group orients into a negative electrostatic-potential region formed by side chain residues Asp1041 and Asn1028. This explains the remarkable 40-fold potency difference between the <i>S</i> and <i>R</i> isomers with respect to TYK2 binding. Compound <b>36a</b> also binds JAK1 in a similar manner, justifying the similar potencies against both enzymes.</div><figure id="fig9" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (top) The cocrystal structure of compound <b>36a</b> bound to TYK2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBM">6DBM</a>, 2.36 Å). (left) Interaction of compound <b>36a</b> with TYK2, the protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>36a</b> in TYK2. The surface of the protein is depicted in blue. (bottom) The cocrystal structure of compound <b>36a</b> bound to JAK1 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBN">6DBN</a>, 2.48 Å). (left) Interaction of compound <b>36a</b> with JAK1. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The compound <b>36a</b> binding site in JAK1. The surface of the protein is depicted in blue. Compound <b>36a</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>36a</b> was progressed through a variety of preclinical testing and exhibited an excellent off-target polypharmacology profile and an ADME profile consistent with once-daily dosing. Compound <b>36a</b> is currently in phase II clinical trials for psoriasis (NCT02969018). Clearly, the application of chirality in the development of compound <b>36a</b> enabled enhanced target selectivity and improved drug properties.</div><div class="NLM_p">Bruton’s tyrosine kinase (BTK) is another nRTK and plays a key role in BCR-mediated activation and development. Phosphorylated BTK activates downstream NFAT and NFκB pathways, resulting in proliferation, cytokine production, and expression of stimulatory molecules. As a result, inhibiting BTK regulates BCR signaling and F<i>c</i>γ and F<i>c</i>ε pathways, thereby ameliorating autoimmune diseases such as rheumatoid arthritis (RA), lupus, and multiple sclerosis etc.<a onclick="showRef(event, 'ref89 ref90 ref91'); return false;" href="javascript:void(0);" class="ref ref89 ref90 ref91">(89−91)</a></div><div class="NLM_p">After much effort in identifying a reversible BTK inhibitor, compound <b>37</b> was discovered as a promising lead.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> SAR exploration led to compound <b>38</b> (<b>BMS-935177</b>) (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>) with reasonable potency against BTK (IC<sub>50</sub> = 0.003 μM),<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> but the compound presented with a very narrow therapeutic window (<20-fold). Researchers believed the toxicity was a result of four interconverting atropisomers with different selectivity and toxicity profiles. Hence, it was envisioned that trapping a single atropisomer, with simultaneous improvement in potency and selectivity, could enhance drug safety. For this reason, another carbonyl was introduced into the quinazolinone ring generating derivative <b>39</b> that provided better pharmacokinetic properties. The two enantiomers were separated and the (<i>S</i>)-isomer was found to be more potent against human whole blood cells (BTK IC<sub>50</sub> = 0.0023 ± 0.0012 μM). Next, a second point of chirality was introduced by locking carbazole C4 through the addition of a C3 chloro substituent, which was found to be 1900-fold selective for BTK over JAK2 with improved potency. Anticipating improvement in kinase selectivity and the overall PK profile, SARs were expanded to an additional point of chirality on tetrahydrocarbazoles <b>40</b>.</div><figure id="sch12" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0031.jpeg" id="GRAPHIC-d7e2028-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Drug Discovery of Compound <b>41</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ultimately, adding (<i>S</i>)-dimethyl carbinol on tetrahydrocarbazoles and locking the carbazole C4 in the bioactive (<i>R</i>)-analogue by a fluoro substituent exhibited good potency (BTK IC<sub>50</sub> = 0.0005 μM and hWB IC<sub>50</sub> = 0.090 μM) and pharmacokinetic properties (AUC = 39 μM·h). The optimized analogue <b>41</b> (<b>BMS-986142</b>) inhibited only five TEC family kinases with less than 100-fold selectivity for BTK and exhibited a good pharmacokinetic profile in mice (with <4% formation of the main <i>des</i>-methylquinazoline dione metabolite) and a clean liability profile.</div><div class="NLM_p">Compound <b>41</b> was cocrystallized with BTK<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> and revealed that the tetrahydrocarbazole NH and the carboxamide carbonyl form two hydrogen bonds at the hinge region (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). The C2 dimethyl carbinol is directed toward the solvent front and does not exhibit any specific interaction. The (<i>R</i>)-configuration of the C5 phenyl linker projects the methyl group into a hydrophobic pocket adjacent to Cys481. The orthogonal nature of the phenyl linker orients the (<i>S</i>)-quinazolinedione into the active site. In the (<i>S</i>)-configuration, the methyl group would be pushed out of the hydrophobic pocket, causing an increase in entropy. Compound <b>41</b> demonstrated a desirable safety profile in multiple species and completed its phase II trials recently for moderate to severe rheumatoid arthritis (NCT02638948). The drug discovery campaign of compound <b>41</b> illustrates the use of axial chirality leading to a single, stable atropisomeric compound with enhanced potency and selectivity profiles.</div><figure id="fig10" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Cocrystal structure of compound <b>41</b> bound to BTK (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T18">5T18</a>, 1.5 Å). (left) Interaction of compound <b>41</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>41</b>. The surface of the protein is depicted in blue. compound <b>41</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With continued interest in discovering BTK inhibitors, compound <b>42</b> (CGI-1746)<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> was developed as a highly selective and potent BTK inhibitor with excellent selectivity but suffered from poor ADME properties. Rat pharmacokinetics focused on two main regions of compound <b>42</b> (<a class="ref internalNav" href="#sch13" aria-label="Scheme 13">Scheme 13</a>).<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> The first region was analogued with moieties to engage the solvent exposed pocket (region 1, H2 pocket). The second region was explored by varying substitution on the phenyl ring or replacing it with alternate arenes or heterocycles (region 2, H3 pocket). Adding polarity to the phenyl ring by substituting different heterocyclic arenes caused a decrease in binding affinity. Finally, a hydrobenzothiophene substituent at the H3 pocket and dimethyl-3-oxopiperazin-2-yl group on the H2 region optimized potency and pharmacokinetic properties. The (<i>R</i>)-isomer of substituent <b>44</b> (IC<sub>50</sub> = 0.006 μM; CL = 4.4 mL/min/kg; <i>F</i> = 35% in rat) provided a 3-fold improvement in potency and clearance from its enantiomeric (<i>S</i>)-isomer (IC<sub>50</sub> = 0.02 μM; CL = 11 mL/min/kg; <i>F</i> = 41%). Additionally, compound <b>44</b> (<b>GDC-0834</b>) was found to have excellent selectivity against a panel of 331 kinases and minimal off-target receptor activity.</div><figure id="sch13" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0032.jpeg" id="GRAPHIC-d7e2156-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Drug Discovery of Compound <b>44</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The cocrystal structure of compound <b>44</b> in complex with BTK revealed that the tetrahydrobenzothiophene moiety engages the hydrophobic pocket created by Leu542, Val546, Ser543, and Tyr551 of the activation loop (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). The amide linking the central aryl to the tetrahydro benzothiophene forms a hydrogen bond to Lys430. The pyrazinone binds Met477 at the hinge, while the dimethyl-3-oxopiperazin-2-yl extends into the solvent front. In the discovery of compound <b>44</b>, chirality was used to improve pharmacokinetic properties and receptor potency.</div><figure id="fig11" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Cocrystal structure of compound <b>44</b> bound to BTK (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OTF">4OTF</a>, 1.95 Å). (left) Interaction of compound <b>44</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>44</b> inBTK. The surface of the protein is depicted in blue. Compound <b>44</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">2.3.  Serine/Threonine Kinase Inhibitors</h3><div class="NLM_p">The human kinome consist of more than 500 human kinases ,of which 300 are serine/threonine kinases (STK).<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> As with any kinase, the prime function of an STK is to phosphorylate an amino acid hydroxy group (serine or threonine), thereby turning on or off a pathway. STKs are regulators of cell proliferation, apoptosis, cell differentiation, and embryonic development and have relevance in numerous forms of disease. STKs can be receptors, which are categorized as type I (including activin like receptors [ALKs], TGFβR1 [transforming growth factor beta receptor 1]), type II (ActR2, ActR2B, MISR2, BMPR1A, TGFβR2), and type III (TGFβR3) or solubilized, cytosolic proteins such as protein kinases A, B (Akt kinase), and C.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Other major classes of STKs include second messenger-dependent protein kinases (cAMP kinase, cGMP kinase, Ca<sup>2+</sup>/calmodulin kinase, protein kinase C), MAP kinases (ERKs, JNKs, or SAPKs), MAPKinase-regulating kinases (MEKs, SEKs, Raf, MEK kinases), CDKs, CDK-regulating kinases (CAK, CAK kinase), GRKs, RSKs, and casein kinases.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> STKs also include dual specificity kinases that act on both tyrosine as well as serine/threonine residues such as MEKs. Additionally, STKs are activated in signal transduction pathways triggered by many RTKs and other receptors.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Another class of serine–threonine kinases include cyclin-dependent kinases (CDKs) known for cell cycle progression. Hence, CDK inhibitors exhibit therapeutic relevance for several diseases including cancer, diabetes, renal, neurodegenerative, and infectious diseases.</div><div id="sec2_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28">2.3.1.  FDA-Orphan Drug Designation</h4><div class="NLM_p">CDK inhibitors have undergone clinical development with no disclosed explanation for incorporating chirality into the clinical candidate (<a class="ref internalNav" href="#sch14" aria-label="Scheme 14">Scheme 14</a>). <b>Alvocidib</b> (<b>45</b>), a flavonoid CDK9 inhibitor, was granted with FDA orphan drug designation in 2014 for AML (acute myeloid leukemia).<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Among other CDK inhibitors, <b>seliciclib</b> (<b>46</b>, <i>R</i>-roscovitine, Cyclacel) is a CDK-2,7,9 inhibitor under phase II development,<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> whereas <b>dinaciclib</b> (<b>47</b>), a CDK-2,7,9 inhibitor, is in phase II clinical trials for advanced breast cancer and NSCLC (NCT00732810).<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><figure id="sch14" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0033.jpeg" id="GRAPHIC-d7e2253-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Chemical Structures of Approved CDK and MEK Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last"><b>Cobimetinib</b> (<b>48</b>, GDC-0973, XL518), a MEK1/2 inhibitor, obtained orphan drug status for malignant melanoma exhibiting BRAF<sup>V600</sup> mutations in 2014.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Compound <b>48</b> is a carboxamide-based, selective MEK inhibitor (100-fold selective over 100 other serine–threonine and tyrosine kinases)<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> and exhibits higher efficacy in BRAF mutated tumors because of its strong MEK inhibition.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div></div><div id="sec2_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30">2.3.2.  Additional STK Inhibitors under Clinical Development</h4><div class="NLM_p">Lee et al. (2017)<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> initiated a drug discovery campaign against IRAK4 (interleukin-1-receptor associated kinase 4) for the treatment of inflammation. IRAK4 is activated by the cytokine receptor interleukin-1-receptor in response to binding of interleukin-1 (IL-1). In addition, IRAK4 is involved in the innate and adaptive immune system and is expressed in T- and B-lymphocytes. Therefore, IRAK4 is an attractive target for treating inflammatory and autoimmune diseases. To initiate development, Lee et al. completed a fragment-based screening using the Pfizer Global Fragment Initiative library. The 10 best hits were cocrystallized with IRAK4. Cocrystal structure analysis suggests that exploration of the three-dimensional space within the ATP pocket could simultaneously improve potency, pharmacological, and pharmaceutical properties. Binding of the carboxamide <b>49</b> to IRAK4 suggested switching the core to a more polar heterocyclic system, such as quinoline or isoquinoline, would improve potency. Compound <b>50</b> was generated, and the resulting protein–ligand complex (<a class="ref internalNav" href="#sch15" aria-label="Scheme 15">Scheme 15</a>) suggested interactions at the base of the binding pocket could be optimized. The piperidine was replaced with a five-membered lactam ring generating compound <b>51</b>. The (<i>S</i>)-isomer (<b>51a</b>) was found to be significantly more potent than the (<i>R</i>)-isomer (<b>51b</b>). The increase in potency of the (<i>S</i>)-isomer stems from its stereochemistry that enables the lactam ring to efficiently hydrogen bond to Ala315 and Asn316. In addition, the carbonyl accepts hydrogen bonds from Ser328 and an interaction between the isoquinoline nitrogen and Asp272 via a water molecule.</div><figure id="sch15" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0034.jpeg" id="GRAPHIC-d7e2319-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Drug Discovery of Compound <b>53</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>51a</b> achieved a good pharmacokinetic profile (CL = 23 L/h/kg, <i>T</i><sub>1/2</sub> = 1.2 h, <i>F</i> = 57% in rat), which suggested oral administration was feasible for dosing. Unfortunately, allometric scaling to determine the human dose led to termination of the compound. To improve pharmacokinetics, compound <b>51</b> was further modified at the lactam position, thereby reducing the planarity of the molecule. A fluoro substituent with <i>syn</i> stereochemistry (<b>52a</b>) to the ether linker provided better potency than the <i>anti</i>-isomer (<b>52b</b>). However, α-<i>syn</i> fluorine substituent and a β-3-ethyl substituent led to compound <b>53</b> (<b>PF-06650833</b>) with improved potency (IRAK4 IC<sub>50</sub> = 0.001 μM, PBMC IC<sub>50</sub> = 0.0024 μM) and optimized ADME properties (LE = 0.52, LipE = 7.4). The potency rise can be attributed to enhanced hydrogen bonding capability of the lactam ring conferred by appropriate positioning of the fluoro substituent.</div><div class="NLM_p">The cocrystal structure of <b>53</b> bound to IRAK4 is shown in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, illustrating key interactions. The terminal, primary amide group forms two hydrogen bonds with Val263 and Met265. The cyclic lactam is involved in a hydrogen bond with the bottom pocket of IRAK4. The (<i>S</i>)-stereochemistry orients the lactam amide into a favorable position to take part in hydrogen bonding with Ala315. Moreover, the ethyl group on the cyclic amide is encapsulated in a lipophilic pocket formed by Gly195, Lys213, and Val261. Hence, introduction of three points of chirality into <b>53</b> reduced planarity, which improved binding site interactions, solubility, and pharmacokinetics.</div><figure id="fig12" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Cocrystal structure of compound <b>53</b> bound to IRAK4 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UIU">5UIU</a>, 2.02 Å). (left) Interaction of compound <b>53</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>53</b> in IRAK4. The surface of the protein is depicted in blue. Compound <b>53</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another serine/threonine kinase closely related to the IRAK family is receptor interacting protein 1 (RIP1). RIP1 is involved in cell death/growth signaling circuits and is affected by exposure to several stress signals such as inflammatory cytokines, infections, and genotoxic stress.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Functions of RIP1 include T-cell homeostasis, activation of NF-κB, and activation of mitogen activated protein kinases (MAPKs), such as p38 MAPK, JNK, and ERK.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> It was also found that RIP1 plays a significant role in various downstream pathways of the death receptors TNFR1, FasL, TRAIL, and Toll-like receptors. Thus, obstructing this pathway may be therapeutically relevant for various inflammatory diseases.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a></div><div class="NLM_p">Initial RIP1 inhibitors suffered from poor pharmacodynamics and pharmacokinetic properties. To identify a more viable RIP1 inhibitor, a GSK DNA-encoded library was screened via high-throughput screening, which uncovered compound <b>54a</b> (<b>GSK-481</b>), a more selective RIP1 benzoxazepinone pharmacophore. The binding interactions of the (<i>S</i>)-analogue <b>54a</b> with the protein is of significance as the (<i>R</i>)-analogue <b>54b</b> is not active. Therefore, chirality is integral for RIP1 activity.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></div><div class="NLM_p">Replacing the heteroatom in the benzoxepinone with −N, −S, −CH<sub>2</sub>, and −NMe provided high RIP1 in vitro potency (<a class="ref internalNav" href="#sch16" aria-label="Scheme 16">Scheme 16</a>). Altering the size of the benzoxazepine or removal of the benzo function yielded inactive analogues as the benzoxazepinone moiety fits tightly into the RIP1 pocket. Heteroaryl substitutions on the aryl ring at 7,8-positions suffered from low solubility. For example, oxazole (<b>56a</b>) and imidazole (<b>56e</b>) were found to be more active than their isomers, whereas thiazole (<b>56b</b>) exhibited lower activity. Also, <i>N</i>-benzyl-1,2,3-triazole (<b>56g</b>) displayed better rat oral exposure than its 1,2,4-triazole (<b>56f</b>) analogue, but the 3-benzyl-1,2,4-triazole isomer provided the best combination of in vitro potency, lipophilicity (log <i>D</i> 3.8), and rat oral exposure (AUC<sub>0–∞</sub> 2.3 μg/h/mL at a dosage of 2 mg/kg). All other tetrazole, phenyl, or pyridine analogues suffered from high lipophilicity and low solubility. Thus, compound <b>57</b> (<b>GSK-2982772</b>) was progressed for further development and has entered phase IIa clinical trials for ulcerative colitis. (NCT02903966)</div><figure id="sch16" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0035.jpeg" id="GRAPHIC-d7e2480-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Drug Discovery of Compound <b>57</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The cocrystal structure of benzoxazepinone <b>57</b> bound to RIP1 demonstrates<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> the binding of the seven-membered ring to an allosteric site between the <i>N</i>-terminal and <i>C</i>-terminal domains without any interaction at the hinge region (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). The triazole and benzyl groups occupy an allosteric lipophilic pocket at the back of the ATP binding site. The benzoxazepinone ring resides in a pocket formed by two β-strands defined by Leu90–Val91–Met92 and Ile43–Met44–Lys45. The amide carbonyl linker makes a direct hydrogen bond with the backbone of Asp156. The (<i>S</i>)-stereochemistry of the molecule allows the benzyl triazole amide access into a hydrophobic tunnel, while the (<i>R</i>)-analogue is not able to access this tunnel and is virtually inactive (>10000-fold potency). Hence, any change in chirality or conformation of the seven membered ring is not tolerated.</div><figure id="fig13" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Cocrystal structure of compound <b>57</b> bound to RIP1 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TX5">5TX5</a>, 2.56 Å). (left) Interaction of compound <b>61</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>57</b> in RIP1. The protein surface is depicted in blue. Compound <b>57</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Polo-like kinases (PLKs), which are serine/threonine kinases, are well-validated cell cycle targets with vital roles in mitosis, spindle formation, chromosome segregation, and cytokinesis.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> They include PLK1, PLK2 (SNK), PLK3 (PRK/FNK), and PLK4 (SAK), among which PLK1 is the most studied in oncology with an established correlation between PLK1 expression and cancer prognosis.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> As such, there have been numerous campaigns targeting PLKs for antineoplastic drug development.</div><div class="NLM_p">The PLK1 inhibitor <b>58</b> exhibited strong activity against PLK1 but was also active on PLK3 and lacked desirable drug properties warranting further clinical studies. Compound <b>58</b> was further optimized to improve potency and pharmacokinetic properties (<a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>). Incorporating a methyl group at the benzylic carbon displayed an improvement in cell potency (40-fold). The (<i>R</i>)-analogue (<b>59a</b>) exhibited approximately 40-fold improvement in growth inhibition of HCT116 (colorectal carcinoma) over the (<i>S</i>)-analogue (<b>59b</b>).<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Further, improvement in solubility was considered by incorporating of more polar groups. By analyzing the binding of <b>59a</b> in the active site of PLK1, it was found that the 6-position of benzimidazole orients toward the solvent and could tolerate polar groups.</div><figure id="sch17" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0036.jpeg" id="GRAPHIC-d7e2572-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Drug Discovery of Compound <b>61</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Methyl ether analogues at the 6-position of benzimidazole (<b>60a</b>) displayed high protein binding but poor solubility. Potency was further refined by eliminating the methylene spacer between the oxygen atom and the piperidine ring (<b>60b</b>). The basic amine analogues displayed an excellent combination of potency, solubility, and reduced protein binding with selectivity over PLK2/PLK3. Homology modeling of compound <b>60c</b> bound to the ATP-binding site of PLK1 displayed a hydrogen bond interaction between Glu140 and the piperidine nitrogen. Whereas in PLK3 and PLK2, Glu140 is replaced by a histidine, whose interaction with the charged amine is not favorable, resulting in reduced potency. Subsequently, more cyclic amines were screened to obtain suitable potency, selectivity, and solubility, which resulted in the discovery of compound <b>61</b> (<b>GSK461364</b>). Compound <b>61</b> is currently under evaluation in phase I clinical trials for non-Hodgkin’s lymphoma (NCT00536835).</div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">2.4.  Lipid Kinase Inhibitors</h3><div id="sec2_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35">2.4.1.  FDA-Approved Lipid Kinase Drugs</h4><div class="NLM_p">Lipid kinases are responsible for phosphorylation of lipids in the cell, which in turn change the reactivity and localization of lipids causing signal transduction.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> For instance, sphingosine kinase, a lipid kinase, catalyzes the conversion of sphingosine to sphingosine-1-phosphate (S1P), whereas phosphatidylinositol kinases generate phosphatidylinositol 3,4-bisphosphate (PI(3,4)P<sub>2</sub>), phosphatidylinositol 3,4,5-trisphosphate (PIP3), and phosphatidylinositol 3-phosphate (PI3P).<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> This family of kinases include phosphoinositide 3-kinases (PI3Ks), phosphatidylinositol-4-phosphate 3-kinase, and phosphatidylinositol-4,5-bisphosphate 3-kinase.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> PI3Ks are lipid kinases that phosphorylate the 3′ position of inositol in phosphatidylinositol, which functions as a secondary messenger that regulates proliferation, motility, and differentiation. PI3Ks are further classified into three classes, among which class I plays a critical role in regulating PIP3 levels in the cell. PIP3 is an essential cellular mediator involved in activation of downstream signaling cascades, which is generated through the phosphorylation of PIP2.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> A lack of regulation in PIP3 levels, such as impairment in PTEN function, is found in numerous, aggressive cancers.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></div><div id="sec2_4_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36">2.4.1.1.  <b>Idelalisib</b> (Jul 2014, Gilead)</h5><div class="NLM_p">In July 2014, <b>idelalisib</b> (<b>62</b>, GS-1101, CAL-101, IC489666) received FDA approval for treatment of relapsed chronic lymphocytic leukemia, follicular B-cell non-Hodgkin’s lymphoma, and small lymphocytic lymphoma.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Idelalisib is the first-in-class small molecule PI3K inhibitor, selectively targeting PI3Kδ. PI3Kδ is a class I PI3K comprised of p110δ as a catalytic subunit and p85 as a regulatory subunit. PI3Kδ expression is restricted to leukocytes, making it an excellent therapeutic target to selectively impair the PI3K-AKT pathway in hematopoietic cells.<a onclick="showRef(event, 'ref121 ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref121 ref122 ref123">(121−123)</a> Idelalisib is similar to <b>63</b> (IC87114), which was discovered by the ICOS corporation and has been studied comprehensively as a PI3Kδ inhibitor.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Idelalisib has an IC<sub>50</sub> for PI3Kδ of 0.019 μM and exhibits better potency and metabolic stability than compound <b>63</b> (IC87114) (<a class="ref internalNav" href="#sch18" aria-label="Scheme 18">Scheme 18</a>).<a onclick="showRef(event, 'ref125 ref126'); return false;" href="javascript:void(0);" class="ref ref125 ref126">(125,126)</a> Further, idelalisib is selective for PI3Kδ with relatively weak inhibition of PI3Kα, PI3Kβ, and PI3Kγ isoforms (IC<sub>50</sub> = 8.6, 4.0, and 2.10 μM, respectively).<a onclick="showRef(event, 'ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref127 ref128">(127,128)</a></div><figure id="sch18" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0037.jpeg" id="GRAPHIC-d7e2682-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. FDA Approved Drug <b>62</b> and Its Chemotype <b>63</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Idelalisib interacts with PI3Kδ hinge residues Val828 and Glu826 via the N3 and N9 nitrogens of the purine group, respectively (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). The (<i>S</i>)-chiral carbon directs the ethyl group of idelalisib into the hydrophobic pocket of PI3Kδ formed by Ile910, Met900, and Met752. The ATP-binding pocket of PI3Kδ undergoes a conformational change (from the apoenzyme PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WXR">2WXR</a>) to accommodate the fluoro quinazolinone ring in a hydrophobic pocket (the specificity pocket) made up of Met752, Trp760, and Lys708 on the top of the active site.<a onclick="showRef(event, 'ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref129 ref130">(129,130)</a> It is hypothesized the energy required to open the specificity pocket defines the selectivity of idelalisib for PI3Kδ over other isoforms. Further, because of geometric constraints in the selectivity pocket, the <i>R</i>-enantiomer of idelalisib does not fit properly in the PI3Kδ active site. The chiral attributes of idelalisib, as well as low energy binding for PI3Kδ, enable selectivity in the PI3K family. The selectivity, in turn, improves toxicity profiles and drug properties of idelalisib.</div><figure id="fig14" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Cocrystal structure of compound <b>62</b> bound to PI3Kδ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XE0">4XE0</a>, 2.35 Å). (left) Interaction of compound <b>62</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>62</b> in PI3Kδ. The protein surface is depicted in blue. Compound <b>62</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2012, Amgen disclosed compound <b>64</b>, an inhibitor of class I PI3Ks with activity in biochemical (<i>K</i><sub><i>i</i></sub> values of 0.012, 0.005, 0.002, and 0.004 μM for PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively) and cellular (U87 MG IC<sub>50</sub> = 0.016 μM) assays (<a class="ref internalNav" href="#sch19" aria-label="Scheme 19">Scheme 19</a>). The compound exhibited promising in vivo activity but exhibited rapid clearance (CL = 2.5 L/h/kg) with a very short mean residence time (MRT = 1.6 h for both), hence, it did not have appropriate drug-like properties.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Upon further investigation, it was found that the metabolites were the product of oxidative metabolism, including <i>O</i>-demethylation (<b>65a</b>) and benzylic oxidation (<b>65b</b>). To reduce metabolism of <b>64</b>, further optimization was completed, which resulted in compound <b>67a</b> (<b>AMG 511</b>).<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div><figure id="sch19" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0038.jpeg" id="GRAPHIC-d7e2774-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Drug Discovery of Compound <b>67a</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To improve drug properties of <b>64</b>, Norman et al. explored altering electron density of the terminal pyridine ring.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Introducing a fluorine atom at the C3 position of the pyridine ring furnished compound <b>66c</b> (<i>K</i><sub><i>i</i></sub> for PI3Kδ = 0.006 μM and <i>K</i><sub><i>i</i></sub> for PI3Kα, PI3Kβ, and PI3Kγ are 0.018, 0.008, and 0.021 μM, respectively) and reduced <i>O</i>-demethylation but did not improve clearance. Introduction of a benzylic methyl decreased PI3Kδ selectivity either with or without substitution at the piperazine position. There was no significant stereochemical preference for PI3K inhibition, but pharmacokinetic properties improved with one isomer. When exploring rat microsomal stability, the (<i>R</i>)-methyl benzylic isomer (<b>67a</b>; IC<sub>50</sub> = 0.004 μM for U87 MG) was more stable than the (<i>S</i>)-methylpiperizine isomer (<b>67b</b>; IC<sub>50</sub> = 0.007 μM for U87 MG). Therefore, compound <b>67a</b> was selected for clinical investigation.</div><div class="NLM_p">The cocrystal structure of <b>67a</b> bound to PI3Kγ showed the aminotriazine of compound <b>67a</b> forms two hydrogen bonds with Val882 at the hinge region (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). The methyl substituent on the triazine occupies a small hydrophobic pocket found only in PI3Ks (near Tyr867), which is responsible for kinase selectivity. Both the methoxy oxygen and the 3-fluoro substituent exhibit a favorable interaction with Lys833 within the affinity pocket. The nitrogen in the pyridine central core forms a network of water-mediated hydrogen bonds with Asp964. The benzylic (<i>R</i>)-methyl group efficiently occupies a hydrophobic pocket at the floor of the enzyme formed by Thr887, Ile963, and Asp950. This directs the methylsulfonamide piperidine moiety to engage in hydrogen bonds with Lys802 and Ala805.</div><figure id="fig15" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Cocrystal structure of compound <b>67a</b> bound to PI3Kγ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FLH">4FLH</a>, 2.6 Å). (left) Interaction of compound <b>67a</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>67a</b> in PI3Kγ. The protein surface is depicted in blue. Compound <b>67a</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>67a</b> was subjected to a kinase panel against phosphatidylinositol 3-kinase-related kinases and exhibited good selectivity against mTOR (<i>K</i><sub>d</sub> > 10.0 μM), hVPS34 (<i>K</i><sub>d</sub> > 9.0 μM), and DNA-PK (<i>K</i><sub>d</sub> > 10.0 μM). From the series, compound <b>67a</b> exhibited the highest stability in rat microsomes (CL<sub>int</sub> = 20 μL/min/mg) and also the lowest in vivo clearance (CL = 0.4 L/kg/h) with a high mean residence time of ∼2–5 h. Compound <b>67a</b> also possessed high oral bioavailability (<i>F</i> = 60%) commensurate with a large oral exposure (AUC = 5.0 μMh). Furthermore, compound <b>67a</b> was also shown to potently block the PI3K pathway in an in vivo rat model and exhibited a dose-dependent decrease in AKT phosphorylation with an EC<sub>50</sub> of 228 ng/mL. In a U87 MG xenograft model, compound <b>67a</b> effectively inhibited tumor growth with an ED<sub>50</sub> of 0.6 mg/kg. Hence, by introducing a chiral methyl at the benzylic position, compound <b>67a</b> achieved enhanced metabolic stability, which improved clearance and mean residence time.</div><div class="NLM_p">Scientists at Amgen discovered another PI3K drug candidate, compound <b>71</b> (<b>AMG 319</b>), which completed phase I/II studies against relapsed or refractory lymphoid malignancies. Compound <b>71</b> was also examined for the treatment of human papillomavirus (HPV) and head and neck squamous cell carcinoma (HNSCC). However, clinical investigation of compound <b>71</b> was terminated due to safety concerns (NCT02540928).<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></div><div class="NLM_p">Compound <b>71</b> was discovered through modeling known PI3K inhibitors from the literature, which uncovered lead compound <b>68</b> (<a class="ref internalNav" href="#sch20" aria-label="Scheme 20">Scheme 20</a>). Compound <b>68</b> served as a validated starting point because the compound achieved an IC<sub>50</sub> of 0.24 μM against PI3Kδ. However, the thioether of <b>68</b> was sensitive to in vivo oxidation.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> SAR exploration revealed that an ether (<b>69b</b>) or amino (<b>69c</b>) linker improved potency against PI3K and also improved selectivity for PI3Kδ over PI3Kγ. However, the ether and amino analogues were still poorly soluble and exhibited microsomal instability. To minimize benzylic oxidation, a methyl was introduced at the α-position to both ether and amine linkers (<b>70a</b>–<b>b</b>). Microsomal stability did not improve, yet enzymatic potency against PI3Kδ did improve (<b>70a</b>) (PI3Kδ IC<sub>50</sub> = 0.071 μM). The introduction of a methyl at this position limits free rotation and rigidified the structure in a low energy state, which may mimic the binding state. Upon further analysis, it was observed that the (<i>S</i>)-methyl isomer (<b>70a</b>) (IC<sub>50</sub> = 0.071 μM) was significantly preferred over the (<i>R</i>)-methyl isomer (<b>70b</b>) (IC<sub>50</sub> = 2.6 μM) due to steric interference. Further SAR exploration resulted in identification of compound <b>71</b>, which involved removal of the metabolically labile methyl, deactivating the quinoline with a fluorine and substituting 2-aryl for 2-pyridyl. Compound <b>71</b> exhibited decent pharmacokinetic properties and solubility (PI3Kδ IC<sub>50</sub> = 0.018 μM; PI3Kβ IC<sub>50</sub> = 2.7 μM; PI3Kα IC<sub>50</sub> = 33 μM; PI3Kγ IC<sub>50</sub> = 0.85 μM, soln (PBS) 146 mg/μL, rat PK CL = 0.34 L/h/kg; <i>F</i> = 54%).</div><figure id="sch20" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0039.jpeg" id="GRAPHIC-d7e3017-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Drug Discovery of Compound <b>71</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>71</b> has been cocrystallized in the PI3Kγ active site. The 7-fluoroquinoline lies in the inducible specificity pocket between Trp812 and Met804, and the pyridine orients toward a hydrophobic pocket comprised of Val882 and Lys890. The chiral (<i>S</i>)-methyl group on the benzylic position efficiently occupies a hydrophobic pocket adjacent to the hinge region formed by Thr887, Ile963, and Asp905 (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>). The purine core binds to the hinge region at Val882 and Glu880. The (<i>R</i>)-enantiomer is unable to form similar interactions in PI3Kγ and therefore has substantially less activity. Therefore, by exploiting chirality, (<i>S</i>)-AMG 319 exhibited improved selectivity, solubility, and pharmacokinetic properties.</div><figure id="fig16" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Cocrystal structure of compound <b>71</b> bound to PI3Kγ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WWN">4WWN</a>, 2.7 Å). (left) Interaction of compound <b>71</b> with the protein. The protein is depicted as yellow ribbons, and hydrogen bonds are illustrated with blue dashed lines. (right) The compound <b>71</b> binding site in PI3Kγ. The surface of the protein is depicted in blue. Compound <b>71</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A series of 4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-ones, illustrated by compound <b>72</b> (<b>TGX-221</b>) (PI3Kβ IC<sub>50</sub> = 0.022 μM), were reported as PI3Kβ inhibitors. Compound <b>72</b> has a benzylic, chiral center, but previous investigations were completed with the racemic mixture. Chirality of compound <b>72</b> was later resolved, and it was observed that the <i>R</i>-enantiomer (<b>73a</b>) (PI3Kβ IC<sub>50</sub> = 0.006 μM) was 100-fold more potent than the <i>S</i>-enantiomer (<b>73b</b>) (PI3Kβ IC<sub>50</sub> = 0.80 μM). This suggests that chirality plays a crucial role in receptor binding and was further investigated to obtain insight about the receptor/ligand complex. Compound <b>72</b> was modeled in a homology model of PI3Kβ and identified that morpholine interacts with Val854 at the hinge and the pyrido-pyrimidinone core interacts in the central pocket formed by Met926 and Ile residues 803, 851, and 936. The carbonyl group engages the back-pocket Tyr839 via a hydrogen bond network. Also, the aniline ring of compound <b>73a</b> (<b>TGX-221-R</b>) is believed to induce a conformational switch in the P-loop at the top of the ATP binding site, forming a specificity pocket as observed with other PI3K inhibitors. Because of the energetics of PI3Kβ, induction of the specificity pocket by <b>73a</b> is selective for the β-isoform over others.<a onclick="showRef(event, 'ref134 ref135'); return false;" href="javascript:void(0);" class="ref ref134 ref135">(134,135)</a></div><div class="NLM_p">Further efforts by AstraZeneca resulted in the discovery of another PI3Kβ inhibitor, <b>AZD6482</b> (<b>74a</b>) (<a class="ref internalNav" href="#sch21" aria-label="Scheme 21">Scheme 21</a>).<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Similar to <b>73a</b>, compound <b>74a</b> (PI3Kβ IC<sub>50</sub> = 0.04 μM) exhibited 200 times more activity than the (<i>S</i>)-enantiomer(<b>74b</b>) (PI3Kβ IC<sub>50</sub> = 2.3 μM). <b>74a</b> was evaluatedfor antiplatelet effects via ADP-induced impedance aggregometry and exhibited efficacy in humans.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a></div><figure id="sch21" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0040.jpeg" id="GRAPHIC-d7e3167-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Drug Discovery of Compounds <b>74a</b> and <b>76</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Barlaam et al. sought to identify an orally available PI3Kβ inhibitor and utilized compounds <b>73a</b> and <b>74a</b>. For this investigation, the researchers considered removing the carboxylic acid on <b>74a</b>, believing the acid was responsible for poor oral exposure. With the objective of balancing lipophilicity and permeability, the researchers identified the <i>R</i>-isomer (<b>75</b>), with a difluoro substituted aniline and a tertiary amide on the core. Compound (<i>R</i>)-<b>75</b> had average metabolic stability and exhibited good cell potency (IC<sub>50</sub> = 0.003 μM), 31% oral bioavailability, and a clearance of 82 mL/min/kg. However, because of solubility issues, (<i>R</i>)-<b>75</b> was terminated.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a></div><div class="NLM_p">The same research group sought to further optimize (<i>R</i>)-<b>75</b> with the intention of generating a more hydrophilic molecule with improved solubility and metabolic stability. By modifying (<i>R</i>)-<b>75</b>, <b>AZD8186</b> (<b>76</b>) was discovered that has a similar difluoro substituted aniline and a tertiary amide on a different core. Compound <b>76</b> exhibited a significant increase in both potency and selectivity (PI3Kβ IC<sub>50</sub> = 0.0004 μM; PI3Kα IC<sub>50</sub> = 0.035 μM; PI3Kδ IC<sub>50</sub> = 0.012 μM; PI3Kγ IC<sub>50</sub> = 0.675 μM, in cell, MDA-MB-468 <i>p</i>AKT IC<sub>50</sub> = 0.003 μM) than compound <b>75</b>. Further, through oral administration, <b>76</b> blocked Akt phosphorylation in PTEN-deficient PC3 xenografts. With moderate permeability (Caco-2 <i>P</i><sub>app</sub> 8.0 × 10<sup>–6</sup> cm/s), high metabolic stability, and potency, <b>76</b> was progressed into clinical studies for patients with advanced castration-resistant prostate cancer (CRPC), squamous NSCLC, triple negative breast cancer (TNBC), and PTEN-deficient/mutated or PIK3CB mutated/amplified advanced, solid malignancies (NCT03218826).<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a></div><div class="NLM_p">In an attempt to develop a PI3Kδ inhibitor that could be administered via inhalation to treat NSCLC, Erra et al. developed <b>LAS195319</b> (<b>78</b>), which displayed less side effects than idelalisib (<a class="ref internalNav" href="#sch22" aria-label="Scheme 22">Scheme 22</a>).<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Modifications to <b>63</b> were performed to reduce systemic side effects by deliberately increasing clearance. These efforts resulted in compound <b>78</b>, which exhibited improved lung retention and potency against PI3Kδ (PI3Kδ IC<sub>50</sub>= 0.0005 μM, PI3Kα IC<sub>50</sub> = 1.9 μM, PI3Kβ IC<sub>50</sub> = 0.01 μM, PI3Kγ IC<sub>50</sub> = 0.036 μM, M-CSF-induced AKT in THP-1 cells IC<sub>50</sub> = 0.027 μM, rat PK AUC = 171 ng/h/mL, <i>F</i> = 1%).<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Erra et al. developed another pyrrolotriazine-based inhibitor by adding a methyl group on the benzylic carbon to minimize benzylic oxidation on IC87114 (<a class="ref internalNav" href="#sch22" aria-label="Scheme 22">Scheme 22</a>). Additional modifications uncovered compound <b>80</b> (<b>LAS191954</b>), which entered clinical development for the treatment of pemphigus (PI3Kδ IC<sub>50</sub> = 0.026 μM, PI3Kα IC<sub>50</sub> = 8.2 μM, PI3Kβ IC<sub>50</sub> = 94.0 μM, PI3Kγ IC<sub>50</sub> = 72.0 μM, M-CSF-induced AKT in THP-1 cells IC<sub>50</sub> = 0.078 μM, rat PK CL = 1.4 mL/min/kg, F = 98%).<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a></div><figure id="sch22" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0041.jpeg" id="GRAPHIC-d7e3345-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Drug Discovery of Compounds <b>78</b> and <b>80</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The cocrystal structure of compound <b>81</b> (an analogue of <b>78</b>) bound to PI3Kδ revealed that the molecule adopts a chirality-induced conformation. The pyrrolopyrimidine forms hydrogen bonds to Glu826 and Val828 at the hinge. As a result, the pyrrolotriazinone moiety is sandwiched orthogonally into the specificity pocket between Trp760 and Met752 (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). Also, the sulfone forms a hydrogen bond with the side chain of Lys779, and the phenol group hydrogen bonds to Asp787.</div><figure id="fig17" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. (left) Cocrystal structure of analogue <b>81</b> bound to catalytic site of PI3Kδ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6G6W">6G6W</a>, 2.72 Å). (right) The cocrystal structure of analogue <b>82</b> bound to catalytic site of PI3Kδ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5M6U">5M6U</a>, 2.85 Å). The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Analogue <b>81</b> and <b>82</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>82</b> (an analogue of <b>80</b>) occupies the prototypical binding pose in PI3Kδ where the pyrrolotriazinone moiety enters the hydrophobic specificity pocket between Trp760 and Met752; the cyanopyrimidine binds to Val828 and Glu826 at the hinge (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). The <i>R</i>-enantiomer of analogue <b>82</b> cannot enter the specificity pocket with the correct geometry and would therefore form undesirable steric clashes in the binding pocket.</div><div class="NLM_p">Additional inhibitors of the PI3K family are under clinical development. This includes <b>umbralisib</b> (<b>83</b>), a selective PI3Kδ inhibitor in phase II clinical trials for chronic lymphocytic leukemia with resistance to BTK inhibitors or prior PI3Kδ inhibitor therapy (NCT03801525) (<a class="ref internalNav" href="#sch23" aria-label="Scheme 23">Scheme 23</a>).<a onclick="showRef(event, 'ref141 ref142'); return false;" href="javascript:void(0);" class="ref ref141 ref142">(141,142)</a> This also includes <b>duvelisib</b> (<b>84</b>), a dual PI3Kδ and PI3Kγ inhibitor in clinical trials for advanced hematologic malignancies and relapsed or refractory peripheral T-cell lymphoma (NCT01476657, NCT03372057), and <b>tenalisib</b> (<b>85</b>), another dual PI3Kδ and PI3Kγ inhibitor in phase II clinical trials for relapsed/refractory indolent non-Hodgkin’s lymphoma and T-cell lymphoma (NCT03711578). The additional PI3K inhibitors are chiral, and the <i>S</i>-enantiomers are active. The <i>S</i>-chiral configuration permits appropriate geometric alignment in the selectivity pocket.</div><figure id="sch23" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0042.jpeg" id="GRAPHIC-d7e3452-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Chemical Structures of PI3K Clinical Candidates <b>83</b>, <b>84</b>, and <b>85</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43">2.5.  Irreversible Chiral Kinase Inhibitors</h3><div class="NLM_p">Irreversible kinase inhibitors form covalent bonds with the target kinase.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> This occurs via nucleophilic attack by a cysteine residue on an electrophilic center of the irreversible inhibitor. The typical electrophilic centers used for this purpose include acrylamides, vinyl sulfonates, quinones, alkynyl amides, propargylic acid derivatives, α-halo ketones, thiocyanates, epoxides, etc. Covalent inhibition serves as a platform to fine-tune selectivity and affinity for the target kinase.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Kinase classes explored with covalent inhibitors include EGFR, Her-2, Her-4, the Tec family (BMX, BTK, ITK, TEC, and TXK), and one member of the Src family (BLK).<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Among clinically approved covalent candidates, two chiral molecules have been approved by the FDA, afatinib and ibrutinib.</div><div id="sec2_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44">2.5.1.  FDA-Approved Irreversible Kinase Inhibitors</h4><div id="sec2_5_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45">2.5.1.1.  <b>Afatinib</b> (Jul 2013, Boehringer Ingelheim Corp)</h5><div class="NLM_p">In 2009, <b>afatinib</b> (<b>88</b>, BIBW-2992) was the first quinazoline-based, irreversible kinase inhibitor approved by the FDA for treatment of NSCLC. Compound <b>88</b> covalently binds to Cys797 (EGFR) and Cys805 (HER2) and exhibits potent phosphorylation inhibition on both EGFR (IC<sub>50</sub> = 0.005 μM) and HER2 (IC<sub>50</sub>= 0.014 μM) compared to other irreversible kinase inhibitors (EKB-569 and HKI-272) (<a class="ref internalNav" href="#sch24" aria-label="Scheme 24">Scheme 24</a>).<a onclick="showRef(event, 'ref146 ref147'); return false;" href="javascript:void(0);" class="ref ref146 ref147">(146,147)</a></div><figure id="sch24" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0043.jpeg" id="GRAPHIC-d7e3518-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Chemical Structures of Irreversible EGFR and Her2 Inhibitors <b>86</b>, <b>87</b>, and <b>88</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The drug discovery campaign for compound <b>88</b> has not been disclosed, but its cocrystal structure with EGFR illustrates a key covalent bond formation between Cys797 and the electrophilic center of afatinib along with a hydrogen bond with Met793 at the hinge region (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>). The specific role of the chiral tetrahydrofuran ring was not described, but because that region is in the solvent, it can be inferred the chirality does not influence the substrate–ligand complex.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Instead, the chiral tetrahydrofuran ring likely influences pharmacokinetic properties of compound <b>88</b>. Metabolic studies reveal minimal cytochrome P450 (CYP) metabolism, while the majority of <b>88</b> is excreted as a covalent adduct with plasma proteins.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Also, compound <b>88</b> exhibits a low renal elimination rate (5%).<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a></div><figure id="fig18" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0018.jpeg" id="GRAPHIC-d7e3561-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Cocrystal structure of compound <b>88</b> bound to EGFR<sup>T790M</sup> mutant (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5P">4G5P</a>, 3.17 Å). The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound <b>88</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47">2.5.1.2.  <b>Ibrutinib</b> (Nov 2013, Pharmacyclics)</h5><div class="NLM_p"><b>Ibrutinib</b> (<b>90b</b>, PCI-32765) is another irreversible inhibitor approved for B-cell non-Hodgkin’s lymphoma. To identify compound <b>90b</b>, a library was screened against the BTK kinase and compound <b>89</b> (PCI-29732) was identified as a hit compound (BTK IC<sub>50</sub> = 0.082 μM) (<a class="ref internalNav" href="#sch25" aria-label="Scheme 25">Scheme 25</a>).<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a></div><figure id="sch25" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Scheme 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0044.jpeg" id="GRAPHIC-d7e3599-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 25. Drug Development of Compound <b>90b</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A series of molecules were synthesized bearing different electrophilic centers to engage the conserved cysteine residue in BTK (Cys481). On the electrophilic center, adding a <i>trans</i> methyl group to the vinyl group reduced potency whereas addition of a tertiary amine improved potency. Investigation into piperidine and pyrrolidine-based Michael acceptors was completed, and it was found that a piperidine-based Michael acceptor with absolute (<i>R</i>)-configuration provided optimal potency (IC<sub>50</sub> = 0.0005 μM).<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a></div><div class="NLM_p">Drug–receptor interaction studies were completed by modeling compound <b>90b</b> in BTK. The 4-amino group hydrogen bonds to Thr474 (gatekeeper) and Glu475, whereas the N–H of the pyrazolo[3,4-<i>d</i>]pyrimidine core forms a hydrogen bond with Met477 at the hinge (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>). The thiol group of Cys481 covalently binds to the electrophilic center of compound <b>90b</b>. Chirality of the piperidine ring places compound <b>90b</b> in an orientation appropriate for covalent interaction with Cys481 and optimizes hydrogen bonding and hydrophobic interactions within the protein.</div><figure id="fig19" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0019.jpeg" id="GRAPHIC-d7e3651-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Compound <b>90b</b> docked into the ATP binding pocket of EGFR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FBN">5FBN</a>, 3.17 Å). (left) Interaction of compound <b>90b</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>90b</b> in EGFR. The protein surface is depicted in blue. Compound <b>90b</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although ibrutinib is effective against B-cell malignancies, the inhibitor has numerous off-target activities due to irreversible binding to other kinases [e.g., EGFR, tyrosine kinase expressed in hepatocellular carcinoma (TEC), interleukin-2-inducible T-cell kinase (ITK), and T-cell X chromosome kinase (TXK)]. This led to the development of more selective, second-generation, irreversible BTK inhibitors <b>tirabrutinib</b><a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> (<b>91</b>, ONO/GS-4059) and <b>acalabrutinib</b> (<b>92</b>, ACP-196, AstraZeneca Pharmaceuticals Inc.) (<a class="ref internalNav" href="#sch26" aria-label="Scheme 26">Scheme 26</a>).<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> Compound <b>92</b> was developed for selectivity while maintaining an efficacious, irreversible profile against BTK. It received FDA approval in 2017 for treatment of adult patients with relapsed mantle cell lymphoma (MCL).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><figure id="sch26" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Scheme 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0045.jpeg" id="GRAPHIC-d7e3689-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 26. Second Generation Irreversible BTK Inhibitors <b>91</b> and <b>92.</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50">3.  Conclusion and Future Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07477" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07477" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Chirality is a prominent attribute in the biological world. Many organic molecules, including sugars and most natural amino acids, are chiral. Furthermore, all biomolecules within the central dogma of biology are chiral. Incorporating chirality into drug discovery is an important technique to better engage biological targets with enhanced drug properties. During drug discovery, the majority of failures are due to a lack of either efficacy or safety, which can be attributed to poor ADME properties of the drug.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Consequently, a balance of optimized pharmacokinetic and pharmacodynamic parameters maximizes the safety and efficacy of a drug candidate. Chirality has the potential to remedy both challenges of drug optimization by exploiting the three-dimensional nature of biology. As such, chiral small molecules are emerging as an attractive clinical advantage in drug discovery.</div><div class="NLM_p">In kinase drug discovery, most approved inhibitors are planar and have no stereocenters. Although planar structures are efficacious, some drug discovery efforts within the kinome are currently focused on the generation of kinase inhibitors with stereocenters. These efforts emphasize chirality as a property to improve pharmacokinetics and selectivity within the kinome. Solubility is also a major liability in drug development, especially with planar drug structures. Because most kinase inhibitors mimic adenine, the structures are planar and aromatic and exhibit intramolecular π–π stacking interaction that limits their aqueous solubility. Hence, incorporation of a chiral center can reduce π–π stacking interaction, thus improving drug solubility and absorption. Axial chirality is also being explored within the kinome by generating atropisomeric structures. Dynamics of such axial systems permits fine-tuning of receptor/ligand interactions. Further, chirality provides a new dimension to access new chemical space increasing novelty in structure and thereby accelerating drug discovery.</div><div class="NLM_p last">Understanding the importance of chirality in interdisciplinary areas of drug development may contribute to major progress in kinase inhibitor development. Crizotinib, the first FDA approved chiral kinase inhibitor for NSCLC, supports the importance of chirality in kinase drug discovery. On similar lines, the recent approval of lorlatinib for the treatment of NSCLC has further galvanized the importance of chirality in kinase research. The recent major advancements in new asymmetric synthetic methodologies and enantiomeric separation techniques encourage the effort of chiral drug development. Other evolving medicinal chemistry practices, such as kinome profiling and X-ray crystallography, are providing better insight into the role of chirality in kinase receptor engagement and receptor selectivity. Hence, developing chiral kinase inhibitors can help enhance druggability within the kinome. It is expected that chirality-driven, drug discovery campaigns will promote the development of kinase inhibitors with improved selectivity, potency, and drug properties. A surge of chiral kinase inhibitors are under clinical investigation and many have been approved in recent years. Enhancing druggability by implementing chirality-focused drug discovery will expand structural diversity when targeting the kinome. This, in turn, will uncover new chemotypes with augmented pharmacokinetic and pharmacodynamic profiles for improved druggability within the human kinome.</div></div><div class="NLM_back"><div class="NLM_notes" id="notes1"><p class="first last">The authors declare no competing financial interest.</p></div><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00640" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02753" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02753" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brendan Frett</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences,
College of Pharmacy, University of Arkansas
for Medical Sciences, Little
Rock, Arkansas 72205, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5b191a1d293e2f2f1b2e3a3628753e3f2e"><span class="__cf_email__" data-cfemail="2e6c6f685c4b5a5a6e5b4f435d004b4a5b">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong-Yu Li</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences,
College of Pharmacy, University of Arkansas
for Medical Sciences, Little
Rock, Arkansas 72205, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9212-2010" title="Orcid link">http://orcid.org/0000-0001-9212-2010</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3c7470550e7c495d514f12595849"><span class="__cf_email__" data-cfemail="7f3733164d3f0a1e120c511a1b0a">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Debasmita Saha</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences,
College of Pharmacy, University of Arkansas
for Medical Sciences, Little
Rock, Arkansas 72205, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anupreet Kharbanda</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences,
College of Pharmacy, University of Arkansas
for Medical Sciences, Little
Rock, Arkansas 72205, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Yan</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences,
College of Pharmacy, University of Arkansas
for Medical Sciences, Little
Rock, Arkansas 72205, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Naga Rajiv Lakkaniga</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences,
College of Pharmacy, University of Arkansas
for Medical Sciences, Little
Rock, Arkansas 72205, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30545" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30545" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Debasmita Saha</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=BIO-d7e3711-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Debasmita Saha</b> received her Ph.D. in organic synthesis from Indian Institute of Technology, Roorkee, India. She also worked as an International Research Scholar at KU Leuven, Belgium, followed by a postdoctoral assignment there. Currently, she is a postdoctoral fellow at University of Arkansas for Medical Sciences working in the area of kinase drug discovery. Her research interests include the design and synthesis of novel organic therapeutic frameworks and medicinal chemistry.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Anupreet Kharbanda</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=BIO-d7e3716-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Anupreet Kharbanda</b> is currently a graduate student in the Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences. She obtained her Bachelor’s in chemistry from University of Delhi and Master’s in chemistry from Indian Institute of Technology, Roorkee, India. Her current research centers on developing small molecule for targeting the tumor microenvironment with TGFβ Inhibitor, using synthetic medicinal chemistry and in vitro assays.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Wei Yan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=BIO-d7e3721-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wei Yan</b> received his Ph.D. from East China University of Science and Technology, Shanghai, China, and worked jointly at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Following this, he worked at WuXi AppTec as a process chemistry scientist. He is currently a postdoctoral researcher at the University of Arkansas for Medical Sciences. His expertise is in medicinal chemistry and process chemistry for pilot plant manufacture of APIs.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Naga Rajiv Lakkaniga</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=BIO-d7e3726-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Naga Rajiv Lakkaniga</b> is currently a Ph.D. candidate in the Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences. He received a Bachelor’s in pharmacy and Master’s in pharmacy in Pharmaceutical Chemistry from the Birla Institute of Technology and Science, Pilani, India. His current research is focused on discovering novel small molecule kinase inhibitors for anticancer therapy using synthetic medicinal chemistry and employing computational methods for lead optimization and conformational study of protein kinases.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Brendan Frett</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=BIO-d7e3731-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Brendan Frett</b> is an Assistant Professor of Pharmaceutical Sciences in the College of Pharmacy at the University of Arkansas for Medical Sciences. He received his Ph.D. degree from the University of Arizona, where he codiscovered a clinical candidate in IND studies. He has successfully transferred academic-based discoveries to pharmaceutical companies for clinical development. He is interested in pursuing translational research projects, where research completed in his laboratory can directly help patients.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Hong-Yu Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=BIO-d7e3736-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hong-Yu Li</b> is a Professor of Medicinal Chemistry at the University of Arkansas for Medical Sciences (UAMS). He is also an Arkansas Research Alliance (ARA) Scholar, the Helen Adams & ARA endowed chair in drug discovery, and codirector for the Therapeutics Science Program, Winthrop P Rockefeller Cancer Institute. He received his Ph.D. degree from the University of Tokyo and did postdoctoral training at Columbia University and Harvard University. He previously worked at Eli Lilly and the University of Arizona, where he focused on oncology drug discovery. His current research interests are in chemical biology and drug discovery, especially for oncology related targets and phenotypes. In his lab at UAMS, a robust oncology pipeline is under development exploiting single agent polypharmacology and synergistic medicinal chemistry approaches.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i57">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71472" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71472" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">H.L. was supported by the grants (NIH 1R01CA194094 and 1R01CA197178)</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">BCR</td><td class="NLM_def"><p class="first last">B-cell receptors</p></td></tr><tr><td class="NLM_term">BLK</td><td class="NLM_def"><p class="first last">B lymphocyte kinase</p></td></tr><tr><td class="NLM_term">CDKs</td><td class="NLM_def"><p class="first last">cyclin-dependent kinases</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">blood clearance</p></td></tr><tr><td class="NLM_term">CRPC</td><td class="NLM_def"><p class="first last">castration-resistant prostate cancer</p></td></tr><tr><td class="NLM_term">ERKs</td><td class="NLM_def"><p class="first last">extracellular signal–regulated kinases</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">FMS like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">GSK</td><td class="NLM_def"><p class="first last">Glaxo-Smith Kline</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">ITK</td><td class="NLM_def"><p class="first last">interleukin-2-inducible T-cell kinase</p></td></tr><tr><td class="NLM_term">IFNγ</td><td class="NLM_def"><p class="first last">interferon gamma</p></td></tr><tr><td class="NLM_term">IGF</td><td class="NLM_def"><p class="first last">insulin-like growth factor-1 receptor</p></td></tr><tr><td class="NLM_term">IL-2R</td><td class="NLM_def"><p class="first last">IL-2 receptors</p></td></tr><tr><td class="NLM_term">IRAK4</td><td class="NLM_def"><p class="first last">interleukin-1-receptor associated kinase</p></td></tr><tr><td class="NLM_term">ITK</td><td class="NLM_def"><p class="first last">interleukin-2-inducible T-cell kinase</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">JNKs</td><td class="NLM_def"><p class="first last"><i>c</i>-Jun N-terminal kinases</p></td></tr><tr><td class="NLM_term">MAPKs</td><td class="NLM_def"><p class="first last">mitogen activated protein kinases</p></td></tr><tr><td class="NLM_term">MDA-MB</td><td class="NLM_def"><p class="first last">M.D. Anderson metastasis breast cancer</p></td></tr><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multidrug resistance</p></td></tr><tr><td class="NLM_term">NFAT</td><td class="NLM_def"><p class="first last">nuclear factor of activated T-cell</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood monomorphonuclear cells</p></td></tr><tr><td class="NLM_term">PDX</td><td class="NLM_def"><p class="first last">patient-derived xenograft</p></td></tr><tr><td class="NLM_term">PI(3,4)P2</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3,4-bisphosphate</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">PI3P</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3-phosphate</p></td></tr><tr><td class="NLM_term">PIP3</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3,4,5-trisphosphate</p></td></tr><tr><td class="NLM_term">PLKs</td><td class="NLM_def"><p class="first last">Polo-like kinases</p></td></tr><tr><td class="NLM_term">PTEN</td><td class="NLM_def"><p class="first last">phosphatase and tensin homologue</p></td></tr><tr><td class="NLM_term">RIP1</td><td class="NLM_def"><p class="first last">receptor interacting protein 1</p></td></tr><tr><td class="NLM_term">S1P</td><td class="NLM_def"><p class="first last">sphingosine-1-phosphate</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">STK</td><td class="NLM_def"><p class="first last">serine threonine kinase</p></td></tr><tr><td class="NLM_term">TCR</td><td class="NLM_def"><p class="first last">T-cell receptors</p></td></tr><tr><td class="NLM_term">TGFβR1</td><td class="NLM_def"><p class="first last">transforming growth factor beta receptor 1</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple negative breast cancer</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i59">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40782" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40782" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 154 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Francotte, E.</span>; <span class="NLM_string-name">Lindne, W.</span></span> <i>Chirality in Drug Research</i>; <span class="NLM_publisher-name">WILEY-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=E.+Francotte&author=W.+Lindne&title=Chirality+in+Drug+Research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DFrancotte%26aufirst%3DE.%26btitle%3DChirality%2520in%2520Drug%2520Research%26pub%3DWILEY-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldeck, B.</span></span> <span> </span><span class="NLM_article-title">Three-dimensional pharmacology, a subject ranging from ignorance to overstatements</span>. <i>Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1046/j.1600-0773.2003.pto930502.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1046%2Fj.1600-0773.2003.pto930502.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=14629731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvVartbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2003&pages=203-210&author=B.+Waldeck&title=Three-dimensional+pharmacology%2C+a+subject+ranging+from+ignorance+to+overstatements&doi=10.1046%2Fj.1600-0773.2003.pto930502.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Three-dimensional pharmacology, a subject ranging from ignorance to overstatements</span></div><div class="casAuthors">Waldeck, Bertil</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Toxicology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">203-210</span>CODEN:
                <span class="NLM_cas:coden">PHTOEH</span>;
        ISSN:<span class="NLM_cas:issn">0901-9928</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Stereoselectivity has been known to play a role in drug action for 100 yr or more.  Nevertheless, chiral drugs have been developed and used as racemates, neglecting the fact that they comprise mixts. of two or more compds. which may have quite different pharmacol. properties.  A very limited access to pure enantiomers in the past has been responsible for this unsatisfactory state of affairs.  During the last 20 yr, significant achievements have made it possible to perform stereoselective synthesis and anal.  Today, novel chiral drugs are as a rule developed as single enantiomers.  Yet, studies of old racemic drugs are still designed, performed and published without mention of the fact that two or more compds. are involved.  In recent years, a no. of old racemic drugs have been re-evaluated and re-introduced into the clin. area as the pure, active enantiomer (the eutomer).  While in principle correct, the clin. benefit of this shift from a well established racemate to a pure enantiomer often seems to be limited and sometimes exaggerated.  Racemic drugs with a deleterious enantiomer that does not contribute to the therapeutic effect (the distomer), may have been sorted out in the safety evaluation process.  However, in the future any pharmacol. study of racemic drugs must include the pure enantiomers.  This will generate new, valuable information on stereoselectivity in drug action and interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYhJNZNDOX4rVg90H21EOLACvtfcHk0ljYcUdpc6yFnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvVartbo%253D&md5=d21aeb221455602cae88fb18bfafda53</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1046%2Fj.1600-0773.2003.pto930502.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1600-0773.2003.pto930502.x%26sid%3Dliteratum%253Aachs%26aulast%3DWaldeck%26aufirst%3DB.%26atitle%3DThree-dimensional%2520pharmacology%252C%2520a%2520subject%2520ranging%2520from%2520ignorance%2520to%2520overstatements%26jtitle%3DPharmacol.%2520Toxicol.%26date%3D2003%26volume%3D93%26spage%3D203%26epage%3D210%26doi%3D10.1046%2Fj.1600-0773.2003.pto930502.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agranat, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, J.</span></span> <span> </span><span class="NLM_article-title">Putting chirality to work: the strategy of chiral switches</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">768</span>, <span class="refDoi"> DOI: 10.1038/nrd915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnrd915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=12360254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVGru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=753-768&author=I.+Agranatauthor=H.+Canerauthor=J.+Caldwell&title=Putting+chirality+to+work%3A+the+strategy+of+chiral+switches&doi=10.1038%2Fnrd915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Putting chirality to work: the strategy of chiral switches</span></div><div class="casAuthors">Agranat, Israel; Caner, Hava; Caldwell, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">753-768</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most of the new drugs reaching the market today are single enantiomers, rather than the racemic mixts. that dominated up to ten years ago.  Many of the new single-enantiomer drugs were developed as such, but there are also important examples of new single-enantiomer drugs derived from 'chiral switches' of established racemates.  Indeed, a well-timed chiral switch can offer enhanced therapy and further profitability as a 'line extension' of a major racemic drug with patents that are expiring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok8OsLio3NMrVg90H21EOLACvtfcHk0lgVbrJNkevJAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVGru7o%253D&md5=5f391aef19f496952f6a066b575b13a9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd915%26sid%3Dliteratum%253Aachs%26aulast%3DAgranat%26aufirst%3DI.%26aulast%3DCaner%26aufirst%3DH.%26aulast%3DCaldwell%26aufirst%3DJ.%26atitle%3DPutting%2520chirality%2520to%2520work%253A%2520the%2520strategy%2520of%2520chiral%2520switches%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D753%26epage%3D768%26doi%3D10.1038%2Fnrd915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, D. J.</span></span> <span> </span><span class="NLM_article-title">Chirality: a blueprint for the future</span>. <i>Br. J. Anaesth.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1093/bja/88.4.563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1093%2Fbja%2F88.4.563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=12066734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1ylsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2002&pages=563-576&author=D.+Burkeauthor=D.+J.+Henderson&title=Chirality%3A+a+blueprint+for+the+future&doi=10.1093%2Fbja%2F88.4.563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Chirality: A blueprint for the future</span></div><div class="casAuthors">Burke, D.; Henderson, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Anaesthesia</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">563-576</span>CODEN:
                <span class="NLM_cas:coden">BJANAD</span>;
        ISSN:<span class="NLM_cas:issn">0007-0912</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review is given on the following aspects of chirality: International Union of Pure and Applied Chem. (IUPAC) terminol., stereospecific biol. interactions, drug development, methods of enantioselective synthesis, pharmacokinetics, and chiral synthesis and its impact on anesthetic practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVd-E6lmB7BbVg90H21EOLACvtfcHk0lgVbrJNkevJAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1ylsbY%253D&md5=546ad9204b8bb48765574761eea0f168</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fbja%2F88.4.563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbja%252F88.4.563%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DD.%26aulast%3DHenderson%26aufirst%3DD.%2BJ.%26atitle%3DChirality%253A%2520a%2520blueprint%2520for%2520the%2520future%26jtitle%3DBr.%2520J.%2520Anaesth.%26date%3D2002%26volume%3D88%26spage%3D563%26epage%3D576%26doi%3D10.1093%2Fbja%2F88.4.563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McConathy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, M. J.</span></span> <span> </span><span class="NLM_article-title">Stereochemistry in drug action</span>. <i>Prim. Care Companion J. Clin. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.4088/PCC.v05n0202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.4088%2FPCC.v05n0202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=15156233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A280%3ADC%252BC2sbnvVensQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=70-73&author=J.+McConathyauthor=M.+J.+Owens&title=Stereochemistry+in+drug+action&doi=10.4088%2FPCC.v05n0202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Stereochemistry in Drug Action</span></div><div class="casAuthors">McConathy Jonathan; Owens Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Primary care companion to the Journal of clinical psychiatry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">70-73</span>
        ISSN:<span class="NLM_cas:issn">1523-5998</span>.
    </div><div class="casAbstract">The importance of stereochemistry in drug action is gaining greater attention in medical practice, and a basic knowledge of the subject will be necessary for clinicians to make informed decisions regarding the use of single-enantiomer drugs.  Many of the drugs currently used in psychiatric practice are mixtures of enantiomers.  For some therapeutics, single-enantiomer formulations can provide greater selectivities for their biological targets, improved therapeutic indices, and/or better pharmacokinetics than a mixture of enantiomers.  This article reviews the nomenclature for describing stereochemistry and enantiomers, emphasizes the potential biological and pharmacologic differences between the 2 enantiomers of a drug, and highlights the clinical experience with single enantiomers of the selective serotonin reuptake inhibitors fluoxetine and citalopram.  In some cases, both a mixture of enantiomers and a single-enantiomer formulation of a drug will be available simultaneously.  In these cases, familiarity with stereochemistry and its pharmacologic implications will aid the practicing physician to provide optimal pharmacotherapy to his or her patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0nrgcR0RzouxsqfvU0ziafW6udTcc2eZMsXP3XworS7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbnvVensQ%253D%253D&md5=5671ec0470b34bd5a958f847df8cba17</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4088%2FPCC.v05n0202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FPCC.v05n0202%26sid%3Dliteratum%253Aachs%26aulast%3DMcConathy%26aufirst%3DJ.%26aulast%3DOwens%26aufirst%3DM.%2BJ.%26atitle%3DStereochemistry%2520in%2520drug%2520action%26jtitle%3DPrim.%2520Care%2520Companion%2520J.%2520Clin.%2520Psychiatry%26date%3D2003%26volume%3D5%26spage%3D70%26epage%3D73%26doi%3D10.4088%2FPCC.v05n0202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, T.</span></span> <i>Pharmacokinetics of the Enantiomers of Thalidomide</i>; <span class="NLM_publisher-name">Malmö University Hospital</span>: <span class="NLM_publisher-loc">Malmö</span>, <span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=T.+Eriksson&title=Pharmacokinetics+of+the+Enantiomers+of+Thalidomide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DEriksson%26aufirst%3DT.%26btitle%3DPharmacokinetics%2520of%2520the%2520Enantiomers%2520of%2520Thalidomide%26pub%3DMalm%25C3%25B6%2520University%2520Hospital%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björkman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höglund, P.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacology of thalidomide</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1007/s002280100320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1007%2Fs002280100320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=11599654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtFWhtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2001&pages=365-376&author=T.+Erikssonauthor=S.+Bj%C3%B6rkmanauthor=P.+H%C3%B6glund&title=Clinical+pharmacology+of+thalidomide&doi=10.1007%2Fs002280100320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacology of thalidomide</span></div><div class="casAuthors">Eriksson, Tommy; Bjorkman, Sven; Hoglund, Peter</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">365-376</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review.  Background: Thalidomide has a chiral center, and the racemate of (R)- and (S)-thalidomide was introduced as a sedative drug in the late 1950s.  In 1961, it was withdrawn due to teratogenicity and neuropathy.  There is now a growing clin. interest in thalidomide due to its unique anti-inflammatory and immunomodulatory effects.  Objective: To critically review pharmacokinetic studies and briefly review pharmacodynamic effects and studies of thalidomide in consideration of its chem. and stereochem. properties and metab.  Methods: Literature search and computer simulations of pharmacokinetics.  Results: Rational use of thalidomide is problematic due to lack of basic knowledge of its mechanism of action, effects of the sep. enantiomers and metabolites, and dose- and concn.-effect relationships.  Due to its inhibition of tumor necrosis factor-α and angiogenesis, racemic thalidomide was tested with good effect in a variety of skin and mucous membrane disorders, Crohn's disease, graft-vs.-host disease, complications to human immunodeficiency virus, and, recently, in multiple myeloma.  Adverse reactions are often related to the sedative effects.  Irreversible toxic peripheral neuropathy and fetal malformations are serious complications that can be prevented.  The results of several published pharmacokinetic studies can be questioned due to poor methodol. and the use of non-stereospecific assays.  The enantiomers of thalidomide undergo spontaneous hydrolysis and fast chiral interconversion at physiol. pH.  The oral bioavailability of thalidomide was not unequivocally detd., but available data suggest that it is high.  Absorption is slow, with a time to max. blood plasma concn. of at least 2 h, and may also be dose-dependent; however, that of the sep. enantiomers may be faster due to higher aq. soly.  Estn. of the vol. of distribution is complicated by probable hydrolysis and chiral inversion also in peripheral compartments.  A value of around 1 l/kg is however plausible.  Plasma protein binding is low with little difference between the enantiomers.  Elimination of thalidomide is mainly by pH-dependent spontaneous hydrolysis in all body fluids with an apparent mean clearance of 10 l/h for the (R)- and 21 l/h for the (S)-enantiomer in adult subjects.  Blood concns. of the (R)-enantiomer are consequently higher than those of the (S)-enantiomer at pseudoequil.  The mean elimination half-life of both enantiomers is 5 h.  One hydroxylated metabolite was found in low concns. in the blood.  Since both enzymic metab. and renal excretion play minor roles in the elimination of thalidomide, the risk of drug interactions seems to be low.  Conclusions: The interest in and use of thalidomide is increasing due to its potential as an immunomodulating and antiangiogenic agent.  The inter-individual variability in distribution and elimination is low.  Apart from this, its use is complicated by the lack of knowledge of dose- or concn.-effect relationships, possible dose-dependent oral absorption and of course by its well-known serious adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPvIHZfdVKUbVg90H21EOLACvtfcHk0lgVbrJNkevJAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtFWhtb4%253D&md5=c440504893ed786bd098b8fff68a3cde</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs002280100320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002280100320%26sid%3Dliteratum%253Aachs%26aulast%3DEriksson%26aufirst%3DT.%26aulast%3DBj%25C3%25B6rkman%26aufirst%3DS.%26aulast%3DH%25C3%25B6glund%26aufirst%3DP.%26atitle%3DClinical%2520pharmacology%2520of%2520thalidomide%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2001%26volume%3D57%26spage%3D365%26epage%3D376%26doi%3D10.1007%2Fs002280100320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björkman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björk, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höglund, P.</span></span> <span> </span><span class="NLM_article-title">Hydroxylated metabolites of thalidomide: formation in-vitro and in-vivo in man</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1409</span>– <span class="NLM_lpage">1416</span>, <span class="refDoi"> DOI: 10.1111/j.2042-7158.1998.tb03368.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1111%2Fj.2042-7158.1998.tb03368.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10052858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK1MXpsFCmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1998&pages=1409-1416&author=T.+Erikssonauthor=S.+Bj%C3%B6rkmanauthor=B.+Rothauthor=H.+Bj%C3%B6rkauthor=P.+H%C3%B6glund&title=Hydroxylated+metabolites+of+thalidomide%3A+formation+in-vitro+and+in-vivo+in+man&doi=10.1111%2Fj.2042-7158.1998.tb03368.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxylated metabolites of thalidomide: formation in-vitro and in-vivo in man</span></div><div class="casAuthors">Eriksson, Tommy; Bjorkman, Seven; Roth, Bodil; Bjork, Henrik; Hoglund, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1409-1416</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">Royal Pharmaceutical Society of Great Britain</span>)
        </div><div class="casAbstract">There is renewed interest in the clin. use of thalidomide, because of its unique immunomodulating action.  Because data on the metab. of thalidomide in man are very sparse, the aim of this study was to develop HPLC assays for the 5-hydroxy, 5,6-dihydroxy, 4,5-dihydroxy and 5'-hydroxy metabolites of thalidomide and to investigate their possible formation in man - in-vitro in liver homogenates and in-vivo in healthy volunteers.  Reversed-phase HPLC assays with UV detection were developed for quantification of the metabolites in the low ng mL-1 range in plasma and incubate samples.  The stability of the metabolites was investigated and degrdn. was avoided by rapid chilling and acidification of the samples.  After incubation of thalidomide with fraction S9 from human liver, formation of the 5-hydroxy and 5'-hydroxy metabolites could be demonstrated.  The 5'-hydroxy metabolite was found, in low concns., in plasma samples from eight healthy male volunteers who had received thalidomide orally.  The other three metabolites could not be found by HPLC with detection limits of 1-2 ng mL-1.  Thus the formation of two hydroxylated metabolites of thalidomide in the liver in man was demonstrated, but only one of these could be detected in the circulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO-pK2ncViKLVg90H21EOLACvtfcHk0lhT_iIyIxoMdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXpsFCmtA%253D%253D&md5=f4d100faec58ad10b09947a6438387b7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.2042-7158.1998.tb03368.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2042-7158.1998.tb03368.x%26sid%3Dliteratum%253Aachs%26aulast%3DEriksson%26aufirst%3DT.%26aulast%3DBj%25C3%25B6rkman%26aufirst%3DS.%26aulast%3DRoth%26aufirst%3DB.%26aulast%3DBj%25C3%25B6rk%26aufirst%3DH.%26aulast%3DH%25C3%25B6glund%26aufirst%3DP.%26atitle%3DHydroxylated%2520metabolites%2520of%2520thalidomide%253A%2520formation%2520in-vitro%2520and%2520in-vivo%2520in%2520man%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D1998%26volume%3D50%26spage%3D1409%26epage%3D1416%26doi%3D10.1111%2Fj.2042-7158.1998.tb03368.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mühlbacher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastner-Pustet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bringmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannschreck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaschke, G.</span></span> <span> </span><span class="NLM_article-title">In vitro biotransformation of (<i>R</i>)-and (<i>S</i>)-thalidomide: application of circular dichroism spectroscopy to the stereochemical characterization of the hydroxylated etabolites</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">3726</span>– <span class="NLM_lpage">3735</span>, <span class="refDoi"> DOI: 10.1021/ac0203138</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ac0203138" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD38XltV2ms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2002&pages=3726-3735&author=M.+Meyringauthor=J.+M%C3%BChlbacherauthor=K.+Messerauthor=N.+Kastner-Pustetauthor=G.+Bringmannauthor=A.+Mannschreckauthor=G.+Blaschke&title=In+vitro+biotransformation+of+%28R%29-and+%28S%29-thalidomide%3A+application+of+circular+dichroism+spectroscopy+to+the+stereochemical+characterization+of+the+hydroxylated+etabolites&doi=10.1021%2Fac0203138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Biotransformation of (R)- and (S)-Thalidomide: Application of Circular Dichroism Spectroscopy to the Stereochemical Characterization of the Hydroxylated Metabolites</span></div><div class="casAuthors">Meyring, Michael; Muehlbacher, Joerg; Messer, Kim; Kastner-Pustet, Nikola; Bringmann, Gerhard; Mannschreck, Albrecht; Blaschke, Gottfried</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3726-3735</span>CODEN:
                <span class="NLM_cas:coden">ANCHAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2700</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CD spectroscopy was successfully used for the stereochem. characterization of the hydroxylated metabolites formed during the in vitro biotransformation of (R)- and (S)-thalidomide by rat liver microsomes.  Incubation exts. of the individual enantiomers were analyzed by HPLC on an achiral stationary phase combined with CD detection.  The CD data of the almost enantiopure eluates of the metabolites were compared with the CD spectra quantum chem. calcd. for the resp. structures.  The results allowed us a reliable detn. of the abs. stereostructure for all of the metabolites.  The chiral center of thalidomide is unaffected by the stereoselective biotransformation process. (3'R,5'R)-trans-5'-hydroxythalidomide is the main metabolite of (R)-thalidomide, which epimerizes spontaneously to give the more stable (3'S,5'R)-cis isomer.  On the contrary, (S)-thalidomide is preferentially metabolized by hydroxylation in the phthalimide moiety, resulting in the formation of (S)-5-hydroxythalidomide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs0TJVv_3WprVg90H21EOLACvtfcHk0lhT_iIyIxoMdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltV2ms7Y%253D&md5=e964e68691179e877e5693baf39195da</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fac0203138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fac0203138%26sid%3Dliteratum%253Aachs%26aulast%3DMeyring%26aufirst%3DM.%26aulast%3DM%25C3%25BChlbacher%26aufirst%3DJ.%26aulast%3DMesser%26aufirst%3DK.%26aulast%3DKastner-Pustet%26aufirst%3DN.%26aulast%3DBringmann%26aufirst%3DG.%26aulast%3DMannschreck%26aufirst%3DA.%26aulast%3DBlaschke%26aufirst%3DG.%26atitle%3DIn%2520vitro%2520biotransformation%2520of%2520%2528R%2529-and%2520%2528S%2529-thalidomide%253A%2520application%2520of%2520circular%2520dichroism%2520spectroscopy%2520to%2520the%2520stereochemical%2520characterization%2520of%2520the%2520hydroxylated%2520etabolites%26jtitle%3DAnal.%2520Chem.%26date%3D2002%26volume%3D74%26spage%3D3726%26epage%3D3735%26doi%3D10.1021%2Fac0203138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vargesson, N.</span></span> <span> </span><span class="NLM_article-title">Thalidomide-induced teratogenesis: history and mechanisms</span>. <i>Birth Defects Res., Part C</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1002/bdrc.21096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1002%2Fbdrc.21096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=26043938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsVWlsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2015&pages=140-156&author=N.+Vargesson&title=Thalidomide-induced+teratogenesis%3A+history+and+mechanisms&doi=10.1002%2Fbdrc.21096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide-induced teratogenesis: History and mechanisms</span></div><div class="casAuthors">Vargesson, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Birth Defects Research, Part C: Embryo Today--Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-156</span>CODEN:
                <span class="NLM_cas:coden">BDRPDV</span>;
        ISSN:<span class="NLM_cas:issn">1542-975X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Nearly 60 years ago thalidomide was prescribed to treat morning sickness in pregnant women.  What followed was the biggest man-made medical disaster ever, where over 10,000 children were born with a range of severe and debilitating malformations.  Despite this, the drug is now used successfully to treat a range of adult conditions, including multiple myeloma and complications of leprosy.  Tragically, a new generation of thalidomide damaged children has been identified in Brazil.  Yet, how thalidomide caused its devastating effects in the forming embryo remains unclear.  However, studies in the past few years have greatly enhanced our understanding of the mol. mechanisms the drug.  This review will look at the history of the drug, and the range and type of damage the drug caused, and outline the mechanisms of action the drug uses including recent mol. advances and new findings.  Some of the remaining challenges facing thalidomide biologists are also discussed.  Birth Defects Research (Part C), 2015. © 2015 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokrUriNAK3wbVg90H21EOLACvtfcHk0lhT_iIyIxoMdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsVWlsbo%253D&md5=40a4f801af5d65d3fa9e322075c6deec</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fbdrc.21096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdrc.21096%26sid%3Dliteratum%253Aachs%26aulast%3DVargesson%26aufirst%3DN.%26atitle%3DThalidomide-induced%2520teratogenesis%253A%2520history%2520and%2520mechanisms%26jtitle%3DBirth%2520Defects%2520Res.%252C%2520Part%2520C%26date%3D2015%26volume%3D105%26spage%3D140%26epage%3D156%26doi%3D10.1002%2Fbdrc.21096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span> <i>Development
of New Stereoisomeric Drugs</i>; <span class="NLM_publisher-name">Food and Drug
Administration</span>: <span class="NLM_publisher-loc">Rockville,
MD</span>, <span class="NLM_year">1992</span>; <a href="https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/guidances/ucm122883.htm" class="extLink">https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/guidances/ucm122883.htm</a> (accessed Jan 19, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Development%0Aof+New+Stereoisomeric+Drugs%3B+Food+and+Drug%0AAdministration%3A+Rockville%2C%0AMD%2C+1992%3B+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fguidancecomplianceregulatoryinformation%2Fguidances%2Fucm122883.htm+%28accessed+Jan+19%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDevelopment%250Aof%2520New%2520Stereoisomeric%2520Drugs%26pub%3DFood%2520and%2520Drug%250AAdministration%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agranat, I.</span></span> <span> </span><span class="NLM_article-title">Trends in the development of chiral drugs</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(03)02904-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2FS1359-6446%2803%2902904-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=15038394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=105-110&author=H.+Canerauthor=E.+Gronerauthor=L.+Levyauthor=I.+Agranat&title=Trends+in+the+development+of+chiral+drugs&doi=10.1016%2FS1359-6446%2803%2902904-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in the development of chiral drugs</span></div><div class="casAuthors">Caner, Hava; Groner, Efrat; Levy, Liron; Agranat, Israel</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">105-110</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Single enantiomers, the leading component of approved drugs today, have already been significant in the 1980's, while racemates, although declining steeply, are not a dead option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0oqR9_DNUw7Vg90H21EOLACvtfcHk0lhNsPMxMQ9SKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOkurg%253D&md5=6cc54e0f9b73862add22632009a4c905</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2803%2902904-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252803%252902904-0%26sid%3Dliteratum%253Aachs%26aulast%3DCaner%26aufirst%3DH.%26aulast%3DGroner%26aufirst%3DE.%26aulast%3DLevy%26aufirst%3DL.%26aulast%3DAgranat%26aufirst%3DI.%26atitle%3DTrends%2520in%2520the%2520development%2520of%2520chiral%2520drugs%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D105%26epage%3D110%26doi%3D10.1016%2FS1359-6446%2803%2902904-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Toenjes, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, J. L.</span></span> <span> </span><span class="NLM_article-title">Atropisomerism in medicinal chemistry: challenges and opportunities</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.4155/fmc-2017-0152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.4155%2Ffmc-2017-0152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=29380622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=409-422&author=S.+T.+Toenjesauthor=J.+L.+Gustafson&title=Atropisomerism+in+medicinal+chemistry%3A+challenges+and+opportunities&doi=10.4155%2Ffmc-2017-0152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Atropisomerism in medicinal chemistry: challenges and opportunities</span></div><div class="casAuthors">Toenjes, Sean T.; Gustafson, Jeffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">409-422</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Atropisomerism is a dynamic type of axial chirality that is ubiquitous in medicinal chem.  There are several examples of stable atropisomeric US FDA-approved drugs and exptl. compds., and in each case the atropisomers of these compds. possess drastically different biol. activities.  Rapidly interconverting atropisomerism is even more prevalent, and while such compds. are typically considered achiral, they bind their protein targets in an atroposelective fashion, with the nonrelevant atropisomer contributing little to the desired activities.  It has been recently demonstrated that various properties of an interconverting atropisomer can be modulated through the synthesis of atropisomer stable and pure analogs.  Herein we discuss examples of atropisomerism in drug discovery as well as challenges and opportunities moving forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaSgfKDqoiYbVg90H21EOLACvtfcHk0lhNsPMxMQ9SKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCntLc%253D&md5=ceb5cc2626d980aa3e3903fd126a3f3a</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2017-0152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2017-0152%26sid%3Dliteratum%253Aachs%26aulast%3DToenjes%26aufirst%3DS.%2BT.%26aulast%3DGustafson%26aufirst%3DJ.%2BL.%26atitle%3DAtropisomerism%2520in%2520medicinal%2520chemistry%253A%2520challenges%2520and%2520opportunities%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2018%26volume%3D10%26spage%3D409%26epage%3D422%26doi%3D10.4155%2Ffmc-2017-0152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Clayden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaPlante, S. R.</span></span> <span> </span><span class="NLM_article-title">The challenge of atropisomerism in drug discovery</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6398</span>– <span class="NLM_lpage">6401</span>, <span class="refDoi"> DOI: 10.1002/anie.200901719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1002%2Fanie.200901719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=19637174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWiurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=6398-6401&author=J.+Claydenauthor=W.+J.+Moranauthor=P.+J.+Edwardsauthor=S.+R.+LaPlante&title=The+challenge+of+atropisomerism+in+drug+discovery&doi=10.1002%2Fanie.200901719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">The Challenge of Atropisomerism in Drug Discovery</span></div><div class="casAuthors">Clayden, Jonathan; Moran, Wesley J.; Edwards, Paul J.; LaPlante, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">6398-6401</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Herein, we address the pharmaceutical implications of a hitherto largely overlooked alternative source of drug chirality: atropisomerism.  Atropisomers are conformers which, owing to steric or electronic constraints, interconvert slowly enough (by definition, with a half life of > 1000 s) that they can be isolated.'781 The stereochem. consequences of hindered rotation about a single bond can be such that an apparent single compd. can actually be a mixt. of two, or an apparently achiral compd. can actually be racemic.  If such pairs of stereoisomers are separable, then the implications for drug discovery may be similar to those of compds. with classical chiral centers.  In the context of a lack of std. procedures for dealing with atropisomerism, and the absence of specific regulatory policies governing conformationally based stereochem., we explore some recent examples of atropisomeric compds. that have been or are in drug development.  We also draw conclusions relating to potential strategies for design and development where atropisomerism is an issue.  We expose and propose options for the management of atropisomerism, which, many view as a lurking menace with the potential to significantly increase the cost of pharmaceutical research and development if ignored.  Atropisomerism may give rise to geometrical isomers, diastereoisomers, or enantiomers, all with the distinctive feature that they can in principle be equilibrated thermally.  In the absence of specific regulatory policies, atropisomeric stereoisomers are best dealt with in the same way as stereoisomers with classical chiral centers, but with isomerization rates and where necessary, differential conformer populations taken into account.  For racemic drug candidates, the FDA policy statement from 1992 emphasizes the importance of understanding the main therapeutic activities of the isomers through in vitro or in vivo studies.  Studies of the pharmacokinetic behavior of the individual enantiomers carried out early in the development of drug candidates are also valuable.  Knowledge gained from these studies can help guide the choice of development of a single enantiomer vs. a racemic mixt.  Development of a drug as a racemic mixt. may be appropriate if the mixt. is not reasonably separable (by synthetic methods, HPLC anal., etc.) or if racemization is rapid in vitro and/or in vivo (as in ibuprofen or thalidomide), thus making it futile to administer only the eutomer (more active isomer).  However, it is nonetheless highly recommended that crit. pharmacol. attributes related to the safety and efficacy of both isomers is investigated: overall, there must be an acceptable toxicol. profile and a suitable therapeutic window (in vitro, in animal models, and in humans).  FDA website provides some useful guidance to their expectations for drug development in this context.  Options for dealing with the phenomenon of atropisomerism can be implemented at the early stage of drug design.  For example, it may be possible to make related analogs that have the following features: (1) symmetry about a hindered bond, thus eliminating a chiral axis; (2) faster rotation about a hindered bond, thus pushing the half-life for conformational interconversion down to the order of seconds; (3) further encumbrance about a hindered bond to produce separable atropisomers whose interconversion is negligibly slow (for example, half-lives of the order of millennia); or (4) introduction of a stable stereogenic center to perturb the population of interconverting atropisomers such that only one desirable conformation predominates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsMjlS3iQPEbVg90H21EOLACvtfcHk0lhNsPMxMQ9SKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWiurfN&md5=70ff6fe476e7db4653130fe74af9325e</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1002%2Fanie.200901719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200901719%26sid%3Dliteratum%253Aachs%26aulast%3DClayden%26aufirst%3DJ.%26aulast%3DMoran%26aufirst%3DW.%2BJ.%26aulast%3DEdwards%26aufirst%3DP.%2BJ.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26atitle%3DThe%2520challenge%2520of%2520atropisomerism%2520in%2520drug%2520discovery%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2009%26volume%3D48%26spage%3D6398%26epage%3D6401%26doi%3D10.1002%2Fanie.200901719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metrano, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rablen, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. J.</span></span> <span> </span><span class="NLM_article-title">Spontaneous transfer of chirality in an atropisomerically enriched two-axis system</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>509</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1038/nature13189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnature13189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=24747399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlyis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=509&publication_year=2014&pages=71-75&author=K.+T.+Barrettauthor=A.+J.+Metranoauthor=P.+R.+Rablenauthor=S.+J.+Miller&title=Spontaneous+transfer+of+chirality+in+an+atropisomerically+enriched+two-axis+system&doi=10.1038%2Fnature13189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Spontaneous transfer of chirality in an atropisomerically enriched two-axis system</span></div><div class="casAuthors">Barrett, Kimberly T.; Metrano, Anthony J.; Rablen, Paul R.; Miller, Scott J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">509</span>
        (<span class="NLM_cas:issue">7498</span>),
    <span class="NLM_cas:pages">71-75</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">One of the most well-recognized stereogenic elements in a chiral mol. is an sp3-hybridized carbon atom that is connected to four different substituents.  Axes of chirality can also exist about bonds with hindered barriers of rotation; mols. contg. such axes are known as atropisomers.  Understanding the dynamics of these systems can be useful, for example, in the design of single-atropisomer drugs or mol. switches and motors.  For mols. that exhibit a single axis of chirality, rotation about that axis leads to racemization as the system reaches equil.  Here we report a two-axis system for which an enantioselective reaction produces four stereoisomers (two enantiomeric pairs): following a catalytic asym. transformation, we observe a kinetically controlled product distribution that is perturbed from the system's equil. position.  As the system undergoes isomerization, one of the diastereomeric pairs drifts spontaneously to a higher enantiomeric ratio.  In a compensatory manner, the enantiomeric ratio of the other diastereomeric pair decreases.  These observations are made for a class of unsym. amides that exhibits two asym. axes-one axis is defined through a benzamide substructure, and the other axis is assocd. with differentially N,N-disubstituted amides.  The stereodynamics of these substrates provides an opportunity to observe a curious interplay of kinetics and thermodn. intrinsic to a system of stereoisomers that is constrained to a situation of partial equil.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO0VsKdgwtgbVg90H21EOLACvtfcHk0liI4AvMY3eTQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlyis78%253D&md5=a7eabd56f3d8815af07417d39e605a7a</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1038%2Fnature13189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13189%26sid%3Dliteratum%253Aachs%26aulast%3DBarrett%26aufirst%3DK.%2BT.%26aulast%3DMetrano%26aufirst%3DA.%2BJ.%26aulast%3DRablen%26aufirst%3DP.%2BR.%26aulast%3DMiller%26aufirst%3DS.%2BJ.%26atitle%3DSpontaneous%2520transfer%2520of%2520chirality%2520in%2520an%2520atropisomerically%2520enriched%2520two-axis%2520system%26jtitle%3DNature%26date%3D2014%26volume%3D509%26spage%3D71%26epage%3D75%26doi%3D10.1038%2Fnature13189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaPlante, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fader, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandrick, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandrick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hucke, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemper, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. J.</span></span> <span> </span><span class="NLM_article-title">Assessing atropisomer axial chirality in drug discovery and development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7005</span>– <span class="NLM_lpage">7022</span>, <span class="refDoi"> DOI: 10.1021/jm200584g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200584g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7005-7022&author=S.+R.+LaPlanteauthor=L.+D.+Faderauthor=K.+R.+Fandrickauthor=D.+R.+Fandrickauthor=O.+Huckeauthor=R.+Kemperauthor=S.+P.+Millerauthor=P.+J.+Edwards&title=Assessing+atropisomer+axial+chirality+in+drug+discovery+and+development&doi=10.1021%2Fjm200584g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing Atropisomer Axial Chirality in Drug Discovery and Development</span></div><div class="casAuthors">LaPlante, Steven R.; Fader, Lee D.; Fandrick, Keith R.; Fandrick, Daniel R.; Hucke, Oliver; Kemper, Ray; Miller, Stephen P. F.; Edwards, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7005-7022</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ8uS-SDx68bVg90H21EOLACvtfcHk0liI4AvMY3eTQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFygu7zN&md5=6b44135b3871d2460fba4b3246b899e3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm200584g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200584g%26sid%3Dliteratum%253Aachs%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DFader%26aufirst%3DL.%2BD.%26aulast%3DFandrick%26aufirst%3DK.%2BR.%26aulast%3DFandrick%26aufirst%3DD.%2BR.%26aulast%3DHucke%26aufirst%3DO.%26aulast%3DKemper%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DS.%2BP.%26aulast%3DEdwards%26aufirst%3DP.%2BJ.%26atitle%3DAssessing%2520atropisomer%2520axial%2520chirality%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7005%26epage%3D7022%26doi%3D10.1021%2Fjm200584g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">Small-molecule kinase inhibitors: an analysis of FDA-approved drugs</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.drudis.2015.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=26210956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=5-10&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=Small-molecule+kinase+inhibitors%3A+an+analysis+of+FDA-approved+drugs&doi=10.1016%2Fj.drudis.2015.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule kinase inhibitors: an analysis of FDA-approved drugs</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-10</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors (SMKIs), 28 of which are approved by the US Food and Drug Administration (FDA), have been actively pursued as promising targeted therapeutics.  Here, we assess the key structural and physicochem. properties, target selectivity and mechanism of function, and therapeutic indications of these approved inhibitors.  Our anal. showed that >30% of approved SMKIs have a mol. wt. (MW) exceeding 500 and all have a total ring count of between three and five.  The assumption that type II inhibitors tend to be more selective than type I inhibitors has been proved to be unreliable.  Although previous SMKI research was concd. on tyrosine kinase inhibitors for cancer treatment, recent progress indicates diversification of SMKI research in terms of new targets, mechanistic types, and therapeutic indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZrY68ZOI2xLVg90H21EOLACvtfcHk0liI4AvMY3eTQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73P&md5=228524fa464393053ecbfac19e994929</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DSmall-molecule%2520kinase%2520inhibitors%253A%2520an%2520analysis%2520of%2520FDA-approved%2520drugs%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D5%26epage%3D10%26doi%3D10.1016%2Fj.drudis.2015.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">FDA-approved small-molecule kinase inhibitors</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.tips.2015.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=25975227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=422-439&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=FDA-approved+small-molecule+kinase+inhibitors&doi=10.1016%2Fj.tips.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-approved small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">422-439</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases have emerged as one of the most intensively pursued targets in current pharmacol. research, esp. for cancer, due to their crit. roles in cellular signaling.  To date, the US FDA has approved 28 small-mol. kinase inhibitors, half of which were approved in the past 3 years.  While the clin. data of these approved mols. are widely presented and structure-activity relationship (SAR) has been reported for individual mols., an updated review that analyzes all approved mols. and summarizes current achievements and trends in the field has yet to be found.  Here we present all approved small-mol. kinase inhibitors with an emphasis on binding mechanism and structural features, summarize current challenges, and discuss future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrudyvM3eO09bVg90H21EOLACvtfcHk0lhIDExIJqEovQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D&md5=a6aa3dbb11e6fe3001fa5fa03a4c950a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DFDA-approved%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D422%26epage%3D439%26doi%3D10.1016%2Fj.tips.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0lhIDExIJqEovQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, K. G.</span></span> <span> </span><span class="NLM_article-title">The significance of chirality in drug design and development</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.2174/156802611795165098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.2174%2F156802611795165098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=21291399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Ojsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=760-770&author=W.+H.+Brooksauthor=W.+C.+Guidaauthor=K.+G.+Daniel&title=The+significance+of+chirality+in+drug+design+and+development&doi=10.2174%2F156802611795165098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The significance of chirality in drug design and development</span></div><div class="casAuthors">Brooks, W. H.; Guida, W. C.; Daniel, K. G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">760-770</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Proteins are often enantioselective towards their binding partners.  When designing small mols. to interact with these targets, one should consider stereoselectivity.  As considerations for exploring structure space evolve, chirality is increasingly important.  Binding affinity for a chiral drug can differ for diastereomers and between enantiomers.  For the virtual screening and computational design stage of drug development, this problem can be compounded by incomplete stereochem. information in structure libraries leading to a "coin toss" as to whether or not the "ideal" chiral structure is present.  Creating every stereoisomer for each chiral compd. in a structure library leads to an exponential increase in the no. of structures resulting in potentially unmanageable file sizes and screening times.  Therefore, only key chiral structures, enantiomeric pairs based on relative stereochem. need be included, and lead to a compromise between exploration of chem. space and maintaining manageable libraries.  In clin. environments, enantiomers of chiral drugs can have reduced, no, or even deleterious effects.  This underscores the need to avoid mixts. of compds. and focus on chiral synthesis.  Governmental regulations emphasizing the need to monitor chirality in drug development have increased.  The United States Food and Drug Administration issued guidelines and policies in 1992 concerning the development of chiral compds.  These guidelines require that abs. stereochem. be known for compds. with chiral centers and that this information should be established early in drug development in order that the anal. can be considered valid.  From exploration of structure space to governmental regulations it is clear that the question of chirality in drug design is of vital importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4TgZ0W1QUdrVg90H21EOLACvtfcHk0lhIDExIJqEovQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Ojsrw%253D&md5=eb78aca17518a7fd04d8cfc3c5d0ec78</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F156802611795165098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611795165098%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DW.%2BH.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26aulast%3DDaniel%26aufirst%3DK.%2BG.%26atitle%3DThe%2520significance%2520of%2520chirality%2520in%2520drug%2520design%2520and%2520development%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D760%26epage%3D770%26doi%3D10.2174%2F156802611795165098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran-Dube, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botrous, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grodsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padrique, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (<i>c</i>-MET) kinase and anaplastic lymphoma kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6342</span>– <span class="NLM_lpage">6363</span>, <span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lhgzDKwQfRRHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10<i>R</i>)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2<i>H</i>-8,4-(metheno)pyrazolo[4,3-<i>h</i>][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and <i>c</i>-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+macrocyclic+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29+and+c-ros+oncogene+1+%28ROS1%29+with+preclinical+brain+exposure+and+broad-spectrum+potency+against+ALK-resistant+mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lhgzDKwQfRRHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520macrocyclic%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520c-ros%2520oncogene%25201%2520%2528ROS1%2529%2520with%2520preclinical%2520brain%2520exposure%2520and%2520broad-spectrum%2520potency%2520against%2520ALK-resistant%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8468</span>– <span class="NLM_lpage">8484</span>, <span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lgvucxzC3_kEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span> <i>Drug Approval Package:
Rapamune (Sirolimus) Oral Solution</i>; <span class="NLM_publisher-name">U.S.
Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver
Spring, MD</span>, <span class="NLM_year">1999</span>; <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21083A.cfm" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21083A.cfm</a> (accessed Aug 30, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Drug+Approval+Package%3A%0ARapamune+%28Sirolimus%29+Oral+Solution%3B+U.S.%0AFood+and+Drug+Administration%3A+Silver%0ASpring%2C+MD%2C+1999%3B+https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Fnda%2F99%2F21083A.cfm+%28accessed+Aug+30%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Approval%2520Package%253A%250ARapamune%2520%2528Sirolimus%2529%2520Oral%2520Solution%26pub%3DU.S.%250AFood%2520and%2520Drug%2520Administration%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwitkowski, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prowell, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2009-0178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1634%2Ftheoncologist.2009-0178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=20332142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmsFynsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=428-435&author=V.+E.+Kwitkowskiauthor=T.+M.+Prowellauthor=A.+Ibrahimauthor=A.+T.+Farrellauthor=R.+Justiceauthor=S.+S.+Mitchellauthor=R.+Sridharaauthor=R.+Pazdur&title=FDA+approval+summary%3A+temsirolimus+as+treatment+for+advanced+renal+cell+carcinoma&doi=10.1634%2Ftheoncologist.2009-0178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma</span></div><div class="casAuthors">Kwitkowski, Virginia E.; Prowell, Tatiana M.; Ibrahim, Amna; Farrell, Ann T.; Justice, Robert; Mitchell, Shan Sun; Sridhara, Rajeshwari; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">428-435</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">This report summarizes the U.S. Food and Drug Administration (FDA)'s approval of temsirolimus (Torisel), on May 30, 2007, for the treatment of advanced renal cell carcinoma (RCC).  Information provided includes regulatory history, study design, study results, and literature review.  A multicenter, three-arm, randomized, open-label study was conducted in previously untreated patients with poor-prognosis, advanced RCC.  The study objectives were to compare overall survival (OS), progression-free survival (PFS), objective response rate, and safety in patients receiving interferon (IFN)-α vs. those receiving temsirolimus alone or in combination with IFN-α.  In the second planned interim anal. of the intent-to-treat population (n = 626), there was a statistically significant longer OS time in the temsirolimus (25 mg) arm than in the IFN-α arm (median, 10.9 mo vs. 7.3 mo; hazard ratio [HR], 0.73; p = .0078).  The combination of temsirolimus (15 mg) and IFN-α did not lead to a significant difference in OS compared with IFN-α alone.  There was also a statistically significant longer PFS time for the temsirolimus (25 mg) arm than for the IFN-α arm (median, 5.5 mo vs. 3.1 mo; HR, 0.66, p = .0001).  Common adverse reactions reported in patients receiving temsirolimus were rash, asthenia, and mucositis.  Common lab. abnormalities were anemia, hyperglycemia, hyperlipidemia, and hypertriglyceridemia.  Serious but rare cases of interstitial lung disease, bowel perforation, and acute renal failure were obsd.  Temsirolimus has demonstrated superiority in terms of OS and PFS over IFN-α and provides an addnl. treatment option for patients with advanced RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVBXF4DKP0uLVg90H21EOLACvtfcHk0lgvucxzC3_kEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmsFynsLg%253D&md5=8338d641486b9a6b18ccf3f2458c67c0</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2009-0178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2009-0178%26sid%3Dliteratum%253Aachs%26aulast%3DKwitkowski%26aufirst%3DV.%2BE.%26aulast%3DProwell%26aufirst%3DT.%2BM.%26aulast%3DIbrahim%26aufirst%3DA.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DMitchell%26aufirst%3DS.%2BS.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520temsirolimus%2520as%2520treatment%2520for%2520advanced%2520renal%2520cell%2520carcinoma%26jtitle%3DOncologist%26date%3D2010%26volume%3D15%26spage%3D428%26epage%3D435%26doi%3D10.1634%2Ftheoncologist.2009-0178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span> <i>Drug Trials Snapshots: COTELLIC</i>; <span class="NLM_publisher-name">U.S. Food
and Drug Administration</span>, <span class="NLM_year">2015</span>; <a href="https://www.fda.gov/Drugs/InformationOnDrugs/ucm478351.htm" class="extLink">https://www.fda.gov/Drugs/InformationOnDrugs/ucm478351.htm</a> (accessed
November 10, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Drug+Trials+Snapshots%3A+COTELLIC%3B+U.S.+Food%0Aand+Drug+Administration%2C+2015%3B+https%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2Fucm478351.htm+%28accessed%0ANovember+10%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Trials%2520Snapshots%253A%2520COTELLIC%26pub%3DU.S.%2520Food%250Aand%2520Drug%2520Administration%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span> <i>Midostaurin</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, <span class="NLM_year">2017</span>; <a href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555756.htm" class="extLink">https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555756.htm</a> (accessed Oct 28, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Midostaurin%3B+U.S.+Food+and+Drug+Administration%2C+2017%3B+https%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm555756.htm+%28accessed+Oct+28%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DMidostaurin%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span> <i>Drug Trials Snapshots:
RHOPRESSA</i>; <span class="NLM_publisher-name">U.S. Food
and Drug Administration</span>, <span class="NLM_year">2017</span>; <a href="https://www.fda.gov/Drugs/InformationOnDrugs/ucm591430.htm" class="extLink">https://www.fda.gov/Drugs/InformationOnDrugs/ucm591430.htm</a> (accessed
Dec 5, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Drug+Trials+Snapshots%3A%0ARHOPRESSA%3B+U.S.+Food%0Aand+Drug+Administration%2C+2017%3B+https%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2Fucm591430.htm+%28accessed%0ADec+5%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Trials%2520Snapshots%253A%250ARHOPRESSA%26pub%3DU.S.%2520Food%250Aand%2520Drug%2520Administration%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span> <i>FDA Grants Accelerated
Approval to Acalabrutinib for Mantle Cell
Lymphoma</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, <span class="NLM_year">2017</span>; <a href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm583106.htm" class="extLink">https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm583106.htm</a> (accessed Dec 31, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Grants+Accelerated%0AApproval+to+Acalabrutinib+for+Mantle+Cell%0ALymphoma%3B+U.S.+Food+and+Drug+Administration%2C+2017%3B+https%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm583106.htm+%28accessed+Dec+31%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Grants%2520Accelerated%250AApproval%2520to%2520Acalabrutinib%2520for%2520Mantle%2520Cell%250ALymphoma%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span> <i>FDA Approves Encorafenib
and Binimetinib in Combination for Unresectable
or Metastatic Melanoma with BRAF Mutations</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm611981.htm" class="extLink">https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm611981.htm</a> (accessed Jan 27, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+Encorafenib%0Aand+Binimetinib+in+Combination+for+Unresectable%0Aor+Metastatic+Melanoma+with+BRAF+Mutations%3B+U.S.+Food+and+Drug+Administration%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm611981.htm+%28accessed+Jan+27%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520Encorafenib%250Aand%2520Binimetinib%2520in%2520Combination%2520for%2520Unresectable%250Aor%2520Metastatic%2520Melanoma%2520with%2520BRAF%2520Mutations%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span> <i>FDA Approves Larotrectinib
for Solid Tumors with NTRK Gene Fusions</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm626720.htm" class="extLink">https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm626720.htm</a> (accessed Dec 28, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+Larotrectinib%0Afor+Solid+Tumors+with+NTRK+Gene+Fusions%3B+U.S.+Food+and+Drug+Administration%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Finformationondrugs%2Fapproveddrugs%2Fucm626720.htm+%28accessed+Dec+28%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520Larotrectinib%250Afor%2520Solid%2520Tumors%2520with%2520NTRK%2520Gene%2520Fusions%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.cell.2010.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=20602996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=1117-1134&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases&doi=10.1016%2Fj.cell.2010.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Lemmon, Mark A.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1117-1134</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected diversity in the mechanisms of their activation by growth factor ligands.  Strategies for inducing dimerization by ligand binding are surprisingly diverse, as are mechanisms that couple this event to activation of the intracellular tyrosine kinase domains.  As the understanding of these details becomes increasingly sophisticated, it provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.  Much remains to be learned, however, about the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd5NvoN0Q9-7Vg90H21EOLACvtfcHk0lhjGqknXyCaXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D&md5=b88b55fe7a3eebc6ff7e883425676e45</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D1117%26epage%3D1134%26doi%3D10.1016%2Fj.cell.2010.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gschwind, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, A.</span></span> <span> </span><span class="NLM_article-title">The discovery of receptor tyrosine kinases: targets for cancer therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1038/nrc1360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnrc1360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=15122207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=361-370&author=A.+Gschwindauthor=O.+M.+Fischerauthor=A.+Ullrich&title=The+discovery+of+receptor+tyrosine+kinases%3A+targets+for+cancer+therapy&doi=10.1038%2Fnrc1360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy</span></div><div class="casAuthors">Gschwind, Andreas; Fischer, Oliver M.; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are a subclass of cell-surface growth-factor receptors with an intrinsic, ligand-controlled tyrosine-kinase activity.  They regulate diverse functions in normal cells and have a crucial role in oncogenesis.  Twenty years ago, the 1st primary structure of a receptor Tyr kinase, the epidermal growth factor receptor, was elucidated.  The characterization of both the mol. architecture of receptor Tyr kinases and the main functions of these proteins and their ligands in tumorigenesis opened the door to a new era in mol. oncol. and paved the way to the development of the 1st target-specific cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NLVNn4dw37Vg90H21EOLACvtfcHk0lhjGqknXyCaXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D&md5=ea24c0ccaea68b743b5da9587ed19406</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnrc1360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1360%26sid%3Dliteratum%253Aachs%26aulast%3DGschwind%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DO.%2BM.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DThe%2520discovery%2520of%2520receptor%2520tyrosine%2520kinases%253A%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D361%26epage%3D370%26doi%3D10.1038%2Fnrc1360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trink, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzai, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidransky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, N. H.</span></span> <span> </span><span class="NLM_article-title">Overexpression of <i>c</i>-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1544</span>– <span class="NLM_lpage">1550</span>, <span class="refDoi"> DOI: 10.1200/JCO.2002.20.6.1544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1200%2FJCO.2002.20.6.1544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=11896103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD38XivFeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=1544-1550&author=H.+L.+Chengauthor=B.+Trinkauthor=T.+S.+Tzaiauthor=H.+S.+Liuauthor=S.+H.+Chanauthor=C.+L.+Hoauthor=D.+Sidranskyauthor=N.+H.+Chow&title=Overexpression+of+c-met+as+a+prognostic+indicator+for+transitional+cell+carcinoma+of+the+urinary+bladder%3A+a+comparison+with+p53+nuclear+accumulation&doi=10.1200%2FJCO.2002.20.6.1544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: A comparison with p53 nuclear accumulation</span></div><div class="casAuthors">Cheng, Hong-Lin; Trink, Barry; Tzai, Tzong-Shin; Liu, Hsiao-Sheng; Chan, Shih-Huang; Ho, Chung-Liang; Sidransky, David; Chow, Nan-Haw</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1544-1550</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: The c-met proto-oncogene encodes a receptor tyrosine kinase (Met) and has been shown to play a role in oncogenesis.  Given that high titers of hepatocyte growth factor, the specific ligand for Met, are excreted in the urine and tend to reflect disease activity of bladder cancer, we performed this study to examine the clin. significance of Met in human bladder cancer.  Materials and Methods: We studied the mRNA expression and genomic alteration of c-met in five bladder cancer cell lines.  Significance of Met overexpression was then compared with p53 nuclear accumulation (TP53) in primary bladder cancer (n = 142 patients).  Results: Expression of c-met mRNA tended to pos. correlate with differentiation of cancer cell lines in the absence of point mutation.  High expression of Met was found in seven cases (4.9%), low expression in 32 cases (22.5%), and neg. expression in 103 cases (72.5%).  Expression of Met was pos. assocd. with histol. grade, stage classification, tumor size, and nodular tumor growth (P < .05, resp.); however, it was not related to TP53 status.  Factors that predicted disease progression were tumor stage, Met status, and TP53 accumulation (P < .05, resp.).  Indicators for poor long-term survival were invasive cancer, multiple tumors, and Met overexpression (P = .0006, .01, and .04, resp.).  Conclusion: The c-met proto-oncogene plays a more important role in the progression of bladder carcinogenesis than p53.  Evaluation of Met expression could identify a subset of bladder cancer patients who may require a more intensive treatment strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGfd5r45qOJLVg90H21EOLACvtfcHk0lhjGqknXyCaXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivFeitrw%253D&md5=2b9b03134c74318b533f82908304a28e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.20.6.1544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.20.6.1544%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%2BL.%26aulast%3DTrink%26aufirst%3DB.%26aulast%3DTzai%26aufirst%3DT.%2BS.%26aulast%3DLiu%26aufirst%3DH.%2BS.%26aulast%3DChan%26aufirst%3DS.%2BH.%26aulast%3DHo%26aufirst%3DC.%2BL.%26aulast%3DSidransky%26aufirst%3DD.%26aulast%3DChow%26aufirst%3DN.%2BH.%26atitle%3DOverexpression%2520of%2520c-met%2520as%2520a%2520prognostic%2520indicator%2520for%2520transitional%2520cell%2520carcinoma%2520of%2520the%2520urinary%2520bladder%253A%2520a%2520comparison%2520with%2520p53%2520nuclear%2520accumulation%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D1544%26epage%3D1550%26doi%3D10.1200%2FJCO.2002.20.6.1544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirstein, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmer, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A. T.</span></span> <span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1126/science.8122112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1126%2Fscience.8122112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=8122112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+Look&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma&doi=10.1126%2Fscience.8122112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma</span></div><div class="casAuthors">Morris, Stephan, W.; Kirstein, Mark, N.; Valentine, Marcus B.; Dittmer, Kristopher G.; Shapiro, David N.; Saltman, David L.; Look, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5151</span>),
    <span class="NLM_cas:pages">1281-4</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes.  This rearrangement was shown to fuse the NPM nucleolar phosphoprotein gene on chromosome 5q35 to a previously unidentified protein tyrosine kinase gene, ALK, on chromosome 2p23.  In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK).  Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases.  Unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3KZnxLYaerVg90H21EOLACvtfcHk0lhjGqknXyCaXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D&md5=219ee9615e613be456a05f8f1ded6066</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1126%2Fscience.8122112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8122112%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284%26doi%3D10.1126%2Fscience.8122112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maulik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrikhande, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kijima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span> <span> </span><span class="NLM_article-title">Role of the hepatocyte growth factor receptor, <i>c</i>-Met, in oncogenesis and potential for therapeutic inhibition</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1016/S1359-6101(01)00029-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2FS1359-6101%2801%2900029-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=11750879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1ahuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=41-59&author=G.+Maulikauthor=A.+Shrikhandeauthor=T.+Kijimaauthor=P.+C.+Maauthor=P.+T.+Morrisonauthor=R.+Salgia&title=Role+of+the+hepatocyte+growth+factor+receptor%2C+c-Met%2C+in+oncogenesis+and+potential+for+therapeutic+inhibition&doi=10.1016%2FS1359-6101%2801%2900029-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition</span></div><div class="casAuthors">Maulik, Gautam; Shrikhande, Amol; Kijima, Takashi; Ma, Patrick C.; Morrison, Paul T.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-59</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review is given.  Receptor tyrosine kinases have become important therapeutic targets for anti-neoplastic molecularly targeted therapies.  C-Met is a receptor tyrosine kinase shown to be over-expressed and mutated in a variety of malignancies.  Stimulation of c-Met via its ligand hepatocyte growth factor also known as scatter factor (HGF/SF), leads to a plethora of biol. and biochem. effects in the cell.  There has been considerable knowledge gained on the role of c-Met-HGF/SF axis in normal and malignant cells.  This review summarizes the structure of c-Met and HGF/SF and their family members.  Since there are known mutations of c-Met in solid tumors, particularly in papillary renal cell carcinoma, we have summarized the various mutations and over-expression of c-Met known thus far.  Stimulation of c-Met can lead to scattering, angiogenesis, proliferation, enhanced cell motility, invasion, and eventual metastasis.  The biol. functions altered by c-Met are quite unique and described in detail.  Along with biol. functions, various signal transduction pathways, including the cytoskeleton are altered with the activation of c-Met-HGF/SF loop.  We have recently shown the phosphorylation of focal adhesion proteins, such as paxillin and p125FAK in response to c-Met stimulation in lung cancer cells, and this is detailed here.  Finally, c-Met when mutated or over-expressed in malignant cells serves as an important therapeutic target and the most recent data in terms of inhibition of c-Met and downstream signal transduction pathways is summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom2mu2QMKr_7Vg90H21EOLACvtfcHk0lh4n-LvW_nibA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1ahuro%253D&md5=aead14efa103c522ef374b0a16e51b35</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS1359-6101%2801%2900029-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6101%252801%252900029-6%26sid%3Dliteratum%253Aachs%26aulast%3DMaulik%26aufirst%3DG.%26aulast%3DShrikhande%26aufirst%3DA.%26aulast%3DKijima%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DMorrison%26aufirst%3DP.%2BT.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DRole%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%252C%2520c-Met%252C%2520in%2520oncogenesis%2520and%2520potential%2520for%2520therapeutic%2520inhibition%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2002%26volume%3D13%26spage%3D41%26epage%3D59%26doi%3D10.1016%2FS1359-6101%2801%2900029-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maulik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span> <span> </span><span class="NLM_article-title"><i>c</i>-Met: structure, functions and potential for therapeutic inhibition</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1023/A:1023768811842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1023%2FA%3A1023768811842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=12884908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslyiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=309-325&author=P.+C.+Maauthor=G.+Maulikauthor=J.+Christensenauthor=R.+Salgia&title=c-Met%3A+structure%2C+functions+and+potential+for+therapeutic+inhibition&doi=10.1023%2FA%3A1023768811842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">c-Met: Structure, functions and potential for therapeutic inhibition</span></div><div class="casAuthors">Ma, Patrick C.; Maulik, Gautam; Christensen, James; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-325</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review.  Studies on signal transduction pathways have generated various promising mol. targets for therapeutic inhibition in cancer therapy.  Receptor tyrosine kinases represent an important class of such therapeutic targets.  C-Met is a receptor tyrosine kinase that has been shown to be overexpressed and/or mutated in a variety of malignancies.  A no. of c-Met activating mutations, many of which are located in the tyrosine kinase domain, have been detected in various solid tumors and have been implicated in invasion and metastasis of tumor cells.  It is known that stimulation of c-Met via its natural ligand, hepatocyte growth factor (also known as scatter factor, HGF/SF) results in a plethora of biol. and biochem. effects in the cell.  Activation of c-Met signaling can lead to scattering, angiogenesis, proliferation, enhanced cell motility, invasion, and eventual metastasis.  In this review, the role of c-Met dysregulation in tumor progression and metastasis is discussed in detail with particular emphasis on c-Met mutations.  Moreover, we summarize current knowledge on various pathways of c-Met signal transduction, highlighting the central role in the cytoskeletal functions.  In this summary is included recent data in our lab. indicating that phosphorylation of focal adhesion proteins, such as paxillin, p125FAK, and PYK2, occurs in response to c-Met stimulation in lung cancer cells.  Most importantly, current data on c-Met suggest that when mutated or overexpressed in malignant cells, c-Met would serve as an important therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9rIdb5Ao4a7Vg90H21EOLACvtfcHk0lh4n-LvW_nibA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslyiurY%253D&md5=7b7bf60da872071a39ce313efd32fd1f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1023%2FA%3A1023768811842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1023768811842%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DMaulik%26aufirst%3DG.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3Dc-Met%253A%2520structure%252C%2520functions%2520and%2520potential%2520for%2520therapeutic%2520inhibition%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2003%26volume%3D22%26spage%3D309%26epage%3D325%26doi%3D10.1023%2FA%3A1023768811842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vande Woude, G.</span></span> <span> </span><span class="NLM_article-title">Showering <i>c</i>-MET-dependent cancers with drugs</span>. <i>Curr. Opin. Genet. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.gde.2008.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.gde.2008.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=18406132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVarur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=87-96&author=B.+S.+Knudsenauthor=G.+Vande+Woude&title=Showering+c-MET-dependent+cancers+with+drugs&doi=10.1016%2Fj.gde.2008.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Showering c-MET-dependent cancers with drugs</span></div><div class="casAuthors">Knudsen, Beatrice S.; Vande Woude, George</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-96</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase, c-MET and its ligand hepatocyte growth factor/scatter factor (HGF/SF) have become leading candidates for targeted cancer therapies.  Inappropriate c-MET signaling through autocrine, paracrine, amplification, and mutational activation occurs in virtually all types of solid tumors (http://www.vai.org/met), contributing to one or a combination of proliferative, invasive, survival, or angiogenic cancer phenotypes. c-MET and HGF/SF participate in all stages of malignant progression and represent promising drug targets in a variety of cancer types, including carcinomas, sarcomas, and brain tumors.  While many are in pre-clin. testing, a few inhibitors have entered clin. trials.  With hundreds of thousands of potential responding cancers that express c-MET, the interest in this mol. as a drug target is not surprising.  However, the cognate c-MET diagnostic tests lag behind.  In addn., despite the great enthusiasm based on response rates in phase I trials, there is a need for caution.  It is almost without question that combination therapies with c-MET-HGF/SF inhibitors will be required for most cancers to achieve a cytotoxic tumor response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonjBq7fWvKhrVg90H21EOLACvtfcHk0lh4n-LvW_nibA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVarur8%253D&md5=d0744275be94658bab067f20644c98d6</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2008.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2008.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DKnudsen%26aufirst%3DB.%2BS.%26aulast%3DVande%2BWoude%26aufirst%3DG.%26atitle%3DShowering%2520c-MET-dependent%2520cancers%2520with%2520drugs%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2008%26volume%3D18%26spage%3D87%26epage%3D96%26doi%3D10.1016%2Fj.gde.2008.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A.</span></span> <span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1126/science.8122112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1126%2Fscience.8122112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=8122112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+Morrisauthor=M.+Kirsteinauthor=M.+Valentineauthor=K.+Dittmerauthor=D.+Shapiroauthor=D.+Saltmanauthor=A.+Look&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma&doi=10.1126%2Fscience.8122112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma</span></div><div class="casAuthors">Morris, Stephan, W.; Kirstein, Mark, N.; Valentine, Marcus B.; Dittmer, Kristopher G.; Shapiro, David N.; Saltman, David L.; Look, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5151</span>),
    <span class="NLM_cas:pages">1281-4</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes.  This rearrangement was shown to fuse the NPM nucleolar phosphoprotein gene on chromosome 5q35 to a previously unidentified protein tyrosine kinase gene, ALK, on chromosome 2p23.  In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK).  Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases.  Unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3KZnxLYaerVg90H21EOLACvtfcHk0ljLITIAyagtgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D&md5=219ee9615e613be456a05f8f1ded6066</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscience.8122112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8122112%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%26aulast%3DKirstein%26aufirst%3DM.%26aulast%3DValentine%26aufirst%3DM.%26aulast%3DDittmer%26aufirst%3DK.%26aulast%3DShapiro%26aufirst%3DD.%26aulast%3DSaltman%26aufirst%3DD.%26aulast%3DLook%26aufirst%3DA.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284%26doi%3D10.1126%2Fscience.8122112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arango, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Los, G.</span></span> <span> </span><span class="NLM_article-title">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and <i>c</i>-Met, in experimental models of anaplastic large-cell lymphoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">3314</span>– <span class="NLM_lpage">3322</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+R.+Altonauthor=B.+Mroczkowskiauthor=G.+Los&title=Cytoreductive+antitumor+activity+of+PF-2341066%2C+a+novel+inhibitor+of+anaplastic+lymphoma+kinase+and+c-Met%2C+in+experimental+models+of+anaplastic+large-cell+lymphoma&doi=10.1158%2F1535-7163.MCT-07-0365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, ∼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-γ, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0ljLITIAyagtgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%2BR.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DLos%26aufirst%3DG.%26atitle%3DCytoreductive%2520antitumor%2520activity%2520of%2520PF-2341066%252C%2520a%2520novel%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520and%2520c-Met%252C%2520in%2520experimental%2520models%2520of%2520anaplastic%2520large-cell%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322%26doi%3D10.1158%2F1535-7163.MCT-07-0365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span> <i>FDA Approves
Crizotinib Capsules</i>; <span class="NLM_publisher-name">U.S. Food
and Drug Administration</span>, <span class="NLM_year">2016</span>; <a href="https://www.fda.gov" class="extLink">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-capsules</a> (accessed Jan. 30, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves%0ACrizotinib+Capsules%3B+U.S.+Food%0Aand+Drug+Administration%2C+2016%3B+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-crizotinib-capsules+%28accessed+Jan.+30%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%250ACrizotinib%2520Capsules%26pub%3DU.S.%2520Food%250Aand%2520Drug%2520Administration%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arango, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Los, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span> <span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of <i>c</i>-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">4408</span>– <span class="NLM_lpage">4417</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.+P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-Met%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms&doi=10.1158%2F0008-5472.CAN-06-4443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0ljLITIAyagtgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-Met%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417%26doi%3D10.1158%2F0008-5472.CAN-06-4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span>; <span class="NLM_string-name">Ramphal, J.</span>; <span class="NLM_string-name">Liang, C.</span>; <span class="NLM_string-name">Sun, L.</span>; <span class="NLM_string-name">Wei, C. C.</span>; <span class="NLM_string-name">Tang, P. C.</span></span> <span> </span><span class="NLM_article-title">Preparation of 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors</span>. U.S. Patent WO <span class="NLM_patent">2002096361</span>, May 30, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=J.+Cui&author=J.+Ramphal&author=C.+Liang&author=L.+Sun&author=C.+C.+Wei&author=P.+C.+Tang&title=Preparation+of+5-aralkylsulfonyl-3-%28pyrrol-2-ylmethylidene%29-2-indolinone+derivatives+as+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DPreparation%2520of%25205-aralkylsulfonyl-3-%2528pyrrol-2-ylmethylidene%2529-2-indolinone%2520derivatives%2520as%2520kinase%2520inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiering, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marconi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flocco, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perego, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristiani, C.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor <i>c</i>-Met and its complex with the microbial alkaloid K-252a</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">12654</span>– <span class="NLM_lpage">12659</span>, <span class="refDoi"> DOI: 10.1073/pnas.1734128100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1073%2Fpnas.1734128100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=14559966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslKnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=12654-12659&author=N.+Schieringauthor=S.+Knappauthor=M.+Marconiauthor=M.+M.+Floccoauthor=J.+Cuiauthor=R.+Peregoauthor=L.+Rusconiauthor=C.+Cristiani&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+the+hepatocyte+growth+factor+receptor+c-Met+and+its+complex+with+the+microbial+alkaloid+K-252a&doi=10.1073%2Fpnas.1734128100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a</span></div><div class="casAuthors">Schiering, Nikolaus; Knapp, Stefan; Marconi, Marina; Flocco, Maria M.; Cui, Jean; Perego, Rita; Rusconi, Luisa; Cristiani, Cinzia</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">12654-12659</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The protooncogene c-met codes for the hepatocyte growth factor receptor tyrosine kinase.  Binding of its ligand, hepatocyte growth factor/scatter factor, stimulates receptor autophosphorylation, which leads to pleiotropic downstream signaling events in epithelial cells, including cell growth, motility, and invasion.  These events are mediated by interaction of cytoplasmic effectors, generally through Src homol. 2 (SH2) domains, with two phosphotyrosine-contg. sequence motifs in the unique C-terminal tail of c-Met (supersite).  2 (SH2) domains, with two phosphotyrosine-contg. sequence motifs in the unique C-terminal tail of c-Met (supersite).  There is a strong link between aberrant c-Met activity and oncogenesis, which makes this kinase an important cancer drug target.  The furanosylated indolocarbazole K-252a belongs to a family of microbial alkaloids that also includes staurosporine.  It was recently shown to be a potent inhibitor of c-Met.  Here we report the crystal structures of an unphosphorylated c-Met kinase domain harboring a human cancer mutation and its complex with K-252a at 1.8-Å resoln.  The structure follows the well established architecture of protein kinases.  It adopts a unique, inhibitory conformation of the activation loop, a catalytically noncompetent orientation of helix αC, and reveals the complete C-terminal docking site.  The first SH2-binding motif (1349YVHV) adopts an extended conformation, whereas the second motif (1356YVNV), a binding site for Grb2-SH2, folds as a type II β-turn.  The intermediate portion of the supersite (1353NATY) assumes a type I β-turn conformation as in an Shc-phosphotyrosine binding domain peptide complex.  K-252a is bound in the adenosine pocket with an analogous binding mode to those obsd. in previously reported structures of protein kinases in complex with staurosporine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13Yf3cKB-ybVg90H21EOLACvtfcHk0ligiZztO4xtMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslKnt74%253D&md5=d8cd3494f2583dfcb11efb6862aff607</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1734128100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1734128100%26sid%3Dliteratum%253Aachs%26aulast%3DSchiering%26aufirst%3DN.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMarconi%26aufirst%3DM.%26aulast%3DFlocco%26aufirst%3DM.%2BM.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DCristiani%26aufirst%3DC.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%2520c-Met%2520and%2520its%2520complex%2520with%2520the%2520microbial%2520alkaloid%2520K-252a%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D12654%26epage%3D12659%26doi%3D10.1073%2Fpnas.1734128100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelis, L. M.</span></span> <span> </span><span class="NLM_article-title">Brain metastases</span>. <i>Neurol. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1173</span>– <span class="NLM_lpage">1192</span>, <span class="refDoi"> DOI: 10.1016/j.ncl.2007.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.ncl.2007.07.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=17964030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A280%3ADC%252BD2snjvFygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=1173-1192&author=T.+D.+Nguyenauthor=L.+M.+DeAngelis&title=Brain+metastases&doi=10.1016%2Fj.ncl.2007.07.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Brain metastases</span></div><div class="casAuthors">Nguyen Teri D; DeAngelis Lisa M</div><div class="citationInfo"><span class="NLM_cas:title">Neurologic clinics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1173-92, x-xi</span>
        ISSN:<span class="NLM_cas:issn">0733-8619</span>.
    </div><div class="casAbstract">Brain metastases are a common complication of cancer and alter patient management more than metastases at any other site of distant progression.  Supportive therapies include steroids and antiseizure medications.  Definitive treatments include radiation therapy, surgery, and chemotherapy.  The optimal choice of treatment and overall prognosis largely depend on patient characteristics and the extent and distribution of disease.  Delaying or decreasing neurologic cause of death and disability are important therapeutic goals for this population.  While better definitive strategies are investigated, physicians must remember to optimize the use of supportive therapies to ameliorate symptoms and maintain quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSYt-AmUO_aF1C8OJBvdfbfW6udTcc2eZSZ49sUIjHzrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2snjvFygtg%253D%253D&md5=a16350bd3ec9d4488bee98cd27c8cd77</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ncl.2007.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ncl.2007.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DT.%2BD.%26aulast%3DDeAngelis%26aufirst%3DL.%2BM.%26atitle%3DBrain%2520metastases%26jtitle%3DNeurol.%2520Clin.%26date%3D2007%26volume%3D25%26spage%3D1173%26epage%3D1192%26doi%3D10.1016%2Fj.ncl.2007.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">7535</span>– <span class="NLM_lpage">7540</span>, <span class="refDoi"> DOI: 10.1073/pnas.1019559108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1073%2Fpnas.1019559108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=21502504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=7535-7540&author=R.+Katayamaauthor=T.+M.+Khanauthor=C.+Benesauthor=E.+Lifshitsauthor=H.+Ebiauthor=V.+M.+Riveraauthor=W.+C.+Shakespeareauthor=A.+J.+Iafrateauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Therapeutic+strategies+to+overcome+crizotinib+resistance+in+non-small+cell+lung+cancers+harboring+the+fusion+oncogene+EML4-ALK&doi=10.1073%2Fpnas.1019559108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span></div><div class="casAuthors">Katayama, Ryohei; Khan, Tahsin M.; Benes, Cyril; Lifshits, Eugene; Ebi, Hiromichi; Rivera, Victor M.; Shakespeare, William C.; Iafrate, A. John; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7535-7540, S7535/1-S7535/17</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represents a mol. target in a small subset of non-small cell lung cancers (NSCLCs).  This fusion leads to constitutive ALK activation with potent transforming activity.  In a pivotal phase 1 clin. trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib (PF-02341066) demonstrated impressive antitumor activity in the majority of patients with NSCLC harboring ALK fusions.  However, despite these remarkable initial responses, cancers eventually develop resistance to crizotinib, usually within 1 y, thereby limiting the potential clin. benefit.  To det. how cancers acquire resistance to ALK inhibitors, we established a model of acquired resistance to crizotinib by exposing a highly sensitive EML4-ALK-pos. NSCLC cell line to increasing doses of crizotinib until resistance emerged.  We found that cells resistant to intermediate doses of crizotinib developed amplification of the EML4-ALK gene.  Cells resistant to higher doses (1 μM) also developed a gatekeeper mutation, L1196M, within the kinase domain, rendering EML4-ALK insensitive to crizotinib.  This gatekeeper mutation was readily detected using a unique and highly sensitive allele-specific PCR assay.  Although crizotinib was ineffectual against EML4-ALK harboring the gatekeeper mutation, we obsd. that two structurally different ALK inhibitors, NVPTAE684 and AP26113, were highly active against the resistant cancer cells in vitro and in vivo.  Furthermore, these resistant cells remained highly sensitive to the Hsp90 inhibitor 17-AAG.  Thus, we have developed a model of acquired resistance to ALK inhibitors and have shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPbiLG5xpg0LVg90H21EOLACvtfcHk0ligiZztO4xtMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D&md5=82f47736429e6f71f9fd5852e4df64cb</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1019559108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1019559108%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520strategies%2520to%2520overcome%2520crizotinib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancers%2520harboring%2520the%2520fusion%2520oncogene%2520EML4-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D7535%26epage%3D7540%26doi%3D10.1073%2Fpnas.1019559108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elleraas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewanicki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span> <span> </span><span class="NLM_article-title">Conformational studies and atropisomerism kinetics of the ALK clinical candidate lorlatinib (PF-06463922) and desmethyl congeners</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3590</span>– <span class="NLM_lpage">3595</span>, <span class="refDoi"> DOI: 10.1002/anie.201509240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1002%2Fanie.201509240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28XisV2hurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=3590-3595&author=J.+Elleraasauthor=J.+Ewanickiauthor=T.+W.+Johnsonauthor=N.+W.+Sachauthor=M.+R.+Collinsauthor=P.+F.+Richardson&title=Conformational+studies+and+atropisomerism+kinetics+of+the+ALK+clinical+candidate+lorlatinib+%28PF-06463922%29+and+desmethyl+congeners&doi=10.1002%2Fanie.201509240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF-06463922) and Desmethyl Congeners</span></div><div class="casAuthors">Elleraas, Jeff; Ewanicki, Jason; Johnson, Ted W.; Sach, Neal W.; Collins, Michael R.; Richardson, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3590-3595</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Lorlatinib (PF-06463922) is an ALK/ROS1 inhibitor and is in clin. trials for the treatment of ALK pos. or ROS1 pos. NSCLC (i.e. specific subsets of NSCLC).  One of the lab. objectives for this mol. indicated that it would be desirable to advance a mol. which was CNS penetrant in order to treat brain metastases.  From this perspective, a macrocyclic template was attractive for a no. of reasons.  In particular, this template reduces the no. of rotatable bonds, provides the potential to shield polar surface area and reinforces binding through a restricted conformation.  All of these features led to better permeability for the mols. of interest and thus increased the chance for better blood brain barrier penetration.  With a CNS penetrant mol., kinase selectivity is a key consideration particularly with regard to proteins such as TrkB, which are believed to influence cognitive function.  Removal of the chiral benzylic Me substituent from lorlatinib was perceived as not only a means to simplify synthetic complexity, but also as a strategy to further truncate the mol. of interest.  Examn. of the NMR of the desmethyl analogs revealed that the compd. existed as a mixt. of atropisomers, which proved separable by chiral SFC.  The individual atropisomers were evaluated through a series of in vitro assays, and shown to have a favorable selectivity profile when compared to lorlatinib.  The challenge to develop such a mol. lies in the rate at which the atropisomers interchange dictated by the energy barrier required to do this.  Here, we describe the synthesis of the desmethyl macrocycles, conformational studies on the atropisomers, and the kinetics of the interconversion.  In addn., the corresponding conformational studies on lorlatinib are reported providing a hypothesis for why a single diastereomer is obsd. when the chiral benzylic Me group is introduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphacUOv-75g7Vg90H21EOLACvtfcHk0likxcA5Yp-NsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisV2hurc%253D&md5=b84cee2b13f663aa2cbeab24f65bb65c</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fanie.201509240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201509240%26sid%3Dliteratum%253Aachs%26aulast%3DElleraas%26aufirst%3DJ.%26aulast%3DEwanicki%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26atitle%3DConformational%2520studies%2520and%2520atropisomerism%2520kinetics%2520of%2520the%2520ALK%2520clinical%2520candidate%2520lorlatinib%2520%2528PF-06463922%2529%2520and%2520desmethyl%2520congeners%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D3590%26epage%3D3595%26doi%3D10.1002%2Fanie.201509240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kothe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladysheva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valtre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crenne, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, M.</span></span> <span> </span><span class="NLM_article-title">The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2012.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.jmb.2012.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22902478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yqu7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2012&pages=439-453&author=T.+Bertrandauthor=M.+Kotheauthor=J.+Liuauthor=A.+Dupuyauthor=A.+Rakauthor=P.+F.+Berneauthor=S.+Davisauthor=T.+Gladyshevaauthor=C.+Valtreauthor=J.+Y.+Crenneauthor=M.+Mathieu&title=The+crystal+structures+of+TrkA+and+TrkB+suggest+key+regions+for+achieving+selective+inhibition&doi=10.1016%2Fj.jmb.2012.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The Crystal Structures of TrkA and TrkB Suggest Key Regions for Achieving Selective Inhibition</span></div><div class="casAuthors">Bertrand, T.; Kothe, M.; Liu, J.; Dupuy, A.; Rak, A.; Berne, P. F.; Davis, S.; Gladysheva, T.; Valtre, C.; Crenne, J. Y.; Mathieu, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">439-453</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Trk family of neurotrophin receptors, which includes the three highly homologous proteins TrkA, TrkB and TrkC, is strongly assocd. with central and peripheral nervous system processes.  Trk proteins are also of interest in oncol., since Trk activation has been obsd. in several cancer types.  While Trk kinases are attractive oncol. targets, selectivity might be more of an issue than for other kinases due to potential CNS side effects if several Trk kinases are simultaneously targeted.  In order to address this issue, we present here the first structures of human TrkA and TrkB kinase domains and three complexes between TrkB and Trk inhibitors.  These structures reveal different conformations of the kinase domain and suggest new regions of selectivity among the Trk family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryh_7mc93WjLVg90H21EOLACvtfcHk0likxcA5Yp-NsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yqu7vN&md5=39409144c4655d93164a881cc28a6115</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2012.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2012.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DT.%26aulast%3DKothe%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDupuy%26aufirst%3DA.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DBerne%26aufirst%3DP.%2BF.%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DGladysheva%26aufirst%3DT.%26aulast%3DValtre%26aufirst%3DC.%26aulast%3DCrenne%26aufirst%3DJ.%2BY.%26aulast%3DMathieu%26aufirst%3DM.%26atitle%3DThe%2520crystal%2520structures%2520of%2520TrkA%2520and%2520TrkB%2520suggest%2520key%2520regions%2520for%2520achieving%2520selective%2520inhibition%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D423%26spage%3D439%26epage%3D453%26doi%3D10.1016%2Fj.jmb.2012.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleasby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">687</span>– <span class="NLM_lpage">693</span>, <span class="refDoi"> DOI: 10.1080/00498250903015402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1080%2F00498250903015402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=19569734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps12gtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=687-693&author=H.+Heauthor=K.+A.+Lyonsauthor=X.+Shenauthor=Z.+Yaoauthor=K.+Bleasbyauthor=G.+Chanauthor=M.+Hafeyauthor=X.+Liauthor=S.+Xuauthor=G.+M.+Salituroauthor=L.+H.+Cohenauthor=W.+Tang&title=Utility+of+unbound+plasma+drug+levels+and+P-glycoprotein+transport+data+in+prediction+of+central+nervous+system+exposure&doi=10.1080%2F00498250903015402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure</span></div><div class="casAuthors">He, H.; Lyons, K. A.; Shen, X.; Yao, Z.; Bleasby, K.; Chan, G.; Hafey, M.; Li, X.; Xu, S.; Salituro, G. M.; Cohen, L. H.; Tang, W.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">687-693</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Drug concns. in cerebrospinal fluid were assumed to be a natural surrogate for total drug exposures in the central nervous system.  The present communication reports a data set from a study of 30 compds. in mice.  An attempt was made to correlate cerebrospinal fluid and unbound plasma drug concns. via incorporation of in vitro P-glycoprotein (Pgp)-mediated transport data.  Pgp-deficient (Pgp -/-) and wild-type mice were dosed with compds. of interest by oral gavage (orally) at 5 mg kg-1.  Plasma and cerebrospinal fluid samples were collected at 1h post-dosing, and analyzed by liq. chromatog.-tandem mass spectrometry (LC-MS/MS) for drug concns.  Mouse and human Pgp-mediated transport were evaluated in vitro by a bi-directional (B to A and A to B) transport assay using LLC-PK1 cells expressing mouse (mdr1a) and human (MDR1) forms of Pgp, resp.  Compds. with B to A/A to B transport ratios <2 were defined as non-substrates of Pgp, whereas those exhibiting B to A/A to B transport ratios ≥2 were considered Pgp substrates.  Plasma protein binding was also detd. in vitro via equil. dialysis.  Of the 30 compds., 13 were identified to be mouse Pgp substrates, all of which were also human Pgp substrates, demonstrating a good agreement between mouse and human data.  In Pgp wild-type mice, the unbound plasma and cerebrospinal fluid concns. of the non-Pgp substrates correlated well, with a regression slope of approx. 1.0.  A similar relationship existed for Pgp substrates in Pgp -/- mice.  On the other hand, an improved correlation of cerebrospinal fluid and systemic exposures of the Pgp substrates in Pgp wild-type mice was obsd. when the unbound plasma concns. were normalized to the corresponding B to A/A to B transport ratios.  These results reinforce the premise that a combined use of unbound plasma drug concns. and in vitro Pgp transport data may be of value for the estn. of central nervous system exposures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrApJIK--rl1rVg90H21EOLACvtfcHk0likxcA5Yp-NsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps12gtbs%253D&md5=f9b7ad759a8ced86e9b8b90c445217f3</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1080%2F00498250903015402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250903015402%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DH.%26aulast%3DLyons%26aufirst%3DK.%2BA.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DBleasby%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DHafey%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DSalituro%26aufirst%3DG.%2BM.%26aulast%3DCohen%26aufirst%3DL.%2BH.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DUtility%2520of%2520unbound%2520plasma%2520drug%2520levels%2520and%2520P-glycoprotein%2520transport%2520data%2520in%2520prediction%2520of%2520central%2520nervous%2520system%2520exposure%26jtitle%3DXenobiotica%26date%3D2009%26volume%3D39%26spage%3D687%26epage%3D693%26doi%3D10.1080%2F00498250903015402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kodaira, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusuhara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ushiki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Quantitative evaluation of the impact of active efflux by P-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">944</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.180398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1124%2Fjpet.111.180398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=21934030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVSksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2011&pages=935-944&author=H.+Kodairaauthor=H.+Kusuharaauthor=T.+Fujitaauthor=J.+Ushikiauthor=E.+Fuseauthor=Y.+Sugiyama&title=Quantitative+evaluation+of+the+impact+of+active+efflux+by+P-glycoprotein+and+breast+cancer+resistance+protein+at+the+blood-brain+barrier+on+the+predictability+of+the+unbound+concentrations+of+drugs+in+the+brain+using+cerebrospinal+fluid+concentration+as+a+surrogate&doi=10.1124%2Fjpet.111.180398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative evaluation of the impact of active efflux by P-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate</span></div><div class="casAuthors">Kodaira, Hiroshi; Kusuhara, Hiroyuki; Fujita, Takuya; Ushiki, Junko; Fuse, Eiichi; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">935-944</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study investigated the impact of the active efflux mediated by P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp) at the blood-brain barrier (BBB) on the predictability of the unbound brain concn. (Cu,brain) by the concn. in the cerebrospinal fluid (CSF) (Cu,CSF) in rats.  Cu,brain is obtained as the product of the total brain concn. and unbound fraction in the brain (fu,brain) detd. in vitro in brain slices.  Twenty-five compds., including P-gp and/or Bcrp substrates, were given a const. i.v. infusion, and their plasma, brain, and CSF concns. were detd.  P-gp and/or Bcrp substrates, such as verapamil, loperamide, flavopiridol, genistein, quinidine, dantrolene, daidzein, cimetidine, and pefloxacin, showed a higher CSF-to-brain unbound concn. ratio (Kp,uu,CSF/brain) compared with non-P-gp and non-Bcrp substrates.  Kp,uu,CSF/brain values of P-gp-specific (quinidine and verapamil) and Bcrp-specific (daidzein and genistein) substrates were significantly decreased in Mdr1a/1b(-/-) and Bcrp(-/-) mice, resp.  Furthermore, consistent with the contribution of P-gp and Bcrp to the net efflux at the BBB, Kp,uu,CSF/brain values of the common substrates (flavopiridol and erlotinib) were markedly decreased in Mdr1a/1b(-/-)/Bcrp(-/-) mice, but only moderately or weakly in Mdr1a/1b(-/-) mice and negligibly in Bcrp(-/-) mice.  In conclusion, predictability of Cu,brain by Cu,CSF decreases along with the net transport activities by P-gp and Bcrp at the BBB.  Cu,CSF of non-P-gp and non-Bcrp substrates can be a reliable surrogate of Cu,brain for lipophilic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6e2OeGRsyrVg90H21EOLACvtfcHk0liMkqQ54HWYfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVSksbo%253D&md5=36a778b164943b101534146120fc6cdf</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.180398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.180398%26sid%3Dliteratum%253Aachs%26aulast%3DKodaira%26aufirst%3DH.%26aulast%3DKusuhara%26aufirst%3DH.%26aulast%3DFujita%26aufirst%3DT.%26aulast%3DUshiki%26aufirst%3DJ.%26aulast%3DFuse%26aufirst%3DE.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DQuantitative%2520evaluation%2520of%2520the%2520impact%2520of%2520active%2520efflux%2520by%2520P-glycoprotein%2520and%2520breast%2520cancer%2520resistance%2520protein%2520at%2520the%2520blood-brain%2520barrier%2520on%2520the%2520predictability%2520of%2520the%2520unbound%2520concentrations%2520of%2520drugs%2520in%2520the%2520brain%2520using%2520cerebrospinal%2520fluid%2520concentration%2520as%2520a%2520surrogate%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D339%26spage%3D935%26epage%3D944%26doi%3D10.1124%2Fjpet.111.180398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span> <i>FDA Approves Lorlatinib for Second- Or Third-Line
Treatment of ALK-Positive
Metastatic NSCLC</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm625027.htm" class="extLink">https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm625027.htm</a> (accessed Feb 14, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+Lorlatinib+for+Second-+Or+Third-Line%0ATreatment+of+ALK-Positive%0AMetastatic+NSCLC%3B+U.S.+Food+and+Drug+Administration%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm625027.htm+%28accessed+Feb+14%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520Lorlatinib%2520for%2520Second-%2520Or%2520Third-Line%250ATreatment%2520of%2520ALK-Positive%250AMetastatic%2520NSCLC%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunker, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dack, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsaparikos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1170</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.1021/jm401805h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401805h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1170-1187&author=Q.+Huangauthor=T.+W.+Johnsonauthor=S.+Baileyauthor=A.+Broounauthor=K.+D.+Bunkerauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=A.+S.+Cookauthor=J.+J.+Cuiauthor=K.+N.+Dackauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=P.+S.+Johnsonauthor=R.+S.+Kaniaauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=Q.+Liauthor=L.+Lingardoauthor=W.+Liuauthor=M.+W.+Luauthor=M.+McTigueauthor=C.+L.+Palmerauthor=P.+F.+Richardsonauthor=N.+W.+Sachauthor=H.+Shenauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=K.+Tsaparikosauthor=H.+Wangauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Design+of+potent+and+selective+inhibitors+to+overcome+clinical+anaplastic+lymphoma+kinase+mutations+resistant+to+crizotinib&doi=10.1021%2Fjm401805h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib</span></div><div class="casAuthors">Huang, Qinhua; Johnson, Ted W.; Bailey, Simon; Brooun, Alexei; Bunker, Kevin D.; Burke, Benjamin J.; Collins, Michael R.; Cook, Andrew S.; Cui, J. Jean; Dack, Kevin N.; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Johnson, Patrick S.; Kania, Robert S.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Li, Qiuhua; Lingardo, Laura; Liu, Wei; Lu, Melissa West; McTigue, Michele; Palmer, Cynthia L.; Richardson, Paul F.; Sach, Neal W.; Shen, Hong; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Tsaparikos, Konstantinos; Wang, Hui; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1170-1187</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Crizotinib, an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S.  Food and Drug Administration in 2011, is efficacious in ALK and ROS pos. patients.  Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease.  The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine (I), which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclin. pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnhF6vRWLUrrVg90H21EOLACvtfcHk0liMkqQ54HWYfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D&md5=c12e0400ac92eb3321fde81ee13a5e92</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm401805h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401805h%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBunker%26aufirst%3DK.%2BD.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDack%26aufirst%3DK.%2BN.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DJohnson%26aufirst%3DP.%2BS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDesign%2520of%2520potent%2520and%2520selective%2520inhibitors%2520to%2520overcome%2520clinical%2520anaplastic%2520lymphoma%2520kinase%2520mutations%2520resistant%2520to%2520crizotinib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1170%26epage%3D1187%26doi%3D10.1021%2Fjm401805h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussault, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrow, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan-Lefko, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimanovich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the <i>c</i>-Met kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2879</span>– <span class="NLM_lpage">2882</span>, <span class="refDoi"> DOI: 10.1021/jm800043g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800043g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvFShtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2879-2882&author=B.+K.+Albrechtauthor=J.+C.+Harmangeauthor=D.+Bauerauthor=L.+Berryauthor=C.+Bodeauthor=A.+A.+Boezioauthor=A.+Chenauthor=D.+Choquetteauthor=I.+Dussaultauthor=C.+Fridrichauthor=S.+Hiraiauthor=D.+Hoffmanauthor=J.+F.+Larrowauthor=P.+Kaplan-Lefkoauthor=J.+Linauthor=J.+Lohmanauthor=A.+M.+Longauthor=J.+Moriguchiauthor=A.+O%E2%80%99Connorauthor=M.+H.+Potashmanauthor=M.+Reeseauthor=K.+Rexauthor=A.+Siegmundauthor=K.+Shahauthor=R.+Shimanovichauthor=S.+K.+Springerauthor=Y.+Tefferaauthor=Y.+Yangauthor=Y.+Zhangauthor=S.+F.+Bellon&title=Discovery+and+optimization+of+triazolopyridazines+as+potent+and+selective+inhibitors+of+the+c-Met+kinase&doi=10.1021%2Fjm800043g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Triazolopyridazines as Potent and Selective Inhibitors of the c-Met Kinase</span></div><div class="casAuthors">Albrecht, Brian K.; Harmange, Jean-Christophe; Bauer, David; Berry, Loren; Bode, Christiane; Boezio, Alessandro A.; Chen, April; Choquette, Deborah; Dussault, Isabelle; Fridrich, Cary; Hirai, Satoko; Hoffman, Doug; Larrow, Jay F.; Kaplan-Lefko, Paula; Lin, Jasmine; Lohman, Julia; Long, Alexander M.; Moriguchi, Jodi; O'Connor, Anne; Potashman, Michele H.; Reese, Monica; Rex, Karen; Siegmund, Aaron; Shah, Kavita; Shimanovich, Roman; Springer, Stephanie K.; Teffera, Yohannes; Yang, Yajing; Zhang, Yihong; Bellon, Steven F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2879-2882</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tumorigenesis is a multistep process in which oncogenes play a key role in tumor formation, growth, and maintenance.  MET was discovered as an oncogene that is activated by its ligand, hepatocyte growth factor.  Deregulated signaling in the c-Met pathway has been obsd. in multiple tumor types.  Herein we report the discovery of potent and selective triazolopyridazine small mols. that inhibit c-Met activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVeQ8sYpasHLVg90H21EOLACvtfcHk0lgvS54lVpc0Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFShtLk%253D&md5=c0aec3ca102d90869884c139372f60a0</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm800043g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800043g%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DHirai%26aufirst%3DS.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DLarrow%26aufirst%3DJ.%2BF.%26aulast%3DKaplan-Lefko%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DA.%2BM.%26aulast%3DMoriguchi%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DA.%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DReese%26aufirst%3DM.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSiegmund%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DS.%2BK.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520triazolopyridazines%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520c-Met%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2879%26epage%3D2882%26doi%3D10.1021%2Fjm800043g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussault, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan-Lefko, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrow, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santostefano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimanovich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of potent and selective triazolopyridazine series of <i>c</i>-Met inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6307</span>– <span class="NLM_lpage">6312</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.09.096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2009.09.096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=19819693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlWlsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6307-6312&author=A.+A.+Boezioauthor=L.+Berryauthor=B.+K.+Albrechtauthor=D.+Bauerauthor=S.+F.+Bellonauthor=C.+Bodeauthor=A.+Chenauthor=D.+Choquetteauthor=I.+Dussaultauthor=S.+Hiraiauthor=P.+Kaplan-Lefkoauthor=J.+F.+Larrowauthor=M.+H.+J.+Linauthor=J.+Lohmanauthor=M.+H.+Potashmanauthor=K.+Rexauthor=M.+Santostefanoauthor=K.+Shahauthor=R.+Shimanovichauthor=S.+K.+Springerauthor=Y.+Tefferaauthor=Y.+Yangauthor=Y.+Zhangauthor=J.+C.+Harmange&title=Discovery+and+optimization+of+potent+and+selective+triazolopyridazine+series+of+c-Met+inhibitors&doi=10.1016%2Fj.bmcl.2009.09.096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors</span></div><div class="casAuthors">Boezio, Alessandro A.; Berry, Loren; Albrecht, Brian K.; Bauer, David; Bellon, Steven F.; Bode, Christiane; Chen, April; Choquette, Deborah; Dussault, Isabelle; Hirai, Satoko; Kaplan-Lefko, Paula; Larrow, Jay F.; Lin, Min-Hwa Jasmine; Lohman, Julia; Potashman, Michele H.; Rex, Karen; Santostefano, Michael; Shah, Kavita; Shimanovich, Roman; Springer, Stephanie K.; Teffera, Yohannes; Yang, Yajing; Zhang, Yihong; Harmange, Jean-Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6307-6312</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small mol. drug discovery.  We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met.  Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase activity and display improved pharmacodynamic profiles.  Specifically, the potent time-dependent inhibition of cytochrome P 450 assocd. with the O-linked triazolopyridazines has been eliminated within this novel series of inhibitors.  N-linked triazolopyridazine 24 exhibited favorable pharmacokinetics and displayed potent inhibition of HGF-mediated c-Met phosphorylation in a mouse liver PD model.  Once-daily oral administration of 24 for 22 days showed significant tumor growth inhibition in an NIH-3T3/TPR-Met xenograft mouse efficacy model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiJYhob-fk_bVg90H21EOLACvtfcHk0lgvS54lVpc0Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlWlsrbF&md5=254e67e6f81b7018b75f73290505e8af</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.09.096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.09.096%26sid%3Dliteratum%253Aachs%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DHirai%26aufirst%3DS.%26aulast%3DKaplan-Lefko%26aufirst%3DP.%26aulast%3DLarrow%26aufirst%3DJ.%2BF.%26aulast%3DLin%26aufirst%3DM.%2BH.%2BJ.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSantostefano%26aufirst%3DM.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DS.%2BK.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520potent%2520and%2520selective%2520triazolopyridazine%2520series%2520of%2520c-Met%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6307%26epage%3D6312%26doi%3D10.1016%2Fj.bmcl.2009.09.096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bode, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broome, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussault, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of a potent and selective triazolopyridinone series of <i>c</i>-Met inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4089</span>– <span class="NLM_lpage">4093</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.04.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2012.04.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22595176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XntVyrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4089-4093&author=C.+M.+Bodeauthor=A.+A.+Boezioauthor=B.+K.+Albrechtauthor=S.+F.+Bellonauthor=L.+Berryauthor=M.+A.+Broomeauthor=D.+Choquetteauthor=I.+Dussaultauthor=R.+T.+Lewisauthor=M.+H.+Linauthor=K.+Rexauthor=D.+A.+Whittingtonauthor=Y.+Yangauthor=J.+C.+Harmange&title=Discovery+and+optimization+of+a+potent+and+selective+triazolopyridinone+series+of+c-Met+inhibitors&doi=10.1016%2Fj.bmcl.2012.04.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors</span></div><div class="casAuthors">Bode, Christiane M.; Boezio, Alessandro A.; Albrecht, Brian K.; Bellon, Steven F.; Berry, Loren; Broome, Martin A.; Choquette, Deborah; Dussault, Isabelle; Lewis, Richard T.; Lin, Min-Hwa Jasmine; Rex, Karen; Whittington, Douglas A.; Yang, Yajing; Harmange, Jean-Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4089-4093</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small mol. drug discovery.  The discovery of a structurally diverse series of quinolinylmethyltriazolopyridinones, which demonstrates nanomolar inhibition of c-Met kinase activity is reported.  This novel series of inhibitors exhibits favorable pharmacokinetics as well as potent inhibition of HGF-mediated c-Met phosphorylation in a mouse liver pharmacodynamic model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2bZorS8wwhrVg90H21EOLACvtfcHk0lgvS54lVpc0Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntVyrtLo%253D&md5=0f80a577ebee0df3c3a219273c43b738</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.04.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.04.072%26sid%3Dliteratum%253Aachs%26aulast%3DBode%26aufirst%3DC.%2BM.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520a%2520potent%2520and%2520selective%2520triazolopyridinone%2520series%2520of%2520c-Met%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4089%26epage%3D4093%26doi%3D10.1016%2Fj.bmcl.2012.04.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broome, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussault, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimanovich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaida, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective 8-fluorotriazolopyridine <i>c</i>-Met inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2417</span>– <span class="NLM_lpage">2430</span>, <span class="refDoi"> DOI: 10.1021/jm501913a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501913a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtV2nt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2417-2430&author=E.+A.+Petersonauthor=Y.+Tefferaauthor=B.+K.+Albrechtauthor=D.+Bauerauthor=S.+F.+Bellonauthor=A.+Boezioauthor=C.+Boezioauthor=M.+A.+Broomeauthor=D.+Choquetteauthor=K.+W.+Copelandauthor=I.+Dussaultauthor=R.+Lewisauthor=M.+H.+Linauthor=J.+Lohmanauthor=J.+Liuauthor=M.+Potashmanauthor=K.+Rexauthor=R.+Shimanovichauthor=D.+A.+Whittingtonauthor=K.+R.+Vaidaauthor=J.+C.+Harmange&title=Discovery+of+potent+and+selective+8-fluorotriazolopyridine+c-Met+inhibitors&doi=10.1021%2Fjm501913a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective 8-Fluorotriazolopyridine c-Met Inhibitors</span></div><div class="casAuthors">Peterson, Emily A.; Teffera, Yohannes; Albrecht, Brian K.; Bauer, David; Bellon, Steven F.; Boezio, Alessandro; Boezio, Christiane; Broome, Martin A.; Choquette, Deborah; Copeland, Katrina W.; Dussault, Isabelle; Lewis, Richard; Lin, Min-Hwa Jasmine; Lohman, Julia; Liu, Jingzhou; Potashman, Michele; Rex, Karen; Shimanovich, Roman; Whittington, Douglas A.; Vaida, Karina R.; Harmange, Jean-Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2417-2430</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The overexpression of c-Met and/or hepatocyte growth factor (HGF), the amplification of the MET gene, and mutations in the c-Met kinase domain can activate signaling pathways that contribute to cancer progression by enabling tumor cell proliferation, survival, invasion, and metastasis.  Herein, the authors report the discovery of 8-fluorotriazolopyridines as inhibitors of c-Met activity.  Optimization of the 8-fluorotriazolopyridine scaffold through the combination of structure-based drug design, SAR studies, and metabolite identification provided potent (cellular IC50 < 10 nM) selective inhibitors of c-Met with desirable pharmacokinetic properties, e.g. I, that demonstrate potent inhibition of HGF-mediated c-Met phosphorylation in a mouse liver pharmacodynamic model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcDhr-rvECKrVg90H21EOLACvtfcHk0lh5CvqiHZuHpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtV2nt70%253D&md5=ae86b1c6fac93caa1deecd89410bd837</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm501913a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501913a%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DE.%2BA.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DBoezio%26aufirst%3DA.%26aulast%3DBoezio%26aufirst%3DC.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DCopeland%26aufirst%3DK.%2BW.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DLewis%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DVaida%26aufirst%3DK.%2BR.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%25208-fluorotriazolopyridine%2520c-Met%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2417%26epage%3D2430%26doi%3D10.1021%2Fjm501913a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broome, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussault, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimanovich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaida, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of (<i>R</i>)-6-(1-(8-fluoro-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6<i>H</i>)-one (AMG 337), a potent and selective inhibitor of MET with high unbound target coverage and robust in <i>vivo</i> antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2328</span>– <span class="NLM_lpage">2342</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01716</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01716" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlKltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2328-2342&author=A.+A.+Boezioauthor=K.+W.+Copelandauthor=K.+Rexauthor=B.+K.+Albrechtauthor=D.+Bauerauthor=S.+F.+Bellonauthor=C.+Boezioauthor=M.+A.+Broomeauthor=D.+Choquetteauthor=A.+Coxonauthor=I.+Dussaultauthor=S.+Hiraiauthor=R.+Lewisauthor=M.+H.+Linauthor=J.+Lohmanauthor=J.+Liuauthor=E.+A.+Petersonauthor=M.+Potashmanauthor=R.+Shimanovichauthor=Y.+Tefferaauthor=D.+A.+Whittingtonauthor=K.+R.+Vaidaauthor=J.+C.+Harmange&title=Discovery+of+%28R%29-6-%281-%288-fluoro-6-%281-methyl-1H-pyrazol-4-yl%29-%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dpyridin-3-yl%29ethyl%29-3-%282-methoxyethoxy%29-1%2C6-naphthyridin-5%286H%29-one+%28AMG+337%29%2C+a+potent+and+selective+inhibitor+of+MET+with+high+unbound+target+coverage+and+robust+in+vivo+antitumor+activity&doi=10.1021%2Facs.jmedchem.5b01716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity</span></div><div class="casAuthors">Boezio, Alessandro A.; Copeland, Katrina W.; Rex, Karen; K. Albrecht, Brian; Bauer, David; Bellon, Steven F.; Boezio, Christiane; Broome, Martin A.; Choquette, Deborah; Coxon, Angela; Dussault, Isabelle; Hirai, Satoko; Lewis, Richard; Lin, Min-Hwa Jasmine; Lohman, Julia; Liu, Jingzhou; Peterson, Emily A.; Potashman, Michele; Shimanovich, Roman; Teffera, Yohannes; Whittington, Douglas A.; Vaida, Karina R.; Harmange, Jean-Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2328-2342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Deregulation of the receptor tyrosine kinase mesenchymal epithelial transition factor (MET) has been implicated in several human cancers and is an attractive target for small mol. drug discovery.  Herein, we report the discovery of compd. 23 (AMG 337), which demonstrates nanomolar inhibition of MET kinase activity, desirable preclin. pharmacokinetics, significant inhibition of MET phosphorylation in mice, and robust tumor growth inhibition in a MET-dependent mouse efficacy model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAOYPFHP_gM7Vg90H21EOLACvtfcHk0lh5CvqiHZuHpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlKltrw%253D&md5=51c002bcb9167f5139f23686b9961afd</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01716%26sid%3Dliteratum%253Aachs%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DCopeland%26aufirst%3DK.%2BW.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DBoezio%26aufirst%3DC.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DHirai%26aufirst%3DS.%26aulast%3DLewis%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DPeterson%26aufirst%3DE.%2BA.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DVaida%26aufirst%3DK.%2BR.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%2520%2528R%2529-6-%25281-%25288-fluoro-6-%25281-methyl-1H-pyrazol-4-yl%2529-%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dpyridin-3-yl%2529ethyl%2529-3-%25282-methoxyethoxy%2529-1%252C6-naphthyridin-5%25286H%2529-one%2520%2528AMG%2520337%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520MET%2520with%2520high%2520unbound%2520target%2520coverage%2520and%2520robust%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2328%26epage%3D2342%26doi%3D10.1021%2Facs.jmedchem.5b01716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinsmore, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcone, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabarda, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunii, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumb, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutterbach, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathvink, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazef, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickert, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenstein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soisson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczak, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of a 5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (MK-2461) inhibitor of <i>c</i>-Met kinase for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4092</span>– <span class="NLM_lpage">4108</span>, <span class="refDoi"> DOI: 10.1021/jm200112k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200112k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFymtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4092-4108&author=J.+D.+Katzauthor=J.+P.+Jewellauthor=D.+J.+Guerinauthor=J.+Limauthor=C.+J.+Dinsmoreauthor=S.+V.+Deshmukhauthor=B.+S.+Panauthor=C.+G.+Marshallauthor=W.+Luauthor=M.+D.+Altmanauthor=W.+K.+Dahlbergauthor=L.+Davisauthor=D.+Falconeauthor=A.+E.+Gabardaauthor=G.+Hangauthor=H.+Hatchauthor=R.+Holmesauthor=K.+Kuniiauthor=K.+J.+Lumbauthor=B.+Lutterbachauthor=R.+Mathvinkauthor=N.+Nazefauthor=S.+B.+Patelauthor=X.+Quauthor=J.+F.+Reillyauthor=K.+W.+Rickertauthor=C.+Rosensteinauthor=S.+M.+Soissonauthor=K.+B.+Spencerauthor=A.+A.+Szewczakauthor=D.+Walkerauthor=W.+Wangauthor=J.+Youngauthor=Q.+Zeng&title=Discovery+of+a+5H-benzo%5B4%2C5%5Dcyclohepta%5B1%2C2-b%5Dpyridin-5-one+%28MK-2461%29+inhibitor+of+c-Met+kinase+for+the+treatment+of+cancer&doi=10.1021%2Fjm200112k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a 5H-Benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer</span></div><div class="casAuthors">Katz, Jason D.; Jewell, James P.; Guerin, David J.; Lim, Jongwon; Dinsmore, Christopher J.; Deshmukh, Sujal V.; Pan, Bo-Sheng; Marshall, C. Gary; Lu, Wei; Altman, Michael D.; Dahlberg, William K.; Davis, Lenora; Falcone, Danielle; Gabarda, Ana E.; Hang, Gaozhen; Hatch, Harold; Holmes, Rachael; Kunii, Kaiko; Lumb, Kevin J.; Lutterbach, Bart; Mathvink, Robert; Nazef, Naim; Patel, Sangita B.; Qu, Xianlu; Reilly, John F.; Rickert, Keith W.; Rosenstein, Craig; Soisson, Stephen M.; Spencer, Kerrie B.; Szewczak, Alexander A.; Walker, Deborah; Wang, Wenxian; Young, Jonathan; Zeng, Qinwen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4092-4108</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">C-Met is a transmembrane tyrosine kinase that mediates activation of several signaling pathways implicated in aggressive cancer phenotypes.  In recent years, research into this area has highlighted c-Met as an attractive cancer drug target, triggering a no. of approaches to disrupt aberrant c-Met signaling.  Screening efforts identified a unique class of 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one kinase inhibitors, exemplified by 1.  Subsequent SAR studies led to the development of MK-2461 (I), a potent inhibitor of c-Met that was efficacious in preclin. animal models of tumor suppression.  In addn., biochem. studies and x-ray anal. have revealed that this unique class of kinase inhibitors binds preferentially to the activated (phosphorylated) form of the kinase.  This report details the development of I and provides a description of its unique biochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6ANuqa7a-NrVg90H21EOLACvtfcHk0li4HfZk_dCSuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFymtbY%253D&md5=82cfe0a146d04d467531e1027f3a1266</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm200112k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200112k%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26aulast%3DJewell%26aufirst%3DJ.%2BP.%26aulast%3DGuerin%26aufirst%3DD.%2BJ.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DPan%26aufirst%3DB.%2BS.%26aulast%3DMarshall%26aufirst%3DC.%2BG.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DDahlberg%26aufirst%3DW.%2BK.%26aulast%3DDavis%26aufirst%3DL.%26aulast%3DFalcone%26aufirst%3DD.%26aulast%3DGabarda%26aufirst%3DA.%2BE.%26aulast%3DHang%26aufirst%3DG.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DHolmes%26aufirst%3DR.%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26aulast%3DLutterbach%26aufirst%3DB.%26aulast%3DMathvink%26aufirst%3DR.%26aulast%3DNazef%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DRickert%26aufirst%3DK.%2BW.%26aulast%3DRosenstein%26aufirst%3DC.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DSpencer%26aufirst%3DK.%2BB.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520a%25205H-benzo%255B4%252C5%255Dcyclohepta%255B1%252C2-b%255Dpyridin-5-one%2520%2528MK-2461%2529%2520inhibitor%2520of%2520c-Met%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4092%26epage%3D4108%26doi%3D10.1021%2Fjm200112k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourpak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4981</span>– <span class="NLM_lpage">5004</span>, <span class="refDoi"> DOI: 10.1021/jm9002395</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9002395" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXos1eht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4981-5004&author=R.+Liauthor=A.+Pourpakauthor=S.+W.+Morris&title=Inhibition+of+the+insulin-like+growth+factor-1+receptor+%28IGF1R%29+tyrosine+kinase+as+a+novel+cancer+therapy+approach&doi=10.1021%2Fjm9002395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach</span></div><div class="casAuthors">Li, Rongshi; Pourpak, Alan; Morris, Stephan W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4981-5004</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This paper reports the use insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase inhibitors in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqan3Tf91Gt-bVg90H21EOLACvtfcHk0li4HfZk_dCSuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXos1eht70%253D&md5=20bfe274451b2dc60e1b2bff7c86b6d8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm9002395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9002395%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DR.%26aulast%3DPourpak%26aufirst%3DA.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26atitle%3DInhibition%2520of%2520the%2520insulin-like%2520growth%2520factor-1%2520receptor%2520%2528IGF1R%2529%2520tyrosine%2520kinase%2520as%2520a%2520novel%2520cancer%2520therapy%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4981%26epage%3D5004%26doi%3D10.1021%2Fjm9002395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samani, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeRoith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodt, P.</span></span> <span> </span><span class="NLM_article-title">The role of the IGF system in cancer growth and metastasis: overview and recent insights</span>. <i>Endocr. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1210/er.2006-0001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1210%2Fer.2006-0001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=16931767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtFCgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=20-47&author=A.+A.+Samaniauthor=S.+Yakarauthor=D.+LeRoithauthor=P.+Brodt&title=The+role+of+the+IGF+system+in+cancer+growth+and+metastasis%3A+overview+and+recent+insights&doi=10.1210%2Fer.2006-0001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the IGF system in cancer growth and metastasis: overview and recent insights</span></div><div class="casAuthors">Samani, Amir Abbas; Yakar, Shoshana; LeRoith, Derek; Brodt, Pnina</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-47</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  IGF-I receptor (IGF-IR) signaling and functions are mediated through the activities of a complex mol. network of pos. (e.g., type I IGF) and neg. (e.g., the type II IGF receptor, IGF-IIR) effectors.  Under normal physiol. conditions, the balance between the expression and activities of these mols. is tightly controlled.  Changes in this delicate balance (e.g., overexpression of one effector) may trigger a cascade of mol. events that can ultimately lead to malignancy.  In recent years, evidence has been mounting that the IGF axis may be involved in human cancer progression and can be targeted for therapeutic intervention.  Here we review old and more recent evidence on the role the IGF system in malignancy and highlight exptl. and clin. studies that provide novel insights into the complex mechanisms that contribute to its oncogenic potential.  Controversies arising from conflicting evidence on the relevance of IGF-IR and its ligands to human cancer are discussed.  Our review highlights the importance of viewing the IGF axis as a complex multifactorial system and shows that changes in the expression levels of any one component of the axis, in a given malignancy, should be interpreted with caution and viewed in a wider context that takes into account the expression levels, state of activation, accessibility, and functionality of other interacting components.  Because IGF targeting for anticancer therapy is rapidly becoming a clin. reality, an understanding of this complexity is timely because it is likely to have an impact on the design, mode of action, and clin. outcomes of newly developed drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMaVO8jlyh3LVg90H21EOLACvtfcHk0li4HfZk_dCSuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtFCgsrg%253D&md5=f900044e75292ad8c7797407fe500025</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1210%2Fer.2006-0001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fer.2006-0001%26sid%3Dliteratum%253Aachs%26aulast%3DSamani%26aufirst%3DA.%2BA.%26aulast%3DYakar%26aufirst%3DS.%26aulast%3DLeRoith%26aufirst%3DD.%26aulast%3DBrodt%26aufirst%3DP.%26atitle%3DThe%2520role%2520of%2520the%2520IGF%2520system%2520in%2520cancer%2520growth%2520and%2520metastasis%253A%2520overview%2520and%2520recent%2520insights%26jtitle%3DEndocr.%2520Rev.%26date%3D2007%26volume%3D28%26spage%3D20%26epage%3D47%26doi%3D10.1210%2Fer.2006-0001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stampfer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovannucci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gann, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennekens, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M.</span></span> <span> </span><span class="NLM_article-title">Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1126/science.279.5350.563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1126%2Fscience.279.5350.563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=9438850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK1cXotVOqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=563-566&author=J.+M.+Chanauthor=M.+J.+Stampferauthor=E.+Giovannucciauthor=P.+H.+Gannauthor=J.+Maauthor=P.+Wilkinsonauthor=C.+H.+Hennekensauthor=M.+Pollak&title=Plasma+insulin-like+growth+factor-I+and+prostate+cancer+risk%3A+a+prospective+study&doi=10.1126%2Fscience.279.5350.563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study</span></div><div class="casAuthors">Chan, June M.; Stempfer, Meir J.; Giovannucci, Edward; Gann, Peter H.; Ma, Jing; Wilkinson, Peter; Hennekens, Charles H.; Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5350</span>),
    <span class="NLM_cas:pages">563-566</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Insulin-like growth factor-I (IGF-I) is a mitogen for prostate epithelial cells.  To investigate assocns. between plasma IGF levels and prostate cancer risk, a nested case-control study within the Physicians' health Study was conducted on prospectively collected plasma from 152 cases and 152 controls.  A strong pos. assocn. was obsd. between IGF-I levels and prostate cancer risk.  Men in the highest quartile of IGF-I levels had a relative risk of 4.3 (95 % confidence interval 1.8 to 10.6) compared with men in the lowest quartile.  This assocn. was independent of baseline prostate-specific antigen levels.  Identification of plasma IGF-I as a predictor of prostate cancer risk may have implications for risk redn. and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN8T4rIgzxMLVg90H21EOLACvtfcHk0lhn_1WIiu5uSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVOqsg%253D%253D&md5=43c076479c5fb946f61a42758043bd92</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5350.563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5350.563%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DJ.%2BM.%26aulast%3DStampfer%26aufirst%3DM.%2BJ.%26aulast%3DGiovannucci%26aufirst%3DE.%26aulast%3DGann%26aufirst%3DP.%2BH.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWilkinson%26aufirst%3DP.%26aulast%3DHennekens%26aufirst%3DC.%2BH.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DPlasma%2520insulin-like%2520growth%2520factor-I%2520and%2520prostate%2520cancer%2520risk%253A%2520a%2520prospective%2520study%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D563%26epage%3D566%26doi%3D10.1126%2Fscience.279.5350.563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perks, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holly, J. M.</span></span> <span> </span><span class="NLM_article-title">The insulin-like growth factor (IGF) family and breast cancer</span>. <i>Breast Dis.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.3233/BD-2003-18106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.3233%2FBD-2003-18106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=15687688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvVehur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2003&pages=45-60&author=C.+M.+Perksauthor=J.+M.+Holly&title=The+insulin-like+growth+factor+%28IGF%29+family+and+breast+cancer&doi=10.3233%2FBD-2003-18106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The Insulin-Like Growth Factor (IGF) Family and Breast Cancer</span></div><div class="casAuthors">Perks, Claire M.; Holly, Jeff M. P.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Disease</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45-60</span>CODEN:
                <span class="NLM_cas:coden">BRDIE5</span>;
        ISSN:<span class="NLM_cas:issn">0888-6008</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  The IGF family, composed of ligands, receptors, binding proteins and proteases, is crit. during development and in the maintenance of normal tissue homeostasis.  This review describes the role of the IGF system in the normal breast but focuses on the changes that occur in breast cancer.  It discusses the cross-talk which can occur between the IGF family with other signaling pathways, including estrogen, epidermal growth factor (EGF) and integrins.  It also describes various cell and animal models which have been developed to elucidate the function and significance of the IGF family in cancer with a view to developing potential therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra9ZrESdTewrVg90H21EOLACvtfcHk0lhn_1WIiu5uSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvVehur8%253D&md5=30ba3c81f50a36dc54681070e38e6547</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3233%2FBD-2003-18106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FBD-2003-18106%26sid%3Dliteratum%253Aachs%26aulast%3DPerks%26aufirst%3DC.%2BM.%26aulast%3DHolly%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520insulin-like%2520growth%2520factor%2520%2528IGF%2529%2520family%2520and%2520breast%2520cancer%26jtitle%3DBreast%2520Dis.%26date%3D2003%26volume%3D18%26spage%3D45%26epage%3D60%26doi%3D10.3233%2FBD-2003-18106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, N.</span></span> <span> </span><span class="NLM_article-title">Discovery of a series of nonpeptide small molecules that inhibit the binding of insulin-like growth factor (IGF) to IGF-binding proteins</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">4001</span>– <span class="NLM_lpage">4010</span>, <span class="refDoi"> DOI: 10.1021/jm010304b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010304b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntF2hsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=4001-4010&author=C.+Chenauthor=Y.-F.+Zhuauthor=X.-J.+Liuauthor=Z.-X.+Luauthor=Q.+Xieauthor=N.+Ling&title=Discovery+of+a+series+of+nonpeptide+small+molecules+that+inhibit+the+binding+of+insulin-like+growth+factor+%28IGF%29+to+IGF-binding+proteins&doi=10.1021%2Fjm010304b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Series of Nonpeptide Small Molecules That Inhibit the Binding of Insulin-like Growth Factor (IGF) to IGF-Binding Proteins</span></div><div class="casAuthors">Chen, Chen; Zhu, Yun-Fei; Liu, Xin-Jun; Lu, Zi-Xian; Xie, Qiu; Ling, Nicholas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4001-4010</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Insulin-like growth factors (IGF-I and II) play an important role in metabolic and mitogenic activities through stimulation of the IGF-I receptor on the cell surface.  Although the concn. of IGF in blood and cerebrospinal fluid is quite high (>100 nM), this large pool of IGF is biol. inactive because of its assocn. with six distinct binding proteins, which form high-affinity complexes with IGF.  Thus, inhibitors of IGF-binding proteins (IGFBPs), esp. IGFBP-3, could potentially alter the distribution between the "free" and "bound" forms of IGF and thereby elevate biol. active IGF-I to exert a beneficial effect on those patients with diseases that respond to the application of exogenous IGF-I.  Whereas IGF-I peptide variants, which bind to IGFBPs but not the IGF-I receptor, have been shown to be potent IGF/IGFBP inhibitors, small mol. nonpeptide IGF/IGFBP inhibitors have the potential advantages of oral bioavailability and flexible dosing regimen.  Here the authors report the discovery of several isoquinoline analogs which bind IGFBP-3 as well as other IGFBPs at low nanomolar concns.  More importantly, both compds. were shown to be able to release biol. active IGF-I from the IGF-I/IGFBP-3 complex.  These results point to the feasibility of developing orally active therapeutics to treat IGF-responsive diseases by optimization of the lead mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeHMB34sQWg7Vg90H21EOLACvtfcHk0lhn_1WIiu5uSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntF2hsrk%253D&md5=f966229b9ab421117ecebd357e28905a</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm010304b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010304b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DY.-F.%26aulast%3DLiu%26aufirst%3DX.-J.%26aulast%3DLu%26aufirst%3DZ.-X.%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DLing%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520a%2520series%2520of%2520nonpeptide%2520small%2520molecules%2520that%2520inhibit%2520the%2520binding%2520of%2520insulin-like%2520growth%2520factor%2520%2528IGF%2529%2520to%2520IGF-binding%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D4001%26epage%3D4010%26doi%3D10.1021%2Fjm010304b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokhale, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foreman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buck, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittner, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadalbajoo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landfair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinig, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvihill, M. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of an orally efficacious imidazo[5,1-<i>f</i>][1,2,4]triazine dual inhibitor of IGF-1R and IR</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">515</span>, <span class="refDoi"> DOI: 10.1021/ml100178g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100178g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyhur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=510-515&author=M.+Jinauthor=P.+C.+Gokhaleauthor=A.+Cookeauthor=K.+Foremanauthor=E.+Buckauthor=E.+W.+Mayauthor=L.+Fengauthor=M.+A.+Bittnerauthor=M.+Kadalbajooauthor=D.+Landfairauthor=K.+W.+Siuauthor=K.+M.+Stolzauthor=D.+S.+Wernerauthor=R.+S.+Lauferauthor=A.+H.+Liauthor=H.+Dongauthor=A.+G.+Steinigauthor=A.+Kleinbergauthor=Y.+Yaoauthor=J.+A.+Pachterauthor=R.+Wildauthor=M.+J.+Mulvihill&title=Discovery+of+an+orally+efficacious+imidazo%5B5%2C1-f%5D%5B1%2C2%2C4%5Dtriazine+dual+inhibitor+of+IGF-1R+and+IR&doi=10.1021%2Fml100178g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR</span></div><div class="casAuthors">Jin, Meizhong; Gokhale, Prafulla C.; Cooke, Andy; Foreman, Kenneth; Buck, Elizabeth; May, Earl W.; Feng, Lixin; Bittner, Mark A.; Kadalbajoo, Mridula; Landfair, Darla; Siu, Kam W.; Stolz, Kathryn M.; Werner, Douglas S.; Laufer, Radoslaw S.; Li, An-Hu; Dong, Hanqing; Steinig, Arno G.; Kleinberg, Andrew; Yao, Yan; Pachter, Jonathan A.; Wild, Robert; Mulvihill, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">510-515</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes the investigation of a series of 5,7-disubstituted imidazo[5,1-f][1,2,4]triazine inhibitors of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR).  Structure-activity relationship exploration and optimization leading to the identification, characterization, and pharmacol. activity of compd. 9b, a potent, selective, well-tolerated, and orally bioavailable dual inhibitor of IGF-1R and IR with in vivo efficacy in tumor xenograft models, is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RZvdH2OAfLVg90H21EOLACvtfcHk0li3lc7emSPyew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyhur3I&md5=1d3cc19c84b347163c6bcbb155595aae</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fml100178g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100178g%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DM.%26aulast%3DGokhale%26aufirst%3DP.%2BC.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DForeman%26aufirst%3DK.%26aulast%3DBuck%26aufirst%3DE.%26aulast%3DMay%26aufirst%3DE.%2BW.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DBittner%26aufirst%3DM.%2BA.%26aulast%3DKadalbajoo%26aufirst%3DM.%26aulast%3DLandfair%26aufirst%3DD.%26aulast%3DSiu%26aufirst%3DK.%2BW.%26aulast%3DStolz%26aufirst%3DK.%2BM.%26aulast%3DWerner%26aufirst%3DD.%2BS.%26aulast%3DLaufer%26aufirst%3DR.%2BS.%26aulast%3DLi%26aufirst%3DA.%2BH.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DSteinig%26aufirst%3DA.%2BG.%26aulast%3DKleinberg%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26atitle%3DDiscovery%2520of%2520an%2520orally%2520efficacious%2520imidazo%255B5%252C1-f%255D%255B1%252C2%252C4%255Dtriazine%2520dual%2520inhibitor%2520of%2520IGF-1R%2520and%2520IR%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D510%26epage%3D515%26doi%3D10.1021%2Fml100178g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokhale, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foreman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittner, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvihill, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landfair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld-Franklin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvihill, M. J.</span></span> <span> </span><span class="NLM_article-title">Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1176</span>– <span class="NLM_lpage">1180</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.12.094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2010.12.094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=21251824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1amtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1176-1180&author=M.+Jinauthor=A.+Kleinbergauthor=A.+Cookeauthor=P.+C.+Gokhaleauthor=K.+Foremanauthor=H.+Dongauthor=K.+W.+Siuauthor=M.+A.+Bittnerauthor=K.+M.+Mulvihillauthor=Y.+Yaoauthor=D.+Landfairauthor=M.+O%E2%80%99Connorauthor=G.+Makauthor=J.+A.+Pachterauthor=R.+Wildauthor=M.+Rosenfeld-Franklinauthor=Q.+Jiauthor=M.+J.+Mulvihill&title=Potent+and+selective+cyclohexyl-derived+imidazopyrazine+insulin-like+growth+factor+1+receptor+inhibitors+with+in+vivo+efficacy&doi=10.1016%2Fj.bmcl.2010.12.094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy</span></div><div class="casAuthors">Jin, Meizhong; Kleinberg, Andrew; Cooke, Andy; Gokhale, Prafulla C.; Foreman, Kenneth; Dong, Hanqing; Siu, Kam W.; Bittner, Mark A.; Mulvihill, Kristen M.; Yao, Yan; Landfair, Darla; O'Connor, Matthew; Mak, Gilda; Pachter, Jonathan A.; Wild, Robert; Rosenfeld-Franklin, Maryland; Ji, Qunsheng; Mulvihill, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1176-1180</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Preclin. and emerging clin. evidence suggests that inhibiting insulin-like growth factor 1 receptor (IGF-1R) signaling may offer a promising therapeutic strategy for the treatment of several types of cancer.  This Letter describes the medicinal chem. effort towards a series of 8-amino-imidazo[1,5-a]pyrazine derived inhibitors of IGF-1R which features a substituted quinoline moiety at the C1 position and a cyclohexyl linking moiety at the C3 position.  Lead optimization efforts which included the optimization of structure-activity relationships and drug metab. and pharmacokinetic properties led to the identification of compd. 9m (I), a potent, selective and orally bioavailable inhibitor of IGF-1R with in vivo efficacy in an IGF-driven mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTghoNgWwGPLVg90H21EOLACvtfcHk0li3lc7emSPyew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1amtr0%253D&md5=777735b116129fe910a30033223dfe8f</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.094%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DM.%26aulast%3DKleinberg%26aufirst%3DA.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DGokhale%26aufirst%3DP.%2BC.%26aulast%3DForeman%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DSiu%26aufirst%3DK.%2BW.%26aulast%3DBittner%26aufirst%3DM.%2BA.%26aulast%3DMulvihill%26aufirst%3DK.%2BM.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DLandfair%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%26aulast%3DMak%26aufirst%3DG.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DRosenfeld-Franklin%26aufirst%3DM.%26aulast%3DJi%26aufirst%3DQ.%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26atitle%3DPotent%2520and%2520selective%2520cyclohexyl-derived%2520imidazopyrazine%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520inhibitors%2520with%2520in%2520vivo%2520efficacy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1176%26epage%3D1180%26doi%3D10.1016%2Fj.bmcl.2010.12.094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mulvihill, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld-Franklin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buck, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foreman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landfair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirritt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Q. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">1153</span>– <span class="NLM_lpage">1171</span>, <span class="refDoi"> DOI: 10.4155/fmc.09.89</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.4155%2Ffmc.09.89" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=21425998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVChs7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=1153-1171&author=M.+J.+Mulvihillauthor=A.+Cookeauthor=M.+Rosenfeld-Franklinauthor=E.+Buckauthor=K.+Foremanauthor=D.+Landfairauthor=M.+O%E2%80%99Connorauthor=C.+Pirrittauthor=Y.+Sunauthor=Y.+Yaoauthor=L.+D.+Arnoldauthor=N.+W.+Gibsonauthor=Q.+S.+Ji&title=Discovery+of+OSI-906%3A+a+selective+and+orally+efficacious+dual+inhibitor+of+the+IGF-1+receptor+and+insulin+receptor&doi=10.4155%2Ffmc.09.89"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-I receptor and insulin receptor</span></div><div class="casAuthors">Mulvihill, Mark J.; Cooke, Andrew; Rosenfeld-Franklin, Maryland; Buck, Elizabeth; Foreman, Ken; Landfair, Darla; O'Connor, Matthew; Pirritt, Caroline; Sun, Yingchaun; Yao, Yan; Arnold, Lee D.; Gibson, Neil W.; Ji, Qun-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1153-1171</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The IGF-I receptor (IGF-IR) has been implicated in the promotion of tumorigenesis, metastasis and resistance to cancer therapies.  Therefore, this receptor has become a major focus for the development of anticancer agents.  Our lead optimization efforts that blended structure-based design and empirical medicinal chem. led to the discovery of OSI-906, a novel small-mol. dual IGF-IR/insulin receptor (IR) kinase inhibitor.  OSI-906 potently and selectively inhibits autophosphorylation of both human IGF-IR and IR, displays in vitro antiproliferative effects in a variety of tumor cell lines and shows robust in vivo anti-tumor efficacy in an IGF-IR-driven xenograft model when administered orally once daily.  OSI-906 is a novel, potent, selective and orally bioavailable dual IGF-IR/IR kinase inhibitor with favorable preclin. drug-like properties, which has demonstrated in vivo efficacy in tumor models and is currently in clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR1FmFisMOHrVg90H21EOLACvtfcHk0lg1F5l6Jau_BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVChs7zM&md5=c7583de9d57e3af55ff2fa0c3708fd93</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.4155%2Ffmc.09.89&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.09.89%26sid%3Dliteratum%253Aachs%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DRosenfeld-Franklin%26aufirst%3DM.%26aulast%3DBuck%26aufirst%3DE.%26aulast%3DForeman%26aufirst%3DK.%26aulast%3DLandfair%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%26aulast%3DPirritt%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DArnold%26aufirst%3DL.%2BD.%26aulast%3DGibson%26aufirst%3DN.%2BW.%26aulast%3DJi%26aufirst%3DQ.%2BS.%26atitle%3DDiscovery%2520of%2520OSI-906%253A%2520a%2520selective%2520and%2520orally%2520efficacious%2520dual%2520inhibitor%2520of%2520the%2520IGF-1%2520receptor%2520and%2520insulin%2520receptor%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2009%26volume%3D1%26spage%3D1153%26epage%3D1171%26doi%3D10.4155%2Ffmc.09.89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wittman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carboni, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frennesson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardis, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurlburt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastalerz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saulnier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velaparthi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, D. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a 2,4-disubstituted pyrrolo[1,2-<i>f</i>][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7360</span>– <span class="NLM_lpage">7363</span>, <span class="refDoi"> DOI: 10.1021/jm900786r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900786r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOiurjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7360-7363&author=M.+D.+Wittmanauthor=J.+M.+Carboniauthor=Z.+Yangauthor=F.+Y.+Leeauthor=M.+Antmanauthor=R.+Attarauthor=P.+Balimaneauthor=C.+Changauthor=C.+Chenauthor=L.+Discenzaauthor=D.+Frennessonauthor=M.+M.+Gottardisauthor=A.+Greerauthor=W.+Hurlburtauthor=W.+Johnsonauthor=D.+R.+Langleyauthor=A.+Liauthor=J.+Liauthor=P.+Liuauthor=H.+Mastalerzauthor=A.+Mathurauthor=K.+Menardauthor=K.+Patelauthor=J.+Sackauthor=X.+Sangauthor=M.+Saulnierauthor=D.+Smithauthor=K.+Stefanskiauthor=G.+Trainorauthor=U.+Velaparthiauthor=G.+Zhangauthor=K.+Zimmermannauthor=D.+M.+Vyas&title=Discovery+of+a+2%2C4-disubstituted+pyrrolo%5B1%2C2-f%5D%5B1%2C2%2C4%5Dtriazine+inhibitor+%28BMS-754807%29+of+insulin-like+growth+factor+receptor+%28IGF-1R%29+kinase+in+clinical+development&doi=10.1021%2Fjm900786r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a 2,4-Disubstituted Pyrrolo[1,2-f][1,2,4]triazine Inhibitor (BMS-754807) of Insulin-like Growth Factor Receptor (IGF-1R) Kinase in Clinical Development</span></div><div class="casAuthors">Wittman, Mark D.; Carboni, Joan M.; Yang, Zheng; Lee, Francis Y.; Antman, Melissa; Attar, Ricardo; Balimane, Praveen; Chang, Chiehying; Chen, Cliff; Discenza, Lorell; Frennesson, David; Gottardis, Marco M.; Greer, Ann; Hurlburt, Warren; Johnson, Walter; Langley, David R.; Li, Aixin; Li, Jianqing; Liu, Peiying; Mastalerz, Harold; Mathur, Arvind; Menard, Krista; Patel, Karishma; Sack, John; Sang, Xiaopeng; Saulnier, Mark; Smith, Daniel; Stefanski, Kevin; Trainor, George; Velaparthi, Upender; Zhang, Guifen; Zimmermann, Kurt; Vyas, Dolatrai M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7360-7363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes the biol. activity, characterization, and SAR leading to 9d (BMS-754807, I) a small mol. IGF-1R kinase inhibitor in clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPOoiaTjr-NbVg90H21EOLACvtfcHk0lg1F5l6Jau_BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOiurjJ&md5=be0fe9adea18595b4ba6f232726ba4df</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjm900786r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900786r%26sid%3Dliteratum%253Aachs%26aulast%3DWittman%26aufirst%3DM.%2BD.%26aulast%3DCarboni%26aufirst%3DJ.%2BM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DAntman%26aufirst%3DM.%26aulast%3DAttar%26aufirst%3DR.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DFrennesson%26aufirst%3DD.%26aulast%3DGottardis%26aufirst%3DM.%2BM.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DHurlburt%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DW.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DMenard%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DSack%26aufirst%3DJ.%26aulast%3DSang%26aufirst%3DX.%26aulast%3DSaulnier%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DTrainor%26aufirst%3DG.%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DVyas%26aufirst%3DD.%2BM.%26atitle%3DDiscovery%2520of%2520a%25202%252C4-disubstituted%2520pyrrolo%255B1%252C2-f%255D%255B1%252C2%252C4%255Dtriazine%2520inhibitor%2520%2528BMS-754807%2529%2520of%2520insulin-like%2520growth%2520factor%2520receptor%2520%2528IGF-1R%2529%2520kinase%2520in%2520clinical%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7360%26epage%3D7363%26doi%3D10.1021%2Fjm900786r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zia-Ebrahimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloem, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D. J.</span></span> <span> </span><span class="NLM_article-title">A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2200</span>– <span class="NLM_lpage">2210</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1158%2F1535-7163.MCT-11-0306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=21900693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2200-2210&author=G.+S.+Zhaoauthor=W.+Y.+Liauthor=D.+H.+Chenauthor=J.+R.+Henryauthor=H.+Y.+Liauthor=Z.+G.+Chenauthor=M.+Zia-Ebrahimiauthor=L.+Bloemauthor=Y.+Zhaiauthor=K.+Hussauthor=S.+B.+Pengauthor=D.+J.+McCann&title=A+novel%2C+selective+inhibitor+of+fibroblast+growth+factor+receptors+that+shows+a+potent+broad+spectrum+of+antitumor+activity+in+several+tumor+xenograft+models&doi=10.1158%2F1535-7163.MCT-11-0306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models</span></div><div class="casAuthors">Zhao, Genshi; Li, Wei-ying; Chen, Daohong; Henry, James R.; Li, Hong-Yu; Chen, Zhaogen; Zia-Ebrahimi, Mohammad; Bloem, Laura; Zhai, Yan; Huss, Karen; Peng, Sheng-bin; McCann, Denis J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2200-2210</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptors (FGFR) are tyrosine kinases that are present in many types of endothelial and tumor cells and play an important role in tumor cell growth, survival, and migration as well as in maintaining tumor angiogenesis.  Overexpression of FGFRs or aberrant regulation of their activities has been implicated in many forms of human malignancies.  Therefore, targeting FGFRs represents an attractive strategy for development of cancer treatment options by simultaneously inhibiting tumor cell growth, survival, and migration as well as tumor angiogenesis.  Here, we describe a potent, selective, small-mol. FGFR inhibitor, (R)-(E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)ethoxy)-1H-indazol-3yl)vinyl)-1H-pyrazol-1-yl)ethanol, designated as LY2874455.  This mol. is active against all 4 FGFRs, with a similar potency in biochem. assays.  It exhibits a potent activity against FGF/FGFR-mediated signaling in several cancer cell lines and shows an excellent broad spectrum of antitumor activity in several tumor xenograft models representing the major FGF/FGFR relevant tumor histologies including lung, gastric, and bladder cancers and multiple myeloma, and with a well-defined pharmacokinetic/pharmacodynamic relationship.  LY2874455 also exhibits a 6- to 9-fold in vitro and in vivo selectivity on inhibition of FGF- over VEGF-mediated target signaling in mice.  Furthermore, LY2874455 did not show VEGF receptor 2-mediated toxicities such as hypertension at efficacious doses.  Currently, this mol. is being evaluated for its potential use in the clinic.  Mol Cancer Ther; 10(11); 2200-10.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLrzAyZQK_grVg90H21EOLACvtfcHk0lhUi-cXnprkcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N&md5=eaf08fd213a836f48da2055e01bd9c29</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0306%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DG.%2BS.%26aulast%3DLi%26aufirst%3DW.%2BY.%26aulast%3DChen%26aufirst%3DD.%2BH.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DLi%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DZ.%2BG.%26aulast%3DZia-Ebrahimi%26aufirst%3DM.%26aulast%3DBloem%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DHuss%26aufirst%3DK.%26aulast%3DPeng%26aufirst%3DS.%2BB.%26aulast%3DMcCann%26aufirst%3DD.%2BJ.%26atitle%3DA%2520novel%252C%2520selective%2520inhibitor%2520of%2520fibroblast%2520growth%2520factor%2520receptors%2520that%2520shows%2520a%2520potent%2520broad%2520spectrum%2520of%2520antitumor%2520activity%2520in%2520several%2520tumor%2520xenograft%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2200%26epage%3D2210%26doi%3D10.1158%2F1535-7163.MCT-11-0306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavine, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilgour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span> <span> </span><span class="NLM_article-title">AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">2045</span>– <span class="NLM_lpage">2056</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1158%2F0008-5472.CAN-11-3034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22369928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2045-2056&author=P.+R.+Gavineauthor=L.+Mooneyauthor=E.+Kilgourauthor=A.+P.+Thomasauthor=K.+Al-Kadhimiauthor=S.+Beckauthor=C.+Rooneyauthor=T.+Colemanauthor=D.+Bakerauthor=M.+J.+Mellorauthor=A.+N.+Brooksauthor=T.+Klinowska&title=AZD4547%3A+an+orally+bioavailable%2C+potent%2C+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+tyrosine+kinase+family&doi=10.1158%2F0008-5472.CAN-11-3034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family</span></div><div class="casAuthors">Gavine, Paul R.; Mooney, Lorraine; Kilgour, Elaine; Thomas, Andrew P.; Al-Kadhimi, Katherine; Beck, Sarah; Rooney, Claire; Coleman, Tanya; Baker, Dawn; Mellor, Martine J.; Brooks, A. Nigel; Klinowska, Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2045-2056</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis and chemoresistance.  Several small-mol. FGF receptor (FGFR) kinase inhibitors are currently in clin. development; however, the predominant activity of the most advanced of these agents is against the kinase insert domain receptor (KDR), which compromises the FGFR selectivity.  Here, we report the pharmacol. profile of AZD4547, a novel and selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases.  AZD4547 inhibited recombinant FGFR kinase activity in vitro and suppressed FGFR signaling and growth in tumor cell lines with deregulated FGFR expression.  In a representative FGFR-driven human tumor xenograft model, oral administration of AZD4547 was well tolerated and resulted in potent dose-dependent antitumor activity, consistent with plasma exposure and pharmacodynamic modulation of tumor FGFR.  Importantly, at efficacious doses, no evidence of anti-KDR-related effects were obsd., confirming the in vivo FGFR selectivity of AZD4547.  Taken together, our findings show that AZD4547 is a novel selective small-mol. inhibitor of FGFR with potent antitumor activity against FGFR-deregulated tumors in preclin. models.  AZD4547 is under clin. investigation for the treatment of FGFR-dependent tumors.  Cancer Res; 72(8); 2045-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnpExryJc9xbVg90H21EOLACvtfcHk0lhUi-cXnprkcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D&md5=cba90ad8f9b9e51cd10288868bbcc85e</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3034%26sid%3Dliteratum%253Aachs%26aulast%3DGavine%26aufirst%3DP.%2BR.%26aulast%3DMooney%26aufirst%3DL.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DRooney%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26aulast%3DKlinowska%26aufirst%3DT.%26atitle%3DAZD4547%253A%2520an%2520orally%2520bioavailable%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D2045%26epage%3D2056%26doi%3D10.1158%2F0008-5472.CAN-11-3034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzilleri, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wautlet, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortillo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeyaseelan, R.,  Sr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derbin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robl, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargnoli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhide, R. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of brivanib alaninate ((<i>S</i>)-((<i>R</i>)-1-(4-(4-fluoro-2-methyl-1<i>H</i>-indol-5-yloxy)-5-methylpyrrolo[2,1-<i>f</i>][1,2,4] triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1976</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1021/jm7013309</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7013309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlCnt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1976-1980&author=Z.+W.+Caiauthor=Y.+Zhangauthor=R.+M.+Borzilleriauthor=L.+Qianauthor=S.+Barbosaauthor=D.+Weiauthor=X.+Zhengauthor=L.+Wuauthor=J.+Fanauthor=Z.+Shiauthor=B.+S.+Wautletauthor=S.+Mortilloauthor=R.+Jeyaseelanauthor=D.+W.+Kukralauthor=A.+Kamathauthor=P.+Maratheauthor=C.+D%E2%80%99Arienzoauthor=G.+Derbinauthor=J.+C.+Barrishauthor=J.+A.+Roblauthor=J.+T.+Huntauthor=L.+J.+Lombardoauthor=J.+Fargnoliauthor=R.+S.+Bhide&title=Discovery+of+brivanib+alaninate+%28%28S%29-%28%28R%29-1-%284-%284-fluoro-2-methyl-1H-indol-5-yloxy%29-5-methylpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5D+triazin-6-yloxy%29propan-2-yl%292-aminopropanoate%29%2C+a+novel+prodrug+of+dual+vascular+endothelial+growth+factor+receptor-2+and+fibroblast+growth+factor+receptor-1+kinase+inhibitor+%28BMS-540215%29&doi=10.1021%2Fjm7013309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)</span></div><div class="casAuthors">Cai, Zhen-wei; Zhang, Yongzheng; Borzilleri, Robert M.; Qian, Ligang; Barbosa, Stephanie; Wei, Donna; Zheng, Xiaoping; Wu, Lawrence; Fan, Junying; Shi, Zhongping; Wautlet, Barri S.; Mortillo, Steve; Jeyaseelan, Robert; Kukral, Daniel W.; Kamath, Amrita; Marathe, Punit; D'Arienzo, Celia; Derbin, George; Barrish, Joel C.; Robl, Jeffrey A.; Hunt, John T.; Lombardo, Louis J.; Fargnoli, Joseph; Bhide, Rajeev S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1976-1980</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of amino acid ester prodrugs of the dual VEGFR-2/FGFR-1 kinase inhibitor (BMS-540215) was prepd. in an effort to improve the aq. soly. and oral bioavailability of the parent compd.  These prodrugs were evaluated for their ability to liberate parent drug BMS-540215 in in vitro and in vivo systems.  The L-alanine prodrug (also known as brivanib alaninate/BMS-582664, I) was selected as a development candidate and is presently in phase II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsRxtPLgh4X7Vg90H21EOLACvtfcHk0lhUi-cXnprkcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlCnt7w%253D&md5=42524ac71a5eebed588c8e7023eff2de</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm7013309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7013309%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DBarbosa%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDerbin%26aufirst%3DG.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26atitle%3DDiscovery%2520of%2520brivanib%2520alaninate%2520%2528%2528S%2529-%2528%2528R%2529-1-%25284-%25284-fluoro-2-methyl-1H-indol-5-yloxy%2529-5-methylpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255D%2520triazin-6-yloxy%2529propan-2-yl%25292-aminopropanoate%2529%252C%2520a%2520novel%2520prodrug%2520of%2520dual%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520and%2520fibroblast%2520growth%2520factor%2520receptor-1%2520kinase%2520inhibitor%2520%2528BMS-540215%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1976%26epage%3D1980%26doi%3D10.1021%2Fjm7013309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littman, D. R.</span></span> <span> </span><span class="NLM_article-title">Signal transduction by lymphocyte antigen receptors</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(94)90334-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2F0092-8674%2894%2990334-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=8293463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK2cXhs1Srtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1994&pages=263-274&author=A.+Weissauthor=D.+R.+Littman&title=Signal+transduction+by+lymphocyte+antigen+receptors&doi=10.1016%2F0092-8674%2894%2990334-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction by lymphocyte antigen receptors</span></div><div class="casAuthors">Weiss, Arthur; Littman, Dan R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-74</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">A review, with 125 refs., discussing T- and B-cell antigen receptors, TCR and BCR interaction with tyrosine kinase families, coreceptors in initiation of signal transduction events, regulation of antigen receptor signal transduction by CD45, and the consequences of antigen receptor-induced tyrosine phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgq0lyR8HICbVg90H21EOLACvtfcHk0lgK0B_hkbDCSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhs1Srtr0%253D&md5=018861d0265c3ee91d2cc871fd3b9843</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2894%2990334-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252894%252990334-4%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DA.%26aulast%3DLittman%26aufirst%3DD.%2BR.%26atitle%3DSignal%2520transduction%2520by%2520lymphocyte%2520antigen%2520receptors%26jtitle%3DCell%26date%3D1994%26volume%3D76%26spage%3D263%26epage%3D274%26doi%3D10.1016%2F0092-8674%2894%2990334-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kontzias, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotlyar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2012.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.coph.2012.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22819198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVymsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=464-470&author=A.+Kontziasauthor=A.+Kotlyarauthor=A.+Laurenceauthor=P.+Changelianauthor=J.+J.+O%E2%80%99Shea&title=Jakinibs%3A+a+new+class+of+kinase+inhibitors+in+cancer+and+autoimmune+disease&doi=10.1016%2Fj.coph.2012.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease</span></div><div class="casAuthors">Kontzias, Apostolos; Kotlyar, Alexander; Laurence, Arian; Changelian, Paul; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">464-470</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines are crit. for normal cell growth and immunoregulation but also contribute to growth of malignant cells and drive immune-mediated disease.  A large subset of immunoregulatory cytokines uses the type I and type II cytokine receptors and pharmacol. targeting of these cytokines/cytokines receptors has proven to be efficacious in treating immune and inflammatory diseases.  These receptors rely on Janus family of kinases (Jaks) for signal transduction.  Recently the first Jak inhibitor (jakinib) has been approved by the FDA and a second has been recommended for approval.  Many other Jakinibs are likely to follow and in this brief review, we will discuss the state-of-the art of this new class of pharmacol. agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmJV4I6HPAx7Vg90H21EOLACvtfcHk0lgK0B_hkbDCSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVymsLbE&md5=22bcfa4414642f3d72214c4d4be84e2c</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2012.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2012.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DKontzias%26aufirst%3DA.%26aulast%3DKotlyar%26aufirst%3DA.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DChangelian%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJakinibs%253A%2520a%2520new%2520class%2520of%2520kinase%2520inhibitors%2520in%2520cancer%2520and%2520autoimmune%2520disease%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2012%26volume%3D12%26spage%3D464%26epage%3D470%26doi%3D10.1016%2Fj.coph.2012.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishore, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of Janus kinases</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>223</i></span>,  <span class="NLM_fpage">132</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00644.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1111%2Fj.1600-065X.2008.00644.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=18613833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2008&pages=132-142&author=M.+Pesuauthor=A.+Laurenceauthor=N.+Kishoreauthor=S.+H.+Zwillichauthor=G.+Chanauthor=J.+J.+O%E2%80%99Shea&title=Therapeutic+targeting+of+Janus+kinases&doi=10.1111%2Fj.1600-065X.2008.00644.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of Janus kinases</span></div><div class="casAuthors">Pesu, Marko; Laurence, Arian; Kishore, Nandini; Zwillich, Samuel H.; Chan, Gary; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">223</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132-142</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines play pivotal roles in immunity and inflammation, and targeting cytokines and their receptors is an effective means of treating such disorders.  Type I and II cytokine receptors assoc. with Janus family kinases (JAKs) to effect intracellular signaling.  These structurally unique protein kinases play essential and specific roles in immune cell development and function.  One JAK, JAK3, has particularly selective functions.  Mutations of this kinase underlie severe combined immunodeficiency, indicative of its crit. role in the development and function of lymphocytes.  Because JAK3 appears not to have functions outside of hematopoietic cells, this kinase has been viewed as an excellent therapeutic target for the development of a new class of immunosuppressive drugs.  In fact, several companies are developing JAK3 inhibitors, and Phase II studies are underway.  Mutations of Tyk2 cause autosomal recessive hyperIgE syndrome, and in principle, Tyk2 inhibitors might also be useful as immunosuppressive drugs.  JAK2 gain-of-function mutations (V617F) underlie a subset of disorders collectively referred to as myeloproliferative diseases and phase 2 trials using JAK inhibitors are underway in this setting.  Thus, we are learning a great deal about the feasibility and effectiveness of targeting Janus kinases, and it appears likely that this will be a fruitful strategy in a variety of settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-VTmlwlhcv7Vg90H21EOLACvtfcHk0lgK0B_hkbDCSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D&md5=73dc15932d0eaa312bc2588bdbce404c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00644.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00644.x%26sid%3Dliteratum%253Aachs%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DTherapeutic%2520targeting%2520of%2520Janus%2520kinases%26jtitle%3DImmunol.%2520Rev.%26date%3D2008%26volume%3D223%26spage%3D132%26epage%3D142%26doi%3D10.1111%2Fj.1600-065X.2008.00644.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J.</span></span> <span> </span><span class="NLM_article-title">JAK kinases in health and disease: an update</span>. <i>Open Rheumatol. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.2174/1874312901206010232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.2174%2F1874312901206010232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=23028408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=232-244&author=A.+Laurenceauthor=M.+Pesuauthor=O.+Silvennoinenauthor=J.+O%E2%80%99Shea&title=JAK+kinases+in+health+and+disease%3A+an+update&doi=10.2174%2F1874312901206010232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">JAK kinases in health and disease: an update</span></div><div class="casAuthors">Laurence, Arian; Pesu, Marko; Silvennoinen, Olli; O'Shea, John</div><div class="citationInfo"><span class="NLM_cas:title">Open Rheumatology Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">232-244</span>CODEN:
                <span class="NLM_cas:coden">ORJPAP</span>;
        ISSN:<span class="NLM_cas:issn">1874-3129</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are crit. signaling elements for a large subset of cytokines.  As a consequence they play pivotal roles in the pathophysiol. of many diseases including neoplastic and autoimmune diseases.  Small mol. JAK inhibitors as therapeutic agents have become a reality and the palette of such inhibitors will likely expand.  This review will summarize our current knowledge on these key enzymes and their assocd. pharmaceutical inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjovQnlyAQvrVg90H21EOLACvtfcHk0lghvgwS8-OQwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO&md5=ed5d20df39001bb27ca8556cae82c289</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.2174%2F1874312901206010232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874312901206010232%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26atitle%3DJAK%2520kinases%2520in%2520health%2520and%2520disease%253A%2520an%2520update%26jtitle%3DOpen%2520Rheumatol.%2520J.%26date%3D2012%26volume%3D6%26spage%3D232%26epage%3D244%26doi%3D10.2174%2F1874312901206010232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span> <span> </span><span class="NLM_article-title">The JAK-STAT pathway: impact on human disease and therapeutic intervention</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-051113-024537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1146%2Fannurev-med-051113-024537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=25587654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFyhsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2015&pages=311-328&author=J.+J.+O%E2%80%99Sheaauthor=D.+M.+Schwartzauthor=A.+V.+Villarinoauthor=M.+Gadinaauthor=I.+B.+McInnesauthor=A.+Laurence&title=The+JAK-STAT+pathway%3A+impact+on+human+disease+and+therapeutic+intervention&doi=10.1146%2Fannurev-med-051113-024537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">The JAK-STAT pathway: impact on human disease and therapeutic intervention</span></div><div class="casAuthors">O'Shea, John J.; Schwartz, Daniella M.; Villarino, Alejandro V.; Gadina, Massimo; McInnes, Iain B.; Laurence, Arian</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">311-328</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)-signal transducer of activators of transcription (STAT) pathway is now recognized as an evolutionarily conserved signaling pathway employed by diverse cytokines, interferons, growth factors, and related mols.  This pathway provides an elegant and remarkably straightforward mechanism whereby extracellular factors control gene expression.  It thus serves as a fundamental paradigm for how cells sense environmental cues and interpret these signals to regulate cell growth and differentiation.  Genetic mutations and polymorphisms are functionally relevant to a variety of human diseases, esp. cancer and immune-related conditions.  The clin. relevance of the pathway has been confirmed by the emergence of a new class of therapeutics that targets JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMxvQCRiTbL7Vg90H21EOLACvtfcHk0lghvgwS8-OQwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFyhsLY%253D&md5=19182154f1a046df039eb4a37b66bf78</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-051113-024537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-051113-024537%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DVillarino%26aufirst%3DA.%2BV.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DLaurence%26aufirst%3DA.%26atitle%3DThe%2520JAK-STAT%2520pathway%253A%2520impact%2520on%2520human%2520disease%2520and%2520therapeutic%2520intervention%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2015%26volume%3D66%26spage%3D311%26epage%3D328%26doi%3D10.1146%2Fannurev-med-051113-024537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span> <span> </span><span class="NLM_article-title">The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders</span>. <i>BioDrugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1007/s40259-013-0040-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1007%2Fs40259-013-0040-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=23743669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=431-438&author=Y.+Furumotoauthor=M.+Gadina&title=The+arrival+of+JAK+inhibitors%3A+advancing+the+treatment+of+immune+and+hematologic+disorders&doi=10.1007%2Fs40259-013-0040-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders</span></div><div class="casAuthors">Furumoto, Yasuko; Gadina, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">431-438</span>CODEN:
                <span class="NLM_cas:coden">BIDRF4</span>;
        ISSN:<span class="NLM_cas:issn">1173-8804</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Altered prodn. of cytokines can result in pathologies ranging from autoimmune diseases to malignancies.  The Janus kinase family is a small group of receptor-assocd. signaling mols. that is essential to the signal cascade originating from type I and type II cytokine receptors.  Inhibition of tyrosine kinase enzymic activity using small mols. has recently become a powerful tool for treatment of several malignancies.  Twenty years after the discovery of these enzymes, two inhibitors for this class of kinases have been approved for clin. use and others are currently in the final stage of development.  Here we review the principles of cytokines signaling, summarize our current knowledge of the approved inhibitors, and briefly introduce some of the inhibitors that are currently under development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQNQJyHX0EDLVg90H21EOLACvtfcHk0lghvgwS8-OQwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsbzI&md5=a593c1f01565b3dc3bf3df8c424595a6</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1007%2Fs40259-013-0040-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-013-0040-7%26sid%3Dliteratum%253Aachs%26aulast%3DFurumoto%26aufirst%3DY.%26aulast%3DGadina%26aufirst%3DM.%26atitle%3DThe%2520arrival%2520of%2520JAK%2520inhibitors%253A%2520advancing%2520the%2520treatment%2520of%2520immune%2520and%2520hematologic%2520disorders%26jtitle%3DBioDrugs%26date%3D2013%26volume%3D27%26spage%3D431%26epage%3D438%26doi%3D10.1007%2Fs40259-013-0040-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreschi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Janus kinases in immune cell signaling</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+in+immune+cell+signaling&doi=10.1111%2Fj.1600-065X.2008.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0lghvgwS8-OQwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520in%2520immune%2520cell%2520signaling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287%26doi%3D10.1111%2Fj.1600-065X.2008.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span> <span> </span><span class="NLM_article-title">Back to the future: oral targeted therapy for RA and other autoimmune diseases</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2013.7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnrrheum.2013.7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=23419429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A280%3ADC%252BC3szpsFGiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=173-182&author=J.+J.+O%E2%80%99Sheaauthor=A.+Laurenceauthor=I.+B.+McInnes&title=Back+to+the+future%3A+oral+targeted+therapy+for+RA+and+other+autoimmune+diseases&doi=10.1038%2Fnrrheum.2013.7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Back to the future: oral targeted therapy for RA and other autoimmune diseases</span></div><div class="casAuthors">O'Shea John J; Laurence Arian; McInnes Iain B</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Rheumatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The molecular biology revolution coupled with the development of monoclonal antibody technology enabled remarkable progress in rheumatology therapy, comprising an array of highly effective biologic agents.  With advances in understanding of the molecular nature of immune cell receptors came elucidation of intracellular signalling pathways downstream of these receptors.  These discoveries raise the question of whether selective targeting of key intracellular factors with small molecules would add to the rheumatologic armamentarium.  In this Review, we discuss several examples of this therapeutic strategy that seem to be successful, and consider their implications for the future of immune-targeted treatments.  We focus on kinase inhibitors, primarily those targeting Janus kinase family members and spleen tyrosine kinase, given their advanced status in clinical development and application.  We also summarize other targets involved in signalling pathways that might offer promise for therapeutic intervention in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmTYwNff3DeTjk2McQZ6XmfW6udTcc2eYYBqkJZ-LPJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szpsFGiug%253D%253D&md5=92218e154d717c374bbe42e1f0a0f34f</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2013.7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2013.7%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26atitle%3DBack%2520to%2520the%2520future%253A%2520oral%2520targeted%2520therapy%2520for%2520RA%2520and%2520other%2520autoimmune%2520diseases%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2013%26volume%3D9%26spage%3D173%26epage%3D182%26doi%3D10.1038%2Fnrrheum.2013.7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasothan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1038/nrd3652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnrd3652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22293561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Crtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=103-104&author=R.+A.+Mesaauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Ruxolitinib&doi=10.1038%2Fnrd3652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib</span></div><div class="casAuthors">Mesa, Ruben A.; Yasothan, Uma; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-104</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In Nov. 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-mol. inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf2yAGCsbIA7Vg90H21EOLACvtfcHk0lg67KnrgDb_zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Crtbs%253D&md5=5bcfbd15f4478268330ffc4c8855762d</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fnrd3652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3652%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DRuxolitinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D103%26epage%3D104%26doi%3D10.1038%2Fnrd3652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andreoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffoux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zini, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousselot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Socie, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parquet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraudier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chomienne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassinat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J. J.</span></span> <span> </span><span class="NLM_article-title">Clinical resistance to ruxolitinib is more frequent in patients without MPN-associated mutations and is rarely due to mutations in the JAK2 kinase drug-binding domain</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">1591</span>– <span class="NLM_lpage">1591</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1182%2Fblood.V122.21.1591.1591" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=1591-1591&author=A.+Andreoliauthor=E.+Vergerauthor=M.+Robinauthor=E.+Raffouxauthor=J.+M.+Ziniauthor=P.+Rousselotauthor=G.+Socieauthor=D.+Reaauthor=N.+Parquetauthor=S.+Giraudierauthor=C.+Chomienneauthor=B.+Cassinatauthor=J.+J.+Kiladjian&title=Clinical+resistance+to+ruxolitinib+is+more+frequent+in+patients+without+MPN-associated+mutations+and+is+rarely+due+to+mutations+in+the+JAK2+kinase+drug-binding+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1182%2Fblood.V122.21.1591.1591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V122.21.1591.1591%26sid%3Dliteratum%253Aachs%26aulast%3DAndreoli%26aufirst%3DA.%26aulast%3DVerger%26aufirst%3DE.%26aulast%3DRobin%26aufirst%3DM.%26aulast%3DRaffoux%26aufirst%3DE.%26aulast%3DZini%26aufirst%3DJ.%2BM.%26aulast%3DRousselot%26aufirst%3DP.%26aulast%3DSocie%26aufirst%3DG.%26aulast%3DRea%26aufirst%3DD.%26aulast%3DParquet%26aufirst%3DN.%26aulast%3DGiraudier%26aufirst%3DS.%26aulast%3DChomienne%26aufirst%3DC.%26aulast%3DCassinat%26aufirst%3DB.%26aulast%3DKiladjian%26aufirst%3DJ.%2BJ.%26atitle%3DClinical%2520resistance%2520to%2520ruxolitinib%2520is%2520more%2520frequent%2520in%2520patients%2520without%2520MPN-associated%2520mutations%2520and%2520is%2520rarely%2520due%2520to%2520mutations%2520in%2520the%2520JAK2%2520kinase%2520drug-binding%2520domain%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D1591%26epage%3D1591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span> <i>FDA Approves Xeljanz for Rheumatoid Arthritis</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, <span class="NLM_year">2012</span>; <a href="https://www.drugs.com/newdrugs/fda-approves-xeljanz-rheumatoid-arthritis-3558.html" class="extLink">https://www.drugs.com/newdrugs/fda-approves-xeljanz-rheumatoid-arthritis-3558.html</a> (accessed Jan 12, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+Xeljanz+for+Rheumatoid+Arthritis%3B+U.S.+Food+and+Drug+Administration%2C+2012%3B+https%3A%2F%2Fwww.drugs.com%2Fnewdrugs%2Ffda-approves-xeljanz-rheumatoid-arthritis-3558.html+%28accessed+Jan+12%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520Xeljanz%2520for%2520Rheumatoid%2520Arthritis%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.+B.+Telliez&title=Discovery+and+development+of+Janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0lj2fkyvmUDziw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520and%2520development%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">Advances in the inhibitors of Janus kinase</span>. <i>Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.4172/2161-0444.1000192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.4172%2F2161-0444.1000192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFGnsbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=540-548&author=J.+J.+J.+Jiangauthor=X.+Y.+Wangauthor=Y.+Zhangauthor=Y.+Jinauthor=J.+Lin&title=Advances+in+the+inhibitors+of+Janus+kinase&doi=10.4172%2F2161-0444.1000192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the inhibitors of janus kinase</span></div><div class="casAuthors">Jiang, Jun-Jie J.; Wang, Xiao-Ying; Zhang, Yv; Jin, Yi; Lin, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry (Los Angeles, CA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">540-548, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCLACZ</span>;
        ISSN:<span class="NLM_cas:issn">2161-0444</span>.
    
            (<span class="NLM_cas:orgname">OMICS Publishing Group</span>)
        </div><div class="casAbstract">A review.  The janus kinases (JAKs) comprise an important class of non-receptor protein tyrosine kinases.  Cytokine and receptor binding can cause the activation of JAKs, and then activate the "signal transcripts and transcriptional activator", making JAK enter the nucleus to induce target gene expression.  JAKs regulate inflammatory diseases, bone marrow hyperplasia and a variety of malignant tumors.  Using JAKs inhibitors as the therapy for organ transplantation and immune disease has a very important significance.  In recent years, many of the JAKs inhibitors have been developed one after another.  Pan JAKs inhibitor and selective JAK2 or JAK3 inhibitor research progress are reviewed in this article.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfLi3ltgXL2bVg90H21EOLACvtfcHk0lj2fkyvmUDziw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFGnsbjO&md5=4021b66d93e661604eeb0d2c33149eaa</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.4172%2F2161-0444.1000192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2161-0444.1000192%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.%2BJ.%2BJ.%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DAdvances%2520in%2520the%2520inhibitors%2520of%2520Janus%2520kinase%26jtitle%3DMed.%2520Chem.%26date%3D2014%26volume%3D4%26spage%3D540%26epage%3D548%26doi%3D10.4172%2F2161-0444.1000192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreschi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deflorian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leister, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span> <span> </span><span class="NLM_article-title">Examining the chirality, conformation and selective kinase inhibition of 3-((3<i>R</i>,4<i>R</i>)-4-methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-y l)-3-oxopropanenitrile (CP-690,550)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">8012</span>– <span class="NLM_lpage">8018</span>, <span class="refDoi"> DOI: 10.1021/jm801142b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801142b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWksr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=8012-8018&author=J.+K.+Jiangauthor=K.+Ghoreschiauthor=F.+Deflorianauthor=Z.+Chenauthor=M.+Perreiraauthor=M.+Pesuauthor=J.+Smithauthor=D.+T.+Nguyenauthor=E.+H.+Liuauthor=W.+Leisterauthor=S.+Costanziauthor=J.+J.+O%E2%80%99Sheaauthor=C.+J.+Thomas&title=Examining+the+chirality%2C+conformation+and+selective+kinase+inhibition+of+3-%28%283R%2C4R%29-4-methyl-3-%28methyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%29piperidin-1-y+l%29-3-oxopropanenitrile+%28CP-690%2C550%29&doi=10.1021%2Fjm801142b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)</span></div><div class="casAuthors">Jiang, Jian-kang; Ghoreschi, Kamran; Deflorian, Francesca; Chen, Zhi; Perreira, Melissa; Pesu, Marko; Smith, Jeremy; Nguyen, Dac-Trung; Liu, Eric H.; Leister, William; Costanzi, Stefano; O'Shea, John J.; Thomas, Craig J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8012-8018</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here, we examine the significance that stereochem. plays within the clin. relevant Janus kinase 3 (Jak3) inhibitor I (CP-690,550).  A synthesis of all four enantiopure stereoisomers of the drug was carried out and an examn. of each compd. revealed that only the enantiopure 3R,4R isomer was capable of blocking Stat5 phosphorylation (Jak3 dependent).  Each compd. was profiled across a panel of over 350 kinases, which revealed a high level of selectivity for the Jak family kinases for these related compds.  Each stereoisomer retained a degree of binding to Jak3 and Jak2 and the 3R,4S and 3S,4R stereoisomers were further revealed to have binding affinity for selected members of the STE7 and STE20 subfamily of kinases.  Finally, an appraisal of the min. energy conformation of each stereoisomer and mol. docking at Jak3 was performed in an effort to better understand each compds. selectivity and potency profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFxbAHrNE0dLVg90H21EOLACvtfcHk0lj2fkyvmUDziw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWksr%252FN&md5=d9b491af79d29b2da94c9200704d546c</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fjm801142b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801142b%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DDeflorian%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DPerreira%26aufirst%3DM.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DD.%2BT.%26aulast%3DLiu%26aufirst%3DE.%2BH.%26aulast%3DLeister%26aufirst%3DW.%26aulast%3DCostanzi%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26atitle%3DExamining%2520the%2520chirality%252C%2520conformation%2520and%2520selective%2520kinase%2520inhibition%2520of%25203-%2528%25283R%252C4R%2529-4-methyl-3-%2528methyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%2529piperidin-1-y%2520l%2529-3-oxopropanenitrile%2520%2528CP-690%252C550%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D8012%26epage%3D8018%26doi%3D10.1021%2Fjm801142b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">996</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-02-0707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1182%2Fblood-2005-02-0707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=15831699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVSmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=996-1002&author=T.+J.+Boggonauthor=Y.+Liauthor=P.+W.+Manleyauthor=M.+J.+Eck&title=Crystal+structure+of+the+Jak3+kinase+domain+in+complex+with+a+staurosporine+analog&doi=10.1182%2Fblood-2005-02-0707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog</span></div><div class="casAuthors">Boggon, Titus J.; Li, Yiqun; Manley, Paul W.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">996-1002</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Jak (Janus kinase) family nonreceptor tyrosine kinases are central mediators of cytokine signaling.  The Jak kinases exhibit distinct cytokine receptor assocn. profiles and so transduce different signals.  Jak3 expression is limited to the immune system, where it plays a key role in signal transduction from cytokine receptors contg. the common gamma chain, γc.  Patients unable to signal via γc present with severe combined immunodeficiency (SCID).  The finding that Jak3 mutations result in SCID has made it a target for development of lymphocyte-specific immunosuppressants.  Here, we present the crystal structure of the Jak3 kinase domain in complex with staurosporine analog AFN941.  The kinase domain is in the active conformation, with both activation loop tyrosine residues phosphorylated.  The phosphate group on pTyr981 in the activation loop is in part coordinated by an arginine residue in the regulatory C-helix, suggesting a direct mechanism by which the active position of the C-helix is induced by phosphorylation of the activation loop.  Such a direct coupling has not been previously obsd. in tyrosine kinases and may be unique to Jak kinases.  The crystal structure provides a detailed view of the Jak3 active site and will facilitate computational and structure-directed approaches to development of Jak3-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ-bnI3-sVjLVg90H21EOLACvtfcHk0lgY3dML3YQV1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVSmsr4%253D&md5=12f87a37a495559c6e34dde019578371</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-02-0707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-02-0707%26sid%3Dliteratum%253Aachs%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520Jak3%2520kinase%2520domain%2520in%2520complex%2520with%2520a%2520staurosporine%2520analog%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D996%26epage%3D1002%26doi%3D10.1182%2Fblood-2005-02-0707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liongue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, A. C.</span></span> <span> </span><span class="NLM_article-title">Cytokine receptor signaling through the JAK-STAT-SOCS pathway in disease</span>. <i>Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2506</span>, <span class="refDoi"> DOI: 10.1016/j.molimm.2006.11.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.molimm.2006.11.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=17208301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVSmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2007&pages=2497-2506&author=L.+A.+O%E2%80%99Sullivanauthor=C.+Liongueauthor=R.+S.+Lewisauthor=S.+E.+Stephensonauthor=A.+C.+Ward&title=Cytokine+receptor+signaling+through+the+JAK-STAT-SOCS+pathway+in+disease&doi=10.1016%2Fj.molimm.2006.11.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease</span></div><div class="casAuthors">O'Sullivan, Lynda A.; Liongue, Clifford; Lewis, Rowena S.; Stephenson, Sarah E. M.; Ward, Alister C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2497-2506</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The complexity of multicellular organisms is dependent on systems enabling cells to respond to specific stimuli.  Cytokines and their receptors are one such system, whose perturbation can lead to a variety of disease states.  This review represents an overview of our current understanding of the cytokine receptors, Janus kinases (Jaks), Signal transducers and activators of transcription (Stats) and Suppressors of cytokine signaling (Socs), focusing on their contribution to diseases of an immune or hematol. nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRJCsJ5di3XbVg90H21EOLACvtfcHk0lgY3dML3YQV1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVSmur8%253D&md5=0011026cc2b9be7e0d7cdb854aab300a</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2006.11.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2006.11.025%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DL.%2BA.%26aulast%3DLiongue%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DR.%2BS.%26aulast%3DStephenson%26aufirst%3DS.%2BE.%26aulast%3DWard%26aufirst%3DA.%2BC.%26atitle%3DCytokine%2520receptor%2520signaling%2520through%2520the%2520JAK-STAT-SOCS%2520pathway%2520in%2520disease%26jtitle%3DMol.%2520Immunol.%26date%3D2007%26volume%3D44%26spage%3D2497%26epage%3D2506%26doi%3D10.1016%2Fj.molimm.2006.11.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rane, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">Hematopoietic cytokine receptor signaling</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">6724</span>– <span class="NLM_lpage">6737</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fsj.onc.1210757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=17934481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKhsLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=6724-6737&author=S.+J.+Bakerauthor=S.+G.+Raneauthor=E.+P.+Reddy&title=Hematopoietic+cytokine+receptor+signaling&doi=10.1038%2Fsj.onc.1210757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Hematopoietic cytokine receptor signaling</span></div><div class="casAuthors">Baker, S. J.; Rane, S. G.; Reddy, E. P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">6724-6737</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Hematopoiesis is the cumulative result of intricately regulated signaling pathways that are mediated by cytokines and their receptors.  Proper culmination of these diverse pathways forms the basis for an orderly generation of different cell types.  Recent studies conducted over the past 10-15 years have revealed that hematopoietic cytokine receptor signaling is largely mediated by a family of tyrosine kinases termed Janus kinases (JAKs) and their downstream transcription factors termed STATs (signal transducers and activators of transcription).  Aberration in these pathways, such as that caused by the recently identified JAK2V617F mutation, is an underlying cause for diseases such as leukemias and other myeloproliferative disorders.  This recent discovery, when coupled with the fact that STATs are activated by oncoproteins such as BCR-ABL, underscores the importance of the JAK-STAT pathway in both normal cellular development and disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCBFLj3Gs4BrVg90H21EOLACvtfcHk0lgY3dML3YQV1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKhsLbN&md5=b003dc7def939f23f5acb98fb79d39de</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210757%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DRane%26aufirst%3DS.%2BG.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DHematopoietic%2520cytokine%2520receptor%2520signaling%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D6724%26epage%3D6737%26doi%3D10.1038%2Fsj.onc.1210757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span> <span> </span><span class="NLM_article-title">A dual inhibition, a better solution: development of a JAK1/TYK2 inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8594</span>– <span class="NLM_lpage">8596</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01397</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01397" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOgtrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8594-8596&author=C.+J.+Menet&title=A+dual+inhibition%2C+a+better+solution%3A+development+of+a+JAK1%2FTYK2+inhibitor&doi=10.1021%2Facs.jmedchem.8b01397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">A Dual Inhibition, a Better Solution: Development of a JAK1/TYK2 inhibitor</span></div><div class="casAuthors">Menet, Christel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8594-8596</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over the past 2 decades, there has been a rapid development of novel therapies for the treatment of autoimmune diseases, with an impressive success in biologics.  Inhibiting different cytokine pathways can tackle different conditions and has proven to have great efficacy.  However, despite these therapeutic developments, immunogenicity will continue to be a downside of therapeutic antibodies, on top of the fact that currently they are only given via parenteral administration.  This article provides an overview of the development of a series of dual JAK1/TYK2 inhibitors from hit to the selection of PF-06700841 (6) as a clin. candidate.  6 Is currently in development for the potential treatment of inflammatory diseases, including inflammatory bowel disease (IBD), alopecia areata, and psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMuUawEe36h7Vg90H21EOLACvtfcHk0lgY3dML3YQV1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOgtrfJ&md5=b526f8855ea539ac0ff76359f5379419</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01397%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26atitle%3DA%2520dual%2520inhibition%252C%2520a%2520better%2520solution%253A%2520development%2520of%2520a%2520JAK1%252FTYK2%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8594%26epage%3D8596%26doi%3D10.1021%2Facs.jmedchem.8b01397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((<i>S</i>)-2,2-difluorocyclopropyl)((1<i>R</i>,5<i>S</i>)-3-(2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8597</span>– <span class="NLM_lpage">8612</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8597-8612&author=A.+Fensomeauthor=C.+M.+Amblerauthor=E.+Arnoldauthor=M.+E.+Bankerauthor=M.+F.+Brownauthor=J.+Chrencikauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=I.+V.+Efremovauthor=A.+Flickauthor=B.+S.+Gerstenbergerauthor=A.+Gopalsamyauthor=M.+M.+Haywardauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+Jussifauthor=J.+D.+Knafelsauthor=D.+C.+Limburgauthor=D.+Linauthor=T.+H.+Linauthor=B.+S.+Pierceauthor=E.+Saiahauthor=R.+Sharmaauthor=P.+T.+Symanowiczauthor=J.+B.+Telliezauthor=J.+I.+Trujilloauthor=F.+F.+Vajdosauthor=F.+Vincentauthor=Z.+K.+Wanauthor=L.+Xingauthor=X.+Yangauthor=X.+Yangauthor=L.+Zhang&title=Dual+inhibition+of+TYK2+and+JAK1+for+the+treatment+of+autoimmune+diseases%3A+discovery+of+%28%28S%29-2%2C2-difluorocyclopropyl%29%28%281R%2C5S%29-3-%282-%28%281-methyl-1H-pyrazol-4-yl%29amino%29pyrimidin-4-yl%29-3%2C8-diazabicyclo%5B3.2.1%5Doctan-8-yl%29methanone+%28PF-06700841%29&doi=10.1021%2Facs.jmedchem.8b00917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span></div><div class="casAuthors">Fensome, Andrew; Ambler, Catherine M.; Arnold, Eric; Banker, Mary Ellen; Brown, Matthew F.; Chrencik, Jill; Clark, James D.; Dowty, Martin E.; Efremov, Ivan V.; Flick, Andrew; Gerstenberger, Brian S.; Gopalsamy, Ariamala; Hayward, Matthew M.; Hegen, Martin; Hollingshead, Brett D.; Jussif, Jason; Knafels, John D.; Limburg, David C.; Lin, David; Lin, Tsung H.; Pierce, Betsy S.; Saiah, Eddine; Sharma, Raman; Symanowicz, Peter T.; Telliez, Jean-Baptiste; Trujillo, John I.; Vajdos, Felix F.; Vincent, Fabien; Wan, Zhao-Kui; Xing, Li; Yang, Xiaojing; Yang, Xin; Zhang, Liying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8597-8612</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytokine signaling is an important characteristic of autoimmune diseases.  Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway.  JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6 and type-I interferon (IFN) family, while TYK2 in addn. to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling.  Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease and rheumatoid arthritis studies, leading to multiple drug approvals.  It is hypothesized that a dual JAK1/TYK2 inhibitor will provide addnl. efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes.  Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compd. 23), which is in Phase II clin. development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNhVkNWDMq7Vg90H21EOLACvtfcHk0lhhSMS3LkxJEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI&md5=c321512f524560cba445d070b9639e55</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00917%26sid%3Dliteratum%253Aachs%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChrencik%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DFlick%26aufirst%3DA.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DZ.%2BK.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDual%2520inhibition%2520of%2520TYK2%2520and%2520JAK1%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%253A%2520discovery%2520of%2520%2528%2528S%2529-2%252C2-difluorocyclopropyl%2529%2528%25281R%252C5S%2529-3-%25282-%2528%25281-methyl-1H-pyrazol-4-yl%2529amino%2529pyrimidin-4-yl%2529-3%252C8-diazabicyclo%255B3.2.1%255Doctan-8-yl%2529methanone%2520%2528PF-06700841%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8597%26epage%3D8612%26doi%3D10.1021%2Facs.jmedchem.8b00917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backesjo, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faryal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aints, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglof, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vihinen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nore, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase (BTK): function, regulation, and transformation with special emphasis on the PH domain</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00741.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1111%2Fj.1600-065X.2008.00741.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=19290921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=58-73&author=A.+J.+Mohamedauthor=L.+Yuauthor=C.+M.+Backesjoauthor=L.+Vargasauthor=R.+Faryalauthor=A.+Aintsauthor=B.+Christenssonauthor=A.+Berglofauthor=M.+Vihinenauthor=B.+F.+Noreauthor=C.+I.+E.+Smith&title=Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29%3A+function%2C+regulation%2C+and+transformation+with+special+emphasis+on+the+PH+domain&doi=10.1111%2Fj.1600-065X.2008.00741.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span></div><div class="casAuthors">Mohamed, Abdalla J.; Yu, Liang; Backesjo, Carl-Magnus; Vargas, Leonardo; Faryal, Rani; Aints, Alar; Christensson, Birger; Berglof, Anna; Vihinen, Mauno; Nore, Beston F.; Smith, C. I. Edvard</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-73</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Bruton's agammaglobulinemia tyrosine kinase (Btk) is a cytoplasmic tyrosine kinase important in B-lymphocyte development, differentiation, and signaling.  Btk is a member of the Tec family of kinases.  Mutations in the Elk gene lead to X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (Xid) in mice.  Activation of Btk triggers a cascade of signaling events that culminates in the generation of calcium mobilization and fluxes, cytoskeletal rearrangements, and transcriptional regulation involving nuclear factor-κB (NF-κB) and nuclear factor of activated T cells (NFAT).  In B cells, NF-κB was shown to bind to the Btk promoter and induce transcription, whereas the B-cell receptor-dependent NF-κB signaling pathway requires functional Btk.  Moreover, Btk activation is tightly regulated by a plethora of other signaling proteins including protein kinase C (PKC), Sab/SH3BP5, and caveolin-1.  For example, the prolyl isomerase Pin1 neg. regulates Btk by decreasing tyrosine phosphorylation and steady state levels of Btk.  It is intriguing that PKC and Pin1, both of which are neg. regulators, bind to the pleckstrin homol. domain of Btk.  To this end, we describe here novel mutations in the pleckstrin homol. domain investigated for their transforming capacity.  In particular, we show that the mutant D43R behaves similar to E41K, already known to possess such activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo1L-Ch4HjNLVg90H21EOLACvtfcHk0lhhSMS3LkxJEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO&md5=7a84f2b3604d67bcc1490fadcbfea234</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00741.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00741.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DBackesjo%26aufirst%3DC.%2BM.%26aulast%3DVargas%26aufirst%3DL.%26aulast%3DFaryal%26aufirst%3DR.%26aulast%3DAints%26aufirst%3DA.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DBerglof%26aufirst%3DA.%26aulast%3DVihinen%26aufirst%3DM.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%253A%2520function%252C%2520regulation%252C%2520and%2520transformation%2520with%2520special%2520emphasis%2520on%2520the%2520PH%2520domain%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D58%26epage%3D73%26doi%3D10.1111%2Fj.1600-065X.2008.00741.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nore, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span> <span> </span><span class="NLM_article-title">Signalling of bruton’s tyrosine kinase, BTK</span>. <i>Scand. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1046/j.1365-3083.1999.00504.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1046%2Fj.1365-3083.1999.00504.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10075013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK1MXhslSisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1999&pages=113-118&author=A.+J.+Mohamedauthor=B.+F.+Noreauthor=B.+Christenssonauthor=C.+I.+E.+Smith&title=Signalling+of+bruton%E2%80%99s+tyrosine+kinase%2C+BTK&doi=10.1046%2Fj.1365-3083.1999.00504.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling of Bruton's tyrosine kinase, Btk</span></div><div class="casAuthors">Mohamed, A. J.; Nore, B. F.; Christensson, B.; Smith, C. I. E.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-118</span>CODEN:
                <span class="NLM_cas:coden">SJIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0300-9475</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">A review with 63 refs.  Bruton's tyrosine kinase, which is encoded by the BTK gene, is a cytoplasmic protein tyrosine kinase (PTK) crucial for B-cell development and differentiation.  It belongs to the Tec family of PTKs contg. several domains that are characteristic of signalling mols.  In humans, mutations that disrupt the function of this gene lead to the classical XLA syndrome (X-linked agammaglobulinemia), a primary immunodeficiency mainly characterized by lack of mature B cells as well as low levels of Igs.  In contrast, animal models of this disease such as the xid mice display profoundly milder XLA phenotype.  BTK phosphorylation and activation in response to engagement of the B-cell receptor (BCR) by antigen is a dynamic process whereby a variety of proteins interact with each other and recruit signalling mols. resulting in a physiol. response such as B-cell proliferation and antibody prodn.  The main players, however, that participate in the intracellular downstream cascade have not yet been identified and are therefore under intense scrutiny in several labs.  This review discusses certain aspects of BTK activation following receptor stimulation by agonists and how this event is translated into the biochem. signals within the cell that eventually lead to nuclear responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphmZBDkpS1ubVg90H21EOLACvtfcHk0lhhSMS3LkxJEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslSisr0%253D&md5=a3842c00d3cd4e45458c050941026476</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-3083.1999.00504.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-3083.1999.00504.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DSignalling%2520of%2520bruton%25E2%2580%2599s%2520tyrosine%2520kinase%252C%2520BTK%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D1999%26volume%3D49%26spage%3D113%26epage%3D118%26doi%3D10.1046%2Fj.1365-3083.1999.00504.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takata, M.</span></span> <span> </span><span class="NLM_article-title">A role for Bruton’s tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1084/jem.184.1.31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1084%2Fjem.184.1.31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=8691147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1ajs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=1996&pages=31-40&author=M.+Takata&title=A+role+for+Bruton%E2%80%99s+tyrosine+kinase+in+B+cell+antigen+receptor-mediated+activation+of+phospholipase+C-gamma+2&doi=10.1084%2Fjem.184.1.31"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-γ2</span></div><div class="casAuthors">Takata, Minoru; Kurosaki, Tomohiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-40</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Defects in the gene encoding Bruton's tyrosine kinase (Btk) result in a disease called X-linked agammaglobulinemia, in which there is a profound decrease of mature B cells due to a block in B cell development.  Recent studies have shown that Btk is tyrosine phosphorylated and activated upon B cell antigen receptor (BCR) stimulation.  To elucidate the functions of this kinase, we examd. BCR signaling of DT40 B cells deficient in Btk.  Tyrosine phosphorylation of phospholipase C (PLC)-γ2 upon receptor stimulation was significantly reduced in the mutant cells, leading to the loss of both BCR-coupled phosphatidylinositol hydrolysis and calcium mobilization.  Pleckstrin homol. and Src-homol. 2 domains of Btk were required for PLC-γ2 activation.  Since Syk is also required for the BCR-induced PLC-γ2 activation, our findings indicate that PLC-γ2 activation is regulated by Btk and Syk through their concerted actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrvJR6GCfI7rVg90H21EOLACvtfcHk0lhHpsJam4qOBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1ajs74%253D&md5=7244a36ac8298ccde274e05016ec68ba</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1084%2Fjem.184.1.31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.184.1.31%26sid%3Dliteratum%253Aachs%26aulast%3DTakata%26aufirst%3DM.%26atitle%3DA%2520role%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cell%2520antigen%2520receptor-mediated%2520activation%2520of%2520phospholipase%2520C-gamma%25202%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1996%26volume%3D184%26spage%3D31%26epage%3D40%26doi%3D10.1084%2Fjem.184.1.31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton’s tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4265</span>– <span class="NLM_lpage">4269</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2015.07.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=26320619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4265-4269&author=Q.+Liuauthor=D.+G.+Battauthor=J.+S.+Lippyauthor=N.+Surtiauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=L.+Chenauthor=Y.+Anauthor=C.+Changauthor=M.+Pokrossauthor=Z.+Yangauthor=H.+Wangauthor=J.+R.+Burkeauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Design+and+synthesis+of+carbazole+carboxamides+as+promising+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+and+Janus+kinase+2+%28JAK2%29&doi=10.1016%2Fj.bmcl.2015.07.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span></div><div class="casAuthors">Liu, Qingjie; Batt, Douglas G.; Lippy, Jonathan S.; Surti, Neha; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chen, Lin; An, Yongmi; Chang, Chiehying; Pokross, Matt; Yang, Zheng; Wang, Haiqing; Burke, James R.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4265-4269</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Four series of disubstituted carbazole-1-carboxamides, e.g. I [R = 2-F, 3-MeO, 2-Me, etc.] were designed and synthesized as inhibitors of Bruton's tyrosine kinase.  4,7- And 4,6-Disubstituted carbazole-1-carboxamides were potent and selective inhibitors of BTK, while 3,7- and 3,6-disubstituted carbazole-1-carboxamides were potent and selective inhibitors of Janus kinase 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD3SZfBfD4ZbVg90H21EOLACvtfcHk0lhHpsJam4qOBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF&md5=3558c8ca9a9c29bb38ef98936f61200a</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.102%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520carbazole%2520carboxamides%2520as%2520promising%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520and%2520Janus%2520kinase%25202%2520%2528JAK2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4265%26epage%3D4269%26doi%3D10.1016%2Fj.bmcl.2015.07.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Small molecule reversible inhibitors of bruton’s tyrosine kinase (BTK): structure-activity relationships leading to the identification of 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9<i>H</i>-carbazole-1-carboxamide (BMS-935177)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7915</span>– <span class="NLM_lpage">7935</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7915-7935&author=G.+V.+De%0ALuccaauthor=Q.+Shiauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin+Bertrandauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=J.+Daiauthor=M.+Obermeierauthor=R.+Vickeryauthor=Y.+Zhangauthor=Z.+Yangauthor=P.+Maratheauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+J.+Changauthor=H.+Zhangauthor=K.+Gilloolyauthor=T.+Taylorauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=D.+W.+Kukralauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Small+molecule+reversible+inhibitors+of+bruton%E2%80%99s+tyrosine+kinase+%28BTK%29%3A+structure-activity+relationships+leading+to+the+identification+of+7-%282-hydroxypropan-2-yl%29-4-%5B2-methyl-3-%284-oxo-3%2C4-dihydroquinazolin-3-yl%29phenyl%5D-9H-carbazole-1-carboxamide+%28BMS-935177%29&doi=10.1021%2Facs.jmedchem.6b00722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span></div><div class="casAuthors">De Lucca, George V.; Shi, Qing; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Rampulla, Rick; Mathur, Arvind; Discenza, Lorell; D'Arienzo, Celia; Dai, Jun; Obermeier, Mary; Vickery, Rodney; Zhang, Yingru; Yang, Zheng; Marathe, Punit; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chang, ChiehYing J.; Zhang, Huiping; Gillooly, Kathleen; Taylor, Tracy; Pattoli, Mark A.; Skala, Stacey; Kukral, Daniel W.; McIntyre, Kim W.; Salter-Cid, Luisa; Fura, Aberra; Burke, James R.; Barrish, Joel C.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7915-7935</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a crit. role in multiple cell types responsible for numerous autoimmune diseases.  This article will detail the structure-activity relationships (SARs) leading to a novel second generation series of potent and selective reversible carbazole inhibitors of BTK.  With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide 6 (BMS-935177) was selected to advance into clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1HUwZaRn_w7Vg90H21EOLACvtfcHk0lhHpsJam4qOBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M&md5=7c7ec1a52121c541753c045c1cbf758b</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00722%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DObermeier%26aufirst%3DM.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DSmall%2520molecule%2520reversible%2520inhibitors%2520of%2520bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%253A%2520structure-activity%2520relationships%2520leading%2520to%2520the%2520identification%2520of%25207-%25282-hydroxypropan-2-yl%2529-4-%255B2-methyl-3-%25284-oxo-3%252C4-dihydroquinazolin-3-yl%2529phenyl%255D-9H-carbazole-1-carboxamide%2520%2528BMS-935177%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7915%26epage%3D7935%26doi%3D10.1021%2Facs.jmedchem.6b00722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langevine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (BMS-986142): a reversible inhibitor of bruton’s tyrosine kinase (BTK) conformationally constrained by two locked atropisomers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9173-9200&author=S.+H.+Wattersonauthor=G.+V.+De+Luccaauthor=Q.+Shiauthor=C.+M.+Langevineauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin+Bertrandauthor=H.+Gongauthor=J.+Daiauthor=S.+Yipauthor=P.+Liauthor=D.+Sunauthor=D.+R.+Wuauthor=C.+Wangauthor=Y.+Zhangauthor=S.+C.+Traegerauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=L.+N.+Discenzaauthor=C.+J.+D%E2%80%99Arienzoauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=K.+W.+McIntyreauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+6-fluoro-5-%28R%29-%283-%28S%29-%288-fluoro-1-methyl-2%2C4-dioxo-1%2C2-dihydroquinazolin-3%284H%29-yl%29-2-methylphenyl%29-2-%28S%29-%282-hydroxypropan-2-yl%29-2%2C3%2C4%2C9-tetrahydro-1H-carbazole-8-carboxamide+%28BMS-986142%29%3A+a+reversible+inhibitor+of+bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+conformationally+constrained+by+two+locked+atropisomers&doi=10.1021%2Facs.jmedchem.6b01088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers</span></div><div class="casAuthors">Watterson, Scott H.; De Lucca, George V.; Shi, Qing; Langevine, Charles M.; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Gong, Hua; Dai, Jun; Yip, Shiuhang; Li, Peng; Sun, Dawn; Wu, Dauh-Rurng; Wang, Chunlei; Zhang, Yingru; Traeger, Sarah C.; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Vickery, Rodney; Discenza, Lorell N.; D'Arienzo, Celia J.; Zhang, Yifan; Heimrich, Elizabeth; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; McIntyre, Kim W.; Galella, Michael A.; Tebben, Andy J.; Muckelbauer, Jodi K.; Chang, ChiehYing; Rampulla, Richard; Mathur, Arvind; Salter-Cid, Luisa; Barrish, Joel C.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9173-9200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases.  BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling in mast cells and basophils, all of which have been implicated in the pathophysiol. of autoimmune disease.  As a result, inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as lupus and rheumatoid arthritis.  This article details the structure-activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK.  Of particular interest is that two atropisomeric centers were rotationally locked to provide a single, stable atropisomer, resulting in enhanced potency and selectivity as well as a redn. in safety liabilities.  With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy, and a very desirable tolerability and safety profile, 14f (BMS-986142) was advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpBAygRAsYrVg90H21EOLACvtfcHk0linIUCqQb7bHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF&md5=91098abc802521b9ad91563d20ac5893</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DD.%2BR.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DDiscenza%26aufirst%3DL.%2BN.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25206-fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-fluoro-1-methyl-2%252C4-dioxo-1%252C2-dihydroquinazolin-3%25284H%2529-yl%2529-2-methylphenyl%2529-2-%2528S%2529-%25282-hydroxypropan-2-yl%2529-2%252C3%252C4%252C9-tetrahydro-1H-carbazole-8-carboxamide%2520%2528BMS-986142%2529%253A%2520a%2520reversible%2520inhibitor%2520of%2520bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520conformationally%2520constrained%2520by%2520two%2520locked%2520atropisomers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9173%26epage%3D9200%26doi%3D10.1021%2Facs.jmedchem.6b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific BTK inhibition suppresses B cell- and myeloid cell-mediated arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di%0APaoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+BTK+inhibition+suppresses+B+cell-+and+myeloid+cell-mediated+arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0ljB-XWcLoWzdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520BTK%2520inhibition%2520suppresses%2520B%2520cell-%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaluso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowell, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Potent and selective Bruton’s tyrosine kinase inhibitors: discovery of GDC-0834</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1337</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2015.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=25701252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1333-1337&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=S.+Gallionauthor=S.+G.+Hymowitzauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=B.+Maurerauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=C.+G.+Sowellauthor=X.+Wangauthor=H.+Wongauthor=J.+M.+Xiongauthor=J.+Xuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+discovery+of+GDC-0834&doi=10.1016%2Fj.bmcl.2015.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Gallion, Steve; Hymowitz, Sarah G.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Maurer, Brigitte; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Sowell, C. Gregory; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1333-1337</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 resulted in the clin. candidate GDC-0834, which retained the potency and selectivity of CGI-1746, but with much improved PK in preclin. animal models.  Structure based design efforts drove this work as modifications to CGI-1746 were investigated at both the solvent exposed region as well as 'H3 binding pocket'.  However, in vitro metabolic evaluation of GDC-0834 revealed a non CYP-mediated metabolic process that was more prevalent in human than preclin. species (mouse, rat, dog, cyno), leading to a high-level of uncertainly in predicting human pharmacokinetics.  Due to its promising potency, selectivity, and preclin. efficacy, a single dose IND was filed and GDC-0834 was taken in to a single dose phase I trial in healthy volunteers to quickly evaluate the human pharmacokinetics.  In human, GDC-0834 was found to be highly labile at the exo-cyclic amide bond that links the tetrahydrobenzothiophene moiety to the central aniline ring, resulting in insufficient parent drug exposure.  This information informed the back-up program and discovery of improved inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhL04eYDiT3bVg90H21EOLACvtfcHk0ljB-XWcLoWzdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D&md5=fdebc0199c8222e093cfb9583244bce3</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.%2BM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPotent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520discovery%2520of%2520GDC-0834%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1333%26epage%3D1337%26doi%3D10.1016%2Fj.bmcl.2015.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrion, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faccenda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. A.</span></span> <span> </span><span class="NLM_article-title">The concise guide to pharmacology 2017/18: G protein-coupled receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">S17</span>– <span class="NLM_lpage">S129</span>, <span class="refDoi"> DOI: 10.1111/bph.13878</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1111%2Fbph.13878" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=29055040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs12ls7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=S17-S129&author=S.+P.+Alexanderauthor=A.+Christopoulosauthor=A.+P.+Davenportauthor=E.+Kellyauthor=N.+V.+Marrionauthor=J.+A.+Petersauthor=E.+Faccendaauthor=S.+D.+Hardingauthor=A.+J.+Pawsonauthor=J.+L.+Sharmanauthor=C.+Southanauthor=J.+A.+Davies&title=The+concise+guide+to+pharmacology+2017%2F18%3A+G+protein-coupled+receptors&doi=10.1111%2Fbph.13878"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors</span></div><div class="casAuthors">Alexander, Stephen P. H.; Christopoulos, Arthur; Davenport, Anthony P.; Kelly, Eamonn; Marrion, Neil V.; Peters, John A.; Faccenda, Elena; Harding, Simon D.; Pawson, Adam J.; Sharman, Joanna L.; Southan, Christopher; Davies, Jamie A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">S17-S129</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The Concise Guide to PHARMACOl. 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacol. (where available), plus links to an open access knowledgebase of drug targets and their ligands (), which provides more detailed views of target and ligand properties.  Although the Concise Guide represents approx. 400 pages, the material presented is substantially reduced compared to information and links presented on the website.  It provides a permanent, citable, point-in-time record that will survive database updates.  The full contents of this section can be found at .  G protein-coupled receptors are one of the eight major pharmacol. targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters.  These are presented with nomenclature guidance and summary information on the best available pharmacol. tools, alongside key refs. and suggestions for further reading.  The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels.  It is produced in close conjunction with the Nomenclature Committee of the Union of Basic and Clin. Pharmacol. (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrktrD3wjuPZ7Vg90H21EOLACvtfcHk0ljB-XWcLoWzdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs12ls7%252FO&md5=2d4bc1acc92b6aa659365aa70ba50983</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1111%2Fbph.13878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13878%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DS.%2BP.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26aulast%3DKelly%26aufirst%3DE.%26aulast%3DMarrion%26aufirst%3DN.%2BV.%26aulast%3DPeters%26aufirst%3DJ.%2BA.%26aulast%3DFaccenda%26aufirst%3DE.%26aulast%3DHarding%26aufirst%3DS.%2BD.%26aulast%3DPawson%26aufirst%3DA.%2BJ.%26aulast%3DSharman%26aufirst%3DJ.%2BL.%26aulast%3DSouthan%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520concise%2520guide%2520to%2520pharmacology%25202017%252F18%253A%2520G%2520protein-coupled%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D174%26spage%3DS17%26epage%3DS129%26doi%3D10.1111%2Fbph.13878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boulton, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nye, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radzlejewska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgenbesser, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panayotatos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobb, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span> <span> </span><span class="NLM_article-title">ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">675</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(91)90098-J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2F0092-8674%2891%2990098-J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=2032290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK38XmsVOltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1991&pages=663-675&author=T.+G.+Boultonauthor=S.+H.+Nyeauthor=D.+J.+Robbinsauthor=N.+Y.+Ipauthor=E.+Radzlejewskaauthor=S.+D.+Morgenbesserauthor=R.+A.+DePinhoauthor=N.+Panayotatosauthor=M.+H.+Cobbauthor=G.+D.+Yancopoulos&title=ERKs%3A+A+family+of+protein-serine%2Fthreonine+kinases+that+are+activated+and+tyrosine+phosphorylated+in+response+to+insulin+and+NGF&doi=10.1016%2F0092-8674%2891%2990098-J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">ERKs:  a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF</span></div><div class="casAuthors">Boulton, Teri G.; Nye, Steven H.; Robbins, David J.; Ip, Nancy Y.; Radziejewska, Elizabeth; Morgenbesser, Sharon D.; DePinho, Ronald A.; Panayotatos, Nikos; Cobb, Melanie H.; Yancopoulos, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">663-75</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The purifn. and cloning of extracellular signal-regulated kinase 1 (ERK1), which appears to play a pivotal role in converting tyrosine phosphorylation into the serine/threonine phosphorylations that regulate downstream events was recently described.  Here, the cloning and characterization of 2 ERK1-related kinases, ERK2 and ERK3 from rat brain are described and evidence is provided suggesting that there are addnl. ERK family members.  At least 2 of the ERKs are activated in response to growth factors; their activations correlate with tyrosine phosphorylation, but also depend on addnl. modifications.  Transcripts corresponding to the 3 cloned ERKs are distinctly regulated both in vivo and in a differentiating cell line.  Thus, this family of kinases may serve as intermediates that depend on tyrosine phosphorylation to activate serine/threonine phosphorylation cascades.  Individual family members may mediate responses in different developmental stages, in different cell types, or following exposure to different extracellular signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGE1DFLrovR7Vg90H21EOLACvtfcHk0lh1YlEbAoRVhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XmsVOltr0%253D&md5=3e02d5a7a9679b8cdedca2471c4d5b04</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2891%2990098-J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252891%252990098-J%26sid%3Dliteratum%253Aachs%26aulast%3DBoulton%26aufirst%3DT.%2BG.%26aulast%3DNye%26aufirst%3DS.%2BH.%26aulast%3DRobbins%26aufirst%3DD.%2BJ.%26aulast%3DIp%26aufirst%3DN.%2BY.%26aulast%3DRadzlejewska%26aufirst%3DE.%26aulast%3DMorgenbesser%26aufirst%3DS.%2BD.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26aulast%3DPanayotatos%26aufirst%3DN.%26aulast%3DCobb%26aufirst%3DM.%2BH.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26atitle%3DERKs%253A%2520A%2520family%2520of%2520protein-serine%252Fthreonine%2520kinases%2520that%2520are%2520activated%2520and%2520tyrosine%2520phosphorylated%2520in%2520response%2520to%2520insulin%2520and%2520NGF%26jtitle%3DCell%26date%3D1991%26volume%3D65%26spage%3D663%26epage%3D675%26doi%3D10.1016%2F0092-8674%2891%2990098-J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nestler, E. J.</span>; <span class="NLM_string-name">Greengard, P.</span></span> <span> </span><span class="NLM_article-title">Serine and threonine phosphorylation</span>. In  <i>Basic Neurochemistry: Molecular, Cellular and Medical Aspects</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, G. J.</span>; <span class="NLM_string-name">Agranoff, B. W.</span>, <span class="NLM_string-name">Albers, R. W.</span></span>, Eds.; <span class="NLM_publisher-name">Lippincott-Raven</span>: <span class="NLM_publisher-loc">Philadelphia</span>, <span class="NLM_year">1999</span>; pp  <span class="NLM_fpage">471</span>− <span class="NLM_lpage">496</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&pages=471-496&author=E.+J.+Nestler&author=P.+Greengardauthor=G.+J.+Siegel&author=B.+W.+Agranoff&author=R.+W.+Albers&title=Basic+Neurochemistry%3A+Molecular%2C+Cellular+and+Medical+Aspects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNestler%26aufirst%3DE.%2BJ.%26atitle%3DSerine%2520and%2520threonine%2520phosphorylation%26btitle%3DBasic%2520Neurochemistry%253A%2520Molecular%252C%2520Cellular%2520and%2520Medical%2520Aspects%26aulast%3DSiegel%26aufirst%3DG.%2BJ.%26pub%3DLippincott-Raven%26date%3D1999%26spage%3D471%26epage%3D496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, J. L.</span></span> <span> </span><span class="NLM_article-title">Pelle kinase is activated by autophosphorylation during toll signaling in drosophila</span>. <i>Development</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1925</span>– <span class="NLM_lpage">1933</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=11934858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD38XjslSlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2002&pages=1925-1933&author=B.+Shenauthor=J.+L.+Manley&title=Pelle+kinase+is+activated+by+autophosphorylation+during+toll+signaling+in+drosophila"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Pelle kinase is activated by autophosphorylation during Toll signaling in Drosophila</span></div><div class="casAuthors">Shen, Baohe; Manley, James L.</div><div class="citationInfo"><span class="NLM_cas:title">Development (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1925-1933</span>CODEN:
                <span class="NLM_cas:coden">DEVPED</span>;
        ISSN:<span class="NLM_cas:issn">0950-1991</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">The Drosophila Pelle kinase plays a key role in the evolutionarily conserved Toll signaling pathway, but the mechanism responsible for its activation has been unknown.  We present in vivo and in vitro evidence establishing an important role for concn.-dependent autophosphorylation in the signaling process.  We first show that Pelle phosphorylation can be detected transiently in early embryos, concomitant with activation of signaling.  Importantly, Pelle phosphorylation is enhanced in a gain-of-function Toll mutant (Toll10b), but decreased by loss-of-function Toll alleles.  Next we found that Pelle is phosphorylated in transfected Schneider L2 cells in a concn.-dependent manner such that significant modification is obsd. only at high Pelle concns., which coincide with levels required for phosphorylation and activation of the downstream target, Dorsal.  Pelle phosphorylation is also enhanced in L2 cells co-expressing Toll10b, and is dependent on Pelle kinase activity.  In vitro kinase assays revealed that recombinant, autophosphorylated Pelle is far more active than unphosphorylated Pelle.  Importantly, unphosphorylated Pelle becomes autophosphorylated, and activated, by incubation at high concns.  We discuss these results in the context of Toll-like receptor mediated signaling in both flies and mammals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRCW9nAaRUwLVg90H21EOLACvtfcHk0lh1YlEbAoRVhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjslSlsrk%253D&md5=364debacdbb832eb0e1299070ed4501a</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DB.%26aulast%3DManley%26aufirst%3DJ.%2BL.%26atitle%3DPelle%2520kinase%2520is%2520activated%2520by%2520autophosphorylation%2520during%2520toll%2520signaling%2520in%2520drosophila%26jtitle%3DDevelopment%26date%3D2002%26volume%3D129%26spage%3D1925%26epage%3D1933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Losiewicz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worland, P. J.</span></span> <span> </span><span class="NLM_article-title">Potent inhibition of CDC2 kinase activity by the flavonoid L86–8275</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1006/bbrc.1994.1742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1006%2Fbbrc.1994.1742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=8002990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK2cXksV2ksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=1994&pages=589-595&author=M.+D.+Losiewiczauthor=B.+A.+Carlsonauthor=G.+Kaurauthor=E.+A.+Sausvilleauthor=P.+J.+Worland&title=Potent+inhibition+of+CDC2+kinase+activity+by+the+flavonoid+L86%E2%80%938275&doi=10.1006%2Fbbrc.1994.1742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Potent inhibition of Cdc2 kinase activity by the flavonoid L86-8275</span></div><div class="casAuthors">Losiewicz, Michael D.; Carlson, Bradley A.; Kaur, Gurmeet; Sausville, Edward A.; Worland, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title"></span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">589-95</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">L86-8275 [(-) cis-5,7-dihydroxy-2-(2-chlorophenyl)-8[4-(3-hydroxy-1-methyl)-piperidinyl]-4H-benzopyran-4-one] directly inhibits immunopptd. Cdc2 kinase activity from G2/M synchronized MDA-MB-468 breast carcinoma cells and is at least 250-fold more potent than either quercetin or genistein.  Purified sea-star Cdc2 kinase (IC50 = 0.5 μM) was inhibited with a similar potency to immunopptd. Cdc2 kinase from MDA-MB-468 cells (IC50 = 0.4 μM).  This inhibition was competitive with respect to ATP (KiATP = 0.041 μM) and noncompetitive with respect to a synthetic peptide substrate, CDK1S1 (AAKAKKTPKKAKK-CONH2, KiCDD1S1 = 0.14 μM).  These data suggest L86-8275 as a lead structure for the development of inhibitors of the cyclin-dependent kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFqJ6zFiGW47Vg90H21EOLACvtfcHk0lh1YlEbAoRVhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksV2ksbs%253D&md5=bbf1b887438a0746aa058ed88d1fc0da</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1994.1742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1994.1742%26sid%3Dliteratum%253Aachs%26aulast%3DLosiewicz%26aufirst%3DM.%2BD.%26aulast%3DCarlson%26aufirst%3DB.%2BA.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DWorland%26aufirst%3DP.%2BJ.%26atitle%3DPotent%2520inhibition%2520of%2520CDC2%2520kinase%2520activity%2520by%2520the%2520flavonoid%2520L86%25E2%2580%25938275%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1994%26volume%3D201%26spage%3D589%26epage%3D595%26doi%3D10.1006%2Fbbrc.1994.1742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulner, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, J. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blow, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcros, J.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulinoux, J.-P.</span></span> <span> </span><span class="NLM_article-title">Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases CDC2, CDK2 and CDK5</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>243</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.1997.t01-2-00527.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1111%2Fj.1432-1033.1997.t01-2-00527.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=9030781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK2sXhtVWiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=1997&pages=527-536&author=L.+Meijerauthor=A.+Borgneauthor=O.+Mulnerauthor=J.+P.+J.+Chongauthor=J.+J.+Blowauthor=N.+Inagakiauthor=M.+Inagakiauthor=J.-G.+Delcrosauthor=J.-P.+Moulinoux&title=Biochemical+and+cellular+effects+of+roscovitine%2C+a+potent+and+selective+inhibitor+of+the+cyclin-dependent+kinases+CDC2%2C+CDK2+and+CDK5&doi=10.1111%2Fj.1432-1033.1997.t01-2-00527.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2, and cdk5</span></div><div class="casAuthors">Meijer, Laurent; Borgne, Annie; Mulner, Odile; Chong, James P. J.; Blow, J. Julian; Inagaki, Naoyuki; Inagaki, Masaki; Delcros, Jean Guy; Moulinoux, Jacques Philippe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">243</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">527-536</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (cdk) play an essential role in the intracellular control of the cell division cycle (cdc).  These kinases and their regulators are frequently deregulated in human tumors.  Enzymic screening has recently led to the discovery of specific inhibitors of cyclin-dependent kinases, such as butyrolactone I, flavopiridol and the purine olomoucine.  Among a series of C2, N6,N9-substituted adenines tested on purified cdc2/cyclin B, 2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine (roscovitine) displays high efficiency and high selectivity towards some cyclin-dependent kinases.  The kinase specificity of roscovitine was investigated with 25 highly purified kinases (including protein kinase A, G and C isoforms, myosin light-chain kinase, casein kinase 2, insulin receptor tyrosine kinase, c-src, v-abl).  Most kinases are not significantly inhibited by roscovitine.  Cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E and cdk5/p35 only are substantially inhibited (IC50 values of 0.65, 0.7, 0.7 and 0.2 μM, resp.).  Cdk4/cyclin D1 and cdk6/cyclin D2 are very poorly inhibited by roscovitine (IC50>100 μM).  Extracellular regulated kinases erk1 and erk2 are inhibited with an IC50 of 34 μM and 14 μM, resp.  Roscovitine reversibly arrests starfish oocytes and sea urchin embryos in late prophase.  Roscovitine inhibits in vitro M-phase-promoting factor activity and in vitro DNA synthesis in Xenopus egg exts.  It blocks progesterone-induced oocyte maturation of Xenopus oocytes and in vivo phosphorylation of the elongation factor eEF-1.  Roscovitine inhibits the proliferation of mammalian cell lines with an av. IC50 of 16 μM.  In the presence of roscovitine L1210 cells arrest in G1 and accumulate in G2.  In vivo phosphorylation of vimentin on Ser55 by cdc2/cyclin B is inhibited by roscovitine.  Through its unique selectivity for some cyclin-dependent kinases, roscovitine provides a useful anti-mitotic reagent for cell cycle studies and may prove interesting to control cells with deregulated cdc2, cdk2 or cdk5 kinase activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO61Tu2_0pWLVg90H21EOLACvtfcHk0lgzM6yMB4Nx3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhtVWiu7g%253D&md5=d55100def53ac8811e485d9d34c46b79</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1997.t01-2-00527.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1997.t01-2-00527.x%26sid%3Dliteratum%253Aachs%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DBorgne%26aufirst%3DA.%26aulast%3DMulner%26aufirst%3DO.%26aulast%3DChong%26aufirst%3DJ.%2BP.%2BJ.%26aulast%3DBlow%26aufirst%3DJ.%2BJ.%26aulast%3DInagaki%26aufirst%3DN.%26aulast%3DInagaki%26aufirst%3DM.%26aulast%3DDelcros%26aufirst%3DJ.-G.%26aulast%3DMoulinoux%26aufirst%3DJ.-P.%26atitle%3DBiochemical%2520and%2520cellular%2520effects%2520of%2520roscovitine%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520the%2520cyclin-dependent%2520kinases%2520CDC2%252C%2520CDK2%2520and%2520CDK5%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1997%26volume%3D243%26spage%3D527%26epage%3D536%26doi%3D10.1111%2Fj.1432-1033.1997.t01-2-00527.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhavalkar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiswell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seghezzi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomeir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oft, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E. M.</span></span> <span> </span><span class="NLM_article-title">Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2344</span>– <span class="NLM_lpage">2353</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1158%2F1535-7163.MCT-10-0324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=20663931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2344-2353&author=D.+Parryauthor=T.+Guziauthor=F.+Shanahanauthor=N.+Davisauthor=D.+Prabhavalkarauthor=D.+Wiswellauthor=W.+Seghezziauthor=K.+Paruchauthor=M.+P.+Dwyerauthor=R.+Dollauthor=A.+Nomeirauthor=W.+Windsorauthor=T.+Fischmannauthor=Y.+Wangauthor=M.+Oftauthor=T.+Chenauthor=P.+Kirschmeierauthor=E.+M.+Lees&title=Dinaciclib+%28SCH+727965%29%2C+a+novel+and+potent+cyclin-dependent+kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-10-0324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor</span></div><div class="casAuthors">Parry, David; Guzi, Timothy; Shanahan, Frances; Davis, Nicole; Prabhavalkar, Deepa; Wiswell, Derek; Seghezzi, Wolfgang; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald; Nomeir, Amin; Windsor, William; Fischmann, Thierry; Wang, Yaolin; Oft, Martin; Chen, Taiying; Kirschmeier, Paul; Lees, Emma M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2344-2353</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDK) are key pos. regulators of cell cycle progression and attractive targets in oncol.  SCH 727965 inhibits CDK2, CDK5, CDK1, and CDK9 activity in vitro with IC50 values of 1, 1, 3, and 4 nmol/L, resp.  SCH 727965 was selected as a clin. candidate using a functional screen in vivo that integrated both efficacy and safety parameters.  Compared with flavopiridol, SCH 727965 exhibits superior activity with an improved therapeutic index.  In cell-based assays, SCH 727965 completely suppressed retinoblastoma phosphorylation, which correlated with apoptosis onset and total inhibition of bromodeoxyuridine incorporation in >100 tumor cell lines of diverse origin and background.  Moreover, short exposures to SCH 727965 were sufficient for long-lasting cellular effects.  SCH 727965 induced regression of established solid tumors in a range of mouse models following intermittent scheduling of doses below the maximally tolerated level.  This was assocd. with modulation of pharmacodynamic biomarkers in skin punch biopsies and rapidly reversible, mechanism-based effects on hematol. parameters.  These results suggest that SCH 727965 is a potent and selective CDK inhibitor and a novel cytotoxic agent.  Mol Cancer Ther; 9(8); 2344-53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxn1NtmEAh7LVg90H21EOLACvtfcHk0lgzM6yMB4Nx3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjtrw%253D&md5=bd2d30fdfdca0f2bceb3f5c0b44b8630</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0324%26sid%3Dliteratum%253Aachs%26aulast%3DParry%26aufirst%3DD.%26aulast%3DGuzi%26aufirst%3DT.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DPrabhavalkar%26aufirst%3DD.%26aulast%3DWiswell%26aufirst%3DD.%26aulast%3DSeghezzi%26aufirst%3DW.%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DDoll%26aufirst%3DR.%26aulast%3DNomeir%26aufirst%3DA.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DFischmann%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DOft%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DLees%26aufirst%3DE.%2BM.%26atitle%3DDinaciclib%2520%2528SCH%2520727965%2529%252C%2520a%2520novel%2520and%2520potent%2520cyclin-dependent%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2344%26epage%3D2353%26doi%3D10.1158%2F1535-7163.MCT-10-0324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liszkay, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Cruz-Merino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutriaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sovak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hack, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Combined vemurafenib and cobimetinib in BRAF-mutated melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">1867</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1408868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1056%2FNEJMoa1408868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=25265494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1867-1876&author=J.+Larkinauthor=P.+A.+Asciertoauthor=B.+Drenoauthor=V.+Atkinsonauthor=G.+Liszkayauthor=M.+Maioauthor=M.+Mandalaauthor=L.+Demidovauthor=D.+Stroyakovskiyauthor=L.+Thomasauthor=L.+de+la+Cruz-Merinoauthor=C.+Dutriauxauthor=C.+Garbeauthor=M.+A.+Sovakauthor=I.+Changauthor=N.+Choongauthor=S.+P.+Hackauthor=G.+A.+McArthurauthor=A.+Ribas&title=Combined+vemurafenib+and+cobimetinib+in+BRAF-mutated+melanoma&doi=10.1056%2FNEJMoa1408868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Combined vemurafenib and cobimetinib in BRAF-mutated melanoma</span></div><div class="casAuthors">Larkin, James; Ascierto, Paolo A.; Dreno, Brigitte; Atkinson, Victoria; Liszkay, Gabriella; Maio, Michele; Mandala, Mario; Demidov, Lev; Stroyakovskiy, Daniil; Thomas, Luc; de la Cruz-Merino, Luis; Dutriaux, Caroline; Garbe, Claus; Sovak, Mika A.; Chang, Ilsung; Choong, Nicholas; Hack, Stephen P.; McArthur, Grant A.; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1867-1876, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The combined inhibition of BRAF and MEK is hypothesized to improve clin. outcomes in patients with melanoma by preventing or delaying the onset of resistance obsd. with BRAF inhibitors alone.  This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib.  We randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-pos. melanoma to receive vemurafenib and cobimetinib (combination group) or vemurafenib and placebo (control group).  The primary end point was investigator-assessed progression-free survival.  The median progression-free survival was 9.9 mo in the combination group and 6.2 mo in the control group (hazard ratio for death or disease progression, 0.51; 95% confidence interval [CI], 0.39 to 0.68; P<0.001).  The rate of complete or partial response in the combination group was 68%, as compared with 45% in the control group (P<0.001), including rates of complete response of 10% in the combination group and 4% in the control group.  Progression-free survival as assessed by independent review was similar to investigator-assessed progression-free survival.  Interim analyses of overall survival showed 9-mo survival rates of 81% (95% CI, 75 to 87) in the combination group and 73% (95% CI, 65 to 80) in the control group.  Vemurafenib and cobimetinib was assocd. with a nonsignificantly higher incidence of adverse events of grade 3 or higher, as compared with vemurafenib and placebo (65% vs. 59%), and there was no significant difference in the rate of study-drug discontinuation.  The no. of secondary cutaneous cancers decreased with the combination therapy.  The addn. of cobimetinib to vemurafenib was assocd. with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpErdkeTyZ9rVg90H21EOLACvtfcHk0lgzM6yMB4Nx3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslGgsQ%253D%253D&md5=9b6fb4f9ea883da579d6435ccb5742eb</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1408868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1408868%26sid%3Dliteratum%253Aachs%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DAtkinson%26aufirst%3DV.%26aulast%3DLiszkay%26aufirst%3DG.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DDemidov%26aufirst%3DL.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3Dde%2Bla%2BCruz-Merino%26aufirst%3DL.%26aulast%3DDutriaux%26aufirst%3DC.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DSovak%26aufirst%3DM.%2BA.%26aulast%3DChang%26aufirst%3DI.%26aulast%3DChoong%26aufirst%3DN.%26aulast%3DHack%26aufirst%3DS.%2BP.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DCombined%2520vemurafenib%2520and%2520cobimetinib%2520in%2520BRAF-mutated%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D1867%26epage%3D1876%26doi%3D10.1056%2FNEJMoa1408868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrlova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiss, F.</span></span> <span> </span><span class="NLM_article-title">Cobimetinib (GDC-0973, XL518)</span>. <i>Recent Results Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>211</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1007/978-3-319-91442-8_12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1007%2F978-3-319-91442-8_12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=30069767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVShu7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=2018&pages=177-186&author=H.+Andrlovaauthor=R.+Zeiserauthor=F.+Meiss&title=Cobimetinib+%28GDC-0973%2C+XL518%29&doi=10.1007%2F978-3-319-91442-8_12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Cobimetinib (GDC-0973, XL518)</span></div><div class="casAuthors">Andrlova, Hana; Zeiser, Robert; Meiss, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Recent Results in Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">Small Molecules in Oncology</span>),
    <span class="NLM_cas:pages">177-186</span>CODEN:
                <span class="NLM_cas:coden">RRCRBU</span>;
        ISSN:<span class="NLM_cas:issn">2197-6767</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  The mitogen-activated protein kinase cascade (MAPK/ERK pathway) is a signaling pathway activated as a cellular response to various stimuli and for regulating the proliferation and survival of several types of eukaryotic cells, among others a wide variety of tumor cells.  Mutations of the proteins involved in this pathway have been discovered in several tumor entities, indicating their inhibition as a potential therapeutic target.  BRAF inhibitors have been in the clin. use since 2011.  Several MEK inhibitors have been studied for metastatic cancer treatment in the recent past.  After trametinib, cobimetinib is another potent, selective oral MEK1/2 inhibitor that was approved by European Medicine Agency (EMA) and Food and Drug Administration (FDA) in 2015 for treatment of malignant melanoma in a combination with the BRAF inhibitor vemurafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCfgT9J9-zhrVg90H21EOLACvtfcHk0lgpJtAzjBY6Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVShu7nP&md5=873393184d0fcfc7028f06868d70d6cb</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-91442-8_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-91442-8_12%26sid%3Dliteratum%253Aachs%26aulast%3DAndrlova%26aufirst%3DH.%26aulast%3DZeiser%26aufirst%3DR.%26aulast%3DMeiss%26aufirst%3DF.%26atitle%3DCobimetinib%2520%2528GDC-0973%252C%2520XL518%2529%26jtitle%3DRecent%2520Results%2520Cancer%2520Res.%26date%3D2018%26volume%3D211%26spage%3D177%26epage%3D186%26doi%3D10.1007%2F978-3-319-91442-8_12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boscoe, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bree, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodfuehrer, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dower, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozda, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisbie, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavrin, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hope, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamtekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaioannou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samardjiev, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samas, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M. W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soutter, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapf, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of clinical candidate 1-{[(2<i>S</i>,3<i>S</i>,4<i>S</i>)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a potent, selective inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4), by fragment-based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5521</span>– <span class="NLM_lpage">5542</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00231</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00231" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5521-5542&author=K.+L.+Leeauthor=C.+M.+Amblerauthor=D.+R.+Andersonauthor=B.+P.+Boscoeauthor=A.+G.+Breeauthor=J.+I.+Brodfuehrerauthor=J.+S.+Changauthor=C.+Choiauthor=S.+Chungauthor=K.+J.+Curranauthor=J.+E.+Dayauthor=C.+M.+Dehnhardtauthor=K.+Dowerauthor=S.+E.+Drozdaauthor=R.+K.+Frisbieauthor=L.+K.+Gavrinauthor=J.+A.+Goldbergauthor=S.+Hanauthor=M.+Hegenauthor=D.+Hepworthauthor=H.+R.+Hopeauthor=S.+Kamtekarauthor=I.+C.+Kiltyauthor=A.+Leeauthor=L.+L.+Linauthor=F.+E.+Loveringauthor=M.+D.+Loweauthor=J.+P.+Mathiasauthor=H.+M.+Morganauthor=E.+A.+Murphyauthor=N.+Papaioannouauthor=A.+Patnyauthor=B.+S.+Pierceauthor=V.+R.+Raoauthor=E.+Saiahauthor=I.+J.+Samardjievauthor=B.+M.+Samasauthor=M.+W.+H.+Shenauthor=J.+H.+Shinauthor=H.+H.+Soutterauthor=J.+W.+Strohbachauthor=P.+T.+Symanowiczauthor=J.+R.+Thomasonauthor=J.+D.+Trzupekauthor=R.+Vargasauthor=F.+Vincentauthor=J.+Yanauthor=C.+W.+Zapfauthor=S.+W.+Wright&title=Discovery+of+clinical+candidate+1-%7B%5B%282S%2C3S%2C4S%29-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%5Dmethoxy%7D-7-methoxyisoquinoline-6-carboxamide+%28PF-06650833%29%2C+a+potent%2C+selective+inhibitor+of+interleukin-1+receptor+associated+kinase+4+%28IRAK4%29%2C+by+fragment-based+drug+design&doi=10.1021%2Facs.jmedchem.7b00231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design</span></div><div class="casAuthors">Lee, Katherine L.; Ambler, Catherine M.; Anderson, David R.; Boscoe, Brian P.; Bree, Andrea G.; Brodfuehrer, Joanne I.; Chang, Jeanne S.; Choi, Chulho; Chung, Seungwon; Curran, Kevin J.; Day, Jacqueline E.; Dehnhardt, Christoph M.; Dower, Ken; Drozda, Susan E.; Frisbie, Richard K.; Gavrin, Lori K.; Goldberg, Joel A.; Han, Seungil; Hegen, Martin; Hepworth, David; Hope, Heidi R.; Kamtekar, Satwik; Kilty, Iain C.; Lee, Arthur; Lin, Lih-Ling; Lovering, Frank E.; Lowe, Michael D.; Mathias, John P.; Morgan, Heidi M.; Murphy, Elizabeth A.; Papaioannou, Nikolaos; Patny, Akshay; Pierce, Betsy S.; Rao, Vikram R.; Saiah, Eddine; Samardjiev, Ivan J.; Samas, Brian M.; Shen, Marina W. H.; Shin, Julia H.; Soutter, Holly H.; Strohbach, Joseph W.; Symanowicz, Peter T.; Thomason, Jennifer R.; Trzupek, John D.; Vargas, Richard; Vincent, Fabien; Yan, Jiangli; Zapf, Christoph W.; Wright, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5521-5542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topol. in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was optimized to afford IRAK4 inhibitors with nanomolar potency in cellular assays.  The medicinal chem. effort featured the judicious placement of lipophilicity, informed by cocrystal structures with IRAK4 and optimization of ADME properties to deliver clin. candidate I.  This compd. benefitted from a 5-unit increase in lipophilic efficiency from the fragment hit, excellent kinase selectivity, and pharmacokinetic properties suitable for oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYrCep64bhMbVg90H21EOLACvtfcHk0lgpJtAzjBY6Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D&md5=9771ad2d33089f6ef3dba3556536ff1a</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00231%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BL.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DBoscoe%26aufirst%3DB.%2BP.%26aulast%3DBree%26aufirst%3DA.%2BG.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%2BI.%26aulast%3DChang%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DChung%26aufirst%3DS.%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DDower%26aufirst%3DK.%26aulast%3DDrozda%26aufirst%3DS.%2BE.%26aulast%3DFrisbie%26aufirst%3DR.%2BK.%26aulast%3DGavrin%26aufirst%3DL.%2BK.%26aulast%3DGoldberg%26aufirst%3DJ.%2BA.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHope%26aufirst%3DH.%2BR.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DL.%2BL.%26aulast%3DLovering%26aufirst%3DF.%2BE.%26aulast%3DLowe%26aufirst%3DM.%2BD.%26aulast%3DMathias%26aufirst%3DJ.%2BP.%26aulast%3DMorgan%26aufirst%3DH.%2BM.%26aulast%3DMurphy%26aufirst%3DE.%2BA.%26aulast%3DPapaioannou%26aufirst%3DN.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DRao%26aufirst%3DV.%2BR.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSamardjiev%26aufirst%3DI.%2BJ.%26aulast%3DSamas%26aufirst%3DB.%2BM.%26aulast%3DShen%26aufirst%3DM.%2BW.%2BH.%26aulast%3DShin%26aufirst%3DJ.%2BH.%26aulast%3DSoutter%26aufirst%3DH.%2BH.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DThomason%26aufirst%3DJ.%2BR.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DVargas%26aufirst%3DR.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DWright%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520clinical%2520candidate%25201-%257B%255B%25282S%252C3S%252C4S%2529-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%255Dmethoxy%257D-7-methoxyisoquinoline-6-carboxamide%2520%2528PF-06650833%2529%252C%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520interleukin-1%2520receptor%2520associated%2520kinase%25204%2520%2528IRAK4%2529%252C%2520by%2520fragment-based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5521%26epage%3D5542%26doi%3D10.1021%2Facs.jmedchem.7b00231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Festjens, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanden Berghe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenabeele, P.</span></span> <span> </span><span class="NLM_article-title">RIP1, a kinase on the crossroads of a cell’s decision to live or die</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">400</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1038/sj.cdd.4402085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fsj.cdd.4402085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=17301840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhslWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=400-410&author=N.+Festjensauthor=T.+Vanden+Bergheauthor=S.+Cornelisauthor=P.+Vandenabeele&title=RIP1%2C+a+kinase+on+the+crossroads+of+a+cell%E2%80%99s+decision+to+live+or+die&doi=10.1038%2Fsj.cdd.4402085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">RIP1, a kinase on the crossroads of a cell's decision to live or die</span></div><div class="casAuthors">Festjens, N.; Vanden Berghe, T.; Cornelis, S.; Vandenabeele, P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">400-410</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Binding of inflammatory cytokines to their receptors, stimulation of pathogen recognition receptors by pathogen-assocd. mol. patterns, and DNA damage induce specific signalling events.  A cell that is exposed to these signals can respond by activation of NF-κB, mitogen-activated protein kinases and interferon regulatory factors, resulting in the upregulation of antiapoptotic proteins and of several cytokines.  The consequent survival may or may not be accompanied by an inflammatory response.  Alternatively, a cell can also activate death-signalling pathways, resulting in apoptosis or alternative cell death such as necrosis or autophagic cell death.  Interplay between survival and death-promoting complexes continues as they compete with each other until one eventually dominates and dets. the cell's fate.  RIP1 is a crucial adaptor kinase on the crossroad of these stress-induced signalling pathways and a cell's decision to live or die.  Following different upstream signals, particular RIP1-contg. complexes are formed; these initiate only a limited no. of cellular responses.  In this review, we describe how RIP1 acts as a key integrator of signalling pathways initiated by stimulation of death receptors, bacterial or viral infection, genotoxic stress and T-cell homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9sr7bI1cyLLVg90H21EOLACvtfcHk0ljJ_gI4TnM7zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhslWht7k%253D&md5=a51d63f952a07646879bd5fc53ab8524</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4402085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4402085%26sid%3Dliteratum%253Aachs%26aulast%3DFestjens%26aufirst%3DN.%26aulast%3DVanden%2BBerghe%26aufirst%3DT.%26aulast%3DCornelis%26aufirst%3DS.%26aulast%3DVandenabeele%26aufirst%3DP.%26atitle%3DRIP1%252C%2520a%2520kinase%2520on%2520the%2520crossroads%2520of%2520a%2520cell%25E2%2580%2599s%2520decision%2520to%2520live%2520or%2520die%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2007%26volume%3D14%26spage%3D400%26epage%3D410%26doi%3D10.1038%2Fsj.cdd.4402085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelliher, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanger, B. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leder, P.</span></span> <span> </span><span class="NLM_article-title">The death domain kinase RIP mediates the TNF-induced NF-κB signal</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1016/S1074-7613(00)80535-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2FS1074-7613%2800%2980535-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=9529147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK1cXitFGgsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=297-303&author=M.+A.+Kelliherauthor=S.+Grimmauthor=Y.+Ishidaauthor=F.+Kuoauthor=B.+Z.+Stangerauthor=P.+Leder&title=The+death+domain+kinase+RIP+mediates+the+TNF-induced+NF-%CE%BAB+signal&doi=10.1016%2FS1074-7613%2800%2980535-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">The death domain kinase RIP mediates the TNF-induced NF-κB signal</span></div><div class="casAuthors">Kelliher, Michelle A.; Grimm, Stefan; Ishida, Yasumasa; Kuo, Frank; Stanger, Ben Z.; Leder, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-303</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The death domain serine/threonine kinase RIP interacts with the death receptors Fas and tumor necrosis receptor 1 (TNFR1).  In vitro, RIP stimulates apoptosis, SAPK/JNK, and NF-κB activation.  To define the physiol. role(s) that RIP plays in regulating apoptosis in vivo, the authors introduced a rip null mutation in mice through homologous recombination.  RIP-deficient mice appear normal at birth but fail to thrive, displaying extensive apoptosis in both the lymphoid and adipose tissue and dying at 1-3 days of age.  In contrast to a normal thymic anti-Fas response, rip-/- cells are highly sensitive to TNFα-induced cell death.  Sensitivity to TNFα-mediated cell death in rip-/- cells is accompanied by a failure to activate the transcription factor NF-κB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWCMrpO6ha77Vg90H21EOLACvtfcHk0ljJ_gI4TnM7zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitFGgsLk%253D&md5=fd4da91b5ae0cb32de05183b0db43d28</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2FS1074-7613%2800%2980535-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-7613%252800%252980535-X%26sid%3Dliteratum%253Aachs%26aulast%3DKelliher%26aufirst%3DM.%2BA.%26aulast%3DGrimm%26aufirst%3DS.%26aulast%3DIshida%26aufirst%3DY.%26aulast%3DKuo%26aufirst%3DF.%26aulast%3DStanger%26aufirst%3DB.%2BZ.%26aulast%3DLeder%26aufirst%3DP.%26atitle%3DThe%2520death%2520domain%2520kinase%2520RIP%2520mediates%2520the%2520TNF-induced%2520NF-%25CE%25BAB%2520signal%26jtitle%3DImmunity%26date%3D1998%26volume%3D8%26spage%3D297%26epage%3D303%26doi%3D10.1016%2FS1074-7613%2800%2980535-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micheau, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschopp, J.</span></span> <span> </span><span class="NLM_article-title">Induction of TNF receptor I-mediated apoptosis <i>via</i> two sequential signaling complexes</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(03)00521-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2FS0092-8674%2803%2900521-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=12887920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvFCgu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2003&pages=181-190&author=O.+Micheauauthor=J.+Tschopp&title=Induction+of+TNF+receptor+I-mediated+apoptosis+via+two+sequential+signaling+complexes&doi=10.1016%2FS0092-8674%2803%2900521-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes</span></div><div class="casAuthors">Micheau, Olivier; Tschopp, Juerg</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-190</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Apoptosis induced by TNF-receptor I (TNFR1) is thought to proceed via recruitment of the adaptor FADD and caspase-8 to the receptor complex.  TNFR1 signaling is also known to activate the transcription factor NF-κB and promote survival.  The mechanism by which this decision between cell death and survival is arbitrated is not clear.  The authors report that TNFR1-induced apoptosis involves two sequential signaling complexes.  The initial plasma membrane bound complex (complex I) consists of TNFR1, the adaptor TRADD, the kinase RIP1, and TRAF2 and rapidly signals activation of NF-κB.  In a second step, TRADD and RIP1 assoc. with FADD and caspase-8, forming a cytoplasmic complex (complex II).  When NF-κB is activated by complex I, complex II harbors the caspase-8 inhibitor FLIPL and the cell survives.  Thus, TNFR1-mediated-signal transduction includes a checkpoint, resulting in cell death (via complex II) in instances where the initial signal (via complex I, NF-κB) fails to be activated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvD_hEcCU4rrVg90H21EOLACvtfcHk0ljJ_gI4TnM7zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvFCgu7Y%253D&md5=9aae140d4da012f1ba51ec5f3ac6e934</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2803%2900521-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252803%252900521-X%26sid%3Dliteratum%253Aachs%26aulast%3DMicheau%26aufirst%3DO.%26aulast%3DTschopp%26aufirst%3DJ.%26atitle%3DInduction%2520of%2520TNF%2520receptor%2520I-mediated%2520apoptosis%2520via%2520two%2520sequential%2520signaling%2520complexes%26jtitle%3DCell%26date%3D2003%26volume%3D114%26spage%3D181%26epage%3D190%26doi%3D10.1016%2FS0092-8674%2803%2900521-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campobasso, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capriotti, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dare, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidam, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finger, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparcova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leister, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lich, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellette, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehon, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhaus, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swift, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totoritis, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vossenkamper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisnoski, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquis, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment ofinflammatory Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1261</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01751</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01751" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVeksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1247-1261&author=P.+A.+Harrisauthor=S.+B.+Bergerauthor=J.+U.+Jeongauthor=R.+Nagillaauthor=D.+Bandyopadhyayauthor=N.+Campobassoauthor=C.+A.+Capriottiauthor=J.+A.+Coxauthor=L.+Dareauthor=X.+Dongauthor=P.+M.+Eidamauthor=J.+N.+Fingerauthor=S.+J.+Hoffmanauthor=J.+Kangauthor=V.+Kasparcovaauthor=B.+W.+Kingauthor=R.+Lehrauthor=Y.+Lanauthor=L.+K.+Leisterauthor=J.+D.+Lichauthor=T.+T.+MacDonaldauthor=N.+A.+Millerauthor=M.+T.+Ouelletteauthor=C.+S.+Paoauthor=A.+Rahmanauthor=M.+A.+Reillyauthor=A.+R.+Rendinaauthor=E.+J.+Riveraauthor=M.+C.+Schaefferauthor=C.+A.+Sehonauthor=R.+R.+Singhausauthor=H.+H.+Sunauthor=B.+A.+Swiftauthor=R.+D.+Totoritisauthor=A.+Vossenkamperauthor=P.+Wardauthor=D.+D.+Wisnoskiauthor=D.+Zhangauthor=R.+W.+Marquisauthor=P.+J.+Goughauthor=J.+Bertin&title=Discovery+of+a+first-in-class+receptor+interacting+protein+1+%28RIP1%29+kinase+specific+clinical+candidate+%28GSK2982772%29+for+the+treatment+ofinflammatory+Diseases&doi=10.1021%2Facs.jmedchem.6b01751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases</span></div><div class="casAuthors">Harris, Philip A.; Berger, Scott B.; Jeong, Jae U.; Nagilla, Rakesh; Bandyopadhyay, Deepak; Campobasso, Nino; Capriotti, Carol A.; Cox, Julie A.; Dare, Lauren; Dong, Xiaoyang; Eidam, Patrick M.; Finger, Joshua N.; Hoffman, Sandra J.; Kang, James; Kasparcova, Viera; King, Bryan W.; Lehr, Ruth; Lan, Yunfeng; Leister, Lara K.; Lich, John D.; MacDonald, Thomas T.; Miller, Nathan A.; Ouellette, Michael T.; Pao, Christina S.; Rahman, Attiq; Reilly, Michael A.; Rendina, Alan R.; Rivera, Elizabeth J.; Schaeffer, Michelle C.; Sehon, Clark A.; Singhaus, Robert R.; Sun, Helen H.; Swift, Barbara A.; Totoritis, Rachel D.; Vossenkamper, Anna; Ward, Paris; Wisnoski, David D.; Zhang, Daohua; Marquis, Robert W.; Gough, Peter J.; Bertin, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1247-1261</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">RIP1 regulates necroptosis and inflammation and may play an important role in contributing to a variety of human pathologies, including immune-mediated inflammatory diseases.  Small-mol. inhibitors of RIP1 kinase that are suitable for advancement into the clinic have yet to be described.  Herein, the authors report the lead optimization of a benzoxazepinone hit from a DNA-encoded library and the discovery and profile of clin. candidate GSK2982772 (compd. I), currently in phase 2a clin. studies for psoriasis, rheumatoid arthritis, and ulcerative colitis.  Compd. I potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses.  Highlighting its potential as a novel anti-inflammatory agent, the inhibitor was also able to reduce spontaneous prodn. of cytokines from human ulcerative colitis explants.  The highly favorable physicochem. and ADMET properties of I, combined with high potency, led to a predicted low oral dose in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZGRDTQv-vs7Vg90H21EOLACvtfcHk0ljU5SEccNnWsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVeksLk%253D&md5=ee0c3c60bb1351dff696490ac9edb1cc</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01751%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DBerger%26aufirst%3DS.%2BB.%26aulast%3DJeong%26aufirst%3DJ.%2BU.%26aulast%3DNagilla%26aufirst%3DR.%26aulast%3DBandyopadhyay%26aufirst%3DD.%26aulast%3DCampobasso%26aufirst%3DN.%26aulast%3DCapriotti%26aufirst%3DC.%2BA.%26aulast%3DCox%26aufirst%3DJ.%2BA.%26aulast%3DDare%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DEidam%26aufirst%3DP.%2BM.%26aulast%3DFinger%26aufirst%3DJ.%2BN.%26aulast%3DHoffman%26aufirst%3DS.%2BJ.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DKasparcova%26aufirst%3DV.%26aulast%3DKing%26aufirst%3DB.%2BW.%26aulast%3DLehr%26aufirst%3DR.%26aulast%3DLan%26aufirst%3DY.%26aulast%3DLeister%26aufirst%3DL.%2BK.%26aulast%3DLich%26aufirst%3DJ.%2BD.%26aulast%3DMacDonald%26aufirst%3DT.%2BT.%26aulast%3DMiller%26aufirst%3DN.%2BA.%26aulast%3DOuellette%26aufirst%3DM.%2BT.%26aulast%3DPao%26aufirst%3DC.%2BS.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DReilly%26aufirst%3DM.%2BA.%26aulast%3DRendina%26aufirst%3DA.%2BR.%26aulast%3DRivera%26aufirst%3DE.%2BJ.%26aulast%3DSchaeffer%26aufirst%3DM.%2BC.%26aulast%3DSehon%26aufirst%3DC.%2BA.%26aulast%3DSinghaus%26aufirst%3DR.%2BR.%26aulast%3DSun%26aufirst%3DH.%2BH.%26aulast%3DSwift%26aufirst%3DB.%2BA.%26aulast%3DTotoritis%26aufirst%3DR.%2BD.%26aulast%3DVossenkamper%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DWisnoski%26aufirst%3DD.%2BD.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMarquis%26aufirst%3DR.%2BW.%26aulast%3DGough%26aufirst%3DP.%2BJ.%26aulast%3DBertin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520first-in-class%2520receptor%2520interacting%2520protein%25201%2520%2528RIP1%2529%2520kinase%2520specific%2520clinical%2520candidate%2520%2528GSK2982772%2529%2520for%2520the%2520treatment%2520ofinflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1247%26epage%3D1261%26doi%3D10.1021%2Facs.jmedchem.6b01751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degterev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Structural basis of RIP1 inhibition by necrostatins</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1016/j.str.2013.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.str.2013.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=23473668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVOqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=493-499&author=T.+Xieauthor=W.+Pengauthor=Y.+Liuauthor=C.+Yanauthor=J.+Makiauthor=A.+Degterevauthor=J.+Yuanauthor=Y.+Shi&title=Structural+basis+of+RIP1+inhibition+by+necrostatins&doi=10.1016%2Fj.str.2013.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of RIP1 Inhibition by Necrostatins</span></div><div class="casAuthors">Xie, Tian; Peng, Wei; Liu, Yexing; Yan, Chuangye; Maki, Jenny; Degterev, Alexei; Yuan, Junying; Shi, Yigong</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">493-499</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Necroptosis is a cellular mechanism that mediates necrotic cell death.  The receptor-interacting serine/threonine protein kinase 1 (RIP1) is an essential upstream signaling mol. in tumor-necrosis-factor-α-induced necroptosis.  Necrostatins, a series of small-mol. inhibitors, suppress necroptosis by specifically inhibiting RIP1 kinase activity.  Both RIP1 structure and the mechanisms by which necrostatins inhibit RIP1 remain unknown.  Here, we report the crystal structures of the RIP1 kinase domain individually bound to necrostatin-1 analog, necrostatin-3 analog, and necrostatin-4.  Necrostatin, caged in a hydrophobic pocket between the N- and C-lobes of the kinase domain, stabilizes RIP1 in an inactive conformation through interactions with highly conserved amino acids in the activation loop and the surrounding structural elements.  Structural comparison of RIP1 with the inhibitor-bound oncogenic kinase B-RAF reveals partially overlapping binding sites for necrostatin and for the anticancer compd. PLX4032.  Our study provides a structural basis for RIP1 inhibition by necrostatins and offers insights into potential structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtw_1OVLFe4rVg90H21EOLACvtfcHk0ljU5SEccNnWsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVOqsLk%253D&md5=42a3f8951b390358b9068bb1b885445e</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2013.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2013.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DT.%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DMaki%26aufirst%3DJ.%26aulast%3DDegterev%26aufirst%3DA.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DStructural%2520basis%2520of%2520RIP1%2520inhibition%2520by%2520necrostatins%26jtitle%3DStructure%26date%3D2013%26volume%3D21%26spage%3D493%26epage%3D499%26doi%3D10.1016%2Fj.str.2013.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zitouni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabais, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jana, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettencourt-Dias, M.</span></span> <span> </span><span class="NLM_article-title">Polo-like kinases: structural variations lead to multiple functions</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1038/nrm3819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnrm3819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=24954208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVaisL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=433-452&author=S.+Zitouniauthor=C.+Nabaisauthor=S.+C.+Janaauthor=A.+Guerreroauthor=M.+Bettencourt-Dias&title=Polo-like+kinases%3A+structural+variations+lead+to+multiple+functions&doi=10.1038%2Fnrm3819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Polo-like kinases: structural variations lead to multiple functions</span></div><div class="casAuthors">Zitouni, Sihem; Nabais, Catarina; Jana, Swadhin Chandra; Guerrero, Adan; Bettencourt-Dias, Monica</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">433-452</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Members of the polo-like kinase (PLK) family are crucial regulators of cell cycle progression, centriole duplication, mitosis, cytokinesis and the DNA damage response.  PLKs undergo major changes in abundance, activity, localization and structure at different stages of the cell cycle.  They interact with other proteins in a tightly controlled spatiotemporal manner as part of a network that coordinates key cell cycle events.  Their essential roles are highlighted by the fact that alterations in PLK function are assocd. with cancers and other diseases.  Recent knowledge gained from PLK crystal structures, evolution and interacting mols. offers important insights into the mechanisms that underlie their regulation and activity, and suggests novel functions unrelated to cell cycle control for this family of kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaF-mmmGZrt7Vg90H21EOLACvtfcHk0ljU5SEccNnWsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVaisL7P&md5=c4201eea6cece3b31094e823e188ce10</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fnrm3819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3819%26sid%3Dliteratum%253Aachs%26aulast%3DZitouni%26aufirst%3DS.%26aulast%3DNabais%26aufirst%3DC.%26aulast%3DJana%26aufirst%3DS.%2BC.%26aulast%3DGuerrero%26aufirst%3DA.%26aulast%3DBettencourt-Dias%26aufirst%3DM.%26atitle%3DPolo-like%2520kinases%253A%2520structural%2520variations%2520lead%2520to%2520multiple%2520functions%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D433%26epage%3D452%26doi%3D10.1038%2Fnrm3819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. A.</span></span> <span> </span><span class="NLM_article-title">Polo-like kinases (plks), a key regulator of cell cycle and new potential target for cancer therapy</span>. <i>Dev. Reprod.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.12717/DR.2014.18.1.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.12717%2FDR.2014.18.1.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=25949173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A280%3ADC%252BC2MfhsFylsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=65-71&author=S.+Y.+Leeauthor=C.+Jangauthor=K.+A.+Lee&title=Polo-like+kinases+%28plks%29%2C+a+key+regulator+of+cell+cycle+and+new+potential+target+for+cancer+therapy&doi=10.12717%2FDR.2014.18.1.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Polo-like kinases (plks), a key regulator of cell cycle and new potential target for cancer therapy</span></div><div class="casAuthors">Lee Su-Yeon; Jang Chuljoon; Lee Kyung-Ah</div><div class="citationInfo"><span class="NLM_cas:title">Development & reproduction</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-71</span>
        ISSN:<span class="NLM_cas:issn">2465-9525</span>.
    </div><div class="casAbstract">Cell cycle process is regulated by a number of protein kinases and among them, serine/threonine kinases carry phosphate group from ATP to substrates.  The most important three kinase families are Cyclin-dependent kinase (Cdk), Polo-like kinase (Plk), and Aurora kinase.  Polo-like kinase family consists of 5 members (Plk1-Plk5) and they are involved in multiple functions in eukaryotic cell division.  It regulates a variety of aspects such as, centrosome maturation, checkpoint recovery, spindle assembly, cytokinesis, apoptosis and many other features.  Recently, it has been reported that Plks are related to tumor development and over-expressed in many kinds of tumor cells.  When injected the anti-Plk antibody into human cells, the cells show aneuploidy, and if inhibit Plks, most of the mitotic cell division does not proceed properly.  For that reasons, many inhibitors of Plk have been recently emerged as new target for remedy of the cancer therapeutic research.  In this paper, we reviewed briefly the characteristics of Plk families and how Plks work in regulating cell cycles and cancer formation, and the possibilities of Plks as target for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTu8gBlm77WhNy3lHz94U-GfW6udTcc2eZUGClnUxApmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfhsFylsQ%253D%253D&md5=9d0b3d34e9e81f920fa25cbc8251d70f</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.12717%2FDR.2014.18.1.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12717%252FDR.2014.18.1.065%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DJang%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DK.%2BA.%26atitle%3DPolo-like%2520kinases%2520%2528plks%2529%252C%2520a%2520key%2520regulator%2520of%2520cell%2520cycle%2520and%2520new%2520potential%2520target%2520for%2520cancer%2520therapy%26jtitle%3DDev.%2520Reprod.%26date%3D2014%26volume%3D18%26spage%3D65%26epage%3D71%26doi%3D10.12717%2FDR.2014.18.1.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emmitte, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjebeng, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberti, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bambal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis-Ward, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassler, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornberger, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansing, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mook, R. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nailor, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pobanz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M.</span></span> <span> </span><span class="NLM_article-title">Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1694</span>– <span class="NLM_lpage">1697</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.01.094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2009.01.094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=19237286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVSltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1694-1697&author=K.+A.+Emmitteauthor=G.+M.+Adjebengauthor=C.+W.+Andrewsauthor=J.+G.+Albertiauthor=R.+Bambalauthor=S.+D.+Chamberlainauthor=R.+G.+Davis-Wardauthor=H.+D.+Dicksonauthor=D.+F.+Hasslerauthor=K.+R.+Hornbergerauthor=J.+R.+Jacksonauthor=K.+W.+Kuntzauthor=T.+J.+Lansingauthor=R.+A.+Mookauthor=K.+E.+Nailorauthor=M.+A.+Pobanzauthor=S.+C.+Smithauthor=C.+M.+Sungauthor=M.+Cheung&title=Design+of+potent+thiophene+inhibitors+of+polo-like+kinase+1+with+improved+solubility+and+reduced+protein+binding&doi=10.1016%2Fj.bmcl.2009.01.094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding</span></div><div class="casAuthors">Emmitte, Kyle A.; Adjebang, George M.; Andrews, C. Webb; Badiang-Alberti, Jennifer G.; Bambal, Ramesh; Chamberlain, Stanley D.; Davis-Ward, Ronda G.; Dickson, Hamilton D.; Hassler, Daniel F.; Hornberger, Keith R.; Jackson, Jeffrey R.; Kuntz, Kevin W.; Lansing, Timothy J.; Mook, Robert A.; Nailor, Kristen E.; Pobanz, Mark A.; Smith, Stephon C.; Sung, Chiu-Mei; Cheung, Mui</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1694-1697</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of thiophene PLK1 inhibitors was optimized for increased soly. and reduced protein binding through the appendage of basic amine functionality.  Interesting selectivity between PLK1 and PLK3 was also obtained through these modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLrXXbB1J4-rVg90H21EOLACvtfcHk0lginyKmt_UuDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVSltrY%253D&md5=30831c589bae973ca9267dfea68971e1</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.01.094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.01.094%26sid%3Dliteratum%253Aachs%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DAdjebeng%26aufirst%3DG.%2BM.%26aulast%3DAndrews%26aufirst%3DC.%2BW.%26aulast%3DAlberti%26aufirst%3DJ.%2BG.%26aulast%3DBambal%26aufirst%3DR.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DDavis-Ward%26aufirst%3DR.%2BG.%26aulast%3DDickson%26aufirst%3DH.%2BD.%26aulast%3DHassler%26aufirst%3DD.%2BF.%26aulast%3DHornberger%26aufirst%3DK.%2BR.%26aulast%3DJackson%26aufirst%3DJ.%2BR.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DLansing%26aufirst%3DT.%2BJ.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DNailor%26aufirst%3DK.%2BE.%26aulast%3DPobanz%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DS.%2BC.%26aulast%3DSung%26aufirst%3DC.%2BM.%26aulast%3DCheung%26aufirst%3DM.%26atitle%3DDesign%2520of%2520potent%2520thiophene%2520inhibitors%2520of%2520polo-like%2520kinase%25201%2520with%2520improved%2520solubility%2520and%2520reduced%2520protein%2520binding%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1694%26epage%3D1697%26doi%3D10.1016%2Fj.bmcl.2009.01.094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Signalling through the lipid products of phosphoinositide-3-OH kinase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1038/42648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2F42648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=9192891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK2sXktVWgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=1997&pages=673-676&author=A.+Tokerauthor=L.+C.+Cantley&title=Signalling+through+the+lipid+products+of+phosphoinositide-3-OH+kinase&doi=10.1038%2F42648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling through the lipid products of phosphoinositide-3-OH kinase</span></div><div class="casAuthors">Toker, Alex; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">6634</span>),
    <span class="NLM_cas:pages">673-676</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">A review, with 47 refs.  When a stimulatory agonist mol. binds at the exterior of the cell membrane, a second messenger transduces the signal to the interior of the cell.  Second messengers can be derived from phospholipids in the membrane by the action of the enzymes phospholipase C or phosphoinositide-3-OH kinase (PI(3)K).  PI(3)K is a key player in many cellular responses, including the movement of organelle membranes, shape alteration through rearrangement of cytoskeletal actin, transformation and chemotaxis.  But how PI(3)K mediates these responses is only now becoming clear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbe14cub5uAbVg90H21EOLACvtfcHk0lginyKmt_UuDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktVWgt7c%253D&md5=9c0d3fdb3a9a10027050c09ed3def89a</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2F42648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F42648%26sid%3Dliteratum%253Aachs%26aulast%3DToker%26aufirst%3DA.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DSignalling%2520through%2520the%2520lipid%2520products%2520of%2520phosphoinositide-3-OH%2520kinase%26jtitle%3DNature%26date%3D1997%26volume%3D387%26spage%3D673%26epage%3D676%26doi%3D10.1038%2F42648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span> <span> </span><span class="NLM_article-title">PI3K and cancer: lessons, challenges and opportunities</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1038/nrd4204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnrd4204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=24481312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=140-156&author=D.+A.+Frumanauthor=C.+Rommel&title=PI3K+and+cancer%3A+lessons%2C+challenges+and+opportunities&doi=10.1038%2Fnrd4204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and cancer: lessons, challenges and opportunities</span></div><div class="casAuthors">Fruman, David A.; Rommel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-156</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The central role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biol. has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and mammalian target of rapamycin (mTOR) in cancer.  However, emerging clin. data show limited single-agent activity of inhibitors targeting PI3K, AKT or mTOR at tolerated doses.  One exception is the response to PI3Kδ inhibitors in chronic lymphocytic leukemia, where a combination of cell-intrinsic and -extrinsic activities drive efficacy.  Here, we review key challenges and opportunities for the clin. development of inhibitors targeting the PI3K-AKT-mTOR pathway.  Through a greater focus on patient selection, increased understanding of immune modulation and strategic application of rational combinations, it should be possible to realize the potential of this promising class of targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlD2rY54m9LbVg90H21EOLACvtfcHk0ljZaTqvMFBvtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D&md5=c4f6b4b9f9fcacd6ef55eb17d3a4f425</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Fnrd4204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4204%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DPI3K%2520and%2520cancer%253A%2520lessons%252C%2520challenges%2520and%2520opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D140%26epage%3D156%26doi%3D10.1038%2Fnrd4204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jean, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiger, A. A.</span></span> <span> </span><span class="NLM_article-title">Classes of phosphoinositide 3-kinases at a glance</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1242/jcs.093773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1242%2Fjcs.093773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=24587488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Smtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2014&pages=923-928&author=S.+Jeanauthor=A.+A.+Kiger&title=Classes+of+phosphoinositide+3-kinases+at+a+glance&doi=10.1242%2Fjcs.093773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Classes of phosphoinositide 3-kinases at a glance</span></div><div class="casAuthors">Jean, Steve; Kiger, Amy A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">923-928</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) family is important to nearly all aspects of cell and tissue biol. and central to human cancer, diabetes and aging.  PI3Ks are spatially regulated and multifunctional, and together, act at nearly all membranes in the cell to regulate a wide range of signaling, membrane trafficking and metabolic processes.  There is a broadening recognition of the importance of distinct roles for each of the three different PI3K classes (I, II and III), as well as for the different isoforms within each class.  Ongoing issues include the need for a better understanding of the in vivo complexity of PI3K regulation and cellular functions.  This Cell Science at a Glance article and the accompanying poster summarize the biochem. activities, cellular roles and functional requirements for the three classes of PI3Ks.  In doing so, we aim to provide an overview of the parallels, the key differences and crucial interplays between the regulation and roles of the three PI3K classes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWxYxoaZNkirVg90H21EOLACvtfcHk0ljZaTqvMFBvtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Smtbk%253D&md5=52e183f6c434e5a0eaa266c5b8c520b2</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1242%2Fjcs.093773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.093773%26sid%3Dliteratum%253Aachs%26aulast%3DJean%26aufirst%3DS.%26aulast%3DKiger%26aufirst%3DA.%2BA.%26atitle%3DClasses%2520of%2520phosphoinositide%25203-kinases%2520at%2520a%2520glance%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2014%26volume%3D127%26spage%3D923%26epage%3D928%26doi%3D10.1242%2Fjcs.093773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, D.</span></span> <span> </span><span class="NLM_article-title">Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2016.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.apsb.2016.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=28119806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ovFOrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=27-37&author=W.+Zhaoauthor=Y.+Qiuauthor=D.+Kong&title=Class+I+phosphatidylinositol+3-kinase+inhibitors+for+cancer+therapy&doi=10.1016%2Fj.apsb.2016.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy</span></div><div class="casAuthors">Zhao Wennan; Qiu Yuling; Kong Dexin</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-37</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in human cancers.  Class I PI3Ks are lipid kinases that phosphorylate phosphatidylinositol 4,5-bisphosphate (PIP2) at the 3-OH of the inositol ring to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3), which in turn activates Akt and the downstream effectors like mammalian target of rapamycin (mTOR) to play key roles in carcinogenesis.  Therefore, PI3K has become an important anticancer drug target, and currently there is very high interest in the pharmaceutical development of PI3K inhibitors.  Idelalisib has been approved in USA and Europe as the first-in-class PI3K inhibitor for cancer therapy.  Dozens of other PI3K inhibitors including BKM120 and ZSTK474 are being evaluated in clinical trials.  Multifaceted studies on these PI3K inhibitors are being performed, such as single and combinational efficacy, resistance, biomarkers, etc.  This review provides an introduction to PI3K and summarizes key advances in the development of PI3K inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfpaqoNC7CEjAyhZbj3lKdfW6udTcc2eZTR-ycXO3UeLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ovFOrsg%253D%253D&md5=9506d6088eb6f72dc579ece97bb19930</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2016.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2016.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DD.%26atitle%3DClass%2520I%2520phosphatidylinositol%25203-kinase%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2017%26volume%3D7%26spage%3D27%26epage%3D37%26doi%3D10.1016%2Fj.apsb.2016.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chalhoub, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span> <span> </span><span class="NLM_article-title">PTEN and the PI3-kinase pathway in cancer</span>. <i>Annu. Rev. Pathol.: Mech. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1146/annurev.pathol.4.110807.092311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1146%2Fannurev.pathol.4.110807.092311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=18767981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1aiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=127-150&author=N.+Chalhoubauthor=S.+J.+Baker&title=PTEN+and+the+PI3-kinase+pathway+in+cancer&doi=10.1146%2Fannurev.pathol.4.110807.092311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">PTEN and the PI3-kinase pathway in cancer</span></div><div class="casAuthors">Chalhoub, Nader; Baker, Suzanne J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pathology: Mechanisms of Disease</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-150</span>CODEN:
                <span class="NLM_cas:coden">ARPMCU</span>;
        ISSN:<span class="NLM_cas:issn">1553-4006</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  PI3-kinase and PTEN are major pos. and neg. regulators, resp., of the PI3-kinase pathway, which regulates growth, survival, and proliferation.  These key signaling components are two of the most frequently mutated proteins in human cancers, resulting in unregulated activation of PI3K signaling and providing irrefutable genetic evidence of the central role of this pathway in tumorigenesis.  PTEN regulates PI3K signaling by dephosphorylating the lipid signaling intermediate PIP3, but PTEN may have addnl. phosphatase-independent activities, as well as other functions in the nucleus.  In this review, we highlight current work showing cancer-relevant complexities in the regulation of PTEN and PI3K activity, potential novel functions for PTEN, and feedback regulation within the pathway.  The significance and complexity of PI3K signaling make it an important but challenging therapeutic target for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYL7OEFJS0L7Vg90H21EOLACvtfcHk0ljZaTqvMFBvtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1aiu78%253D&md5=3a85209dd4803ce16557d4cdafc51613</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pathol.4.110807.092311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pathol.4.110807.092311%26sid%3Dliteratum%253Aachs%26aulast%3DChalhoub%26aufirst%3DN.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26atitle%3DPTEN%2520and%2520the%2520PI3-kinase%2520pathway%2520in%2520cancer%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2009%26volume%3D4%26spage%3D127%26epage%3D150%26doi%3D10.1146%2Fannurev.pathol.4.110807.092311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span> <i>FDA Approves Zydelig (idelalisib) for CLL and
Lymphoma</i>; <span class="NLM_publisher-name">Drugs.com</span>, <span class="NLM_year">2014</span>; <a href="https://www.drugs.com/newdrugs/fda-approves-zydelig-idelalisib-cll-lymphoma-4056.html" class="extLink">https://www.drugs.com/newdrugs/fda-approves-zydelig-idelalisib-cll-lymphoma-4056.html</a> (accessed Aug 23, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+Zydelig+%28idelalisib%29+for+CLL+and%0ALymphoma%3B+Drugs.com%2C+2014%3B+https%3A%2F%2Fwww.drugs.com%2Fnewdrugs%2Ffda-approves-zydelig-idelalisib-cll-lymphoma-4056.html+%28accessed+Aug+23%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520Zydelig%2520%2528idelalisib%2529%2520for%2520CLL%2520and%250ALymphoma%26pub%3DDrugs.com%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buitenhuis, M.</span></span> <span> </span><span class="NLM_article-title">The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">911</span>– <span class="NLM_lpage">923</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-07-366203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1182%2Fblood-2011-07-366203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22065598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XitVKqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=911-923&author=R.+Polakauthor=M.+Buitenhuis&title=The+PI3K%2FPKB+signaling+module+as+key+regulator+of+hematopoiesis%3A+implications+for+therapeutic+strategies+in+leukemia&doi=10.1182%2Fblood-2011-07-366203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia</span></div><div class="casAuthors">Polak, Roel; Buitenhuis, Miranda</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">911-923</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  An important mediator of cytokine signaling implicated in regulation of hematopoiesis is the PI3K/protein kinase B (PKB/c-Akt) signaling module.  Constitutive activation of this signaling module was obsd. in a large group of leukemias.  Because activation of this signaling pathway was demonstrated to be sufficient to induce hematol. malignancies and is thought to correlate with poor prognosis and enhanced drug resistance, it is considered to be a promising target for therapy.  A high no. of pharmacol. inhibitors directed against either individual or multiple components of this pathway have already been developed to improve therapy.  In this review, the safety and efficacy of both single and dual-specificity inhibitors will be discussed as well as the potential of combination therapy with either inhibitors directed against other signal transduction mols. or classic chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPVWKYSyAgjrVg90H21EOLACvtfcHk0ligNqPWOHWLvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitVKqt70%253D&md5=dd01c2d662a6b1efc919d293fdf589a3</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-07-366203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-07-366203%26sid%3Dliteratum%253Aachs%26aulast%3DPolak%26aufirst%3DR.%26aulast%3DBuitenhuis%26aufirst%3DM.%26atitle%3DThe%2520PI3K%252FPKB%2520signaling%2520module%2520as%2520key%2520regulator%2520of%2520hematopoiesis%253A%2520implications%2520for%2520therapeutic%2520strategies%2520in%2520leukemia%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D911%26epage%3D923%26doi%3D10.1182%2Fblood-2011-07-366203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelisti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaldi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCubrey, J. A.</span></span> <span> </span><span class="NLM_article-title">The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1576</span>– <span class="NLM_lpage">1596</span>, <span class="refDoi"> DOI: 10.3390/cancers2031576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.3390%2Fcancers2031576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=24281174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVKqsb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=1576-1596&author=A.+M.+Martelliauthor=C.+Evangelistiauthor=F.+Chiariniauthor=C.+Grimaldiauthor=J.+A.+McCubrey&title=The+emerging+role+of+the+phosphatidylinositol+3-kinase%2F+akt%2Fmammalian+target+of+rapamycin+signaling+network+in+cancer+stem+cell+biology&doi=10.3390%2Fcancers2031576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cell biology</span></div><div class="casAuthors">Martelli, Alberto M.; Evangelisti, Camilla; Chiarini, Francesca; Grimaldi, Cecilia; McCubrey, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1576-1596</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  The cancer stem cell theory entails the existence of a hierarchically organized, rare population of cells which are responsible for tumor initiation, self-renewal/maintenance, and mutation accumulation.  The cancer stem cell proposition could explain the high frequency of cancer relapse and resistance to currently available therapies.  The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway regulates a wide array of physiol. cell functions which include differentiation, proliferation, survival, metab., autophagy, and motility.  Dysregulated PI3K/Akt/mTOR signaling has been documented in many types of neoplasias.  It is now emerging that this signaling network plays a key role in cancer stem cell biol.  Interestingly, cancer stem cells displayed preferential sensitivity to pathway inhibition when compared to healthy stem cells.  This observation provides the proof-of-principle that functional differences in signaling pathways between neoplastic stem cells and healthy stem cells could be identified.  In this review, we present the evidence which links the signals emanating from the PI3K/Akt/mTOR cascade with the functions of cancer stem cells, both in solid and hematol. tumors.  We then highlight how targeting PI3K/Akt/mTOR signaling with small mols. could improve cancer patient outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoopiE6kAtVrbVg90H21EOLACvtfcHk0ligNqPWOHWLvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVKqsb3P&md5=162774f3695a5ea8fedac291d46c4e8c</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.3390%2Fcancers2031576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers2031576%26sid%3Dliteratum%253Aachs%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26aulast%3DEvangelisti%26aufirst%3DC.%26aulast%3DChiarini%26aufirst%3DF.%26aulast%3DGrimaldi%26aufirst%3DC.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520emerging%2520role%2520of%2520the%2520phosphatidylinositol%25203-kinase%252F%2520akt%252Fmammalian%2520target%2520of%2520rapamycin%2520signaling%2520network%2520in%2520cancer%2520stem%2520cell%2520biology%26jtitle%3DCancers%26date%3D2010%26volume%3D2%26spage%3D1576%26epage%3D1596%26doi%3D10.3390%2Fcancers2031576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meadows, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashishian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span> <span> </span><span class="NLM_article-title">PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of hodgkin lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1897</span>– <span class="NLM_lpage">1900</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-10-386763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1182%2Fblood-2011-10-386763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22210877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2lsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=1897-1900&author=S.+A.+Meadowsauthor=F.+Vegaauthor=A.+Kashishianauthor=D.+Johnsonauthor=V.+Diehlauthor=L.+L.+Millerauthor=A.+Younesauthor=B.+J.+Lannutti&title=PI3Kdelta+inhibitor%2C+GS-1101+%28CAL-101%29%2C+attenuates+pathway+signaling%2C+induces+apoptosis%2C+and+overcomes+signals+from+the+microenvironment+in+cellular+models+of+hodgkin+lymphoma&doi=10.1182%2Fblood-2011-10-386763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma</span></div><div class="casAuthors">Meadows, Sarah A.; Vega, Francisco; Kashishian, Adam; Johnson, Dave; Diehl, Volker; Miller, Langdon L.; Younes, Anas; Lannutti, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1897-1900</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">GS-1101 (CAL-101) is an oral PI3Kδ-specific inhibitor that has shown preclin. and clin. activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.  To investigate the potential role of PI3Kδ in Hodgkin lymphoma (HL), we screened 5 HL cell lines and primary samples from patients with HL for PI3Kδ isoform expression and constitutive PI3K pathway activation.  Inhibition of PI3Kδ by GS-1101 resulted in the inhibition of Akt phosphorylation.  Cocultures with stroma cells induced Akt activation in HL cells, and this effect was blocked by GS-1101.  Conversely, prodn. of the stroma-stimulating chemokine, CCL5, by HL cells was reduced by GS-1101.  GS-1101 also induced dose-dependent apoptosis of HL cells at 48 h.  Redns. in cell viability and apoptosis were enhanced when combining GS-1101 with the mTOR inhibitor everolimus.  Our findings suggest that excessive PI3Kδ activity is characteristic in HL and support clin. evaluation of GS-1101, alone and in combination, as targeted therapy for HL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZzwmb3X6oQ7Vg90H21EOLACvtfcHk0ligNqPWOHWLvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2lsrg%253D&md5=cee2562ed9ede3dfaa32ef6055f6580a</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-10-386763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-10-386763%26sid%3Dliteratum%253Aachs%26aulast%3DMeadows%26aufirst%3DS.%2BA.%26aulast%3DVega%26aufirst%3DF.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DDiehl%26aufirst%3DV.%26aulast%3DMiller%26aufirst%3DL.%2BL.%26aulast%3DYounes%26aufirst%3DA.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26atitle%3DPI3Kdelta%2520inhibitor%252C%2520GS-1101%2520%2528CAL-101%2529%252C%2520attenuates%2520pathway%2520signaling%252C%2520induces%2520apoptosis%252C%2520and%2520overcomes%2520signals%2520from%2520the%2520microenvironment%2520in%2520cellular%2520models%2520of%2520hodgkin%2520lymphoma%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D1897%26epage%3D1900%26doi%3D10.1182%2Fblood-2011-10-386763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masinovsky, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowell, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staunton, D. E.</span></span> <span> </span><span class="NLM_article-title">Essential role of phosphoinositide 3-kinase in neutrophil directional movement</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">2647</span>– <span class="NLM_lpage">2654</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.170.5.2647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.4049%2Fjimmunol.170.5.2647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=12594293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht12htLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2003&pages=2647-2654&author=C.+Sadhuauthor=B.+Masinovskyauthor=K.+Dickauthor=C.+G.+Sowellauthor=D.+E.+Staunton&title=Essential+role+of+phosphoinositide+3-kinase+in+neutrophil+directional+movement&doi=10.4049%2Fjimmunol.170.5.2647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Essential Role of Phosphoinositide 3-Kinase δ in Neutrophil Directional Movement</span></div><div class="casAuthors">Sadhu, Chanchal; Masinovsky, Boris; Dick, Ken; Sowell, C. Gregory; Staunton, Donald E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2647-2654</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Neutrophil chemotaxis is a crit. component of the innate immune response.  Neutrophils can sense an extremely shallow gradient of chemoattractants and produce relatively robust chemotactic behavior.  This directional migration requires cell polarization with actin polymn. occurring predominantly in the leading edge.  Synthesis of phosphatidylinositol (3,4,5) trisphosphate (PIP3) by phosphoinositide 3-kinase (PI3K) contributes to asym. F-actin synthesis and cell polarization during neutrophil chemotaxis.  To det. the contribution of the hemopoietic cell-restricted PI3Kδ in neutrophil chemotaxis, the authors have developed a potent and selective PI3Kδ inhibitor, IC87114.  IC87114 inhibited polarized morphol. of neutrophils, fMLP-stimulated PIP3 prodn. and chemotaxis.  Tracking anal. of IC87114-treated neutrophils indicated that PI3Kδ activity was required for the directional component of chemotaxis, but not for random movement.  Inhibition of PI3Kδ, however, did not block F-actin synthesis or neutrophil adhesion.  Thus, PI3Kδ can play a selective role in the amplification of PIP3 levels that lead to neutrophil polarization and directional migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc4QZDaVi8b7Vg90H21EOLACvtfcHk0lj5b2ihPMWyJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht12htLY%253D&md5=bc8815df15bc87d89f4df86a62f68cfa</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.170.5.2647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.170.5.2647%26sid%3Dliteratum%253Aachs%26aulast%3DSadhu%26aufirst%3DC.%26aulast%3DMasinovsky%26aufirst%3DB.%26aulast%3DDick%26aufirst%3DK.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DStaunton%26aufirst%3DD.%2BE.%26atitle%3DEssential%2520role%2520of%2520phosphoinositide%25203-kinase%2520in%2520neutrophil%2520directional%2520movement%26jtitle%3DJ.%2520Immunol.%26date%3D2003%26volume%3D170%26spage%3D2647%26epage%3D2654%26doi%3D10.4049%2Fjimmunol.170.5.2647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berndt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, D. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houseman, B. T</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacold, J. I</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorrec, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hon, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaillard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, M. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, J. P</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L</span></span> <span> </span><span class="NLM_article-title">The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1038/nchembio.293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnchembio.293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=20081827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFGrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=117-124&author=A.+Berndtauthor=S.+Millerauthor=O.+Williamsauthor=D.+D+Leauthor=B.+T+Housemanauthor=J.+I+Pacoldauthor=F.+Gorrecauthor=W.-C.+Honauthor=P.+Renauthor=Y.+Liuauthor=C.+Rommelauthor=P.+Gaillardauthor=T.+Ruckleauthor=M.+K+Schwarzauthor=K.+M+Shokatauthor=J.+P+Shawauthor=R.+L+Williams&title=The+p110+delta+structure%3A+mechanisms+for+selectivity+and+potency+of+new+PI%283%29K+inhibitors&doi=10.1038%2Fnchembio.293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors</span></div><div class="casAuthors">Berndt, Alex; Miller, Simon; Williams, Olusegun; Le, Daniel D.; Houseman, Benjamin T.; Pacold, Joseph I.; Gorrec, Fabrice; Hon, Wai-Ching; Liu, Yi; Rommel, Christian; Gaillard, Pascale; Rueckle, Thomas; Schwarz, Matthias K.; Shokat, Kevan M.; Shaw, Jeffrey P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-124</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Deregulation of the phosphoinositide-3-OH kinase (PI(3)K) pathway has been implicated in numerous pathologies including cancer, diabetes, thrombosis, rheumatoid arthritis, and asthma.  Recently, small-mol. and ATP-competitive PI(3)K inhibitors with a wide range of selectivities have entered clin. development.  To understand the mechanisms underlying the isoform selectivity of these inhibitors, we developed a new expression strategy that enabled us to det. to our knowledge the first crystal structure of the catalytic subunit of the class IA PI(3)K p110δ.  Structures of this enzyme in complex with a broad panel of isoform- and pan-selective class I PI(3)K inhibitors reveal that selectivity toward p110δ can be achieved by exploiting its conformational flexibility and the sequence diversity of active site residues that do not contact ATP.  We have used these observations to rationalize and synthesize highly selective inhibitors for p110δ with greatly improved potencies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL8d01cEl_y7Vg90H21EOLACvtfcHk0lj5b2ihPMWyJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFGrsw%253D%253D&md5=8a0ce73ab8ca88ea9a48a2cb7fdb1975</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.293%26sid%3Dliteratum%253Aachs%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLe%26aufirst%3DD.%2BD%26aulast%3DHouseman%26aufirst%3DB.%2BT%26aulast%3DPacold%26aufirst%3DJ.%2BI%26aulast%3DGorrec%26aufirst%3DF.%26aulast%3DHon%26aufirst%3DW.-C.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DGaillard%26aufirst%3DP.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DSchwarz%26aufirst%3DM.%2BK%26aulast%3DShokat%26aufirst%3DK.%2BM%26aulast%3DShaw%26aufirst%3DJ.%2BP%26aulast%3DWilliams%26aufirst%3DR.%2BL%26atitle%3DThe%2520p110%2520delta%2520structure%253A%2520mechanisms%2520for%2520selectivity%2520and%2520potency%2520of%2520new%2520PI%25283%2529K%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D117%26epage%3D124%26doi%3D10.1038%2Fnchembio.293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcomb, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, V.</span></span> <span> </span><span class="NLM_article-title">Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1537</span>– <span class="NLM_lpage">1542</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1158%2F1078-0432.CCR-14-2034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=25670221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVahsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1537-1542&author=Q.+Yangauthor=P.+Modiauthor=T.+Newcombauthor=C.+Quevaauthor=V.+Gandhi&title=Idelalisib%3A+first-in-class+PI3K+delta+inhibitor+for+the+treatment+of+chronic+lymphocytic+leukemia%2C+small+lymphocytic+leukemia%2C+and+follicular+lymphoma&doi=10.1158%2F1078-0432.CCR-14-2034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma</span></div><div class="casAuthors">Yang, Qingshan; Modi, Prexy; Newcomb, Terry; Queva, Christophe; Gandhi, Varsha</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1537-1542</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Idelalisib [Zydelig (Gilead Sciences, Inc.), also known as CAL-101 and GS-1101] was approved in 2014 in the United States and European Union for the treatment of three indolent B-cell neoplasms: relapsed/refractory chronic lymphocytic leukemia (CLL, in combination with rituximab), relapsed follicular lymphoma, and relapsed small lymphocytic lymphoma (as monotherapy).  Furthermore, it was approved in the European Union as first-line therapy for poor-prognosis CLL with 17p deletions or TP53 mutations and in patients unsuitable for chemoimmunotherapy.  Idelalisib is an orally bioavailable ATP-competitive kinase inhibitor that targets the PI3K p110 isoform δ (PI3Kδ) with high potency and selectivity.  PI3Kδ is hyperactivated in B-cell malignancies and plays a pivotal role in the B-cell receptor pathway, a key oncogenic driver in B-cell malignancies.  The near exclusive expression of the PI3Kδ isoform in hematopoietic cells and the selectivity of idelalisib for the PI3Kδ isoform are essential for its efficacy and tolerability, even in elderly patients unfit for chemotherapy.  Idelalisib is the first PI3K inhibitor approved by the regulatory agencies; this approval will change the treatment landscape of indolent B-cell malignancies.  Clin Cancer Res; 21(7); 1537-42. ©2015 AACR.  See related article by Miller et al., p.  1525.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNvlp-jsFsjbVg90H21EOLACvtfcHk0lj5b2ihPMWyJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVahsrk%253D&md5=1cd89cd74f7f60a61303aa037c2a54a0</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2034%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DModi%26aufirst%3DP.%26aulast%3DNewcomb%26aufirst%3DT.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DGandhi%26aufirst%3DV.%26atitle%3DIdelalisib%253A%2520first-in-class%2520PI3K%2520delta%2520inhibitor%2520for%2520the%2520treatment%2520of%2520chronic%2520lymphocytic%2520leukemia%252C%2520small%2520lymphocytic%2520leukemia%252C%2520and%2520follicular%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1537%26epage%3D1542%26doi%3D10.1158%2F1078-0432.CCR-14-2034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Do, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mace, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rexwinkle, A.</span></span> <span> </span><span class="NLM_article-title">Idelalisib for treatment of B-cell malignancies</span>. <i>Am. J. Health-Syst. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.2146/ajhp150281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.2146%2Fajhp150281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=26933132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVOht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2016&pages=547-555&author=B.+Doauthor=M.+Maceauthor=A.+Rexwinkle&title=Idelalisib+for+treatment+of+B-cell+malignancies&doi=10.2146%2Fajhp150281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Idelalisib for treatment of B-cell malignancies</span></div><div class="casAuthors">Do, Bryan; Mace, Morgan; Rexwinkle, Amber</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Health-System Pharmacy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">547-555</span>CODEN:
                <span class="NLM_cas:coden">AHSPEK</span>;
        ISSN:<span class="NLM_cas:issn">1079-2082</span>.
    
            (<span class="NLM_cas:orgname">American Society of Health-System Pharmacists</span>)
        </div><div class="casAbstract">Purpose The pharmacol., pharmacokinetics, clin. efficacy, safety and tolerability, dosing and administration, and place in therapy of idelalisib, a targeted therapy for certain types of non-Hodgkin's lymphoma (NHL), are reviewed.  Summary Historically, conventional cancer chemotherapy agents were recommended for the management of progressive lymphomas requiring systemic treatment; in recent years, however, emerging targeted therapies have altered the landscape of lymphoma treatment.  Idelalisib, a novel oral phosphatidylinositol 3-kinase (PI3K) inhibitor, disrupts downstream signaling pathways involved in cancer cell growth and survival.  Inhibition of PI3K has been demonstrated to produce durable treatment responses and improved survival outcomes in clin. trials involving patients with indolent forms of NHL.  Idelalisib is indicated for use in combination with rituximab for treatment of relapsed chronic lymphocytic leukemia (CLL) and as monotherapy for relapsed small lymphocytic leukemia and follicular lymphoma after the failure of at least two systemic treatments.  The recommended dosage of idelalisib is 150 mg orally twice daily; the medication can be taken without regard to mealtimes.  The most common adverse effects of idelalisib include diarrhea, nausea, fatigue, cough, and pyrexia.  Severe hepatotoxicity and gastrointestinal toxicities, including colitis and intestinal perforation, have also been reported in assocn. with idelalisib use.  Ongoing clin. studies are exploring the potential for expanded use of idelalisib in the management of other B-cell malignancies.  Conclusion Idelalisib is a well-tolerated and effective treatment for patients with relapsed or refractory CLL or indolent NHL, providing a novel targeted therapeutic option for the management of these hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTBhrG6L37zLVg90H21EOLACvtfcHk0ljqNDXG52rXlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVOht7g%253D&md5=118029cda72d99310663a3300aa698d7</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.2146%2Fajhp150281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252Fajhp150281%26sid%3Dliteratum%253Aachs%26aulast%3DDo%26aufirst%3DB.%26aulast%3DMace%26aufirst%3DM.%26aulast%3DRexwinkle%26aufirst%3DA.%26atitle%3DIdelalisib%2520for%2520treatment%2520of%2520B-cell%2520malignancies%26jtitle%3DAm.%2520J.%2520Health-Syst.%2520Pharm.%26date%3D2016%26volume%3D73%26spage%3D547%26epage%3D555%26doi%3D10.2146%2Fajhp150281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meadows, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashishian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriaux, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, N. A.</span></span> <span> </span><span class="NLM_article-title">CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">594</span>, <span class="refDoi"> DOI: 10.1182/blood-2010-03-275305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1182%2Fblood-2010-03-275305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=20959606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1aqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=591-594&author=B.+J.+Lannuttiauthor=S.+A.+Meadowsauthor=S.+E.+Hermanauthor=A.+Kashishianauthor=B.+Steinerauthor=A.+J.+Johnsonauthor=J.+C.+Byrdauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=M.+Deiningerauthor=B.+J.+Drukerauthor=K.+D.+Puriauthor=R.+G.+Ulrichauthor=N.+A.+Giese&title=CAL-101%2C+a+p110delta+selective+phosphatidylinositol-3-kinase+inhibitor+for+the+treatment+of+B-cell+malignancies%2C+inhibits+PI3K+signaling+and+cellular+viability&doi=10.1182%2Fblood-2010-03-275305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability</span></div><div class="casAuthors">Lannutti, Brian J.; Meadows, Sarah A.; Herman, Sarah E. M.; Kashishian, Adam; Steiner, Bart; Johnson, Amy J.; Byrd, John C.; Tyner, Jeffrey W.; Loriaux, Marc M.; Deininger, Mike; Druker, Brian J.; Puri, Kamal D.; Ulrich, Roger G.; Giese, Neill A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">591-594</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase p110δ serves as a central integration point for signaling from cell surface receptors known to promote malignant B-cell proliferation and survival.  This provides a rationale for the development of small mol. inhibitors that selectively target p110δ as a treatment approach for patients with B-cell malignancies.  We thus identified 5-fluoro-3-phenyl-2-[(S)-1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one (CAL-101), a highly selective and potent p110δ small mol. inhibitor (half-maximal effective concn. [EC50] = 8nM).  Using tumor cell lines and primary patient samples representing multiple B-cell malignancies, we have demonstrated that constitutive phosphatidylinositol-3-kinase pathway activation is p110δ-dependent.  CAL-101 blocked constitutive phosphatidylinositol-3-kinase signaling, resulting in decreased phosphorylation of Akt and other downstream effectors, an increase in poly(ADP-ribose) polymerase and caspase cleavage and an induction of apoptosis.  These effects have been obsd. across a broad range of immature and mature B-cell malignancies, thereby providing a rationale for the ongoing clin. evaluation of CAL-101.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrID8zgXRVmvbVg90H21EOLACvtfcHk0ljqNDXG52rXlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1aqtro%253D&md5=423bf1fbea274424db3b818fdc6733b0</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-03-275305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-03-275305%26sid%3Dliteratum%253Aachs%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DMeadows%26aufirst%3DS.%2BA.%26aulast%3DHerman%26aufirst%3DS.%2BE.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DDeininger%26aufirst%3DM.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DUlrich%26aufirst%3DR.%2BG.%26aulast%3DGiese%26aufirst%3DN.%2BA.%26atitle%3DCAL-101%252C%2520a%2520p110delta%2520selective%2520phosphatidylinositol-3-kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520B-cell%2520malignancies%252C%2520inhibits%2520PI3K%2520signaling%2520and%2520cellular%2520viability%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D591%26epage%3D594%26doi%3D10.1182%2Fblood-2010-03-275305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koditek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villasenor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novikov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liclican, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagpacan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papalia, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span> <span> </span><span class="NLM_article-title">Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase delta</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">8439</span>– <span class="NLM_lpage">8446</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.634683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1074%2Fjbc.M114.634683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=25631052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVSqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=8439-8446&author=J.+R.+Somozaauthor=D.+Koditekauthor=A.+G.+Villasenorauthor=N.+Novikovauthor=M.+H.+Wongauthor=A.+Liclicanauthor=W.+Xingauthor=L.+Lagpacanauthor=R.+Wangauthor=B.+E.+Schultzauthor=G.+A.+Papaliaauthor=D.+Samuelauthor=L.+Ladauthor=M.+E.+McGrath&title=Structural%2C+biochemical%2C+and+biophysical+characterization+of+idelalisib+binding+to+phosphoinositide+3-kinase+delta&doi=10.1074%2Fjbc.M114.634683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ</span></div><div class="casAuthors">Somoza, John R.; Koditek, David; Villasenor, Armando G.; Novikov, Nikolai; Wong, Melanie H.; Liclican, Albert; Xing, Weimei; Lagpacan, Leanna; Wang, Ruth; Schultz, Brian E.; Papalia, Giuseppe A.; Samuel, Dharmaraj; Lad, Latesh; McGrath, Mary E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">8439-8446</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Idelalisib (also known as GS-1101, CAL-101, IC489666, and Zydelig) is a PI3Kδ inhibitor that has recently been approved for the treatment of several hematol. malignancies.  Given its use in human diseases, we needed a clear picture of how idelalisib binds to and inhibits PI3Kδ.  Our data show that idelalisib is a potent and selective inhibitor of the kinase activity of PI3Kδ.  A kinetic characterization clearly demonstrated ATP-competitive inhibition, and several addnl. biochem. and biophys. assays showed that the compd. binds reversibly and noncovalently to the kinase.  A crystal structure of idelalisib bound to the p110δ subunit of PI3Kδ furthers our understanding of the binding interactions that confer the potency and selectivity of idelalisib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnXZo8_qK79rVg90H21EOLACvtfcHk0ljqNDXG52rXlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVSqtrs%253D&md5=2969b7407f4edc367249215bbbf22a0e</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.634683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.634683%26sid%3Dliteratum%253Aachs%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DNovikov%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DM.%2BH.%26aulast%3DLiclican%26aufirst%3DA.%26aulast%3DXing%26aufirst%3DW.%26aulast%3DLagpacan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DPapalia%26aufirst%3DG.%2BA.%26aulast%3DSamuel%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26atitle%3DStructural%252C%2520biochemical%252C%2520and%2520biophysical%2520characterization%2520of%2520idelalisib%2520binding%2520to%2520phosphoinositide%25203-kinase%2520delta%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D8439%26epage%3D8446%26doi%3D10.1074%2Fjbc.M114.634683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Angelo, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herberich, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5188</span>– <span class="NLM_lpage">5219</span>, <span class="refDoi"> DOI: 10.1021/jm300184s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300184s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1Oqt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5188-5219&author=A.+L.+Smithauthor=N.+D.+D%E2%80%99Angeloauthor=Y.+Y.+Boauthor=S.+K.+Bookerauthor=V.+J.+Ceeauthor=B.+Herberichauthor=F.+T.+Hongauthor=C.+L.+Jacksonauthor=B.+A.+Lanmanauthor=L.+Liuauthor=N.+Nishimuraauthor=L.+H.+Pettusauthor=A.+B.+Reedauthor=S.+Tadesseauthor=N.+A.+Tamayoauthor=R.+P.+Wurzauthor=K.+Yangauthor=K.+L.+Andrewsauthor=D.+A.+Whittingtonauthor=J.+D.+McCarterauthor=T.+S.+Miguelauthor=L.+Zalamedaauthor=J.+Jiangauthor=R.+Subramanianauthor=E.+L.+Mulladyauthor=S.+Caenepeelauthor=D.+J.+Freemanauthor=L.+Wangauthor=N.+Zhangauthor=T.+Wuauthor=P.+E.+Hughesauthor=M.+H.+Norman&title=Structure-based+design+of+a+novel+series+of+potent%2C+selective+inhibitors+of+the+class+I+phosphatidylinositol+3-kinases&doi=10.1021%2Fjm300184s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases</span></div><div class="casAuthors">Smith, Adrian L.; D'Angelo, Noel D.; Bo, Yunxin Y.; Booker, Shon K.; Cee, Victor J.; Herberich, Brad; Hong, Fang-Tsao; Jackson, Claire L. M.; Lanman, Brian A.; Liu, Longbin; Nishimura, Nobuko; Pettus, Liping H.; Reed, Anthony B.; Tadesse, Seifu; Tamayo, Nuria A.; Wurz, Ryan P.; Yang, Kevin; Andrews, Kristin L.; Whittington, Douglas A.; McCarter, John D.; Miguel, Tisha San; Zalameda, Leeanne; Jiang, Jian; Subramanian, Raju; Mullady, Erin L.; Caenepeel, Sean; Freeman, Daniel J.; Wang, Ling; Zhang, Nancy; Wu, Tian; Hughes, Paul E.; Norman, Mark H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5188-5219</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Biheteroaryl arylamines such as I were prepd. as selective inhibitors of class I phosphatidylinositol 3-kinases (PI3K) selective for PI3K over mTOR for potential use as antitumor agents.  The dual PI3K/mTOR inhibitor II was used as a lead compd.; refinement of its structure to improve its potency and selectivity resulted in the identification of I as a potent inhibitor of the class I PI3Ks with excellent selectivity over mTOR, related phosphatidylinositol kinases, and a broad panel of protein kinases.  The pharmacokinetics of orally and i.v. administered I and selected biheteroaryl arylamines were detd.  I inhibited the PI3K/Akt pathway in vivo in a mouse model and potently inhibited tumor growth in a xenograft model with an activated PI3K/Akt pathway.  The structures of I and II bound to PI3Kγ were detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwj78DmYgaeLVg90H21EOLACvtfcHk0lgafn6xmAmL9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1Oqt74%253D&md5=673cc3677c40dca6090dc33df7cde330</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fjm300184s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300184s%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DBo%26aufirst%3DY.%2BY.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DHerberich%26aufirst%3DB.%26aulast%3DHong%26aufirst%3DF.%2BT.%26aulast%3DJackson%26aufirst%3DC.%2BL.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DTamayo%26aufirst%3DN.%2BA.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMiguel%26aufirst%3DT.%2BS.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DFreeman%26aufirst%3DD.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26atitle%3DStructure-based%2520design%2520of%2520a%2520novel%2520series%2520of%2520potent%252C%2520selective%2520inhibitors%2520of%2520the%2520class%2520I%2520phosphatidylinositol%25203-kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5188%26epage%3D5219%26doi%3D10.1021%2Fjm300184s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Angelo, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herberich, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aidasani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span> <span> </span><span class="NLM_article-title">Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7796</span>– <span class="NLM_lpage">7816</span>, <span class="refDoi"> DOI: 10.1021/jm300846z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300846z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Wls7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7796-7816&author=M.+H.+Normanauthor=K.+L.+Andrewsauthor=Y.+Y.+Boauthor=S.+K.+Bookerauthor=S.+Caenepeelauthor=V.+J.+Ceeauthor=N.+D.+D%E2%80%99Angeloauthor=D.+J.+Freemanauthor=B.+J.+Herberichauthor=F.+T.+Hongauthor=C.+L.+Jacksonauthor=J.+Jiangauthor=B.+A.+Lanmanauthor=L.+Liuauthor=J.+D.+McCarterauthor=E.+L.+Mulladyauthor=N.+Nishimuraauthor=L.+H.+Pettusauthor=A.+B.+Reedauthor=T.+S.+Miguelauthor=A.+L.+Smithauthor=M.+M.+Stecauthor=S.+Tadesseauthor=A.+Taskerauthor=D.+Aidasaniauthor=X.+Zhuauthor=R.+Subramanianauthor=N.+A.+Tamayoauthor=L.+Wangauthor=D.+A.+Whittingtonauthor=B.+Wuauthor=T.+Wuauthor=R.+P.+Wurzauthor=K.+Yangauthor=L.+Zalamedaauthor=N.+Zhangauthor=P.+E.+Hughes&title=Selective+class+I+phosphoinositide+3-kinase+inhibitors%3A+optimization+of+a+series+of+pyridyltriazines+leading+to+the+identification+of+a+clinical+candidate%2C+AMG+511&doi=10.1021%2Fjm300846z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511</span></div><div class="casAuthors">Norman, Mark H.; Andrews, Kristin L.; Bo, Yunxin Y.; Booker, Shon K.; Caenepeel, Sean; Cee, Victor J.; D'Angelo, Noel D.; Freeman, Daniel J.; Herberich, Bradley J.; Hong, Fang-Tsao; Jackson, Claire L. M.; Jiang, Jian; Lanman, Brian A.; Liu, Longbin; McCarter, John D.; Mullady, Erin L.; Nishimura, Nobuko; Pettus, Liping H.; Reed, Anthony B.; Miguel, Tisha San; Smith, Adrian L.; Stec, Markian M.; Tadesse, Seifu; Tasker, Andrew; Aidasani, Divesh; Zhu, Xiaochun; Subramanian, Raju; Tamayo, Nuria A.; Wang, Ling; Whittington, Douglas A.; Wu, Bin; Wu, Tian; Wurz, Ryan P.; Yang, Kevin; Zalameda, Leeanne; Zhang, Nancy; Hughes, Paul E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7796-7816</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The phosphoinositide 3-kinase family catalyzes the phosphorylation of phosphatidylinositol-4,5-diphosphate to phosphatidylinositol-3,4,5-triphosphate, a secondary messenger which plays a crit. role in important cellular functions such as metab., cell growth, and cell survival.  Our efforts to identify potent, efficacious, and orally available phosphatidylinositol 3-kinase (PI3K) inhibitors as potential cancer therapeutics have resulted in the discovery of 4-(2-((6-methoxypyridin-3-yl)amino)-5-((4-(methylsulfonyl)piperazin-1-yl)methyl)pyridin-3-yl)-6-methyl-1,3,5-triazin-2-amine (I).  In this paper, we describe the optimization of I, which led to the design and synthesis of pyridyltriazine (II), a potent pan inhibitor of class I PI3Ks with a superior pharmacokinetic profile.  II was shown to potently block the targeted PI3K pathway in a mouse liver pharmacodynamic model and inhibit tumor growth in a U87 malignant glioma glioblastoma xenograft model.  On the basis of its excellent in vivo efficacy and pharmacokinetic profile, II was selected for further evaluation as a clin. candidate and was designated AMG 511.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZl70tnsqvELVg90H21EOLACvtfcHk0lgafn6xmAmL9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Wls7%252FK&md5=0ee0a61fc0d919c3e9c3c4dc86f4070b</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Fjm300846z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300846z%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DBo%26aufirst%3DY.%2BY.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DFreeman%26aufirst%3DD.%2BJ.%26aulast%3DHerberich%26aufirst%3DB.%2BJ.%26aulast%3DHong%26aufirst%3DF.%2BT.%26aulast%3DJackson%26aufirst%3DC.%2BL.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DMiguel%26aufirst%3DT.%2BS.%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DStec%26aufirst%3DM.%2BM.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DAidasani%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DTamayo%26aufirst%3DN.%2BA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26atitle%3DSelective%2520class%2520I%2520phosphoinositide%25203-kinase%2520inhibitors%253A%2520optimization%2520of%2520a%2520series%2520of%2520pyridyltriazines%2520leading%2520to%2520the%2520identification%2520of%2520a%2520clinical%2520candidate%252C%2520AMG%2520511%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7796%26epage%3D7816%26doi%3D10.1021%2Fjm300846z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span> </span><span class="NLM_article-title">AMG 319 in HPV Positive and Negative HNSCC</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, <span class="NLM_year">2015</span>; <a href="https://clinicaltrials.gov/ct2/show/NCT02540928" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02540928</a> (accessed Oct 18, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AMG+319+in+HPV+Positive+and+Negative+HNSCC.+ClinicalTrials.gov%3B+U.S.+Food+and+Drug+Administration%2C+2015%3B+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02540928+%28accessed+Oct+18%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DAMG%2520319%2520in%2520HPV%2520Positive%2520and%2520Negative%2520HNSCC%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Lopez
de Turiso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungate, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattaropong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichelt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rzasa, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seganish, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whoriskey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and in vivo evaluation of (<i>S</i>)-<i>N</i>-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine (AMG319) and related PI3Kdelta inhibitors for inflammation and autoimmune disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1021/jm501624r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501624r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVegur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=480-511&author=T.+D.+Cushingauthor=X.+Haoauthor=Y.+Shinauthor=K.+Andrewsauthor=M.+Brownauthor=M.+Cardozoauthor=Y.+Chenauthor=J.+Duquetteauthor=B.+Fisherauthor=F.+Gonzalez-Lopez%0Ade+Turisoauthor=X.+Heauthor=K.+R.+Henneauthor=Y.+L.+Huauthor=R.+Hungateauthor=M.+G.+Johnsonauthor=R.+C.+Kellyauthor=B.+Lucasauthor=J.+D.+McCarterauthor=L.+R.+McGeeauthor=J.+C.+Medinaauthor=T.+San+Miguelauthor=D.+Mohnauthor=V.+Pattaropongauthor=L.+H.+Pettusauthor=A.+Reicheltauthor=R.+M.+Rzasaauthor=J.+Seganishauthor=A.+S.+Taskerauthor=R.+C.+Wahlauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=J.+Whoriskeyauthor=G.+Yuauthor=L.+Zalamedaauthor=D.+Zhangauthor=D.+P.+Metz&title=Discovery+and+in+vivo+evaluation+of+%28S%29-N-%281-%287-fluoro-2-%28pyridin-2-yl%29quinolin-3-yl%29ethyl%29-9H-purin-6-amine+%28AMG319%29+and+related+PI3Kdelta+inhibitors+for+inflammation+and+autoimmune+disease&doi=10.1021%2Fjm501624r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease</span></div><div class="casAuthors">Cushing, Timothy D.; Hao, Xiaolin; Shin, Youngsook; Andrews, Kristin; Brown, Matthew; Cardozo, Mario; Chen, Yi; Duquette, Jason; Fisher, Ben; Gonzalez-Lopez de Turiso, Felix; He, Xiao; Henne, Kirk R.; Hu, Yi-Ling; Hungate, Randall; Johnson, Michael G.; Kelly, Ron C.; Lucas, Brian; McCarter, John D.; McGee, Lawrence R.; Medina, Julio C.; San Miguel, Tisha; Mohn, Deanna; Pattaropong, Vatee; Pettus, Liping H.; Reichelt, Andreas; Rzasa, Robert M.; Seganish, Jennifer; Tasker, Andrew S.; Wahl, Robert C.; Wannberg, Sharon; Whittington, Douglas A.; Whoriskey, John; Yu, Gang; Zalameda, Leeanne; Zhang, Dawei; Metz, Daniela P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">480-511</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development and optimization of a series of quinolinylpurines as potent and selective PI3Kδ kinase inhibitors with excellent physicochem. properties are described.  This medicinal chem. effort led to the identification of I (AMG319), a compd. with an IC50 of 16 nM in a human whole blood assay (HWB), excellent selectivity over a large panel of protein kinases, and a high level of in vivo efficacy as measured by two rodent disease models of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt3BtsoY7G2rVg90H21EOLACvtfcHk0ljHTvzvovyhpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVegur%252FL&md5=08af48a5c6208d6f61bea77e9ad840aa</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Fjm501624r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501624r%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DAndrews%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DGonzalez-Lopez%2Bde%2BTuriso%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DHu%26aufirst%3DY.%2BL.%26aulast%3DHungate%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DKelly%26aufirst%3DR.%2BC.%26aulast%3DLucas%26aufirst%3DB.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReichelt%26aufirst%3DA.%26aulast%3DRzasa%26aufirst%3DR.%2BM.%26aulast%3DSeganish%26aufirst%3DJ.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWhoriskey%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26atitle%3DDiscovery%2520and%2520in%2520vivo%2520evaluation%2520of%2520%2528S%2529-N-%25281-%25287-fluoro-2-%2528pyridin-2-yl%2529quinolin-3-yl%2529ethyl%2529-9H-purin-6-amine%2520%2528AMG319%2529%2520and%2520related%2520PI3Kdelta%2520inhibitors%2520for%2520inflammation%2520and%2520autoimmune%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D480%26epage%3D511%26doi%3D10.1021%2Fjm501624r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erhard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardwicke, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luengo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McSurdy-Freed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spengler, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivero, R. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of imidazo[1,2-<i>a</i>]pyrimidin-5(1<i>H</i>)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2230</span>– <span class="NLM_lpage">2234</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2012.01.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22361133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtV2ksrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2230-2234&author=H.+Linauthor=K.+Erhardauthor=M.+A.+Hardwickeauthor=J.+I.+Luengoauthor=J.+F.+Mackauthor=J.+McSurdy-Freedauthor=R.+Plantauthor=K.+Rahaauthor=C.+M.+Romingerauthor=R.+M.+Sanchezauthor=M.+D.+Schaberauthor=M.+J.+Schulzauthor=M.+D.+Spenglerauthor=R.+Tedescoauthor=R.+Xieauthor=J.+J.+Zengauthor=R.+A.+Rivero&title=Synthesis+and+structure-activity+relationships+of+imidazo%5B1%2C2-a%5Dpyrimidin-5%281H%29-ones+as+a+novel+series+of+beta+isoform+selective+phosphatidylinositol+3-kinase+inhibitors&doi=10.1016%2Fj.bmcl.2012.01.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of imidazo[1,2-a]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors</span></div><div class="casAuthors">Lin, Hong; Erhard, Karl; Hardwicke, Mary Ann; Luengo, Juan I.; Mack, James F.; McSurdy-Freed, Jeanelle; Plant, Ramona; Raha, Kaushik; Rominger, Cynthia M.; Sanchez, Robert M.; Schaber, Michael D.; Schulz, Mark J.; Spengler, Michael D.; Tedesco, Rosanna; Xie, Ren; Zeng, Jin J.; Rivero, Ralph A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2230-2234</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of PI3K-beta selective inhibitors, imidazo[1,2-a]-pyrimidin-5(1H)-ones, has been rationally designed based on the docking model of the more potent R enantiomer of TGX-221, identified by a chiral sepn., in a PI3K-beta homol. model.  Synthesis and SAR of this novel chemotype are described.  Several compds. in the series demonstrated potent growth inhibition in a PTEN-deficient breast cancer cell line MDA-MB-468 under anchorage independent conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOCJin9HDxtLVg90H21EOLACvtfcHk0ljHTvzvovyhpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtV2ksrg%253D&md5=6428a89baa3e88253799ddb534eacd27</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.092%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%26aulast%3DErhard%26aufirst%3DK.%26aulast%3DHardwicke%26aufirst%3DM.%2BA.%26aulast%3DLuengo%26aufirst%3DJ.%2BI.%26aulast%3DMack%26aufirst%3DJ.%2BF.%26aulast%3DMcSurdy-Freed%26aufirst%3DJ.%26aulast%3DPlant%26aufirst%3DR.%26aulast%3DRaha%26aufirst%3DK.%26aulast%3DRominger%26aufirst%3DC.%2BM.%26aulast%3DSanchez%26aufirst%3DR.%2BM.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DSchulz%26aufirst%3DM.%2BJ.%26aulast%3DSpengler%26aufirst%3DM.%2BD.%26aulast%3DTedesco%26aufirst%3DR.%26aulast%3DXie%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DJ.%2BJ.%26aulast%3DRivero%26aufirst%3DR.%2BA.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520imidazo%255B1%252C2-a%255Dpyrimidin-5%25281H%2529-ones%2520as%2520a%2520novel%2520series%2520of%2520beta%2520isoform%2520selective%2520phosphatidylinositol%25203-kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2230%26epage%3D2234%26doi%3D10.1016%2Fj.bmcl.2012.01.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunder, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loewith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">A pharmacological map of the PI3K family defines a role for p110alpha in insulin signaling</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.cell.2006.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=16647110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=733-747&author=Z.+A.+Knightauthor=B.+Gonzalezauthor=M.+E.+Feldmanauthor=E.+R.+Zunderauthor=D.+D.+Goldenbergauthor=O.+Williamsauthor=R.+Loewithauthor=D.+Stokoeauthor=A.+Ballaauthor=B.+Tothauthor=T.+Ballaauthor=W.+A.+Weissauthor=R.+L.+Williamsauthor=K.+M.+Shokat&title=A+pharmacological+map+of+the+PI3K+family+defines+a+role+for+p110alpha+in+insulin+signaling&doi=10.1016%2Fj.cell.2006.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling</span></div><div class="casAuthors">Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; Balla, Tamas; Weiss, William A.; Williams, Roger L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-747</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3-Ks) are an important emerging class of drug targets, but the unique roles of PI3-K isoforms remain poorly defined.  We describe here an approach to pharmacol. interrogate the PI3-K family.  A chem. diverse panel of PI3-K inhibitors was synthesized, and their target selectivity was biochem. enumerated, revealing cryptic homologies across targets and chemotypes.  Crystal structures of three inhibitors bound to p110γ identify a conformationally mobile region that is uniquely exploited by selective compds.  This chem. array was then used to define the PI3-K isoforms required for insulin signaling.  We find that p110α is the primary insulin-responsive PI3-K in cultured cells, whereas p110β is dispensable but sets a phenotypic threshold for p110α activity.  Compds. targeting p110α block the acute effects of insulin treatment in vivo, whereas a p110β inhibitor has no effect.  These results illustrate systematic target validation using a matrix of inhibitors that span a protein family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrozjvOeMXP3bVg90H21EOLACvtfcHk0liIP53OZaPZ_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D&md5=b95a8cb433927ff9a75b33fc4ac2c8a0</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DZunder%26aufirst%3DE.%2BR.%26aulast%3DGoldenberg%26aufirst%3DD.%2BD.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DBalla%26aufirst%3DA.%26aulast%3DToth%26aufirst%3DB.%26aulast%3DBalla%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DA%2520pharmacological%2520map%2520of%2520the%2520PI3K%2520family%2520defines%2520a%2520role%2520for%2520p110alpha%2520in%2520insulin%2520signaling%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D733%26epage%3D747%26doi%3D10.1016%2Fj.cell.2006.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosulich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghardt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennequin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert-Van der Brempt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgentin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ple, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-<i>a</i>]pyrimidine-7-carboxamides as PI3Kbeta/delta inhibitors for the treatment of PTEN-deficient tumours</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3928</span>– <span class="NLM_lpage">3935</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2014.06.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=24992874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtV2jtL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3928-3935&author=B.+Barlaamauthor=S.+Cosulichauthor=S.+Degorceauthor=M.+Fitzekauthor=F.+Giordanettoauthor=S.+Greenauthor=T.+Inghardtauthor=L.+Hennequinauthor=U.+Hancoxauthor=C.+Lambert-Van+der+Bremptauthor=R.+Morgentinauthor=S.+Passauthor=P.+Pleauthor=T.+Salehauthor=L.+Ward&title=Discovery+of+9-%281-anilinoethyl%29-2-morpholino-4-oxo-pyrido%5B1%2C2-a%5Dpyrimidine-7-carboxamides+as+PI3Kbeta%2Fdelta+inhibitors+for+the+treatment+of+PTEN-deficient+tumours&doi=10.1016%2Fj.bmcl.2014.06.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours</span></div><div class="casAuthors">Barlaam, Bernard; Cosulich, Sabina; Degorce, Sebastien; Fitzek, Martina; Giordanetto, Fabrizio; Green, Stephen; Inghardt, Tord; Hennequin, Laurent; Hancox, Urs; Lambert-van der Brempt, Christine; Morgentin, Remy; Pass, Sarah; Ple, Patrick; Saleh, Twana; Ward, Lara</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3928-3935</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting from TGX-221, we designed a series of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as potent and selective PI3Kβ/δ inhibitors.  Structure-activity relationships and structure-property relationships around the aniline and the amide substituents are discussed.  We identified compds. 17 and 18, which showed profound pharmacodynamic modulation of phosphorylated Akt in the PC3 prostate tumor xenograft, after a single oral dose.  Compd. 17 also gave significant inhibition of tumor growth in the PC3 prostate tumor xenograft model after chronic oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphtYz40Us0V7Vg90H21EOLACvtfcHk0liIP53OZaPZ_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtV2jtL%252FN&md5=3a55171f50d0fcc62e2a87da8c4d2290</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.040%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DDegorce%26aufirst%3DS.%26aulast%3DFitzek%26aufirst%3DM.%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DInghardt%26aufirst%3DT.%26aulast%3DHennequin%26aufirst%3DL.%26aulast%3DHancox%26aufirst%3DU.%26aulast%3DLambert-Van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DPass%26aufirst%3DS.%26aulast%3DPle%26aufirst%3DP.%26aulast%3DSaleh%26aufirst%3DT.%26aulast%3DWard%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25209-%25281-anilinoethyl%2529-2-morpholino-4-oxo-pyrido%255B1%252C2-a%255Dpyrimidine-7-carboxamides%2520as%2520PI3Kbeta%252Fdelta%2520inhibitors%2520for%2520the%2520treatment%2520of%2520PTEN-deficient%2520tumours%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3928%26epage%3D3935%26doi%3D10.1016%2Fj.bmcl.2014.06.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nylander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kull, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorkman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulvinge, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emanuelsson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skarby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghardt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fjellstrom, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, D.</span></span> <span> </span><span class="NLM_article-title">Human target validation of phosphoinositide 3-kinase (PI3K)beta: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor</span>. <i>J. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2127</span>– <span class="NLM_lpage">2136</span>, <span class="refDoi"> DOI: 10.1111/j.1538-7836.2012.04898.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1111%2Fj.1538-7836.2012.04898.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22906130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslSku77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=2127-2136&author=S.+Nylanderauthor=B.+Kullauthor=J.+A.+Bjorkmanauthor=J.+C.+Ulvingeauthor=N.+Oakesauthor=B.+M.+Emanuelssonauthor=M.+Anderssonauthor=T.+Skarbyauthor=T.+Inghardtauthor=O.+Fjellstromauthor=D.+Gustafsson&title=Human+target+validation+of+phosphoinositide+3-kinase+%28PI3K%29beta%3A+effects+on+platelets+and+insulin+sensitivity%2C+using+AZD6482+a+novel+PI3Kbeta+inhibitor&doi=10.1111%2Fj.1538-7836.2012.04898.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor</span></div><div class="casAuthors">Nylander, S.; Kull, B.; Bjoerkman, J. A.; Ulvinge, J. C.; Oakes, N.; Emanuelsson, B. M.; Andersson, M.; Skaerby, T.; Inghardt, T.; Fjellstroem, O.; Gustafsson, D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2127-2136</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: Based on in vitro and animal data, PI3Kβ is given an important role in platelet adhesion and aggregation but its role in insulin signaling is unclear.  Objective: To strengthen the PI3Kβ target validation using the novel, short-acting inhibitor AZD6482.  Methods and results: AZD6482 is a potent, selective and ATP competitive PI3Kβ inhibitor (IC50 0.01 μM).  A maximal anti-platelet effect was achieved at 1 μM in the in vitro and ex vivo tests both in dog and in man.  In dog, in vivo AZD6482 produced a complete anti-thrombotic effect without an increased bleeding time or blood loss.  AZD6482 was well tolerated in healthy volunteers during a 3-h infusion.  The ex vivo anti-platelet effect and minimal bleeding time prolongation in the dog model translated well to data obtained in healthy volunteers.  AZD6482 inhibited insulin-induced human adipocyte glucose uptake in vitro (IC50 of 4.4 μM).  In the euglycemic hyperinsulinemic clamp model, in rats, glucose infusion rate was not affected at 2.3 μM but reduced by about 60% at a plasma exposure of 27 μM.  In man, the homeostasis model anal. (HOMA) index increased by about 10-20% at the highest plasma concn. of 5.3 μM.  Conclusions: This is the first human target validation for PI3Kβ inhibition as anti-platelet therapy showing a mild and generalized antiplatelet effect attenuating but not completely inhibiting multiple signaling pathways with an impressive sepn. towards primary hemostasis.  AZD6482 at 'supra-therapeutic' plasma concns. may attenuate insulin signaling, most likely through PI3Kα inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol96EaByjORbVg90H21EOLACvtfcHk0liIP53OZaPZ_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslSku77I&md5=120c48254154a7a4449630c791f172fd</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1111%2Fj.1538-7836.2012.04898.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1538-7836.2012.04898.x%26sid%3Dliteratum%253Aachs%26aulast%3DNylander%26aufirst%3DS.%26aulast%3DKull%26aufirst%3DB.%26aulast%3DBjorkman%26aufirst%3DJ.%2BA.%26aulast%3DUlvinge%26aufirst%3DJ.%2BC.%26aulast%3DOakes%26aufirst%3DN.%26aulast%3DEmanuelsson%26aufirst%3DB.%2BM.%26aulast%3DAndersson%26aufirst%3DM.%26aulast%3DSkarby%26aufirst%3DT.%26aulast%3DInghardt%26aufirst%3DT.%26aulast%3DFjellstrom%26aufirst%3DO.%26aulast%3DGustafsson%26aufirst%3DD.%26atitle%3DHuman%2520target%2520validation%2520of%2520phosphoinositide%25203-kinase%2520%2528PI3K%2529beta%253A%2520effects%2520on%2520platelets%2520and%2520insulin%2520sensitivity%252C%2520using%2520AZD6482%2520a%2520novel%2520PI3Kbeta%2520inhibitor%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2012%26volume%3D10%26spage%3D2127%26epage%3D2136%26doi%3D10.1111%2Fj.1538-7836.2012.04898.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosulich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert-Van
der Brempt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maudet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgentin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquet, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ple, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vautier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warin, N.</span></span> <span> </span><span class="NLM_article-title">Discovery of (<i>R</i>)-8-(1-(3,5-difluorophenylamino)ethyl)-<i>N,N</i>-dimethyl-2-morpholino-4-oxo-4H-chrom ene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kbeta and PI3Kdelta for the treatment of PTEN-deficient cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">943</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.1021/jm501629p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501629p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOhu7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=943-962&author=B.+Barlaamauthor=S.+Cosulichauthor=S.+Degorceauthor=M.+Fitzekauthor=S.+Greenauthor=U.+Hancoxauthor=C.+Lambert-Van%0Ader+Bremptauthor=J.+J.+Lohmannauthor=M.+Maudetauthor=R.+Morgentinauthor=M.+J.+Pasquetauthor=A.+Peruauthor=P.+Pleauthor=T.+Salehauthor=M.+Vautierauthor=M.+Walkerauthor=L.+Wardauthor=N.+Warin&title=Discovery+of+%28R%29-8-%281-%283%2C5-difluorophenylamino%29ethyl%29-N%2CN-dimethyl-2-morpholino-4-oxo-4H-chrom+ene-6-carboxamide+%28AZD8186%29%3A+a+potent+and+selective+inhibitor+of+PI3Kbeta+and+PI3Kdelta+for+the+treatment+of+PTEN-deficient+cancers&doi=10.1021%2Fjm501629p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers</span></div><div class="casAuthors">Barlaam, Bernard; Cosulich, Sabina; Degorce, Sebastien; Fitzek, Martina; Green, Stephen; Hancox, Urs; Lambert-van der Brempt, Christine; Lohmann, Jean-Jacques; Maudet, Mickael; Morgentin, Remy; Pasquet, Marie-Jeanne; Peru, Aurelien; Ple, Patrick; Saleh, Twana; Vautier, Michel; Walker, Mike; Ward, Lara; Warin, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">943-962</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several studies have highlighted the dependency of PTEN deficient tumors to PI3Kβ activity and specific inhibition of PI3Kδ has been shown activity against human B-cell cancers.  We describe the discovery and optimization of a series of 8-(1-anilino)ethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamides as PI3Kβ/δ inhibitors, which led to the discovery of the clin. candidate 13, also known as AZD8186.  On the basis of the lower lipophilicity of the chromen-4-one core compared to the previously utilized pyrido[1,2-a]pyrimid-4-one core, this series of compds. displayed high metabolic stability and suitable phys. properties for oral administration.  Compd. 13 showed profound pharmacodynamic modulation of p-Akt in PTEN-deficient PC3 prostate tumor bearing mice after oral administration and showed complete inhibition of tumor growth in the mouse PTEN-deficient PC3 prostate tumor xenograft model.  13 Was selected as a clin. candidate for treatment of PTEN-deficient cancers and has recently entered phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxcZtIvYY3MLVg90H21EOLACvtfcHk0li5Ea_yifLBUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOhu7%252FJ&md5=b0a1a7b7c1d7e7c27015535573ab77e5</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Fjm501629p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501629p%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DDegorce%26aufirst%3DS.%26aulast%3DFitzek%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DHancox%26aufirst%3DU.%26aulast%3DLambert-Van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DLohmann%26aufirst%3DJ.%2BJ.%26aulast%3DMaudet%26aufirst%3DM.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DPasquet%26aufirst%3DM.%2BJ.%26aulast%3DPeru%26aufirst%3DA.%26aulast%3DPle%26aufirst%3DP.%26aulast%3DSaleh%26aufirst%3DT.%26aulast%3DVautier%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DWard%26aufirst%3DL.%26aulast%3DWarin%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520%2528R%2529-8-%25281-%25283%252C5-difluorophenylamino%2529ethyl%2529-N%252CN-dimethyl-2-morpholino-4-oxo-4H-chrom%2520ene-6-carboxamide%2520%2528AZD8186%2529%253A%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520PI3Kbeta%2520and%2520PI3Kdelta%2520for%2520the%2520treatment%2520of%2520PTEN-deficient%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D943%26epage%3D962%26doi%3D10.1021%2Fjm501629p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houseman, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aizenstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.chembiol.2010.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=20189103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1Wksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=123-134&author=O.+Williamsauthor=B.+T.+Housemanauthor=E.+J.+Kunkelauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=Z.+A.+Knightauthor=K.+M.+Shokat&title=Discovery+of+dual+inhibitors+of+the+immune+cell+PI3Ks+p110delta+and+p110gamma%3A+a+prototype+for+new+anti-inflammatory+drugs&doi=10.1016%2Fj.chembiol.2010.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Dual Inhibitors of the Immune Cell PI3Ks p110δ and p110γ: A Prototype for New Anti-inflammatory Drugs</span></div><div class="casAuthors">Williams, Olusegun; Houseman, Benjamin T.; Kunkel, Eric J.; Aizenstein, Brian; Hoffman, Randy; Knight, Zachary A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-134</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PI3Kδ and PI3Kγ regulate immune cell signaling, while the related PI3Kα and PI3Kβ regulate cell survival and metab.  Selective inhibitors of PI3Kδ/γ represent a potential class of anti-inflammatory agents lacking the antiproliferative effects assocd. with PI3Kα/β inhibition.  Here we report the discovery of PI3Kδ/γ inhibitors that display up to 1000-fold selectivity over PI3Kα/β and evaluate these compds. in a high-content inflammation assay using mixts. of primary human cells.  We find selective inhibition of only PI3Kδ is weakly anti-inflammatory, but PI3Kδ/γ inhibitors show superior inflammatory marker suppression through suppression of lipopolysaccharide-induced TNFα prodn. and T cell activation.  Moreover, PI3Kδ/γ inhibition yields an anti-inflammatory signature distinct from pan-PI3K inhibition and known anti-inflammatory drugs, yet bears striking similarities to glucocorticoid receptor agonists.  These results highlight the potential of selectively designing drugs that target kinases with shared biol. function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9YDqq1G_IirVg90H21EOLACvtfcHk0li5Ea_yifLBUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1Wksrc%253D&md5=a42b5b326cd3aebe67b0c5ce18bb66ca</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DHouseman%26aufirst%3DB.%2BT.%26aulast%3DKunkel%26aufirst%3DE.%2BJ.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DDiscovery%2520of%2520dual%2520inhibitors%2520of%2520the%2520immune%2520cell%2520PI3Ks%2520p110delta%2520and%2520p110gamma%253A%2520a%2520prototype%2520for%2520new%2520anti-inflammatory%2520drugs%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D123%26epage%3D134%26doi%3D10.1016%2Fj.chembiol.2010.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taltavull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caturla, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrascal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pages, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinosa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabate, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calbet, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel inhaled PI3Kdelta inhibitor for the treatment of respiratory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9551</span>– <span class="NLM_lpage">9567</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00873</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00873" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFaltbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9551-9567&author=M.+Erraauthor=J.+Taltavullauthor=F.+J.+Bernalauthor=J.+F.+Caturlaauthor=M.+Carrascalauthor=L.+Pagesauthor=M.+Mirauthor=S.+Espinosaauthor=J.+Graciaauthor=M.+Dominguezauthor=M.+Sabateauthor=S.+Parisauthor=M.+Maldonadoauthor=B.+Hernandezauthor=M.+Bravoauthor=E.+Calamaauthor=M.+Miralpeixauthor=M.+D.+Lehnerauthor=M.+Calbet&title=Discovery+of+a+novel+inhaled+PI3Kdelta+inhibitor+for+the+treatment+of+respiratory+diseases&doi=10.1021%2Facs.jmedchem.8b00873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Inhaled PI3Kδ Inhibitor for the Treatment of Respiratory Diseases</span></div><div class="casAuthors">Erra, Montse; Taltavull, Joan; Bernal, Francisco Javier; Caturla, Juan Francisco; Carrascal, Marta; Pages, Lluis; Mir, Marta; Espinosa, Sonia; Gracia, Jordi; Dominguez, Maria; Sabate, Mar; Paris, Stephane; Maldonado, Monica; Hernandez, Begona; Bravo, Monica; Calama, Elena; Miralpeix, Montserrat; Lehner, Martin D.; Calbet, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9551-9567</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral PI3Kδ inhibitors such as Idelalisib and Duvelisib have shown efficacy as anticancer agents and Idelalisib has been approved for the treatment of three B-cell cancers.  However, Idelalisib has a black box warning on its product label regarding the risks of fatal and serious toxicities including hepatic toxicity, severe diarrhea, colitis, pneumonitis, infections, and intestinal perforation.  Some of these side effects are mechanism-related and could hinder the development of Idelalisib for less severe conditions.  For respiratory diseases, compds. administered by inhalation are delivered directly to the site of action and may improve the therapeutic index of a drug, minimizing undesired side effects.  This work describes the discovery and optimization of inhaled PI3Kδ inhibitors intended for the treatment of severe asthma and COPD.  Once the potency was in the desired range, efforts were focused on identifying the particular physicochem. properties that could translate into better lung retention.  This medicinal chem. exercise led to the identification of LAS195319 as a candidate for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtstrCaE6BArVg90H21EOLACvtfcHk0li5Ea_yifLBUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFaltbbK&md5=f7f14dd277a8ef119a2aeabb1558a838</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00873%26sid%3Dliteratum%253Aachs%26aulast%3DErra%26aufirst%3DM.%26aulast%3DTaltavull%26aufirst%3DJ.%26aulast%3DBernal%26aufirst%3DF.%2BJ.%26aulast%3DCaturla%26aufirst%3DJ.%2BF.%26aulast%3DCarrascal%26aufirst%3DM.%26aulast%3DPages%26aufirst%3DL.%26aulast%3DMir%26aufirst%3DM.%26aulast%3DEspinosa%26aufirst%3DS.%26aulast%3DGracia%26aufirst%3DJ.%26aulast%3DDominguez%26aufirst%3DM.%26aulast%3DSabate%26aufirst%3DM.%26aulast%3DParis%26aufirst%3DS.%26aulast%3DMaldonado%26aufirst%3DM.%26aulast%3DHernandez%26aufirst%3DB.%26aulast%3DBravo%26aufirst%3DM.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26aulast%3DCalbet%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520inhaled%2520PI3Kdelta%2520inhibitor%2520for%2520the%2520treatment%2520of%2520respiratory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9551%26epage%3D9567%26doi%3D10.1021%2Facs.jmedchem.8b00873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taltavull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caturla, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabate, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armengol, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabedo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally available PI3Kdelta inhibitor for the treatment of inflammatory diseases</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00438</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00438" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFyntrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=118-123&author=M.+Erraauthor=J.+Taltavullauthor=A.+Grecoauthor=F.+J.+Bernalauthor=J.+F.+Caturlaauthor=J.+Graciaauthor=M.+Dominguezauthor=M.+Sabateauthor=S.+Parisauthor=S.+Soriaauthor=B.+Hernandezauthor=C.+Armengolauthor=J.+Cabedoauthor=M.+Bravoauthor=E.+Calamaauthor=M.+Miralpeixauthor=M.+D.+Lehner&title=Discovery+of+a+potent%2C+selective%2C+and+orally+available+PI3Kdelta+inhibitor+for+the+treatment+of+inflammatory+diseases&doi=10.1021%2Facsmedchemlett.6b00438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases</span></div><div class="casAuthors">Erra, Montse; Taltavull, Joan; Greco, Angelique; Bernal, Francisco Javier; Caturla, Juan Francisco; Gracia, Jordi; Dominguez, Maria; Sabate, Mar; Paris, Stephane; Soria, Salome; Hernandez, Begona; Armengol, Clara; Cabedo, Judit; Bravo, Monica; Calama, Elena; Miralpeix, Montserrat; Lehner, Martin D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">118-123</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The delta isoform of the phosphatidylinositol 3-kinase (PI3Kδ) has been shown to have an essential role in specific immune cell functions and thus represents a potential therapeutic target for autoimmune and inflammatory diseases.  Herein, the optimization of a series of pyrrolotriazinones as potent and selective PI3Kδ inhibitors is described.  The main challenge of the optimization process was to identify an orally available compd. with a good pharmacokinetic profile in preclin. species that predicted a suitable dosing regimen in humans.  Structure-activity relationships and structure-property relationships are discussed.  This medicinal chem. exercise led to the identification of LAS191954 as a candidate for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGKftcFDPpSLVg90H21EOLACvtfcHk0lhjfTgHQvehZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFyntrzN&md5=120b642b7adb9a5e2a1014abc93aaa98</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00438%26sid%3Dliteratum%253Aachs%26aulast%3DErra%26aufirst%3DM.%26aulast%3DTaltavull%26aufirst%3DJ.%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DBernal%26aufirst%3DF.%2BJ.%26aulast%3DCaturla%26aufirst%3DJ.%2BF.%26aulast%3DGracia%26aufirst%3DJ.%26aulast%3DDominguez%26aufirst%3DM.%26aulast%3DSabate%26aufirst%3DM.%26aulast%3DParis%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DS.%26aulast%3DHernandez%26aufirst%3DB.%26aulast%3DArmengol%26aufirst%3DC.%26aulast%3DCabedo%26aufirst%3DJ.%26aulast%3DBravo%26aufirst%3DM.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520PI3Kdelta%2520inhibitor%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D118%26epage%3D123%26doi%3D10.1021%2Facsmedchemlett.6b00438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garces, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M. J.</span></span> <span> </span><span class="NLM_article-title">Class 1 PI3K clinical candidates and recent inhibitor design strategies: a medicinal chemistry perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4815</span>– <span class="NLM_lpage">4850</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01492</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01492" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFOku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4815-4850&author=A.+E.+Garcesauthor=M.+J.+Stocks&title=Class+1+PI3K+clinical+candidates+and+recent+inhibitor+design+strategies%3A+a+medicinal+chemistry+perspective&doi=10.1021%2Facs.jmedchem.8b01492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective</span></div><div class="casAuthors">Garces, Aimie E.; Stocks, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4815-4850</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate the 3-OH of the inositol ring of phosphoinositides, and deregulation of this pathway has implications in many diseases.  The search for novel PI3K inhibitors has been at the forefront of academic and industrial medicinal chem. with over 600 medicinal chem.-based publications and patents appearing to date, leading to 38 clin. candidates and the launch of two drugs, idelalisib in 2014 and copanlisib in 2017.  This Perspective will discuss medicinal chem. design approaches to novel isoform-selective inhibitors through consideration of brief case histories of compds. that have progressed into clin. development or that have revealed new structural motifs in this highly competitive area of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUu2mgndklHbVg90H21EOLACvtfcHk0lhjfTgHQvehZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFOku7bK&md5=907395a39ed6fb683464ee92c6a2537f</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01492%26sid%3Dliteratum%253Aachs%26aulast%3DGarces%26aufirst%3DA.%2BE.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26atitle%3DClass%25201%2520PI3K%2520clinical%2520candidates%2520and%2520recent%2520inhibitor%2520design%2520strategies%253A%2520a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4815%26epage%3D4850%26doi%3D10.1021%2Facs.jmedchem.8b01492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourne, P. E.</span></span> <span> </span><span class="NLM_article-title">Progress with covalent small-molecule kinase inhibitors</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">735</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2018.01.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.drudis.2018.01.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=29337202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslShurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=727-735&author=Z.+Zhaoauthor=P.+E.+Bourne&title=Progress+with+covalent+small-molecule+kinase+inhibitors&doi=10.1016%2Fj.drudis.2018.01.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Progress with covalent small-molecule kinase inhibitors</span></div><div class="casAuthors">Zhao, Zheng; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">727-735</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">With reduced risk of toxicity and high selectivity, covalent small-mol. kinase inhibitors (CSKIs) have emerged rapidly.  Through the lens of structural system pharmacol., here we review this rapid progress by considering design strategies and the challenges and opportunities offered by current CSKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog6l6qMAopYLVg90H21EOLACvtfcHk0lhjfTgHQvehZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslShurg%253D&md5=f97a19f53a72044812a778ee9351fe94</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2018.01.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2018.01.035%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DProgress%2520with%2520covalent%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2018%26volume%3D23%26spage%3D727%26epage%3D735%26doi%3D10.1016%2Fj.drudis.2018.01.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Developing irreversible inhibitors of the protein kinase cysteinome</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.chembiol.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=23438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=146-159&author=Q.+Liuauthor=Y.+Sabnisauthor=Z.+Zhaoauthor=T.+Zhangauthor=S.+J.+Buhrlageauthor=L.+H.+Jonesauthor=N.+S.+Gray&title=Developing+irreversible+inhibitors+of+the+protein+kinase+cysteinome&doi=10.1016%2Fj.chembiol.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span></div><div class="casAuthors">Liu, Qingsong; Sabnis, Yogesh; Zhao, Zheng; Zhang, Tinghu; Buhrlage, Sara J.; Jones, Lyn H.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-159</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a large family of approx. 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction.  The clin. success of a no. of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large no. of kinases may represent therapeutically relevant targets.  To date, the majority of clin. and preclin. kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases.  Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket.  Irreversible kinase inhibitors have a no. of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacol. specificity through mutation of the reactive cysteine residue.  Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biol. activity profiles.  In addn., we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVGD7TX3oIeLVg90H21EOLACvtfcHk0lh9MOXmZNcd6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D&md5=cef80823123bae88362e816a0a638133</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDeveloping%2520irreversible%2520inhibitors%2520of%2520the%2520protein%2520kinase%2520cysteinome%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D146%26epage%3D159%26doi%3D10.1016%2Fj.chembiol.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velentza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flatauer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valente, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagorska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Didonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balk, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5916</span>– <span class="NLM_lpage">5919</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2008.07.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=18667312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOht7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5916-5919&author=W.+Hurauthor=A.+Velentzaauthor=S.+Kimauthor=L.+Flatauerauthor=X.+Jiangauthor=D.+Valenteauthor=D.+E.+Masonauthor=M.+Suzukiauthor=B.+Larsonauthor=J.+Zhangauthor=A.+Zagorskaauthor=M.+Didonatoauthor=A.+Nagleauthor=M.+Warmuthauthor=S.+P.+Balkauthor=E.+C.+Petersauthor=N.+S.+Gray&title=Clinical+stage+EGFR+inhibitors+irreversibly+alkylate+Bmx+kinase&doi=10.1016%2Fj.bmcl.2008.07.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase</span></div><div class="casAuthors">Hur, Wooyoung; Velentza, Anastasia; Kim, Sungjoon; Flatauer, Laura; Jiang, Xinnong; Valente, David; Mason, Daniel E.; Suzuki, Melissa; Larson, Brad; Zhang, Jianming; Zagorska, Anna; DiDonato, Michael; Nagle, Advait; Warmuth, Markus; Balk, Steven P.; Peters, Eric C.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5916-5919</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Irreversible HER/erbB inhibitors selectively inhibit HER-family kinases by targeting a unique cysteine residue located within the ATP-binding pocket.  Sequence alignment reveals that this rare cysteine is also present in ten other protein kinases including all five Tec-family members.  We demonstrate that the Tec-family kinase Bmx is potently inhibited by irreversible modification at Cys496 by clin. stage EGFR inhibitors such as CI-1033.  This cross-reactivity may have significant clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_hlFgn2jwY7Vg90H21EOLACvtfcHk0lh9MOXmZNcd6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOht7vM&md5=2f704e42920d0a18f9dfdcc688347f0a</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.062%26sid%3Dliteratum%253Aachs%26aulast%3DHur%26aufirst%3DW.%26aulast%3DVelentza%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DFlatauer%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DValente%26aufirst%3DD.%26aulast%3DMason%26aufirst%3DD.%2BE.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DLarson%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZagorska%26aufirst%3DA.%26aulast%3DDidonato%26aufirst%3DM.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DBalk%26aufirst%3DS.%2BP.%26aulast%3DPeters%26aufirst%3DE.%2BC.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DClinical%2520stage%2520EGFR%2520inhibitors%2520irreversibly%2520alkylate%2520Bmx%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5916%26epage%3D5919%26doi%3D10.1016%2Fj.bmcl.2008.07.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bordoni, R. E.</span></span> <span> </span><span class="NLM_article-title">Afatinib (BIBW-2992): a novel dual EGFR/HER2neu inhibitor with promising activity in non-small-cell lung cancer</span>. <i>Therapy</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.2217/thy.10.86</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.2217%2Fthy.10.86" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sju7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=15-22&author=R.+E.+Bordoni&title=Afatinib+%28BIBW-2992%29%3A+a+novel+dual+EGFR%2FHER2neu+inhibitor+with+promising+activity+in+non-small-cell+lung+cancer&doi=10.2217%2Fthy.10.86"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib (BIBW-2992): a novel dual EGFR/HER2neu inhibitor with promising activity in non-small-cell lung cancer</span></div><div class="casAuthors">Bordoni, Rodolfo E.</div><div class="citationInfo"><span class="NLM_cas:title">Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-22</span>CODEN:
                <span class="NLM_cas:coden">THERCR</span>;
        ISSN:<span class="NLM_cas:issn">1475-0708</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Lung cancer is not one disease but many diseases with specific mol. profiles and treatment alternatives.  EGF receptor-activating mutations predict a high, albeit short-lived, response to reversible tyrosine kinase inhibitors (e.g., gefitinib and erlotinib).  Acquired resistance mutations can result in tumor progression.  Dual EGFR/HER2 irreversible inhibitors are small novel mols. that can overcome gefitinib/erlotinib resistance by potentially circumventing multiple mechanisms of acquired resistance, as shown in vitro.  Afatinib is an irreversible inhibitor with potent phosphorylation inhibitory activity of both EGF receptor and HER2.  Durable responses were obsd. in Phase I trials in advanced non-small-cell lung cancer at 50 mg once daily.  In Phase II trials, redn. in tumor size was obsd. in 90% of patients.  The objective response and disease control rate were 62 and 94%, resp.  Median progression-free survival was estd. at 12 mo (95% CI: 10.0-19.2).  The most common drug-related adverse events were diarrhea and rash/acne, 18% were grade 3 and none grade 4.  LUX-Lung 1, one of two global Phase III studies, was presented in Oct. 2010.  At primary anal. (358 events), the study did not meet its primary end point to improve overall survival compared with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Iip5iQtcdLVg90H21EOLACvtfcHk0lh9MOXmZNcd6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sju7fO&md5=d3ab1dc591e5f6e64462ade250396306</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.2217%2Fthy.10.86&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fthy.10.86%26sid%3Dliteratum%253Aachs%26aulast%3DBordoni%26aufirst%3DR.%2BE.%26atitle%3DAfatinib%2520%2528BIBW-2992%2529%253A%2520a%2520novel%2520dual%2520EGFR%252FHER2neu%2520inhibitor%2520with%2520promising%2520activity%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DTherapy%26date%3D2011%26volume%3D8%26spage%3D15%26epage%3D22%26doi%3D10.2217%2Fthy.10.86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, V.</span></span> <span> </span><span class="NLM_article-title">Afatinib (BIBW 2992) development in non-small-cell lung cancer</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">825</span>, <span class="refDoi"> DOI: 10.2217/fon.11.62</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.2217%2Ffon.11.62" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=21732753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1SlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=817-825&author=V.+Hirsh&title=Afatinib+%28BIBW+2992%29+development+in+non-small-cell+lung+cancer&doi=10.2217%2Ffon.11.62"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib (BIBW 2992) development in non-small-cell lung cancer</span></div><div class="casAuthors">Hirsh, Vera</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">817-825</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Afatinib (BIBW 2992), a novel aniline--quinazoline deriv., irreversibly and equipotently targets the intrinsic kinase activity of all active ErbB receptor family members.  Preclin. results show that afatinib is effective in lung cancer models, including those with EGF receptor (EGFR) mutations resistant to reversible first-generation EGFR inhibitors.  Afatinib is being investigated in the LUX-Lung program, which will evaluate afatinib as a first-line treatment in patients with EGFR-activating mutations (LUX-Lung 2, 3 and 6) and as a second- or third-line treatment in patients that have acquired resistance to gefitinib and/or erlotinib (LUX-Lung 1, 4 and 5).  LUX-Lung 1 and 2 have demonstrated, within their resp. target groups, a significant increase in the disease control rate of 58 and 86%, resp., and significant prolongation of progression-free survival.  Further Phase III clin. trials are currently ongoing to assess afatinib in combination with paclitaxel (LUX-Lung 5), and compared with cisplatin/pemetrexed (LUX-Lung 3) or cisplatin/gemcitabine (LUX-Lung 6).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMXffZwNyKfLVg90H21EOLACvtfcHk0lgzigMyUG7B9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1SlurY%253D&md5=1359e73d0a77b146a80545db338d34a4</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.2217%2Ffon.11.62&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.11.62%26sid%3Dliteratum%253Aachs%26aulast%3DHirsh%26aufirst%3DV.%26atitle%3DAfatinib%2520%2528BIBW%25202992%2529%2520development%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2011%26volume%3D7%26spage%3D817%26epage%3D825%26doi%3D10.2217%2Ffon.11.62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraemer, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Himmelsbach, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haaksma, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolf, G. R.</span></span> <span> </span><span class="NLM_article-title">Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.197756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1124%2Fjpet.112.197756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22888144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKktbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2012&pages=342-350&author=F.+Solcaauthor=G.+Dahlauthor=A.+Zoephelauthor=G.+Baderauthor=M.+Sandersonauthor=C.+Kleinauthor=O.+Kraemerauthor=F.+Himmelsbachauthor=E.+Haaksmaauthor=G.+R.+Adolf&title=Target+binding+properties+and+cellular+activity+of+afatinib+%28BIBW+2992%29%2C+an+irreversible+ErbB+family+blocker&doi=10.1124%2Fjpet.112.197756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker</span></div><div class="casAuthors">Solca, Flavio; Dahl, Goeran; Zoephel, Andreas; Bader, Gerd; Sanderson, Michael; Klein, Christian; Kraemer, Oliver; Himmelsbach, Frank; Haaksma, Eric; Adolf, Guenther R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">342-350</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Deregulation of the ErbB (proto-oncogene B of the avian erythroblastosis virus AEV-H strain) receptor network is well recognized as an oncogenic driver in epithelial cancers.  Several targeted drugs have been developed, including antibodies and small-mol. kinase inhibitors, each of them characterized by distinct patterns of ErbB receptor interactions.  Understanding the precise pharmacol. properties of these compds. is important for optimal use in clin. practice.  Afatinib [BIBW 2992; N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide] is an ATP-competitive anilinoquinazoline deriv. harboring a reactive acrylamide group.  It was designed to covalently bind and irreversibly block enzymically active ErbB receptor family members.  Here, we show by X-ray crystallog. the covalent binding of afatinib to wild-type epidermal growth factor receptor (EGFR) and by mass spectrometry the covalent interaction with EGFR, EGFRL858R/T790M, human epidermal growth factor receptor 2 (HER2), and ErbB-4.  Afatinib potently inhibits the enzymatic activity of ErbB-4 (EC50 = 1 nM) and the proliferation of cancer cell lines driven by multiple ErbB receptor aberrations at concns. below 100 nM.  N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butanamide (BI 37781), a close analog of afatinib lacking the acrylamide group and thus incapable of covalent bond formation, had similar potency on cells driven by EGFR or EGFRL858R, but less or no detectable activity on cells expressing EGFRL858R/T790M HER2 or ErbB-4.  These results stress the importance of the acrylamide group and show that afatinib differs from approved ErbB targeting agents by irreversibly inhibiting the kinase activity of all ErbB family members.  They provide a mechanistic rationale for the distinct pharmacol. features of this compd. and explain the clin. activity seen in some patients who are resistant to antibody or kinase inhibitor therapy because of secondary mutations or ErbB receptor "reprogramming.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofXgQqaKXv-bVg90H21EOLACvtfcHk0lgzigMyUG7B9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKktbzE&md5=4a57df32abe8101f287fc6251f63f92d</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.197756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.197756%26sid%3Dliteratum%253Aachs%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DDahl%26aufirst%3DG.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DSanderson%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DKraemer%26aufirst%3DO.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DHaaksma%26aufirst%3DE.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DTarget%2520binding%2520properties%2520and%2520cellular%2520activity%2520of%2520afatinib%2520%2528BIBW%25202992%2529%252C%2520an%2520irreversible%2520ErbB%2520family%2520blocker%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D343%26spage%3D342%26epage%3D350%26doi%3D10.1124%2Fjpet.112.197756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stopfer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narjes, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gansser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uttereuther-Fischer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebner, T.</span></span> <span> </span><span class="NLM_article-title">Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1051</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1007/s00280-011-1803-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1007%2Fs00280-011-1803-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22200729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVCrsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=1051-1061&author=P.+Stopferauthor=K.+Marzinauthor=H.+Narjesauthor=D.+Gansserauthor=M.+Shahidiauthor=M.+Uttereuther-Fischerauthor=T.+Ebner&title=Afatinib+pharmacokinetics+and+metabolism+after+oral+administration+to+healthy+male+volunteers&doi=10.1007%2Fs00280-011-1803-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers</span></div><div class="casAuthors">Stopfer, Peter; Marzin, Kristell; Narjes, Hans; Gansser, Dietmar; Shahidi, Mehdi; Uttereuther-Fischer, Martina; Ebner, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1051-1061</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To investigate the pharmacokinetics, metab. and tolerability of afatinib (BIBW 2992), an oral irreversible ErbB family blocker, in healthy male volunteers.  Methods: In this open-label, single-center study, 8 healthy male volunteers received a single oral dose of 15 mg [14C]-radiolabeled afatinib (equiv. to 22.2 mg of the dimaleinate salt) as a soln.  Blood, urine and fecal samples were collected for at least 96 h (h) after dosing.  Plasma and urine concns. of afatinib were analyzed using high-performance liq. chromatog.-tandem mass spectrometry. [14C]-radioactivity levels in plasma, whole blood, urine and feces were measured by liq. scintillation counting methods.  Metabolite patterns were assessed by high-performance liq. chromatog.  Results: [14C]-radioactivity was mainly excreted via feces (85.4%).  Overall recovery of [14C]-radioactivity was 89.5%, indicative of a complete mass balance.  Afatinib was slowly absorbed, with max. plasma concns. achieved at a median of 6 h after dosing, declining thereafter in a biexponential manner.  The geometric mean terminal half-life of afatinib was 33.9 h in plasma and longer for [14C]-radioactivity in plasma and whole blood.  Apparent total body clearance for afatinib was high (geometric mean 1,530 mL/min).  The high vol. of distribution (4,500 L) in plasma may indicate a high tissue distribution.  Afatinib was metabolized to only a minor extent, with the main metabolite afatinib covalently bound to plasma proteins.  Oxidative metab. mediated via cytochrome P 450 was of negligible importance for the elimination of afatinib.  Afatinib was well tolerated.  Conclusions: Afatinib displayed a complete mass balance with the main route of excretion via feces.  Afatinib undergoes minimal metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL0nIa1u5anbVg90H21EOLACvtfcHk0lgzigMyUG7B9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVCrsL4%253D&md5=37fe411022609ca26b2b52fdaee905d3</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1803-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1803-9%26sid%3Dliteratum%253Aachs%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DMarzin%26aufirst%3DK.%26aulast%3DNarjes%26aufirst%3DH.%26aulast%3DGansser%26aufirst%3DD.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DUttereuther-Fischer%26aufirst%3DM.%26aulast%3DEbner%26aufirst%3DT.%26atitle%3DAfatinib%2520pharmacokinetics%2520and%2520metabolism%2520after%2520oral%2520administration%2520to%2520healthy%2520male%2520volunteers%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D1051%26epage%3D1061%26doi%3D10.1007%2Fs00280-011-1803-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothaus, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.+J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+selective+irreversible+inhibitors+for+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0ljIlhDspNi3Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib inhibition of bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.phrs.2016.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=27641927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFCrt7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=395-408&author=R.+Roskoski&title=Ibrutinib+inhibition+of+bruton+protein-tyrosine+kinase+%28BTK%29+in+the+treatment+of+B+cell+neoplasms&doi=10.1016%2Fj.phrs.2016.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms</span></div><div class="casAuthors">Roskoski, Robert Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">Part_A</span>),
    <span class="NLM_cas:pages">395-408</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Bruton non-receptor protein-tyrosine kinase (BTK), a deficiency of which leads to X-linked agammaglobulinemia, plays a central role in B cell antigen receptor signaling.  Owing to the exclusivity of this enzyme in B cells, the acronym could represent B cell tyrosine kinase.  BTK is activated by the Lyn and SYK protein kinases following activation of the B cell receptor.  BTK in turn catalyzes the phosphorylation and activation of phospholipase Cγ2 leading to the downstream activation of the Ras/RAF/MEK/ERK pathway and the NF-κB pathways.  Both pathways participate in the maturation of antibody-producing B cells.  The BTK domains include a PH (pleckstrin homol.) domain that interacts with membrane-assocd. phosphatidyl inositol trisphosphate, a TH (TEC homol.) domain, which is followed by an SH3, SH2, and finally a protein kinase domain.  Dysregulation of B cell receptor signaling occurs in several B cell neoplasms including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia.  Ibrutinib is FDA-approved as first-line or second line treatment for these diseases.  The drug binds tightly in the ATP-binding pocket of BTK making salt bridges with residues within the hinge that connects the two lobes of the enzyme; then its unsatd. acrylamide group forms a covalent bond with BTK cysteine 481 to form an inactive adduct.  In addn. to the treatment of various B cell lymphomas, ibrutinib is under clin. trials for the treatment of numerous solid tumors owing to the role of tumor-promoting inflammation in the pathogenesis of neoplastic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRjiClU2y-abVg90H21EOLACvtfcHk0ljIlhDspNi3Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFCrt7zN&md5=147a5a3fe0a242bbd8a931188f585b09</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DIbrutinib%2520inhibition%2520of%2520bruton%2520protein-tyrosine%2520kinase%2520%2528BTK%2529%2520in%2520the%2520treatment%2520of%2520B%2520cell%2520neoplasms%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D113%26spage%3D395%26epage%3D408%26doi%3D10.1016%2Fj.phrs.2016.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quittet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtenay-Luck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, G.</span></span> <span> </span><span class="NLM_article-title">A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-08-664086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1182%2Fblood-2015-08-664086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=26542378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Cis7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=411-419&author=H.+S.+Walterauthor=S.+A.+Ruleauthor=M.+J.+Dyerauthor=L.+Karlinauthor=C.+Jonesauthor=B.+Cazinauthor=P.+Quittetauthor=N.+Shahauthor=C.+V.+Hutchinsonauthor=H.+Hondaauthor=K.+Duffyauthor=J.+Birkettauthor=V.+Jamiesonauthor=N.+Courtenay-Luckauthor=T.+Yoshizawaauthor=J.+Sharpeauthor=T.+Ohnoauthor=S.+Abeauthor=A.+Nishimuraauthor=G.+Cartronauthor=F.+Morschhauserauthor=C.+Feganauthor=G.+Salles&title=A+phase+1+clinical+trial+of+the+selective+BTK+inhibitor+ONO%2FGS-4059+in+relapsed+and+refractory+mature+B-cell+malignancies&doi=10.1182%2Fblood-2015-08-664086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies</span></div><div class="casAuthors">Walter, Harriet S.; Rule, Simon A.; Dyer, Martin J. S.; Karlin, Lionel; Jones, Ceri; Cazin, Bruno; Quittet, Philippe; Shah, Nimish; Hutchinson, Claire V.; Honda, Hideyuki; Duffy, Kevin; Birkett, Joseph; Jamieson, Virginia; Courtenay-Luck, Nigel; Yoshizawa, Toshio; Sharpe, John; Ohno, Tomoya; Abe, Shinichiro; Nishimura, Akihisa; Cartron, Guillaume; Morschhauser, Franck; Fegan, Christopher; Salles, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">411-419</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies.  There were 9 dose-escalation cohorts ranging from 20 mg to 600 mg once daily with twice-daily regimens of 240 mg and 300 mg.  Twenty-four of 25 evaluable chronic lymphocytic leukemia (CLL) patients (96%) responded to ONO/GS-4059, with a median treatment duration of 80 wk; 21 CLL patients remain on treatment.  Lymph node responses were rapid and assocd. with a concurrent lymphocytosis.  Eleven of 12 evaluable patients with mantle cell lymphoma (92%) responded (median treatment duration, 40 wk).  Eleven of 31 non-germinal center B-cell diffuse large B-cell lymphoma patients (35%) responded but median treatment duration was 12 wk due to development of progressive disease.  ONO/GS-4059 was very well tolerated with 75% of adverse events (AEs) being Common Toxicity Criteria for Adverse Events version 4.0 grade 1 or grade 2.  Grade 3/4 AEs were mainly hematol. and recovered spontaneously during therapy.  One CLL patient experienced a grade 3 treatment-related bleeding event (spontaneous muscle hematoma) but no clin. significant diarrhea, cardiac dysrhythmias, or arthralgia were obsd.  No maximal tolerated dose (MTD) was reached in the CLL cohort.  In the non-Hodgkin lymphoma cohort, 4 patients developed a dose-limiting toxicity, yielding an MTD of 480 mg once daily.  ONO/GS-4059 has significant activity in relapsed/refractory B-cell malignancies without major drug-related toxicity.  The selectivity of ONO/GS-4059 should confer advantages in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZFfZyaWsIdbVg90H21EOLACvtfcHk0ljIlhDspNi3Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Cis7zO&md5=f12cd01520c82ddd2067f2b329bd38a9</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-08-664086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-08-664086%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DH.%2BS.%26aulast%3DRule%26aufirst%3DS.%2BA.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%26aulast%3DKarlin%26aufirst%3DL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DCazin%26aufirst%3DB.%26aulast%3DQuittet%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DN.%26aulast%3DHutchinson%26aufirst%3DC.%2BV.%26aulast%3DHonda%26aufirst%3DH.%26aulast%3DDuffy%26aufirst%3DK.%26aulast%3DBirkett%26aufirst%3DJ.%26aulast%3DJamieson%26aufirst%3DV.%26aulast%3DCourtenay-Luck%26aufirst%3DN.%26aulast%3DYoshizawa%26aufirst%3DT.%26aulast%3DSharpe%26aufirst%3DJ.%26aulast%3DOhno%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DA.%26aulast%3DCartron%26aufirst%3DG.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DFegan%26aufirst%3DC.%26aulast%3DSalles%26aufirst%3DG.%26atitle%3DA%2520phase%25201%2520clinical%2520trial%2520of%2520the%2520selective%2520BTK%2520inhibitor%2520ONO%252FGS-4059%2520in%2520relapsed%2520and%2520refractory%2520mature%2520B-cell%2520malignancies%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D411%26epage%3D419%26doi%3D10.1182%2Fblood-2015-08-664086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awan, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothbaum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacovo, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1509981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1056%2FNEJMoa1509981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=26641137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=323-332&author=J.+C.+Byrdauthor=B.+Harringtonauthor=S.+O%E2%80%99Brienauthor=J.+A.+Jonesauthor=A.+Schuhauthor=S.+Devereuxauthor=J.+Chavesauthor=W.+G.+Wierdaauthor=F.+T.+Awanauthor=J.+R.+Brownauthor=P.+Hillmenauthor=D.+M.+Stephensauthor=P.+Ghiaauthor=J.+C.+Barrientosauthor=J.+M.+Pagelauthor=J.+Woyachauthor=D.+Johnsonauthor=J.+Huangauthor=X.+Wangauthor=A.+Kapteinauthor=B.+J.+Lannuttiauthor=T.+Coveyauthor=M.+Fardisauthor=J.+McGreivyauthor=A.+Hamdyauthor=W.+Rothbaumauthor=R.+Izumiauthor=T.+G.+Diacovoauthor=A.+J.+Johnsonauthor=R.+R.+Furman&title=Acalabrutinib+%28ACP-196%29+in+relapsed+chronic+lymphocytic+leukemia&doi=10.1056%2FNEJMoa1509981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Harrington, Bonnie; O'Brien, Susan; Jones, Jeffrey A.; Schuh, Anna; Devereux, Steve; Chaves, Jorge; Wierda, William G.; Awan, Farrukh T.; Brown, Jennifer R.; Hillmen, Peter; Stephens, Deborah M.; Ghia, Paolo; Barrientos, Jacqueline C.; Pagel, John M.; Woyach, Jennifer; Johnson, Dave; Huang, Jane; Wang, Xiaolin; Kaptein, Allard; Lannutti, Brian J.; Covey, Todd; Fardis, Maria; McGreivy, Jesse; Hamdy, Ahmed; Rothbaum, Wayne; Izumi, Raquel; Diacovo, Thomas G.; Johnson, Amy J.; Furman, Richard R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">323-332</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).  However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index.  Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors.  In this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib.  Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twice daily in the expansion (phase 2) portion.  The median age of the patients was 62 years, and patients had received a median of three previous therapies for CLL; 31% had chromosome 17p13.1 deletion, and 75% had unmutated Ig heavy-chain variable genes.  No dose-limiting toxic effects occurred during the dose-escalation portion of the study.  The most common adverse events obsd. were headache (in 43% of the patients), diarrhea (in 39%), and in- creased wt. (in 26%).  Most adverse events were of grade 1 or 2.  At a median follow- up of 14.3 mo, the overall response rate was 95%, including 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable disease.  Among patients with chromosome 17p13.1 deletion, the overall response rate was 100%.  No cases of Richter's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progression have occurred.  In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGHCPciF9hPrVg90H21EOLACvtfcHk0lhFqxInNSX6nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI&md5=d20e0158f9ea308b9d06fa668154516e</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509981%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DHarrington%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DSchuh%26aufirst%3DA.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DChaves%26aufirst%3DJ.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DAwan%26aufirst%3DF.%2BT.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DHillmen%26aufirst%3DP.%26aulast%3DStephens%26aufirst%3DD.%2BM.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DWoyach%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DRothbaum%26aufirst%3DW.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DDiacovo%26aufirst%3DT.%2BG.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D323%26epage%3D332%26doi%3D10.1056%2FNEJMoa1509981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, R. K.</span></span> <span> </span><span class="NLM_article-title">Phase II and phase III failures: 2013–2015</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">818</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnrd.2016.184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=27811931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslynsLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=817-818&author=R.+K.+Harrison&title=Phase+II+and+phase+III+failures%3A+2013%E2%80%932015&doi=10.1038%2Fnrd.2016.184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II and phase III failures: 2013-2015</span></div><div class="casAuthors">Harrison, Richard K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">817-818</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This article analyses recent data on the reported causes of drug candidate attrition, which indicate that lack of efficacy is the reason for approx. half of all phase II and phase III failures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy7ibspDa6WLVg90H21EOLACvtfcHk0lhFqxInNSX6nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslynsLvN&md5=370ee63ca081ca3e958dc17e5315e140</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.184%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DR.%2BK.%26atitle%3DPhase%2520II%2520and%2520phase%2520III%2520failures%253A%25202013%25E2%2580%25932015%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D817%26epage%3D818%26doi%3D10.1038%2Fnrd.2016.184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a'],'ref14':['cit14a','cit14b'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Sumanta Garai, Luciana M. Leo, Anna-Maria Szczesniak, Dow P. Hurst, Peter C. Schaffer, Ayat Zagzoog, Tallan Black, Jeffrey R. Deschamps, Elke Miess, Stefan Schulz, David R. Janero, Alex Straiker, Roger G. Pertwee, Mary E. Abood, Melanie E. M. Kelly, Patricia H. Reggio, Robert B. Laprairie, <span class="NLM_string-name hlFld-ContribAuthor">Ganesh A. Thakur</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8104-8126. <a href="https://doi.org/10.1021/acs.jmedchem.1c00040" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00040%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BBiased%252BAllosteric%252BModulator%252Bfor%252BCannabinoid%252B1%252BReceptor%25253A%252BPreclinical%252BAnti-Glaucoma%252BEfficacy%26aulast%3DGarai%26aufirst%3DSumanta%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D09012021%26date%3D07042021%26volume%3D64%26issue%3D12%26spage%3D8104%26epage%3D8126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasmita  Saha</span>, <span class="hlFld-ContribAuthor ">Katie Rose  Ryan</span>, <span class="hlFld-ContribAuthor ">Naga Rajiv  Lakkaniga</span>, <span class="hlFld-ContribAuthor ">Erica Lane  Smith</span>, <span class="hlFld-ContribAuthor ">Brendan  Frett</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (10)
                                     , 1605-1608. <a href="https://doi.org/10.1002/cmdc.202100013" title="DOI URL">https://doi.org/10.1002/cmdc.202100013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100013%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DPyrazoloadenine%252BInhibitors%252Bof%252Bthe%252BRET%252BLung%252BCancer%252BOncoprotein%252BDiscovered%252Bby%252Ba%252BFragment%252BOptimization%252BApproach%26aulast%3DSaha%26aufirst%3DDebasmita%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D10%26spage%3D1605%26epage%3D1608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena  Molteni</span>, <span class="hlFld-ContribAuthor ">Giovanni  Onida</span>, <span class="hlFld-ContribAuthor ">Matteo  Ceccarelli</span>, <span class="hlFld-ContribAuthor ">Giancarlo  Cappellini</span>. </span><span class="cited-content_cbyCitation_article-title">Ab Initio Spectroscopic Investigation of Pharmacologically Relevant Chiral Molecules: The Cases of Avibactam, Cephems, and Idelalisib as Benchmarks for Antibiotics and Anticancer Drugs. </span><span class="cited-content_cbyCitation_journal-name">Symmetry</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     , 601. <a href="https://doi.org/10.3390/sym13040601" title="DOI URL">https://doi.org/10.3390/sym13040601</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/sym13040601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fsym13040601%26sid%3Dliteratum%253Aachs%26jtitle%3DSymmetry%26atitle%3DAb%252BInitio%252BSpectroscopic%252BInvestigation%252Bof%252BPharmacologically%252BRelevant%252BChiral%252BMolecules%25253A%252BThe%252BCases%252Bof%252BAvibactam%25252C%252BCephems%25252C%252Band%252BIdelalisib%252Bas%252BBenchmarks%252Bfor%252BAntibiotics%252Band%252BAnticancer%252BDrugs%26aulast%3DMolteni%26aufirst%3DElena%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4%26spage%3D601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Yan</span>, <span class="hlFld-ContribAuthor ">Lingtian  Zhang</span>, <span class="hlFld-ContribAuthor ">Fengping  Lv</span>, <span class="hlFld-ContribAuthor ">Marialuisa  Moccia</span>, <span class="hlFld-ContribAuthor ">Francesca  Carlomagno</span>, <span class="hlFld-ContribAuthor ">Christophe  Landry</span>, <span class="hlFld-ContribAuthor ">Massimo  Santoro</span>, <span class="hlFld-ContribAuthor ">Fabien  Gosselet</span>, <span class="hlFld-ContribAuthor ">Brendan  Frett</span>, <span class="hlFld-ContribAuthor ">Hong-yu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>216 </em>, 113265. <a href="https://doi.org/10.1016/j.ejmech.2021.113265" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113265</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113265%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpyrazolo-thieno%25255B3%25252C2-d%25255Dpyrimidinylamino-phenyl%252Bacetamides%252Bas%252Btype-II%252Bpan-tropomyosin%252Breceptor%252Bkinase%252B%252528TRK%252529%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%26aulast%3DYan%26aufirst%3DWei%26date%3D2021%26volume%3D216%26spage%3D113265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giorgio  Facchetti</span>, <span class="hlFld-ContribAuthor ">Michael S.  Christodoulou</span>, <span class="hlFld-ContribAuthor ">Lina Barragán  Mendoza</span>, <span class="hlFld-ContribAuthor ">Federico  Cusinato</span>, <span class="hlFld-ContribAuthor ">Lisa  Dalla Via</span>, <span class="hlFld-ContribAuthor ">Isabella  Rimoldi</span>. </span><span class="cited-content_cbyCitation_article-title">Biological Properties of New Chiral 2-Methyl-5,6,7,8-tetrahydroquinolin-8-amine-based Compounds. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (23)
                                     , 5561. <a href="https://doi.org/10.3390/molecules25235561" title="DOI URL">https://doi.org/10.3390/molecules25235561</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25235561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25235561%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBiological%252BProperties%252Bof%252BNew%252BChiral%252B2-Methyl-5%25252C6%25252C7%25252C8-tetrahydroquinolin-8-amine-based%252BCompounds%26aulast%3DFacchetti%26aufirst%3DGiorgio%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D23%26spage%3D5561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roberta  Listro</span>, <span class="hlFld-ContribAuthor ">Giacomo  Rossino</span>, <span class="hlFld-ContribAuthor ">Serena  Della Volpe</span>, <span class="hlFld-ContribAuthor ">Rita  Stabile</span>, <span class="hlFld-ContribAuthor ">Massimo  Boiocchi</span>, <span class="hlFld-ContribAuthor ">Lorenzo  Malavasi</span>, <span class="hlFld-ContribAuthor ">Daniela  Rossi</span>, <span class="hlFld-ContribAuthor ">Simona  Collina</span>. </span><span class="cited-content_cbyCitation_article-title">Enantiomeric Resolution and Absolute Configuration of a Chiral δ-Lactam, Useful Intermediate for the Synthesis of Bioactive Compounds. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (24)
                                     , 6023. <a href="https://doi.org/10.3390/molecules25246023" title="DOI URL">https://doi.org/10.3390/molecules25246023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25246023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25246023%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DEnantiomeric%252BResolution%252Band%252BAbsolute%252BConfiguration%252Bof%252Ba%252BChiral%252B%2525CE%2525B4-Lactam%25252C%252BUseful%252BIntermediate%252Bfor%252Bthe%252BSynthesis%252Bof%252BBioactive%252BCompounds%26aulast%3DListro%26aufirst%3DRoberta%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D24%26spage%3D6023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Naga Rajiv  Lakkaniga</span>, <span class="hlFld-ContribAuthor ">Naresh  Gunaganti</span>, <span class="hlFld-ContribAuthor ">Lingtian  Zhang</span>, <span class="hlFld-ContribAuthor ">Binyam  Belachew</span>, <span class="hlFld-ContribAuthor ">Brendan  Frett</span>, <span class="hlFld-ContribAuthor ">Yuet-Kin  Leung</span>, <span class="hlFld-ContribAuthor ">Hong-yu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>206 </em>, 112691. <a href="https://doi.org/10.1016/j.ejmech.2020.112691" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112691</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112691%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bas%252Binhibitors%252Bof%252BRET%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DLakkaniga%26aufirst%3DNaga%2BRajiv%26date%3D2020%26volume%3D206%26spage%3D112691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephanie  Greed</span>, <span class="hlFld-ContribAuthor ">Edward L.  Briggs</span>, <span class="hlFld-ContribAuthor ">Fahima I. M.  Idiris</span>, <span class="hlFld-ContribAuthor ">Andrew J. P.  White</span>, <span class="hlFld-ContribAuthor ">Ulrich  Lücking</span>, <span class="hlFld-ContribAuthor ">James A.  Bull</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Highly Enantioenriched Sulfonimidoyl Fluorides and Sulfonimidamides by Stereospecific Sulfur–Fluorine Exchange (SuFEx) Reaction. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2020,</strong> <em>26 </em>
                                    (55)
                                     , 12533-12538. <a href="https://doi.org/10.1002/chem.202002265" title="DOI URL">https://doi.org/10.1002/chem.202002265</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202002265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202002265%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DSynthesis%252Bof%252BHighly%252BEnantioenriched%252BSulfonimidoyl%252BFluorides%252Band%252BSulfonimidamides%252Bby%252BStereospecific%252BSulfur%2525E2%252580%252593Fluorine%252BExchange%252B%252528SuFEx%252529%252BReaction%26aulast%3DGreed%26aufirst%3DStephanie%26date%3D2020%26date%3D2020%26volume%3D26%26issue%3D55%26spage%3D12533%26epage%3D12538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huilong  Zhu</span>, <span class="hlFld-ContribAuthor ">Long  Yin</span>, <span class="hlFld-ContribAuthor ">Zhiqian  Chang</span>, <span class="hlFld-ContribAuthor ">Yuhan  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaowei  Dou</span>. </span><span class="cited-content_cbyCitation_article-title">Rhodium-Catalyzed Asymmetric Conjugate Addition of Organoboronic Acids to Carbonyl-Activated Alkenyl Azaarenes. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2020,</strong> <em>362 </em>
                                    (15)
                                     , 3142-3147. <a href="https://doi.org/10.1002/adsc.202000211" title="DOI URL">https://doi.org/10.1002/adsc.202000211</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202000211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202000211%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DRhodium-Catalyzed%252BAsymmetric%252BConjugate%252BAddition%252Bof%252BOrganoboronic%252BAcids%252Bto%252BCarbonyl-Activated%252BAlkenyl%252BAzaarenes%26aulast%3DZhu%26aufirst%3DHuilong%26date%3D2020%26date%3D2020%26volume%3D362%26issue%3D15%26spage%3D3142%26epage%3D3147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hyun Su  Kim</span>, <span class="hlFld-ContribAuthor ">Sungkyun  Chung</span>, <span class="hlFld-ContribAuthor ">Moon-Young  Song</span>, <span class="hlFld-ContribAuthor ">Changjin  Lim</span>, <span class="hlFld-ContribAuthor ">Hyeyoung  Shin</span>, <span class="hlFld-ContribAuthor ">Joonseong  Hur</span>, <span class="hlFld-ContribAuthor ">Hyuk  Kwon</span>, <span class="hlFld-ContribAuthor ">Young-Ger  Suh</span>, <span class="hlFld-ContribAuthor ">Eun-Hee  Kim</span>, <span class="hlFld-ContribAuthor ">Dongyun  Shin</span>, <span class="hlFld-ContribAuthor ">Seok-Ho  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient and Divergent Enantioselective Syntheses of DHPVs and Anti-Inflammatory Effect on IEC-6 Cells. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (9)
                                     , 2215. <a href="https://doi.org/10.3390/molecules25092215" title="DOI URL">https://doi.org/10.3390/molecules25092215</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25092215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25092215%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DEfficient%252Band%252BDivergent%252BEnantioselective%252BSyntheses%252Bof%252BDHPVs%252Band%252BAnti-Inflammatory%252BEffect%252Bon%252BIEC-6%252BCells%26aulast%3DKim%26aufirst%3DHyun%2BSu%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D9%26spage%3D2215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0046.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Drug Design of Compound <b>7</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Cocrystal structure of compound <b>7</b> bound to <i>c</i>-MET (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WGJ">2WGJ</a>, 2.0 Å). (left) Interaction of compound <b>7</b> with the protein. The protein is depicted as yellow ribbons, and hydrogen bonds are illustrated with blue dashed lines. (right) The compound <b>7</b> binding site in <i>c</i>-MET. The surface of the protein is depicted in blue. Compound <b>7</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Drug Design of Compound <b>9</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structure of compound <b>9</b> bound to ALK (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CMU">4CMU</a>, 1.8 Å). (left) Interaction of compound <b>9</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) Compound <b>9</b> binding site in ALK, protein is shown as surface. Compound <b>9</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Drug Design of Compound <b>12</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cocrystal structure of compound <b>12</b> bound to ALK L1196M protein (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CD0">4CD0</a>, 2.23 Å). Interaction of compound <b>12</b> into the binding site of the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound <b>12</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Drug Design of Compound <b>16</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cocrystal structure of compound <b>16</b> bound to <i>c</i>-MET (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EYD">5EYD</a>, 1.85 Å). (left) Interaction of compound <b>16</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) Compound <b>16</b> binding site in <i>c</i>-MET, protein is shown as surface. Compound <b>16</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Drug Design of Compound <b>18</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Cocrystal structure of analogue <b>18c</b> bound to <i>c</i>-MET (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7O">3R7O</a>, 2.3 Å). Interaction of analogue <b>18c</b> at the binding site of the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound <b>18c</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0025.jpeg" id="rightTab-GRAPHIC-d7e1401-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Drug Design of Compound <b>23</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cocrystal structure of compound <b>23</b> bound to IGF-1R (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3I81">3I81</a>, 2.08 Å). (left) Interaction of compound <b>23</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>23</b> in IGFR-1R. The surface of the protein is depicted in blue. Compound <b>23</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0026.jpeg" id="rightTab-GRAPHIC-d7e1518-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Chemical Structures of Chiral RTK Inhibitors <b>24</b> and <b>25</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0027.jpeg" id="rightTab-GRAPHIC-d7e1569-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. FDA Approved Chiral JAK Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0028.jpeg" id="rightTab-GRAPHIC-d7e1632-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Drug Development of Compound <b>27</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Binding of compound <b>27</b> into JAK3 active site (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YVJ">1YVJ</a>, 2.55 Å). Interaction of compound <b>27</b> at the binding site of protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound <b>27</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch10" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0029.jpeg" id="rightTab-GRAPHIC-d7e1690-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Four Stereoisomers of Tofacitinib</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Superimposition of the six-membered ring of the lowest energy conformation (MM2 energy minimization) of compounds (A) [<b>27</b> (<i>R</i>,<i>R</i>)], (B) [<b>27a</b> (<i>R</i>,<i>S</i>)], (C) [<b>27b</b> (<i>S</i>,<i>R</i>)], and (D) [<b>27c</b> (<i>S</i>,<i>S</i>)] (colored by atom type) and their respective best docked poses (colored in pink).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch11" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0030.jpeg" id="rightTab-GRAPHIC-d7e1900-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Discovery of Compound <b>36a</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (top) The cocrystal structure of compound <b>36a</b> bound to TYK2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBM">6DBM</a>, 2.36 Å). (left) Interaction of compound <b>36a</b> with TYK2, the protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>36a</b> in TYK2. The surface of the protein is depicted in blue. (bottom) The cocrystal structure of compound <b>36a</b> bound to JAK1 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBN">6DBN</a>, 2.48 Å). (left) Interaction of compound <b>36a</b> with JAK1. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The compound <b>36a</b> binding site in JAK1. The surface of the protein is depicted in blue. Compound <b>36a</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch12" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0031.jpeg" id="rightTab-GRAPHIC-d7e2028-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Drug Discovery of Compound <b>41</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Cocrystal structure of compound <b>41</b> bound to BTK (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T18">5T18</a>, 1.5 Å). (left) Interaction of compound <b>41</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>41</b>. The surface of the protein is depicted in blue. compound <b>41</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch13" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0032.jpeg" id="rightTab-GRAPHIC-d7e2156-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Drug Discovery of Compound <b>44</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Cocrystal structure of compound <b>44</b> bound to BTK (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OTF">4OTF</a>, 1.95 Å). (left) Interaction of compound <b>44</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>44</b> inBTK. The surface of the protein is depicted in blue. Compound <b>44</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch14" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0033.jpeg" id="rightTab-GRAPHIC-d7e2253-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Chemical Structures of Approved CDK and MEK Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch15" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0034.jpeg" id="rightTab-GRAPHIC-d7e2319-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Drug Discovery of Compound <b>53</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Cocrystal structure of compound <b>53</b> bound to IRAK4 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UIU">5UIU</a>, 2.02 Å). (left) Interaction of compound <b>53</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>53</b> in IRAK4. The surface of the protein is depicted in blue. Compound <b>53</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch16" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0035.jpeg" id="rightTab-GRAPHIC-d7e2480-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Drug Discovery of Compound <b>57</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Cocrystal structure of compound <b>57</b> bound to RIP1 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TX5">5TX5</a>, 2.56 Å). (left) Interaction of compound <b>61</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>57</b> in RIP1. The protein surface is depicted in blue. Compound <b>57</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch17" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0036.jpeg" id="rightTab-GRAPHIC-d7e2572-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Drug Discovery of Compound <b>61</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch18" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0037.jpeg" id="rightTab-GRAPHIC-d7e2682-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. FDA Approved Drug <b>62</b> and Its Chemotype <b>63</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Cocrystal structure of compound <b>62</b> bound to PI3Kδ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XE0">4XE0</a>, 2.35 Å). (left) Interaction of compound <b>62</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>62</b> in PI3Kδ. The protein surface is depicted in blue. Compound <b>62</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch19" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0038.jpeg" id="rightTab-GRAPHIC-d7e2774-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Drug Discovery of Compound <b>67a</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Cocrystal structure of compound <b>67a</b> bound to PI3Kγ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FLH">4FLH</a>, 2.6 Å). (left) Interaction of compound <b>67a</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>67a</b> in PI3Kγ. The protein surface is depicted in blue. Compound <b>67a</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch20" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0039.jpeg" id="rightTab-GRAPHIC-d7e3017-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Drug Discovery of Compound <b>71</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Cocrystal structure of compound <b>71</b> bound to PI3Kγ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WWN">4WWN</a>, 2.7 Å). (left) Interaction of compound <b>71</b> with the protein. The protein is depicted as yellow ribbons, and hydrogen bonds are illustrated with blue dashed lines. (right) The compound <b>71</b> binding site in PI3Kγ. The surface of the protein is depicted in blue. Compound <b>71</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch21" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0040.jpeg" id="rightTab-GRAPHIC-d7e3167-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Drug Discovery of Compounds <b>74a</b> and <b>76</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch22" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0041.jpeg" id="rightTab-GRAPHIC-d7e3345-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Drug Discovery of Compounds <b>78</b> and <b>80</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. (left) Cocrystal structure of analogue <b>81</b> bound to catalytic site of PI3Kδ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6G6W">6G6W</a>, 2.72 Å). (right) The cocrystal structure of analogue <b>82</b> bound to catalytic site of PI3Kδ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5M6U">5M6U</a>, 2.85 Å). The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Analogue <b>81</b> and <b>82</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch23" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0042.jpeg" id="rightTab-GRAPHIC-d7e3452-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Chemical Structures of PI3K Clinical Candidates <b>83</b>, <b>84</b>, and <b>85</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch24" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0043.jpeg" id="rightTab-GRAPHIC-d7e3518-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Chemical Structures of Irreversible EGFR and Her2 Inhibitors <b>86</b>, <b>87</b>, and <b>88</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0018.jpeg" id="rightTab-GRAPHIC-d7e3561-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Cocrystal structure of compound <b>88</b> bound to EGFR<sup>T790M</sup> mutant (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5P">4G5P</a>, 3.17 Å). The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. Compound <b>88</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch25" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Scheme 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0044.jpeg" id="rightTab-GRAPHIC-d7e3599-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 25. Drug Development of Compound <b>90b</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0019.jpeg" id="rightTab-GRAPHIC-d7e3651-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Compound <b>90b</b> docked into the ATP binding pocket of EGFR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FBN">5FBN</a>, 3.17 Å). (left) Interaction of compound <b>90b</b> with the protein. The protein is depicted as yellow ribbons, and the hydrogen bonds are illustrated with blue dashed lines. (right) The binding site of compound <b>90b</b> in EGFR. The protein surface is depicted in blue. Compound <b>90b</b> atoms are colored as follows: carbon, red-orange; nitrogen, blue; oxygen, red; chlorine, green; fluorine, jade; hydrogen, white; the chiral carbon is highlighted in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch26" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Scheme 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/medium/jm9b00640_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0045.jpeg" id="rightTab-GRAPHIC-d7e3689-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 26. Second Generation Irreversible BTK Inhibitors <b>91</b> and <b>92.</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b00640/20200115/images/large/jm9b00640_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00640&amp;id=sch26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i59">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42257" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42257" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 154 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Francotte, E.</span>; <span class="NLM_string-name">Lindne, W.</span></span> <i>Chirality in Drug Research</i>; <span class="NLM_publisher-name">WILEY-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=E.+Francotte&author=W.+Lindne&title=Chirality+in+Drug+Research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DFrancotte%26aufirst%3DE.%26btitle%3DChirality%2520in%2520Drug%2520Research%26pub%3DWILEY-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldeck, B.</span></span> <span> </span><span class="NLM_article-title">Three-dimensional pharmacology, a subject ranging from ignorance to overstatements</span>. <i>Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1046/j.1600-0773.2003.pto930502.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1046%2Fj.1600-0773.2003.pto930502.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=14629731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvVartbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2003&pages=203-210&author=B.+Waldeck&title=Three-dimensional+pharmacology%2C+a+subject+ranging+from+ignorance+to+overstatements&doi=10.1046%2Fj.1600-0773.2003.pto930502.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Three-dimensional pharmacology, a subject ranging from ignorance to overstatements</span></div><div class="casAuthors">Waldeck, Bertil</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Toxicology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">203-210</span>CODEN:
                <span class="NLM_cas:coden">PHTOEH</span>;
        ISSN:<span class="NLM_cas:issn">0901-9928</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Stereoselectivity has been known to play a role in drug action for 100 yr or more.  Nevertheless, chiral drugs have been developed and used as racemates, neglecting the fact that they comprise mixts. of two or more compds. which may have quite different pharmacol. properties.  A very limited access to pure enantiomers in the past has been responsible for this unsatisfactory state of affairs.  During the last 20 yr, significant achievements have made it possible to perform stereoselective synthesis and anal.  Today, novel chiral drugs are as a rule developed as single enantiomers.  Yet, studies of old racemic drugs are still designed, performed and published without mention of the fact that two or more compds. are involved.  In recent years, a no. of old racemic drugs have been re-evaluated and re-introduced into the clin. area as the pure, active enantiomer (the eutomer).  While in principle correct, the clin. benefit of this shift from a well established racemate to a pure enantiomer often seems to be limited and sometimes exaggerated.  Racemic drugs with a deleterious enantiomer that does not contribute to the therapeutic effect (the distomer), may have been sorted out in the safety evaluation process.  However, in the future any pharmacol. study of racemic drugs must include the pure enantiomers.  This will generate new, valuable information on stereoselectivity in drug action and interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYhJNZNDOX4rVg90H21EOLACvtfcHk0lgNmd8KXMUt_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvVartbo%253D&md5=d21aeb221455602cae88fb18bfafda53</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1046%2Fj.1600-0773.2003.pto930502.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1600-0773.2003.pto930502.x%26sid%3Dliteratum%253Aachs%26aulast%3DWaldeck%26aufirst%3DB.%26atitle%3DThree-dimensional%2520pharmacology%252C%2520a%2520subject%2520ranging%2520from%2520ignorance%2520to%2520overstatements%26jtitle%3DPharmacol.%2520Toxicol.%26date%3D2003%26volume%3D93%26spage%3D203%26epage%3D210%26doi%3D10.1046%2Fj.1600-0773.2003.pto930502.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agranat, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, J.</span></span> <span> </span><span class="NLM_article-title">Putting chirality to work: the strategy of chiral switches</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">768</span>, <span class="refDoi"> DOI: 10.1038/nrd915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnrd915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=12360254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVGru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=753-768&author=I.+Agranatauthor=H.+Canerauthor=J.+Caldwell&title=Putting+chirality+to+work%3A+the+strategy+of+chiral+switches&doi=10.1038%2Fnrd915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Putting chirality to work: the strategy of chiral switches</span></div><div class="casAuthors">Agranat, Israel; Caner, Hava; Caldwell, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">753-768</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most of the new drugs reaching the market today are single enantiomers, rather than the racemic mixts. that dominated up to ten years ago.  Many of the new single-enantiomer drugs were developed as such, but there are also important examples of new single-enantiomer drugs derived from 'chiral switches' of established racemates.  Indeed, a well-timed chiral switch can offer enhanced therapy and further profitability as a 'line extension' of a major racemic drug with patents that are expiring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok8OsLio3NMrVg90H21EOLACvtfcHk0lh-KANq2hkUCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVGru7o%253D&md5=5f391aef19f496952f6a066b575b13a9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd915%26sid%3Dliteratum%253Aachs%26aulast%3DAgranat%26aufirst%3DI.%26aulast%3DCaner%26aufirst%3DH.%26aulast%3DCaldwell%26aufirst%3DJ.%26atitle%3DPutting%2520chirality%2520to%2520work%253A%2520the%2520strategy%2520of%2520chiral%2520switches%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D753%26epage%3D768%26doi%3D10.1038%2Fnrd915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, D. J.</span></span> <span> </span><span class="NLM_article-title">Chirality: a blueprint for the future</span>. <i>Br. J. Anaesth.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1093/bja/88.4.563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1093%2Fbja%2F88.4.563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=12066734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1ylsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2002&pages=563-576&author=D.+Burkeauthor=D.+J.+Henderson&title=Chirality%3A+a+blueprint+for+the+future&doi=10.1093%2Fbja%2F88.4.563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Chirality: A blueprint for the future</span></div><div class="casAuthors">Burke, D.; Henderson, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Anaesthesia</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">563-576</span>CODEN:
                <span class="NLM_cas:coden">BJANAD</span>;
        ISSN:<span class="NLM_cas:issn">0007-0912</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review is given on the following aspects of chirality: International Union of Pure and Applied Chem. (IUPAC) terminol., stereospecific biol. interactions, drug development, methods of enantioselective synthesis, pharmacokinetics, and chiral synthesis and its impact on anesthetic practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVd-E6lmB7BbVg90H21EOLACvtfcHk0lh-KANq2hkUCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1ylsbY%253D&md5=546ad9204b8bb48765574761eea0f168</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fbja%2F88.4.563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbja%252F88.4.563%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DD.%26aulast%3DHenderson%26aufirst%3DD.%2BJ.%26atitle%3DChirality%253A%2520a%2520blueprint%2520for%2520the%2520future%26jtitle%3DBr.%2520J.%2520Anaesth.%26date%3D2002%26volume%3D88%26spage%3D563%26epage%3D576%26doi%3D10.1093%2Fbja%2F88.4.563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McConathy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, M. J.</span></span> <span> </span><span class="NLM_article-title">Stereochemistry in drug action</span>. <i>Prim. Care Companion J. Clin. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.4088/PCC.v05n0202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.4088%2FPCC.v05n0202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=15156233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A280%3ADC%252BC2sbnvVensQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=70-73&author=J.+McConathyauthor=M.+J.+Owens&title=Stereochemistry+in+drug+action&doi=10.4088%2FPCC.v05n0202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Stereochemistry in Drug Action</span></div><div class="casAuthors">McConathy Jonathan; Owens Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Primary care companion to the Journal of clinical psychiatry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">70-73</span>
        ISSN:<span class="NLM_cas:issn">1523-5998</span>.
    </div><div class="casAbstract">The importance of stereochemistry in drug action is gaining greater attention in medical practice, and a basic knowledge of the subject will be necessary for clinicians to make informed decisions regarding the use of single-enantiomer drugs.  Many of the drugs currently used in psychiatric practice are mixtures of enantiomers.  For some therapeutics, single-enantiomer formulations can provide greater selectivities for their biological targets, improved therapeutic indices, and/or better pharmacokinetics than a mixture of enantiomers.  This article reviews the nomenclature for describing stereochemistry and enantiomers, emphasizes the potential biological and pharmacologic differences between the 2 enantiomers of a drug, and highlights the clinical experience with single enantiomers of the selective serotonin reuptake inhibitors fluoxetine and citalopram.  In some cases, both a mixture of enantiomers and a single-enantiomer formulation of a drug will be available simultaneously.  In these cases, familiarity with stereochemistry and its pharmacologic implications will aid the practicing physician to provide optimal pharmacotherapy to his or her patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0nrgcR0RzouxsqfvU0ziafW6udTcc2eY734fCdL6Pcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbnvVensQ%253D%253D&md5=5671ec0470b34bd5a958f847df8cba17</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4088%2FPCC.v05n0202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FPCC.v05n0202%26sid%3Dliteratum%253Aachs%26aulast%3DMcConathy%26aufirst%3DJ.%26aulast%3DOwens%26aufirst%3DM.%2BJ.%26atitle%3DStereochemistry%2520in%2520drug%2520action%26jtitle%3DPrim.%2520Care%2520Companion%2520J.%2520Clin.%2520Psychiatry%26date%3D2003%26volume%3D5%26spage%3D70%26epage%3D73%26doi%3D10.4088%2FPCC.v05n0202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, T.</span></span> <i>Pharmacokinetics of the Enantiomers of Thalidomide</i>; <span class="NLM_publisher-name">Malmö University Hospital</span>: <span class="NLM_publisher-loc">Malmö</span>, <span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=T.+Eriksson&title=Pharmacokinetics+of+the+Enantiomers+of+Thalidomide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DEriksson%26aufirst%3DT.%26btitle%3DPharmacokinetics%2520of%2520the%2520Enantiomers%2520of%2520Thalidomide%26pub%3DMalm%25C3%25B6%2520University%2520Hospital%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björkman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höglund, P.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacology of thalidomide</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1007/s002280100320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1007%2Fs002280100320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=11599654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtFWhtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2001&pages=365-376&author=T.+Erikssonauthor=S.+Bj%C3%B6rkmanauthor=P.+H%C3%B6glund&title=Clinical+pharmacology+of+thalidomide&doi=10.1007%2Fs002280100320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacology of thalidomide</span></div><div class="casAuthors">Eriksson, Tommy; Bjorkman, Sven; Hoglund, Peter</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">365-376</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review.  Background: Thalidomide has a chiral center, and the racemate of (R)- and (S)-thalidomide was introduced as a sedative drug in the late 1950s.  In 1961, it was withdrawn due to teratogenicity and neuropathy.  There is now a growing clin. interest in thalidomide due to its unique anti-inflammatory and immunomodulatory effects.  Objective: To critically review pharmacokinetic studies and briefly review pharmacodynamic effects and studies of thalidomide in consideration of its chem. and stereochem. properties and metab.  Methods: Literature search and computer simulations of pharmacokinetics.  Results: Rational use of thalidomide is problematic due to lack of basic knowledge of its mechanism of action, effects of the sep. enantiomers and metabolites, and dose- and concn.-effect relationships.  Due to its inhibition of tumor necrosis factor-α and angiogenesis, racemic thalidomide was tested with good effect in a variety of skin and mucous membrane disorders, Crohn's disease, graft-vs.-host disease, complications to human immunodeficiency virus, and, recently, in multiple myeloma.  Adverse reactions are often related to the sedative effects.  Irreversible toxic peripheral neuropathy and fetal malformations are serious complications that can be prevented.  The results of several published pharmacokinetic studies can be questioned due to poor methodol. and the use of non-stereospecific assays.  The enantiomers of thalidomide undergo spontaneous hydrolysis and fast chiral interconversion at physiol. pH.  The oral bioavailability of thalidomide was not unequivocally detd., but available data suggest that it is high.  Absorption is slow, with a time to max. blood plasma concn. of at least 2 h, and may also be dose-dependent; however, that of the sep. enantiomers may be faster due to higher aq. soly.  Estn. of the vol. of distribution is complicated by probable hydrolysis and chiral inversion also in peripheral compartments.  A value of around 1 l/kg is however plausible.  Plasma protein binding is low with little difference between the enantiomers.  Elimination of thalidomide is mainly by pH-dependent spontaneous hydrolysis in all body fluids with an apparent mean clearance of 10 l/h for the (R)- and 21 l/h for the (S)-enantiomer in adult subjects.  Blood concns. of the (R)-enantiomer are consequently higher than those of the (S)-enantiomer at pseudoequil.  The mean elimination half-life of both enantiomers is 5 h.  One hydroxylated metabolite was found in low concns. in the blood.  Since both enzymic metab. and renal excretion play minor roles in the elimination of thalidomide, the risk of drug interactions seems to be low.  Conclusions: The interest in and use of thalidomide is increasing due to its potential as an immunomodulating and antiangiogenic agent.  The inter-individual variability in distribution and elimination is low.  Apart from this, its use is complicated by the lack of knowledge of dose- or concn.-effect relationships, possible dose-dependent oral absorption and of course by its well-known serious adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPvIHZfdVKUbVg90H21EOLACvtfcHk0lh-KANq2hkUCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtFWhtb4%253D&md5=c440504893ed786bd098b8fff68a3cde</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs002280100320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002280100320%26sid%3Dliteratum%253Aachs%26aulast%3DEriksson%26aufirst%3DT.%26aulast%3DBj%25C3%25B6rkman%26aufirst%3DS.%26aulast%3DH%25C3%25B6glund%26aufirst%3DP.%26atitle%3DClinical%2520pharmacology%2520of%2520thalidomide%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2001%26volume%3D57%26spage%3D365%26epage%3D376%26doi%3D10.1007%2Fs002280100320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björkman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björk, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höglund, P.</span></span> <span> </span><span class="NLM_article-title">Hydroxylated metabolites of thalidomide: formation in-vitro and in-vivo in man</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1409</span>– <span class="NLM_lpage">1416</span>, <span class="refDoi"> DOI: 10.1111/j.2042-7158.1998.tb03368.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1111%2Fj.2042-7158.1998.tb03368.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10052858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK1MXpsFCmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1998&pages=1409-1416&author=T.+Erikssonauthor=S.+Bj%C3%B6rkmanauthor=B.+Rothauthor=H.+Bj%C3%B6rkauthor=P.+H%C3%B6glund&title=Hydroxylated+metabolites+of+thalidomide%3A+formation+in-vitro+and+in-vivo+in+man&doi=10.1111%2Fj.2042-7158.1998.tb03368.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxylated metabolites of thalidomide: formation in-vitro and in-vivo in man</span></div><div class="casAuthors">Eriksson, Tommy; Bjorkman, Seven; Roth, Bodil; Bjork, Henrik; Hoglund, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1409-1416</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">Royal Pharmaceutical Society of Great Britain</span>)
        </div><div class="casAbstract">There is renewed interest in the clin. use of thalidomide, because of its unique immunomodulating action.  Because data on the metab. of thalidomide in man are very sparse, the aim of this study was to develop HPLC assays for the 5-hydroxy, 5,6-dihydroxy, 4,5-dihydroxy and 5'-hydroxy metabolites of thalidomide and to investigate their possible formation in man - in-vitro in liver homogenates and in-vivo in healthy volunteers.  Reversed-phase HPLC assays with UV detection were developed for quantification of the metabolites in the low ng mL-1 range in plasma and incubate samples.  The stability of the metabolites was investigated and degrdn. was avoided by rapid chilling and acidification of the samples.  After incubation of thalidomide with fraction S9 from human liver, formation of the 5-hydroxy and 5'-hydroxy metabolites could be demonstrated.  The 5'-hydroxy metabolite was found, in low concns., in plasma samples from eight healthy male volunteers who had received thalidomide orally.  The other three metabolites could not be found by HPLC with detection limits of 1-2 ng mL-1.  Thus the formation of two hydroxylated metabolites of thalidomide in the liver in man was demonstrated, but only one of these could be detected in the circulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO-pK2ncViKLVg90H21EOLACvtfcHk0lg1foAO-tl77Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXpsFCmtA%253D%253D&md5=f4d100faec58ad10b09947a6438387b7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.2042-7158.1998.tb03368.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2042-7158.1998.tb03368.x%26sid%3Dliteratum%253Aachs%26aulast%3DEriksson%26aufirst%3DT.%26aulast%3DBj%25C3%25B6rkman%26aufirst%3DS.%26aulast%3DRoth%26aufirst%3DB.%26aulast%3DBj%25C3%25B6rk%26aufirst%3DH.%26aulast%3DH%25C3%25B6glund%26aufirst%3DP.%26atitle%3DHydroxylated%2520metabolites%2520of%2520thalidomide%253A%2520formation%2520in-vitro%2520and%2520in-vivo%2520in%2520man%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D1998%26volume%3D50%26spage%3D1409%26epage%3D1416%26doi%3D10.1111%2Fj.2042-7158.1998.tb03368.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mühlbacher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastner-Pustet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bringmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannschreck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaschke, G.</span></span> <span> </span><span class="NLM_article-title">In vitro biotransformation of (<i>R</i>)-and (<i>S</i>)-thalidomide: application of circular dichroism spectroscopy to the stereochemical characterization of the hydroxylated etabolites</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">3726</span>– <span class="NLM_lpage">3735</span>, <span class="refDoi"> DOI: 10.1021/ac0203138</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ac0203138" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD38XltV2ms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2002&pages=3726-3735&author=M.+Meyringauthor=J.+M%C3%BChlbacherauthor=K.+Messerauthor=N.+Kastner-Pustetauthor=G.+Bringmannauthor=A.+Mannschreckauthor=G.+Blaschke&title=In+vitro+biotransformation+of+%28R%29-and+%28S%29-thalidomide%3A+application+of+circular+dichroism+spectroscopy+to+the+stereochemical+characterization+of+the+hydroxylated+etabolites&doi=10.1021%2Fac0203138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Biotransformation of (R)- and (S)-Thalidomide: Application of Circular Dichroism Spectroscopy to the Stereochemical Characterization of the Hydroxylated Metabolites</span></div><div class="casAuthors">Meyring, Michael; Muehlbacher, Joerg; Messer, Kim; Kastner-Pustet, Nikola; Bringmann, Gerhard; Mannschreck, Albrecht; Blaschke, Gottfried</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3726-3735</span>CODEN:
                <span class="NLM_cas:coden">ANCHAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2700</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CD spectroscopy was successfully used for the stereochem. characterization of the hydroxylated metabolites formed during the in vitro biotransformation of (R)- and (S)-thalidomide by rat liver microsomes.  Incubation exts. of the individual enantiomers were analyzed by HPLC on an achiral stationary phase combined with CD detection.  The CD data of the almost enantiopure eluates of the metabolites were compared with the CD spectra quantum chem. calcd. for the resp. structures.  The results allowed us a reliable detn. of the abs. stereostructure for all of the metabolites.  The chiral center of thalidomide is unaffected by the stereoselective biotransformation process. (3'R,5'R)-trans-5'-hydroxythalidomide is the main metabolite of (R)-thalidomide, which epimerizes spontaneously to give the more stable (3'S,5'R)-cis isomer.  On the contrary, (S)-thalidomide is preferentially metabolized by hydroxylation in the phthalimide moiety, resulting in the formation of (S)-5-hydroxythalidomide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs0TJVv_3WprVg90H21EOLACvtfcHk0lg1foAO-tl77Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltV2ms7Y%253D&md5=e964e68691179e877e5693baf39195da</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fac0203138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fac0203138%26sid%3Dliteratum%253Aachs%26aulast%3DMeyring%26aufirst%3DM.%26aulast%3DM%25C3%25BChlbacher%26aufirst%3DJ.%26aulast%3DMesser%26aufirst%3DK.%26aulast%3DKastner-Pustet%26aufirst%3DN.%26aulast%3DBringmann%26aufirst%3DG.%26aulast%3DMannschreck%26aufirst%3DA.%26aulast%3DBlaschke%26aufirst%3DG.%26atitle%3DIn%2520vitro%2520biotransformation%2520of%2520%2528R%2529-and%2520%2528S%2529-thalidomide%253A%2520application%2520of%2520circular%2520dichroism%2520spectroscopy%2520to%2520the%2520stereochemical%2520characterization%2520of%2520the%2520hydroxylated%2520etabolites%26jtitle%3DAnal.%2520Chem.%26date%3D2002%26volume%3D74%26spage%3D3726%26epage%3D3735%26doi%3D10.1021%2Fac0203138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vargesson, N.</span></span> <span> </span><span class="NLM_article-title">Thalidomide-induced teratogenesis: history and mechanisms</span>. <i>Birth Defects Res., Part C</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1002/bdrc.21096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1002%2Fbdrc.21096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=26043938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsVWlsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2015&pages=140-156&author=N.+Vargesson&title=Thalidomide-induced+teratogenesis%3A+history+and+mechanisms&doi=10.1002%2Fbdrc.21096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide-induced teratogenesis: History and mechanisms</span></div><div class="casAuthors">Vargesson, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Birth Defects Research, Part C: Embryo Today--Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-156</span>CODEN:
                <span class="NLM_cas:coden">BDRPDV</span>;
        ISSN:<span class="NLM_cas:issn">1542-975X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Nearly 60 years ago thalidomide was prescribed to treat morning sickness in pregnant women.  What followed was the biggest man-made medical disaster ever, where over 10,000 children were born with a range of severe and debilitating malformations.  Despite this, the drug is now used successfully to treat a range of adult conditions, including multiple myeloma and complications of leprosy.  Tragically, a new generation of thalidomide damaged children has been identified in Brazil.  Yet, how thalidomide caused its devastating effects in the forming embryo remains unclear.  However, studies in the past few years have greatly enhanced our understanding of the mol. mechanisms the drug.  This review will look at the history of the drug, and the range and type of damage the drug caused, and outline the mechanisms of action the drug uses including recent mol. advances and new findings.  Some of the remaining challenges facing thalidomide biologists are also discussed.  Birth Defects Research (Part C), 2015. © 2015 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokrUriNAK3wbVg90H21EOLACvtfcHk0lg1foAO-tl77Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsVWlsbo%253D&md5=40a4f801af5d65d3fa9e322075c6deec</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fbdrc.21096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdrc.21096%26sid%3Dliteratum%253Aachs%26aulast%3DVargesson%26aufirst%3DN.%26atitle%3DThalidomide-induced%2520teratogenesis%253A%2520history%2520and%2520mechanisms%26jtitle%3DBirth%2520Defects%2520Res.%252C%2520Part%2520C%26date%3D2015%26volume%3D105%26spage%3D140%26epage%3D156%26doi%3D10.1002%2Fbdrc.21096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span> <i>Development
of New Stereoisomeric Drugs</i>; <span class="NLM_publisher-name">Food and Drug
Administration</span>: <span class="NLM_publisher-loc">Rockville,
MD</span>, <span class="NLM_year">1992</span>; <a href="https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/guidances/ucm122883.htm" class="extLink">https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/guidances/ucm122883.htm</a> (accessed Jan 19, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Development%0Aof+New+Stereoisomeric+Drugs%3B+Food+and+Drug%0AAdministration%3A+Rockville%2C%0AMD%2C+1992%3B+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fguidancecomplianceregulatoryinformation%2Fguidances%2Fucm122883.htm+%28accessed+Jan+19%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDevelopment%250Aof%2520New%2520Stereoisomeric%2520Drugs%26pub%3DFood%2520and%2520Drug%250AAdministration%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agranat, I.</span></span> <span> </span><span class="NLM_article-title">Trends in the development of chiral drugs</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(03)02904-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2FS1359-6446%2803%2902904-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=15038394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=105-110&author=H.+Canerauthor=E.+Gronerauthor=L.+Levyauthor=I.+Agranat&title=Trends+in+the+development+of+chiral+drugs&doi=10.1016%2FS1359-6446%2803%2902904-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in the development of chiral drugs</span></div><div class="casAuthors">Caner, Hava; Groner, Efrat; Levy, Liron; Agranat, Israel</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">105-110</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Single enantiomers, the leading component of approved drugs today, have already been significant in the 1980's, while racemates, although declining steeply, are not a dead option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0oqR9_DNUw7Vg90H21EOLACvtfcHk0lidSD_Il8n0Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOkurg%253D&md5=6cc54e0f9b73862add22632009a4c905</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2803%2902904-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252803%252902904-0%26sid%3Dliteratum%253Aachs%26aulast%3DCaner%26aufirst%3DH.%26aulast%3DGroner%26aufirst%3DE.%26aulast%3DLevy%26aufirst%3DL.%26aulast%3DAgranat%26aufirst%3DI.%26atitle%3DTrends%2520in%2520the%2520development%2520of%2520chiral%2520drugs%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D105%26epage%3D110%26doi%3D10.1016%2FS1359-6446%2803%2902904-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Toenjes, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, J. L.</span></span> <span> </span><span class="NLM_article-title">Atropisomerism in medicinal chemistry: challenges and opportunities</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.4155/fmc-2017-0152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.4155%2Ffmc-2017-0152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=29380622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=409-422&author=S.+T.+Toenjesauthor=J.+L.+Gustafson&title=Atropisomerism+in+medicinal+chemistry%3A+challenges+and+opportunities&doi=10.4155%2Ffmc-2017-0152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Atropisomerism in medicinal chemistry: challenges and opportunities</span></div><div class="casAuthors">Toenjes, Sean T.; Gustafson, Jeffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">409-422</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Atropisomerism is a dynamic type of axial chirality that is ubiquitous in medicinal chem.  There are several examples of stable atropisomeric US FDA-approved drugs and exptl. compds., and in each case the atropisomers of these compds. possess drastically different biol. activities.  Rapidly interconverting atropisomerism is even more prevalent, and while such compds. are typically considered achiral, they bind their protein targets in an atroposelective fashion, with the nonrelevant atropisomer contributing little to the desired activities.  It has been recently demonstrated that various properties of an interconverting atropisomer can be modulated through the synthesis of atropisomer stable and pure analogs.  Herein we discuss examples of atropisomerism in drug discovery as well as challenges and opportunities moving forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaSgfKDqoiYbVg90H21EOLACvtfcHk0lidSD_Il8n0Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCntLc%253D&md5=ceb5cc2626d980aa3e3903fd126a3f3a</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2017-0152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2017-0152%26sid%3Dliteratum%253Aachs%26aulast%3DToenjes%26aufirst%3DS.%2BT.%26aulast%3DGustafson%26aufirst%3DJ.%2BL.%26atitle%3DAtropisomerism%2520in%2520medicinal%2520chemistry%253A%2520challenges%2520and%2520opportunities%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2018%26volume%3D10%26spage%3D409%26epage%3D422%26doi%3D10.4155%2Ffmc-2017-0152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Clayden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaPlante, S. R.</span></span> <span> </span><span class="NLM_article-title">The challenge of atropisomerism in drug discovery</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6398</span>– <span class="NLM_lpage">6401</span>, <span class="refDoi"> DOI: 10.1002/anie.200901719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1002%2Fanie.200901719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=19637174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWiurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=6398-6401&author=J.+Claydenauthor=W.+J.+Moranauthor=P.+J.+Edwardsauthor=S.+R.+LaPlante&title=The+challenge+of+atropisomerism+in+drug+discovery&doi=10.1002%2Fanie.200901719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">The Challenge of Atropisomerism in Drug Discovery</span></div><div class="casAuthors">Clayden, Jonathan; Moran, Wesley J.; Edwards, Paul J.; LaPlante, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">6398-6401</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Herein, we address the pharmaceutical implications of a hitherto largely overlooked alternative source of drug chirality: atropisomerism.  Atropisomers are conformers which, owing to steric or electronic constraints, interconvert slowly enough (by definition, with a half life of > 1000 s) that they can be isolated.'781 The stereochem. consequences of hindered rotation about a single bond can be such that an apparent single compd. can actually be a mixt. of two, or an apparently achiral compd. can actually be racemic.  If such pairs of stereoisomers are separable, then the implications for drug discovery may be similar to those of compds. with classical chiral centers.  In the context of a lack of std. procedures for dealing with atropisomerism, and the absence of specific regulatory policies governing conformationally based stereochem., we explore some recent examples of atropisomeric compds. that have been or are in drug development.  We also draw conclusions relating to potential strategies for design and development where atropisomerism is an issue.  We expose and propose options for the management of atropisomerism, which, many view as a lurking menace with the potential to significantly increase the cost of pharmaceutical research and development if ignored.  Atropisomerism may give rise to geometrical isomers, diastereoisomers, or enantiomers, all with the distinctive feature that they can in principle be equilibrated thermally.  In the absence of specific regulatory policies, atropisomeric stereoisomers are best dealt with in the same way as stereoisomers with classical chiral centers, but with isomerization rates and where necessary, differential conformer populations taken into account.  For racemic drug candidates, the FDA policy statement from 1992 emphasizes the importance of understanding the main therapeutic activities of the isomers through in vitro or in vivo studies.  Studies of the pharmacokinetic behavior of the individual enantiomers carried out early in the development of drug candidates are also valuable.  Knowledge gained from these studies can help guide the choice of development of a single enantiomer vs. a racemic mixt.  Development of a drug as a racemic mixt. may be appropriate if the mixt. is not reasonably separable (by synthetic methods, HPLC anal., etc.) or if racemization is rapid in vitro and/or in vivo (as in ibuprofen or thalidomide), thus making it futile to administer only the eutomer (more active isomer).  However, it is nonetheless highly recommended that crit. pharmacol. attributes related to the safety and efficacy of both isomers is investigated: overall, there must be an acceptable toxicol. profile and a suitable therapeutic window (in vitro, in animal models, and in humans).  FDA website provides some useful guidance to their expectations for drug development in this context.  Options for dealing with the phenomenon of atropisomerism can be implemented at the early stage of drug design.  For example, it may be possible to make related analogs that have the following features: (1) symmetry about a hindered bond, thus eliminating a chiral axis; (2) faster rotation about a hindered bond, thus pushing the half-life for conformational interconversion down to the order of seconds; (3) further encumbrance about a hindered bond to produce separable atropisomers whose interconversion is negligibly slow (for example, half-lives of the order of millennia); or (4) introduction of a stable stereogenic center to perturb the population of interconverting atropisomers such that only one desirable conformation predominates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsMjlS3iQPEbVg90H21EOLACvtfcHk0lidSD_Il8n0Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWiurfN&md5=70ff6fe476e7db4653130fe74af9325e</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1002%2Fanie.200901719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200901719%26sid%3Dliteratum%253Aachs%26aulast%3DClayden%26aufirst%3DJ.%26aulast%3DMoran%26aufirst%3DW.%2BJ.%26aulast%3DEdwards%26aufirst%3DP.%2BJ.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26atitle%3DThe%2520challenge%2520of%2520atropisomerism%2520in%2520drug%2520discovery%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2009%26volume%3D48%26spage%3D6398%26epage%3D6401%26doi%3D10.1002%2Fanie.200901719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metrano, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rablen, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. J.</span></span> <span> </span><span class="NLM_article-title">Spontaneous transfer of chirality in an atropisomerically enriched two-axis system</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>509</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1038/nature13189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnature13189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=24747399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlyis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=509&publication_year=2014&pages=71-75&author=K.+T.+Barrettauthor=A.+J.+Metranoauthor=P.+R.+Rablenauthor=S.+J.+Miller&title=Spontaneous+transfer+of+chirality+in+an+atropisomerically+enriched+two-axis+system&doi=10.1038%2Fnature13189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Spontaneous transfer of chirality in an atropisomerically enriched two-axis system</span></div><div class="casAuthors">Barrett, Kimberly T.; Metrano, Anthony J.; Rablen, Paul R.; Miller, Scott J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">509</span>
        (<span class="NLM_cas:issue">7498</span>),
    <span class="NLM_cas:pages">71-75</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">One of the most well-recognized stereogenic elements in a chiral mol. is an sp3-hybridized carbon atom that is connected to four different substituents.  Axes of chirality can also exist about bonds with hindered barriers of rotation; mols. contg. such axes are known as atropisomers.  Understanding the dynamics of these systems can be useful, for example, in the design of single-atropisomer drugs or mol. switches and motors.  For mols. that exhibit a single axis of chirality, rotation about that axis leads to racemization as the system reaches equil.  Here we report a two-axis system for which an enantioselective reaction produces four stereoisomers (two enantiomeric pairs): following a catalytic asym. transformation, we observe a kinetically controlled product distribution that is perturbed from the system's equil. position.  As the system undergoes isomerization, one of the diastereomeric pairs drifts spontaneously to a higher enantiomeric ratio.  In a compensatory manner, the enantiomeric ratio of the other diastereomeric pair decreases.  These observations are made for a class of unsym. amides that exhibits two asym. axes-one axis is defined through a benzamide substructure, and the other axis is assocd. with differentially N,N-disubstituted amides.  The stereodynamics of these substrates provides an opportunity to observe a curious interplay of kinetics and thermodn. intrinsic to a system of stereoisomers that is constrained to a situation of partial equil.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO0VsKdgwtgbVg90H21EOLACvtfcHk0lirfpkPja_MpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlyis78%253D&md5=a7eabd56f3d8815af07417d39e605a7a</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1038%2Fnature13189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13189%26sid%3Dliteratum%253Aachs%26aulast%3DBarrett%26aufirst%3DK.%2BT.%26aulast%3DMetrano%26aufirst%3DA.%2BJ.%26aulast%3DRablen%26aufirst%3DP.%2BR.%26aulast%3DMiller%26aufirst%3DS.%2BJ.%26atitle%3DSpontaneous%2520transfer%2520of%2520chirality%2520in%2520an%2520atropisomerically%2520enriched%2520two-axis%2520system%26jtitle%3DNature%26date%3D2014%26volume%3D509%26spage%3D71%26epage%3D75%26doi%3D10.1038%2Fnature13189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaPlante, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fader, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandrick, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandrick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hucke, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemper, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. J.</span></span> <span> </span><span class="NLM_article-title">Assessing atropisomer axial chirality in drug discovery and development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7005</span>– <span class="NLM_lpage">7022</span>, <span class="refDoi"> DOI: 10.1021/jm200584g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200584g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7005-7022&author=S.+R.+LaPlanteauthor=L.+D.+Faderauthor=K.+R.+Fandrickauthor=D.+R.+Fandrickauthor=O.+Huckeauthor=R.+Kemperauthor=S.+P.+Millerauthor=P.+J.+Edwards&title=Assessing+atropisomer+axial+chirality+in+drug+discovery+and+development&doi=10.1021%2Fjm200584g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing Atropisomer Axial Chirality in Drug Discovery and Development</span></div><div class="casAuthors">LaPlante, Steven R.; Fader, Lee D.; Fandrick, Keith R.; Fandrick, Daniel R.; Hucke, Oliver; Kemper, Ray; Miller, Stephen P. F.; Edwards, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7005-7022</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ8uS-SDx68bVg90H21EOLACvtfcHk0lirfpkPja_MpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFygu7zN&md5=6b44135b3871d2460fba4b3246b899e3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm200584g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200584g%26sid%3Dliteratum%253Aachs%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DFader%26aufirst%3DL.%2BD.%26aulast%3DFandrick%26aufirst%3DK.%2BR.%26aulast%3DFandrick%26aufirst%3DD.%2BR.%26aulast%3DHucke%26aufirst%3DO.%26aulast%3DKemper%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DS.%2BP.%26aulast%3DEdwards%26aufirst%3DP.%2BJ.%26atitle%3DAssessing%2520atropisomer%2520axial%2520chirality%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7005%26epage%3D7022%26doi%3D10.1021%2Fjm200584g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">Small-molecule kinase inhibitors: an analysis of FDA-approved drugs</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.drudis.2015.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=26210956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=5-10&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=Small-molecule+kinase+inhibitors%3A+an+analysis+of+FDA-approved+drugs&doi=10.1016%2Fj.drudis.2015.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule kinase inhibitors: an analysis of FDA-approved drugs</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-10</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors (SMKIs), 28 of which are approved by the US Food and Drug Administration (FDA), have been actively pursued as promising targeted therapeutics.  Here, we assess the key structural and physicochem. properties, target selectivity and mechanism of function, and therapeutic indications of these approved inhibitors.  Our anal. showed that >30% of approved SMKIs have a mol. wt. (MW) exceeding 500 and all have a total ring count of between three and five.  The assumption that type II inhibitors tend to be more selective than type I inhibitors has been proved to be unreliable.  Although previous SMKI research was concd. on tyrosine kinase inhibitors for cancer treatment, recent progress indicates diversification of SMKI research in terms of new targets, mechanistic types, and therapeutic indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZrY68ZOI2xLVg90H21EOLACvtfcHk0lirfpkPja_MpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73P&md5=228524fa464393053ecbfac19e994929</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DSmall-molecule%2520kinase%2520inhibitors%253A%2520an%2520analysis%2520of%2520FDA-approved%2520drugs%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D5%26epage%3D10%26doi%3D10.1016%2Fj.drudis.2015.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">FDA-approved small-molecule kinase inhibitors</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.tips.2015.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=25975227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=422-439&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=FDA-approved+small-molecule+kinase+inhibitors&doi=10.1016%2Fj.tips.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-approved small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">422-439</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases have emerged as one of the most intensively pursued targets in current pharmacol. research, esp. for cancer, due to their crit. roles in cellular signaling.  To date, the US FDA has approved 28 small-mol. kinase inhibitors, half of which were approved in the past 3 years.  While the clin. data of these approved mols. are widely presented and structure-activity relationship (SAR) has been reported for individual mols., an updated review that analyzes all approved mols. and summarizes current achievements and trends in the field has yet to be found.  Here we present all approved small-mol. kinase inhibitors with an emphasis on binding mechanism and structural features, summarize current challenges, and discuss future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrudyvM3eO09bVg90H21EOLACvtfcHk0lirfpkPja_MpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D&md5=a6aa3dbb11e6fe3001fa5fa03a4c950a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DFDA-approved%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D422%26epage%3D439%26doi%3D10.1016%2Fj.tips.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0ljC9g6s5QQVug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, K. G.</span></span> <span> </span><span class="NLM_article-title">The significance of chirality in drug design and development</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.2174/156802611795165098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.2174%2F156802611795165098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=21291399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Ojsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=760-770&author=W.+H.+Brooksauthor=W.+C.+Guidaauthor=K.+G.+Daniel&title=The+significance+of+chirality+in+drug+design+and+development&doi=10.2174%2F156802611795165098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The significance of chirality in drug design and development</span></div><div class="casAuthors">Brooks, W. H.; Guida, W. C.; Daniel, K. G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">760-770</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Proteins are often enantioselective towards their binding partners.  When designing small mols. to interact with these targets, one should consider stereoselectivity.  As considerations for exploring structure space evolve, chirality is increasingly important.  Binding affinity for a chiral drug can differ for diastereomers and between enantiomers.  For the virtual screening and computational design stage of drug development, this problem can be compounded by incomplete stereochem. information in structure libraries leading to a "coin toss" as to whether or not the "ideal" chiral structure is present.  Creating every stereoisomer for each chiral compd. in a structure library leads to an exponential increase in the no. of structures resulting in potentially unmanageable file sizes and screening times.  Therefore, only key chiral structures, enantiomeric pairs based on relative stereochem. need be included, and lead to a compromise between exploration of chem. space and maintaining manageable libraries.  In clin. environments, enantiomers of chiral drugs can have reduced, no, or even deleterious effects.  This underscores the need to avoid mixts. of compds. and focus on chiral synthesis.  Governmental regulations emphasizing the need to monitor chirality in drug development have increased.  The United States Food and Drug Administration issued guidelines and policies in 1992 concerning the development of chiral compds.  These guidelines require that abs. stereochem. be known for compds. with chiral centers and that this information should be established early in drug development in order that the anal. can be considered valid.  From exploration of structure space to governmental regulations it is clear that the question of chirality in drug design is of vital importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4TgZ0W1QUdrVg90H21EOLACvtfcHk0ljC9g6s5QQVug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Ojsrw%253D&md5=eb78aca17518a7fd04d8cfc3c5d0ec78</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F156802611795165098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611795165098%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DW.%2BH.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26aulast%3DDaniel%26aufirst%3DK.%2BG.%26atitle%3DThe%2520significance%2520of%2520chirality%2520in%2520drug%2520design%2520and%2520development%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D760%26epage%3D770%26doi%3D10.2174%2F156802611795165098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran-Dube, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botrous, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grodsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padrique, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (<i>c</i>-MET) kinase and anaplastic lymphoma kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6342</span>– <span class="NLM_lpage">6363</span>, <span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0ljC9g6s5QQVug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10<i>R</i>)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2<i>H</i>-8,4-(metheno)pyrazolo[4,3-<i>h</i>][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and <i>c</i>-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+macrocyclic+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29+and+c-ros+oncogene+1+%28ROS1%29+with+preclinical+brain+exposure+and+broad-spectrum+potency+against+ALK-resistant+mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lhy4ocGFBNB2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520macrocyclic%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520c-ros%2520oncogene%25201%2520%2528ROS1%2529%2520with%2520preclinical%2520brain%2520exposure%2520and%2520broad-spectrum%2520potency%2520against%2520ALK-resistant%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8468</span>– <span class="NLM_lpage">8484</span>, <span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lhy4ocGFBNB2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span> <i>Drug Approval Package:
Rapamune (Sirolimus) Oral Solution</i>; <span class="NLM_publisher-name">U.S.
Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver
Spring, MD</span>, <span class="NLM_year">1999</span>; <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21083A.cfm" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21083A.cfm</a> (accessed Aug 30, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Drug+Approval+Package%3A%0ARapamune+%28Sirolimus%29+Oral+Solution%3B+U.S.%0AFood+and+Drug+Administration%3A+Silver%0ASpring%2C+MD%2C+1999%3B+https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Fnda%2F99%2F21083A.cfm+%28accessed+Aug+30%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Approval%2520Package%253A%250ARapamune%2520%2528Sirolimus%2529%2520Oral%2520Solution%26pub%3DU.S.%250AFood%2520and%2520Drug%2520Administration%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwitkowski, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prowell, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2009-0178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1634%2Ftheoncologist.2009-0178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=20332142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmsFynsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=428-435&author=V.+E.+Kwitkowskiauthor=T.+M.+Prowellauthor=A.+Ibrahimauthor=A.+T.+Farrellauthor=R.+Justiceauthor=S.+S.+Mitchellauthor=R.+Sridharaauthor=R.+Pazdur&title=FDA+approval+summary%3A+temsirolimus+as+treatment+for+advanced+renal+cell+carcinoma&doi=10.1634%2Ftheoncologist.2009-0178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma</span></div><div class="casAuthors">Kwitkowski, Virginia E.; Prowell, Tatiana M.; Ibrahim, Amna; Farrell, Ann T.; Justice, Robert; Mitchell, Shan Sun; Sridhara, Rajeshwari; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">428-435</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">This report summarizes the U.S. Food and Drug Administration (FDA)'s approval of temsirolimus (Torisel), on May 30, 2007, for the treatment of advanced renal cell carcinoma (RCC).  Information provided includes regulatory history, study design, study results, and literature review.  A multicenter, three-arm, randomized, open-label study was conducted in previously untreated patients with poor-prognosis, advanced RCC.  The study objectives were to compare overall survival (OS), progression-free survival (PFS), objective response rate, and safety in patients receiving interferon (IFN)-α vs. those receiving temsirolimus alone or in combination with IFN-α.  In the second planned interim anal. of the intent-to-treat population (n = 626), there was a statistically significant longer OS time in the temsirolimus (25 mg) arm than in the IFN-α arm (median, 10.9 mo vs. 7.3 mo; hazard ratio [HR], 0.73; p = .0078).  The combination of temsirolimus (15 mg) and IFN-α did not lead to a significant difference in OS compared with IFN-α alone.  There was also a statistically significant longer PFS time for the temsirolimus (25 mg) arm than for the IFN-α arm (median, 5.5 mo vs. 3.1 mo; HR, 0.66, p = .0001).  Common adverse reactions reported in patients receiving temsirolimus were rash, asthenia, and mucositis.  Common lab. abnormalities were anemia, hyperglycemia, hyperlipidemia, and hypertriglyceridemia.  Serious but rare cases of interstitial lung disease, bowel perforation, and acute renal failure were obsd.  Temsirolimus has demonstrated superiority in terms of OS and PFS over IFN-α and provides an addnl. treatment option for patients with advanced RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVBXF4DKP0uLVg90H21EOLACvtfcHk0lhmI43pyjB9Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmsFynsLg%253D&md5=8338d641486b9a6b18ccf3f2458c67c0</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2009-0178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2009-0178%26sid%3Dliteratum%253Aachs%26aulast%3DKwitkowski%26aufirst%3DV.%2BE.%26aulast%3DProwell%26aufirst%3DT.%2BM.%26aulast%3DIbrahim%26aufirst%3DA.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DMitchell%26aufirst%3DS.%2BS.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520temsirolimus%2520as%2520treatment%2520for%2520advanced%2520renal%2520cell%2520carcinoma%26jtitle%3DOncologist%26date%3D2010%26volume%3D15%26spage%3D428%26epage%3D435%26doi%3D10.1634%2Ftheoncologist.2009-0178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span> <i>Drug Trials Snapshots: COTELLIC</i>; <span class="NLM_publisher-name">U.S. Food
and Drug Administration</span>, <span class="NLM_year">2015</span>; <a href="https://www.fda.gov/Drugs/InformationOnDrugs/ucm478351.htm" class="extLink">https://www.fda.gov/Drugs/InformationOnDrugs/ucm478351.htm</a> (accessed
November 10, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Drug+Trials+Snapshots%3A+COTELLIC%3B+U.S.+Food%0Aand+Drug+Administration%2C+2015%3B+https%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2Fucm478351.htm+%28accessed%0ANovember+10%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Trials%2520Snapshots%253A%2520COTELLIC%26pub%3DU.S.%2520Food%250Aand%2520Drug%2520Administration%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span> <i>Midostaurin</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, <span class="NLM_year">2017</span>; <a href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555756.htm" class="extLink">https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555756.htm</a> (accessed Oct 28, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Midostaurin%3B+U.S.+Food+and+Drug+Administration%2C+2017%3B+https%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm555756.htm+%28accessed+Oct+28%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DMidostaurin%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span> <i>Drug Trials Snapshots:
RHOPRESSA</i>; <span class="NLM_publisher-name">U.S. Food
and Drug Administration</span>, <span class="NLM_year">2017</span>; <a href="https://www.fda.gov/Drugs/InformationOnDrugs/ucm591430.htm" class="extLink">https://www.fda.gov/Drugs/InformationOnDrugs/ucm591430.htm</a> (accessed
Dec 5, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Drug+Trials+Snapshots%3A%0ARHOPRESSA%3B+U.S.+Food%0Aand+Drug+Administration%2C+2017%3B+https%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2Fucm591430.htm+%28accessed%0ADec+5%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Trials%2520Snapshots%253A%250ARHOPRESSA%26pub%3DU.S.%2520Food%250Aand%2520Drug%2520Administration%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span> <i>FDA Grants Accelerated
Approval to Acalabrutinib for Mantle Cell
Lymphoma</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, <span class="NLM_year">2017</span>; <a href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm583106.htm" class="extLink">https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm583106.htm</a> (accessed Dec 31, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Grants+Accelerated%0AApproval+to+Acalabrutinib+for+Mantle+Cell%0ALymphoma%3B+U.S.+Food+and+Drug+Administration%2C+2017%3B+https%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm583106.htm+%28accessed+Dec+31%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Grants%2520Accelerated%250AApproval%2520to%2520Acalabrutinib%2520for%2520Mantle%2520Cell%250ALymphoma%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span> <i>FDA Approves Encorafenib
and Binimetinib in Combination for Unresectable
or Metastatic Melanoma with BRAF Mutations</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm611981.htm" class="extLink">https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm611981.htm</a> (accessed Jan 27, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+Encorafenib%0Aand+Binimetinib+in+Combination+for+Unresectable%0Aor+Metastatic+Melanoma+with+BRAF+Mutations%3B+U.S.+Food+and+Drug+Administration%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm611981.htm+%28accessed+Jan+27%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520Encorafenib%250Aand%2520Binimetinib%2520in%2520Combination%2520for%2520Unresectable%250Aor%2520Metastatic%2520Melanoma%2520with%2520BRAF%2520Mutations%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span> <i>FDA Approves Larotrectinib
for Solid Tumors with NTRK Gene Fusions</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm626720.htm" class="extLink">https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm626720.htm</a> (accessed Dec 28, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+Larotrectinib%0Afor+Solid+Tumors+with+NTRK+Gene+Fusions%3B+U.S.+Food+and+Drug+Administration%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Finformationondrugs%2Fapproveddrugs%2Fucm626720.htm+%28accessed+Dec+28%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520Larotrectinib%250Afor%2520Solid%2520Tumors%2520with%2520NTRK%2520Gene%2520Fusions%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.cell.2010.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=20602996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=1117-1134&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases&doi=10.1016%2Fj.cell.2010.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Lemmon, Mark A.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1117-1134</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected diversity in the mechanisms of their activation by growth factor ligands.  Strategies for inducing dimerization by ligand binding are surprisingly diverse, as are mechanisms that couple this event to activation of the intracellular tyrosine kinase domains.  As the understanding of these details becomes increasingly sophisticated, it provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.  Much remains to be learned, however, about the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd5NvoN0Q9-7Vg90H21EOLACvtfcHk0lhmI43pyjB9Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D&md5=b88b55fe7a3eebc6ff7e883425676e45</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D1117%26epage%3D1134%26doi%3D10.1016%2Fj.cell.2010.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gschwind, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, A.</span></span> <span> </span><span class="NLM_article-title">The discovery of receptor tyrosine kinases: targets for cancer therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1038/nrc1360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnrc1360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=15122207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=361-370&author=A.+Gschwindauthor=O.+M.+Fischerauthor=A.+Ullrich&title=The+discovery+of+receptor+tyrosine+kinases%3A+targets+for+cancer+therapy&doi=10.1038%2Fnrc1360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy</span></div><div class="casAuthors">Gschwind, Andreas; Fischer, Oliver M.; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are a subclass of cell-surface growth-factor receptors with an intrinsic, ligand-controlled tyrosine-kinase activity.  They regulate diverse functions in normal cells and have a crucial role in oncogenesis.  Twenty years ago, the 1st primary structure of a receptor Tyr kinase, the epidermal growth factor receptor, was elucidated.  The characterization of both the mol. architecture of receptor Tyr kinases and the main functions of these proteins and their ligands in tumorigenesis opened the door to a new era in mol. oncol. and paved the way to the development of the 1st target-specific cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NLVNn4dw37Vg90H21EOLACvtfcHk0liVsRol6PcgAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D&md5=ea24c0ccaea68b743b5da9587ed19406</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnrc1360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1360%26sid%3Dliteratum%253Aachs%26aulast%3DGschwind%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DO.%2BM.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DThe%2520discovery%2520of%2520receptor%2520tyrosine%2520kinases%253A%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D361%26epage%3D370%26doi%3D10.1038%2Fnrc1360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trink, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzai, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidransky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, N. H.</span></span> <span> </span><span class="NLM_article-title">Overexpression of <i>c</i>-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1544</span>– <span class="NLM_lpage">1550</span>, <span class="refDoi"> DOI: 10.1200/JCO.2002.20.6.1544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1200%2FJCO.2002.20.6.1544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=11896103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD38XivFeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=1544-1550&author=H.+L.+Chengauthor=B.+Trinkauthor=T.+S.+Tzaiauthor=H.+S.+Liuauthor=S.+H.+Chanauthor=C.+L.+Hoauthor=D.+Sidranskyauthor=N.+H.+Chow&title=Overexpression+of+c-met+as+a+prognostic+indicator+for+transitional+cell+carcinoma+of+the+urinary+bladder%3A+a+comparison+with+p53+nuclear+accumulation&doi=10.1200%2FJCO.2002.20.6.1544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: A comparison with p53 nuclear accumulation</span></div><div class="casAuthors">Cheng, Hong-Lin; Trink, Barry; Tzai, Tzong-Shin; Liu, Hsiao-Sheng; Chan, Shih-Huang; Ho, Chung-Liang; Sidransky, David; Chow, Nan-Haw</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1544-1550</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: The c-met proto-oncogene encodes a receptor tyrosine kinase (Met) and has been shown to play a role in oncogenesis.  Given that high titers of hepatocyte growth factor, the specific ligand for Met, are excreted in the urine and tend to reflect disease activity of bladder cancer, we performed this study to examine the clin. significance of Met in human bladder cancer.  Materials and Methods: We studied the mRNA expression and genomic alteration of c-met in five bladder cancer cell lines.  Significance of Met overexpression was then compared with p53 nuclear accumulation (TP53) in primary bladder cancer (n = 142 patients).  Results: Expression of c-met mRNA tended to pos. correlate with differentiation of cancer cell lines in the absence of point mutation.  High expression of Met was found in seven cases (4.9%), low expression in 32 cases (22.5%), and neg. expression in 103 cases (72.5%).  Expression of Met was pos. assocd. with histol. grade, stage classification, tumor size, and nodular tumor growth (P < .05, resp.); however, it was not related to TP53 status.  Factors that predicted disease progression were tumor stage, Met status, and TP53 accumulation (P < .05, resp.).  Indicators for poor long-term survival were invasive cancer, multiple tumors, and Met overexpression (P = .0006, .01, and .04, resp.).  Conclusion: The c-met proto-oncogene plays a more important role in the progression of bladder carcinogenesis than p53.  Evaluation of Met expression could identify a subset of bladder cancer patients who may require a more intensive treatment strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGfd5r45qOJLVg90H21EOLACvtfcHk0liVsRol6PcgAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivFeitrw%253D&md5=2b9b03134c74318b533f82908304a28e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.20.6.1544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.20.6.1544%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%2BL.%26aulast%3DTrink%26aufirst%3DB.%26aulast%3DTzai%26aufirst%3DT.%2BS.%26aulast%3DLiu%26aufirst%3DH.%2BS.%26aulast%3DChan%26aufirst%3DS.%2BH.%26aulast%3DHo%26aufirst%3DC.%2BL.%26aulast%3DSidransky%26aufirst%3DD.%26aulast%3DChow%26aufirst%3DN.%2BH.%26atitle%3DOverexpression%2520of%2520c-met%2520as%2520a%2520prognostic%2520indicator%2520for%2520transitional%2520cell%2520carcinoma%2520of%2520the%2520urinary%2520bladder%253A%2520a%2520comparison%2520with%2520p53%2520nuclear%2520accumulation%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D1544%26epage%3D1550%26doi%3D10.1200%2FJCO.2002.20.6.1544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirstein, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmer, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A. T.</span></span> <span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1126/science.8122112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1126%2Fscience.8122112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=8122112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+Look&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma&doi=10.1126%2Fscience.8122112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma</span></div><div class="casAuthors">Morris, Stephan, W.; Kirstein, Mark, N.; Valentine, Marcus B.; Dittmer, Kristopher G.; Shapiro, David N.; Saltman, David L.; Look, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5151</span>),
    <span class="NLM_cas:pages">1281-4</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes.  This rearrangement was shown to fuse the NPM nucleolar phosphoprotein gene on chromosome 5q35 to a previously unidentified protein tyrosine kinase gene, ALK, on chromosome 2p23.  In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK).  Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases.  Unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3KZnxLYaerVg90H21EOLACvtfcHk0liVsRol6PcgAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D&md5=219ee9615e613be456a05f8f1ded6066</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1126%2Fscience.8122112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8122112%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284%26doi%3D10.1126%2Fscience.8122112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maulik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrikhande, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kijima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span> <span> </span><span class="NLM_article-title">Role of the hepatocyte growth factor receptor, <i>c</i>-Met, in oncogenesis and potential for therapeutic inhibition</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1016/S1359-6101(01)00029-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2FS1359-6101%2801%2900029-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=11750879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1ahuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=41-59&author=G.+Maulikauthor=A.+Shrikhandeauthor=T.+Kijimaauthor=P.+C.+Maauthor=P.+T.+Morrisonauthor=R.+Salgia&title=Role+of+the+hepatocyte+growth+factor+receptor%2C+c-Met%2C+in+oncogenesis+and+potential+for+therapeutic+inhibition&doi=10.1016%2FS1359-6101%2801%2900029-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition</span></div><div class="casAuthors">Maulik, Gautam; Shrikhande, Amol; Kijima, Takashi; Ma, Patrick C.; Morrison, Paul T.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-59</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review is given.  Receptor tyrosine kinases have become important therapeutic targets for anti-neoplastic molecularly targeted therapies.  C-Met is a receptor tyrosine kinase shown to be over-expressed and mutated in a variety of malignancies.  Stimulation of c-Met via its ligand hepatocyte growth factor also known as scatter factor (HGF/SF), leads to a plethora of biol. and biochem. effects in the cell.  There has been considerable knowledge gained on the role of c-Met-HGF/SF axis in normal and malignant cells.  This review summarizes the structure of c-Met and HGF/SF and their family members.  Since there are known mutations of c-Met in solid tumors, particularly in papillary renal cell carcinoma, we have summarized the various mutations and over-expression of c-Met known thus far.  Stimulation of c-Met can lead to scattering, angiogenesis, proliferation, enhanced cell motility, invasion, and eventual metastasis.  The biol. functions altered by c-Met are quite unique and described in detail.  Along with biol. functions, various signal transduction pathways, including the cytoskeleton are altered with the activation of c-Met-HGF/SF loop.  We have recently shown the phosphorylation of focal adhesion proteins, such as paxillin and p125FAK in response to c-Met stimulation in lung cancer cells, and this is detailed here.  Finally, c-Met when mutated or over-expressed in malignant cells serves as an important therapeutic target and the most recent data in terms of inhibition of c-Met and downstream signal transduction pathways is summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom2mu2QMKr_7Vg90H21EOLACvtfcHk0lh3ThbcwccJsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1ahuro%253D&md5=aead14efa103c522ef374b0a16e51b35</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS1359-6101%2801%2900029-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6101%252801%252900029-6%26sid%3Dliteratum%253Aachs%26aulast%3DMaulik%26aufirst%3DG.%26aulast%3DShrikhande%26aufirst%3DA.%26aulast%3DKijima%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DMorrison%26aufirst%3DP.%2BT.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DRole%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%252C%2520c-Met%252C%2520in%2520oncogenesis%2520and%2520potential%2520for%2520therapeutic%2520inhibition%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2002%26volume%3D13%26spage%3D41%26epage%3D59%26doi%3D10.1016%2FS1359-6101%2801%2900029-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maulik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span> <span> </span><span class="NLM_article-title"><i>c</i>-Met: structure, functions and potential for therapeutic inhibition</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1023/A:1023768811842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1023%2FA%3A1023768811842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=12884908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslyiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=309-325&author=P.+C.+Maauthor=G.+Maulikauthor=J.+Christensenauthor=R.+Salgia&title=c-Met%3A+structure%2C+functions+and+potential+for+therapeutic+inhibition&doi=10.1023%2FA%3A1023768811842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">c-Met: Structure, functions and potential for therapeutic inhibition</span></div><div class="casAuthors">Ma, Patrick C.; Maulik, Gautam; Christensen, James; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-325</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review.  Studies on signal transduction pathways have generated various promising mol. targets for therapeutic inhibition in cancer therapy.  Receptor tyrosine kinases represent an important class of such therapeutic targets.  C-Met is a receptor tyrosine kinase that has been shown to be overexpressed and/or mutated in a variety of malignancies.  A no. of c-Met activating mutations, many of which are located in the tyrosine kinase domain, have been detected in various solid tumors and have been implicated in invasion and metastasis of tumor cells.  It is known that stimulation of c-Met via its natural ligand, hepatocyte growth factor (also known as scatter factor, HGF/SF) results in a plethora of biol. and biochem. effects in the cell.  Activation of c-Met signaling can lead to scattering, angiogenesis, proliferation, enhanced cell motility, invasion, and eventual metastasis.  In this review, the role of c-Met dysregulation in tumor progression and metastasis is discussed in detail with particular emphasis on c-Met mutations.  Moreover, we summarize current knowledge on various pathways of c-Met signal transduction, highlighting the central role in the cytoskeletal functions.  In this summary is included recent data in our lab. indicating that phosphorylation of focal adhesion proteins, such as paxillin, p125FAK, and PYK2, occurs in response to c-Met stimulation in lung cancer cells.  Most importantly, current data on c-Met suggest that when mutated or overexpressed in malignant cells, c-Met would serve as an important therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9rIdb5Ao4a7Vg90H21EOLACvtfcHk0lh3ThbcwccJsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslyiurY%253D&md5=7b7bf60da872071a39ce313efd32fd1f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1023%2FA%3A1023768811842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1023768811842%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DMaulik%26aufirst%3DG.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3Dc-Met%253A%2520structure%252C%2520functions%2520and%2520potential%2520for%2520therapeutic%2520inhibition%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2003%26volume%3D22%26spage%3D309%26epage%3D325%26doi%3D10.1023%2FA%3A1023768811842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vande Woude, G.</span></span> <span> </span><span class="NLM_article-title">Showering <i>c</i>-MET-dependent cancers with drugs</span>. <i>Curr. Opin. Genet. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.gde.2008.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.gde.2008.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=18406132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVarur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=87-96&author=B.+S.+Knudsenauthor=G.+Vande+Woude&title=Showering+c-MET-dependent+cancers+with+drugs&doi=10.1016%2Fj.gde.2008.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Showering c-MET-dependent cancers with drugs</span></div><div class="casAuthors">Knudsen, Beatrice S.; Vande Woude, George</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-96</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase, c-MET and its ligand hepatocyte growth factor/scatter factor (HGF/SF) have become leading candidates for targeted cancer therapies.  Inappropriate c-MET signaling through autocrine, paracrine, amplification, and mutational activation occurs in virtually all types of solid tumors (http://www.vai.org/met), contributing to one or a combination of proliferative, invasive, survival, or angiogenic cancer phenotypes. c-MET and HGF/SF participate in all stages of malignant progression and represent promising drug targets in a variety of cancer types, including carcinomas, sarcomas, and brain tumors.  While many are in pre-clin. testing, a few inhibitors have entered clin. trials.  With hundreds of thousands of potential responding cancers that express c-MET, the interest in this mol. as a drug target is not surprising.  However, the cognate c-MET diagnostic tests lag behind.  In addn., despite the great enthusiasm based on response rates in phase I trials, there is a need for caution.  It is almost without question that combination therapies with c-MET-HGF/SF inhibitors will be required for most cancers to achieve a cytotoxic tumor response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonjBq7fWvKhrVg90H21EOLACvtfcHk0lh3ThbcwccJsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVarur8%253D&md5=d0744275be94658bab067f20644c98d6</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2008.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2008.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DKnudsen%26aufirst%3DB.%2BS.%26aulast%3DVande%2BWoude%26aufirst%3DG.%26atitle%3DShowering%2520c-MET-dependent%2520cancers%2520with%2520drugs%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2008%26volume%3D18%26spage%3D87%26epage%3D96%26doi%3D10.1016%2Fj.gde.2008.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A.</span></span> <span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1126/science.8122112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1126%2Fscience.8122112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=8122112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+Morrisauthor=M.+Kirsteinauthor=M.+Valentineauthor=K.+Dittmerauthor=D.+Shapiroauthor=D.+Saltmanauthor=A.+Look&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma&doi=10.1126%2Fscience.8122112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma</span></div><div class="casAuthors">Morris, Stephan, W.; Kirstein, Mark, N.; Valentine, Marcus B.; Dittmer, Kristopher G.; Shapiro, David N.; Saltman, David L.; Look, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5151</span>),
    <span class="NLM_cas:pages">1281-4</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes.  This rearrangement was shown to fuse the NPM nucleolar phosphoprotein gene on chromosome 5q35 to a previously unidentified protein tyrosine kinase gene, ALK, on chromosome 2p23.  In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK).  Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases.  Unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3KZnxLYaerVg90H21EOLACvtfcHk0liDmZ9dc2MhoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D&md5=219ee9615e613be456a05f8f1ded6066</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscience.8122112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8122112%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%26aulast%3DKirstein%26aufirst%3DM.%26aulast%3DValentine%26aufirst%3DM.%26aulast%3DDittmer%26aufirst%3DK.%26aulast%3DShapiro%26aufirst%3DD.%26aulast%3DSaltman%26aufirst%3DD.%26aulast%3DLook%26aufirst%3DA.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284%26doi%3D10.1126%2Fscience.8122112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arango, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Los, G.</span></span> <span> </span><span class="NLM_article-title">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and <i>c</i>-Met, in experimental models of anaplastic large-cell lymphoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">3314</span>– <span class="NLM_lpage">3322</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+R.+Altonauthor=B.+Mroczkowskiauthor=G.+Los&title=Cytoreductive+antitumor+activity+of+PF-2341066%2C+a+novel+inhibitor+of+anaplastic+lymphoma+kinase+and+c-Met%2C+in+experimental+models+of+anaplastic+large-cell+lymphoma&doi=10.1158%2F1535-7163.MCT-07-0365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, ∼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-γ, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0liDmZ9dc2MhoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%2BR.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DLos%26aufirst%3DG.%26atitle%3DCytoreductive%2520antitumor%2520activity%2520of%2520PF-2341066%252C%2520a%2520novel%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520and%2520c-Met%252C%2520in%2520experimental%2520models%2520of%2520anaplastic%2520large-cell%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322%26doi%3D10.1158%2F1535-7163.MCT-07-0365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span> <i>FDA Approves
Crizotinib Capsules</i>; <span class="NLM_publisher-name">U.S. Food
and Drug Administration</span>, <span class="NLM_year">2016</span>; <a href="https://www.fda.gov" class="extLink">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-capsules</a> (accessed Jan. 30, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves%0ACrizotinib+Capsules%3B+U.S.+Food%0Aand+Drug+Administration%2C+2016%3B+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-crizotinib-capsules+%28accessed+Jan.+30%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%250ACrizotinib%2520Capsules%26pub%3DU.S.%2520Food%250Aand%2520Drug%2520Administration%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arango, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Los, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span> <span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of <i>c</i>-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">4408</span>– <span class="NLM_lpage">4417</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.+P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-Met%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms&doi=10.1158%2F0008-5472.CAN-06-4443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0liDmZ9dc2MhoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-Met%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417%26doi%3D10.1158%2F0008-5472.CAN-06-4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span>; <span class="NLM_string-name">Ramphal, J.</span>; <span class="NLM_string-name">Liang, C.</span>; <span class="NLM_string-name">Sun, L.</span>; <span class="NLM_string-name">Wei, C. C.</span>; <span class="NLM_string-name">Tang, P. C.</span></span> <span> </span><span class="NLM_article-title">Preparation of 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors</span>. U.S. Patent WO <span class="NLM_patent">2002096361</span>, May 30, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=J.+Cui&author=J.+Ramphal&author=C.+Liang&author=L.+Sun&author=C.+C.+Wei&author=P.+C.+Tang&title=Preparation+of+5-aralkylsulfonyl-3-%28pyrrol-2-ylmethylidene%29-2-indolinone+derivatives+as+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DPreparation%2520of%25205-aralkylsulfonyl-3-%2528pyrrol-2-ylmethylidene%2529-2-indolinone%2520derivatives%2520as%2520kinase%2520inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiering, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marconi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flocco, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perego, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristiani, C.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor <i>c</i>-Met and its complex with the microbial alkaloid K-252a</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">12654</span>– <span class="NLM_lpage">12659</span>, <span class="refDoi"> DOI: 10.1073/pnas.1734128100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1073%2Fpnas.1734128100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=14559966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslKnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=12654-12659&author=N.+Schieringauthor=S.+Knappauthor=M.+Marconiauthor=M.+M.+Floccoauthor=J.+Cuiauthor=R.+Peregoauthor=L.+Rusconiauthor=C.+Cristiani&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+the+hepatocyte+growth+factor+receptor+c-Met+and+its+complex+with+the+microbial+alkaloid+K-252a&doi=10.1073%2Fpnas.1734128100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a</span></div><div class="casAuthors">Schiering, Nikolaus; Knapp, Stefan; Marconi, Marina; Flocco, Maria M.; Cui, Jean; Perego, Rita; Rusconi, Luisa; Cristiani, Cinzia</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">12654-12659</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The protooncogene c-met codes for the hepatocyte growth factor receptor tyrosine kinase.  Binding of its ligand, hepatocyte growth factor/scatter factor, stimulates receptor autophosphorylation, which leads to pleiotropic downstream signaling events in epithelial cells, including cell growth, motility, and invasion.  These events are mediated by interaction of cytoplasmic effectors, generally through Src homol. 2 (SH2) domains, with two phosphotyrosine-contg. sequence motifs in the unique C-terminal tail of c-Met (supersite).  2 (SH2) domains, with two phosphotyrosine-contg. sequence motifs in the unique C-terminal tail of c-Met (supersite).  There is a strong link between aberrant c-Met activity and oncogenesis, which makes this kinase an important cancer drug target.  The furanosylated indolocarbazole K-252a belongs to a family of microbial alkaloids that also includes staurosporine.  It was recently shown to be a potent inhibitor of c-Met.  Here we report the crystal structures of an unphosphorylated c-Met kinase domain harboring a human cancer mutation and its complex with K-252a at 1.8-Å resoln.  The structure follows the well established architecture of protein kinases.  It adopts a unique, inhibitory conformation of the activation loop, a catalytically noncompetent orientation of helix αC, and reveals the complete C-terminal docking site.  The first SH2-binding motif (1349YVHV) adopts an extended conformation, whereas the second motif (1356YVNV), a binding site for Grb2-SH2, folds as a type II β-turn.  The intermediate portion of the supersite (1353NATY) assumes a type I β-turn conformation as in an Shc-phosphotyrosine binding domain peptide complex.  K-252a is bound in the adenosine pocket with an analogous binding mode to those obsd. in previously reported structures of protein kinases in complex with staurosporine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13Yf3cKB-ybVg90H21EOLACvtfcHk0ljmbh-FzqErdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslKnt74%253D&md5=d8cd3494f2583dfcb11efb6862aff607</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1734128100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1734128100%26sid%3Dliteratum%253Aachs%26aulast%3DSchiering%26aufirst%3DN.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMarconi%26aufirst%3DM.%26aulast%3DFlocco%26aufirst%3DM.%2BM.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DCristiani%26aufirst%3DC.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%2520c-Met%2520and%2520its%2520complex%2520with%2520the%2520microbial%2520alkaloid%2520K-252a%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D12654%26epage%3D12659%26doi%3D10.1073%2Fpnas.1734128100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelis, L. M.</span></span> <span> </span><span class="NLM_article-title">Brain metastases</span>. <i>Neurol. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1173</span>– <span class="NLM_lpage">1192</span>, <span class="refDoi"> DOI: 10.1016/j.ncl.2007.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.ncl.2007.07.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=17964030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A280%3ADC%252BD2snjvFygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=1173-1192&author=T.+D.+Nguyenauthor=L.+M.+DeAngelis&title=Brain+metastases&doi=10.1016%2Fj.ncl.2007.07.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Brain metastases</span></div><div class="casAuthors">Nguyen Teri D; DeAngelis Lisa M</div><div class="citationInfo"><span class="NLM_cas:title">Neurologic clinics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1173-92, x-xi</span>
        ISSN:<span class="NLM_cas:issn">0733-8619</span>.
    </div><div class="casAbstract">Brain metastases are a common complication of cancer and alter patient management more than metastases at any other site of distant progression.  Supportive therapies include steroids and antiseizure medications.  Definitive treatments include radiation therapy, surgery, and chemotherapy.  The optimal choice of treatment and overall prognosis largely depend on patient characteristics and the extent and distribution of disease.  Delaying or decreasing neurologic cause of death and disability are important therapeutic goals for this population.  While better definitive strategies are investigated, physicians must remember to optimize the use of supportive therapies to ameliorate symptoms and maintain quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSYt-AmUO_aF1C8OJBvdfbfW6udTcc2eYzQmO2DMV-Brntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2snjvFygtg%253D%253D&md5=a16350bd3ec9d4488bee98cd27c8cd77</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ncl.2007.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ncl.2007.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DT.%2BD.%26aulast%3DDeAngelis%26aufirst%3DL.%2BM.%26atitle%3DBrain%2520metastases%26jtitle%3DNeurol.%2520Clin.%26date%3D2007%26volume%3D25%26spage%3D1173%26epage%3D1192%26doi%3D10.1016%2Fj.ncl.2007.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">7535</span>– <span class="NLM_lpage">7540</span>, <span class="refDoi"> DOI: 10.1073/pnas.1019559108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1073%2Fpnas.1019559108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=21502504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=7535-7540&author=R.+Katayamaauthor=T.+M.+Khanauthor=C.+Benesauthor=E.+Lifshitsauthor=H.+Ebiauthor=V.+M.+Riveraauthor=W.+C.+Shakespeareauthor=A.+J.+Iafrateauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Therapeutic+strategies+to+overcome+crizotinib+resistance+in+non-small+cell+lung+cancers+harboring+the+fusion+oncogene+EML4-ALK&doi=10.1073%2Fpnas.1019559108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span></div><div class="casAuthors">Katayama, Ryohei; Khan, Tahsin M.; Benes, Cyril; Lifshits, Eugene; Ebi, Hiromichi; Rivera, Victor M.; Shakespeare, William C.; Iafrate, A. John; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7535-7540, S7535/1-S7535/17</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represents a mol. target in a small subset of non-small cell lung cancers (NSCLCs).  This fusion leads to constitutive ALK activation with potent transforming activity.  In a pivotal phase 1 clin. trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib (PF-02341066) demonstrated impressive antitumor activity in the majority of patients with NSCLC harboring ALK fusions.  However, despite these remarkable initial responses, cancers eventually develop resistance to crizotinib, usually within 1 y, thereby limiting the potential clin. benefit.  To det. how cancers acquire resistance to ALK inhibitors, we established a model of acquired resistance to crizotinib by exposing a highly sensitive EML4-ALK-pos. NSCLC cell line to increasing doses of crizotinib until resistance emerged.  We found that cells resistant to intermediate doses of crizotinib developed amplification of the EML4-ALK gene.  Cells resistant to higher doses (1 μM) also developed a gatekeeper mutation, L1196M, within the kinase domain, rendering EML4-ALK insensitive to crizotinib.  This gatekeeper mutation was readily detected using a unique and highly sensitive allele-specific PCR assay.  Although crizotinib was ineffectual against EML4-ALK harboring the gatekeeper mutation, we obsd. that two structurally different ALK inhibitors, NVPTAE684 and AP26113, were highly active against the resistant cancer cells in vitro and in vivo.  Furthermore, these resistant cells remained highly sensitive to the Hsp90 inhibitor 17-AAG.  Thus, we have developed a model of acquired resistance to ALK inhibitors and have shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPbiLG5xpg0LVg90H21EOLACvtfcHk0liKPAiCGfZxrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D&md5=82f47736429e6f71f9fd5852e4df64cb</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1019559108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1019559108%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520strategies%2520to%2520overcome%2520crizotinib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancers%2520harboring%2520the%2520fusion%2520oncogene%2520EML4-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D7535%26epage%3D7540%26doi%3D10.1073%2Fpnas.1019559108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elleraas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewanicki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span> <span> </span><span class="NLM_article-title">Conformational studies and atropisomerism kinetics of the ALK clinical candidate lorlatinib (PF-06463922) and desmethyl congeners</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3590</span>– <span class="NLM_lpage">3595</span>, <span class="refDoi"> DOI: 10.1002/anie.201509240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1002%2Fanie.201509240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28XisV2hurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=3590-3595&author=J.+Elleraasauthor=J.+Ewanickiauthor=T.+W.+Johnsonauthor=N.+W.+Sachauthor=M.+R.+Collinsauthor=P.+F.+Richardson&title=Conformational+studies+and+atropisomerism+kinetics+of+the+ALK+clinical+candidate+lorlatinib+%28PF-06463922%29+and+desmethyl+congeners&doi=10.1002%2Fanie.201509240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF-06463922) and Desmethyl Congeners</span></div><div class="casAuthors">Elleraas, Jeff; Ewanicki, Jason; Johnson, Ted W.; Sach, Neal W.; Collins, Michael R.; Richardson, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3590-3595</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Lorlatinib (PF-06463922) is an ALK/ROS1 inhibitor and is in clin. trials for the treatment of ALK pos. or ROS1 pos. NSCLC (i.e. specific subsets of NSCLC).  One of the lab. objectives for this mol. indicated that it would be desirable to advance a mol. which was CNS penetrant in order to treat brain metastases.  From this perspective, a macrocyclic template was attractive for a no. of reasons.  In particular, this template reduces the no. of rotatable bonds, provides the potential to shield polar surface area and reinforces binding through a restricted conformation.  All of these features led to better permeability for the mols. of interest and thus increased the chance for better blood brain barrier penetration.  With a CNS penetrant mol., kinase selectivity is a key consideration particularly with regard to proteins such as TrkB, which are believed to influence cognitive function.  Removal of the chiral benzylic Me substituent from lorlatinib was perceived as not only a means to simplify synthetic complexity, but also as a strategy to further truncate the mol. of interest.  Examn. of the NMR of the desmethyl analogs revealed that the compd. existed as a mixt. of atropisomers, which proved separable by chiral SFC.  The individual atropisomers were evaluated through a series of in vitro assays, and shown to have a favorable selectivity profile when compared to lorlatinib.  The challenge to develop such a mol. lies in the rate at which the atropisomers interchange dictated by the energy barrier required to do this.  Here, we describe the synthesis of the desmethyl macrocycles, conformational studies on the atropisomers, and the kinetics of the interconversion.  In addn., the corresponding conformational studies on lorlatinib are reported providing a hypothesis for why a single diastereomer is obsd. when the chiral benzylic Me group is introduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphacUOv-75g7Vg90H21EOLACvtfcHk0liKPAiCGfZxrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisV2hurc%253D&md5=b84cee2b13f663aa2cbeab24f65bb65c</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fanie.201509240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201509240%26sid%3Dliteratum%253Aachs%26aulast%3DElleraas%26aufirst%3DJ.%26aulast%3DEwanicki%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26atitle%3DConformational%2520studies%2520and%2520atropisomerism%2520kinetics%2520of%2520the%2520ALK%2520clinical%2520candidate%2520lorlatinib%2520%2528PF-06463922%2529%2520and%2520desmethyl%2520congeners%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D3590%26epage%3D3595%26doi%3D10.1002%2Fanie.201509240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kothe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladysheva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valtre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crenne, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, M.</span></span> <span> </span><span class="NLM_article-title">The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2012.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.jmb.2012.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22902478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yqu7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2012&pages=439-453&author=T.+Bertrandauthor=M.+Kotheauthor=J.+Liuauthor=A.+Dupuyauthor=A.+Rakauthor=P.+F.+Berneauthor=S.+Davisauthor=T.+Gladyshevaauthor=C.+Valtreauthor=J.+Y.+Crenneauthor=M.+Mathieu&title=The+crystal+structures+of+TrkA+and+TrkB+suggest+key+regions+for+achieving+selective+inhibition&doi=10.1016%2Fj.jmb.2012.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The Crystal Structures of TrkA and TrkB Suggest Key Regions for Achieving Selective Inhibition</span></div><div class="casAuthors">Bertrand, T.; Kothe, M.; Liu, J.; Dupuy, A.; Rak, A.; Berne, P. F.; Davis, S.; Gladysheva, T.; Valtre, C.; Crenne, J. Y.; Mathieu, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">439-453</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Trk family of neurotrophin receptors, which includes the three highly homologous proteins TrkA, TrkB and TrkC, is strongly assocd. with central and peripheral nervous system processes.  Trk proteins are also of interest in oncol., since Trk activation has been obsd. in several cancer types.  While Trk kinases are attractive oncol. targets, selectivity might be more of an issue than for other kinases due to potential CNS side effects if several Trk kinases are simultaneously targeted.  In order to address this issue, we present here the first structures of human TrkA and TrkB kinase domains and three complexes between TrkB and Trk inhibitors.  These structures reveal different conformations of the kinase domain and suggest new regions of selectivity among the Trk family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryh_7mc93WjLVg90H21EOLACvtfcHk0liKPAiCGfZxrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yqu7vN&md5=39409144c4655d93164a881cc28a6115</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2012.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2012.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DT.%26aulast%3DKothe%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDupuy%26aufirst%3DA.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DBerne%26aufirst%3DP.%2BF.%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DGladysheva%26aufirst%3DT.%26aulast%3DValtre%26aufirst%3DC.%26aulast%3DCrenne%26aufirst%3DJ.%2BY.%26aulast%3DMathieu%26aufirst%3DM.%26atitle%3DThe%2520crystal%2520structures%2520of%2520TrkA%2520and%2520TrkB%2520suggest%2520key%2520regions%2520for%2520achieving%2520selective%2520inhibition%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D423%26spage%3D439%26epage%3D453%26doi%3D10.1016%2Fj.jmb.2012.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleasby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">687</span>– <span class="NLM_lpage">693</span>, <span class="refDoi"> DOI: 10.1080/00498250903015402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1080%2F00498250903015402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=19569734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps12gtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=687-693&author=H.+Heauthor=K.+A.+Lyonsauthor=X.+Shenauthor=Z.+Yaoauthor=K.+Bleasbyauthor=G.+Chanauthor=M.+Hafeyauthor=X.+Liauthor=S.+Xuauthor=G.+M.+Salituroauthor=L.+H.+Cohenauthor=W.+Tang&title=Utility+of+unbound+plasma+drug+levels+and+P-glycoprotein+transport+data+in+prediction+of+central+nervous+system+exposure&doi=10.1080%2F00498250903015402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure</span></div><div class="casAuthors">He, H.; Lyons, K. A.; Shen, X.; Yao, Z.; Bleasby, K.; Chan, G.; Hafey, M.; Li, X.; Xu, S.; Salituro, G. M.; Cohen, L. H.; Tang, W.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">687-693</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Drug concns. in cerebrospinal fluid were assumed to be a natural surrogate for total drug exposures in the central nervous system.  The present communication reports a data set from a study of 30 compds. in mice.  An attempt was made to correlate cerebrospinal fluid and unbound plasma drug concns. via incorporation of in vitro P-glycoprotein (Pgp)-mediated transport data.  Pgp-deficient (Pgp -/-) and wild-type mice were dosed with compds. of interest by oral gavage (orally) at 5 mg kg-1.  Plasma and cerebrospinal fluid samples were collected at 1h post-dosing, and analyzed by liq. chromatog.-tandem mass spectrometry (LC-MS/MS) for drug concns.  Mouse and human Pgp-mediated transport were evaluated in vitro by a bi-directional (B to A and A to B) transport assay using LLC-PK1 cells expressing mouse (mdr1a) and human (MDR1) forms of Pgp, resp.  Compds. with B to A/A to B transport ratios <2 were defined as non-substrates of Pgp, whereas those exhibiting B to A/A to B transport ratios ≥2 were considered Pgp substrates.  Plasma protein binding was also detd. in vitro via equil. dialysis.  Of the 30 compds., 13 were identified to be mouse Pgp substrates, all of which were also human Pgp substrates, demonstrating a good agreement between mouse and human data.  In Pgp wild-type mice, the unbound plasma and cerebrospinal fluid concns. of the non-Pgp substrates correlated well, with a regression slope of approx. 1.0.  A similar relationship existed for Pgp substrates in Pgp -/- mice.  On the other hand, an improved correlation of cerebrospinal fluid and systemic exposures of the Pgp substrates in Pgp wild-type mice was obsd. when the unbound plasma concns. were normalized to the corresponding B to A/A to B transport ratios.  These results reinforce the premise that a combined use of unbound plasma drug concns. and in vitro Pgp transport data may be of value for the estn. of central nervous system exposures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrApJIK--rl1rVg90H21EOLACvtfcHk0lg3Eaar_r6KPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps12gtbs%253D&md5=f9b7ad759a8ced86e9b8b90c445217f3</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1080%2F00498250903015402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250903015402%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DH.%26aulast%3DLyons%26aufirst%3DK.%2BA.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DBleasby%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DHafey%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DSalituro%26aufirst%3DG.%2BM.%26aulast%3DCohen%26aufirst%3DL.%2BH.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DUtility%2520of%2520unbound%2520plasma%2520drug%2520levels%2520and%2520P-glycoprotein%2520transport%2520data%2520in%2520prediction%2520of%2520central%2520nervous%2520system%2520exposure%26jtitle%3DXenobiotica%26date%3D2009%26volume%3D39%26spage%3D687%26epage%3D693%26doi%3D10.1080%2F00498250903015402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kodaira, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusuhara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ushiki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Quantitative evaluation of the impact of active efflux by P-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">944</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.180398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1124%2Fjpet.111.180398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=21934030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVSksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2011&pages=935-944&author=H.+Kodairaauthor=H.+Kusuharaauthor=T.+Fujitaauthor=J.+Ushikiauthor=E.+Fuseauthor=Y.+Sugiyama&title=Quantitative+evaluation+of+the+impact+of+active+efflux+by+P-glycoprotein+and+breast+cancer+resistance+protein+at+the+blood-brain+barrier+on+the+predictability+of+the+unbound+concentrations+of+drugs+in+the+brain+using+cerebrospinal+fluid+concentration+as+a+surrogate&doi=10.1124%2Fjpet.111.180398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative evaluation of the impact of active efflux by P-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate</span></div><div class="casAuthors">Kodaira, Hiroshi; Kusuhara, Hiroyuki; Fujita, Takuya; Ushiki, Junko; Fuse, Eiichi; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">935-944</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study investigated the impact of the active efflux mediated by P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp) at the blood-brain barrier (BBB) on the predictability of the unbound brain concn. (Cu,brain) by the concn. in the cerebrospinal fluid (CSF) (Cu,CSF) in rats.  Cu,brain is obtained as the product of the total brain concn. and unbound fraction in the brain (fu,brain) detd. in vitro in brain slices.  Twenty-five compds., including P-gp and/or Bcrp substrates, were given a const. i.v. infusion, and their plasma, brain, and CSF concns. were detd.  P-gp and/or Bcrp substrates, such as verapamil, loperamide, flavopiridol, genistein, quinidine, dantrolene, daidzein, cimetidine, and pefloxacin, showed a higher CSF-to-brain unbound concn. ratio (Kp,uu,CSF/brain) compared with non-P-gp and non-Bcrp substrates.  Kp,uu,CSF/brain values of P-gp-specific (quinidine and verapamil) and Bcrp-specific (daidzein and genistein) substrates were significantly decreased in Mdr1a/1b(-/-) and Bcrp(-/-) mice, resp.  Furthermore, consistent with the contribution of P-gp and Bcrp to the net efflux at the BBB, Kp,uu,CSF/brain values of the common substrates (flavopiridol and erlotinib) were markedly decreased in Mdr1a/1b(-/-)/Bcrp(-/-) mice, but only moderately or weakly in Mdr1a/1b(-/-) mice and negligibly in Bcrp(-/-) mice.  In conclusion, predictability of Cu,brain by Cu,CSF decreases along with the net transport activities by P-gp and Bcrp at the BBB.  Cu,CSF of non-P-gp and non-Bcrp substrates can be a reliable surrogate of Cu,brain for lipophilic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6e2OeGRsyrVg90H21EOLACvtfcHk0lg3Eaar_r6KPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVSksbo%253D&md5=36a778b164943b101534146120fc6cdf</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.180398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.180398%26sid%3Dliteratum%253Aachs%26aulast%3DKodaira%26aufirst%3DH.%26aulast%3DKusuhara%26aufirst%3DH.%26aulast%3DFujita%26aufirst%3DT.%26aulast%3DUshiki%26aufirst%3DJ.%26aulast%3DFuse%26aufirst%3DE.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DQuantitative%2520evaluation%2520of%2520the%2520impact%2520of%2520active%2520efflux%2520by%2520P-glycoprotein%2520and%2520breast%2520cancer%2520resistance%2520protein%2520at%2520the%2520blood-brain%2520barrier%2520on%2520the%2520predictability%2520of%2520the%2520unbound%2520concentrations%2520of%2520drugs%2520in%2520the%2520brain%2520using%2520cerebrospinal%2520fluid%2520concentration%2520as%2520a%2520surrogate%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D339%26spage%3D935%26epage%3D944%26doi%3D10.1124%2Fjpet.111.180398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span> <i>FDA Approves Lorlatinib for Second- Or Third-Line
Treatment of ALK-Positive
Metastatic NSCLC</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm625027.htm" class="extLink">https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm625027.htm</a> (accessed Feb 14, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+Lorlatinib+for+Second-+Or+Third-Line%0ATreatment+of+ALK-Positive%0AMetastatic+NSCLC%3B+U.S.+Food+and+Drug+Administration%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm625027.htm+%28accessed+Feb+14%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520Lorlatinib%2520for%2520Second-%2520Or%2520Third-Line%250ATreatment%2520of%2520ALK-Positive%250AMetastatic%2520NSCLC%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunker, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dack, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsaparikos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1170</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.1021/jm401805h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401805h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1170-1187&author=Q.+Huangauthor=T.+W.+Johnsonauthor=S.+Baileyauthor=A.+Broounauthor=K.+D.+Bunkerauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=A.+S.+Cookauthor=J.+J.+Cuiauthor=K.+N.+Dackauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=P.+S.+Johnsonauthor=R.+S.+Kaniaauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=Q.+Liauthor=L.+Lingardoauthor=W.+Liuauthor=M.+W.+Luauthor=M.+McTigueauthor=C.+L.+Palmerauthor=P.+F.+Richardsonauthor=N.+W.+Sachauthor=H.+Shenauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=K.+Tsaparikosauthor=H.+Wangauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Design+of+potent+and+selective+inhibitors+to+overcome+clinical+anaplastic+lymphoma+kinase+mutations+resistant+to+crizotinib&doi=10.1021%2Fjm401805h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib</span></div><div class="casAuthors">Huang, Qinhua; Johnson, Ted W.; Bailey, Simon; Brooun, Alexei; Bunker, Kevin D.; Burke, Benjamin J.; Collins, Michael R.; Cook, Andrew S.; Cui, J. Jean; Dack, Kevin N.; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Johnson, Patrick S.; Kania, Robert S.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Li, Qiuhua; Lingardo, Laura; Liu, Wei; Lu, Melissa West; McTigue, Michele; Palmer, Cynthia L.; Richardson, Paul F.; Sach, Neal W.; Shen, Hong; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Tsaparikos, Konstantinos; Wang, Hui; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1170-1187</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Crizotinib, an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S.  Food and Drug Administration in 2011, is efficacious in ALK and ROS pos. patients.  Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease.  The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine (I), which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclin. pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnhF6vRWLUrrVg90H21EOLACvtfcHk0lg3Eaar_r6KPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D&md5=c12e0400ac92eb3321fde81ee13a5e92</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm401805h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401805h%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBunker%26aufirst%3DK.%2BD.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDack%26aufirst%3DK.%2BN.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DJohnson%26aufirst%3DP.%2BS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDesign%2520of%2520potent%2520and%2520selective%2520inhibitors%2520to%2520overcome%2520clinical%2520anaplastic%2520lymphoma%2520kinase%2520mutations%2520resistant%2520to%2520crizotinib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1170%26epage%3D1187%26doi%3D10.1021%2Fjm401805h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussault, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrow, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan-Lefko, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimanovich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the <i>c</i>-Met kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2879</span>– <span class="NLM_lpage">2882</span>, <span class="refDoi"> DOI: 10.1021/jm800043g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800043g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvFShtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2879-2882&author=B.+K.+Albrechtauthor=J.+C.+Harmangeauthor=D.+Bauerauthor=L.+Berryauthor=C.+Bodeauthor=A.+A.+Boezioauthor=A.+Chenauthor=D.+Choquetteauthor=I.+Dussaultauthor=C.+Fridrichauthor=S.+Hiraiauthor=D.+Hoffmanauthor=J.+F.+Larrowauthor=P.+Kaplan-Lefkoauthor=J.+Linauthor=J.+Lohmanauthor=A.+M.+Longauthor=J.+Moriguchiauthor=A.+O%E2%80%99Connorauthor=M.+H.+Potashmanauthor=M.+Reeseauthor=K.+Rexauthor=A.+Siegmundauthor=K.+Shahauthor=R.+Shimanovichauthor=S.+K.+Springerauthor=Y.+Tefferaauthor=Y.+Yangauthor=Y.+Zhangauthor=S.+F.+Bellon&title=Discovery+and+optimization+of+triazolopyridazines+as+potent+and+selective+inhibitors+of+the+c-Met+kinase&doi=10.1021%2Fjm800043g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Triazolopyridazines as Potent and Selective Inhibitors of the c-Met Kinase</span></div><div class="casAuthors">Albrecht, Brian K.; Harmange, Jean-Christophe; Bauer, David; Berry, Loren; Bode, Christiane; Boezio, Alessandro A.; Chen, April; Choquette, Deborah; Dussault, Isabelle; Fridrich, Cary; Hirai, Satoko; Hoffman, Doug; Larrow, Jay F.; Kaplan-Lefko, Paula; Lin, Jasmine; Lohman, Julia; Long, Alexander M.; Moriguchi, Jodi; O'Connor, Anne; Potashman, Michele H.; Reese, Monica; Rex, Karen; Siegmund, Aaron; Shah, Kavita; Shimanovich, Roman; Springer, Stephanie K.; Teffera, Yohannes; Yang, Yajing; Zhang, Yihong; Bellon, Steven F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2879-2882</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tumorigenesis is a multistep process in which oncogenes play a key role in tumor formation, growth, and maintenance.  MET was discovered as an oncogene that is activated by its ligand, hepatocyte growth factor.  Deregulated signaling in the c-Met pathway has been obsd. in multiple tumor types.  Herein we report the discovery of potent and selective triazolopyridazine small mols. that inhibit c-Met activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVeQ8sYpasHLVg90H21EOLACvtfcHk0liyqWhEpD7JaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFShtLk%253D&md5=c0aec3ca102d90869884c139372f60a0</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm800043g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800043g%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DHirai%26aufirst%3DS.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DLarrow%26aufirst%3DJ.%2BF.%26aulast%3DKaplan-Lefko%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DA.%2BM.%26aulast%3DMoriguchi%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DA.%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DReese%26aufirst%3DM.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSiegmund%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DS.%2BK.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520triazolopyridazines%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520c-Met%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2879%26epage%3D2882%26doi%3D10.1021%2Fjm800043g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussault, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan-Lefko, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrow, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santostefano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimanovich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of potent and selective triazolopyridazine series of <i>c</i>-Met inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6307</span>– <span class="NLM_lpage">6312</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.09.096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2009.09.096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=19819693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlWlsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6307-6312&author=A.+A.+Boezioauthor=L.+Berryauthor=B.+K.+Albrechtauthor=D.+Bauerauthor=S.+F.+Bellonauthor=C.+Bodeauthor=A.+Chenauthor=D.+Choquetteauthor=I.+Dussaultauthor=S.+Hiraiauthor=P.+Kaplan-Lefkoauthor=J.+F.+Larrowauthor=M.+H.+J.+Linauthor=J.+Lohmanauthor=M.+H.+Potashmanauthor=K.+Rexauthor=M.+Santostefanoauthor=K.+Shahauthor=R.+Shimanovichauthor=S.+K.+Springerauthor=Y.+Tefferaauthor=Y.+Yangauthor=Y.+Zhangauthor=J.+C.+Harmange&title=Discovery+and+optimization+of+potent+and+selective+triazolopyridazine+series+of+c-Met+inhibitors&doi=10.1016%2Fj.bmcl.2009.09.096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors</span></div><div class="casAuthors">Boezio, Alessandro A.; Berry, Loren; Albrecht, Brian K.; Bauer, David; Bellon, Steven F.; Bode, Christiane; Chen, April; Choquette, Deborah; Dussault, Isabelle; Hirai, Satoko; Kaplan-Lefko, Paula; Larrow, Jay F.; Lin, Min-Hwa Jasmine; Lohman, Julia; Potashman, Michele H.; Rex, Karen; Santostefano, Michael; Shah, Kavita; Shimanovich, Roman; Springer, Stephanie K.; Teffera, Yohannes; Yang, Yajing; Zhang, Yihong; Harmange, Jean-Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6307-6312</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small mol. drug discovery.  We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met.  Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase activity and display improved pharmacodynamic profiles.  Specifically, the potent time-dependent inhibition of cytochrome P 450 assocd. with the O-linked triazolopyridazines has been eliminated within this novel series of inhibitors.  N-linked triazolopyridazine 24 exhibited favorable pharmacokinetics and displayed potent inhibition of HGF-mediated c-Met phosphorylation in a mouse liver PD model.  Once-daily oral administration of 24 for 22 days showed significant tumor growth inhibition in an NIH-3T3/TPR-Met xenograft mouse efficacy model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiJYhob-fk_bVg90H21EOLACvtfcHk0liyqWhEpD7JaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlWlsrbF&md5=254e67e6f81b7018b75f73290505e8af</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.09.096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.09.096%26sid%3Dliteratum%253Aachs%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DHirai%26aufirst%3DS.%26aulast%3DKaplan-Lefko%26aufirst%3DP.%26aulast%3DLarrow%26aufirst%3DJ.%2BF.%26aulast%3DLin%26aufirst%3DM.%2BH.%2BJ.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSantostefano%26aufirst%3DM.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DS.%2BK.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520potent%2520and%2520selective%2520triazolopyridazine%2520series%2520of%2520c-Met%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6307%26epage%3D6312%26doi%3D10.1016%2Fj.bmcl.2009.09.096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bode, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broome, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussault, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of a potent and selective triazolopyridinone series of <i>c</i>-Met inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4089</span>– <span class="NLM_lpage">4093</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.04.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2012.04.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22595176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XntVyrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4089-4093&author=C.+M.+Bodeauthor=A.+A.+Boezioauthor=B.+K.+Albrechtauthor=S.+F.+Bellonauthor=L.+Berryauthor=M.+A.+Broomeauthor=D.+Choquetteauthor=I.+Dussaultauthor=R.+T.+Lewisauthor=M.+H.+Linauthor=K.+Rexauthor=D.+A.+Whittingtonauthor=Y.+Yangauthor=J.+C.+Harmange&title=Discovery+and+optimization+of+a+potent+and+selective+triazolopyridinone+series+of+c-Met+inhibitors&doi=10.1016%2Fj.bmcl.2012.04.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors</span></div><div class="casAuthors">Bode, Christiane M.; Boezio, Alessandro A.; Albrecht, Brian K.; Bellon, Steven F.; Berry, Loren; Broome, Martin A.; Choquette, Deborah; Dussault, Isabelle; Lewis, Richard T.; Lin, Min-Hwa Jasmine; Rex, Karen; Whittington, Douglas A.; Yang, Yajing; Harmange, Jean-Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4089-4093</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small mol. drug discovery.  The discovery of a structurally diverse series of quinolinylmethyltriazolopyridinones, which demonstrates nanomolar inhibition of c-Met kinase activity is reported.  This novel series of inhibitors exhibits favorable pharmacokinetics as well as potent inhibition of HGF-mediated c-Met phosphorylation in a mouse liver pharmacodynamic model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2bZorS8wwhrVg90H21EOLACvtfcHk0lh9y2GAYaTQYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntVyrtLo%253D&md5=0f80a577ebee0df3c3a219273c43b738</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.04.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.04.072%26sid%3Dliteratum%253Aachs%26aulast%3DBode%26aufirst%3DC.%2BM.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520a%2520potent%2520and%2520selective%2520triazolopyridinone%2520series%2520of%2520c-Met%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4089%26epage%3D4093%26doi%3D10.1016%2Fj.bmcl.2012.04.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broome, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussault, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimanovich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaida, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective 8-fluorotriazolopyridine <i>c</i>-Met inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2417</span>– <span class="NLM_lpage">2430</span>, <span class="refDoi"> DOI: 10.1021/jm501913a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501913a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtV2nt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2417-2430&author=E.+A.+Petersonauthor=Y.+Tefferaauthor=B.+K.+Albrechtauthor=D.+Bauerauthor=S.+F.+Bellonauthor=A.+Boezioauthor=C.+Boezioauthor=M.+A.+Broomeauthor=D.+Choquetteauthor=K.+W.+Copelandauthor=I.+Dussaultauthor=R.+Lewisauthor=M.+H.+Linauthor=J.+Lohmanauthor=J.+Liuauthor=M.+Potashmanauthor=K.+Rexauthor=R.+Shimanovichauthor=D.+A.+Whittingtonauthor=K.+R.+Vaidaauthor=J.+C.+Harmange&title=Discovery+of+potent+and+selective+8-fluorotriazolopyridine+c-Met+inhibitors&doi=10.1021%2Fjm501913a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective 8-Fluorotriazolopyridine c-Met Inhibitors</span></div><div class="casAuthors">Peterson, Emily A.; Teffera, Yohannes; Albrecht, Brian K.; Bauer, David; Bellon, Steven F.; Boezio, Alessandro; Boezio, Christiane; Broome, Martin A.; Choquette, Deborah; Copeland, Katrina W.; Dussault, Isabelle; Lewis, Richard; Lin, Min-Hwa Jasmine; Lohman, Julia; Liu, Jingzhou; Potashman, Michele; Rex, Karen; Shimanovich, Roman; Whittington, Douglas A.; Vaida, Karina R.; Harmange, Jean-Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2417-2430</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The overexpression of c-Met and/or hepatocyte growth factor (HGF), the amplification of the MET gene, and mutations in the c-Met kinase domain can activate signaling pathways that contribute to cancer progression by enabling tumor cell proliferation, survival, invasion, and metastasis.  Herein, the authors report the discovery of 8-fluorotriazolopyridines as inhibitors of c-Met activity.  Optimization of the 8-fluorotriazolopyridine scaffold through the combination of structure-based drug design, SAR studies, and metabolite identification provided potent (cellular IC50 < 10 nM) selective inhibitors of c-Met with desirable pharmacokinetic properties, e.g. I, that demonstrate potent inhibition of HGF-mediated c-Met phosphorylation in a mouse liver pharmacodynamic model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcDhr-rvECKrVg90H21EOLACvtfcHk0lh9y2GAYaTQYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtV2nt70%253D&md5=ae86b1c6fac93caa1deecd89410bd837</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm501913a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501913a%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DE.%2BA.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DBoezio%26aufirst%3DA.%26aulast%3DBoezio%26aufirst%3DC.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DCopeland%26aufirst%3DK.%2BW.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DLewis%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DVaida%26aufirst%3DK.%2BR.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%25208-fluorotriazolopyridine%2520c-Met%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2417%26epage%3D2430%26doi%3D10.1021%2Fjm501913a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broome, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussault, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimanovich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaida, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of (<i>R</i>)-6-(1-(8-fluoro-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6<i>H</i>)-one (AMG 337), a potent and selective inhibitor of MET with high unbound target coverage and robust in <i>vivo</i> antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2328</span>– <span class="NLM_lpage">2342</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01716</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01716" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlKltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2328-2342&author=A.+A.+Boezioauthor=K.+W.+Copelandauthor=K.+Rexauthor=B.+K.+Albrechtauthor=D.+Bauerauthor=S.+F.+Bellonauthor=C.+Boezioauthor=M.+A.+Broomeauthor=D.+Choquetteauthor=A.+Coxonauthor=I.+Dussaultauthor=S.+Hiraiauthor=R.+Lewisauthor=M.+H.+Linauthor=J.+Lohmanauthor=J.+Liuauthor=E.+A.+Petersonauthor=M.+Potashmanauthor=R.+Shimanovichauthor=Y.+Tefferaauthor=D.+A.+Whittingtonauthor=K.+R.+Vaidaauthor=J.+C.+Harmange&title=Discovery+of+%28R%29-6-%281-%288-fluoro-6-%281-methyl-1H-pyrazol-4-yl%29-%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dpyridin-3-yl%29ethyl%29-3-%282-methoxyethoxy%29-1%2C6-naphthyridin-5%286H%29-one+%28AMG+337%29%2C+a+potent+and+selective+inhibitor+of+MET+with+high+unbound+target+coverage+and+robust+in+vivo+antitumor+activity&doi=10.1021%2Facs.jmedchem.5b01716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity</span></div><div class="casAuthors">Boezio, Alessandro A.; Copeland, Katrina W.; Rex, Karen; K. Albrecht, Brian; Bauer, David; Bellon, Steven F.; Boezio, Christiane; Broome, Martin A.; Choquette, Deborah; Coxon, Angela; Dussault, Isabelle; Hirai, Satoko; Lewis, Richard; Lin, Min-Hwa Jasmine; Lohman, Julia; Liu, Jingzhou; Peterson, Emily A.; Potashman, Michele; Shimanovich, Roman; Teffera, Yohannes; Whittington, Douglas A.; Vaida, Karina R.; Harmange, Jean-Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2328-2342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Deregulation of the receptor tyrosine kinase mesenchymal epithelial transition factor (MET) has been implicated in several human cancers and is an attractive target for small mol. drug discovery.  Herein, we report the discovery of compd. 23 (AMG 337), which demonstrates nanomolar inhibition of MET kinase activity, desirable preclin. pharmacokinetics, significant inhibition of MET phosphorylation in mice, and robust tumor growth inhibition in a MET-dependent mouse efficacy model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAOYPFHP_gM7Vg90H21EOLACvtfcHk0lgEvSokV3bLsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlKltrw%253D&md5=51c002bcb9167f5139f23686b9961afd</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01716%26sid%3Dliteratum%253Aachs%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DCopeland%26aufirst%3DK.%2BW.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DBoezio%26aufirst%3DC.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DHirai%26aufirst%3DS.%26aulast%3DLewis%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DPeterson%26aufirst%3DE.%2BA.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DVaida%26aufirst%3DK.%2BR.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%2520%2528R%2529-6-%25281-%25288-fluoro-6-%25281-methyl-1H-pyrazol-4-yl%2529-%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dpyridin-3-yl%2529ethyl%2529-3-%25282-methoxyethoxy%2529-1%252C6-naphthyridin-5%25286H%2529-one%2520%2528AMG%2520337%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520MET%2520with%2520high%2520unbound%2520target%2520coverage%2520and%2520robust%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2328%26epage%3D2342%26doi%3D10.1021%2Facs.jmedchem.5b01716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinsmore, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcone, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabarda, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunii, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumb, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutterbach, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathvink, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazef, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickert, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenstein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soisson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczak, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of a 5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (MK-2461) inhibitor of <i>c</i>-Met kinase for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4092</span>– <span class="NLM_lpage">4108</span>, <span class="refDoi"> DOI: 10.1021/jm200112k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200112k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFymtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4092-4108&author=J.+D.+Katzauthor=J.+P.+Jewellauthor=D.+J.+Guerinauthor=J.+Limauthor=C.+J.+Dinsmoreauthor=S.+V.+Deshmukhauthor=B.+S.+Panauthor=C.+G.+Marshallauthor=W.+Luauthor=M.+D.+Altmanauthor=W.+K.+Dahlbergauthor=L.+Davisauthor=D.+Falconeauthor=A.+E.+Gabardaauthor=G.+Hangauthor=H.+Hatchauthor=R.+Holmesauthor=K.+Kuniiauthor=K.+J.+Lumbauthor=B.+Lutterbachauthor=R.+Mathvinkauthor=N.+Nazefauthor=S.+B.+Patelauthor=X.+Quauthor=J.+F.+Reillyauthor=K.+W.+Rickertauthor=C.+Rosensteinauthor=S.+M.+Soissonauthor=K.+B.+Spencerauthor=A.+A.+Szewczakauthor=D.+Walkerauthor=W.+Wangauthor=J.+Youngauthor=Q.+Zeng&title=Discovery+of+a+5H-benzo%5B4%2C5%5Dcyclohepta%5B1%2C2-b%5Dpyridin-5-one+%28MK-2461%29+inhibitor+of+c-Met+kinase+for+the+treatment+of+cancer&doi=10.1021%2Fjm200112k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a 5H-Benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer</span></div><div class="casAuthors">Katz, Jason D.; Jewell, James P.; Guerin, David J.; Lim, Jongwon; Dinsmore, Christopher J.; Deshmukh, Sujal V.; Pan, Bo-Sheng; Marshall, C. Gary; Lu, Wei; Altman, Michael D.; Dahlberg, William K.; Davis, Lenora; Falcone, Danielle; Gabarda, Ana E.; Hang, Gaozhen; Hatch, Harold; Holmes, Rachael; Kunii, Kaiko; Lumb, Kevin J.; Lutterbach, Bart; Mathvink, Robert; Nazef, Naim; Patel, Sangita B.; Qu, Xianlu; Reilly, John F.; Rickert, Keith W.; Rosenstein, Craig; Soisson, Stephen M.; Spencer, Kerrie B.; Szewczak, Alexander A.; Walker, Deborah; Wang, Wenxian; Young, Jonathan; Zeng, Qinwen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4092-4108</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">C-Met is a transmembrane tyrosine kinase that mediates activation of several signaling pathways implicated in aggressive cancer phenotypes.  In recent years, research into this area has highlighted c-Met as an attractive cancer drug target, triggering a no. of approaches to disrupt aberrant c-Met signaling.  Screening efforts identified a unique class of 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one kinase inhibitors, exemplified by 1.  Subsequent SAR studies led to the development of MK-2461 (I), a potent inhibitor of c-Met that was efficacious in preclin. animal models of tumor suppression.  In addn., biochem. studies and x-ray anal. have revealed that this unique class of kinase inhibitors binds preferentially to the activated (phosphorylated) form of the kinase.  This report details the development of I and provides a description of its unique biochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6ANuqa7a-NrVg90H21EOLACvtfcHk0lgEvSokV3bLsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFymtbY%253D&md5=82cfe0a146d04d467531e1027f3a1266</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm200112k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200112k%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26aulast%3DJewell%26aufirst%3DJ.%2BP.%26aulast%3DGuerin%26aufirst%3DD.%2BJ.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DPan%26aufirst%3DB.%2BS.%26aulast%3DMarshall%26aufirst%3DC.%2BG.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DDahlberg%26aufirst%3DW.%2BK.%26aulast%3DDavis%26aufirst%3DL.%26aulast%3DFalcone%26aufirst%3DD.%26aulast%3DGabarda%26aufirst%3DA.%2BE.%26aulast%3DHang%26aufirst%3DG.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DHolmes%26aufirst%3DR.%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26aulast%3DLutterbach%26aufirst%3DB.%26aulast%3DMathvink%26aufirst%3DR.%26aulast%3DNazef%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DRickert%26aufirst%3DK.%2BW.%26aulast%3DRosenstein%26aufirst%3DC.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DSpencer%26aufirst%3DK.%2BB.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520a%25205H-benzo%255B4%252C5%255Dcyclohepta%255B1%252C2-b%255Dpyridin-5-one%2520%2528MK-2461%2529%2520inhibitor%2520of%2520c-Met%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4092%26epage%3D4108%26doi%3D10.1021%2Fjm200112k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourpak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4981</span>– <span class="NLM_lpage">5004</span>, <span class="refDoi"> DOI: 10.1021/jm9002395</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9002395" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXos1eht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4981-5004&author=R.+Liauthor=A.+Pourpakauthor=S.+W.+Morris&title=Inhibition+of+the+insulin-like+growth+factor-1+receptor+%28IGF1R%29+tyrosine+kinase+as+a+novel+cancer+therapy+approach&doi=10.1021%2Fjm9002395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach</span></div><div class="casAuthors">Li, Rongshi; Pourpak, Alan; Morris, Stephan W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4981-5004</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This paper reports the use insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase inhibitors in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqan3Tf91Gt-bVg90H21EOLACvtfcHk0lgEvSokV3bLsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXos1eht70%253D&md5=20bfe274451b2dc60e1b2bff7c86b6d8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm9002395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9002395%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DR.%26aulast%3DPourpak%26aufirst%3DA.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26atitle%3DInhibition%2520of%2520the%2520insulin-like%2520growth%2520factor-1%2520receptor%2520%2528IGF1R%2529%2520tyrosine%2520kinase%2520as%2520a%2520novel%2520cancer%2520therapy%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4981%26epage%3D5004%26doi%3D10.1021%2Fjm9002395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samani, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeRoith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodt, P.</span></span> <span> </span><span class="NLM_article-title">The role of the IGF system in cancer growth and metastasis: overview and recent insights</span>. <i>Endocr. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1210/er.2006-0001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1210%2Fer.2006-0001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=16931767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtFCgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=20-47&author=A.+A.+Samaniauthor=S.+Yakarauthor=D.+LeRoithauthor=P.+Brodt&title=The+role+of+the+IGF+system+in+cancer+growth+and+metastasis%3A+overview+and+recent+insights&doi=10.1210%2Fer.2006-0001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the IGF system in cancer growth and metastasis: overview and recent insights</span></div><div class="casAuthors">Samani, Amir Abbas; Yakar, Shoshana; LeRoith, Derek; Brodt, Pnina</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-47</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  IGF-I receptor (IGF-IR) signaling and functions are mediated through the activities of a complex mol. network of pos. (e.g., type I IGF) and neg. (e.g., the type II IGF receptor, IGF-IIR) effectors.  Under normal physiol. conditions, the balance between the expression and activities of these mols. is tightly controlled.  Changes in this delicate balance (e.g., overexpression of one effector) may trigger a cascade of mol. events that can ultimately lead to malignancy.  In recent years, evidence has been mounting that the IGF axis may be involved in human cancer progression and can be targeted for therapeutic intervention.  Here we review old and more recent evidence on the role the IGF system in malignancy and highlight exptl. and clin. studies that provide novel insights into the complex mechanisms that contribute to its oncogenic potential.  Controversies arising from conflicting evidence on the relevance of IGF-IR and its ligands to human cancer are discussed.  Our review highlights the importance of viewing the IGF axis as a complex multifactorial system and shows that changes in the expression levels of any one component of the axis, in a given malignancy, should be interpreted with caution and viewed in a wider context that takes into account the expression levels, state of activation, accessibility, and functionality of other interacting components.  Because IGF targeting for anticancer therapy is rapidly becoming a clin. reality, an understanding of this complexity is timely because it is likely to have an impact on the design, mode of action, and clin. outcomes of newly developed drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMaVO8jlyh3LVg90H21EOLACvtfcHk0ljBt6F0siIRTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtFCgsrg%253D&md5=f900044e75292ad8c7797407fe500025</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1210%2Fer.2006-0001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fer.2006-0001%26sid%3Dliteratum%253Aachs%26aulast%3DSamani%26aufirst%3DA.%2BA.%26aulast%3DYakar%26aufirst%3DS.%26aulast%3DLeRoith%26aufirst%3DD.%26aulast%3DBrodt%26aufirst%3DP.%26atitle%3DThe%2520role%2520of%2520the%2520IGF%2520system%2520in%2520cancer%2520growth%2520and%2520metastasis%253A%2520overview%2520and%2520recent%2520insights%26jtitle%3DEndocr.%2520Rev.%26date%3D2007%26volume%3D28%26spage%3D20%26epage%3D47%26doi%3D10.1210%2Fer.2006-0001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stampfer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovannucci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gann, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennekens, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M.</span></span> <span> </span><span class="NLM_article-title">Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1126/science.279.5350.563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1126%2Fscience.279.5350.563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=9438850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK1cXotVOqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=563-566&author=J.+M.+Chanauthor=M.+J.+Stampferauthor=E.+Giovannucciauthor=P.+H.+Gannauthor=J.+Maauthor=P.+Wilkinsonauthor=C.+H.+Hennekensauthor=M.+Pollak&title=Plasma+insulin-like+growth+factor-I+and+prostate+cancer+risk%3A+a+prospective+study&doi=10.1126%2Fscience.279.5350.563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study</span></div><div class="casAuthors">Chan, June M.; Stempfer, Meir J.; Giovannucci, Edward; Gann, Peter H.; Ma, Jing; Wilkinson, Peter; Hennekens, Charles H.; Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5350</span>),
    <span class="NLM_cas:pages">563-566</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Insulin-like growth factor-I (IGF-I) is a mitogen for prostate epithelial cells.  To investigate assocns. between plasma IGF levels and prostate cancer risk, a nested case-control study within the Physicians' health Study was conducted on prospectively collected plasma from 152 cases and 152 controls.  A strong pos. assocn. was obsd. between IGF-I levels and prostate cancer risk.  Men in the highest quartile of IGF-I levels had a relative risk of 4.3 (95 % confidence interval 1.8 to 10.6) compared with men in the lowest quartile.  This assocn. was independent of baseline prostate-specific antigen levels.  Identification of plasma IGF-I as a predictor of prostate cancer risk may have implications for risk redn. and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN8T4rIgzxMLVg90H21EOLACvtfcHk0ljBt6F0siIRTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVOqsg%253D%253D&md5=43c076479c5fb946f61a42758043bd92</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5350.563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5350.563%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DJ.%2BM.%26aulast%3DStampfer%26aufirst%3DM.%2BJ.%26aulast%3DGiovannucci%26aufirst%3DE.%26aulast%3DGann%26aufirst%3DP.%2BH.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWilkinson%26aufirst%3DP.%26aulast%3DHennekens%26aufirst%3DC.%2BH.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DPlasma%2520insulin-like%2520growth%2520factor-I%2520and%2520prostate%2520cancer%2520risk%253A%2520a%2520prospective%2520study%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D563%26epage%3D566%26doi%3D10.1126%2Fscience.279.5350.563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perks, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holly, J. M.</span></span> <span> </span><span class="NLM_article-title">The insulin-like growth factor (IGF) family and breast cancer</span>. <i>Breast Dis.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.3233/BD-2003-18106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.3233%2FBD-2003-18106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=15687688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvVehur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2003&pages=45-60&author=C.+M.+Perksauthor=J.+M.+Holly&title=The+insulin-like+growth+factor+%28IGF%29+family+and+breast+cancer&doi=10.3233%2FBD-2003-18106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The Insulin-Like Growth Factor (IGF) Family and Breast Cancer</span></div><div class="casAuthors">Perks, Claire M.; Holly, Jeff M. P.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Disease</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45-60</span>CODEN:
                <span class="NLM_cas:coden">BRDIE5</span>;
        ISSN:<span class="NLM_cas:issn">0888-6008</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  The IGF family, composed of ligands, receptors, binding proteins and proteases, is crit. during development and in the maintenance of normal tissue homeostasis.  This review describes the role of the IGF system in the normal breast but focuses on the changes that occur in breast cancer.  It discusses the cross-talk which can occur between the IGF family with other signaling pathways, including estrogen, epidermal growth factor (EGF) and integrins.  It also describes various cell and animal models which have been developed to elucidate the function and significance of the IGF family in cancer with a view to developing potential therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra9ZrESdTewrVg90H21EOLACvtfcHk0ljBt6F0siIRTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvVehur8%253D&md5=30ba3c81f50a36dc54681070e38e6547</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3233%2FBD-2003-18106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FBD-2003-18106%26sid%3Dliteratum%253Aachs%26aulast%3DPerks%26aufirst%3DC.%2BM.%26aulast%3DHolly%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520insulin-like%2520growth%2520factor%2520%2528IGF%2529%2520family%2520and%2520breast%2520cancer%26jtitle%3DBreast%2520Dis.%26date%3D2003%26volume%3D18%26spage%3D45%26epage%3D60%26doi%3D10.3233%2FBD-2003-18106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, N.</span></span> <span> </span><span class="NLM_article-title">Discovery of a series of nonpeptide small molecules that inhibit the binding of insulin-like growth factor (IGF) to IGF-binding proteins</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">4001</span>– <span class="NLM_lpage">4010</span>, <span class="refDoi"> DOI: 10.1021/jm010304b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010304b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntF2hsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=4001-4010&author=C.+Chenauthor=Y.-F.+Zhuauthor=X.-J.+Liuauthor=Z.-X.+Luauthor=Q.+Xieauthor=N.+Ling&title=Discovery+of+a+series+of+nonpeptide+small+molecules+that+inhibit+the+binding+of+insulin-like+growth+factor+%28IGF%29+to+IGF-binding+proteins&doi=10.1021%2Fjm010304b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Series of Nonpeptide Small Molecules That Inhibit the Binding of Insulin-like Growth Factor (IGF) to IGF-Binding Proteins</span></div><div class="casAuthors">Chen, Chen; Zhu, Yun-Fei; Liu, Xin-Jun; Lu, Zi-Xian; Xie, Qiu; Ling, Nicholas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4001-4010</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Insulin-like growth factors (IGF-I and II) play an important role in metabolic and mitogenic activities through stimulation of the IGF-I receptor on the cell surface.  Although the concn. of IGF in blood and cerebrospinal fluid is quite high (>100 nM), this large pool of IGF is biol. inactive because of its assocn. with six distinct binding proteins, which form high-affinity complexes with IGF.  Thus, inhibitors of IGF-binding proteins (IGFBPs), esp. IGFBP-3, could potentially alter the distribution between the "free" and "bound" forms of IGF and thereby elevate biol. active IGF-I to exert a beneficial effect on those patients with diseases that respond to the application of exogenous IGF-I.  Whereas IGF-I peptide variants, which bind to IGFBPs but not the IGF-I receptor, have been shown to be potent IGF/IGFBP inhibitors, small mol. nonpeptide IGF/IGFBP inhibitors have the potential advantages of oral bioavailability and flexible dosing regimen.  Here the authors report the discovery of several isoquinoline analogs which bind IGFBP-3 as well as other IGFBPs at low nanomolar concns.  More importantly, both compds. were shown to be able to release biol. active IGF-I from the IGF-I/IGFBP-3 complex.  These results point to the feasibility of developing orally active therapeutics to treat IGF-responsive diseases by optimization of the lead mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeHMB34sQWg7Vg90H21EOLACvtfcHk0lgBsjjDTYhKxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntF2hsrk%253D&md5=f966229b9ab421117ecebd357e28905a</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm010304b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010304b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DY.-F.%26aulast%3DLiu%26aufirst%3DX.-J.%26aulast%3DLu%26aufirst%3DZ.-X.%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DLing%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520a%2520series%2520of%2520nonpeptide%2520small%2520molecules%2520that%2520inhibit%2520the%2520binding%2520of%2520insulin-like%2520growth%2520factor%2520%2528IGF%2529%2520to%2520IGF-binding%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D4001%26epage%3D4010%26doi%3D10.1021%2Fjm010304b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokhale, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foreman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buck, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittner, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadalbajoo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landfair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinig, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvihill, M. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of an orally efficacious imidazo[5,1-<i>f</i>][1,2,4]triazine dual inhibitor of IGF-1R and IR</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">515</span>, <span class="refDoi"> DOI: 10.1021/ml100178g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100178g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyhur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=510-515&author=M.+Jinauthor=P.+C.+Gokhaleauthor=A.+Cookeauthor=K.+Foremanauthor=E.+Buckauthor=E.+W.+Mayauthor=L.+Fengauthor=M.+A.+Bittnerauthor=M.+Kadalbajooauthor=D.+Landfairauthor=K.+W.+Siuauthor=K.+M.+Stolzauthor=D.+S.+Wernerauthor=R.+S.+Lauferauthor=A.+H.+Liauthor=H.+Dongauthor=A.+G.+Steinigauthor=A.+Kleinbergauthor=Y.+Yaoauthor=J.+A.+Pachterauthor=R.+Wildauthor=M.+J.+Mulvihill&title=Discovery+of+an+orally+efficacious+imidazo%5B5%2C1-f%5D%5B1%2C2%2C4%5Dtriazine+dual+inhibitor+of+IGF-1R+and+IR&doi=10.1021%2Fml100178g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR</span></div><div class="casAuthors">Jin, Meizhong; Gokhale, Prafulla C.; Cooke, Andy; Foreman, Kenneth; Buck, Elizabeth; May, Earl W.; Feng, Lixin; Bittner, Mark A.; Kadalbajoo, Mridula; Landfair, Darla; Siu, Kam W.; Stolz, Kathryn M.; Werner, Douglas S.; Laufer, Radoslaw S.; Li, An-Hu; Dong, Hanqing; Steinig, Arno G.; Kleinberg, Andrew; Yao, Yan; Pachter, Jonathan A.; Wild, Robert; Mulvihill, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">510-515</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes the investigation of a series of 5,7-disubstituted imidazo[5,1-f][1,2,4]triazine inhibitors of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR).  Structure-activity relationship exploration and optimization leading to the identification, characterization, and pharmacol. activity of compd. 9b, a potent, selective, well-tolerated, and orally bioavailable dual inhibitor of IGF-1R and IR with in vivo efficacy in tumor xenograft models, is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RZvdH2OAfLVg90H21EOLACvtfcHk0lgBsjjDTYhKxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyhur3I&md5=1d3cc19c84b347163c6bcbb155595aae</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fml100178g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100178g%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DM.%26aulast%3DGokhale%26aufirst%3DP.%2BC.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DForeman%26aufirst%3DK.%26aulast%3DBuck%26aufirst%3DE.%26aulast%3DMay%26aufirst%3DE.%2BW.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DBittner%26aufirst%3DM.%2BA.%26aulast%3DKadalbajoo%26aufirst%3DM.%26aulast%3DLandfair%26aufirst%3DD.%26aulast%3DSiu%26aufirst%3DK.%2BW.%26aulast%3DStolz%26aufirst%3DK.%2BM.%26aulast%3DWerner%26aufirst%3DD.%2BS.%26aulast%3DLaufer%26aufirst%3DR.%2BS.%26aulast%3DLi%26aufirst%3DA.%2BH.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DSteinig%26aufirst%3DA.%2BG.%26aulast%3DKleinberg%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26atitle%3DDiscovery%2520of%2520an%2520orally%2520efficacious%2520imidazo%255B5%252C1-f%255D%255B1%252C2%252C4%255Dtriazine%2520dual%2520inhibitor%2520of%2520IGF-1R%2520and%2520IR%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D510%26epage%3D515%26doi%3D10.1021%2Fml100178g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokhale, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foreman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittner, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvihill, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landfair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld-Franklin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvihill, M. J.</span></span> <span> </span><span class="NLM_article-title">Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1176</span>– <span class="NLM_lpage">1180</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.12.094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2010.12.094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=21251824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1amtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1176-1180&author=M.+Jinauthor=A.+Kleinbergauthor=A.+Cookeauthor=P.+C.+Gokhaleauthor=K.+Foremanauthor=H.+Dongauthor=K.+W.+Siuauthor=M.+A.+Bittnerauthor=K.+M.+Mulvihillauthor=Y.+Yaoauthor=D.+Landfairauthor=M.+O%E2%80%99Connorauthor=G.+Makauthor=J.+A.+Pachterauthor=R.+Wildauthor=M.+Rosenfeld-Franklinauthor=Q.+Jiauthor=M.+J.+Mulvihill&title=Potent+and+selective+cyclohexyl-derived+imidazopyrazine+insulin-like+growth+factor+1+receptor+inhibitors+with+in+vivo+efficacy&doi=10.1016%2Fj.bmcl.2010.12.094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy</span></div><div class="casAuthors">Jin, Meizhong; Kleinberg, Andrew; Cooke, Andy; Gokhale, Prafulla C.; Foreman, Kenneth; Dong, Hanqing; Siu, Kam W.; Bittner, Mark A.; Mulvihill, Kristen M.; Yao, Yan; Landfair, Darla; O'Connor, Matthew; Mak, Gilda; Pachter, Jonathan A.; Wild, Robert; Rosenfeld-Franklin, Maryland; Ji, Qunsheng; Mulvihill, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1176-1180</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Preclin. and emerging clin. evidence suggests that inhibiting insulin-like growth factor 1 receptor (IGF-1R) signaling may offer a promising therapeutic strategy for the treatment of several types of cancer.  This Letter describes the medicinal chem. effort towards a series of 8-amino-imidazo[1,5-a]pyrazine derived inhibitors of IGF-1R which features a substituted quinoline moiety at the C1 position and a cyclohexyl linking moiety at the C3 position.  Lead optimization efforts which included the optimization of structure-activity relationships and drug metab. and pharmacokinetic properties led to the identification of compd. 9m (I), a potent, selective and orally bioavailable inhibitor of IGF-1R with in vivo efficacy in an IGF-driven mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTghoNgWwGPLVg90H21EOLACvtfcHk0lgBsjjDTYhKxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1amtr0%253D&md5=777735b116129fe910a30033223dfe8f</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.094%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DM.%26aulast%3DKleinberg%26aufirst%3DA.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DGokhale%26aufirst%3DP.%2BC.%26aulast%3DForeman%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DSiu%26aufirst%3DK.%2BW.%26aulast%3DBittner%26aufirst%3DM.%2BA.%26aulast%3DMulvihill%26aufirst%3DK.%2BM.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DLandfair%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%26aulast%3DMak%26aufirst%3DG.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DRosenfeld-Franklin%26aufirst%3DM.%26aulast%3DJi%26aufirst%3DQ.%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26atitle%3DPotent%2520and%2520selective%2520cyclohexyl-derived%2520imidazopyrazine%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520inhibitors%2520with%2520in%2520vivo%2520efficacy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1176%26epage%3D1180%26doi%3D10.1016%2Fj.bmcl.2010.12.094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mulvihill, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld-Franklin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buck, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foreman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landfair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirritt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Q. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">1153</span>– <span class="NLM_lpage">1171</span>, <span class="refDoi"> DOI: 10.4155/fmc.09.89</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.4155%2Ffmc.09.89" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=21425998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVChs7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=1153-1171&author=M.+J.+Mulvihillauthor=A.+Cookeauthor=M.+Rosenfeld-Franklinauthor=E.+Buckauthor=K.+Foremanauthor=D.+Landfairauthor=M.+O%E2%80%99Connorauthor=C.+Pirrittauthor=Y.+Sunauthor=Y.+Yaoauthor=L.+D.+Arnoldauthor=N.+W.+Gibsonauthor=Q.+S.+Ji&title=Discovery+of+OSI-906%3A+a+selective+and+orally+efficacious+dual+inhibitor+of+the+IGF-1+receptor+and+insulin+receptor&doi=10.4155%2Ffmc.09.89"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-I receptor and insulin receptor</span></div><div class="casAuthors">Mulvihill, Mark J.; Cooke, Andrew; Rosenfeld-Franklin, Maryland; Buck, Elizabeth; Foreman, Ken; Landfair, Darla; O'Connor, Matthew; Pirritt, Caroline; Sun, Yingchaun; Yao, Yan; Arnold, Lee D.; Gibson, Neil W.; Ji, Qun-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1153-1171</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The IGF-I receptor (IGF-IR) has been implicated in the promotion of tumorigenesis, metastasis and resistance to cancer therapies.  Therefore, this receptor has become a major focus for the development of anticancer agents.  Our lead optimization efforts that blended structure-based design and empirical medicinal chem. led to the discovery of OSI-906, a novel small-mol. dual IGF-IR/insulin receptor (IR) kinase inhibitor.  OSI-906 potently and selectively inhibits autophosphorylation of both human IGF-IR and IR, displays in vitro antiproliferative effects in a variety of tumor cell lines and shows robust in vivo anti-tumor efficacy in an IGF-IR-driven xenograft model when administered orally once daily.  OSI-906 is a novel, potent, selective and orally bioavailable dual IGF-IR/IR kinase inhibitor with favorable preclin. drug-like properties, which has demonstrated in vivo efficacy in tumor models and is currently in clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR1FmFisMOHrVg90H21EOLACvtfcHk0liwFr5dd4Og2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVChs7zM&md5=c7583de9d57e3af55ff2fa0c3708fd93</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.4155%2Ffmc.09.89&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.09.89%26sid%3Dliteratum%253Aachs%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DRosenfeld-Franklin%26aufirst%3DM.%26aulast%3DBuck%26aufirst%3DE.%26aulast%3DForeman%26aufirst%3DK.%26aulast%3DLandfair%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%26aulast%3DPirritt%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DArnold%26aufirst%3DL.%2BD.%26aulast%3DGibson%26aufirst%3DN.%2BW.%26aulast%3DJi%26aufirst%3DQ.%2BS.%26atitle%3DDiscovery%2520of%2520OSI-906%253A%2520a%2520selective%2520and%2520orally%2520efficacious%2520dual%2520inhibitor%2520of%2520the%2520IGF-1%2520receptor%2520and%2520insulin%2520receptor%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2009%26volume%3D1%26spage%3D1153%26epage%3D1171%26doi%3D10.4155%2Ffmc.09.89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wittman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carboni, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frennesson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardis, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurlburt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastalerz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saulnier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velaparthi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, D. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a 2,4-disubstituted pyrrolo[1,2-<i>f</i>][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7360</span>– <span class="NLM_lpage">7363</span>, <span class="refDoi"> DOI: 10.1021/jm900786r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900786r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOiurjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7360-7363&author=M.+D.+Wittmanauthor=J.+M.+Carboniauthor=Z.+Yangauthor=F.+Y.+Leeauthor=M.+Antmanauthor=R.+Attarauthor=P.+Balimaneauthor=C.+Changauthor=C.+Chenauthor=L.+Discenzaauthor=D.+Frennessonauthor=M.+M.+Gottardisauthor=A.+Greerauthor=W.+Hurlburtauthor=W.+Johnsonauthor=D.+R.+Langleyauthor=A.+Liauthor=J.+Liauthor=P.+Liuauthor=H.+Mastalerzauthor=A.+Mathurauthor=K.+Menardauthor=K.+Patelauthor=J.+Sackauthor=X.+Sangauthor=M.+Saulnierauthor=D.+Smithauthor=K.+Stefanskiauthor=G.+Trainorauthor=U.+Velaparthiauthor=G.+Zhangauthor=K.+Zimmermannauthor=D.+M.+Vyas&title=Discovery+of+a+2%2C4-disubstituted+pyrrolo%5B1%2C2-f%5D%5B1%2C2%2C4%5Dtriazine+inhibitor+%28BMS-754807%29+of+insulin-like+growth+factor+receptor+%28IGF-1R%29+kinase+in+clinical+development&doi=10.1021%2Fjm900786r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a 2,4-Disubstituted Pyrrolo[1,2-f][1,2,4]triazine Inhibitor (BMS-754807) of Insulin-like Growth Factor Receptor (IGF-1R) Kinase in Clinical Development</span></div><div class="casAuthors">Wittman, Mark D.; Carboni, Joan M.; Yang, Zheng; Lee, Francis Y.; Antman, Melissa; Attar, Ricardo; Balimane, Praveen; Chang, Chiehying; Chen, Cliff; Discenza, Lorell; Frennesson, David; Gottardis, Marco M.; Greer, Ann; Hurlburt, Warren; Johnson, Walter; Langley, David R.; Li, Aixin; Li, Jianqing; Liu, Peiying; Mastalerz, Harold; Mathur, Arvind; Menard, Krista; Patel, Karishma; Sack, John; Sang, Xiaopeng; Saulnier, Mark; Smith, Daniel; Stefanski, Kevin; Trainor, George; Velaparthi, Upender; Zhang, Guifen; Zimmermann, Kurt; Vyas, Dolatrai M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7360-7363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes the biol. activity, characterization, and SAR leading to 9d (BMS-754807, I) a small mol. IGF-1R kinase inhibitor in clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPOoiaTjr-NbVg90H21EOLACvtfcHk0liwFr5dd4Og2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOiurjJ&md5=be0fe9adea18595b4ba6f232726ba4df</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjm900786r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900786r%26sid%3Dliteratum%253Aachs%26aulast%3DWittman%26aufirst%3DM.%2BD.%26aulast%3DCarboni%26aufirst%3DJ.%2BM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DAntman%26aufirst%3DM.%26aulast%3DAttar%26aufirst%3DR.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DFrennesson%26aufirst%3DD.%26aulast%3DGottardis%26aufirst%3DM.%2BM.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DHurlburt%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DW.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DMenard%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DSack%26aufirst%3DJ.%26aulast%3DSang%26aufirst%3DX.%26aulast%3DSaulnier%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DTrainor%26aufirst%3DG.%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DVyas%26aufirst%3DD.%2BM.%26atitle%3DDiscovery%2520of%2520a%25202%252C4-disubstituted%2520pyrrolo%255B1%252C2-f%255D%255B1%252C2%252C4%255Dtriazine%2520inhibitor%2520%2528BMS-754807%2529%2520of%2520insulin-like%2520growth%2520factor%2520receptor%2520%2528IGF-1R%2529%2520kinase%2520in%2520clinical%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7360%26epage%3D7363%26doi%3D10.1021%2Fjm900786r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zia-Ebrahimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloem, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D. J.</span></span> <span> </span><span class="NLM_article-title">A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2200</span>– <span class="NLM_lpage">2210</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1158%2F1535-7163.MCT-11-0306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=21900693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2200-2210&author=G.+S.+Zhaoauthor=W.+Y.+Liauthor=D.+H.+Chenauthor=J.+R.+Henryauthor=H.+Y.+Liauthor=Z.+G.+Chenauthor=M.+Zia-Ebrahimiauthor=L.+Bloemauthor=Y.+Zhaiauthor=K.+Hussauthor=S.+B.+Pengauthor=D.+J.+McCann&title=A+novel%2C+selective+inhibitor+of+fibroblast+growth+factor+receptors+that+shows+a+potent+broad+spectrum+of+antitumor+activity+in+several+tumor+xenograft+models&doi=10.1158%2F1535-7163.MCT-11-0306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models</span></div><div class="casAuthors">Zhao, Genshi; Li, Wei-ying; Chen, Daohong; Henry, James R.; Li, Hong-Yu; Chen, Zhaogen; Zia-Ebrahimi, Mohammad; Bloem, Laura; Zhai, Yan; Huss, Karen; Peng, Sheng-bin; McCann, Denis J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2200-2210</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptors (FGFR) are tyrosine kinases that are present in many types of endothelial and tumor cells and play an important role in tumor cell growth, survival, and migration as well as in maintaining tumor angiogenesis.  Overexpression of FGFRs or aberrant regulation of their activities has been implicated in many forms of human malignancies.  Therefore, targeting FGFRs represents an attractive strategy for development of cancer treatment options by simultaneously inhibiting tumor cell growth, survival, and migration as well as tumor angiogenesis.  Here, we describe a potent, selective, small-mol. FGFR inhibitor, (R)-(E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)ethoxy)-1H-indazol-3yl)vinyl)-1H-pyrazol-1-yl)ethanol, designated as LY2874455.  This mol. is active against all 4 FGFRs, with a similar potency in biochem. assays.  It exhibits a potent activity against FGF/FGFR-mediated signaling in several cancer cell lines and shows an excellent broad spectrum of antitumor activity in several tumor xenograft models representing the major FGF/FGFR relevant tumor histologies including lung, gastric, and bladder cancers and multiple myeloma, and with a well-defined pharmacokinetic/pharmacodynamic relationship.  LY2874455 also exhibits a 6- to 9-fold in vitro and in vivo selectivity on inhibition of FGF- over VEGF-mediated target signaling in mice.  Furthermore, LY2874455 did not show VEGF receptor 2-mediated toxicities such as hypertension at efficacious doses.  Currently, this mol. is being evaluated for its potential use in the clinic.  Mol Cancer Ther; 10(11); 2200-10.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLrzAyZQK_grVg90H21EOLACvtfcHk0lgj4hTxk8lm_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N&md5=eaf08fd213a836f48da2055e01bd9c29</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0306%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DG.%2BS.%26aulast%3DLi%26aufirst%3DW.%2BY.%26aulast%3DChen%26aufirst%3DD.%2BH.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DLi%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DZ.%2BG.%26aulast%3DZia-Ebrahimi%26aufirst%3DM.%26aulast%3DBloem%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DHuss%26aufirst%3DK.%26aulast%3DPeng%26aufirst%3DS.%2BB.%26aulast%3DMcCann%26aufirst%3DD.%2BJ.%26atitle%3DA%2520novel%252C%2520selective%2520inhibitor%2520of%2520fibroblast%2520growth%2520factor%2520receptors%2520that%2520shows%2520a%2520potent%2520broad%2520spectrum%2520of%2520antitumor%2520activity%2520in%2520several%2520tumor%2520xenograft%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2200%26epage%3D2210%26doi%3D10.1158%2F1535-7163.MCT-11-0306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavine, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilgour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span> <span> </span><span class="NLM_article-title">AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">2045</span>– <span class="NLM_lpage">2056</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1158%2F0008-5472.CAN-11-3034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22369928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2045-2056&author=P.+R.+Gavineauthor=L.+Mooneyauthor=E.+Kilgourauthor=A.+P.+Thomasauthor=K.+Al-Kadhimiauthor=S.+Beckauthor=C.+Rooneyauthor=T.+Colemanauthor=D.+Bakerauthor=M.+J.+Mellorauthor=A.+N.+Brooksauthor=T.+Klinowska&title=AZD4547%3A+an+orally+bioavailable%2C+potent%2C+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+tyrosine+kinase+family&doi=10.1158%2F0008-5472.CAN-11-3034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family</span></div><div class="casAuthors">Gavine, Paul R.; Mooney, Lorraine; Kilgour, Elaine; Thomas, Andrew P.; Al-Kadhimi, Katherine; Beck, Sarah; Rooney, Claire; Coleman, Tanya; Baker, Dawn; Mellor, Martine J.; Brooks, A. Nigel; Klinowska, Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2045-2056</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis and chemoresistance.  Several small-mol. FGF receptor (FGFR) kinase inhibitors are currently in clin. development; however, the predominant activity of the most advanced of these agents is against the kinase insert domain receptor (KDR), which compromises the FGFR selectivity.  Here, we report the pharmacol. profile of AZD4547, a novel and selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases.  AZD4547 inhibited recombinant FGFR kinase activity in vitro and suppressed FGFR signaling and growth in tumor cell lines with deregulated FGFR expression.  In a representative FGFR-driven human tumor xenograft model, oral administration of AZD4547 was well tolerated and resulted in potent dose-dependent antitumor activity, consistent with plasma exposure and pharmacodynamic modulation of tumor FGFR.  Importantly, at efficacious doses, no evidence of anti-KDR-related effects were obsd., confirming the in vivo FGFR selectivity of AZD4547.  Taken together, our findings show that AZD4547 is a novel selective small-mol. inhibitor of FGFR with potent antitumor activity against FGFR-deregulated tumors in preclin. models.  AZD4547 is under clin. investigation for the treatment of FGFR-dependent tumors.  Cancer Res; 72(8); 2045-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnpExryJc9xbVg90H21EOLACvtfcHk0lgj4hTxk8lm_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D&md5=cba90ad8f9b9e51cd10288868bbcc85e</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3034%26sid%3Dliteratum%253Aachs%26aulast%3DGavine%26aufirst%3DP.%2BR.%26aulast%3DMooney%26aufirst%3DL.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DRooney%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26aulast%3DKlinowska%26aufirst%3DT.%26atitle%3DAZD4547%253A%2520an%2520orally%2520bioavailable%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D2045%26epage%3D2056%26doi%3D10.1158%2F0008-5472.CAN-11-3034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzilleri, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wautlet, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortillo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeyaseelan, R.,  Sr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derbin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robl, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargnoli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhide, R. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of brivanib alaninate ((<i>S</i>)-((<i>R</i>)-1-(4-(4-fluoro-2-methyl-1<i>H</i>-indol-5-yloxy)-5-methylpyrrolo[2,1-<i>f</i>][1,2,4] triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1976</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1021/jm7013309</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7013309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlCnt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1976-1980&author=Z.+W.+Caiauthor=Y.+Zhangauthor=R.+M.+Borzilleriauthor=L.+Qianauthor=S.+Barbosaauthor=D.+Weiauthor=X.+Zhengauthor=L.+Wuauthor=J.+Fanauthor=Z.+Shiauthor=B.+S.+Wautletauthor=S.+Mortilloauthor=R.+Jeyaseelanauthor=D.+W.+Kukralauthor=A.+Kamathauthor=P.+Maratheauthor=C.+D%E2%80%99Arienzoauthor=G.+Derbinauthor=J.+C.+Barrishauthor=J.+A.+Roblauthor=J.+T.+Huntauthor=L.+J.+Lombardoauthor=J.+Fargnoliauthor=R.+S.+Bhide&title=Discovery+of+brivanib+alaninate+%28%28S%29-%28%28R%29-1-%284-%284-fluoro-2-methyl-1H-indol-5-yloxy%29-5-methylpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5D+triazin-6-yloxy%29propan-2-yl%292-aminopropanoate%29%2C+a+novel+prodrug+of+dual+vascular+endothelial+growth+factor+receptor-2+and+fibroblast+growth+factor+receptor-1+kinase+inhibitor+%28BMS-540215%29&doi=10.1021%2Fjm7013309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)</span></div><div class="casAuthors">Cai, Zhen-wei; Zhang, Yongzheng; Borzilleri, Robert M.; Qian, Ligang; Barbosa, Stephanie; Wei, Donna; Zheng, Xiaoping; Wu, Lawrence; Fan, Junying; Shi, Zhongping; Wautlet, Barri S.; Mortillo, Steve; Jeyaseelan, Robert; Kukral, Daniel W.; Kamath, Amrita; Marathe, Punit; D'Arienzo, Celia; Derbin, George; Barrish, Joel C.; Robl, Jeffrey A.; Hunt, John T.; Lombardo, Louis J.; Fargnoli, Joseph; Bhide, Rajeev S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1976-1980</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of amino acid ester prodrugs of the dual VEGFR-2/FGFR-1 kinase inhibitor (BMS-540215) was prepd. in an effort to improve the aq. soly. and oral bioavailability of the parent compd.  These prodrugs were evaluated for their ability to liberate parent drug BMS-540215 in in vitro and in vivo systems.  The L-alanine prodrug (also known as brivanib alaninate/BMS-582664, I) was selected as a development candidate and is presently in phase II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsRxtPLgh4X7Vg90H21EOLACvtfcHk0lgj4hTxk8lm_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlCnt7w%253D&md5=42524ac71a5eebed588c8e7023eff2de</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm7013309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7013309%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DBarbosa%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDerbin%26aufirst%3DG.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26atitle%3DDiscovery%2520of%2520brivanib%2520alaninate%2520%2528%2528S%2529-%2528%2528R%2529-1-%25284-%25284-fluoro-2-methyl-1H-indol-5-yloxy%2529-5-methylpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255D%2520triazin-6-yloxy%2529propan-2-yl%25292-aminopropanoate%2529%252C%2520a%2520novel%2520prodrug%2520of%2520dual%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520and%2520fibroblast%2520growth%2520factor%2520receptor-1%2520kinase%2520inhibitor%2520%2528BMS-540215%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1976%26epage%3D1980%26doi%3D10.1021%2Fjm7013309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littman, D. R.</span></span> <span> </span><span class="NLM_article-title">Signal transduction by lymphocyte antigen receptors</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(94)90334-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2F0092-8674%2894%2990334-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=8293463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK2cXhs1Srtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1994&pages=263-274&author=A.+Weissauthor=D.+R.+Littman&title=Signal+transduction+by+lymphocyte+antigen+receptors&doi=10.1016%2F0092-8674%2894%2990334-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction by lymphocyte antigen receptors</span></div><div class="casAuthors">Weiss, Arthur; Littman, Dan R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-74</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">A review, with 125 refs., discussing T- and B-cell antigen receptors, TCR and BCR interaction with tyrosine kinase families, coreceptors in initiation of signal transduction events, regulation of antigen receptor signal transduction by CD45, and the consequences of antigen receptor-induced tyrosine phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgq0lyR8HICbVg90H21EOLACvtfcHk0lgEkLjN5vWUwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhs1Srtr0%253D&md5=018861d0265c3ee91d2cc871fd3b9843</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2894%2990334-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252894%252990334-4%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DA.%26aulast%3DLittman%26aufirst%3DD.%2BR.%26atitle%3DSignal%2520transduction%2520by%2520lymphocyte%2520antigen%2520receptors%26jtitle%3DCell%26date%3D1994%26volume%3D76%26spage%3D263%26epage%3D274%26doi%3D10.1016%2F0092-8674%2894%2990334-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kontzias, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotlyar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2012.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.coph.2012.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22819198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVymsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=464-470&author=A.+Kontziasauthor=A.+Kotlyarauthor=A.+Laurenceauthor=P.+Changelianauthor=J.+J.+O%E2%80%99Shea&title=Jakinibs%3A+a+new+class+of+kinase+inhibitors+in+cancer+and+autoimmune+disease&doi=10.1016%2Fj.coph.2012.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease</span></div><div class="casAuthors">Kontzias, Apostolos; Kotlyar, Alexander; Laurence, Arian; Changelian, Paul; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">464-470</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines are crit. for normal cell growth and immunoregulation but also contribute to growth of malignant cells and drive immune-mediated disease.  A large subset of immunoregulatory cytokines uses the type I and type II cytokine receptors and pharmacol. targeting of these cytokines/cytokines receptors has proven to be efficacious in treating immune and inflammatory diseases.  These receptors rely on Janus family of kinases (Jaks) for signal transduction.  Recently the first Jak inhibitor (jakinib) has been approved by the FDA and a second has been recommended for approval.  Many other Jakinibs are likely to follow and in this brief review, we will discuss the state-of-the art of this new class of pharmacol. agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmJV4I6HPAx7Vg90H21EOLACvtfcHk0lgEkLjN5vWUwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVymsLbE&md5=22bcfa4414642f3d72214c4d4be84e2c</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2012.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2012.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DKontzias%26aufirst%3DA.%26aulast%3DKotlyar%26aufirst%3DA.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DChangelian%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJakinibs%253A%2520a%2520new%2520class%2520of%2520kinase%2520inhibitors%2520in%2520cancer%2520and%2520autoimmune%2520disease%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2012%26volume%3D12%26spage%3D464%26epage%3D470%26doi%3D10.1016%2Fj.coph.2012.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishore, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of Janus kinases</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>223</i></span>,  <span class="NLM_fpage">132</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00644.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1111%2Fj.1600-065X.2008.00644.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=18613833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2008&pages=132-142&author=M.+Pesuauthor=A.+Laurenceauthor=N.+Kishoreauthor=S.+H.+Zwillichauthor=G.+Chanauthor=J.+J.+O%E2%80%99Shea&title=Therapeutic+targeting+of+Janus+kinases&doi=10.1111%2Fj.1600-065X.2008.00644.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of Janus kinases</span></div><div class="casAuthors">Pesu, Marko; Laurence, Arian; Kishore, Nandini; Zwillich, Samuel H.; Chan, Gary; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">223</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132-142</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines play pivotal roles in immunity and inflammation, and targeting cytokines and their receptors is an effective means of treating such disorders.  Type I and II cytokine receptors assoc. with Janus family kinases (JAKs) to effect intracellular signaling.  These structurally unique protein kinases play essential and specific roles in immune cell development and function.  One JAK, JAK3, has particularly selective functions.  Mutations of this kinase underlie severe combined immunodeficiency, indicative of its crit. role in the development and function of lymphocytes.  Because JAK3 appears not to have functions outside of hematopoietic cells, this kinase has been viewed as an excellent therapeutic target for the development of a new class of immunosuppressive drugs.  In fact, several companies are developing JAK3 inhibitors, and Phase II studies are underway.  Mutations of Tyk2 cause autosomal recessive hyperIgE syndrome, and in principle, Tyk2 inhibitors might also be useful as immunosuppressive drugs.  JAK2 gain-of-function mutations (V617F) underlie a subset of disorders collectively referred to as myeloproliferative diseases and phase 2 trials using JAK inhibitors are underway in this setting.  Thus, we are learning a great deal about the feasibility and effectiveness of targeting Janus kinases, and it appears likely that this will be a fruitful strategy in a variety of settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-VTmlwlhcv7Vg90H21EOLACvtfcHk0lgEkLjN5vWUwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D&md5=73dc15932d0eaa312bc2588bdbce404c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00644.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00644.x%26sid%3Dliteratum%253Aachs%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DTherapeutic%2520targeting%2520of%2520Janus%2520kinases%26jtitle%3DImmunol.%2520Rev.%26date%3D2008%26volume%3D223%26spage%3D132%26epage%3D142%26doi%3D10.1111%2Fj.1600-065X.2008.00644.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J.</span></span> <span> </span><span class="NLM_article-title">JAK kinases in health and disease: an update</span>. <i>Open Rheumatol. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.2174/1874312901206010232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.2174%2F1874312901206010232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=23028408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=232-244&author=A.+Laurenceauthor=M.+Pesuauthor=O.+Silvennoinenauthor=J.+O%E2%80%99Shea&title=JAK+kinases+in+health+and+disease%3A+an+update&doi=10.2174%2F1874312901206010232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">JAK kinases in health and disease: an update</span></div><div class="casAuthors">Laurence, Arian; Pesu, Marko; Silvennoinen, Olli; O'Shea, John</div><div class="citationInfo"><span class="NLM_cas:title">Open Rheumatology Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">232-244</span>CODEN:
                <span class="NLM_cas:coden">ORJPAP</span>;
        ISSN:<span class="NLM_cas:issn">1874-3129</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are crit. signaling elements for a large subset of cytokines.  As a consequence they play pivotal roles in the pathophysiol. of many diseases including neoplastic and autoimmune diseases.  Small mol. JAK inhibitors as therapeutic agents have become a reality and the palette of such inhibitors will likely expand.  This review will summarize our current knowledge on these key enzymes and their assocd. pharmaceutical inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjovQnlyAQvrVg90H21EOLACvtfcHk0lgEkLjN5vWUwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO&md5=ed5d20df39001bb27ca8556cae82c289</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.2174%2F1874312901206010232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874312901206010232%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26atitle%3DJAK%2520kinases%2520in%2520health%2520and%2520disease%253A%2520an%2520update%26jtitle%3DOpen%2520Rheumatol.%2520J.%26date%3D2012%26volume%3D6%26spage%3D232%26epage%3D244%26doi%3D10.2174%2F1874312901206010232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span> <span> </span><span class="NLM_article-title">The JAK-STAT pathway: impact on human disease and therapeutic intervention</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-051113-024537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1146%2Fannurev-med-051113-024537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=25587654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFyhsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2015&pages=311-328&author=J.+J.+O%E2%80%99Sheaauthor=D.+M.+Schwartzauthor=A.+V.+Villarinoauthor=M.+Gadinaauthor=I.+B.+McInnesauthor=A.+Laurence&title=The+JAK-STAT+pathway%3A+impact+on+human+disease+and+therapeutic+intervention&doi=10.1146%2Fannurev-med-051113-024537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">The JAK-STAT pathway: impact on human disease and therapeutic intervention</span></div><div class="casAuthors">O'Shea, John J.; Schwartz, Daniella M.; Villarino, Alejandro V.; Gadina, Massimo; McInnes, Iain B.; Laurence, Arian</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">311-328</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)-signal transducer of activators of transcription (STAT) pathway is now recognized as an evolutionarily conserved signaling pathway employed by diverse cytokines, interferons, growth factors, and related mols.  This pathway provides an elegant and remarkably straightforward mechanism whereby extracellular factors control gene expression.  It thus serves as a fundamental paradigm for how cells sense environmental cues and interpret these signals to regulate cell growth and differentiation.  Genetic mutations and polymorphisms are functionally relevant to a variety of human diseases, esp. cancer and immune-related conditions.  The clin. relevance of the pathway has been confirmed by the emergence of a new class of therapeutics that targets JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMxvQCRiTbL7Vg90H21EOLACvtfcHk0lhzJ944d6mY_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFyhsLY%253D&md5=19182154f1a046df039eb4a37b66bf78</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-051113-024537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-051113-024537%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DVillarino%26aufirst%3DA.%2BV.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DLaurence%26aufirst%3DA.%26atitle%3DThe%2520JAK-STAT%2520pathway%253A%2520impact%2520on%2520human%2520disease%2520and%2520therapeutic%2520intervention%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2015%26volume%3D66%26spage%3D311%26epage%3D328%26doi%3D10.1146%2Fannurev-med-051113-024537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span> <span> </span><span class="NLM_article-title">The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders</span>. <i>BioDrugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1007/s40259-013-0040-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1007%2Fs40259-013-0040-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=23743669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=431-438&author=Y.+Furumotoauthor=M.+Gadina&title=The+arrival+of+JAK+inhibitors%3A+advancing+the+treatment+of+immune+and+hematologic+disorders&doi=10.1007%2Fs40259-013-0040-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders</span></div><div class="casAuthors">Furumoto, Yasuko; Gadina, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">431-438</span>CODEN:
                <span class="NLM_cas:coden">BIDRF4</span>;
        ISSN:<span class="NLM_cas:issn">1173-8804</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Altered prodn. of cytokines can result in pathologies ranging from autoimmune diseases to malignancies.  The Janus kinase family is a small group of receptor-assocd. signaling mols. that is essential to the signal cascade originating from type I and type II cytokine receptors.  Inhibition of tyrosine kinase enzymic activity using small mols. has recently become a powerful tool for treatment of several malignancies.  Twenty years after the discovery of these enzymes, two inhibitors for this class of kinases have been approved for clin. use and others are currently in the final stage of development.  Here we review the principles of cytokines signaling, summarize our current knowledge of the approved inhibitors, and briefly introduce some of the inhibitors that are currently under development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQNQJyHX0EDLVg90H21EOLACvtfcHk0lhzJ944d6mY_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsbzI&md5=a593c1f01565b3dc3bf3df8c424595a6</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1007%2Fs40259-013-0040-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-013-0040-7%26sid%3Dliteratum%253Aachs%26aulast%3DFurumoto%26aufirst%3DY.%26aulast%3DGadina%26aufirst%3DM.%26atitle%3DThe%2520arrival%2520of%2520JAK%2520inhibitors%253A%2520advancing%2520the%2520treatment%2520of%2520immune%2520and%2520hematologic%2520disorders%26jtitle%3DBioDrugs%26date%3D2013%26volume%3D27%26spage%3D431%26epage%3D438%26doi%3D10.1007%2Fs40259-013-0040-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreschi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Janus kinases in immune cell signaling</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+in+immune+cell+signaling&doi=10.1111%2Fj.1600-065X.2008.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0lhzJ944d6mY_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520in%2520immune%2520cell%2520signaling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287%26doi%3D10.1111%2Fj.1600-065X.2008.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span> <span> </span><span class="NLM_article-title">Back to the future: oral targeted therapy for RA and other autoimmune diseases</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2013.7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnrrheum.2013.7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=23419429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A280%3ADC%252BC3szpsFGiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=173-182&author=J.+J.+O%E2%80%99Sheaauthor=A.+Laurenceauthor=I.+B.+McInnes&title=Back+to+the+future%3A+oral+targeted+therapy+for+RA+and+other+autoimmune+diseases&doi=10.1038%2Fnrrheum.2013.7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Back to the future: oral targeted therapy for RA and other autoimmune diseases</span></div><div class="casAuthors">O'Shea John J; Laurence Arian; McInnes Iain B</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Rheumatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The molecular biology revolution coupled with the development of monoclonal antibody technology enabled remarkable progress in rheumatology therapy, comprising an array of highly effective biologic agents.  With advances in understanding of the molecular nature of immune cell receptors came elucidation of intracellular signalling pathways downstream of these receptors.  These discoveries raise the question of whether selective targeting of key intracellular factors with small molecules would add to the rheumatologic armamentarium.  In this Review, we discuss several examples of this therapeutic strategy that seem to be successful, and consider their implications for the future of immune-targeted treatments.  We focus on kinase inhibitors, primarily those targeting Janus kinase family members and spleen tyrosine kinase, given their advanced status in clinical development and application.  We also summarize other targets involved in signalling pathways that might offer promise for therapeutic intervention in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmTYwNff3DeTjk2McQZ6XmfW6udTcc2eZc1tglogaJmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szpsFGiug%253D%253D&md5=92218e154d717c374bbe42e1f0a0f34f</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2013.7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2013.7%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26atitle%3DBack%2520to%2520the%2520future%253A%2520oral%2520targeted%2520therapy%2520for%2520RA%2520and%2520other%2520autoimmune%2520diseases%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2013%26volume%3D9%26spage%3D173%26epage%3D182%26doi%3D10.1038%2Fnrrheum.2013.7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasothan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1038/nrd3652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnrd3652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22293561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Crtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=103-104&author=R.+A.+Mesaauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Ruxolitinib&doi=10.1038%2Fnrd3652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib</span></div><div class="casAuthors">Mesa, Ruben A.; Yasothan, Uma; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-104</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In Nov. 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-mol. inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf2yAGCsbIA7Vg90H21EOLACvtfcHk0li_RUFocQlFDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Crtbs%253D&md5=5bcfbd15f4478268330ffc4c8855762d</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fnrd3652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3652%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DRuxolitinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D103%26epage%3D104%26doi%3D10.1038%2Fnrd3652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andreoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffoux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zini, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousselot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Socie, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parquet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraudier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chomienne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassinat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J. J.</span></span> <span> </span><span class="NLM_article-title">Clinical resistance to ruxolitinib is more frequent in patients without MPN-associated mutations and is rarely due to mutations in the JAK2 kinase drug-binding domain</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">1591</span>– <span class="NLM_lpage">1591</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1182%2Fblood.V122.21.1591.1591" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=1591-1591&author=A.+Andreoliauthor=E.+Vergerauthor=M.+Robinauthor=E.+Raffouxauthor=J.+M.+Ziniauthor=P.+Rousselotauthor=G.+Socieauthor=D.+Reaauthor=N.+Parquetauthor=S.+Giraudierauthor=C.+Chomienneauthor=B.+Cassinatauthor=J.+J.+Kiladjian&title=Clinical+resistance+to+ruxolitinib+is+more+frequent+in+patients+without+MPN-associated+mutations+and+is+rarely+due+to+mutations+in+the+JAK2+kinase+drug-binding+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1182%2Fblood.V122.21.1591.1591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V122.21.1591.1591%26sid%3Dliteratum%253Aachs%26aulast%3DAndreoli%26aufirst%3DA.%26aulast%3DVerger%26aufirst%3DE.%26aulast%3DRobin%26aufirst%3DM.%26aulast%3DRaffoux%26aufirst%3DE.%26aulast%3DZini%26aufirst%3DJ.%2BM.%26aulast%3DRousselot%26aufirst%3DP.%26aulast%3DSocie%26aufirst%3DG.%26aulast%3DRea%26aufirst%3DD.%26aulast%3DParquet%26aufirst%3DN.%26aulast%3DGiraudier%26aufirst%3DS.%26aulast%3DChomienne%26aufirst%3DC.%26aulast%3DCassinat%26aufirst%3DB.%26aulast%3DKiladjian%26aufirst%3DJ.%2BJ.%26atitle%3DClinical%2520resistance%2520to%2520ruxolitinib%2520is%2520more%2520frequent%2520in%2520patients%2520without%2520MPN-associated%2520mutations%2520and%2520is%2520rarely%2520due%2520to%2520mutations%2520in%2520the%2520JAK2%2520kinase%2520drug-binding%2520domain%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D1591%26epage%3D1591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span> <i>FDA Approves Xeljanz for Rheumatoid Arthritis</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, <span class="NLM_year">2012</span>; <a href="https://www.drugs.com/newdrugs/fda-approves-xeljanz-rheumatoid-arthritis-3558.html" class="extLink">https://www.drugs.com/newdrugs/fda-approves-xeljanz-rheumatoid-arthritis-3558.html</a> (accessed Jan 12, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+Xeljanz+for+Rheumatoid+Arthritis%3B+U.S.+Food+and+Drug+Administration%2C+2012%3B+https%3A%2F%2Fwww.drugs.com%2Fnewdrugs%2Ffda-approves-xeljanz-rheumatoid-arthritis-3558.html+%28accessed+Jan+12%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520Xeljanz%2520for%2520Rheumatoid%2520Arthritis%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.+B.+Telliez&title=Discovery+and+development+of+Janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0li_RUFocQlFDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520and%2520development%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">Advances in the inhibitors of Janus kinase</span>. <i>Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.4172/2161-0444.1000192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.4172%2F2161-0444.1000192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFGnsbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=540-548&author=J.+J.+J.+Jiangauthor=X.+Y.+Wangauthor=Y.+Zhangauthor=Y.+Jinauthor=J.+Lin&title=Advances+in+the+inhibitors+of+Janus+kinase&doi=10.4172%2F2161-0444.1000192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the inhibitors of janus kinase</span></div><div class="casAuthors">Jiang, Jun-Jie J.; Wang, Xiao-Ying; Zhang, Yv; Jin, Yi; Lin, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry (Los Angeles, CA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">540-548, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCLACZ</span>;
        ISSN:<span class="NLM_cas:issn">2161-0444</span>.
    
            (<span class="NLM_cas:orgname">OMICS Publishing Group</span>)
        </div><div class="casAbstract">A review.  The janus kinases (JAKs) comprise an important class of non-receptor protein tyrosine kinases.  Cytokine and receptor binding can cause the activation of JAKs, and then activate the "signal transcripts and transcriptional activator", making JAK enter the nucleus to induce target gene expression.  JAKs regulate inflammatory diseases, bone marrow hyperplasia and a variety of malignant tumors.  Using JAKs inhibitors as the therapy for organ transplantation and immune disease has a very important significance.  In recent years, many of the JAKs inhibitors have been developed one after another.  Pan JAKs inhibitor and selective JAK2 or JAK3 inhibitor research progress are reviewed in this article.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfLi3ltgXL2bVg90H21EOLACvtfcHk0lh-29VsugZ-Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFGnsbjO&md5=4021b66d93e661604eeb0d2c33149eaa</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.4172%2F2161-0444.1000192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2161-0444.1000192%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.%2BJ.%2BJ.%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DAdvances%2520in%2520the%2520inhibitors%2520of%2520Janus%2520kinase%26jtitle%3DMed.%2520Chem.%26date%3D2014%26volume%3D4%26spage%3D540%26epage%3D548%26doi%3D10.4172%2F2161-0444.1000192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreschi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deflorian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leister, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span> <span> </span><span class="NLM_article-title">Examining the chirality, conformation and selective kinase inhibition of 3-((3<i>R</i>,4<i>R</i>)-4-methyl-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)piperidin-1-y l)-3-oxopropanenitrile (CP-690,550)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">8012</span>– <span class="NLM_lpage">8018</span>, <span class="refDoi"> DOI: 10.1021/jm801142b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801142b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWksr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=8012-8018&author=J.+K.+Jiangauthor=K.+Ghoreschiauthor=F.+Deflorianauthor=Z.+Chenauthor=M.+Perreiraauthor=M.+Pesuauthor=J.+Smithauthor=D.+T.+Nguyenauthor=E.+H.+Liuauthor=W.+Leisterauthor=S.+Costanziauthor=J.+J.+O%E2%80%99Sheaauthor=C.+J.+Thomas&title=Examining+the+chirality%2C+conformation+and+selective+kinase+inhibition+of+3-%28%283R%2C4R%29-4-methyl-3-%28methyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%29piperidin-1-y+l%29-3-oxopropanenitrile+%28CP-690%2C550%29&doi=10.1021%2Fjm801142b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)</span></div><div class="casAuthors">Jiang, Jian-kang; Ghoreschi, Kamran; Deflorian, Francesca; Chen, Zhi; Perreira, Melissa; Pesu, Marko; Smith, Jeremy; Nguyen, Dac-Trung; Liu, Eric H.; Leister, William; Costanzi, Stefano; O'Shea, John J.; Thomas, Craig J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8012-8018</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here, we examine the significance that stereochem. plays within the clin. relevant Janus kinase 3 (Jak3) inhibitor I (CP-690,550).  A synthesis of all four enantiopure stereoisomers of the drug was carried out and an examn. of each compd. revealed that only the enantiopure 3R,4R isomer was capable of blocking Stat5 phosphorylation (Jak3 dependent).  Each compd. was profiled across a panel of over 350 kinases, which revealed a high level of selectivity for the Jak family kinases for these related compds.  Each stereoisomer retained a degree of binding to Jak3 and Jak2 and the 3R,4S and 3S,4R stereoisomers were further revealed to have binding affinity for selected members of the STE7 and STE20 subfamily of kinases.  Finally, an appraisal of the min. energy conformation of each stereoisomer and mol. docking at Jak3 was performed in an effort to better understand each compds. selectivity and potency profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFxbAHrNE0dLVg90H21EOLACvtfcHk0lh-29VsugZ-Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWksr%252FN&md5=d9b491af79d29b2da94c9200704d546c</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fjm801142b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801142b%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DDeflorian%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DPerreira%26aufirst%3DM.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DD.%2BT.%26aulast%3DLiu%26aufirst%3DE.%2BH.%26aulast%3DLeister%26aufirst%3DW.%26aulast%3DCostanzi%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26atitle%3DExamining%2520the%2520chirality%252C%2520conformation%2520and%2520selective%2520kinase%2520inhibition%2520of%25203-%2528%25283R%252C4R%2529-4-methyl-3-%2528methyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%2529piperidin-1-y%2520l%2529-3-oxopropanenitrile%2520%2528CP-690%252C550%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D8012%26epage%3D8018%26doi%3D10.1021%2Fjm801142b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">996</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-02-0707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1182%2Fblood-2005-02-0707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=15831699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVSmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=996-1002&author=T.+J.+Boggonauthor=Y.+Liauthor=P.+W.+Manleyauthor=M.+J.+Eck&title=Crystal+structure+of+the+Jak3+kinase+domain+in+complex+with+a+staurosporine+analog&doi=10.1182%2Fblood-2005-02-0707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog</span></div><div class="casAuthors">Boggon, Titus J.; Li, Yiqun; Manley, Paul W.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">996-1002</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Jak (Janus kinase) family nonreceptor tyrosine kinases are central mediators of cytokine signaling.  The Jak kinases exhibit distinct cytokine receptor assocn. profiles and so transduce different signals.  Jak3 expression is limited to the immune system, where it plays a key role in signal transduction from cytokine receptors contg. the common gamma chain, γc.  Patients unable to signal via γc present with severe combined immunodeficiency (SCID).  The finding that Jak3 mutations result in SCID has made it a target for development of lymphocyte-specific immunosuppressants.  Here, we present the crystal structure of the Jak3 kinase domain in complex with staurosporine analog AFN941.  The kinase domain is in the active conformation, with both activation loop tyrosine residues phosphorylated.  The phosphate group on pTyr981 in the activation loop is in part coordinated by an arginine residue in the regulatory C-helix, suggesting a direct mechanism by which the active position of the C-helix is induced by phosphorylation of the activation loop.  Such a direct coupling has not been previously obsd. in tyrosine kinases and may be unique to Jak kinases.  The crystal structure provides a detailed view of the Jak3 active site and will facilitate computational and structure-directed approaches to development of Jak3-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ-bnI3-sVjLVg90H21EOLACvtfcHk0lh-29VsugZ-Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVSmsr4%253D&md5=12f87a37a495559c6e34dde019578371</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-02-0707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-02-0707%26sid%3Dliteratum%253Aachs%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520Jak3%2520kinase%2520domain%2520in%2520complex%2520with%2520a%2520staurosporine%2520analog%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D996%26epage%3D1002%26doi%3D10.1182%2Fblood-2005-02-0707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liongue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, A. C.</span></span> <span> </span><span class="NLM_article-title">Cytokine receptor signaling through the JAK-STAT-SOCS pathway in disease</span>. <i>Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2506</span>, <span class="refDoi"> DOI: 10.1016/j.molimm.2006.11.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.molimm.2006.11.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=17208301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVSmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2007&pages=2497-2506&author=L.+A.+O%E2%80%99Sullivanauthor=C.+Liongueauthor=R.+S.+Lewisauthor=S.+E.+Stephensonauthor=A.+C.+Ward&title=Cytokine+receptor+signaling+through+the+JAK-STAT-SOCS+pathway+in+disease&doi=10.1016%2Fj.molimm.2006.11.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease</span></div><div class="casAuthors">O'Sullivan, Lynda A.; Liongue, Clifford; Lewis, Rowena S.; Stephenson, Sarah E. M.; Ward, Alister C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2497-2506</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The complexity of multicellular organisms is dependent on systems enabling cells to respond to specific stimuli.  Cytokines and their receptors are one such system, whose perturbation can lead to a variety of disease states.  This review represents an overview of our current understanding of the cytokine receptors, Janus kinases (Jaks), Signal transducers and activators of transcription (Stats) and Suppressors of cytokine signaling (Socs), focusing on their contribution to diseases of an immune or hematol. nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRJCsJ5di3XbVg90H21EOLACvtfcHk0li7-0KcaQ-NNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVSmur8%253D&md5=0011026cc2b9be7e0d7cdb854aab300a</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2006.11.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2006.11.025%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DL.%2BA.%26aulast%3DLiongue%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DR.%2BS.%26aulast%3DStephenson%26aufirst%3DS.%2BE.%26aulast%3DWard%26aufirst%3DA.%2BC.%26atitle%3DCytokine%2520receptor%2520signaling%2520through%2520the%2520JAK-STAT-SOCS%2520pathway%2520in%2520disease%26jtitle%3DMol.%2520Immunol.%26date%3D2007%26volume%3D44%26spage%3D2497%26epage%3D2506%26doi%3D10.1016%2Fj.molimm.2006.11.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rane, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">Hematopoietic cytokine receptor signaling</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">6724</span>– <span class="NLM_lpage">6737</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fsj.onc.1210757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=17934481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKhsLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=6724-6737&author=S.+J.+Bakerauthor=S.+G.+Raneauthor=E.+P.+Reddy&title=Hematopoietic+cytokine+receptor+signaling&doi=10.1038%2Fsj.onc.1210757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Hematopoietic cytokine receptor signaling</span></div><div class="casAuthors">Baker, S. J.; Rane, S. G.; Reddy, E. P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">6724-6737</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Hematopoiesis is the cumulative result of intricately regulated signaling pathways that are mediated by cytokines and their receptors.  Proper culmination of these diverse pathways forms the basis for an orderly generation of different cell types.  Recent studies conducted over the past 10-15 years have revealed that hematopoietic cytokine receptor signaling is largely mediated by a family of tyrosine kinases termed Janus kinases (JAKs) and their downstream transcription factors termed STATs (signal transducers and activators of transcription).  Aberration in these pathways, such as that caused by the recently identified JAK2V617F mutation, is an underlying cause for diseases such as leukemias and other myeloproliferative disorders.  This recent discovery, when coupled with the fact that STATs are activated by oncoproteins such as BCR-ABL, underscores the importance of the JAK-STAT pathway in both normal cellular development and disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCBFLj3Gs4BrVg90H21EOLACvtfcHk0li7-0KcaQ-NNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKhsLbN&md5=b003dc7def939f23f5acb98fb79d39de</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210757%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DRane%26aufirst%3DS.%2BG.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DHematopoietic%2520cytokine%2520receptor%2520signaling%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D6724%26epage%3D6737%26doi%3D10.1038%2Fsj.onc.1210757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span> <span> </span><span class="NLM_article-title">A dual inhibition, a better solution: development of a JAK1/TYK2 inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8594</span>– <span class="NLM_lpage">8596</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01397</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01397" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOgtrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8594-8596&author=C.+J.+Menet&title=A+dual+inhibition%2C+a+better+solution%3A+development+of+a+JAK1%2FTYK2+inhibitor&doi=10.1021%2Facs.jmedchem.8b01397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">A Dual Inhibition, a Better Solution: Development of a JAK1/TYK2 inhibitor</span></div><div class="casAuthors">Menet, Christel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8594-8596</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over the past 2 decades, there has been a rapid development of novel therapies for the treatment of autoimmune diseases, with an impressive success in biologics.  Inhibiting different cytokine pathways can tackle different conditions and has proven to have great efficacy.  However, despite these therapeutic developments, immunogenicity will continue to be a downside of therapeutic antibodies, on top of the fact that currently they are only given via parenteral administration.  This article provides an overview of the development of a series of dual JAK1/TYK2 inhibitors from hit to the selection of PF-06700841 (6) as a clin. candidate.  6 Is currently in development for the potential treatment of inflammatory diseases, including inflammatory bowel disease (IBD), alopecia areata, and psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMuUawEe36h7Vg90H21EOLACvtfcHk0li7-0KcaQ-NNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOgtrfJ&md5=b526f8855ea539ac0ff76359f5379419</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01397%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26atitle%3DA%2520dual%2520inhibition%252C%2520a%2520better%2520solution%253A%2520development%2520of%2520a%2520JAK1%252FTYK2%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8594%26epage%3D8596%26doi%3D10.1021%2Facs.jmedchem.8b01397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((<i>S</i>)-2,2-difluorocyclopropyl)((1<i>R</i>,5<i>S</i>)-3-(2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8597</span>– <span class="NLM_lpage">8612</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8597-8612&author=A.+Fensomeauthor=C.+M.+Amblerauthor=E.+Arnoldauthor=M.+E.+Bankerauthor=M.+F.+Brownauthor=J.+Chrencikauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=I.+V.+Efremovauthor=A.+Flickauthor=B.+S.+Gerstenbergerauthor=A.+Gopalsamyauthor=M.+M.+Haywardauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+Jussifauthor=J.+D.+Knafelsauthor=D.+C.+Limburgauthor=D.+Linauthor=T.+H.+Linauthor=B.+S.+Pierceauthor=E.+Saiahauthor=R.+Sharmaauthor=P.+T.+Symanowiczauthor=J.+B.+Telliezauthor=J.+I.+Trujilloauthor=F.+F.+Vajdosauthor=F.+Vincentauthor=Z.+K.+Wanauthor=L.+Xingauthor=X.+Yangauthor=X.+Yangauthor=L.+Zhang&title=Dual+inhibition+of+TYK2+and+JAK1+for+the+treatment+of+autoimmune+diseases%3A+discovery+of+%28%28S%29-2%2C2-difluorocyclopropyl%29%28%281R%2C5S%29-3-%282-%28%281-methyl-1H-pyrazol-4-yl%29amino%29pyrimidin-4-yl%29-3%2C8-diazabicyclo%5B3.2.1%5Doctan-8-yl%29methanone+%28PF-06700841%29&doi=10.1021%2Facs.jmedchem.8b00917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span></div><div class="casAuthors">Fensome, Andrew; Ambler, Catherine M.; Arnold, Eric; Banker, Mary Ellen; Brown, Matthew F.; Chrencik, Jill; Clark, James D.; Dowty, Martin E.; Efremov, Ivan V.; Flick, Andrew; Gerstenberger, Brian S.; Gopalsamy, Ariamala; Hayward, Matthew M.; Hegen, Martin; Hollingshead, Brett D.; Jussif, Jason; Knafels, John D.; Limburg, David C.; Lin, David; Lin, Tsung H.; Pierce, Betsy S.; Saiah, Eddine; Sharma, Raman; Symanowicz, Peter T.; Telliez, Jean-Baptiste; Trujillo, John I.; Vajdos, Felix F.; Vincent, Fabien; Wan, Zhao-Kui; Xing, Li; Yang, Xiaojing; Yang, Xin; Zhang, Liying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8597-8612</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytokine signaling is an important characteristic of autoimmune diseases.  Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway.  JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6 and type-I interferon (IFN) family, while TYK2 in addn. to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling.  Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease and rheumatoid arthritis studies, leading to multiple drug approvals.  It is hypothesized that a dual JAK1/TYK2 inhibitor will provide addnl. efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes.  Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compd. 23), which is in Phase II clin. development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNhVkNWDMq7Vg90H21EOLACvtfcHk0lh3jxQe4_oa8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI&md5=c321512f524560cba445d070b9639e55</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00917%26sid%3Dliteratum%253Aachs%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChrencik%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DFlick%26aufirst%3DA.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DZ.%2BK.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDual%2520inhibition%2520of%2520TYK2%2520and%2520JAK1%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%253A%2520discovery%2520of%2520%2528%2528S%2529-2%252C2-difluorocyclopropyl%2529%2528%25281R%252C5S%2529-3-%25282-%2528%25281-methyl-1H-pyrazol-4-yl%2529amino%2529pyrimidin-4-yl%2529-3%252C8-diazabicyclo%255B3.2.1%255Doctan-8-yl%2529methanone%2520%2528PF-06700841%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8597%26epage%3D8612%26doi%3D10.1021%2Facs.jmedchem.8b00917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backesjo, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faryal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aints, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglof, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vihinen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nore, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase (BTK): function, regulation, and transformation with special emphasis on the PH domain</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00741.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1111%2Fj.1600-065X.2008.00741.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=19290921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=58-73&author=A.+J.+Mohamedauthor=L.+Yuauthor=C.+M.+Backesjoauthor=L.+Vargasauthor=R.+Faryalauthor=A.+Aintsauthor=B.+Christenssonauthor=A.+Berglofauthor=M.+Vihinenauthor=B.+F.+Noreauthor=C.+I.+E.+Smith&title=Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29%3A+function%2C+regulation%2C+and+transformation+with+special+emphasis+on+the+PH+domain&doi=10.1111%2Fj.1600-065X.2008.00741.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span></div><div class="casAuthors">Mohamed, Abdalla J.; Yu, Liang; Backesjo, Carl-Magnus; Vargas, Leonardo; Faryal, Rani; Aints, Alar; Christensson, Birger; Berglof, Anna; Vihinen, Mauno; Nore, Beston F.; Smith, C. I. Edvard</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-73</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Bruton's agammaglobulinemia tyrosine kinase (Btk) is a cytoplasmic tyrosine kinase important in B-lymphocyte development, differentiation, and signaling.  Btk is a member of the Tec family of kinases.  Mutations in the Elk gene lead to X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (Xid) in mice.  Activation of Btk triggers a cascade of signaling events that culminates in the generation of calcium mobilization and fluxes, cytoskeletal rearrangements, and transcriptional regulation involving nuclear factor-κB (NF-κB) and nuclear factor of activated T cells (NFAT).  In B cells, NF-κB was shown to bind to the Btk promoter and induce transcription, whereas the B-cell receptor-dependent NF-κB signaling pathway requires functional Btk.  Moreover, Btk activation is tightly regulated by a plethora of other signaling proteins including protein kinase C (PKC), Sab/SH3BP5, and caveolin-1.  For example, the prolyl isomerase Pin1 neg. regulates Btk by decreasing tyrosine phosphorylation and steady state levels of Btk.  It is intriguing that PKC and Pin1, both of which are neg. regulators, bind to the pleckstrin homol. domain of Btk.  To this end, we describe here novel mutations in the pleckstrin homol. domain investigated for their transforming capacity.  In particular, we show that the mutant D43R behaves similar to E41K, already known to possess such activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo1L-Ch4HjNLVg90H21EOLACvtfcHk0lh3jxQe4_oa8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO&md5=7a84f2b3604d67bcc1490fadcbfea234</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00741.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00741.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DBackesjo%26aufirst%3DC.%2BM.%26aulast%3DVargas%26aufirst%3DL.%26aulast%3DFaryal%26aufirst%3DR.%26aulast%3DAints%26aufirst%3DA.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DBerglof%26aufirst%3DA.%26aulast%3DVihinen%26aufirst%3DM.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%253A%2520function%252C%2520regulation%252C%2520and%2520transformation%2520with%2520special%2520emphasis%2520on%2520the%2520PH%2520domain%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D58%26epage%3D73%26doi%3D10.1111%2Fj.1600-065X.2008.00741.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nore, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span> <span> </span><span class="NLM_article-title">Signalling of bruton’s tyrosine kinase, BTK</span>. <i>Scand. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1046/j.1365-3083.1999.00504.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1046%2Fj.1365-3083.1999.00504.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10075013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK1MXhslSisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1999&pages=113-118&author=A.+J.+Mohamedauthor=B.+F.+Noreauthor=B.+Christenssonauthor=C.+I.+E.+Smith&title=Signalling+of+bruton%E2%80%99s+tyrosine+kinase%2C+BTK&doi=10.1046%2Fj.1365-3083.1999.00504.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling of Bruton's tyrosine kinase, Btk</span></div><div class="casAuthors">Mohamed, A. J.; Nore, B. F.; Christensson, B.; Smith, C. I. E.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-118</span>CODEN:
                <span class="NLM_cas:coden">SJIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0300-9475</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">A review with 63 refs.  Bruton's tyrosine kinase, which is encoded by the BTK gene, is a cytoplasmic protein tyrosine kinase (PTK) crucial for B-cell development and differentiation.  It belongs to the Tec family of PTKs contg. several domains that are characteristic of signalling mols.  In humans, mutations that disrupt the function of this gene lead to the classical XLA syndrome (X-linked agammaglobulinemia), a primary immunodeficiency mainly characterized by lack of mature B cells as well as low levels of Igs.  In contrast, animal models of this disease such as the xid mice display profoundly milder XLA phenotype.  BTK phosphorylation and activation in response to engagement of the B-cell receptor (BCR) by antigen is a dynamic process whereby a variety of proteins interact with each other and recruit signalling mols. resulting in a physiol. response such as B-cell proliferation and antibody prodn.  The main players, however, that participate in the intracellular downstream cascade have not yet been identified and are therefore under intense scrutiny in several labs.  This review discusses certain aspects of BTK activation following receptor stimulation by agonists and how this event is translated into the biochem. signals within the cell that eventually lead to nuclear responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphmZBDkpS1ubVg90H21EOLACvtfcHk0lh3jxQe4_oa8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslSisr0%253D&md5=a3842c00d3cd4e45458c050941026476</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-3083.1999.00504.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-3083.1999.00504.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DSignalling%2520of%2520bruton%25E2%2580%2599s%2520tyrosine%2520kinase%252C%2520BTK%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D1999%26volume%3D49%26spage%3D113%26epage%3D118%26doi%3D10.1046%2Fj.1365-3083.1999.00504.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takata, M.</span></span> <span> </span><span class="NLM_article-title">A role for Bruton’s tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1084/jem.184.1.31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1084%2Fjem.184.1.31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=8691147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1ajs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=1996&pages=31-40&author=M.+Takata&title=A+role+for+Bruton%E2%80%99s+tyrosine+kinase+in+B+cell+antigen+receptor-mediated+activation+of+phospholipase+C-gamma+2&doi=10.1084%2Fjem.184.1.31"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-γ2</span></div><div class="casAuthors">Takata, Minoru; Kurosaki, Tomohiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-40</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Defects in the gene encoding Bruton's tyrosine kinase (Btk) result in a disease called X-linked agammaglobulinemia, in which there is a profound decrease of mature B cells due to a block in B cell development.  Recent studies have shown that Btk is tyrosine phosphorylated and activated upon B cell antigen receptor (BCR) stimulation.  To elucidate the functions of this kinase, we examd. BCR signaling of DT40 B cells deficient in Btk.  Tyrosine phosphorylation of phospholipase C (PLC)-γ2 upon receptor stimulation was significantly reduced in the mutant cells, leading to the loss of both BCR-coupled phosphatidylinositol hydrolysis and calcium mobilization.  Pleckstrin homol. and Src-homol. 2 domains of Btk were required for PLC-γ2 activation.  Since Syk is also required for the BCR-induced PLC-γ2 activation, our findings indicate that PLC-γ2 activation is regulated by Btk and Syk through their concerted actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrvJR6GCfI7rVg90H21EOLACvtfcHk0lhQ3Vmn1vkfhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1ajs74%253D&md5=7244a36ac8298ccde274e05016ec68ba</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1084%2Fjem.184.1.31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.184.1.31%26sid%3Dliteratum%253Aachs%26aulast%3DTakata%26aufirst%3DM.%26atitle%3DA%2520role%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cell%2520antigen%2520receptor-mediated%2520activation%2520of%2520phospholipase%2520C-gamma%25202%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1996%26volume%3D184%26spage%3D31%26epage%3D40%26doi%3D10.1084%2Fjem.184.1.31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton’s tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4265</span>– <span class="NLM_lpage">4269</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2015.07.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=26320619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4265-4269&author=Q.+Liuauthor=D.+G.+Battauthor=J.+S.+Lippyauthor=N.+Surtiauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=L.+Chenauthor=Y.+Anauthor=C.+Changauthor=M.+Pokrossauthor=Z.+Yangauthor=H.+Wangauthor=J.+R.+Burkeauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Design+and+synthesis+of+carbazole+carboxamides+as+promising+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+and+Janus+kinase+2+%28JAK2%29&doi=10.1016%2Fj.bmcl.2015.07.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span></div><div class="casAuthors">Liu, Qingjie; Batt, Douglas G.; Lippy, Jonathan S.; Surti, Neha; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chen, Lin; An, Yongmi; Chang, Chiehying; Pokross, Matt; Yang, Zheng; Wang, Haiqing; Burke, James R.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4265-4269</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Four series of disubstituted carbazole-1-carboxamides, e.g. I [R = 2-F, 3-MeO, 2-Me, etc.] were designed and synthesized as inhibitors of Bruton's tyrosine kinase.  4,7- And 4,6-Disubstituted carbazole-1-carboxamides were potent and selective inhibitors of BTK, while 3,7- and 3,6-disubstituted carbazole-1-carboxamides were potent and selective inhibitors of Janus kinase 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD3SZfBfD4ZbVg90H21EOLACvtfcHk0lhQ3Vmn1vkfhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF&md5=3558c8ca9a9c29bb38ef98936f61200a</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.102%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520carbazole%2520carboxamides%2520as%2520promising%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520and%2520Janus%2520kinase%25202%2520%2528JAK2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4265%26epage%3D4269%26doi%3D10.1016%2Fj.bmcl.2015.07.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Small molecule reversible inhibitors of bruton’s tyrosine kinase (BTK): structure-activity relationships leading to the identification of 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9<i>H</i>-carbazole-1-carboxamide (BMS-935177)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7915</span>– <span class="NLM_lpage">7935</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7915-7935&author=G.+V.+De%0ALuccaauthor=Q.+Shiauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin+Bertrandauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=J.+Daiauthor=M.+Obermeierauthor=R.+Vickeryauthor=Y.+Zhangauthor=Z.+Yangauthor=P.+Maratheauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+J.+Changauthor=H.+Zhangauthor=K.+Gilloolyauthor=T.+Taylorauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=D.+W.+Kukralauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Small+molecule+reversible+inhibitors+of+bruton%E2%80%99s+tyrosine+kinase+%28BTK%29%3A+structure-activity+relationships+leading+to+the+identification+of+7-%282-hydroxypropan-2-yl%29-4-%5B2-methyl-3-%284-oxo-3%2C4-dihydroquinazolin-3-yl%29phenyl%5D-9H-carbazole-1-carboxamide+%28BMS-935177%29&doi=10.1021%2Facs.jmedchem.6b00722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span></div><div class="casAuthors">De Lucca, George V.; Shi, Qing; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Rampulla, Rick; Mathur, Arvind; Discenza, Lorell; D'Arienzo, Celia; Dai, Jun; Obermeier, Mary; Vickery, Rodney; Zhang, Yingru; Yang, Zheng; Marathe, Punit; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chang, ChiehYing J.; Zhang, Huiping; Gillooly, Kathleen; Taylor, Tracy; Pattoli, Mark A.; Skala, Stacey; Kukral, Daniel W.; McIntyre, Kim W.; Salter-Cid, Luisa; Fura, Aberra; Burke, James R.; Barrish, Joel C.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7915-7935</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a crit. role in multiple cell types responsible for numerous autoimmune diseases.  This article will detail the structure-activity relationships (SARs) leading to a novel second generation series of potent and selective reversible carbazole inhibitors of BTK.  With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide 6 (BMS-935177) was selected to advance into clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1HUwZaRn_w7Vg90H21EOLACvtfcHk0lhQ3Vmn1vkfhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M&md5=7c7ec1a52121c541753c045c1cbf758b</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00722%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DObermeier%26aufirst%3DM.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DSmall%2520molecule%2520reversible%2520inhibitors%2520of%2520bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%253A%2520structure-activity%2520relationships%2520leading%2520to%2520the%2520identification%2520of%25207-%25282-hydroxypropan-2-yl%2529-4-%255B2-methyl-3-%25284-oxo-3%252C4-dihydroquinazolin-3-yl%2529phenyl%255D-9H-carbazole-1-carboxamide%2520%2528BMS-935177%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7915%26epage%3D7935%26doi%3D10.1021%2Facs.jmedchem.6b00722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langevine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (BMS-986142): a reversible inhibitor of bruton’s tyrosine kinase (BTK) conformationally constrained by two locked atropisomers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9173-9200&author=S.+H.+Wattersonauthor=G.+V.+De+Luccaauthor=Q.+Shiauthor=C.+M.+Langevineauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin+Bertrandauthor=H.+Gongauthor=J.+Daiauthor=S.+Yipauthor=P.+Liauthor=D.+Sunauthor=D.+R.+Wuauthor=C.+Wangauthor=Y.+Zhangauthor=S.+C.+Traegerauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=L.+N.+Discenzaauthor=C.+J.+D%E2%80%99Arienzoauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=K.+W.+McIntyreauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+6-fluoro-5-%28R%29-%283-%28S%29-%288-fluoro-1-methyl-2%2C4-dioxo-1%2C2-dihydroquinazolin-3%284H%29-yl%29-2-methylphenyl%29-2-%28S%29-%282-hydroxypropan-2-yl%29-2%2C3%2C4%2C9-tetrahydro-1H-carbazole-8-carboxamide+%28BMS-986142%29%3A+a+reversible+inhibitor+of+bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+conformationally+constrained+by+two+locked+atropisomers&doi=10.1021%2Facs.jmedchem.6b01088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers</span></div><div class="casAuthors">Watterson, Scott H.; De Lucca, George V.; Shi, Qing; Langevine, Charles M.; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Gong, Hua; Dai, Jun; Yip, Shiuhang; Li, Peng; Sun, Dawn; Wu, Dauh-Rurng; Wang, Chunlei; Zhang, Yingru; Traeger, Sarah C.; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Vickery, Rodney; Discenza, Lorell N.; D'Arienzo, Celia J.; Zhang, Yifan; Heimrich, Elizabeth; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; McIntyre, Kim W.; Galella, Michael A.; Tebben, Andy J.; Muckelbauer, Jodi K.; Chang, ChiehYing; Rampulla, Richard; Mathur, Arvind; Salter-Cid, Luisa; Barrish, Joel C.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9173-9200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases.  BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling in mast cells and basophils, all of which have been implicated in the pathophysiol. of autoimmune disease.  As a result, inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as lupus and rheumatoid arthritis.  This article details the structure-activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK.  Of particular interest is that two atropisomeric centers were rotationally locked to provide a single, stable atropisomer, resulting in enhanced potency and selectivity as well as a redn. in safety liabilities.  With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy, and a very desirable tolerability and safety profile, 14f (BMS-986142) was advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpBAygRAsYrVg90H21EOLACvtfcHk0lg2EGJ31tKhkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF&md5=91098abc802521b9ad91563d20ac5893</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DD.%2BR.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DDiscenza%26aufirst%3DL.%2BN.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25206-fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-fluoro-1-methyl-2%252C4-dioxo-1%252C2-dihydroquinazolin-3%25284H%2529-yl%2529-2-methylphenyl%2529-2-%2528S%2529-%25282-hydroxypropan-2-yl%2529-2%252C3%252C4%252C9-tetrahydro-1H-carbazole-8-carboxamide%2520%2528BMS-986142%2529%253A%2520a%2520reversible%2520inhibitor%2520of%2520bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520conformationally%2520constrained%2520by%2520two%2520locked%2520atropisomers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9173%26epage%3D9200%26doi%3D10.1021%2Facs.jmedchem.6b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific BTK inhibition suppresses B cell- and myeloid cell-mediated arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di%0APaoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+BTK+inhibition+suppresses+B+cell-+and+myeloid+cell-mediated+arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0lg2EGJ31tKhkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520BTK%2520inhibition%2520suppresses%2520B%2520cell-%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaluso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowell, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Potent and selective Bruton’s tyrosine kinase inhibitors: discovery of GDC-0834</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1337</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2015.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=25701252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1333-1337&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=S.+Gallionauthor=S.+G.+Hymowitzauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=B.+Maurerauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=C.+G.+Sowellauthor=X.+Wangauthor=H.+Wongauthor=J.+M.+Xiongauthor=J.+Xuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+discovery+of+GDC-0834&doi=10.1016%2Fj.bmcl.2015.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Gallion, Steve; Hymowitz, Sarah G.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Maurer, Brigitte; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Sowell, C. Gregory; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1333-1337</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 resulted in the clin. candidate GDC-0834, which retained the potency and selectivity of CGI-1746, but with much improved PK in preclin. animal models.  Structure based design efforts drove this work as modifications to CGI-1746 were investigated at both the solvent exposed region as well as 'H3 binding pocket'.  However, in vitro metabolic evaluation of GDC-0834 revealed a non CYP-mediated metabolic process that was more prevalent in human than preclin. species (mouse, rat, dog, cyno), leading to a high-level of uncertainly in predicting human pharmacokinetics.  Due to its promising potency, selectivity, and preclin. efficacy, a single dose IND was filed and GDC-0834 was taken in to a single dose phase I trial in healthy volunteers to quickly evaluate the human pharmacokinetics.  In human, GDC-0834 was found to be highly labile at the exo-cyclic amide bond that links the tetrahydrobenzothiophene moiety to the central aniline ring, resulting in insufficient parent drug exposure.  This information informed the back-up program and discovery of improved inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhL04eYDiT3bVg90H21EOLACvtfcHk0lh-4tWXYogwRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D&md5=fdebc0199c8222e093cfb9583244bce3</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.%2BM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPotent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520discovery%2520of%2520GDC-0834%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1333%26epage%3D1337%26doi%3D10.1016%2Fj.bmcl.2015.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrion, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faccenda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. A.</span></span> <span> </span><span class="NLM_article-title">The concise guide to pharmacology 2017/18: G protein-coupled receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">S17</span>– <span class="NLM_lpage">S129</span>, <span class="refDoi"> DOI: 10.1111/bph.13878</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1111%2Fbph.13878" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=29055040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs12ls7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=S17-S129&author=S.+P.+Alexanderauthor=A.+Christopoulosauthor=A.+P.+Davenportauthor=E.+Kellyauthor=N.+V.+Marrionauthor=J.+A.+Petersauthor=E.+Faccendaauthor=S.+D.+Hardingauthor=A.+J.+Pawsonauthor=J.+L.+Sharmanauthor=C.+Southanauthor=J.+A.+Davies&title=The+concise+guide+to+pharmacology+2017%2F18%3A+G+protein-coupled+receptors&doi=10.1111%2Fbph.13878"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors</span></div><div class="casAuthors">Alexander, Stephen P. H.; Christopoulos, Arthur; Davenport, Anthony P.; Kelly, Eamonn; Marrion, Neil V.; Peters, John A.; Faccenda, Elena; Harding, Simon D.; Pawson, Adam J.; Sharman, Joanna L.; Southan, Christopher; Davies, Jamie A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">S17-S129</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The Concise Guide to PHARMACOl. 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacol. (where available), plus links to an open access knowledgebase of drug targets and their ligands (), which provides more detailed views of target and ligand properties.  Although the Concise Guide represents approx. 400 pages, the material presented is substantially reduced compared to information and links presented on the website.  It provides a permanent, citable, point-in-time record that will survive database updates.  The full contents of this section can be found at .  G protein-coupled receptors are one of the eight major pharmacol. targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters.  These are presented with nomenclature guidance and summary information on the best available pharmacol. tools, alongside key refs. and suggestions for further reading.  The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels.  It is produced in close conjunction with the Nomenclature Committee of the Union of Basic and Clin. Pharmacol. (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrktrD3wjuPZ7Vg90H21EOLACvtfcHk0lh-4tWXYogwRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs12ls7%252FO&md5=2d4bc1acc92b6aa659365aa70ba50983</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1111%2Fbph.13878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13878%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DS.%2BP.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26aulast%3DKelly%26aufirst%3DE.%26aulast%3DMarrion%26aufirst%3DN.%2BV.%26aulast%3DPeters%26aufirst%3DJ.%2BA.%26aulast%3DFaccenda%26aufirst%3DE.%26aulast%3DHarding%26aufirst%3DS.%2BD.%26aulast%3DPawson%26aufirst%3DA.%2BJ.%26aulast%3DSharman%26aufirst%3DJ.%2BL.%26aulast%3DSouthan%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520concise%2520guide%2520to%2520pharmacology%25202017%252F18%253A%2520G%2520protein-coupled%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D174%26spage%3DS17%26epage%3DS129%26doi%3D10.1111%2Fbph.13878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boulton, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nye, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radzlejewska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgenbesser, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panayotatos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobb, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span> <span> </span><span class="NLM_article-title">ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">675</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(91)90098-J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2F0092-8674%2891%2990098-J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=2032290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK38XmsVOltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1991&pages=663-675&author=T.+G.+Boultonauthor=S.+H.+Nyeauthor=D.+J.+Robbinsauthor=N.+Y.+Ipauthor=E.+Radzlejewskaauthor=S.+D.+Morgenbesserauthor=R.+A.+DePinhoauthor=N.+Panayotatosauthor=M.+H.+Cobbauthor=G.+D.+Yancopoulos&title=ERKs%3A+A+family+of+protein-serine%2Fthreonine+kinases+that+are+activated+and+tyrosine+phosphorylated+in+response+to+insulin+and+NGF&doi=10.1016%2F0092-8674%2891%2990098-J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">ERKs:  a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF</span></div><div class="casAuthors">Boulton, Teri G.; Nye, Steven H.; Robbins, David J.; Ip, Nancy Y.; Radziejewska, Elizabeth; Morgenbesser, Sharon D.; DePinho, Ronald A.; Panayotatos, Nikos; Cobb, Melanie H.; Yancopoulos, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">663-75</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The purifn. and cloning of extracellular signal-regulated kinase 1 (ERK1), which appears to play a pivotal role in converting tyrosine phosphorylation into the serine/threonine phosphorylations that regulate downstream events was recently described.  Here, the cloning and characterization of 2 ERK1-related kinases, ERK2 and ERK3 from rat brain are described and evidence is provided suggesting that there are addnl. ERK family members.  At least 2 of the ERKs are activated in response to growth factors; their activations correlate with tyrosine phosphorylation, but also depend on addnl. modifications.  Transcripts corresponding to the 3 cloned ERKs are distinctly regulated both in vivo and in a differentiating cell line.  Thus, this family of kinases may serve as intermediates that depend on tyrosine phosphorylation to activate serine/threonine phosphorylation cascades.  Individual family members may mediate responses in different developmental stages, in different cell types, or following exposure to different extracellular signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGE1DFLrovR7Vg90H21EOLACvtfcHk0lhdjFrrDgiOFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XmsVOltr0%253D&md5=3e02d5a7a9679b8cdedca2471c4d5b04</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2891%2990098-J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252891%252990098-J%26sid%3Dliteratum%253Aachs%26aulast%3DBoulton%26aufirst%3DT.%2BG.%26aulast%3DNye%26aufirst%3DS.%2BH.%26aulast%3DRobbins%26aufirst%3DD.%2BJ.%26aulast%3DIp%26aufirst%3DN.%2BY.%26aulast%3DRadzlejewska%26aufirst%3DE.%26aulast%3DMorgenbesser%26aufirst%3DS.%2BD.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26aulast%3DPanayotatos%26aufirst%3DN.%26aulast%3DCobb%26aufirst%3DM.%2BH.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26atitle%3DERKs%253A%2520A%2520family%2520of%2520protein-serine%252Fthreonine%2520kinases%2520that%2520are%2520activated%2520and%2520tyrosine%2520phosphorylated%2520in%2520response%2520to%2520insulin%2520and%2520NGF%26jtitle%3DCell%26date%3D1991%26volume%3D65%26spage%3D663%26epage%3D675%26doi%3D10.1016%2F0092-8674%2891%2990098-J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nestler, E. J.</span>; <span class="NLM_string-name">Greengard, P.</span></span> <span> </span><span class="NLM_article-title">Serine and threonine phosphorylation</span>. In  <i>Basic Neurochemistry: Molecular, Cellular and Medical Aspects</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, G. J.</span>; <span class="NLM_string-name">Agranoff, B. W.</span>, <span class="NLM_string-name">Albers, R. W.</span></span>, Eds.; <span class="NLM_publisher-name">Lippincott-Raven</span>: <span class="NLM_publisher-loc">Philadelphia</span>, <span class="NLM_year">1999</span>; pp  <span class="NLM_fpage">471</span>− <span class="NLM_lpage">496</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&pages=471-496&author=E.+J.+Nestler&author=P.+Greengardauthor=G.+J.+Siegel&author=B.+W.+Agranoff&author=R.+W.+Albers&title=Basic+Neurochemistry%3A+Molecular%2C+Cellular+and+Medical+Aspects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNestler%26aufirst%3DE.%2BJ.%26atitle%3DSerine%2520and%2520threonine%2520phosphorylation%26btitle%3DBasic%2520Neurochemistry%253A%2520Molecular%252C%2520Cellular%2520and%2520Medical%2520Aspects%26aulast%3DSiegel%26aufirst%3DG.%2BJ.%26pub%3DLippincott-Raven%26date%3D1999%26spage%3D471%26epage%3D496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, J. L.</span></span> <span> </span><span class="NLM_article-title">Pelle kinase is activated by autophosphorylation during toll signaling in drosophila</span>. <i>Development</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1925</span>– <span class="NLM_lpage">1933</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=11934858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD38XjslSlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2002&pages=1925-1933&author=B.+Shenauthor=J.+L.+Manley&title=Pelle+kinase+is+activated+by+autophosphorylation+during+toll+signaling+in+drosophila"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Pelle kinase is activated by autophosphorylation during Toll signaling in Drosophila</span></div><div class="casAuthors">Shen, Baohe; Manley, James L.</div><div class="citationInfo"><span class="NLM_cas:title">Development (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1925-1933</span>CODEN:
                <span class="NLM_cas:coden">DEVPED</span>;
        ISSN:<span class="NLM_cas:issn">0950-1991</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">The Drosophila Pelle kinase plays a key role in the evolutionarily conserved Toll signaling pathway, but the mechanism responsible for its activation has been unknown.  We present in vivo and in vitro evidence establishing an important role for concn.-dependent autophosphorylation in the signaling process.  We first show that Pelle phosphorylation can be detected transiently in early embryos, concomitant with activation of signaling.  Importantly, Pelle phosphorylation is enhanced in a gain-of-function Toll mutant (Toll10b), but decreased by loss-of-function Toll alleles.  Next we found that Pelle is phosphorylated in transfected Schneider L2 cells in a concn.-dependent manner such that significant modification is obsd. only at high Pelle concns., which coincide with levels required for phosphorylation and activation of the downstream target, Dorsal.  Pelle phosphorylation is also enhanced in L2 cells co-expressing Toll10b, and is dependent on Pelle kinase activity.  In vitro kinase assays revealed that recombinant, autophosphorylated Pelle is far more active than unphosphorylated Pelle.  Importantly, unphosphorylated Pelle becomes autophosphorylated, and activated, by incubation at high concns.  We discuss these results in the context of Toll-like receptor mediated signaling in both flies and mammals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRCW9nAaRUwLVg90H21EOLACvtfcHk0lhdjFrrDgiOFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjslSlsrk%253D&md5=364debacdbb832eb0e1299070ed4501a</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DB.%26aulast%3DManley%26aufirst%3DJ.%2BL.%26atitle%3DPelle%2520kinase%2520is%2520activated%2520by%2520autophosphorylation%2520during%2520toll%2520signaling%2520in%2520drosophila%26jtitle%3DDevelopment%26date%3D2002%26volume%3D129%26spage%3D1925%26epage%3D1933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Losiewicz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worland, P. J.</span></span> <span> </span><span class="NLM_article-title">Potent inhibition of CDC2 kinase activity by the flavonoid L86–8275</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1006/bbrc.1994.1742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1006%2Fbbrc.1994.1742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=8002990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK2cXksV2ksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=1994&pages=589-595&author=M.+D.+Losiewiczauthor=B.+A.+Carlsonauthor=G.+Kaurauthor=E.+A.+Sausvilleauthor=P.+J.+Worland&title=Potent+inhibition+of+CDC2+kinase+activity+by+the+flavonoid+L86%E2%80%938275&doi=10.1006%2Fbbrc.1994.1742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Potent inhibition of Cdc2 kinase activity by the flavonoid L86-8275</span></div><div class="casAuthors">Losiewicz, Michael D.; Carlson, Bradley A.; Kaur, Gurmeet; Sausville, Edward A.; Worland, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title"></span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">589-95</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">L86-8275 [(-) cis-5,7-dihydroxy-2-(2-chlorophenyl)-8[4-(3-hydroxy-1-methyl)-piperidinyl]-4H-benzopyran-4-one] directly inhibits immunopptd. Cdc2 kinase activity from G2/M synchronized MDA-MB-468 breast carcinoma cells and is at least 250-fold more potent than either quercetin or genistein.  Purified sea-star Cdc2 kinase (IC50 = 0.5 μM) was inhibited with a similar potency to immunopptd. Cdc2 kinase from MDA-MB-468 cells (IC50 = 0.4 μM).  This inhibition was competitive with respect to ATP (KiATP = 0.041 μM) and noncompetitive with respect to a synthetic peptide substrate, CDK1S1 (AAKAKKTPKKAKK-CONH2, KiCDD1S1 = 0.14 μM).  These data suggest L86-8275 as a lead structure for the development of inhibitors of the cyclin-dependent kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFqJ6zFiGW47Vg90H21EOLACvtfcHk0lhdjFrrDgiOFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksV2ksbs%253D&md5=bbf1b887438a0746aa058ed88d1fc0da</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1994.1742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1994.1742%26sid%3Dliteratum%253Aachs%26aulast%3DLosiewicz%26aufirst%3DM.%2BD.%26aulast%3DCarlson%26aufirst%3DB.%2BA.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DWorland%26aufirst%3DP.%2BJ.%26atitle%3DPotent%2520inhibition%2520of%2520CDC2%2520kinase%2520activity%2520by%2520the%2520flavonoid%2520L86%25E2%2580%25938275%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1994%26volume%3D201%26spage%3D589%26epage%3D595%26doi%3D10.1006%2Fbbrc.1994.1742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulner, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, J. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blow, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcros, J.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulinoux, J.-P.</span></span> <span> </span><span class="NLM_article-title">Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases CDC2, CDK2 and CDK5</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>243</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.1997.t01-2-00527.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1111%2Fj.1432-1033.1997.t01-2-00527.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=9030781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK2sXhtVWiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=1997&pages=527-536&author=L.+Meijerauthor=A.+Borgneauthor=O.+Mulnerauthor=J.+P.+J.+Chongauthor=J.+J.+Blowauthor=N.+Inagakiauthor=M.+Inagakiauthor=J.-G.+Delcrosauthor=J.-P.+Moulinoux&title=Biochemical+and+cellular+effects+of+roscovitine%2C+a+potent+and+selective+inhibitor+of+the+cyclin-dependent+kinases+CDC2%2C+CDK2+and+CDK5&doi=10.1111%2Fj.1432-1033.1997.t01-2-00527.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2, and cdk5</span></div><div class="casAuthors">Meijer, Laurent; Borgne, Annie; Mulner, Odile; Chong, James P. J.; Blow, J. Julian; Inagaki, Naoyuki; Inagaki, Masaki; Delcros, Jean Guy; Moulinoux, Jacques Philippe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">243</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">527-536</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (cdk) play an essential role in the intracellular control of the cell division cycle (cdc).  These kinases and their regulators are frequently deregulated in human tumors.  Enzymic screening has recently led to the discovery of specific inhibitors of cyclin-dependent kinases, such as butyrolactone I, flavopiridol and the purine olomoucine.  Among a series of C2, N6,N9-substituted adenines tested on purified cdc2/cyclin B, 2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine (roscovitine) displays high efficiency and high selectivity towards some cyclin-dependent kinases.  The kinase specificity of roscovitine was investigated with 25 highly purified kinases (including protein kinase A, G and C isoforms, myosin light-chain kinase, casein kinase 2, insulin receptor tyrosine kinase, c-src, v-abl).  Most kinases are not significantly inhibited by roscovitine.  Cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E and cdk5/p35 only are substantially inhibited (IC50 values of 0.65, 0.7, 0.7 and 0.2 μM, resp.).  Cdk4/cyclin D1 and cdk6/cyclin D2 are very poorly inhibited by roscovitine (IC50>100 μM).  Extracellular regulated kinases erk1 and erk2 are inhibited with an IC50 of 34 μM and 14 μM, resp.  Roscovitine reversibly arrests starfish oocytes and sea urchin embryos in late prophase.  Roscovitine inhibits in vitro M-phase-promoting factor activity and in vitro DNA synthesis in Xenopus egg exts.  It blocks progesterone-induced oocyte maturation of Xenopus oocytes and in vivo phosphorylation of the elongation factor eEF-1.  Roscovitine inhibits the proliferation of mammalian cell lines with an av. IC50 of 16 μM.  In the presence of roscovitine L1210 cells arrest in G1 and accumulate in G2.  In vivo phosphorylation of vimentin on Ser55 by cdc2/cyclin B is inhibited by roscovitine.  Through its unique selectivity for some cyclin-dependent kinases, roscovitine provides a useful anti-mitotic reagent for cell cycle studies and may prove interesting to control cells with deregulated cdc2, cdk2 or cdk5 kinase activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO61Tu2_0pWLVg90H21EOLACvtfcHk0lhqPDfChE6eGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhtVWiu7g%253D&md5=d55100def53ac8811e485d9d34c46b79</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1997.t01-2-00527.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1997.t01-2-00527.x%26sid%3Dliteratum%253Aachs%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DBorgne%26aufirst%3DA.%26aulast%3DMulner%26aufirst%3DO.%26aulast%3DChong%26aufirst%3DJ.%2BP.%2BJ.%26aulast%3DBlow%26aufirst%3DJ.%2BJ.%26aulast%3DInagaki%26aufirst%3DN.%26aulast%3DInagaki%26aufirst%3DM.%26aulast%3DDelcros%26aufirst%3DJ.-G.%26aulast%3DMoulinoux%26aufirst%3DJ.-P.%26atitle%3DBiochemical%2520and%2520cellular%2520effects%2520of%2520roscovitine%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520the%2520cyclin-dependent%2520kinases%2520CDC2%252C%2520CDK2%2520and%2520CDK5%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1997%26volume%3D243%26spage%3D527%26epage%3D536%26doi%3D10.1111%2Fj.1432-1033.1997.t01-2-00527.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhavalkar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiswell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seghezzi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomeir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oft, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E. M.</span></span> <span> </span><span class="NLM_article-title">Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2344</span>– <span class="NLM_lpage">2353</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1158%2F1535-7163.MCT-10-0324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=20663931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2344-2353&author=D.+Parryauthor=T.+Guziauthor=F.+Shanahanauthor=N.+Davisauthor=D.+Prabhavalkarauthor=D.+Wiswellauthor=W.+Seghezziauthor=K.+Paruchauthor=M.+P.+Dwyerauthor=R.+Dollauthor=A.+Nomeirauthor=W.+Windsorauthor=T.+Fischmannauthor=Y.+Wangauthor=M.+Oftauthor=T.+Chenauthor=P.+Kirschmeierauthor=E.+M.+Lees&title=Dinaciclib+%28SCH+727965%29%2C+a+novel+and+potent+cyclin-dependent+kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-10-0324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor</span></div><div class="casAuthors">Parry, David; Guzi, Timothy; Shanahan, Frances; Davis, Nicole; Prabhavalkar, Deepa; Wiswell, Derek; Seghezzi, Wolfgang; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald; Nomeir, Amin; Windsor, William; Fischmann, Thierry; Wang, Yaolin; Oft, Martin; Chen, Taiying; Kirschmeier, Paul; Lees, Emma M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2344-2353</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDK) are key pos. regulators of cell cycle progression and attractive targets in oncol.  SCH 727965 inhibits CDK2, CDK5, CDK1, and CDK9 activity in vitro with IC50 values of 1, 1, 3, and 4 nmol/L, resp.  SCH 727965 was selected as a clin. candidate using a functional screen in vivo that integrated both efficacy and safety parameters.  Compared with flavopiridol, SCH 727965 exhibits superior activity with an improved therapeutic index.  In cell-based assays, SCH 727965 completely suppressed retinoblastoma phosphorylation, which correlated with apoptosis onset and total inhibition of bromodeoxyuridine incorporation in >100 tumor cell lines of diverse origin and background.  Moreover, short exposures to SCH 727965 were sufficient for long-lasting cellular effects.  SCH 727965 induced regression of established solid tumors in a range of mouse models following intermittent scheduling of doses below the maximally tolerated level.  This was assocd. with modulation of pharmacodynamic biomarkers in skin punch biopsies and rapidly reversible, mechanism-based effects on hematol. parameters.  These results suggest that SCH 727965 is a potent and selective CDK inhibitor and a novel cytotoxic agent.  Mol Cancer Ther; 9(8); 2344-53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxn1NtmEAh7LVg90H21EOLACvtfcHk0lhqPDfChE6eGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjtrw%253D&md5=bd2d30fdfdca0f2bceb3f5c0b44b8630</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0324%26sid%3Dliteratum%253Aachs%26aulast%3DParry%26aufirst%3DD.%26aulast%3DGuzi%26aufirst%3DT.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DPrabhavalkar%26aufirst%3DD.%26aulast%3DWiswell%26aufirst%3DD.%26aulast%3DSeghezzi%26aufirst%3DW.%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DDoll%26aufirst%3DR.%26aulast%3DNomeir%26aufirst%3DA.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DFischmann%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DOft%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DLees%26aufirst%3DE.%2BM.%26atitle%3DDinaciclib%2520%2528SCH%2520727965%2529%252C%2520a%2520novel%2520and%2520potent%2520cyclin-dependent%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2344%26epage%3D2353%26doi%3D10.1158%2F1535-7163.MCT-10-0324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liszkay, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Cruz-Merino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutriaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sovak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hack, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Combined vemurafenib and cobimetinib in BRAF-mutated melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">1867</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1408868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1056%2FNEJMoa1408868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=25265494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1867-1876&author=J.+Larkinauthor=P.+A.+Asciertoauthor=B.+Drenoauthor=V.+Atkinsonauthor=G.+Liszkayauthor=M.+Maioauthor=M.+Mandalaauthor=L.+Demidovauthor=D.+Stroyakovskiyauthor=L.+Thomasauthor=L.+de+la+Cruz-Merinoauthor=C.+Dutriauxauthor=C.+Garbeauthor=M.+A.+Sovakauthor=I.+Changauthor=N.+Choongauthor=S.+P.+Hackauthor=G.+A.+McArthurauthor=A.+Ribas&title=Combined+vemurafenib+and+cobimetinib+in+BRAF-mutated+melanoma&doi=10.1056%2FNEJMoa1408868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Combined vemurafenib and cobimetinib in BRAF-mutated melanoma</span></div><div class="casAuthors">Larkin, James; Ascierto, Paolo A.; Dreno, Brigitte; Atkinson, Victoria; Liszkay, Gabriella; Maio, Michele; Mandala, Mario; Demidov, Lev; Stroyakovskiy, Daniil; Thomas, Luc; de la Cruz-Merino, Luis; Dutriaux, Caroline; Garbe, Claus; Sovak, Mika A.; Chang, Ilsung; Choong, Nicholas; Hack, Stephen P.; McArthur, Grant A.; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1867-1876, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The combined inhibition of BRAF and MEK is hypothesized to improve clin. outcomes in patients with melanoma by preventing or delaying the onset of resistance obsd. with BRAF inhibitors alone.  This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib.  We randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-pos. melanoma to receive vemurafenib and cobimetinib (combination group) or vemurafenib and placebo (control group).  The primary end point was investigator-assessed progression-free survival.  The median progression-free survival was 9.9 mo in the combination group and 6.2 mo in the control group (hazard ratio for death or disease progression, 0.51; 95% confidence interval [CI], 0.39 to 0.68; P<0.001).  The rate of complete or partial response in the combination group was 68%, as compared with 45% in the control group (P<0.001), including rates of complete response of 10% in the combination group and 4% in the control group.  Progression-free survival as assessed by independent review was similar to investigator-assessed progression-free survival.  Interim analyses of overall survival showed 9-mo survival rates of 81% (95% CI, 75 to 87) in the combination group and 73% (95% CI, 65 to 80) in the control group.  Vemurafenib and cobimetinib was assocd. with a nonsignificantly higher incidence of adverse events of grade 3 or higher, as compared with vemurafenib and placebo (65% vs. 59%), and there was no significant difference in the rate of study-drug discontinuation.  The no. of secondary cutaneous cancers decreased with the combination therapy.  The addn. of cobimetinib to vemurafenib was assocd. with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpErdkeTyZ9rVg90H21EOLACvtfcHk0lhqPDfChE6eGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslGgsQ%253D%253D&md5=9b6fb4f9ea883da579d6435ccb5742eb</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1408868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1408868%26sid%3Dliteratum%253Aachs%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DAtkinson%26aufirst%3DV.%26aulast%3DLiszkay%26aufirst%3DG.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DDemidov%26aufirst%3DL.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3Dde%2Bla%2BCruz-Merino%26aufirst%3DL.%26aulast%3DDutriaux%26aufirst%3DC.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DSovak%26aufirst%3DM.%2BA.%26aulast%3DChang%26aufirst%3DI.%26aulast%3DChoong%26aufirst%3DN.%26aulast%3DHack%26aufirst%3DS.%2BP.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DCombined%2520vemurafenib%2520and%2520cobimetinib%2520in%2520BRAF-mutated%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D1867%26epage%3D1876%26doi%3D10.1056%2FNEJMoa1408868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrlova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiss, F.</span></span> <span> </span><span class="NLM_article-title">Cobimetinib (GDC-0973, XL518)</span>. <i>Recent Results Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>211</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1007/978-3-319-91442-8_12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1007%2F978-3-319-91442-8_12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=30069767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVShu7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=2018&pages=177-186&author=H.+Andrlovaauthor=R.+Zeiserauthor=F.+Meiss&title=Cobimetinib+%28GDC-0973%2C+XL518%29&doi=10.1007%2F978-3-319-91442-8_12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Cobimetinib (GDC-0973, XL518)</span></div><div class="casAuthors">Andrlova, Hana; Zeiser, Robert; Meiss, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Recent Results in Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">Small Molecules in Oncology</span>),
    <span class="NLM_cas:pages">177-186</span>CODEN:
                <span class="NLM_cas:coden">RRCRBU</span>;
        ISSN:<span class="NLM_cas:issn">2197-6767</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  The mitogen-activated protein kinase cascade (MAPK/ERK pathway) is a signaling pathway activated as a cellular response to various stimuli and for regulating the proliferation and survival of several types of eukaryotic cells, among others a wide variety of tumor cells.  Mutations of the proteins involved in this pathway have been discovered in several tumor entities, indicating their inhibition as a potential therapeutic target.  BRAF inhibitors have been in the clin. use since 2011.  Several MEK inhibitors have been studied for metastatic cancer treatment in the recent past.  After trametinib, cobimetinib is another potent, selective oral MEK1/2 inhibitor that was approved by European Medicine Agency (EMA) and Food and Drug Administration (FDA) in 2015 for treatment of malignant melanoma in a combination with the BRAF inhibitor vemurafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCfgT9J9-zhrVg90H21EOLACvtfcHk0lhxNnW46ODtog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVShu7nP&md5=873393184d0fcfc7028f06868d70d6cb</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-91442-8_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-91442-8_12%26sid%3Dliteratum%253Aachs%26aulast%3DAndrlova%26aufirst%3DH.%26aulast%3DZeiser%26aufirst%3DR.%26aulast%3DMeiss%26aufirst%3DF.%26atitle%3DCobimetinib%2520%2528GDC-0973%252C%2520XL518%2529%26jtitle%3DRecent%2520Results%2520Cancer%2520Res.%26date%3D2018%26volume%3D211%26spage%3D177%26epage%3D186%26doi%3D10.1007%2F978-3-319-91442-8_12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boscoe, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bree, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodfuehrer, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dower, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozda, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisbie, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavrin, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hope, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamtekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaioannou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samardjiev, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samas, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M. W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soutter, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapf, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of clinical candidate 1-{[(2<i>S</i>,3<i>S</i>,4<i>S</i>)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a potent, selective inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4), by fragment-based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5521</span>– <span class="NLM_lpage">5542</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00231</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00231" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5521-5542&author=K.+L.+Leeauthor=C.+M.+Amblerauthor=D.+R.+Andersonauthor=B.+P.+Boscoeauthor=A.+G.+Breeauthor=J.+I.+Brodfuehrerauthor=J.+S.+Changauthor=C.+Choiauthor=S.+Chungauthor=K.+J.+Curranauthor=J.+E.+Dayauthor=C.+M.+Dehnhardtauthor=K.+Dowerauthor=S.+E.+Drozdaauthor=R.+K.+Frisbieauthor=L.+K.+Gavrinauthor=J.+A.+Goldbergauthor=S.+Hanauthor=M.+Hegenauthor=D.+Hepworthauthor=H.+R.+Hopeauthor=S.+Kamtekarauthor=I.+C.+Kiltyauthor=A.+Leeauthor=L.+L.+Linauthor=F.+E.+Loveringauthor=M.+D.+Loweauthor=J.+P.+Mathiasauthor=H.+M.+Morganauthor=E.+A.+Murphyauthor=N.+Papaioannouauthor=A.+Patnyauthor=B.+S.+Pierceauthor=V.+R.+Raoauthor=E.+Saiahauthor=I.+J.+Samardjievauthor=B.+M.+Samasauthor=M.+W.+H.+Shenauthor=J.+H.+Shinauthor=H.+H.+Soutterauthor=J.+W.+Strohbachauthor=P.+T.+Symanowiczauthor=J.+R.+Thomasonauthor=J.+D.+Trzupekauthor=R.+Vargasauthor=F.+Vincentauthor=J.+Yanauthor=C.+W.+Zapfauthor=S.+W.+Wright&title=Discovery+of+clinical+candidate+1-%7B%5B%282S%2C3S%2C4S%29-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%5Dmethoxy%7D-7-methoxyisoquinoline-6-carboxamide+%28PF-06650833%29%2C+a+potent%2C+selective+inhibitor+of+interleukin-1+receptor+associated+kinase+4+%28IRAK4%29%2C+by+fragment-based+drug+design&doi=10.1021%2Facs.jmedchem.7b00231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design</span></div><div class="casAuthors">Lee, Katherine L.; Ambler, Catherine M.; Anderson, David R.; Boscoe, Brian P.; Bree, Andrea G.; Brodfuehrer, Joanne I.; Chang, Jeanne S.; Choi, Chulho; Chung, Seungwon; Curran, Kevin J.; Day, Jacqueline E.; Dehnhardt, Christoph M.; Dower, Ken; Drozda, Susan E.; Frisbie, Richard K.; Gavrin, Lori K.; Goldberg, Joel A.; Han, Seungil; Hegen, Martin; Hepworth, David; Hope, Heidi R.; Kamtekar, Satwik; Kilty, Iain C.; Lee, Arthur; Lin, Lih-Ling; Lovering, Frank E.; Lowe, Michael D.; Mathias, John P.; Morgan, Heidi M.; Murphy, Elizabeth A.; Papaioannou, Nikolaos; Patny, Akshay; Pierce, Betsy S.; Rao, Vikram R.; Saiah, Eddine; Samardjiev, Ivan J.; Samas, Brian M.; Shen, Marina W. H.; Shin, Julia H.; Soutter, Holly H.; Strohbach, Joseph W.; Symanowicz, Peter T.; Thomason, Jennifer R.; Trzupek, John D.; Vargas, Richard; Vincent, Fabien; Yan, Jiangli; Zapf, Christoph W.; Wright, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5521-5542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topol. in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was optimized to afford IRAK4 inhibitors with nanomolar potency in cellular assays.  The medicinal chem. effort featured the judicious placement of lipophilicity, informed by cocrystal structures with IRAK4 and optimization of ADME properties to deliver clin. candidate I.  This compd. benefitted from a 5-unit increase in lipophilic efficiency from the fragment hit, excellent kinase selectivity, and pharmacokinetic properties suitable for oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYrCep64bhMbVg90H21EOLACvtfcHk0lhxNnW46ODtog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D&md5=9771ad2d33089f6ef3dba3556536ff1a</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00231%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BL.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DBoscoe%26aufirst%3DB.%2BP.%26aulast%3DBree%26aufirst%3DA.%2BG.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%2BI.%26aulast%3DChang%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DChung%26aufirst%3DS.%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DDower%26aufirst%3DK.%26aulast%3DDrozda%26aufirst%3DS.%2BE.%26aulast%3DFrisbie%26aufirst%3DR.%2BK.%26aulast%3DGavrin%26aufirst%3DL.%2BK.%26aulast%3DGoldberg%26aufirst%3DJ.%2BA.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHope%26aufirst%3DH.%2BR.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DL.%2BL.%26aulast%3DLovering%26aufirst%3DF.%2BE.%26aulast%3DLowe%26aufirst%3DM.%2BD.%26aulast%3DMathias%26aufirst%3DJ.%2BP.%26aulast%3DMorgan%26aufirst%3DH.%2BM.%26aulast%3DMurphy%26aufirst%3DE.%2BA.%26aulast%3DPapaioannou%26aufirst%3DN.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DRao%26aufirst%3DV.%2BR.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSamardjiev%26aufirst%3DI.%2BJ.%26aulast%3DSamas%26aufirst%3DB.%2BM.%26aulast%3DShen%26aufirst%3DM.%2BW.%2BH.%26aulast%3DShin%26aufirst%3DJ.%2BH.%26aulast%3DSoutter%26aufirst%3DH.%2BH.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DThomason%26aufirst%3DJ.%2BR.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DVargas%26aufirst%3DR.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DWright%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520clinical%2520candidate%25201-%257B%255B%25282S%252C3S%252C4S%2529-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%255Dmethoxy%257D-7-methoxyisoquinoline-6-carboxamide%2520%2528PF-06650833%2529%252C%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520interleukin-1%2520receptor%2520associated%2520kinase%25204%2520%2528IRAK4%2529%252C%2520by%2520fragment-based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5521%26epage%3D5542%26doi%3D10.1021%2Facs.jmedchem.7b00231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Festjens, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanden Berghe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenabeele, P.</span></span> <span> </span><span class="NLM_article-title">RIP1, a kinase on the crossroads of a cell’s decision to live or die</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">400</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1038/sj.cdd.4402085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fsj.cdd.4402085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=17301840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhslWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=400-410&author=N.+Festjensauthor=T.+Vanden+Bergheauthor=S.+Cornelisauthor=P.+Vandenabeele&title=RIP1%2C+a+kinase+on+the+crossroads+of+a+cell%E2%80%99s+decision+to+live+or+die&doi=10.1038%2Fsj.cdd.4402085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">RIP1, a kinase on the crossroads of a cell's decision to live or die</span></div><div class="casAuthors">Festjens, N.; Vanden Berghe, T.; Cornelis, S.; Vandenabeele, P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">400-410</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Binding of inflammatory cytokines to their receptors, stimulation of pathogen recognition receptors by pathogen-assocd. mol. patterns, and DNA damage induce specific signalling events.  A cell that is exposed to these signals can respond by activation of NF-κB, mitogen-activated protein kinases and interferon regulatory factors, resulting in the upregulation of antiapoptotic proteins and of several cytokines.  The consequent survival may or may not be accompanied by an inflammatory response.  Alternatively, a cell can also activate death-signalling pathways, resulting in apoptosis or alternative cell death such as necrosis or autophagic cell death.  Interplay between survival and death-promoting complexes continues as they compete with each other until one eventually dominates and dets. the cell's fate.  RIP1 is a crucial adaptor kinase on the crossroad of these stress-induced signalling pathways and a cell's decision to live or die.  Following different upstream signals, particular RIP1-contg. complexes are formed; these initiate only a limited no. of cellular responses.  In this review, we describe how RIP1 acts as a key integrator of signalling pathways initiated by stimulation of death receptors, bacterial or viral infection, genotoxic stress and T-cell homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9sr7bI1cyLLVg90H21EOLACvtfcHk0lhxNnW46ODtog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhslWht7k%253D&md5=a51d63f952a07646879bd5fc53ab8524</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4402085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4402085%26sid%3Dliteratum%253Aachs%26aulast%3DFestjens%26aufirst%3DN.%26aulast%3DVanden%2BBerghe%26aufirst%3DT.%26aulast%3DCornelis%26aufirst%3DS.%26aulast%3DVandenabeele%26aufirst%3DP.%26atitle%3DRIP1%252C%2520a%2520kinase%2520on%2520the%2520crossroads%2520of%2520a%2520cell%25E2%2580%2599s%2520decision%2520to%2520live%2520or%2520die%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2007%26volume%3D14%26spage%3D400%26epage%3D410%26doi%3D10.1038%2Fsj.cdd.4402085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelliher, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanger, B. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leder, P.</span></span> <span> </span><span class="NLM_article-title">The death domain kinase RIP mediates the TNF-induced NF-κB signal</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1016/S1074-7613(00)80535-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2FS1074-7613%2800%2980535-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=9529147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK1cXitFGgsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=297-303&author=M.+A.+Kelliherauthor=S.+Grimmauthor=Y.+Ishidaauthor=F.+Kuoauthor=B.+Z.+Stangerauthor=P.+Leder&title=The+death+domain+kinase+RIP+mediates+the+TNF-induced+NF-%CE%BAB+signal&doi=10.1016%2FS1074-7613%2800%2980535-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">The death domain kinase RIP mediates the TNF-induced NF-κB signal</span></div><div class="casAuthors">Kelliher, Michelle A.; Grimm, Stefan; Ishida, Yasumasa; Kuo, Frank; Stanger, Ben Z.; Leder, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-303</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The death domain serine/threonine kinase RIP interacts with the death receptors Fas and tumor necrosis receptor 1 (TNFR1).  In vitro, RIP stimulates apoptosis, SAPK/JNK, and NF-κB activation.  To define the physiol. role(s) that RIP plays in regulating apoptosis in vivo, the authors introduced a rip null mutation in mice through homologous recombination.  RIP-deficient mice appear normal at birth but fail to thrive, displaying extensive apoptosis in both the lymphoid and adipose tissue and dying at 1-3 days of age.  In contrast to a normal thymic anti-Fas response, rip-/- cells are highly sensitive to TNFα-induced cell death.  Sensitivity to TNFα-mediated cell death in rip-/- cells is accompanied by a failure to activate the transcription factor NF-κB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWCMrpO6ha77Vg90H21EOLACvtfcHk0ljS6WEZoEyhrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitFGgsLk%253D&md5=fd4da91b5ae0cb32de05183b0db43d28</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2FS1074-7613%2800%2980535-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-7613%252800%252980535-X%26sid%3Dliteratum%253Aachs%26aulast%3DKelliher%26aufirst%3DM.%2BA.%26aulast%3DGrimm%26aufirst%3DS.%26aulast%3DIshida%26aufirst%3DY.%26aulast%3DKuo%26aufirst%3DF.%26aulast%3DStanger%26aufirst%3DB.%2BZ.%26aulast%3DLeder%26aufirst%3DP.%26atitle%3DThe%2520death%2520domain%2520kinase%2520RIP%2520mediates%2520the%2520TNF-induced%2520NF-%25CE%25BAB%2520signal%26jtitle%3DImmunity%26date%3D1998%26volume%3D8%26spage%3D297%26epage%3D303%26doi%3D10.1016%2FS1074-7613%2800%2980535-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micheau, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschopp, J.</span></span> <span> </span><span class="NLM_article-title">Induction of TNF receptor I-mediated apoptosis <i>via</i> two sequential signaling complexes</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(03)00521-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2FS0092-8674%2803%2900521-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=12887920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvFCgu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2003&pages=181-190&author=O.+Micheauauthor=J.+Tschopp&title=Induction+of+TNF+receptor+I-mediated+apoptosis+via+two+sequential+signaling+complexes&doi=10.1016%2FS0092-8674%2803%2900521-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes</span></div><div class="casAuthors">Micheau, Olivier; Tschopp, Juerg</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-190</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Apoptosis induced by TNF-receptor I (TNFR1) is thought to proceed via recruitment of the adaptor FADD and caspase-8 to the receptor complex.  TNFR1 signaling is also known to activate the transcription factor NF-κB and promote survival.  The mechanism by which this decision between cell death and survival is arbitrated is not clear.  The authors report that TNFR1-induced apoptosis involves two sequential signaling complexes.  The initial plasma membrane bound complex (complex I) consists of TNFR1, the adaptor TRADD, the kinase RIP1, and TRAF2 and rapidly signals activation of NF-κB.  In a second step, TRADD and RIP1 assoc. with FADD and caspase-8, forming a cytoplasmic complex (complex II).  When NF-κB is activated by complex I, complex II harbors the caspase-8 inhibitor FLIPL and the cell survives.  Thus, TNFR1-mediated-signal transduction includes a checkpoint, resulting in cell death (via complex II) in instances where the initial signal (via complex I, NF-κB) fails to be activated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvD_hEcCU4rrVg90H21EOLACvtfcHk0ljS6WEZoEyhrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvFCgu7Y%253D&md5=9aae140d4da012f1ba51ec5f3ac6e934</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2803%2900521-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252803%252900521-X%26sid%3Dliteratum%253Aachs%26aulast%3DMicheau%26aufirst%3DO.%26aulast%3DTschopp%26aufirst%3DJ.%26atitle%3DInduction%2520of%2520TNF%2520receptor%2520I-mediated%2520apoptosis%2520via%2520two%2520sequential%2520signaling%2520complexes%26jtitle%3DCell%26date%3D2003%26volume%3D114%26spage%3D181%26epage%3D190%26doi%3D10.1016%2FS0092-8674%2803%2900521-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campobasso, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capriotti, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dare, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidam, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finger, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparcova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leister, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lich, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellette, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehon, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhaus, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swift, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totoritis, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vossenkamper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisnoski, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquis, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment ofinflammatory Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1261</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01751</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01751" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVeksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1247-1261&author=P.+A.+Harrisauthor=S.+B.+Bergerauthor=J.+U.+Jeongauthor=R.+Nagillaauthor=D.+Bandyopadhyayauthor=N.+Campobassoauthor=C.+A.+Capriottiauthor=J.+A.+Coxauthor=L.+Dareauthor=X.+Dongauthor=P.+M.+Eidamauthor=J.+N.+Fingerauthor=S.+J.+Hoffmanauthor=J.+Kangauthor=V.+Kasparcovaauthor=B.+W.+Kingauthor=R.+Lehrauthor=Y.+Lanauthor=L.+K.+Leisterauthor=J.+D.+Lichauthor=T.+T.+MacDonaldauthor=N.+A.+Millerauthor=M.+T.+Ouelletteauthor=C.+S.+Paoauthor=A.+Rahmanauthor=M.+A.+Reillyauthor=A.+R.+Rendinaauthor=E.+J.+Riveraauthor=M.+C.+Schaefferauthor=C.+A.+Sehonauthor=R.+R.+Singhausauthor=H.+H.+Sunauthor=B.+A.+Swiftauthor=R.+D.+Totoritisauthor=A.+Vossenkamperauthor=P.+Wardauthor=D.+D.+Wisnoskiauthor=D.+Zhangauthor=R.+W.+Marquisauthor=P.+J.+Goughauthor=J.+Bertin&title=Discovery+of+a+first-in-class+receptor+interacting+protein+1+%28RIP1%29+kinase+specific+clinical+candidate+%28GSK2982772%29+for+the+treatment+ofinflammatory+Diseases&doi=10.1021%2Facs.jmedchem.6b01751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases</span></div><div class="casAuthors">Harris, Philip A.; Berger, Scott B.; Jeong, Jae U.; Nagilla, Rakesh; Bandyopadhyay, Deepak; Campobasso, Nino; Capriotti, Carol A.; Cox, Julie A.; Dare, Lauren; Dong, Xiaoyang; Eidam, Patrick M.; Finger, Joshua N.; Hoffman, Sandra J.; Kang, James; Kasparcova, Viera; King, Bryan W.; Lehr, Ruth; Lan, Yunfeng; Leister, Lara K.; Lich, John D.; MacDonald, Thomas T.; Miller, Nathan A.; Ouellette, Michael T.; Pao, Christina S.; Rahman, Attiq; Reilly, Michael A.; Rendina, Alan R.; Rivera, Elizabeth J.; Schaeffer, Michelle C.; Sehon, Clark A.; Singhaus, Robert R.; Sun, Helen H.; Swift, Barbara A.; Totoritis, Rachel D.; Vossenkamper, Anna; Ward, Paris; Wisnoski, David D.; Zhang, Daohua; Marquis, Robert W.; Gough, Peter J.; Bertin, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1247-1261</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">RIP1 regulates necroptosis and inflammation and may play an important role in contributing to a variety of human pathologies, including immune-mediated inflammatory diseases.  Small-mol. inhibitors of RIP1 kinase that are suitable for advancement into the clinic have yet to be described.  Herein, the authors report the lead optimization of a benzoxazepinone hit from a DNA-encoded library and the discovery and profile of clin. candidate GSK2982772 (compd. I), currently in phase 2a clin. studies for psoriasis, rheumatoid arthritis, and ulcerative colitis.  Compd. I potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses.  Highlighting its potential as a novel anti-inflammatory agent, the inhibitor was also able to reduce spontaneous prodn. of cytokines from human ulcerative colitis explants.  The highly favorable physicochem. and ADMET properties of I, combined with high potency, led to a predicted low oral dose in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZGRDTQv-vs7Vg90H21EOLACvtfcHk0ljS6WEZoEyhrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVeksLk%253D&md5=ee0c3c60bb1351dff696490ac9edb1cc</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01751%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DBerger%26aufirst%3DS.%2BB.%26aulast%3DJeong%26aufirst%3DJ.%2BU.%26aulast%3DNagilla%26aufirst%3DR.%26aulast%3DBandyopadhyay%26aufirst%3DD.%26aulast%3DCampobasso%26aufirst%3DN.%26aulast%3DCapriotti%26aufirst%3DC.%2BA.%26aulast%3DCox%26aufirst%3DJ.%2BA.%26aulast%3DDare%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DEidam%26aufirst%3DP.%2BM.%26aulast%3DFinger%26aufirst%3DJ.%2BN.%26aulast%3DHoffman%26aufirst%3DS.%2BJ.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DKasparcova%26aufirst%3DV.%26aulast%3DKing%26aufirst%3DB.%2BW.%26aulast%3DLehr%26aufirst%3DR.%26aulast%3DLan%26aufirst%3DY.%26aulast%3DLeister%26aufirst%3DL.%2BK.%26aulast%3DLich%26aufirst%3DJ.%2BD.%26aulast%3DMacDonald%26aufirst%3DT.%2BT.%26aulast%3DMiller%26aufirst%3DN.%2BA.%26aulast%3DOuellette%26aufirst%3DM.%2BT.%26aulast%3DPao%26aufirst%3DC.%2BS.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DReilly%26aufirst%3DM.%2BA.%26aulast%3DRendina%26aufirst%3DA.%2BR.%26aulast%3DRivera%26aufirst%3DE.%2BJ.%26aulast%3DSchaeffer%26aufirst%3DM.%2BC.%26aulast%3DSehon%26aufirst%3DC.%2BA.%26aulast%3DSinghaus%26aufirst%3DR.%2BR.%26aulast%3DSun%26aufirst%3DH.%2BH.%26aulast%3DSwift%26aufirst%3DB.%2BA.%26aulast%3DTotoritis%26aufirst%3DR.%2BD.%26aulast%3DVossenkamper%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DWisnoski%26aufirst%3DD.%2BD.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMarquis%26aufirst%3DR.%2BW.%26aulast%3DGough%26aufirst%3DP.%2BJ.%26aulast%3DBertin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520first-in-class%2520receptor%2520interacting%2520protein%25201%2520%2528RIP1%2529%2520kinase%2520specific%2520clinical%2520candidate%2520%2528GSK2982772%2529%2520for%2520the%2520treatment%2520ofinflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1247%26epage%3D1261%26doi%3D10.1021%2Facs.jmedchem.6b01751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degterev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Structural basis of RIP1 inhibition by necrostatins</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1016/j.str.2013.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.str.2013.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=23473668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVOqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=493-499&author=T.+Xieauthor=W.+Pengauthor=Y.+Liuauthor=C.+Yanauthor=J.+Makiauthor=A.+Degterevauthor=J.+Yuanauthor=Y.+Shi&title=Structural+basis+of+RIP1+inhibition+by+necrostatins&doi=10.1016%2Fj.str.2013.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of RIP1 Inhibition by Necrostatins</span></div><div class="casAuthors">Xie, Tian; Peng, Wei; Liu, Yexing; Yan, Chuangye; Maki, Jenny; Degterev, Alexei; Yuan, Junying; Shi, Yigong</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">493-499</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Necroptosis is a cellular mechanism that mediates necrotic cell death.  The receptor-interacting serine/threonine protein kinase 1 (RIP1) is an essential upstream signaling mol. in tumor-necrosis-factor-α-induced necroptosis.  Necrostatins, a series of small-mol. inhibitors, suppress necroptosis by specifically inhibiting RIP1 kinase activity.  Both RIP1 structure and the mechanisms by which necrostatins inhibit RIP1 remain unknown.  Here, we report the crystal structures of the RIP1 kinase domain individually bound to necrostatin-1 analog, necrostatin-3 analog, and necrostatin-4.  Necrostatin, caged in a hydrophobic pocket between the N- and C-lobes of the kinase domain, stabilizes RIP1 in an inactive conformation through interactions with highly conserved amino acids in the activation loop and the surrounding structural elements.  Structural comparison of RIP1 with the inhibitor-bound oncogenic kinase B-RAF reveals partially overlapping binding sites for necrostatin and for the anticancer compd. PLX4032.  Our study provides a structural basis for RIP1 inhibition by necrostatins and offers insights into potential structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtw_1OVLFe4rVg90H21EOLACvtfcHk0lhsbck88Igedg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVOqsLk%253D&md5=42a3f8951b390358b9068bb1b885445e</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2013.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2013.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DT.%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DMaki%26aufirst%3DJ.%26aulast%3DDegterev%26aufirst%3DA.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DStructural%2520basis%2520of%2520RIP1%2520inhibition%2520by%2520necrostatins%26jtitle%3DStructure%26date%3D2013%26volume%3D21%26spage%3D493%26epage%3D499%26doi%3D10.1016%2Fj.str.2013.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zitouni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabais, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jana, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettencourt-Dias, M.</span></span> <span> </span><span class="NLM_article-title">Polo-like kinases: structural variations lead to multiple functions</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1038/nrm3819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnrm3819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=24954208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVaisL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=433-452&author=S.+Zitouniauthor=C.+Nabaisauthor=S.+C.+Janaauthor=A.+Guerreroauthor=M.+Bettencourt-Dias&title=Polo-like+kinases%3A+structural+variations+lead+to+multiple+functions&doi=10.1038%2Fnrm3819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Polo-like kinases: structural variations lead to multiple functions</span></div><div class="casAuthors">Zitouni, Sihem; Nabais, Catarina; Jana, Swadhin Chandra; Guerrero, Adan; Bettencourt-Dias, Monica</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">433-452</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Members of the polo-like kinase (PLK) family are crucial regulators of cell cycle progression, centriole duplication, mitosis, cytokinesis and the DNA damage response.  PLKs undergo major changes in abundance, activity, localization and structure at different stages of the cell cycle.  They interact with other proteins in a tightly controlled spatiotemporal manner as part of a network that coordinates key cell cycle events.  Their essential roles are highlighted by the fact that alterations in PLK function are assocd. with cancers and other diseases.  Recent knowledge gained from PLK crystal structures, evolution and interacting mols. offers important insights into the mechanisms that underlie their regulation and activity, and suggests novel functions unrelated to cell cycle control for this family of kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaF-mmmGZrt7Vg90H21EOLACvtfcHk0lhsbck88Igedg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVaisL7P&md5=c4201eea6cece3b31094e823e188ce10</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fnrm3819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3819%26sid%3Dliteratum%253Aachs%26aulast%3DZitouni%26aufirst%3DS.%26aulast%3DNabais%26aufirst%3DC.%26aulast%3DJana%26aufirst%3DS.%2BC.%26aulast%3DGuerrero%26aufirst%3DA.%26aulast%3DBettencourt-Dias%26aufirst%3DM.%26atitle%3DPolo-like%2520kinases%253A%2520structural%2520variations%2520lead%2520to%2520multiple%2520functions%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D433%26epage%3D452%26doi%3D10.1038%2Fnrm3819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. A.</span></span> <span> </span><span class="NLM_article-title">Polo-like kinases (plks), a key regulator of cell cycle and new potential target for cancer therapy</span>. <i>Dev. Reprod.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.12717/DR.2014.18.1.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.12717%2FDR.2014.18.1.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=25949173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A280%3ADC%252BC2MfhsFylsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=65-71&author=S.+Y.+Leeauthor=C.+Jangauthor=K.+A.+Lee&title=Polo-like+kinases+%28plks%29%2C+a+key+regulator+of+cell+cycle+and+new+potential+target+for+cancer+therapy&doi=10.12717%2FDR.2014.18.1.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Polo-like kinases (plks), a key regulator of cell cycle and new potential target for cancer therapy</span></div><div class="casAuthors">Lee Su-Yeon; Jang Chuljoon; Lee Kyung-Ah</div><div class="citationInfo"><span class="NLM_cas:title">Development & reproduction</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-71</span>
        ISSN:<span class="NLM_cas:issn">2465-9525</span>.
    </div><div class="casAbstract">Cell cycle process is regulated by a number of protein kinases and among them, serine/threonine kinases carry phosphate group from ATP to substrates.  The most important three kinase families are Cyclin-dependent kinase (Cdk), Polo-like kinase (Plk), and Aurora kinase.  Polo-like kinase family consists of 5 members (Plk1-Plk5) and they are involved in multiple functions in eukaryotic cell division.  It regulates a variety of aspects such as, centrosome maturation, checkpoint recovery, spindle assembly, cytokinesis, apoptosis and many other features.  Recently, it has been reported that Plks are related to tumor development and over-expressed in many kinds of tumor cells.  When injected the anti-Plk antibody into human cells, the cells show aneuploidy, and if inhibit Plks, most of the mitotic cell division does not proceed properly.  For that reasons, many inhibitors of Plk have been recently emerged as new target for remedy of the cancer therapeutic research.  In this paper, we reviewed briefly the characteristics of Plk families and how Plks work in regulating cell cycles and cancer formation, and the possibilities of Plks as target for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTu8gBlm77WhNy3lHz94U-GfW6udTcc2eYjAiqZwQExO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfhsFylsQ%253D%253D&md5=9d0b3d34e9e81f920fa25cbc8251d70f</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.12717%2FDR.2014.18.1.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12717%252FDR.2014.18.1.065%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DJang%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DK.%2BA.%26atitle%3DPolo-like%2520kinases%2520%2528plks%2529%252C%2520a%2520key%2520regulator%2520of%2520cell%2520cycle%2520and%2520new%2520potential%2520target%2520for%2520cancer%2520therapy%26jtitle%3DDev.%2520Reprod.%26date%3D2014%26volume%3D18%26spage%3D65%26epage%3D71%26doi%3D10.12717%2FDR.2014.18.1.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emmitte, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjebeng, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberti, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bambal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis-Ward, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassler, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornberger, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansing, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mook, R. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nailor, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pobanz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M.</span></span> <span> </span><span class="NLM_article-title">Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1694</span>– <span class="NLM_lpage">1697</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.01.094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2009.01.094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=19237286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVSltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1694-1697&author=K.+A.+Emmitteauthor=G.+M.+Adjebengauthor=C.+W.+Andrewsauthor=J.+G.+Albertiauthor=R.+Bambalauthor=S.+D.+Chamberlainauthor=R.+G.+Davis-Wardauthor=H.+D.+Dicksonauthor=D.+F.+Hasslerauthor=K.+R.+Hornbergerauthor=J.+R.+Jacksonauthor=K.+W.+Kuntzauthor=T.+J.+Lansingauthor=R.+A.+Mookauthor=K.+E.+Nailorauthor=M.+A.+Pobanzauthor=S.+C.+Smithauthor=C.+M.+Sungauthor=M.+Cheung&title=Design+of+potent+thiophene+inhibitors+of+polo-like+kinase+1+with+improved+solubility+and+reduced+protein+binding&doi=10.1016%2Fj.bmcl.2009.01.094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding</span></div><div class="casAuthors">Emmitte, Kyle A.; Adjebang, George M.; Andrews, C. Webb; Badiang-Alberti, Jennifer G.; Bambal, Ramesh; Chamberlain, Stanley D.; Davis-Ward, Ronda G.; Dickson, Hamilton D.; Hassler, Daniel F.; Hornberger, Keith R.; Jackson, Jeffrey R.; Kuntz, Kevin W.; Lansing, Timothy J.; Mook, Robert A.; Nailor, Kristen E.; Pobanz, Mark A.; Smith, Stephon C.; Sung, Chiu-Mei; Cheung, Mui</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1694-1697</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of thiophene PLK1 inhibitors was optimized for increased soly. and reduced protein binding through the appendage of basic amine functionality.  Interesting selectivity between PLK1 and PLK3 was also obtained through these modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLrXXbB1J4-rVg90H21EOLACvtfcHk0ljcPno1jWWWNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVSltrY%253D&md5=30831c589bae973ca9267dfea68971e1</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.01.094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.01.094%26sid%3Dliteratum%253Aachs%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DAdjebeng%26aufirst%3DG.%2BM.%26aulast%3DAndrews%26aufirst%3DC.%2BW.%26aulast%3DAlberti%26aufirst%3DJ.%2BG.%26aulast%3DBambal%26aufirst%3DR.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DDavis-Ward%26aufirst%3DR.%2BG.%26aulast%3DDickson%26aufirst%3DH.%2BD.%26aulast%3DHassler%26aufirst%3DD.%2BF.%26aulast%3DHornberger%26aufirst%3DK.%2BR.%26aulast%3DJackson%26aufirst%3DJ.%2BR.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DLansing%26aufirst%3DT.%2BJ.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DNailor%26aufirst%3DK.%2BE.%26aulast%3DPobanz%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DS.%2BC.%26aulast%3DSung%26aufirst%3DC.%2BM.%26aulast%3DCheung%26aufirst%3DM.%26atitle%3DDesign%2520of%2520potent%2520thiophene%2520inhibitors%2520of%2520polo-like%2520kinase%25201%2520with%2520improved%2520solubility%2520and%2520reduced%2520protein%2520binding%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1694%26epage%3D1697%26doi%3D10.1016%2Fj.bmcl.2009.01.094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Signalling through the lipid products of phosphoinositide-3-OH kinase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1038/42648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2F42648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=9192891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADyaK2sXktVWgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=1997&pages=673-676&author=A.+Tokerauthor=L.+C.+Cantley&title=Signalling+through+the+lipid+products+of+phosphoinositide-3-OH+kinase&doi=10.1038%2F42648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling through the lipid products of phosphoinositide-3-OH kinase</span></div><div class="casAuthors">Toker, Alex; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">6634</span>),
    <span class="NLM_cas:pages">673-676</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">A review, with 47 refs.  When a stimulatory agonist mol. binds at the exterior of the cell membrane, a second messenger transduces the signal to the interior of the cell.  Second messengers can be derived from phospholipids in the membrane by the action of the enzymes phospholipase C or phosphoinositide-3-OH kinase (PI(3)K).  PI(3)K is a key player in many cellular responses, including the movement of organelle membranes, shape alteration through rearrangement of cytoskeletal actin, transformation and chemotaxis.  But how PI(3)K mediates these responses is only now becoming clear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbe14cub5uAbVg90H21EOLACvtfcHk0ljcPno1jWWWNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktVWgt7c%253D&md5=9c0d3fdb3a9a10027050c09ed3def89a</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2F42648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F42648%26sid%3Dliteratum%253Aachs%26aulast%3DToker%26aufirst%3DA.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DSignalling%2520through%2520the%2520lipid%2520products%2520of%2520phosphoinositide-3-OH%2520kinase%26jtitle%3DNature%26date%3D1997%26volume%3D387%26spage%3D673%26epage%3D676%26doi%3D10.1038%2F42648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span> <span> </span><span class="NLM_article-title">PI3K and cancer: lessons, challenges and opportunities</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1038/nrd4204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnrd4204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=24481312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=140-156&author=D.+A.+Frumanauthor=C.+Rommel&title=PI3K+and+cancer%3A+lessons%2C+challenges+and+opportunities&doi=10.1038%2Fnrd4204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and cancer: lessons, challenges and opportunities</span></div><div class="casAuthors">Fruman, David A.; Rommel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-156</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The central role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biol. has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and mammalian target of rapamycin (mTOR) in cancer.  However, emerging clin. data show limited single-agent activity of inhibitors targeting PI3K, AKT or mTOR at tolerated doses.  One exception is the response to PI3Kδ inhibitors in chronic lymphocytic leukemia, where a combination of cell-intrinsic and -extrinsic activities drive efficacy.  Here, we review key challenges and opportunities for the clin. development of inhibitors targeting the PI3K-AKT-mTOR pathway.  Through a greater focus on patient selection, increased understanding of immune modulation and strategic application of rational combinations, it should be possible to realize the potential of this promising class of targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlD2rY54m9LbVg90H21EOLACvtfcHk0ljcPno1jWWWNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D&md5=c4f6b4b9f9fcacd6ef55eb17d3a4f425</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Fnrd4204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4204%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DPI3K%2520and%2520cancer%253A%2520lessons%252C%2520challenges%2520and%2520opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D140%26epage%3D156%26doi%3D10.1038%2Fnrd4204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jean, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiger, A. A.</span></span> <span> </span><span class="NLM_article-title">Classes of phosphoinositide 3-kinases at a glance</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1242/jcs.093773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1242%2Fjcs.093773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=24587488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Smtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2014&pages=923-928&author=S.+Jeanauthor=A.+A.+Kiger&title=Classes+of+phosphoinositide+3-kinases+at+a+glance&doi=10.1242%2Fjcs.093773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Classes of phosphoinositide 3-kinases at a glance</span></div><div class="casAuthors">Jean, Steve; Kiger, Amy A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">923-928</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) family is important to nearly all aspects of cell and tissue biol. and central to human cancer, diabetes and aging.  PI3Ks are spatially regulated and multifunctional, and together, act at nearly all membranes in the cell to regulate a wide range of signaling, membrane trafficking and metabolic processes.  There is a broadening recognition of the importance of distinct roles for each of the three different PI3K classes (I, II and III), as well as for the different isoforms within each class.  Ongoing issues include the need for a better understanding of the in vivo complexity of PI3K regulation and cellular functions.  This Cell Science at a Glance article and the accompanying poster summarize the biochem. activities, cellular roles and functional requirements for the three classes of PI3Ks.  In doing so, we aim to provide an overview of the parallels, the key differences and crucial interplays between the regulation and roles of the three PI3K classes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWxYxoaZNkirVg90H21EOLACvtfcHk0lgTJ2Kj2zCyBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Smtbk%253D&md5=52e183f6c434e5a0eaa266c5b8c520b2</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1242%2Fjcs.093773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.093773%26sid%3Dliteratum%253Aachs%26aulast%3DJean%26aufirst%3DS.%26aulast%3DKiger%26aufirst%3DA.%2BA.%26atitle%3DClasses%2520of%2520phosphoinositide%25203-kinases%2520at%2520a%2520glance%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2014%26volume%3D127%26spage%3D923%26epage%3D928%26doi%3D10.1242%2Fjcs.093773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, D.</span></span> <span> </span><span class="NLM_article-title">Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2016.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.apsb.2016.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=28119806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ovFOrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=27-37&author=W.+Zhaoauthor=Y.+Qiuauthor=D.+Kong&title=Class+I+phosphatidylinositol+3-kinase+inhibitors+for+cancer+therapy&doi=10.1016%2Fj.apsb.2016.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy</span></div><div class="casAuthors">Zhao Wennan; Qiu Yuling; Kong Dexin</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-37</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in human cancers.  Class I PI3Ks are lipid kinases that phosphorylate phosphatidylinositol 4,5-bisphosphate (PIP2) at the 3-OH of the inositol ring to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3), which in turn activates Akt and the downstream effectors like mammalian target of rapamycin (mTOR) to play key roles in carcinogenesis.  Therefore, PI3K has become an important anticancer drug target, and currently there is very high interest in the pharmaceutical development of PI3K inhibitors.  Idelalisib has been approved in USA and Europe as the first-in-class PI3K inhibitor for cancer therapy.  Dozens of other PI3K inhibitors including BKM120 and ZSTK474 are being evaluated in clinical trials.  Multifaceted studies on these PI3K inhibitors are being performed, such as single and combinational efficacy, resistance, biomarkers, etc.  This review provides an introduction to PI3K and summarizes key advances in the development of PI3K inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfpaqoNC7CEjAyhZbj3lKdfW6udTcc2eaQZPamrU1kIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ovFOrsg%253D%253D&md5=9506d6088eb6f72dc579ece97bb19930</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2016.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2016.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DD.%26atitle%3DClass%2520I%2520phosphatidylinositol%25203-kinase%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2017%26volume%3D7%26spage%3D27%26epage%3D37%26doi%3D10.1016%2Fj.apsb.2016.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chalhoub, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span> <span> </span><span class="NLM_article-title">PTEN and the PI3-kinase pathway in cancer</span>. <i>Annu. Rev. Pathol.: Mech. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1146/annurev.pathol.4.110807.092311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1146%2Fannurev.pathol.4.110807.092311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=18767981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1aiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=127-150&author=N.+Chalhoubauthor=S.+J.+Baker&title=PTEN+and+the+PI3-kinase+pathway+in+cancer&doi=10.1146%2Fannurev.pathol.4.110807.092311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">PTEN and the PI3-kinase pathway in cancer</span></div><div class="casAuthors">Chalhoub, Nader; Baker, Suzanne J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pathology: Mechanisms of Disease</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-150</span>CODEN:
                <span class="NLM_cas:coden">ARPMCU</span>;
        ISSN:<span class="NLM_cas:issn">1553-4006</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  PI3-kinase and PTEN are major pos. and neg. regulators, resp., of the PI3-kinase pathway, which regulates growth, survival, and proliferation.  These key signaling components are two of the most frequently mutated proteins in human cancers, resulting in unregulated activation of PI3K signaling and providing irrefutable genetic evidence of the central role of this pathway in tumorigenesis.  PTEN regulates PI3K signaling by dephosphorylating the lipid signaling intermediate PIP3, but PTEN may have addnl. phosphatase-independent activities, as well as other functions in the nucleus.  In this review, we highlight current work showing cancer-relevant complexities in the regulation of PTEN and PI3K activity, potential novel functions for PTEN, and feedback regulation within the pathway.  The significance and complexity of PI3K signaling make it an important but challenging therapeutic target for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYL7OEFJS0L7Vg90H21EOLACvtfcHk0lgTJ2Kj2zCyBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1aiu78%253D&md5=3a85209dd4803ce16557d4cdafc51613</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pathol.4.110807.092311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pathol.4.110807.092311%26sid%3Dliteratum%253Aachs%26aulast%3DChalhoub%26aufirst%3DN.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26atitle%3DPTEN%2520and%2520the%2520PI3-kinase%2520pathway%2520in%2520cancer%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2009%26volume%3D4%26spage%3D127%26epage%3D150%26doi%3D10.1146%2Fannurev.pathol.4.110807.092311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span> <i>FDA Approves Zydelig (idelalisib) for CLL and
Lymphoma</i>; <span class="NLM_publisher-name">Drugs.com</span>, <span class="NLM_year">2014</span>; <a href="https://www.drugs.com/newdrugs/fda-approves-zydelig-idelalisib-cll-lymphoma-4056.html" class="extLink">https://www.drugs.com/newdrugs/fda-approves-zydelig-idelalisib-cll-lymphoma-4056.html</a> (accessed Aug 23, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+Zydelig+%28idelalisib%29+for+CLL+and%0ALymphoma%3B+Drugs.com%2C+2014%3B+https%3A%2F%2Fwww.drugs.com%2Fnewdrugs%2Ffda-approves-zydelig-idelalisib-cll-lymphoma-4056.html+%28accessed+Aug+23%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520Zydelig%2520%2528idelalisib%2529%2520for%2520CLL%2520and%250ALymphoma%26pub%3DDrugs.com%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buitenhuis, M.</span></span> <span> </span><span class="NLM_article-title">The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">911</span>– <span class="NLM_lpage">923</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-07-366203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1182%2Fblood-2011-07-366203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22065598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XitVKqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=911-923&author=R.+Polakauthor=M.+Buitenhuis&title=The+PI3K%2FPKB+signaling+module+as+key+regulator+of+hematopoiesis%3A+implications+for+therapeutic+strategies+in+leukemia&doi=10.1182%2Fblood-2011-07-366203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia</span></div><div class="casAuthors">Polak, Roel; Buitenhuis, Miranda</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">911-923</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  An important mediator of cytokine signaling implicated in regulation of hematopoiesis is the PI3K/protein kinase B (PKB/c-Akt) signaling module.  Constitutive activation of this signaling module was obsd. in a large group of leukemias.  Because activation of this signaling pathway was demonstrated to be sufficient to induce hematol. malignancies and is thought to correlate with poor prognosis and enhanced drug resistance, it is considered to be a promising target for therapy.  A high no. of pharmacol. inhibitors directed against either individual or multiple components of this pathway have already been developed to improve therapy.  In this review, the safety and efficacy of both single and dual-specificity inhibitors will be discussed as well as the potential of combination therapy with either inhibitors directed against other signal transduction mols. or classic chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPVWKYSyAgjrVg90H21EOLACvtfcHk0lgTJ2Kj2zCyBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitVKqt70%253D&md5=dd01c2d662a6b1efc919d293fdf589a3</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-07-366203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-07-366203%26sid%3Dliteratum%253Aachs%26aulast%3DPolak%26aufirst%3DR.%26aulast%3DBuitenhuis%26aufirst%3DM.%26atitle%3DThe%2520PI3K%252FPKB%2520signaling%2520module%2520as%2520key%2520regulator%2520of%2520hematopoiesis%253A%2520implications%2520for%2520therapeutic%2520strategies%2520in%2520leukemia%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D911%26epage%3D923%26doi%3D10.1182%2Fblood-2011-07-366203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelisti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaldi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCubrey, J. A.</span></span> <span> </span><span class="NLM_article-title">The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1576</span>– <span class="NLM_lpage">1596</span>, <span class="refDoi"> DOI: 10.3390/cancers2031576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.3390%2Fcancers2031576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=24281174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVKqsb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=1576-1596&author=A.+M.+Martelliauthor=C.+Evangelistiauthor=F.+Chiariniauthor=C.+Grimaldiauthor=J.+A.+McCubrey&title=The+emerging+role+of+the+phosphatidylinositol+3-kinase%2F+akt%2Fmammalian+target+of+rapamycin+signaling+network+in+cancer+stem+cell+biology&doi=10.3390%2Fcancers2031576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cell biology</span></div><div class="casAuthors">Martelli, Alberto M.; Evangelisti, Camilla; Chiarini, Francesca; Grimaldi, Cecilia; McCubrey, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1576-1596</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  The cancer stem cell theory entails the existence of a hierarchically organized, rare population of cells which are responsible for tumor initiation, self-renewal/maintenance, and mutation accumulation.  The cancer stem cell proposition could explain the high frequency of cancer relapse and resistance to currently available therapies.  The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway regulates a wide array of physiol. cell functions which include differentiation, proliferation, survival, metab., autophagy, and motility.  Dysregulated PI3K/Akt/mTOR signaling has been documented in many types of neoplasias.  It is now emerging that this signaling network plays a key role in cancer stem cell biol.  Interestingly, cancer stem cells displayed preferential sensitivity to pathway inhibition when compared to healthy stem cells.  This observation provides the proof-of-principle that functional differences in signaling pathways between neoplastic stem cells and healthy stem cells could be identified.  In this review, we present the evidence which links the signals emanating from the PI3K/Akt/mTOR cascade with the functions of cancer stem cells, both in solid and hematol. tumors.  We then highlight how targeting PI3K/Akt/mTOR signaling with small mols. could improve cancer patient outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoopiE6kAtVrbVg90H21EOLACvtfcHk0ljIYrrfc7cbFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVKqsb3P&md5=162774f3695a5ea8fedac291d46c4e8c</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.3390%2Fcancers2031576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers2031576%26sid%3Dliteratum%253Aachs%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26aulast%3DEvangelisti%26aufirst%3DC.%26aulast%3DChiarini%26aufirst%3DF.%26aulast%3DGrimaldi%26aufirst%3DC.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520emerging%2520role%2520of%2520the%2520phosphatidylinositol%25203-kinase%252F%2520akt%252Fmammalian%2520target%2520of%2520rapamycin%2520signaling%2520network%2520in%2520cancer%2520stem%2520cell%2520biology%26jtitle%3DCancers%26date%3D2010%26volume%3D2%26spage%3D1576%26epage%3D1596%26doi%3D10.3390%2Fcancers2031576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meadows, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashishian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span> <span> </span><span class="NLM_article-title">PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of hodgkin lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1897</span>– <span class="NLM_lpage">1900</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-10-386763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1182%2Fblood-2011-10-386763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22210877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2lsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=1897-1900&author=S.+A.+Meadowsauthor=F.+Vegaauthor=A.+Kashishianauthor=D.+Johnsonauthor=V.+Diehlauthor=L.+L.+Millerauthor=A.+Younesauthor=B.+J.+Lannutti&title=PI3Kdelta+inhibitor%2C+GS-1101+%28CAL-101%29%2C+attenuates+pathway+signaling%2C+induces+apoptosis%2C+and+overcomes+signals+from+the+microenvironment+in+cellular+models+of+hodgkin+lymphoma&doi=10.1182%2Fblood-2011-10-386763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma</span></div><div class="casAuthors">Meadows, Sarah A.; Vega, Francisco; Kashishian, Adam; Johnson, Dave; Diehl, Volker; Miller, Langdon L.; Younes, Anas; Lannutti, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1897-1900</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">GS-1101 (CAL-101) is an oral PI3Kδ-specific inhibitor that has shown preclin. and clin. activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.  To investigate the potential role of PI3Kδ in Hodgkin lymphoma (HL), we screened 5 HL cell lines and primary samples from patients with HL for PI3Kδ isoform expression and constitutive PI3K pathway activation.  Inhibition of PI3Kδ by GS-1101 resulted in the inhibition of Akt phosphorylation.  Cocultures with stroma cells induced Akt activation in HL cells, and this effect was blocked by GS-1101.  Conversely, prodn. of the stroma-stimulating chemokine, CCL5, by HL cells was reduced by GS-1101.  GS-1101 also induced dose-dependent apoptosis of HL cells at 48 h.  Redns. in cell viability and apoptosis were enhanced when combining GS-1101 with the mTOR inhibitor everolimus.  Our findings suggest that excessive PI3Kδ activity is characteristic in HL and support clin. evaluation of GS-1101, alone and in combination, as targeted therapy for HL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZzwmb3X6oQ7Vg90H21EOLACvtfcHk0ljIYrrfc7cbFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2lsrg%253D&md5=cee2562ed9ede3dfaa32ef6055f6580a</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-10-386763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-10-386763%26sid%3Dliteratum%253Aachs%26aulast%3DMeadows%26aufirst%3DS.%2BA.%26aulast%3DVega%26aufirst%3DF.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DDiehl%26aufirst%3DV.%26aulast%3DMiller%26aufirst%3DL.%2BL.%26aulast%3DYounes%26aufirst%3DA.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26atitle%3DPI3Kdelta%2520inhibitor%252C%2520GS-1101%2520%2528CAL-101%2529%252C%2520attenuates%2520pathway%2520signaling%252C%2520induces%2520apoptosis%252C%2520and%2520overcomes%2520signals%2520from%2520the%2520microenvironment%2520in%2520cellular%2520models%2520of%2520hodgkin%2520lymphoma%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D1897%26epage%3D1900%26doi%3D10.1182%2Fblood-2011-10-386763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masinovsky, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowell, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staunton, D. E.</span></span> <span> </span><span class="NLM_article-title">Essential role of phosphoinositide 3-kinase in neutrophil directional movement</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">2647</span>– <span class="NLM_lpage">2654</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.170.5.2647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.4049%2Fjimmunol.170.5.2647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=12594293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht12htLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2003&pages=2647-2654&author=C.+Sadhuauthor=B.+Masinovskyauthor=K.+Dickauthor=C.+G.+Sowellauthor=D.+E.+Staunton&title=Essential+role+of+phosphoinositide+3-kinase+in+neutrophil+directional+movement&doi=10.4049%2Fjimmunol.170.5.2647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Essential Role of Phosphoinositide 3-Kinase δ in Neutrophil Directional Movement</span></div><div class="casAuthors">Sadhu, Chanchal; Masinovsky, Boris; Dick, Ken; Sowell, C. Gregory; Staunton, Donald E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2647-2654</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Neutrophil chemotaxis is a crit. component of the innate immune response.  Neutrophils can sense an extremely shallow gradient of chemoattractants and produce relatively robust chemotactic behavior.  This directional migration requires cell polarization with actin polymn. occurring predominantly in the leading edge.  Synthesis of phosphatidylinositol (3,4,5) trisphosphate (PIP3) by phosphoinositide 3-kinase (PI3K) contributes to asym. F-actin synthesis and cell polarization during neutrophil chemotaxis.  To det. the contribution of the hemopoietic cell-restricted PI3Kδ in neutrophil chemotaxis, the authors have developed a potent and selective PI3Kδ inhibitor, IC87114.  IC87114 inhibited polarized morphol. of neutrophils, fMLP-stimulated PIP3 prodn. and chemotaxis.  Tracking anal. of IC87114-treated neutrophils indicated that PI3Kδ activity was required for the directional component of chemotaxis, but not for random movement.  Inhibition of PI3Kδ, however, did not block F-actin synthesis or neutrophil adhesion.  Thus, PI3Kδ can play a selective role in the amplification of PIP3 levels that lead to neutrophil polarization and directional migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc4QZDaVi8b7Vg90H21EOLACvtfcHk0ljIYrrfc7cbFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht12htLY%253D&md5=bc8815df15bc87d89f4df86a62f68cfa</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.170.5.2647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.170.5.2647%26sid%3Dliteratum%253Aachs%26aulast%3DSadhu%26aufirst%3DC.%26aulast%3DMasinovsky%26aufirst%3DB.%26aulast%3DDick%26aufirst%3DK.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DStaunton%26aufirst%3DD.%2BE.%26atitle%3DEssential%2520role%2520of%2520phosphoinositide%25203-kinase%2520in%2520neutrophil%2520directional%2520movement%26jtitle%3DJ.%2520Immunol.%26date%3D2003%26volume%3D170%26spage%3D2647%26epage%3D2654%26doi%3D10.4049%2Fjimmunol.170.5.2647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berndt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, D. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houseman, B. T</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacold, J. I</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorrec, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hon, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaillard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, M. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, J. P</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L</span></span> <span> </span><span class="NLM_article-title">The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1038/nchembio.293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnchembio.293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=20081827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFGrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=117-124&author=A.+Berndtauthor=S.+Millerauthor=O.+Williamsauthor=D.+D+Leauthor=B.+T+Housemanauthor=J.+I+Pacoldauthor=F.+Gorrecauthor=W.-C.+Honauthor=P.+Renauthor=Y.+Liuauthor=C.+Rommelauthor=P.+Gaillardauthor=T.+Ruckleauthor=M.+K+Schwarzauthor=K.+M+Shokatauthor=J.+P+Shawauthor=R.+L+Williams&title=The+p110+delta+structure%3A+mechanisms+for+selectivity+and+potency+of+new+PI%283%29K+inhibitors&doi=10.1038%2Fnchembio.293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors</span></div><div class="casAuthors">Berndt, Alex; Miller, Simon; Williams, Olusegun; Le, Daniel D.; Houseman, Benjamin T.; Pacold, Joseph I.; Gorrec, Fabrice; Hon, Wai-Ching; Liu, Yi; Rommel, Christian; Gaillard, Pascale; Rueckle, Thomas; Schwarz, Matthias K.; Shokat, Kevan M.; Shaw, Jeffrey P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-124</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Deregulation of the phosphoinositide-3-OH kinase (PI(3)K) pathway has been implicated in numerous pathologies including cancer, diabetes, thrombosis, rheumatoid arthritis, and asthma.  Recently, small-mol. and ATP-competitive PI(3)K inhibitors with a wide range of selectivities have entered clin. development.  To understand the mechanisms underlying the isoform selectivity of these inhibitors, we developed a new expression strategy that enabled us to det. to our knowledge the first crystal structure of the catalytic subunit of the class IA PI(3)K p110δ.  Structures of this enzyme in complex with a broad panel of isoform- and pan-selective class I PI(3)K inhibitors reveal that selectivity toward p110δ can be achieved by exploiting its conformational flexibility and the sequence diversity of active site residues that do not contact ATP.  We have used these observations to rationalize and synthesize highly selective inhibitors for p110δ with greatly improved potencies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL8d01cEl_y7Vg90H21EOLACvtfcHk0ljVMz-kkQuIQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFGrsw%253D%253D&md5=8a0ce73ab8ca88ea9a48a2cb7fdb1975</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.293%26sid%3Dliteratum%253Aachs%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLe%26aufirst%3DD.%2BD%26aulast%3DHouseman%26aufirst%3DB.%2BT%26aulast%3DPacold%26aufirst%3DJ.%2BI%26aulast%3DGorrec%26aufirst%3DF.%26aulast%3DHon%26aufirst%3DW.-C.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DGaillard%26aufirst%3DP.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DSchwarz%26aufirst%3DM.%2BK%26aulast%3DShokat%26aufirst%3DK.%2BM%26aulast%3DShaw%26aufirst%3DJ.%2BP%26aulast%3DWilliams%26aufirst%3DR.%2BL%26atitle%3DThe%2520p110%2520delta%2520structure%253A%2520mechanisms%2520for%2520selectivity%2520and%2520potency%2520of%2520new%2520PI%25283%2529K%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D117%26epage%3D124%26doi%3D10.1038%2Fnchembio.293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcomb, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, V.</span></span> <span> </span><span class="NLM_article-title">Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1537</span>– <span class="NLM_lpage">1542</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1158%2F1078-0432.CCR-14-2034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=25670221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVahsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1537-1542&author=Q.+Yangauthor=P.+Modiauthor=T.+Newcombauthor=C.+Quevaauthor=V.+Gandhi&title=Idelalisib%3A+first-in-class+PI3K+delta+inhibitor+for+the+treatment+of+chronic+lymphocytic+leukemia%2C+small+lymphocytic+leukemia%2C+and+follicular+lymphoma&doi=10.1158%2F1078-0432.CCR-14-2034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma</span></div><div class="casAuthors">Yang, Qingshan; Modi, Prexy; Newcomb, Terry; Queva, Christophe; Gandhi, Varsha</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1537-1542</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Idelalisib [Zydelig (Gilead Sciences, Inc.), also known as CAL-101 and GS-1101] was approved in 2014 in the United States and European Union for the treatment of three indolent B-cell neoplasms: relapsed/refractory chronic lymphocytic leukemia (CLL, in combination with rituximab), relapsed follicular lymphoma, and relapsed small lymphocytic lymphoma (as monotherapy).  Furthermore, it was approved in the European Union as first-line therapy for poor-prognosis CLL with 17p deletions or TP53 mutations and in patients unsuitable for chemoimmunotherapy.  Idelalisib is an orally bioavailable ATP-competitive kinase inhibitor that targets the PI3K p110 isoform δ (PI3Kδ) with high potency and selectivity.  PI3Kδ is hyperactivated in B-cell malignancies and plays a pivotal role in the B-cell receptor pathway, a key oncogenic driver in B-cell malignancies.  The near exclusive expression of the PI3Kδ isoform in hematopoietic cells and the selectivity of idelalisib for the PI3Kδ isoform are essential for its efficacy and tolerability, even in elderly patients unfit for chemotherapy.  Idelalisib is the first PI3K inhibitor approved by the regulatory agencies; this approval will change the treatment landscape of indolent B-cell malignancies.  Clin Cancer Res; 21(7); 1537-42. ©2015 AACR.  See related article by Miller et al., p.  1525.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNvlp-jsFsjbVg90H21EOLACvtfcHk0ljVMz-kkQuIQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVahsrk%253D&md5=1cd89cd74f7f60a61303aa037c2a54a0</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2034%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DModi%26aufirst%3DP.%26aulast%3DNewcomb%26aufirst%3DT.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DGandhi%26aufirst%3DV.%26atitle%3DIdelalisib%253A%2520first-in-class%2520PI3K%2520delta%2520inhibitor%2520for%2520the%2520treatment%2520of%2520chronic%2520lymphocytic%2520leukemia%252C%2520small%2520lymphocytic%2520leukemia%252C%2520and%2520follicular%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1537%26epage%3D1542%26doi%3D10.1158%2F1078-0432.CCR-14-2034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Do, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mace, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rexwinkle, A.</span></span> <span> </span><span class="NLM_article-title">Idelalisib for treatment of B-cell malignancies</span>. <i>Am. J. Health-Syst. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.2146/ajhp150281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.2146%2Fajhp150281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=26933132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVOht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2016&pages=547-555&author=B.+Doauthor=M.+Maceauthor=A.+Rexwinkle&title=Idelalisib+for+treatment+of+B-cell+malignancies&doi=10.2146%2Fajhp150281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Idelalisib for treatment of B-cell malignancies</span></div><div class="casAuthors">Do, Bryan; Mace, Morgan; Rexwinkle, Amber</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Health-System Pharmacy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">547-555</span>CODEN:
                <span class="NLM_cas:coden">AHSPEK</span>;
        ISSN:<span class="NLM_cas:issn">1079-2082</span>.
    
            (<span class="NLM_cas:orgname">American Society of Health-System Pharmacists</span>)
        </div><div class="casAbstract">Purpose The pharmacol., pharmacokinetics, clin. efficacy, safety and tolerability, dosing and administration, and place in therapy of idelalisib, a targeted therapy for certain types of non-Hodgkin's lymphoma (NHL), are reviewed.  Summary Historically, conventional cancer chemotherapy agents were recommended for the management of progressive lymphomas requiring systemic treatment; in recent years, however, emerging targeted therapies have altered the landscape of lymphoma treatment.  Idelalisib, a novel oral phosphatidylinositol 3-kinase (PI3K) inhibitor, disrupts downstream signaling pathways involved in cancer cell growth and survival.  Inhibition of PI3K has been demonstrated to produce durable treatment responses and improved survival outcomes in clin. trials involving patients with indolent forms of NHL.  Idelalisib is indicated for use in combination with rituximab for treatment of relapsed chronic lymphocytic leukemia (CLL) and as monotherapy for relapsed small lymphocytic leukemia and follicular lymphoma after the failure of at least two systemic treatments.  The recommended dosage of idelalisib is 150 mg orally twice daily; the medication can be taken without regard to mealtimes.  The most common adverse effects of idelalisib include diarrhea, nausea, fatigue, cough, and pyrexia.  Severe hepatotoxicity and gastrointestinal toxicities, including colitis and intestinal perforation, have also been reported in assocn. with idelalisib use.  Ongoing clin. studies are exploring the potential for expanded use of idelalisib in the management of other B-cell malignancies.  Conclusion Idelalisib is a well-tolerated and effective treatment for patients with relapsed or refractory CLL or indolent NHL, providing a novel targeted therapeutic option for the management of these hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTBhrG6L37zLVg90H21EOLACvtfcHk0ljVMz-kkQuIQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVOht7g%253D&md5=118029cda72d99310663a3300aa698d7</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.2146%2Fajhp150281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252Fajhp150281%26sid%3Dliteratum%253Aachs%26aulast%3DDo%26aufirst%3DB.%26aulast%3DMace%26aufirst%3DM.%26aulast%3DRexwinkle%26aufirst%3DA.%26atitle%3DIdelalisib%2520for%2520treatment%2520of%2520B-cell%2520malignancies%26jtitle%3DAm.%2520J.%2520Health-Syst.%2520Pharm.%26date%3D2016%26volume%3D73%26spage%3D547%26epage%3D555%26doi%3D10.2146%2Fajhp150281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meadows, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashishian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriaux, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, N. A.</span></span> <span> </span><span class="NLM_article-title">CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">594</span>, <span class="refDoi"> DOI: 10.1182/blood-2010-03-275305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1182%2Fblood-2010-03-275305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=20959606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1aqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=591-594&author=B.+J.+Lannuttiauthor=S.+A.+Meadowsauthor=S.+E.+Hermanauthor=A.+Kashishianauthor=B.+Steinerauthor=A.+J.+Johnsonauthor=J.+C.+Byrdauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=M.+Deiningerauthor=B.+J.+Drukerauthor=K.+D.+Puriauthor=R.+G.+Ulrichauthor=N.+A.+Giese&title=CAL-101%2C+a+p110delta+selective+phosphatidylinositol-3-kinase+inhibitor+for+the+treatment+of+B-cell+malignancies%2C+inhibits+PI3K+signaling+and+cellular+viability&doi=10.1182%2Fblood-2010-03-275305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability</span></div><div class="casAuthors">Lannutti, Brian J.; Meadows, Sarah A.; Herman, Sarah E. M.; Kashishian, Adam; Steiner, Bart; Johnson, Amy J.; Byrd, John C.; Tyner, Jeffrey W.; Loriaux, Marc M.; Deininger, Mike; Druker, Brian J.; Puri, Kamal D.; Ulrich, Roger G.; Giese, Neill A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">591-594</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase p110δ serves as a central integration point for signaling from cell surface receptors known to promote malignant B-cell proliferation and survival.  This provides a rationale for the development of small mol. inhibitors that selectively target p110δ as a treatment approach for patients with B-cell malignancies.  We thus identified 5-fluoro-3-phenyl-2-[(S)-1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one (CAL-101), a highly selective and potent p110δ small mol. inhibitor (half-maximal effective concn. [EC50] = 8nM).  Using tumor cell lines and primary patient samples representing multiple B-cell malignancies, we have demonstrated that constitutive phosphatidylinositol-3-kinase pathway activation is p110δ-dependent.  CAL-101 blocked constitutive phosphatidylinositol-3-kinase signaling, resulting in decreased phosphorylation of Akt and other downstream effectors, an increase in poly(ADP-ribose) polymerase and caspase cleavage and an induction of apoptosis.  These effects have been obsd. across a broad range of immature and mature B-cell malignancies, thereby providing a rationale for the ongoing clin. evaluation of CAL-101.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrID8zgXRVmvbVg90H21EOLACvtfcHk0lgx_UVNvdPEDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1aqtro%253D&md5=423bf1fbea274424db3b818fdc6733b0</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-03-275305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-03-275305%26sid%3Dliteratum%253Aachs%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DMeadows%26aufirst%3DS.%2BA.%26aulast%3DHerman%26aufirst%3DS.%2BE.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DDeininger%26aufirst%3DM.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DUlrich%26aufirst%3DR.%2BG.%26aulast%3DGiese%26aufirst%3DN.%2BA.%26atitle%3DCAL-101%252C%2520a%2520p110delta%2520selective%2520phosphatidylinositol-3-kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520B-cell%2520malignancies%252C%2520inhibits%2520PI3K%2520signaling%2520and%2520cellular%2520viability%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D591%26epage%3D594%26doi%3D10.1182%2Fblood-2010-03-275305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koditek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villasenor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novikov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liclican, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagpacan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papalia, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span> <span> </span><span class="NLM_article-title">Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase delta</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">8439</span>– <span class="NLM_lpage">8446</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.634683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1074%2Fjbc.M114.634683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=25631052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVSqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=8439-8446&author=J.+R.+Somozaauthor=D.+Koditekauthor=A.+G.+Villasenorauthor=N.+Novikovauthor=M.+H.+Wongauthor=A.+Liclicanauthor=W.+Xingauthor=L.+Lagpacanauthor=R.+Wangauthor=B.+E.+Schultzauthor=G.+A.+Papaliaauthor=D.+Samuelauthor=L.+Ladauthor=M.+E.+McGrath&title=Structural%2C+biochemical%2C+and+biophysical+characterization+of+idelalisib+binding+to+phosphoinositide+3-kinase+delta&doi=10.1074%2Fjbc.M114.634683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ</span></div><div class="casAuthors">Somoza, John R.; Koditek, David; Villasenor, Armando G.; Novikov, Nikolai; Wong, Melanie H.; Liclican, Albert; Xing, Weimei; Lagpacan, Leanna; Wang, Ruth; Schultz, Brian E.; Papalia, Giuseppe A.; Samuel, Dharmaraj; Lad, Latesh; McGrath, Mary E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">8439-8446</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Idelalisib (also known as GS-1101, CAL-101, IC489666, and Zydelig) is a PI3Kδ inhibitor that has recently been approved for the treatment of several hematol. malignancies.  Given its use in human diseases, we needed a clear picture of how idelalisib binds to and inhibits PI3Kδ.  Our data show that idelalisib is a potent and selective inhibitor of the kinase activity of PI3Kδ.  A kinetic characterization clearly demonstrated ATP-competitive inhibition, and several addnl. biochem. and biophys. assays showed that the compd. binds reversibly and noncovalently to the kinase.  A crystal structure of idelalisib bound to the p110δ subunit of PI3Kδ furthers our understanding of the binding interactions that confer the potency and selectivity of idelalisib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnXZo8_qK79rVg90H21EOLACvtfcHk0lgx_UVNvdPEDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVSqtrs%253D&md5=2969b7407f4edc367249215bbbf22a0e</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.634683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.634683%26sid%3Dliteratum%253Aachs%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DNovikov%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DM.%2BH.%26aulast%3DLiclican%26aufirst%3DA.%26aulast%3DXing%26aufirst%3DW.%26aulast%3DLagpacan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DPapalia%26aufirst%3DG.%2BA.%26aulast%3DSamuel%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26atitle%3DStructural%252C%2520biochemical%252C%2520and%2520biophysical%2520characterization%2520of%2520idelalisib%2520binding%2520to%2520phosphoinositide%25203-kinase%2520delta%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D8439%26epage%3D8446%26doi%3D10.1074%2Fjbc.M114.634683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Angelo, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herberich, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5188</span>– <span class="NLM_lpage">5219</span>, <span class="refDoi"> DOI: 10.1021/jm300184s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300184s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1Oqt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5188-5219&author=A.+L.+Smithauthor=N.+D.+D%E2%80%99Angeloauthor=Y.+Y.+Boauthor=S.+K.+Bookerauthor=V.+J.+Ceeauthor=B.+Herberichauthor=F.+T.+Hongauthor=C.+L.+Jacksonauthor=B.+A.+Lanmanauthor=L.+Liuauthor=N.+Nishimuraauthor=L.+H.+Pettusauthor=A.+B.+Reedauthor=S.+Tadesseauthor=N.+A.+Tamayoauthor=R.+P.+Wurzauthor=K.+Yangauthor=K.+L.+Andrewsauthor=D.+A.+Whittingtonauthor=J.+D.+McCarterauthor=T.+S.+Miguelauthor=L.+Zalamedaauthor=J.+Jiangauthor=R.+Subramanianauthor=E.+L.+Mulladyauthor=S.+Caenepeelauthor=D.+J.+Freemanauthor=L.+Wangauthor=N.+Zhangauthor=T.+Wuauthor=P.+E.+Hughesauthor=M.+H.+Norman&title=Structure-based+design+of+a+novel+series+of+potent%2C+selective+inhibitors+of+the+class+I+phosphatidylinositol+3-kinases&doi=10.1021%2Fjm300184s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases</span></div><div class="casAuthors">Smith, Adrian L.; D'Angelo, Noel D.; Bo, Yunxin Y.; Booker, Shon K.; Cee, Victor J.; Herberich, Brad; Hong, Fang-Tsao; Jackson, Claire L. M.; Lanman, Brian A.; Liu, Longbin; Nishimura, Nobuko; Pettus, Liping H.; Reed, Anthony B.; Tadesse, Seifu; Tamayo, Nuria A.; Wurz, Ryan P.; Yang, Kevin; Andrews, Kristin L.; Whittington, Douglas A.; McCarter, John D.; Miguel, Tisha San; Zalameda, Leeanne; Jiang, Jian; Subramanian, Raju; Mullady, Erin L.; Caenepeel, Sean; Freeman, Daniel J.; Wang, Ling; Zhang, Nancy; Wu, Tian; Hughes, Paul E.; Norman, Mark H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5188-5219</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Biheteroaryl arylamines such as I were prepd. as selective inhibitors of class I phosphatidylinositol 3-kinases (PI3K) selective for PI3K over mTOR for potential use as antitumor agents.  The dual PI3K/mTOR inhibitor II was used as a lead compd.; refinement of its structure to improve its potency and selectivity resulted in the identification of I as a potent inhibitor of the class I PI3Ks with excellent selectivity over mTOR, related phosphatidylinositol kinases, and a broad panel of protein kinases.  The pharmacokinetics of orally and i.v. administered I and selected biheteroaryl arylamines were detd.  I inhibited the PI3K/Akt pathway in vivo in a mouse model and potently inhibited tumor growth in a xenograft model with an activated PI3K/Akt pathway.  The structures of I and II bound to PI3Kγ were detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwj78DmYgaeLVg90H21EOLACvtfcHk0lgx_UVNvdPEDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1Oqt74%253D&md5=673cc3677c40dca6090dc33df7cde330</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fjm300184s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300184s%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DBo%26aufirst%3DY.%2BY.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DHerberich%26aufirst%3DB.%26aulast%3DHong%26aufirst%3DF.%2BT.%26aulast%3DJackson%26aufirst%3DC.%2BL.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DTamayo%26aufirst%3DN.%2BA.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMiguel%26aufirst%3DT.%2BS.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DFreeman%26aufirst%3DD.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26atitle%3DStructure-based%2520design%2520of%2520a%2520novel%2520series%2520of%2520potent%252C%2520selective%2520inhibitors%2520of%2520the%2520class%2520I%2520phosphatidylinositol%25203-kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5188%26epage%3D5219%26doi%3D10.1021%2Fjm300184s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Angelo, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herberich, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aidasani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span> <span> </span><span class="NLM_article-title">Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7796</span>– <span class="NLM_lpage">7816</span>, <span class="refDoi"> DOI: 10.1021/jm300846z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300846z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Wls7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7796-7816&author=M.+H.+Normanauthor=K.+L.+Andrewsauthor=Y.+Y.+Boauthor=S.+K.+Bookerauthor=S.+Caenepeelauthor=V.+J.+Ceeauthor=N.+D.+D%E2%80%99Angeloauthor=D.+J.+Freemanauthor=B.+J.+Herberichauthor=F.+T.+Hongauthor=C.+L.+Jacksonauthor=J.+Jiangauthor=B.+A.+Lanmanauthor=L.+Liuauthor=J.+D.+McCarterauthor=E.+L.+Mulladyauthor=N.+Nishimuraauthor=L.+H.+Pettusauthor=A.+B.+Reedauthor=T.+S.+Miguelauthor=A.+L.+Smithauthor=M.+M.+Stecauthor=S.+Tadesseauthor=A.+Taskerauthor=D.+Aidasaniauthor=X.+Zhuauthor=R.+Subramanianauthor=N.+A.+Tamayoauthor=L.+Wangauthor=D.+A.+Whittingtonauthor=B.+Wuauthor=T.+Wuauthor=R.+P.+Wurzauthor=K.+Yangauthor=L.+Zalamedaauthor=N.+Zhangauthor=P.+E.+Hughes&title=Selective+class+I+phosphoinositide+3-kinase+inhibitors%3A+optimization+of+a+series+of+pyridyltriazines+leading+to+the+identification+of+a+clinical+candidate%2C+AMG+511&doi=10.1021%2Fjm300846z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511</span></div><div class="casAuthors">Norman, Mark H.; Andrews, Kristin L.; Bo, Yunxin Y.; Booker, Shon K.; Caenepeel, Sean; Cee, Victor J.; D'Angelo, Noel D.; Freeman, Daniel J.; Herberich, Bradley J.; Hong, Fang-Tsao; Jackson, Claire L. M.; Jiang, Jian; Lanman, Brian A.; Liu, Longbin; McCarter, John D.; Mullady, Erin L.; Nishimura, Nobuko; Pettus, Liping H.; Reed, Anthony B.; Miguel, Tisha San; Smith, Adrian L.; Stec, Markian M.; Tadesse, Seifu; Tasker, Andrew; Aidasani, Divesh; Zhu, Xiaochun; Subramanian, Raju; Tamayo, Nuria A.; Wang, Ling; Whittington, Douglas A.; Wu, Bin; Wu, Tian; Wurz, Ryan P.; Yang, Kevin; Zalameda, Leeanne; Zhang, Nancy; Hughes, Paul E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7796-7816</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The phosphoinositide 3-kinase family catalyzes the phosphorylation of phosphatidylinositol-4,5-diphosphate to phosphatidylinositol-3,4,5-triphosphate, a secondary messenger which plays a crit. role in important cellular functions such as metab., cell growth, and cell survival.  Our efforts to identify potent, efficacious, and orally available phosphatidylinositol 3-kinase (PI3K) inhibitors as potential cancer therapeutics have resulted in the discovery of 4-(2-((6-methoxypyridin-3-yl)amino)-5-((4-(methylsulfonyl)piperazin-1-yl)methyl)pyridin-3-yl)-6-methyl-1,3,5-triazin-2-amine (I).  In this paper, we describe the optimization of I, which led to the design and synthesis of pyridyltriazine (II), a potent pan inhibitor of class I PI3Ks with a superior pharmacokinetic profile.  II was shown to potently block the targeted PI3K pathway in a mouse liver pharmacodynamic model and inhibit tumor growth in a U87 malignant glioma glioblastoma xenograft model.  On the basis of its excellent in vivo efficacy and pharmacokinetic profile, II was selected for further evaluation as a clin. candidate and was designated AMG 511.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZl70tnsqvELVg90H21EOLACvtfcHk0lhqChNzPyIVuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Wls7%252FK&md5=0ee0a61fc0d919c3e9c3c4dc86f4070b</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Fjm300846z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300846z%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DBo%26aufirst%3DY.%2BY.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DFreeman%26aufirst%3DD.%2BJ.%26aulast%3DHerberich%26aufirst%3DB.%2BJ.%26aulast%3DHong%26aufirst%3DF.%2BT.%26aulast%3DJackson%26aufirst%3DC.%2BL.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DMiguel%26aufirst%3DT.%2BS.%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DStec%26aufirst%3DM.%2BM.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DAidasani%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DTamayo%26aufirst%3DN.%2BA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26atitle%3DSelective%2520class%2520I%2520phosphoinositide%25203-kinase%2520inhibitors%253A%2520optimization%2520of%2520a%2520series%2520of%2520pyridyltriazines%2520leading%2520to%2520the%2520identification%2520of%2520a%2520clinical%2520candidate%252C%2520AMG%2520511%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7796%26epage%3D7816%26doi%3D10.1021%2Fjm300846z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span> </span><span class="NLM_article-title">AMG 319 in HPV Positive and Negative HNSCC</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, <span class="NLM_year">2015</span>; <a href="https://clinicaltrials.gov/ct2/show/NCT02540928" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02540928</a> (accessed Oct 18, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AMG+319+in+HPV+Positive+and+Negative+HNSCC.+ClinicalTrials.gov%3B+U.S.+Food+and+Drug+Administration%2C+2015%3B+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02540928+%28accessed+Oct+18%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DAMG%2520319%2520in%2520HPV%2520Positive%2520and%2520Negative%2520HNSCC%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Lopez
de Turiso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungate, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattaropong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichelt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rzasa, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seganish, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whoriskey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and in vivo evaluation of (<i>S</i>)-<i>N</i>-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine (AMG319) and related PI3Kdelta inhibitors for inflammation and autoimmune disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1021/jm501624r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501624r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVegur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=480-511&author=T.+D.+Cushingauthor=X.+Haoauthor=Y.+Shinauthor=K.+Andrewsauthor=M.+Brownauthor=M.+Cardozoauthor=Y.+Chenauthor=J.+Duquetteauthor=B.+Fisherauthor=F.+Gonzalez-Lopez%0Ade+Turisoauthor=X.+Heauthor=K.+R.+Henneauthor=Y.+L.+Huauthor=R.+Hungateauthor=M.+G.+Johnsonauthor=R.+C.+Kellyauthor=B.+Lucasauthor=J.+D.+McCarterauthor=L.+R.+McGeeauthor=J.+C.+Medinaauthor=T.+San+Miguelauthor=D.+Mohnauthor=V.+Pattaropongauthor=L.+H.+Pettusauthor=A.+Reicheltauthor=R.+M.+Rzasaauthor=J.+Seganishauthor=A.+S.+Taskerauthor=R.+C.+Wahlauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=J.+Whoriskeyauthor=G.+Yuauthor=L.+Zalamedaauthor=D.+Zhangauthor=D.+P.+Metz&title=Discovery+and+in+vivo+evaluation+of+%28S%29-N-%281-%287-fluoro-2-%28pyridin-2-yl%29quinolin-3-yl%29ethyl%29-9H-purin-6-amine+%28AMG319%29+and+related+PI3Kdelta+inhibitors+for+inflammation+and+autoimmune+disease&doi=10.1021%2Fjm501624r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease</span></div><div class="casAuthors">Cushing, Timothy D.; Hao, Xiaolin; Shin, Youngsook; Andrews, Kristin; Brown, Matthew; Cardozo, Mario; Chen, Yi; Duquette, Jason; Fisher, Ben; Gonzalez-Lopez de Turiso, Felix; He, Xiao; Henne, Kirk R.; Hu, Yi-Ling; Hungate, Randall; Johnson, Michael G.; Kelly, Ron C.; Lucas, Brian; McCarter, John D.; McGee, Lawrence R.; Medina, Julio C.; San Miguel, Tisha; Mohn, Deanna; Pattaropong, Vatee; Pettus, Liping H.; Reichelt, Andreas; Rzasa, Robert M.; Seganish, Jennifer; Tasker, Andrew S.; Wahl, Robert C.; Wannberg, Sharon; Whittington, Douglas A.; Whoriskey, John; Yu, Gang; Zalameda, Leeanne; Zhang, Dawei; Metz, Daniela P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">480-511</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development and optimization of a series of quinolinylpurines as potent and selective PI3Kδ kinase inhibitors with excellent physicochem. properties are described.  This medicinal chem. effort led to the identification of I (AMG319), a compd. with an IC50 of 16 nM in a human whole blood assay (HWB), excellent selectivity over a large panel of protein kinases, and a high level of in vivo efficacy as measured by two rodent disease models of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt3BtsoY7G2rVg90H21EOLACvtfcHk0lhqChNzPyIVuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVegur%252FL&md5=08af48a5c6208d6f61bea77e9ad840aa</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Fjm501624r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501624r%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DAndrews%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DGonzalez-Lopez%2Bde%2BTuriso%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DHu%26aufirst%3DY.%2BL.%26aulast%3DHungate%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DKelly%26aufirst%3DR.%2BC.%26aulast%3DLucas%26aufirst%3DB.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReichelt%26aufirst%3DA.%26aulast%3DRzasa%26aufirst%3DR.%2BM.%26aulast%3DSeganish%26aufirst%3DJ.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWhoriskey%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26atitle%3DDiscovery%2520and%2520in%2520vivo%2520evaluation%2520of%2520%2528S%2529-N-%25281-%25287-fluoro-2-%2528pyridin-2-yl%2529quinolin-3-yl%2529ethyl%2529-9H-purin-6-amine%2520%2528AMG319%2529%2520and%2520related%2520PI3Kdelta%2520inhibitors%2520for%2520inflammation%2520and%2520autoimmune%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D480%26epage%3D511%26doi%3D10.1021%2Fjm501624r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erhard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardwicke, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luengo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McSurdy-Freed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spengler, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivero, R. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of imidazo[1,2-<i>a</i>]pyrimidin-5(1<i>H</i>)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2230</span>– <span class="NLM_lpage">2234</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2012.01.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22361133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtV2ksrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2230-2234&author=H.+Linauthor=K.+Erhardauthor=M.+A.+Hardwickeauthor=J.+I.+Luengoauthor=J.+F.+Mackauthor=J.+McSurdy-Freedauthor=R.+Plantauthor=K.+Rahaauthor=C.+M.+Romingerauthor=R.+M.+Sanchezauthor=M.+D.+Schaberauthor=M.+J.+Schulzauthor=M.+D.+Spenglerauthor=R.+Tedescoauthor=R.+Xieauthor=J.+J.+Zengauthor=R.+A.+Rivero&title=Synthesis+and+structure-activity+relationships+of+imidazo%5B1%2C2-a%5Dpyrimidin-5%281H%29-ones+as+a+novel+series+of+beta+isoform+selective+phosphatidylinositol+3-kinase+inhibitors&doi=10.1016%2Fj.bmcl.2012.01.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of imidazo[1,2-a]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors</span></div><div class="casAuthors">Lin, Hong; Erhard, Karl; Hardwicke, Mary Ann; Luengo, Juan I.; Mack, James F.; McSurdy-Freed, Jeanelle; Plant, Ramona; Raha, Kaushik; Rominger, Cynthia M.; Sanchez, Robert M.; Schaber, Michael D.; Schulz, Mark J.; Spengler, Michael D.; Tedesco, Rosanna; Xie, Ren; Zeng, Jin J.; Rivero, Ralph A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2230-2234</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of PI3K-beta selective inhibitors, imidazo[1,2-a]-pyrimidin-5(1H)-ones, has been rationally designed based on the docking model of the more potent R enantiomer of TGX-221, identified by a chiral sepn., in a PI3K-beta homol. model.  Synthesis and SAR of this novel chemotype are described.  Several compds. in the series demonstrated potent growth inhibition in a PTEN-deficient breast cancer cell line MDA-MB-468 under anchorage independent conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOCJin9HDxtLVg90H21EOLACvtfcHk0lgeqXcp-uk_DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtV2ksrg%253D&md5=6428a89baa3e88253799ddb534eacd27</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.092%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%26aulast%3DErhard%26aufirst%3DK.%26aulast%3DHardwicke%26aufirst%3DM.%2BA.%26aulast%3DLuengo%26aufirst%3DJ.%2BI.%26aulast%3DMack%26aufirst%3DJ.%2BF.%26aulast%3DMcSurdy-Freed%26aufirst%3DJ.%26aulast%3DPlant%26aufirst%3DR.%26aulast%3DRaha%26aufirst%3DK.%26aulast%3DRominger%26aufirst%3DC.%2BM.%26aulast%3DSanchez%26aufirst%3DR.%2BM.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DSchulz%26aufirst%3DM.%2BJ.%26aulast%3DSpengler%26aufirst%3DM.%2BD.%26aulast%3DTedesco%26aufirst%3DR.%26aulast%3DXie%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DJ.%2BJ.%26aulast%3DRivero%26aufirst%3DR.%2BA.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520imidazo%255B1%252C2-a%255Dpyrimidin-5%25281H%2529-ones%2520as%2520a%2520novel%2520series%2520of%2520beta%2520isoform%2520selective%2520phosphatidylinositol%25203-kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2230%26epage%3D2234%26doi%3D10.1016%2Fj.bmcl.2012.01.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunder, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loewith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">A pharmacological map of the PI3K family defines a role for p110alpha in insulin signaling</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.cell.2006.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=16647110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=733-747&author=Z.+A.+Knightauthor=B.+Gonzalezauthor=M.+E.+Feldmanauthor=E.+R.+Zunderauthor=D.+D.+Goldenbergauthor=O.+Williamsauthor=R.+Loewithauthor=D.+Stokoeauthor=A.+Ballaauthor=B.+Tothauthor=T.+Ballaauthor=W.+A.+Weissauthor=R.+L.+Williamsauthor=K.+M.+Shokat&title=A+pharmacological+map+of+the+PI3K+family+defines+a+role+for+p110alpha+in+insulin+signaling&doi=10.1016%2Fj.cell.2006.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling</span></div><div class="casAuthors">Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; Balla, Tamas; Weiss, William A.; Williams, Roger L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-747</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3-Ks) are an important emerging class of drug targets, but the unique roles of PI3-K isoforms remain poorly defined.  We describe here an approach to pharmacol. interrogate the PI3-K family.  A chem. diverse panel of PI3-K inhibitors was synthesized, and their target selectivity was biochem. enumerated, revealing cryptic homologies across targets and chemotypes.  Crystal structures of three inhibitors bound to p110γ identify a conformationally mobile region that is uniquely exploited by selective compds.  This chem. array was then used to define the PI3-K isoforms required for insulin signaling.  We find that p110α is the primary insulin-responsive PI3-K in cultured cells, whereas p110β is dispensable but sets a phenotypic threshold for p110α activity.  Compds. targeting p110α block the acute effects of insulin treatment in vivo, whereas a p110β inhibitor has no effect.  These results illustrate systematic target validation using a matrix of inhibitors that span a protein family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrozjvOeMXP3bVg90H21EOLACvtfcHk0lgeqXcp-uk_DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D&md5=b95a8cb433927ff9a75b33fc4ac2c8a0</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DZunder%26aufirst%3DE.%2BR.%26aulast%3DGoldenberg%26aufirst%3DD.%2BD.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DBalla%26aufirst%3DA.%26aulast%3DToth%26aufirst%3DB.%26aulast%3DBalla%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DA%2520pharmacological%2520map%2520of%2520the%2520PI3K%2520family%2520defines%2520a%2520role%2520for%2520p110alpha%2520in%2520insulin%2520signaling%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D733%26epage%3D747%26doi%3D10.1016%2Fj.cell.2006.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosulich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghardt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennequin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert-Van der Brempt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgentin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ple, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-<i>a</i>]pyrimidine-7-carboxamides as PI3Kbeta/delta inhibitors for the treatment of PTEN-deficient tumours</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3928</span>– <span class="NLM_lpage">3935</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2014.06.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=24992874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtV2jtL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3928-3935&author=B.+Barlaamauthor=S.+Cosulichauthor=S.+Degorceauthor=M.+Fitzekauthor=F.+Giordanettoauthor=S.+Greenauthor=T.+Inghardtauthor=L.+Hennequinauthor=U.+Hancoxauthor=C.+Lambert-Van+der+Bremptauthor=R.+Morgentinauthor=S.+Passauthor=P.+Pleauthor=T.+Salehauthor=L.+Ward&title=Discovery+of+9-%281-anilinoethyl%29-2-morpholino-4-oxo-pyrido%5B1%2C2-a%5Dpyrimidine-7-carboxamides+as+PI3Kbeta%2Fdelta+inhibitors+for+the+treatment+of+PTEN-deficient+tumours&doi=10.1016%2Fj.bmcl.2014.06.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours</span></div><div class="casAuthors">Barlaam, Bernard; Cosulich, Sabina; Degorce, Sebastien; Fitzek, Martina; Giordanetto, Fabrizio; Green, Stephen; Inghardt, Tord; Hennequin, Laurent; Hancox, Urs; Lambert-van der Brempt, Christine; Morgentin, Remy; Pass, Sarah; Ple, Patrick; Saleh, Twana; Ward, Lara</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3928-3935</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting from TGX-221, we designed a series of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as potent and selective PI3Kβ/δ inhibitors.  Structure-activity relationships and structure-property relationships around the aniline and the amide substituents are discussed.  We identified compds. 17 and 18, which showed profound pharmacodynamic modulation of phosphorylated Akt in the PC3 prostate tumor xenograft, after a single oral dose.  Compd. 17 also gave significant inhibition of tumor growth in the PC3 prostate tumor xenograft model after chronic oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphtYz40Us0V7Vg90H21EOLACvtfcHk0lj0os4tndYyXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtV2jtL%252FN&md5=3a55171f50d0fcc62e2a87da8c4d2290</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.040%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DDegorce%26aufirst%3DS.%26aulast%3DFitzek%26aufirst%3DM.%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DInghardt%26aufirst%3DT.%26aulast%3DHennequin%26aufirst%3DL.%26aulast%3DHancox%26aufirst%3DU.%26aulast%3DLambert-Van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DPass%26aufirst%3DS.%26aulast%3DPle%26aufirst%3DP.%26aulast%3DSaleh%26aufirst%3DT.%26aulast%3DWard%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25209-%25281-anilinoethyl%2529-2-morpholino-4-oxo-pyrido%255B1%252C2-a%255Dpyrimidine-7-carboxamides%2520as%2520PI3Kbeta%252Fdelta%2520inhibitors%2520for%2520the%2520treatment%2520of%2520PTEN-deficient%2520tumours%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3928%26epage%3D3935%26doi%3D10.1016%2Fj.bmcl.2014.06.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nylander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kull, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorkman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulvinge, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emanuelsson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skarby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghardt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fjellstrom, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, D.</span></span> <span> </span><span class="NLM_article-title">Human target validation of phosphoinositide 3-kinase (PI3K)beta: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor</span>. <i>J. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2127</span>– <span class="NLM_lpage">2136</span>, <span class="refDoi"> DOI: 10.1111/j.1538-7836.2012.04898.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1111%2Fj.1538-7836.2012.04898.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22906130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslSku77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=2127-2136&author=S.+Nylanderauthor=B.+Kullauthor=J.+A.+Bjorkmanauthor=J.+C.+Ulvingeauthor=N.+Oakesauthor=B.+M.+Emanuelssonauthor=M.+Anderssonauthor=T.+Skarbyauthor=T.+Inghardtauthor=O.+Fjellstromauthor=D.+Gustafsson&title=Human+target+validation+of+phosphoinositide+3-kinase+%28PI3K%29beta%3A+effects+on+platelets+and+insulin+sensitivity%2C+using+AZD6482+a+novel+PI3Kbeta+inhibitor&doi=10.1111%2Fj.1538-7836.2012.04898.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor</span></div><div class="casAuthors">Nylander, S.; Kull, B.; Bjoerkman, J. A.; Ulvinge, J. C.; Oakes, N.; Emanuelsson, B. M.; Andersson, M.; Skaerby, T.; Inghardt, T.; Fjellstroem, O.; Gustafsson, D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2127-2136</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: Based on in vitro and animal data, PI3Kβ is given an important role in platelet adhesion and aggregation but its role in insulin signaling is unclear.  Objective: To strengthen the PI3Kβ target validation using the novel, short-acting inhibitor AZD6482.  Methods and results: AZD6482 is a potent, selective and ATP competitive PI3Kβ inhibitor (IC50 0.01 μM).  A maximal anti-platelet effect was achieved at 1 μM in the in vitro and ex vivo tests both in dog and in man.  In dog, in vivo AZD6482 produced a complete anti-thrombotic effect without an increased bleeding time or blood loss.  AZD6482 was well tolerated in healthy volunteers during a 3-h infusion.  The ex vivo anti-platelet effect and minimal bleeding time prolongation in the dog model translated well to data obtained in healthy volunteers.  AZD6482 inhibited insulin-induced human adipocyte glucose uptake in vitro (IC50 of 4.4 μM).  In the euglycemic hyperinsulinemic clamp model, in rats, glucose infusion rate was not affected at 2.3 μM but reduced by about 60% at a plasma exposure of 27 μM.  In man, the homeostasis model anal. (HOMA) index increased by about 10-20% at the highest plasma concn. of 5.3 μM.  Conclusions: This is the first human target validation for PI3Kβ inhibition as anti-platelet therapy showing a mild and generalized antiplatelet effect attenuating but not completely inhibiting multiple signaling pathways with an impressive sepn. towards primary hemostasis.  AZD6482 at 'supra-therapeutic' plasma concns. may attenuate insulin signaling, most likely through PI3Kα inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol96EaByjORbVg90H21EOLACvtfcHk0lj0os4tndYyXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslSku77I&md5=120c48254154a7a4449630c791f172fd</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1111%2Fj.1538-7836.2012.04898.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1538-7836.2012.04898.x%26sid%3Dliteratum%253Aachs%26aulast%3DNylander%26aufirst%3DS.%26aulast%3DKull%26aufirst%3DB.%26aulast%3DBjorkman%26aufirst%3DJ.%2BA.%26aulast%3DUlvinge%26aufirst%3DJ.%2BC.%26aulast%3DOakes%26aufirst%3DN.%26aulast%3DEmanuelsson%26aufirst%3DB.%2BM.%26aulast%3DAndersson%26aufirst%3DM.%26aulast%3DSkarby%26aufirst%3DT.%26aulast%3DInghardt%26aufirst%3DT.%26aulast%3DFjellstrom%26aufirst%3DO.%26aulast%3DGustafsson%26aufirst%3DD.%26atitle%3DHuman%2520target%2520validation%2520of%2520phosphoinositide%25203-kinase%2520%2528PI3K%2529beta%253A%2520effects%2520on%2520platelets%2520and%2520insulin%2520sensitivity%252C%2520using%2520AZD6482%2520a%2520novel%2520PI3Kbeta%2520inhibitor%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2012%26volume%3D10%26spage%3D2127%26epage%3D2136%26doi%3D10.1111%2Fj.1538-7836.2012.04898.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosulich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert-Van
der Brempt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maudet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgentin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquet, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ple, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vautier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warin, N.</span></span> <span> </span><span class="NLM_article-title">Discovery of (<i>R</i>)-8-(1-(3,5-difluorophenylamino)ethyl)-<i>N,N</i>-dimethyl-2-morpholino-4-oxo-4H-chrom ene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kbeta and PI3Kdelta for the treatment of PTEN-deficient cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">943</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.1021/jm501629p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501629p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOhu7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=943-962&author=B.+Barlaamauthor=S.+Cosulichauthor=S.+Degorceauthor=M.+Fitzekauthor=S.+Greenauthor=U.+Hancoxauthor=C.+Lambert-Van%0Ader+Bremptauthor=J.+J.+Lohmannauthor=M.+Maudetauthor=R.+Morgentinauthor=M.+J.+Pasquetauthor=A.+Peruauthor=P.+Pleauthor=T.+Salehauthor=M.+Vautierauthor=M.+Walkerauthor=L.+Wardauthor=N.+Warin&title=Discovery+of+%28R%29-8-%281-%283%2C5-difluorophenylamino%29ethyl%29-N%2CN-dimethyl-2-morpholino-4-oxo-4H-chrom+ene-6-carboxamide+%28AZD8186%29%3A+a+potent+and+selective+inhibitor+of+PI3Kbeta+and+PI3Kdelta+for+the+treatment+of+PTEN-deficient+cancers&doi=10.1021%2Fjm501629p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers</span></div><div class="casAuthors">Barlaam, Bernard; Cosulich, Sabina; Degorce, Sebastien; Fitzek, Martina; Green, Stephen; Hancox, Urs; Lambert-van der Brempt, Christine; Lohmann, Jean-Jacques; Maudet, Mickael; Morgentin, Remy; Pasquet, Marie-Jeanne; Peru, Aurelien; Ple, Patrick; Saleh, Twana; Vautier, Michel; Walker, Mike; Ward, Lara; Warin, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">943-962</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several studies have highlighted the dependency of PTEN deficient tumors to PI3Kβ activity and specific inhibition of PI3Kδ has been shown activity against human B-cell cancers.  We describe the discovery and optimization of a series of 8-(1-anilino)ethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamides as PI3Kβ/δ inhibitors, which led to the discovery of the clin. candidate 13, also known as AZD8186.  On the basis of the lower lipophilicity of the chromen-4-one core compared to the previously utilized pyrido[1,2-a]pyrimid-4-one core, this series of compds. displayed high metabolic stability and suitable phys. properties for oral administration.  Compd. 13 showed profound pharmacodynamic modulation of p-Akt in PTEN-deficient PC3 prostate tumor bearing mice after oral administration and showed complete inhibition of tumor growth in the mouse PTEN-deficient PC3 prostate tumor xenograft model.  13 Was selected as a clin. candidate for treatment of PTEN-deficient cancers and has recently entered phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxcZtIvYY3MLVg90H21EOLACvtfcHk0lj0os4tndYyXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOhu7%252FJ&md5=b0a1a7b7c1d7e7c27015535573ab77e5</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Fjm501629p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501629p%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DDegorce%26aufirst%3DS.%26aulast%3DFitzek%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DHancox%26aufirst%3DU.%26aulast%3DLambert-Van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DLohmann%26aufirst%3DJ.%2BJ.%26aulast%3DMaudet%26aufirst%3DM.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DPasquet%26aufirst%3DM.%2BJ.%26aulast%3DPeru%26aufirst%3DA.%26aulast%3DPle%26aufirst%3DP.%26aulast%3DSaleh%26aufirst%3DT.%26aulast%3DVautier%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DWard%26aufirst%3DL.%26aulast%3DWarin%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520%2528R%2529-8-%25281-%25283%252C5-difluorophenylamino%2529ethyl%2529-N%252CN-dimethyl-2-morpholino-4-oxo-4H-chrom%2520ene-6-carboxamide%2520%2528AZD8186%2529%253A%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520PI3Kbeta%2520and%2520PI3Kdelta%2520for%2520the%2520treatment%2520of%2520PTEN-deficient%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D943%26epage%3D962%26doi%3D10.1021%2Fjm501629p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houseman, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aizenstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.chembiol.2010.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=20189103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1Wksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=123-134&author=O.+Williamsauthor=B.+T.+Housemanauthor=E.+J.+Kunkelauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=Z.+A.+Knightauthor=K.+M.+Shokat&title=Discovery+of+dual+inhibitors+of+the+immune+cell+PI3Ks+p110delta+and+p110gamma%3A+a+prototype+for+new+anti-inflammatory+drugs&doi=10.1016%2Fj.chembiol.2010.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Dual Inhibitors of the Immune Cell PI3Ks p110δ and p110γ: A Prototype for New Anti-inflammatory Drugs</span></div><div class="casAuthors">Williams, Olusegun; Houseman, Benjamin T.; Kunkel, Eric J.; Aizenstein, Brian; Hoffman, Randy; Knight, Zachary A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-134</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PI3Kδ and PI3Kγ regulate immune cell signaling, while the related PI3Kα and PI3Kβ regulate cell survival and metab.  Selective inhibitors of PI3Kδ/γ represent a potential class of anti-inflammatory agents lacking the antiproliferative effects assocd. with PI3Kα/β inhibition.  Here we report the discovery of PI3Kδ/γ inhibitors that display up to 1000-fold selectivity over PI3Kα/β and evaluate these compds. in a high-content inflammation assay using mixts. of primary human cells.  We find selective inhibition of only PI3Kδ is weakly anti-inflammatory, but PI3Kδ/γ inhibitors show superior inflammatory marker suppression through suppression of lipopolysaccharide-induced TNFα prodn. and T cell activation.  Moreover, PI3Kδ/γ inhibition yields an anti-inflammatory signature distinct from pan-PI3K inhibition and known anti-inflammatory drugs, yet bears striking similarities to glucocorticoid receptor agonists.  These results highlight the potential of selectively designing drugs that target kinases with shared biol. function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9YDqq1G_IirVg90H21EOLACvtfcHk0ljhKxV1SPuUJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1Wksrc%253D&md5=a42b5b326cd3aebe67b0c5ce18bb66ca</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DHouseman%26aufirst%3DB.%2BT.%26aulast%3DKunkel%26aufirst%3DE.%2BJ.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DDiscovery%2520of%2520dual%2520inhibitors%2520of%2520the%2520immune%2520cell%2520PI3Ks%2520p110delta%2520and%2520p110gamma%253A%2520a%2520prototype%2520for%2520new%2520anti-inflammatory%2520drugs%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D123%26epage%3D134%26doi%3D10.1016%2Fj.chembiol.2010.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taltavull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caturla, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrascal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pages, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinosa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabate, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calbet, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel inhaled PI3Kdelta inhibitor for the treatment of respiratory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9551</span>– <span class="NLM_lpage">9567</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00873</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00873" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFaltbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9551-9567&author=M.+Erraauthor=J.+Taltavullauthor=F.+J.+Bernalauthor=J.+F.+Caturlaauthor=M.+Carrascalauthor=L.+Pagesauthor=M.+Mirauthor=S.+Espinosaauthor=J.+Graciaauthor=M.+Dominguezauthor=M.+Sabateauthor=S.+Parisauthor=M.+Maldonadoauthor=B.+Hernandezauthor=M.+Bravoauthor=E.+Calamaauthor=M.+Miralpeixauthor=M.+D.+Lehnerauthor=M.+Calbet&title=Discovery+of+a+novel+inhaled+PI3Kdelta+inhibitor+for+the+treatment+of+respiratory+diseases&doi=10.1021%2Facs.jmedchem.8b00873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Inhaled PI3Kδ Inhibitor for the Treatment of Respiratory Diseases</span></div><div class="casAuthors">Erra, Montse; Taltavull, Joan; Bernal, Francisco Javier; Caturla, Juan Francisco; Carrascal, Marta; Pages, Lluis; Mir, Marta; Espinosa, Sonia; Gracia, Jordi; Dominguez, Maria; Sabate, Mar; Paris, Stephane; Maldonado, Monica; Hernandez, Begona; Bravo, Monica; Calama, Elena; Miralpeix, Montserrat; Lehner, Martin D.; Calbet, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9551-9567</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral PI3Kδ inhibitors such as Idelalisib and Duvelisib have shown efficacy as anticancer agents and Idelalisib has been approved for the treatment of three B-cell cancers.  However, Idelalisib has a black box warning on its product label regarding the risks of fatal and serious toxicities including hepatic toxicity, severe diarrhea, colitis, pneumonitis, infections, and intestinal perforation.  Some of these side effects are mechanism-related and could hinder the development of Idelalisib for less severe conditions.  For respiratory diseases, compds. administered by inhalation are delivered directly to the site of action and may improve the therapeutic index of a drug, minimizing undesired side effects.  This work describes the discovery and optimization of inhaled PI3Kδ inhibitors intended for the treatment of severe asthma and COPD.  Once the potency was in the desired range, efforts were focused on identifying the particular physicochem. properties that could translate into better lung retention.  This medicinal chem. exercise led to the identification of LAS195319 as a candidate for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtstrCaE6BArVg90H21EOLACvtfcHk0ljhKxV1SPuUJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFaltbbK&md5=f7f14dd277a8ef119a2aeabb1558a838</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00873%26sid%3Dliteratum%253Aachs%26aulast%3DErra%26aufirst%3DM.%26aulast%3DTaltavull%26aufirst%3DJ.%26aulast%3DBernal%26aufirst%3DF.%2BJ.%26aulast%3DCaturla%26aufirst%3DJ.%2BF.%26aulast%3DCarrascal%26aufirst%3DM.%26aulast%3DPages%26aufirst%3DL.%26aulast%3DMir%26aufirst%3DM.%26aulast%3DEspinosa%26aufirst%3DS.%26aulast%3DGracia%26aufirst%3DJ.%26aulast%3DDominguez%26aufirst%3DM.%26aulast%3DSabate%26aufirst%3DM.%26aulast%3DParis%26aufirst%3DS.%26aulast%3DMaldonado%26aufirst%3DM.%26aulast%3DHernandez%26aufirst%3DB.%26aulast%3DBravo%26aufirst%3DM.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26aulast%3DCalbet%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520inhaled%2520PI3Kdelta%2520inhibitor%2520for%2520the%2520treatment%2520of%2520respiratory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9551%26epage%3D9567%26doi%3D10.1021%2Facs.jmedchem.8b00873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taltavull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caturla, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabate, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armengol, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabedo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally available PI3Kdelta inhibitor for the treatment of inflammatory diseases</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00438</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00438" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFyntrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=118-123&author=M.+Erraauthor=J.+Taltavullauthor=A.+Grecoauthor=F.+J.+Bernalauthor=J.+F.+Caturlaauthor=J.+Graciaauthor=M.+Dominguezauthor=M.+Sabateauthor=S.+Parisauthor=S.+Soriaauthor=B.+Hernandezauthor=C.+Armengolauthor=J.+Cabedoauthor=M.+Bravoauthor=E.+Calamaauthor=M.+Miralpeixauthor=M.+D.+Lehner&title=Discovery+of+a+potent%2C+selective%2C+and+orally+available+PI3Kdelta+inhibitor+for+the+treatment+of+inflammatory+diseases&doi=10.1021%2Facsmedchemlett.6b00438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases</span></div><div class="casAuthors">Erra, Montse; Taltavull, Joan; Greco, Angelique; Bernal, Francisco Javier; Caturla, Juan Francisco; Gracia, Jordi; Dominguez, Maria; Sabate, Mar; Paris, Stephane; Soria, Salome; Hernandez, Begona; Armengol, Clara; Cabedo, Judit; Bravo, Monica; Calama, Elena; Miralpeix, Montserrat; Lehner, Martin D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">118-123</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The delta isoform of the phosphatidylinositol 3-kinase (PI3Kδ) has been shown to have an essential role in specific immune cell functions and thus represents a potential therapeutic target for autoimmune and inflammatory diseases.  Herein, the optimization of a series of pyrrolotriazinones as potent and selective PI3Kδ inhibitors is described.  The main challenge of the optimization process was to identify an orally available compd. with a good pharmacokinetic profile in preclin. species that predicted a suitable dosing regimen in humans.  Structure-activity relationships and structure-property relationships are discussed.  This medicinal chem. exercise led to the identification of LAS191954 as a candidate for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGKftcFDPpSLVg90H21EOLACvtfcHk0ljhKxV1SPuUJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFyntrzN&md5=120b642b7adb9a5e2a1014abc93aaa98</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00438%26sid%3Dliteratum%253Aachs%26aulast%3DErra%26aufirst%3DM.%26aulast%3DTaltavull%26aufirst%3DJ.%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DBernal%26aufirst%3DF.%2BJ.%26aulast%3DCaturla%26aufirst%3DJ.%2BF.%26aulast%3DGracia%26aufirst%3DJ.%26aulast%3DDominguez%26aufirst%3DM.%26aulast%3DSabate%26aufirst%3DM.%26aulast%3DParis%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DS.%26aulast%3DHernandez%26aufirst%3DB.%26aulast%3DArmengol%26aufirst%3DC.%26aulast%3DCabedo%26aufirst%3DJ.%26aulast%3DBravo%26aufirst%3DM.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520PI3Kdelta%2520inhibitor%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D118%26epage%3D123%26doi%3D10.1021%2Facsmedchemlett.6b00438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garces, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M. J.</span></span> <span> </span><span class="NLM_article-title">Class 1 PI3K clinical candidates and recent inhibitor design strategies: a medicinal chemistry perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4815</span>– <span class="NLM_lpage">4850</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01492</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01492" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFOku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4815-4850&author=A.+E.+Garcesauthor=M.+J.+Stocks&title=Class+1+PI3K+clinical+candidates+and+recent+inhibitor+design+strategies%3A+a+medicinal+chemistry+perspective&doi=10.1021%2Facs.jmedchem.8b01492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective</span></div><div class="casAuthors">Garces, Aimie E.; Stocks, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4815-4850</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate the 3-OH of the inositol ring of phosphoinositides, and deregulation of this pathway has implications in many diseases.  The search for novel PI3K inhibitors has been at the forefront of academic and industrial medicinal chem. with over 600 medicinal chem.-based publications and patents appearing to date, leading to 38 clin. candidates and the launch of two drugs, idelalisib in 2014 and copanlisib in 2017.  This Perspective will discuss medicinal chem. design approaches to novel isoform-selective inhibitors through consideration of brief case histories of compds. that have progressed into clin. development or that have revealed new structural motifs in this highly competitive area of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUu2mgndklHbVg90H21EOLACvtfcHk0lgCU9z7PbmwMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFOku7bK&md5=907395a39ed6fb683464ee92c6a2537f</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01492%26sid%3Dliteratum%253Aachs%26aulast%3DGarces%26aufirst%3DA.%2BE.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26atitle%3DClass%25201%2520PI3K%2520clinical%2520candidates%2520and%2520recent%2520inhibitor%2520design%2520strategies%253A%2520a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4815%26epage%3D4850%26doi%3D10.1021%2Facs.jmedchem.8b01492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourne, P. E.</span></span> <span> </span><span class="NLM_article-title">Progress with covalent small-molecule kinase inhibitors</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">735</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2018.01.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.drudis.2018.01.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=29337202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslShurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=727-735&author=Z.+Zhaoauthor=P.+E.+Bourne&title=Progress+with+covalent+small-molecule+kinase+inhibitors&doi=10.1016%2Fj.drudis.2018.01.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Progress with covalent small-molecule kinase inhibitors</span></div><div class="casAuthors">Zhao, Zheng; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">727-735</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">With reduced risk of toxicity and high selectivity, covalent small-mol. kinase inhibitors (CSKIs) have emerged rapidly.  Through the lens of structural system pharmacol., here we review this rapid progress by considering design strategies and the challenges and opportunities offered by current CSKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog6l6qMAopYLVg90H21EOLACvtfcHk0lgCU9z7PbmwMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslShurg%253D&md5=f97a19f53a72044812a778ee9351fe94</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2018.01.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2018.01.035%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DProgress%2520with%2520covalent%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2018%26volume%3D23%26spage%3D727%26epage%3D735%26doi%3D10.1016%2Fj.drudis.2018.01.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Developing irreversible inhibitors of the protein kinase cysteinome</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.chembiol.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=23438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=146-159&author=Q.+Liuauthor=Y.+Sabnisauthor=Z.+Zhaoauthor=T.+Zhangauthor=S.+J.+Buhrlageauthor=L.+H.+Jonesauthor=N.+S.+Gray&title=Developing+irreversible+inhibitors+of+the+protein+kinase+cysteinome&doi=10.1016%2Fj.chembiol.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span></div><div class="casAuthors">Liu, Qingsong; Sabnis, Yogesh; Zhao, Zheng; Zhang, Tinghu; Buhrlage, Sara J.; Jones, Lyn H.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-159</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a large family of approx. 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction.  The clin. success of a no. of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large no. of kinases may represent therapeutically relevant targets.  To date, the majority of clin. and preclin. kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases.  Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket.  Irreversible kinase inhibitors have a no. of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacol. specificity through mutation of the reactive cysteine residue.  Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biol. activity profiles.  In addn., we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVGD7TX3oIeLVg90H21EOLACvtfcHk0lgCU9z7PbmwMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D&md5=cef80823123bae88362e816a0a638133</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDeveloping%2520irreversible%2520inhibitors%2520of%2520the%2520protein%2520kinase%2520cysteinome%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D146%26epage%3D159%26doi%3D10.1016%2Fj.chembiol.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velentza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flatauer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valente, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagorska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Didonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balk, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5916</span>– <span class="NLM_lpage">5919</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.bmcl.2008.07.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=18667312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOht7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5916-5919&author=W.+Hurauthor=A.+Velentzaauthor=S.+Kimauthor=L.+Flatauerauthor=X.+Jiangauthor=D.+Valenteauthor=D.+E.+Masonauthor=M.+Suzukiauthor=B.+Larsonauthor=J.+Zhangauthor=A.+Zagorskaauthor=M.+Didonatoauthor=A.+Nagleauthor=M.+Warmuthauthor=S.+P.+Balkauthor=E.+C.+Petersauthor=N.+S.+Gray&title=Clinical+stage+EGFR+inhibitors+irreversibly+alkylate+Bmx+kinase&doi=10.1016%2Fj.bmcl.2008.07.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase</span></div><div class="casAuthors">Hur, Wooyoung; Velentza, Anastasia; Kim, Sungjoon; Flatauer, Laura; Jiang, Xinnong; Valente, David; Mason, Daniel E.; Suzuki, Melissa; Larson, Brad; Zhang, Jianming; Zagorska, Anna; DiDonato, Michael; Nagle, Advait; Warmuth, Markus; Balk, Steven P.; Peters, Eric C.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5916-5919</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Irreversible HER/erbB inhibitors selectively inhibit HER-family kinases by targeting a unique cysteine residue located within the ATP-binding pocket.  Sequence alignment reveals that this rare cysteine is also present in ten other protein kinases including all five Tec-family members.  We demonstrate that the Tec-family kinase Bmx is potently inhibited by irreversible modification at Cys496 by clin. stage EGFR inhibitors such as CI-1033.  This cross-reactivity may have significant clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_hlFgn2jwY7Vg90H21EOLACvtfcHk0lhUmi3fffRpbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOht7vM&md5=2f704e42920d0a18f9dfdcc688347f0a</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.062%26sid%3Dliteratum%253Aachs%26aulast%3DHur%26aufirst%3DW.%26aulast%3DVelentza%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DFlatauer%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DValente%26aufirst%3DD.%26aulast%3DMason%26aufirst%3DD.%2BE.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DLarson%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZagorska%26aufirst%3DA.%26aulast%3DDidonato%26aufirst%3DM.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DBalk%26aufirst%3DS.%2BP.%26aulast%3DPeters%26aufirst%3DE.%2BC.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DClinical%2520stage%2520EGFR%2520inhibitors%2520irreversibly%2520alkylate%2520Bmx%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5916%26epage%3D5919%26doi%3D10.1016%2Fj.bmcl.2008.07.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bordoni, R. E.</span></span> <span> </span><span class="NLM_article-title">Afatinib (BIBW-2992): a novel dual EGFR/HER2neu inhibitor with promising activity in non-small-cell lung cancer</span>. <i>Therapy</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.2217/thy.10.86</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.2217%2Fthy.10.86" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sju7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=15-22&author=R.+E.+Bordoni&title=Afatinib+%28BIBW-2992%29%3A+a+novel+dual+EGFR%2FHER2neu+inhibitor+with+promising+activity+in+non-small-cell+lung+cancer&doi=10.2217%2Fthy.10.86"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib (BIBW-2992): a novel dual EGFR/HER2neu inhibitor with promising activity in non-small-cell lung cancer</span></div><div class="casAuthors">Bordoni, Rodolfo E.</div><div class="citationInfo"><span class="NLM_cas:title">Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-22</span>CODEN:
                <span class="NLM_cas:coden">THERCR</span>;
        ISSN:<span class="NLM_cas:issn">1475-0708</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Lung cancer is not one disease but many diseases with specific mol. profiles and treatment alternatives.  EGF receptor-activating mutations predict a high, albeit short-lived, response to reversible tyrosine kinase inhibitors (e.g., gefitinib and erlotinib).  Acquired resistance mutations can result in tumor progression.  Dual EGFR/HER2 irreversible inhibitors are small novel mols. that can overcome gefitinib/erlotinib resistance by potentially circumventing multiple mechanisms of acquired resistance, as shown in vitro.  Afatinib is an irreversible inhibitor with potent phosphorylation inhibitory activity of both EGF receptor and HER2.  Durable responses were obsd. in Phase I trials in advanced non-small-cell lung cancer at 50 mg once daily.  In Phase II trials, redn. in tumor size was obsd. in 90% of patients.  The objective response and disease control rate were 62 and 94%, resp.  Median progression-free survival was estd. at 12 mo (95% CI: 10.0-19.2).  The most common drug-related adverse events were diarrhea and rash/acne, 18% were grade 3 and none grade 4.  LUX-Lung 1, one of two global Phase III studies, was presented in Oct. 2010.  At primary anal. (358 events), the study did not meet its primary end point to improve overall survival compared with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Iip5iQtcdLVg90H21EOLACvtfcHk0lhUmi3fffRpbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sju7fO&md5=d3ab1dc591e5f6e64462ade250396306</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.2217%2Fthy.10.86&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fthy.10.86%26sid%3Dliteratum%253Aachs%26aulast%3DBordoni%26aufirst%3DR.%2BE.%26atitle%3DAfatinib%2520%2528BIBW-2992%2529%253A%2520a%2520novel%2520dual%2520EGFR%252FHER2neu%2520inhibitor%2520with%2520promising%2520activity%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DTherapy%26date%3D2011%26volume%3D8%26spage%3D15%26epage%3D22%26doi%3D10.2217%2Fthy.10.86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, V.</span></span> <span> </span><span class="NLM_article-title">Afatinib (BIBW 2992) development in non-small-cell lung cancer</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">825</span>, <span class="refDoi"> DOI: 10.2217/fon.11.62</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.2217%2Ffon.11.62" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=21732753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1SlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=817-825&author=V.+Hirsh&title=Afatinib+%28BIBW+2992%29+development+in+non-small-cell+lung+cancer&doi=10.2217%2Ffon.11.62"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib (BIBW 2992) development in non-small-cell lung cancer</span></div><div class="casAuthors">Hirsh, Vera</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">817-825</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Afatinib (BIBW 2992), a novel aniline--quinazoline deriv., irreversibly and equipotently targets the intrinsic kinase activity of all active ErbB receptor family members.  Preclin. results show that afatinib is effective in lung cancer models, including those with EGF receptor (EGFR) mutations resistant to reversible first-generation EGFR inhibitors.  Afatinib is being investigated in the LUX-Lung program, which will evaluate afatinib as a first-line treatment in patients with EGFR-activating mutations (LUX-Lung 2, 3 and 6) and as a second- or third-line treatment in patients that have acquired resistance to gefitinib and/or erlotinib (LUX-Lung 1, 4 and 5).  LUX-Lung 1 and 2 have demonstrated, within their resp. target groups, a significant increase in the disease control rate of 58 and 86%, resp., and significant prolongation of progression-free survival.  Further Phase III clin. trials are currently ongoing to assess afatinib in combination with paclitaxel (LUX-Lung 5), and compared with cisplatin/pemetrexed (LUX-Lung 3) or cisplatin/gemcitabine (LUX-Lung 6).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMXffZwNyKfLVg90H21EOLACvtfcHk0lhUmi3fffRpbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1SlurY%253D&md5=1359e73d0a77b146a80545db338d34a4</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.2217%2Ffon.11.62&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.11.62%26sid%3Dliteratum%253Aachs%26aulast%3DHirsh%26aufirst%3DV.%26atitle%3DAfatinib%2520%2528BIBW%25202992%2529%2520development%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2011%26volume%3D7%26spage%3D817%26epage%3D825%26doi%3D10.2217%2Ffon.11.62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraemer, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Himmelsbach, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haaksma, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolf, G. R.</span></span> <span> </span><span class="NLM_article-title">Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.197756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1124%2Fjpet.112.197756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22888144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKktbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2012&pages=342-350&author=F.+Solcaauthor=G.+Dahlauthor=A.+Zoephelauthor=G.+Baderauthor=M.+Sandersonauthor=C.+Kleinauthor=O.+Kraemerauthor=F.+Himmelsbachauthor=E.+Haaksmaauthor=G.+R.+Adolf&title=Target+binding+properties+and+cellular+activity+of+afatinib+%28BIBW+2992%29%2C+an+irreversible+ErbB+family+blocker&doi=10.1124%2Fjpet.112.197756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker</span></div><div class="casAuthors">Solca, Flavio; Dahl, Goeran; Zoephel, Andreas; Bader, Gerd; Sanderson, Michael; Klein, Christian; Kraemer, Oliver; Himmelsbach, Frank; Haaksma, Eric; Adolf, Guenther R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">342-350</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Deregulation of the ErbB (proto-oncogene B of the avian erythroblastosis virus AEV-H strain) receptor network is well recognized as an oncogenic driver in epithelial cancers.  Several targeted drugs have been developed, including antibodies and small-mol. kinase inhibitors, each of them characterized by distinct patterns of ErbB receptor interactions.  Understanding the precise pharmacol. properties of these compds. is important for optimal use in clin. practice.  Afatinib [BIBW 2992; N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide] is an ATP-competitive anilinoquinazoline deriv. harboring a reactive acrylamide group.  It was designed to covalently bind and irreversibly block enzymically active ErbB receptor family members.  Here, we show by X-ray crystallog. the covalent binding of afatinib to wild-type epidermal growth factor receptor (EGFR) and by mass spectrometry the covalent interaction with EGFR, EGFRL858R/T790M, human epidermal growth factor receptor 2 (HER2), and ErbB-4.  Afatinib potently inhibits the enzymatic activity of ErbB-4 (EC50 = 1 nM) and the proliferation of cancer cell lines driven by multiple ErbB receptor aberrations at concns. below 100 nM.  N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butanamide (BI 37781), a close analog of afatinib lacking the acrylamide group and thus incapable of covalent bond formation, had similar potency on cells driven by EGFR or EGFRL858R, but less or no detectable activity on cells expressing EGFRL858R/T790M HER2 or ErbB-4.  These results stress the importance of the acrylamide group and show that afatinib differs from approved ErbB targeting agents by irreversibly inhibiting the kinase activity of all ErbB family members.  They provide a mechanistic rationale for the distinct pharmacol. features of this compd. and explain the clin. activity seen in some patients who are resistant to antibody or kinase inhibitor therapy because of secondary mutations or ErbB receptor "reprogramming.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofXgQqaKXv-bVg90H21EOLACvtfcHk0ljzgb_TmCzxsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKktbzE&md5=4a57df32abe8101f287fc6251f63f92d</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.197756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.197756%26sid%3Dliteratum%253Aachs%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DDahl%26aufirst%3DG.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DSanderson%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DKraemer%26aufirst%3DO.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DHaaksma%26aufirst%3DE.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DTarget%2520binding%2520properties%2520and%2520cellular%2520activity%2520of%2520afatinib%2520%2528BIBW%25202992%2529%252C%2520an%2520irreversible%2520ErbB%2520family%2520blocker%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D343%26spage%3D342%26epage%3D350%26doi%3D10.1124%2Fjpet.112.197756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stopfer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narjes, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gansser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uttereuther-Fischer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebner, T.</span></span> <span> </span><span class="NLM_article-title">Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1051</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1007/s00280-011-1803-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1007%2Fs00280-011-1803-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=22200729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVCrsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=1051-1061&author=P.+Stopferauthor=K.+Marzinauthor=H.+Narjesauthor=D.+Gansserauthor=M.+Shahidiauthor=M.+Uttereuther-Fischerauthor=T.+Ebner&title=Afatinib+pharmacokinetics+and+metabolism+after+oral+administration+to+healthy+male+volunteers&doi=10.1007%2Fs00280-011-1803-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers</span></div><div class="casAuthors">Stopfer, Peter; Marzin, Kristell; Narjes, Hans; Gansser, Dietmar; Shahidi, Mehdi; Uttereuther-Fischer, Martina; Ebner, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1051-1061</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To investigate the pharmacokinetics, metab. and tolerability of afatinib (BIBW 2992), an oral irreversible ErbB family blocker, in healthy male volunteers.  Methods: In this open-label, single-center study, 8 healthy male volunteers received a single oral dose of 15 mg [14C]-radiolabeled afatinib (equiv. to 22.2 mg of the dimaleinate salt) as a soln.  Blood, urine and fecal samples were collected for at least 96 h (h) after dosing.  Plasma and urine concns. of afatinib were analyzed using high-performance liq. chromatog.-tandem mass spectrometry. [14C]-radioactivity levels in plasma, whole blood, urine and feces were measured by liq. scintillation counting methods.  Metabolite patterns were assessed by high-performance liq. chromatog.  Results: [14C]-radioactivity was mainly excreted via feces (85.4%).  Overall recovery of [14C]-radioactivity was 89.5%, indicative of a complete mass balance.  Afatinib was slowly absorbed, with max. plasma concns. achieved at a median of 6 h after dosing, declining thereafter in a biexponential manner.  The geometric mean terminal half-life of afatinib was 33.9 h in plasma and longer for [14C]-radioactivity in plasma and whole blood.  Apparent total body clearance for afatinib was high (geometric mean 1,530 mL/min).  The high vol. of distribution (4,500 L) in plasma may indicate a high tissue distribution.  Afatinib was metabolized to only a minor extent, with the main metabolite afatinib covalently bound to plasma proteins.  Oxidative metab. mediated via cytochrome P 450 was of negligible importance for the elimination of afatinib.  Afatinib was well tolerated.  Conclusions: Afatinib displayed a complete mass balance with the main route of excretion via feces.  Afatinib undergoes minimal metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL0nIa1u5anbVg90H21EOLACvtfcHk0ljzgb_TmCzxsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVCrsL4%253D&md5=37fe411022609ca26b2b52fdaee905d3</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1803-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1803-9%26sid%3Dliteratum%253Aachs%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DMarzin%26aufirst%3DK.%26aulast%3DNarjes%26aufirst%3DH.%26aulast%3DGansser%26aufirst%3DD.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DUttereuther-Fischer%26aufirst%3DM.%26aulast%3DEbner%26aufirst%3DT.%26atitle%3DAfatinib%2520pharmacokinetics%2520and%2520metabolism%2520after%2520oral%2520administration%2520to%2520healthy%2520male%2520volunteers%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D1051%26epage%3D1061%26doi%3D10.1007%2Fs00280-011-1803-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothaus, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.+J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+selective+irreversible+inhibitors+for+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0ljzgb_TmCzxsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib inhibition of bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1016%2Fj.phrs.2016.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=27641927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFCrt7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=395-408&author=R.+Roskoski&title=Ibrutinib+inhibition+of+bruton+protein-tyrosine+kinase+%28BTK%29+in+the+treatment+of+B+cell+neoplasms&doi=10.1016%2Fj.phrs.2016.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms</span></div><div class="casAuthors">Roskoski, Robert Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">Part_A</span>),
    <span class="NLM_cas:pages">395-408</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Bruton non-receptor protein-tyrosine kinase (BTK), a deficiency of which leads to X-linked agammaglobulinemia, plays a central role in B cell antigen receptor signaling.  Owing to the exclusivity of this enzyme in B cells, the acronym could represent B cell tyrosine kinase.  BTK is activated by the Lyn and SYK protein kinases following activation of the B cell receptor.  BTK in turn catalyzes the phosphorylation and activation of phospholipase Cγ2 leading to the downstream activation of the Ras/RAF/MEK/ERK pathway and the NF-κB pathways.  Both pathways participate in the maturation of antibody-producing B cells.  The BTK domains include a PH (pleckstrin homol.) domain that interacts with membrane-assocd. phosphatidyl inositol trisphosphate, a TH (TEC homol.) domain, which is followed by an SH3, SH2, and finally a protein kinase domain.  Dysregulation of B cell receptor signaling occurs in several B cell neoplasms including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia.  Ibrutinib is FDA-approved as first-line or second line treatment for these diseases.  The drug binds tightly in the ATP-binding pocket of BTK making salt bridges with residues within the hinge that connects the two lobes of the enzyme; then its unsatd. acrylamide group forms a covalent bond with BTK cysteine 481 to form an inactive adduct.  In addn. to the treatment of various B cell lymphomas, ibrutinib is under clin. trials for the treatment of numerous solid tumors owing to the role of tumor-promoting inflammation in the pathogenesis of neoplastic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRjiClU2y-abVg90H21EOLACvtfcHk0ljqPlJgXhI4Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFCrt7zN&md5=147a5a3fe0a242bbd8a931188f585b09</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DIbrutinib%2520inhibition%2520of%2520bruton%2520protein-tyrosine%2520kinase%2520%2528BTK%2529%2520in%2520the%2520treatment%2520of%2520B%2520cell%2520neoplasms%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D113%26spage%3D395%26epage%3D408%26doi%3D10.1016%2Fj.phrs.2016.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quittet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtenay-Luck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, G.</span></span> <span> </span><span class="NLM_article-title">A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-08-664086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1182%2Fblood-2015-08-664086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=26542378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Cis7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=411-419&author=H.+S.+Walterauthor=S.+A.+Ruleauthor=M.+J.+Dyerauthor=L.+Karlinauthor=C.+Jonesauthor=B.+Cazinauthor=P.+Quittetauthor=N.+Shahauthor=C.+V.+Hutchinsonauthor=H.+Hondaauthor=K.+Duffyauthor=J.+Birkettauthor=V.+Jamiesonauthor=N.+Courtenay-Luckauthor=T.+Yoshizawaauthor=J.+Sharpeauthor=T.+Ohnoauthor=S.+Abeauthor=A.+Nishimuraauthor=G.+Cartronauthor=F.+Morschhauserauthor=C.+Feganauthor=G.+Salles&title=A+phase+1+clinical+trial+of+the+selective+BTK+inhibitor+ONO%2FGS-4059+in+relapsed+and+refractory+mature+B-cell+malignancies&doi=10.1182%2Fblood-2015-08-664086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies</span></div><div class="casAuthors">Walter, Harriet S.; Rule, Simon A.; Dyer, Martin J. S.; Karlin, Lionel; Jones, Ceri; Cazin, Bruno; Quittet, Philippe; Shah, Nimish; Hutchinson, Claire V.; Honda, Hideyuki; Duffy, Kevin; Birkett, Joseph; Jamieson, Virginia; Courtenay-Luck, Nigel; Yoshizawa, Toshio; Sharpe, John; Ohno, Tomoya; Abe, Shinichiro; Nishimura, Akihisa; Cartron, Guillaume; Morschhauser, Franck; Fegan, Christopher; Salles, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">411-419</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies.  There were 9 dose-escalation cohorts ranging from 20 mg to 600 mg once daily with twice-daily regimens of 240 mg and 300 mg.  Twenty-four of 25 evaluable chronic lymphocytic leukemia (CLL) patients (96%) responded to ONO/GS-4059, with a median treatment duration of 80 wk; 21 CLL patients remain on treatment.  Lymph node responses were rapid and assocd. with a concurrent lymphocytosis.  Eleven of 12 evaluable patients with mantle cell lymphoma (92%) responded (median treatment duration, 40 wk).  Eleven of 31 non-germinal center B-cell diffuse large B-cell lymphoma patients (35%) responded but median treatment duration was 12 wk due to development of progressive disease.  ONO/GS-4059 was very well tolerated with 75% of adverse events (AEs) being Common Toxicity Criteria for Adverse Events version 4.0 grade 1 or grade 2.  Grade 3/4 AEs were mainly hematol. and recovered spontaneously during therapy.  One CLL patient experienced a grade 3 treatment-related bleeding event (spontaneous muscle hematoma) but no clin. significant diarrhea, cardiac dysrhythmias, or arthralgia were obsd.  No maximal tolerated dose (MTD) was reached in the CLL cohort.  In the non-Hodgkin lymphoma cohort, 4 patients developed a dose-limiting toxicity, yielding an MTD of 480 mg once daily.  ONO/GS-4059 has significant activity in relapsed/refractory B-cell malignancies without major drug-related toxicity.  The selectivity of ONO/GS-4059 should confer advantages in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZFfZyaWsIdbVg90H21EOLACvtfcHk0ljqPlJgXhI4Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Cis7zO&md5=f12cd01520c82ddd2067f2b329bd38a9</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-08-664086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-08-664086%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DH.%2BS.%26aulast%3DRule%26aufirst%3DS.%2BA.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%26aulast%3DKarlin%26aufirst%3DL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DCazin%26aufirst%3DB.%26aulast%3DQuittet%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DN.%26aulast%3DHutchinson%26aufirst%3DC.%2BV.%26aulast%3DHonda%26aufirst%3DH.%26aulast%3DDuffy%26aufirst%3DK.%26aulast%3DBirkett%26aufirst%3DJ.%26aulast%3DJamieson%26aufirst%3DV.%26aulast%3DCourtenay-Luck%26aufirst%3DN.%26aulast%3DYoshizawa%26aufirst%3DT.%26aulast%3DSharpe%26aufirst%3DJ.%26aulast%3DOhno%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DA.%26aulast%3DCartron%26aufirst%3DG.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DFegan%26aufirst%3DC.%26aulast%3DSalles%26aufirst%3DG.%26atitle%3DA%2520phase%25201%2520clinical%2520trial%2520of%2520the%2520selective%2520BTK%2520inhibitor%2520ONO%252FGS-4059%2520in%2520relapsed%2520and%2520refractory%2520mature%2520B-cell%2520malignancies%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D411%26epage%3D419%26doi%3D10.1182%2Fblood-2015-08-664086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awan, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothbaum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacovo, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1509981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1056%2FNEJMoa1509981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=26641137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=323-332&author=J.+C.+Byrdauthor=B.+Harringtonauthor=S.+O%E2%80%99Brienauthor=J.+A.+Jonesauthor=A.+Schuhauthor=S.+Devereuxauthor=J.+Chavesauthor=W.+G.+Wierdaauthor=F.+T.+Awanauthor=J.+R.+Brownauthor=P.+Hillmenauthor=D.+M.+Stephensauthor=P.+Ghiaauthor=J.+C.+Barrientosauthor=J.+M.+Pagelauthor=J.+Woyachauthor=D.+Johnsonauthor=J.+Huangauthor=X.+Wangauthor=A.+Kapteinauthor=B.+J.+Lannuttiauthor=T.+Coveyauthor=M.+Fardisauthor=J.+McGreivyauthor=A.+Hamdyauthor=W.+Rothbaumauthor=R.+Izumiauthor=T.+G.+Diacovoauthor=A.+J.+Johnsonauthor=R.+R.+Furman&title=Acalabrutinib+%28ACP-196%29+in+relapsed+chronic+lymphocytic+leukemia&doi=10.1056%2FNEJMoa1509981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Harrington, Bonnie; O'Brien, Susan; Jones, Jeffrey A.; Schuh, Anna; Devereux, Steve; Chaves, Jorge; Wierda, William G.; Awan, Farrukh T.; Brown, Jennifer R.; Hillmen, Peter; Stephens, Deborah M.; Ghia, Paolo; Barrientos, Jacqueline C.; Pagel, John M.; Woyach, Jennifer; Johnson, Dave; Huang, Jane; Wang, Xiaolin; Kaptein, Allard; Lannutti, Brian J.; Covey, Todd; Fardis, Maria; McGreivy, Jesse; Hamdy, Ahmed; Rothbaum, Wayne; Izumi, Raquel; Diacovo, Thomas G.; Johnson, Amy J.; Furman, Richard R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">323-332</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).  However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index.  Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors.  In this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib.  Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twice daily in the expansion (phase 2) portion.  The median age of the patients was 62 years, and patients had received a median of three previous therapies for CLL; 31% had chromosome 17p13.1 deletion, and 75% had unmutated Ig heavy-chain variable genes.  No dose-limiting toxic effects occurred during the dose-escalation portion of the study.  The most common adverse events obsd. were headache (in 43% of the patients), diarrhea (in 39%), and in- creased wt. (in 26%).  Most adverse events were of grade 1 or 2.  At a median follow- up of 14.3 mo, the overall response rate was 95%, including 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable disease.  Among patients with chromosome 17p13.1 deletion, the overall response rate was 100%.  No cases of Richter's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progression have occurred.  In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGHCPciF9hPrVg90H21EOLACvtfcHk0lhRywOqSgoZvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI&md5=d20e0158f9ea308b9d06fa668154516e</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509981%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DHarrington%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DSchuh%26aufirst%3DA.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DChaves%26aufirst%3DJ.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DAwan%26aufirst%3DF.%2BT.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DHillmen%26aufirst%3DP.%26aulast%3DStephens%26aufirst%3DD.%2BM.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DWoyach%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DRothbaum%26aufirst%3DW.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DDiacovo%26aufirst%3DT.%2BG.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D323%26epage%3D332%26doi%3D10.1056%2FNEJMoa1509981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, R. K.</span></span> <span> </span><span class="NLM_article-title">Phase II and phase III failures: 2013–2015</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">818</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=10.1038%2Fnrd.2016.184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=27811931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslynsLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=817-818&author=R.+K.+Harrison&title=Phase+II+and+phase+III+failures%3A+2013%E2%80%932015&doi=10.1038%2Fnrd.2016.184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II and phase III failures: 2013-2015</span></div><div class="casAuthors">Harrison, Richard K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">817-818</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This article analyses recent data on the reported causes of drug candidate attrition, which indicate that lack of efficacy is the reason for approx. half of all phase II and phase III failures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy7ibspDa6WLVg90H21EOLACvtfcHk0lhRywOqSgoZvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslynsLvN&md5=370ee63ca081ca3e958dc17e5315e140</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.184%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DR.%2BK.%26atitle%3DPhase%2520II%2520and%2520phase%2520III%2520failures%253A%25202013%25E2%2580%25932015%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D817%26epage%3D818%26doi%3D10.1038%2Fnrd.2016.184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WGJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WGJ','PDB','2WGJ'); return false;">PDB: 2WGJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CMU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CMU','PDB','4CMU'); return false;">PDB: 4CMU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CD0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CD0','PDB','4CD0'); return false;">PDB: 4CD0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EYD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EYD','PDB','5EYD'); return false;">PDB: 5EYD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7O" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7O','PDB','3R7O'); return false;">PDB: 3R7O</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3I81" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3I81','PDB','3I81'); return false;">PDB: 3I81</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YVJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YVJ','PDB','1YVJ'); return false;">PDB: 1YVJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBM','PDB','6DBM'); return false;">PDB: 6DBM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBN','PDB','6DBN'); return false;">PDB: 6DBN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T18" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T18','PDB','5T18'); return false;">PDB: 5T18</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OTF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OTF','PDB','4OTF'); return false;">PDB: 4OTF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UIU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UIU','PDB','5UIU'); return false;">PDB: 5UIU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TX5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TX5','PDB','5TX5'); return false;">PDB: 5TX5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WXR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WXR','PDB','2WXR'); return false;">PDB: 2WXR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XE0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XE0','PDB','4XE0'); return false;">PDB: 4XE0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FLH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FLH','PDB','4FLH'); return false;">PDB: 4FLH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WWN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WWN','PDB','4WWN'); return false;">PDB: 4WWN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6G6W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6G6W','PDB','6G6W'); return false;">PDB: 6G6W</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5M6U" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5M6U','PDB','5M6U'); return false;">PDB: 5M6U</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5P" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5P','PDB','4G5P'); return false;">PDB: 4G5P</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FBN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FBN','PDB','5FBN'); return false;">PDB: 5FBN</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00640%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-2%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00640" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797e291b332367","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
